<s> O None
Binding I None
of I None
dimemorfan I CHEMICAL
to I None
sigma I GENE-Y
- O GENE-Y
1 O GENE-Y
receptor O GENE-Y
and I None
its I None
anticonvulsant I None
and I None
locomotor I None
effects I None
in I None
mice I None
, I None
compared I None
with I None
dextromethorphan I CHEMICAL
and I None
dextrorphan I CHEMICAL
. I None
<eof> I None

<s> O None
Dextromethorphan I CHEMICAL
( I None
( I CHEMICAL
+ O CHEMICAL
) O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
methoxy O CHEMICAL
- O CHEMICAL
N O CHEMICAL
- O CHEMICAL
methylmorphinan O CHEMICAL
, I None
DM I CHEMICAL
) I None
has I None
been I None
shown I None
to I None
have I None
both I None
anticonvulsant I None
and I None
neuroprotective I None
effects I None
. I None
<eof> I None

<s> O None
The I None
mechanisms I None
of I None
these I None
CNS I None
effects I None
of I None
DM I CHEMICAL
have I None
been I None
suggested I None
to I None
be I None
associated I None
with I None
the I None
low I None
- I None
affinity I None
, I None
noncompetitive I None
, I None
N I CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
- O CHEMICAL
d O CHEMICAL
- O CHEMICAL
aspartate O CHEMICAL
( I None
NMDA I CHEMICAL
) I None
antagonism I None
of I None
DM I CHEMICAL
and I None
/ I None
or I None
the I None
high I None
- I None
affinity I None
DM I CHEMICAL
/ I None
sigma I None
receptors I None
. I None
<eof> I None

<s> O None
DM I CHEMICAL
is I None
largely I None
O I CHEMICAL
- I None
demethylated I None
into I None
the I None
phencyclidine I CHEMICAL
( I None
PCP I CHEMICAL
) I None
- I None
like I None
compound I None
dextrorphan I CHEMICAL
( I None
DR I CHEMICAL
) I None
, I None
which I None
may I None
limit I None
its I None
therapeutic I None
use I None
by I None
producing I None
PCP I CHEMICAL
- I None
like I None
adverse I None
effects I None
, I None
such I None
as I None
hyperlocomotion I None
. I None
<eof> I None

<s> O None
Dimemorfan I CHEMICAL
( I None
( I CHEMICAL
+ O CHEMICAL
) O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
- O CHEMICAL
N O CHEMICAL
- O CHEMICAL
methylmorphinan O CHEMICAL
, I None
DF I CHEMICAL
) I None
, I None
an I None
analog I None
of I None
DM I CHEMICAL
, I None
which I None
has I None
been I None
safely I None
used I None
as I None
an I None
antitussive I None
for I None
more I None
than I None
20 I None
years I None
, I None
is I None
also I None
known I None
not I None
to I None
form I None
DR I CHEMICAL
. I None
<eof> I None

<s> O None
This I None
study I None
therefore I None
characterized I None
the I None
binding I None
of I None
DF I CHEMICAL
to I None
the I None
sigma I GENE-N
receptors O GENE-N
and I None
NMDA I CHEMICAL
- I None
linked I None
PCP I CHEMICAL
sites I None
and I None
examined I None
the I None
anticonvulsant I None
as I None
well I None
as I None
locomotor I None
effects I None
of I None
DF I CHEMICAL
in I None
mice I None
in I None
comparison I None
with I None
those I None
of I None
DM I CHEMICAL
and I None
DR I CHEMICAL
. I None
<eof> I None

<s> O None
We I None
found I None
that I None
DF I CHEMICAL
, I None
DM I CHEMICAL
, I None
and I None
DR I CHEMICAL
were I None
relative I None
high I None
- I None
affinity I None
ligands I None
at I None
sigma I GENE-Y
- O GENE-Y
1 O GENE-Y
receptors O GENE-Y
( I None
Ki I None
= I None
151 I None
, I None
205 I None
, I None
144 I None
nM I None
, I None
respectively I None
) I None
while I None
all I None
of I None
them I None
were I None
with I None
low I None
affinity I None
at I None
sigma I GENE-N
- O GENE-N
2 O GENE-N
receptors O GENE-N
( I None
Ki I None
= I None
4 I None
- I None
11 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
Only I None
DR I CHEMICAL
exhibited I None
moderate I None
affinity I None
for I None
PCP I CHEMICAL
sites I None
( I None
Ki I None
= I None
0 I None
. I None
9 I None
microM I None
) I None
, I None
whereas I None
DF I CHEMICAL
( I None
Ki I None
= I None
17 I None
microM I None
) I None
and I None
DM I CHEMICAL
( I None
Ki I None
= I None
7 I None
microM I None
) I None
were I None
much I None
less I None
active I None
. I None
<eof> I None

<s> O None
DF I None
, I None
DM I CHEMICAL
and I None
DR I CHEMICAL
produced I None
prominent I None
anticonvulsant I None
effects I None
in I None
mice I None
as I None
measured I None
by I None
the I None
supramaximal I None
electroshock I None
test I None
with I None
comparable I None
potency I None
( I None
ED50 I None
approximately I None
70 I None
micromol I None
/ I None
kg I None
, I None
i I None
. I None
p I None
. I None
) I None
. I None
<eof> I None

<s> O None
At I None
the I None
tested I None
doses I None
( I None
20 I None
- I None
260 I None
micromol I None
/ I None
kg I None
, I None
i I None
. I None
p I None
. I None
) I None
, I None
DM I CHEMICAL
and I None
DR I CHEMICAL
exhibited I None
biphasic I None
effects I None
on I None
the I None
locomotor I None
activity I None
whereas I None
DF I CHEMICAL
produced I None
a I None
consistent I None
dose I None
- I None
dependent I None
decrease I None
. I None
<eof> I None

<s> O None
These I None
results I None
revealed I None
that I None
, I None
unlike I None
DM I CHEMICAL
and I None
DR I CHEMICAL
, I None
DF I CHEMICAL
did I None
not I None
cause I None
a I None
PCP I CHEMICAL
- I None
like I None
hyperlocomotion I None
adverse I None
effect I None
that I None
is I None
parallel I None
with I None
the I None
PCP I CHEMICAL
sites I None
binding I None
data I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
since I None
they I None
have I None
equipotent I None
anticonvulsant I None
effects I None
and I None
similar I None
binding I None
affinities I None
to I None
sigma I GENE-Y
- O GENE-Y
1 O GENE-Y
receptors O GENE-Y
, I None
the I None
very I None
low I None
affinity I None
of I None
DF I CHEMICAL
at I None
PCP I CHEMICAL
sites I None
may I None
suggest I None
that I None
acting I None
on I None
the I None
PCP I CHEMICAL
sites I None
may I None
not I None
be I None
the I None
requisite I None
for I None
mediating I None
the I None
anticonvulsant I None
activity I None
of I None
these I None
DM I CHEMICAL
analogs I None
. I None
<eof> I None

<s> O None
With I None
the I None
history I None
of I None
safety I None
and I None
relative I None
less I None
adverse I None
effects I None
, I None
DF I CHEMICAL
appears I None
to I None
be I None
worth I None
further I None
studying I None
on I None
its I None
CNS I None
effects I None
other I None
than I None
the I None
antitussive I None
effect I None
. I None
<eof> I None

<s> O None
Angiotensin I GENE-N
II O GENE-N
receptor O GENE-N
blockade I None
in I None
normotensive I None
subjects I None
: I None
A I None
direct I None
comparison I None
of I None
three I None
AT1 I GENE-Y
receptor O GENE-Y
antagonists I None
. I None
<eof> I None

<s> O None
Use I None
of I None
angiotensin I GENE-Y
( O GENE-Y
Ang O GENE-Y
) O GENE-Y
II O GENE-Y
AT1 O GENE-Y
receptor O GENE-Y
antagonists I None
for I None
treatment I None
of I None
hypertension I None
is I None
rapidly I None
increasing I None
, I None
yet I None
direct I None
comparisons I None
of I None
the I None
relative I None
efficacy I None
of I None
antagonists I None
to I None
block I None
the I None
renin I None
- I None
angiotensin I None
system I None
in I None
humans I None
are I None
lacking I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
the I None
Ang I GENE-N
II O GENE-N
receptor O GENE-N
blockade I None
induced I None
by I None
the I None
recommended I None
starting I None
dose I None
of I None
3 I None
antagonists I None
was I None
evaluated I None
in I None
normotensive I None
subjects I None
in I None
a I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
, I None
randomized I None
, I None
4 I None
- I None
way I None
crossover I None
study I None
. I None
<eof> I None

<s> O None
At I None
1 I None
- I None
week I None
intervals I None
, I None
12 I None
subjects I None
received I None
a I None
single I None
dose I None
of I None
losartan I CHEMICAL
( I None
50 I None
mg I None
) I None
, I None
valsartan I CHEMICAL
( I None
80 I None
mg I None
) I None
, I None
irbesartan I CHEMICAL
( I None
150 I None
mg I None
) I None
, I None
or I None
placebo I None
. I None
<eof> I None

<s> O None
Blockade I None
of I None
the I None
renin I GENE-Y
- I None
angiotensin I CHEMICAL
system I None
was I None
assessed I None
before I None
and I None
4 I None
, I None
24 I None
, I None
and I None
30 I None
hours I None
after I None
drug I None
intake I None
by I None
3 I None
independent I None
methods I None
: I None
inhibition I None
of I None
the I None
blood I None
pressure I None
response I None
to I None
exogenous I None
Ang I CHEMICAL
II O CHEMICAL
, I None
in I None
vitro I None
Ang I GENE-N
II O GENE-N
receptor O GENE-N
assay I None
, I None
and I None
reactive I None
changes I None
in I None
plasma I None
Ang I CHEMICAL
II O CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
At I None
4 I None
hours I None
, I None
losartan I None
blocked I None
43 I None
% I None
of I None
the I None
Ang I CHEMICAL
II O CHEMICAL
- I None
induced I None
systolic I None
blood I None
pressure I None
increase I None
; I None
valsartan I CHEMICAL
, I None
51 I None
% I None
; I None
and I None
irbesartan I CHEMICAL
, I None
88 I None
% I None
( I None
P I None
< I None
0 I None
. I None
01 I None
between I None
drugs I None
) I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
each I None
drug I None
declined I None
with I None
time I None
. I None
<eof> I None

<s> O None
At I None
24 I None
hours I None
, I None
a I None
residual I None
effect I None
was I None
found I None
with I None
all I None
3 I None
drugs I None
, I None
but I None
at I None
30 I None
hours I None
, I None
only I None
irbesartan I CHEMICAL
induced I None
a I None
marked I None
, I None
significant I None
blockade I None
versus I None
placebo I None
. I None
<eof> I None

<s> O None
Similar I None
results I None
were I None
obtained I None
when I None
Ang I GENE-N
II O GENE-N
receptor O GENE-N
blockade I None
was I None
assessed I None
with I None
an I None
in I None
vitro I None
receptor I None
assay I None
and I None
by I None
the I None
reactive I None
rise I None
in I None
plasma I None
Ang I CHEMICAL
II O CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
This I None
study I None
thus I None
demonstrates I None
that I None
the I None
first I None
administration I None
of I None
the I None
recommended I None
starting I None
dose I None
of I None
irbesartan I CHEMICAL
induces I None
a I None
greater I None
and I None
longer I None
lasting I None
Ang I GENE-N
II O GENE-N
receptor O GENE-N
blockade I None
than I None
that I None
of I None
valsartan I CHEMICAL
and I None
losartan I CHEMICAL
in I None
normotensive I None
subjects I None
. I None
<eof> I None

<s> O None
Characterisation I None
of I None
the I None
5 I GENE-N
- O GENE-N
HT O GENE-N
receptor O GENE-N
binding I None
profile I None
of I None
eletriptan I CHEMICAL
and I None
kinetics I None
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
eletriptan O CHEMICAL
binding I None
at I None
human I GENE-Y
5 O GENE-Y
- O GENE-Y
HT1B O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT1D O GENE-Y
receptors I None
. I None
<eof> I None

<s> O None
The I None
affinity I None
of I None
eletriptan I CHEMICAL
( I None
( I CHEMICAL
R O CHEMICAL
) O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
pyrrolidinylmethyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
phenylsulphonyl O CHEMICAL
) O CHEMICAL
ethyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
1H O CHEMICAL
- O CHEMICAL
indole O CHEMICAL
) I None
for I None
a I None
range I None
of I None
5 I GENE-N
- O GENE-N
HT O GENE-N
receptors O GENE-N
was I None
compared I None
to I None
values I None
obtained I None
for I None
other I None
5 I GENE-N
- O GENE-N
HT1B O GENE-N
/ O GENE-N
1D O GENE-N
receptor I None
agonists I None
known I None
to I None
be I None
effective I None
in I None
the I None
treatment I None
of I None
migraine I None
. I None
<eof> I None

<s> O None
Eletriptan I CHEMICAL
, I None
like I None
sumatriptan I CHEMICAL
, I None
zolmitriptan I CHEMICAL
, I None
naratriptan I CHEMICAL
and I None
rizatriptan I CHEMICAL
had I None
highest I None
affinity I None
for I None
the I None
human I GENE-Y
5 O GENE-Y
- O GENE-Y
HT1B O GENE-Y
, I None
5 I GENE-Y
- O GENE-Y
HT1D O GENE-Y
and I None
putative I None
5 I GENE-Y
- O GENE-Y
ht1f O GENE-Y
receptor I None
. I None
<eof> I None

<s> O None
Kinetic I None
studies I None
comparing I None
the I None
binding I None
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
eletriptan O CHEMICAL
and I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
sumatriptan O CHEMICAL
to I None
the I None
human I GENE-Y
recombinant O GENE-Y
5 O GENE-Y
- O GENE-Y
HT1B O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT1D O GENE-Y
receptors I None
expressed I None
in I None
HeLa I None
cells I None
revealed I None
that I None
both I None
radioligands I None
bound I None
with I None
high I None
specificity I None
( I None
> I None
90 I None
% I None
) I None
and I None
reached I None
equilibrium I None
within I None
10 I None
- I None
15 I None
min I None
. I None
<eof> I None

<s> O None
However I None
, I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
eletriptan O CHEMICAL
had I None
over I None
6 I None
- I None
fold I None
higher I None
affinity I None
than I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
sumatriptan O CHEMICAL
at I None
the I None
5 I GENE-Y
- O GENE-Y
HT1D O GENE-Y
receptor I None
( I None
K I None
( I None
D I None
) I None
) I None
: I None
0 I None
. I None
92 I None
and I None
6 I None
. I None
58 I None
nM I None
, I None
respectively I None
) I None
and I None
over I None
3 I None
- I None
fold I None
higher I None
affinity I None
than I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
sumatriptan O CHEMICAL
at I None
the I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptor I None
( I None
K I None
( I None
D I None
) I None
: I None
3 I None
. I None
14 I None
and I None
11 I None
. I None
07 I None
nM I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
Association I None
and I None
dissociation I None
rates I None
for I None
both I None
radioligands I None
could I None
only I None
be I None
accurately I None
determined I None
at I None
the I None
5 I GENE-Y
- O GENE-Y
HT1D O GENE-Y
receptor I None
and I None
then I None
only I None
at I None
4 I None
degrees I None
C I None
. I None
<eof> I None

<s> O None
At I None
this I None
temperature I None
, I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
eletriptan O CHEMICAL
had I None
a I None
significantly I None
( I None
P I None
< I None
0 I None
. I None
05 I None
) I None
faster I None
association I None
rate I None
( I None
K I None
( I None
on I None
) I None
0 I None
. I None
249 I None
min I None
( I None
- I None
1 I None
) I None
nM I None
( I None
- I None
1 I None
) I None
) I None
than I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
sumatriptan O CHEMICAL
( I None
K I None
( I None
on I None
) I None
0 I None
. I None
024 I None
min I None
( I None
- I None
1 I None
) I None
nM I None
( I None
- I None
1 I None
) I None
) I None
and I None
a I None
significantly I None
( I None
P I None
< I None
0 I None
. I None
05 I None
) I None
slower I None
off I None
- I None
rate I None
( I None
K I None
( I None
off I None
) I None
0 I None
. I None
027 I None
min I None
( I None
- I None
1 I None
) I None
compared I None
to I None
0 I None
. I None
037 I None
min I None
( I None
- I None
1 I None
) I None
for I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
sumatriptan O CHEMICAL
) I None
. I None
<eof> I None

<s> O None
These I None
data I None
indicate I None
that I None
eletriptan I None
is I None
a I None
potent I None
ligand I None
at I None
the I None
human I GENE-Y
5 O GENE-Y
- O GENE-Y
HT1B O GENE-Y
, I None
5 I GENE-Y
- O GENE-Y
HT1D O GENE-Y
, I None
and I None
5 I GENE-Y
- O GENE-Y
ht1f O GENE-Y
receptors I None
and I None
are I None
consistent I None
with I None
its I None
potent I None
vasoconstrictor I None
activity I None
and I None
use I None
as I None
a I None
drug I None
for I None
the I None
acute I None
treatment I None
of I None
migraine I None
headache I None
. I None
<eof> I None

<s> O None
Pharmacological I None
profile I None
of I None
neuroleptics I CHEMICAL
at I None
human I GENE-N
monoamine O GENE-N
transporters O GENE-N
. I None
<eof> I None

<s> O None
Using I None
radioligand I None
binding I None
techniques I None
, I None
we I None
determined I None
the I None
equilibrium I None
dissociation I None
constants I None
( I None
K I None
( I None
D I None
) I None
) I None
for I None
37 I None
neuroleptics I CHEMICAL
and I None
one I None
metabolite I None
of I None
a I None
neuroleptic I None
( I None
haloperidol I CHEMICAL
metabolite I None
) I None
for I None
the I None
human I GENE-N
serotonin O GENE-N
, O GENE-N
norepinephrine O GENE-N
, O GENE-N
and O GENE-N
dopamine O GENE-N
transporters O GENE-N
with I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
imipramine O CHEMICAL
, I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
nisoxetine O CHEMICAL
, I None
and I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
WIN35428 O CHEMICAL
, I None
respectively I None
. I None
<eof> I None

<s> O None
Among I None
neuroleptics I CHEMICAL
, I None
the I None
four I None
most I None
potent I None
compounds I None
at I None
the I None
human I GENE-Y
serotonin O GENE-Y
transporter O GENE-Y
were I None
triflupromazine I CHEMICAL
, I None
fluperlapine I CHEMICAL
, I None
chlorpromazine I CHEMICAL
, I None
and I None
ziprasidone I CHEMICAL
( I None
K I None
( I None
D I None
) I None
24 I None
- I None
39 I None
nM I None
) I None
; I None
and I None
at I None
the I None
norepinephrine I GENE-Y
transporter O GENE-Y
, I None
chlorpromazine I CHEMICAL
, I None
zotepine I CHEMICAL
, I None
chlorprothixene I CHEMICAL
, I None
and I None
promazine I CHEMICAL
( I None
K I None
( I None
D I None
) I None
19 I None
- I None
25 I None
nM I None
) I None
. I None
<eof> I None

<s> O None
At I None
the I None
human I GENE-Y
dopamine O GENE-Y
transporter O GENE-Y
, I None
only I None
pimozide I CHEMICAL
( I None
K I None
( I None
D I None
) I None
= I None
69 I None
+ I None
/ I None
- I None
3 I None
) I None
ziprasidone I CHEMICAL
( I None
K I None
( I None
D I None
) I None
= I None
76 I None
+ I None
/ I None
- I None
5 I None
) I None
had I None
notable I None
potency I None
. I None
<eof> I None

<s> O None
These I None
data I None
may I None
be I None
useful I None
in I None
predicting I None
therapeutic I None
and I None
adverse I None
effects I None
, I None
including I None
drug I None
interactions I None
of I None
neuroleptics I CHEMICAL
. I None
<eof> I None

<s> O None
Disodium I CHEMICAL
cromoglycate O CHEMICAL
does I None
not I None
prevent I None
terbutaline I CHEMICAL
- I None
induced I None
desensitization I None
of I None
beta I GENE-Y
2 O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
- I None
mediated I None
cardiovascular I None
in I None
vivo I None
functions I None
in I None
human I None
volunteers I None
. I None
<eof> I None

<s> O None
In I None
humans I None
, I None
prolonged I None
administration I None
of I None
the I None
beta I GENE-Y
2 O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
agonist I None
terbutaline I CHEMICAL
leads I None
to I None
a I None
desensitization I None
of I None
beta I GENE-Y
2 O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
- I None
mediated I None
cardiovascular I None
responses I None
, I None
which I None
can I None
be I None
blunted I None
by I None
concomitant I None
administration I None
of I None
the I None
antianaphylactic I None
drug I None
ketotifen I CHEMICAL
. I None
<eof> I None

<s> O None
This I None
study I None
investigated I None
the I None
effect I None
of I None
disodium I CHEMICAL
cromoglycate O CHEMICAL
, I None
another I None
antiallergic I None
drug I None
, I None
on I None
terbutaline I CHEMICAL
- I None
induced I None
desensitization I None
of I None
beta I GENE-N
- O GENE-N
adrenoceptor O GENE-N
- I None
mediated I None
cardiovascular I None
and I None
noncardiovascular I None
responses I None
. I None
<eof> I None

<s> O None
In I None
a I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
, I None
randomized I None
design I None
, I None
nine I None
healthy I None
male I None
volunteers I None
received I None
disodium I CHEMICAL
cromoglycate O CHEMICAL
( I None
4 I None
x I None
200 I None
mg I None
/ I None
day I None
, I None
p I None
. I None
o I None
. I None
) I None
or I None
placebo I None
for I None
3 I None
weeks I None
with I None
terbutaline I CHEMICAL
( I None
3 I None
x I None
5 I None
mg I None
/ I None
day I None
, I None
p I None
. I None
o I None
. I None
) I None
administered I None
concomitantly I None
during I None
the I None
last I None
2 I None
weeks I None
. I None
beta I GENE-Y
2 O GENE-Y
- O GENE-Y
Adrenoceptor O GENE-Y
cardiovascular I None
function I None
was I None
assessed I None
by I None
the I None
increase I None
in I None
heart I None
rate I None
and I None
reduction I None
of I None
diastolic I None
blood I None
pressure I None
induced I None
by I None
an I None
incremental I None
intravenous I None
infusion I None
of I None
the I None
unselective I None
beta I GENE-N
- O GENE-N
adrenoceptor O GENE-N
agonist I None
isoprenaline I CHEMICAL
; I None
beta I GENE-Y
1 O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
cardiovascular I None
function I None
was I None
assessed I None
by I None
exercise I None
- I None
induced I None
tachycardia I None
. I None
<eof> I None

<s> O None
Tremulousness I None
was I None
monitored I None
as I None
a I None
beta I GENE-Y
2 O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
- I None
mediated I None
noncardiovascular I None
effect I None
. I None
<eof> I None

<s> O None
After I None
2 I None
weeks I None
' I None
administration I None
of I None
terbutaline I CHEMICAL
, I None
there I None
was I None
a I None
marked I None
and I None
significant I None
( I None
p I None
< I None
0 I None
. I None
001 I None
) I None
attenuation I None
of I None
isoprenaline I CHEMICAL
- I None
induced I None
tachycardia I None
( I None
mean I None
percentage I None
attenuation I None
, I None
53 I None
. I None
3 I None
% I None
) I None
and I None
of I None
the I None
isoprenaline I CHEMICAL
- I None
induced I None
decrease I None
in I None
diastolic I None
blood I None
pressure I None
( I None
mean I None
percentage I None
attenuation I None
, I None
55 I None
. I None
6 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Exercise I None
- I None
induced I None
tachycardia I None
also I None
was I None
significantly I None
( I None
p I None
< I None
0 I None
. I None
001 I None
) I None
blunted I None
, I None
but I None
the I None
magnitude I None
of I None
this I None
attenuation I None
was I None
only I None
very I None
small I None
( I None
mean I None
attenuation I None
, I None
5 I None
. I None
6 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Disodium I CHEMICAL
cromoglycate O CHEMICAL
affected I None
neither I None
the I None
rightward I None
shift I None
of I None
beta I GENE-Y
2 O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
- I None
mediated I None
responses I None
nor I None
the I None
small I None
rightward I None
shift I None
in I None
beta I GENE-Y
1 O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
- I None
mediated I None
exercise I None
tachycardia I None
after I None
2 I None
weeks I None
' I None
administration I None
of I None
terbutaline I CHEMICAL
. I None
<eof> I None

<s> O None
Tremulousness I None
observed I None
during I None
the I None
first I None
few I None
days I None
of I None
terbutaline I CHEMICAL
administration I None
disappeared I None
after I None
4 I None
to I None
8 I None
days I None
, I None
indicating I None
development I None
of I None
desensitization I None
of I None
beta I GENE-Y
2 O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
- I None
mediated I None
noncardiovascular I None
responses I None
. I None
<eof> I None

<s> O None
This I None
was I None
not I None
prevented I None
by I None
disodium I CHEMICAL
cromoglycate O CHEMICAL
. I None
<eof> I None

<s> O None
These I None
results I None
confirm I None
that I None
long I None
- I None
term I None
beta I GENE-Y
2 O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
agonist I None
therapy I None
leads I None
to I None
a I None
desensitization I None
of I None
beta I GENE-Y
2 O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
- I None
mediated I None
cardiovascular I None
and I None
noncardiovascular I None
effects I None
in I None
humans I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
However I None
, I None
unlike I None
ketotifen I CHEMICAL
, I None
cromolyn I CHEMICAL
sodium O CHEMICAL
is I None
not I None
able I None
to I None
attenuate I None
this I None
desensitization I None
. I None
<eof> I None

<s> O None
A I None
multicenter I None
, I None
randomized I None
study I None
of I None
argatroban I CHEMICAL
versus I None
heparin I None
as I None
adjunct I None
to I None
tissue I GENE-Y
plasminogen O GENE-Y
activator O GENE-Y
( I None
TPA I GENE-Y
) I None
in I None
acute I None
myocardial I None
infarction I None
: I None
myocardial I None
infarction I None
with I None
novastan I CHEMICAL
and I None
TPA I GENE-Y
( I None
MINT I None
) I None
study I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
This I None
study I None
examined I None
the I None
effect I None
of I None
a I None
small I None
- I None
molecule I None
, I None
direct I None
thrombin I GENE-Y
inhibitor I None
, I None
argatroban I CHEMICAL
, I None
on I None
reperfusion I None
induced I None
by I None
tissue I GENE-Y
plasminogen O GENE-Y
activator O GENE-Y
( I None
TPA I GENE-Y
) I None
in I None
patients I None
with I None
acute I None
myocardial I None
infarction I None
( I None
AMI I None
) I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Thrombin I GENE-Y
plays I None
a I None
crucial I None
role I None
in I None
thrombosis I None
and I None
thrombolysis I None
. I None
<eof> I None

<s> O None
In I None
vitro I None
and I None
in I None
vivo I None
studies I None
have I None
shown I None
that I None
argatroban I CHEMICAL
has I None
advantages I None
over I None
heparin I None
for I None
the I None
inhibition I None
of I None
clot I None
- I None
bound I None
thrombin I GENE-Y
and I None
for I None
the I None
enhancement I None
of I None
thrombolysis I None
with I None
TPA I GENE-Y
. I None
<eof> I None

<s> O None
METHODS I None
: I None
One I None
hundred I None
and I None
twenty I None
- I None
five I None
patients I None
with I None
AMI I None
within I None
6 I None
h I None
were I None
randomized I None
to I None
heparin I None
, I None
low I None
- I None
dose I None
argatroban I CHEMICAL
or I None
high I None
- I None
dose I None
argatroban I CHEMICAL
in I None
addition I None
to I None
TPA I GENE-Y
. I None
<eof> I None

<s> O None
The I None
primary I None
end I None
point I None
was I None
the I None
rate I None
of I None
thrombolysis I None
in I None
myocardial I None
infarction I None
( I None
TIMI I None
) I None
grade I None
3 I None
flow I None
at I None
90 I None
min I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
TIMI I None
grade I None
3 I None
flow I None
was I None
achieved I None
in I None
42 I None
. I None
1 I None
% I None
of I None
heparin I None
, I None
56 I None
. I None
8 I None
% I None
of I None
low I None
- I None
dose I None
argatroban I CHEMICAL
( I None
p I None
= I None
0 I None
. I None
20 I None
vs I None
. I None
heparin I None
) I None
and I None
58 I None
. I None
7 I None
% I None
of I None
high I None
- I None
dose I None
argatroban I CHEMICAL
patients I None
( I None
p I None
= I None
0 I None
. I None
13 I None
vs I None
. I None
heparin I None
) I None
. I None
<eof> I None

<s> O None
In I None
patients I None
presenting I None
after I None
3 I None
h I None
, I None
TIMI I None
grade I None
3 I None
flow I None
was I None
significantly I None
more I None
frequent I None
in I None
high I None
- I None
dose I None
argatroban I CHEMICAL
versus I None
heparin I None
patients I None
: I None
57 I None
. I None
1 I None
% I None
versus I None
20 I None
. I None
0 I None
% I None
( I None
p I None
= I None
0 I None
. I None
03 I None
vs I None
. I None
heparin I None
) I None
. I None
<eof> I None

<s> O None
Major I None
bleeding I None
was I None
observed I None
in I None
10 I None
. I None
0 I None
% I None
of I None
heparin I None
, I None
and I None
in I None
2 I None
. I None
6 I None
% I None
and I None
4 I None
. I None
3 I None
% I None
of I None
low I None
- I None
dose I None
and I None
high I None
- I None
dose I None
argatroban I CHEMICAL
patients I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
composite I None
of I None
death I None
, I None
recurrent I None
myocardial I None
infarction I None
, I None
cardiogenic I None
shock I None
or I None
congestive I None
heart I None
failure I None
, I None
revascularization I None
and I None
recurrent I None
ischemia I None
at I None
30 I None
days I None
occurred I None
in I None
37 I None
. I None
5 I None
% I None
of I None
heparin I None
, I None
32 I None
. I None
0 I None
% I None
of I None
low I None
- I None
dose I None
argatroban I CHEMICAL
and I None
25 I None
. I None
5 I None
% I None
of I None
high I None
- I None
dose I None
argatroban I CHEMICAL
patients I None
( I None
p I None
= I None
0 I None
. I None
23 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
Argatroban I CHEMICAL
, I None
as I None
compared I None
with I None
heparin I None
, I None
appears I None
to I None
enhance I None
reperfusion I None
with I None
TPA I GENE-Y
in I None
patients I None
with I None
AMI I None
, I None
particularly I None
in I None
those I None
patients I None
with I None
delayed I None
presentation I None
. I None
<eof> I None

<s> O None
The I None
incidences I None
of I None
major I None
bleeding I None
and I None
adverse I None
clinical I None
outcome I None
were I None
lower I None
in I None
the I None
patients I None
receiving I None
argatroban I CHEMICAL
. I None
<eof> I None

<s> O None
Mechanistic I None
differences I None
of I None
various I None
AT1 I GENE-Y
- I None
receptor I None
blockers I None
in I None
isolated I None
vessels I None
of I None
different I None
origin I None
. I None
<eof> I None

<s> O None
The I None
functional I None
inhibitory I None
characteristics I None
of I None
the I None
angiotensin I GENE-N
II O GENE-N
type O GENE-N
1 O GENE-N
receptor O GENE-N
blockers I None
( I None
ARB I None
) I None
candesartan I CHEMICAL
; I None
irbesartan I CHEMICAL
; I None
and I None
losartan I CHEMICAL
and I None
its I None
active I None
metabolite I None
EXP I CHEMICAL
3174 O CHEMICAL
( I None
EXP I CHEMICAL
) I None
were I None
studied I None
in I None
rabbit I None
aortic I None
strips I None
and I None
rat I None
portal I None
vein I None
preparations I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
plasma I None
- I None
protein I None
binding I None
was I None
determined I None
, I None
and I None
the I None
binding I None
was I None
high I None
( I None
> I None
98 I None
. I None
5 I None
% I None
) I None
for I None
all I None
ARBs I None
. I None
<eof> I None

<s> O None
These I None
values I None
were I None
needed I None
to I None
relate I None
the I None
concentrations I None
of I None
the I None
ARBs I None
used I None
in I None
vitro I None
to I None
the I None
nonprotein I None
bound I None
concentrations I None
in I None
clinical I None
use I None
. I None
<eof> I None

<s> O None
In I None
both I None
vascular I None
preparations I None
, I None
candesartan I CHEMICAL
caused I None
a I None
marked I None
decrease I None
in I None
the I None
maximal I None
contractile I None
response I None
of I None
the I None
angiotensin I CHEMICAL
II O CHEMICAL
( I None
Ang I CHEMICAL
II O CHEMICAL
) I None
concentration I None
- I None
response I None
curve I None
. I None
<eof> I None

<s> O None
Losartan I CHEMICAL
, I None
EXP I CHEMICAL
, I None
and I None
irbesartan I CHEMICAL
caused I None
a I None
rightward I None
parallel I None
shift I None
without I None
any I None
major I None
effects I None
on I None
the I None
maximal I None
response I None
to I None
Ang I CHEMICAL
II O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
inhibitory I None
effect I None
of I None
candesartan I CHEMICAL
developed I None
slowly I None
( I None
maximal I None
effect I None
after I None
> I None
30 I None
minutes I None
) I None
and I None
lasted I None
> I None
2 I None
hours I None
despite I None
repeated I None
washing I None
of I None
the I None
vessels I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
losartan I CHEMICAL
, I None
irbesartan I CHEMICAL
, I None
and I None
EXP I CHEMICAL
had I None
a I None
faster I None
onset I None
, I None
and I None
most I None
of I None
the I None
inhibitory I None
effect I None
disappeared I None
after I None
washing I None
. I None
<eof> I None

<s> O None
The I None
duration I None
of I None
the I None
inhibitory I None
effects I None
of I None
the I None
ARBs I None
were I None
not I None
related I None
to I None
lipophilicity I None
of I None
the I None
compounds I None
. I None
<eof> I None

<s> O None
Cooling I None
of I None
the I None
rat I None
portal I None
vein I None
preparations I None
to I None
4 I None
degrees I None
C I None
before I None
administration I None
of I None
candesartan I CHEMICAL
prevented I None
the I None
persistent I None
inhibition I None
of I None
Ang I CHEMICAL
II O CHEMICAL
response I None
seen I None
at I None
37 I None
degrees I None
C I None
. I None
<eof> I None

<s> O None
For I None
the I None
other I None
ARBs I None
studied I None
, I None
the I None
magnitude I None
of I None
inhibition I None
and I None
the I None
speed I None
of I None
recovery I None
of I None
the I None
Ang I CHEMICAL
II O CHEMICAL
response I None
were I None
independent I None
of I None
the I None
incubation I None
temperature I None
before I None
washing I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
when I None
candesartan I CHEMICAL
was I None
given I None
to I None
conscious I None
rats I None
, I None
the I None
inhibitory I None
effect I None
on I None
Ang I CHEMICAL
II O CHEMICAL
- I None
induced I None
blood I None
pressure I None
responses I None
persisted I None
during I None
the I None
24 I None
- I None
hour I None
period I None
despite I None
nondetectable I None
plasma I None
concentrations I None
of I None
candesartan I CHEMICAL
at I None
24 I None
hours I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
functional I None
inhibitory I None
characteristics I None
of I None
candesartan I CHEMICAL
differ I None
from I None
those I None
of I None
the I None
other I None
ARBs I None
tested I None
. I None
<eof> I None

<s> O None
At I None
clinically I None
relevant I None
concentrations I None
, I None
candesartan I CHEMICAL
is I None
an I None
insurmountable I None
and I None
long I None
- I None
lasting I None
antagonist I None
of I None
the I None
vascular I None
contractile I None
responses I None
to I None
Ang I CHEMICAL
II O CHEMICAL
. I None
<eof> I None

<s> O None
Dose I None
- I None
dependent I None
inhibition I None
of I None
platelet I None
cyclooxygenase I GENE-Y
- O GENE-Y
1 O GENE-Y
and I None
monocyte I None
cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
by I None
meloxicam I CHEMICAL
in I None
healthy I None
subjects I None
. I None
<eof> I None

<s> O None
We I None
evaluated I None
whether I None
therapeutic I None
blood I None
levels I None
of I None
meloxicam I CHEMICAL
are I None
associated I None
with I None
selective I None
inhibition I None
of I None
monocyte I None
cyclooxygenase I GENE-Y
( O GENE-Y
COX O GENE-Y
) O GENE-Y
- O GENE-Y
2 O GENE-Y
in I None
vitro I None
and I None
ex I None
vivo I None
. I None
<eof> I None

<s> O None
Concentration I None
- I None
response I None
curves I None
for I None
the I None
inhibition I None
of I None
monocyte I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
and I None
platelet I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
were I None
obtained I None
in I None
vitro I None
after I None
the I None
incubation I None
of I None
meloxicam I CHEMICAL
with I None
whole I None
blood I None
samples I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
11 I None
healthy I None
volunteers I None
received I None
placebo I None
or I None
7 I None
. I None
5 I None
or I None
15 I None
mg I None
/ I None
day I None
meloxicam I CHEMICAL
, I None
each I None
treatment I None
for I None
7 I None
consecutive I None
days I None
, I None
according I None
to I None
a I None
randomized I None
, I None
double I None
- I None
blind I None
, I None
crossover I None
design I None
. I None
<eof> I None

<s> O None
Before I None
dosing I None
and I None
24 I None
h I None
after I None
the I None
seventh I None
dose I None
of I None
each I None
regimen I None
, I None
heparinized I None
whole I None
blood I None
samples I None
were I None
incubated I None
with I None
lipopolysaccharide I None
( I None
10 I None
microgram I None
/ I None
ml I None
) I None
for I None
24 I None
h I None
at I None
37 I None
degrees I None
C I None
, I None
and I None
prostaglandin I CHEMICAL
E2 O CHEMICAL
was I None
measured I None
in I None
plasma I None
as I None
an I None
index I None
of I None
monocyte I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
activity I None
. I None
<eof> I None

<s> O None
The I None
production I None
of I None
thromboxane I CHEMICAL
B2 O CHEMICAL
in I None
whole I None
blood I None
allowed I None
to I None
clot I None
at I None
37 I None
degrees I None
C I None
for I None
60 I None
min I None
was I None
assessed I None
as I None
an I None
index I None
of I None
platelet I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
activity I None
. I None
<eof> I None

<s> O None
The I None
administration I None
of I None
placebo I None
did I None
not I None
significantly I None
affect I None
plasma I None
prostaglandin I CHEMICAL
E2 O CHEMICAL
( I None
21 I None
. I None
3 I None
+ I None
/ I None
- I None
7 I None
. I None
5 I None
versus I None
19 I None
. I None
1 I None
+ I None
/ I None
- I None
4 I None
ng I None
/ I None
ml I None
, I None
mean I None
+ I None
/ I None
- I None
S I None
. I None
D I None
. I None
, I None
n I None
= I None
11 I None
) I None
or I None
serum I None
thromboxane I CHEMICAL
B2 O CHEMICAL
( I None
426 I None
+ I None
/ I None
- I None
167 I None
versus I None
425 I None
+ I None
/ I None
- I None
150 I None
ng I None
/ I None
ml I None
) I None
levels I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
administration I None
of I None
7 I None
. I None
5 I None
and I None
15 I None
mg I None
of I None
meloxicam I CHEMICAL
caused I None
dose I None
- I None
dependent I None
reductions I None
in I None
monocyte I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
activity I None
by I None
51 I None
% I None
and I None
70 I None
% I None
, I None
respectively I None
, I None
and I None
in I None
platelet I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
activity I None
by I None
25 I None
% I None
and I None
35 I None
% I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Although I None
the I None
IC50 I None
value I None
of I None
meloxicam I CHEMICAL
for I None
inhibition I None
of I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
was I None
10 I None
- I None
fold I None
higher I None
than I None
the I None
IC50 I None
value I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
in I None
vitro I None
, I None
this I None
biochemical I None
selectivity I None
was I None
inadequate I None
to I None
clearly I None
separate I None
the I None
effects I None
of I None
meloxicam I CHEMICAL
on I None
the I None
two I None
isozymes I None
after I None
oral I None
dosing I None
as I None
a I None
function I None
of I None
the I None
daily I None
dose I None
and I None
interindividual I None
variation I None
in I None
steady I None
- I None
state I None
plasma I None
levels I None
. I None
<eof> I None

<s> O None
Modulation I None
of I None
dialysate I None
levels I None
of I None
dopamine I CHEMICAL
, I None
noradrenaline I CHEMICAL
, I None
and I None
serotonin I CHEMICAL
( I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
) I None
in I None
the I None
frontal I None
cortex I None
of I None
freely I None
- I None
moving I None
rats I None
by I None
( I CHEMICAL
- O CHEMICAL
) O CHEMICAL
- O CHEMICAL
pindolol O CHEMICAL
alone I None
and I None
in I None
association I None
with I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
reuptake I None
inhibitors I None
: I None
comparative I None
roles I None
of I None
beta I None
- I None
adrenergic I None
, I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
, O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptors I None
. I None
<eof> I None

<s> O None
( I CHEMICAL
- O CHEMICAL
) O CHEMICAL
- O CHEMICAL
Pindolol O CHEMICAL
, I None
which I None
possesses I None
significant I None
affinity I None
for I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
, I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
, I None
and I None
beta I GENE-N
1 O GENE-N
/ O GENE-N
2 O GENE-N
- O GENE-N
adrenergic O GENE-N
receptors O GENE-N
( I GENE-N
AR O GENE-N
) O GENE-N
s O GENE-N
, I None
dose I None
- I None
dependently I None
increased I None
extracellular I None
levels I None
of I None
dopamine I CHEMICAL
( I None
DA I CHEMICAL
) I None
and I None
noradrenaline I CHEMICAL
( I None
NAD I CHEMICAL
) I None
versus I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
, I None
in I None
dialysates I None
of I None
the I None
frontal I None
cortex I None
( I None
FCX I None
) I None
, I None
but I None
not I None
accumbens I None
and I None
striatum I None
, I None
of I None
freely I None
- I None
moving I None
rats I None
. I None
<eof> I None

<s> O None
In I None
distinction I None
, I None
the I None
preferential I None
beta I GENE-Y
1 O GENE-Y
- O GENE-Y
AR O GENE-Y
antagonist I None
, I None
betaxolol I CHEMICAL
, I None
and I None
the I None
preferential I None
beta I GENE-Y
2 O GENE-Y
- O GENE-Y
AR O GENE-Y
antagonist I None
, I None
ICI118 I CHEMICAL
, O CHEMICAL
551 O CHEMICAL
, I None
did I None
not I None
increase I None
basal I None
levels I None
of I None
DA I CHEMICAL
, I None
NAD I CHEMICAL
, I None
or I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
. I None
<eof> I None

<s> O None
Further I None
, I None
they I None
both I None
dose I None
- I None
dependently I None
and I None
markedly I None
blunted I None
the I None
influence I None
of I None
( I CHEMICAL
- O CHEMICAL
) O CHEMICAL
- O CHEMICAL
pindolol O CHEMICAL
upon I None
DA I CHEMICAL
and I None
NAD I CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
The I None
selective I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
receptor I None
antagonist I None
, I None
WAY100 I CHEMICAL
, O CHEMICAL
635 O CHEMICAL
, I None
slightly I None
attenuated I None
the I None
( I CHEMICAL
- O CHEMICAL
) O CHEMICAL
- O CHEMICAL
pindolol O CHEMICAL
- I None
induced I None
increase I None
in I None
DA I CHEMICAL
and I None
NAD I CHEMICAL
levels I None
, I None
while I None
the I None
selective I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
antagonist I None
, I None
SB224 I CHEMICAL
, O CHEMICAL
289 O CHEMICAL
, I None
was I None
ineffective I None
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
that I None
( I CHEMICAL
- O CHEMICAL
) O CHEMICAL
- O CHEMICAL
pindolol O CHEMICAL
facilitates I None
frontocortical I None
dopaminergic I None
( I None
and I None
adrenergic I None
) I None
transmission I None
primarily I None
by I None
activation I None
of I None
beta I GENE-N
1 O GENE-N
/ O GENE-N
2 O GENE-N
- O GENE-N
ARs O GENE-N
and I None
, I None
to I None
a I None
lesser I None
degree I None
, I None
by I None
stimulation I None
of I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
receptors I None
, I None
whereas I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptors I None
are I None
not I None
involved I None
. I None
<eof> I None

<s> O None
( I CHEMICAL
- O CHEMICAL
) O CHEMICAL
- O CHEMICAL
Pindolol O CHEMICAL
potentiated I None
the I None
increase I None
in I None
FCX I None
levels I None
of I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
elicited I None
by I None
the I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
reuptake I None
inhibitors I None
, I None
fluoxetine I CHEMICAL
and I None
duloxetine I CHEMICAL
, I None
and I None
also I None
enhanced I None
their I None
ability I None
to I None
elevate I None
FCX I None
levels I None
of I None
DA I CHEMICAL
- I None
- I None
though I None
not I None
of I None
NAD I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
contrast I None
to I None
( I CHEMICAL
- O CHEMICAL
) O CHEMICAL
- O CHEMICAL
pindolol O CHEMICAL
, I None
betaxolol I CHEMICAL
and I None
ICI118 I CHEMICAL
, O CHEMICAL
551 O CHEMICAL
did I None
not I None
affect I None
the I None
actions I None
of I None
fluoxetine I CHEMICAL
, I None
whereas I None
both I None
WAY100 I CHEMICAL
, O CHEMICAL
635 O CHEMICAL
and I None
SB224 I CHEMICAL
, O CHEMICAL
289 O CHEMICAL
potentiated I None
the I None
increase I None
in I None
levels I None
of I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
- I None
- I None
but I None
not I None
DA I CHEMICAL
or I None
NAD I CHEMICAL
levels I None
- I None
- I None
elicited I None
by I None
fluoxetine I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
( I CHEMICAL
- O CHEMICAL
) O CHEMICAL
- O CHEMICAL
pindolol O CHEMICAL
modulates I None
, I None
both I None
alone I None
and I None
together I None
with I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
reuptake I None
inhibitors I None
, I None
dopaminergic I None
, I None
adrenergic I None
, I None
and I None
serotonergic I None
transmission I None
in I None
the I None
FCX I None
via I None
a I None
complex I None
pattern I None
of I None
actions I None
at I None
beta I GENE-N
1 O GENE-N
/ O GENE-N
2 O GENE-N
- O GENE-N
ARs O GENE-N
, I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
, I None
and I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptors I None
. I None
<eof> I None

<s> O None
These I None
findings I None
have I None
important I None
implications I None
for I None
clinical I None
studies I None
of I None
the I None
influence I None
of I None
( I CHEMICAL
- O CHEMICAL
) O CHEMICAL
- O CHEMICAL
pindolol O CHEMICAL
upon I None
the I None
actions I None
of I None
antidepressant I None
agents I None
. I None
<eof> I None

<s> O None
Entacapone I CHEMICAL
. I None
<eof> I None

<s> O None
A I None
review I None
of I None
its I None
use I None
in I None
Parkinson I None
' I None
s I None
disease I None
. I None
<eof> I None

<s> O None
UNLABELLED I None
: I None
Entacapone I CHEMICAL
is I None
a I None
potent I None
and I None
specific I None
peripheral I None
catechol I GENE-Y
- O GENE-Y
O O GENE-Y
- O GENE-Y
methyltransferase O GENE-Y
( I None
COMT I GENE-Y
) I None
inhibitor I None
. I None
<eof> I None

<s> O None
It I None
has I None
been I None
shown I None
to I None
improve I None
the I None
clinical I None
benefits I None
of I None
levodopa I CHEMICAL
plus I None
an I None
aromatic I GENE-Y
L O GENE-Y
- O GENE-Y
amino O GENE-Y
acid O GENE-Y
decarboxylase O GENE-Y
inhibitor I None
( I None
AADC I GENE-Y
) I None
when I None
given I None
to I None
patients I None
with I None
Parkinson I None
' I None
s I None
disease I None
and I None
end I None
- I None
of I None
- I None
dose I None
deterioration I None
in I None
the I None
response I None
to I None
levodopa I CHEMICAL
( I None
the I None
' I None
wearing I None
off I None
' I None
phenomenon I None
) I None
. I None
<eof> I None

<s> O None
The I None
efficacy I None
of I None
entacapone I CHEMICAL
is I None
currently I None
being I None
assessed I None
in I None
patients I None
with I None
stable I None
Parkinson I None
' I None
s I None
disease I None
. I None
<eof> I None

<s> O None
In I None
2 I None
well I None
conducted I None
trials I None
of I None
6 I None
months I None
' I None
duration I None
and I None
smaller I None
short I None
term I None
studies I None
, I None
treatment I None
with I None
entacapone I CHEMICAL
( I None
200 I None
mg I None
with I None
each I None
dose I None
of I None
levodopa I CHEMICAL
/ I None
AADC I GENE-Y
inhibitor I None
) I None
was I None
associated I None
with I None
significant I None
increases I None
in I None
daily I None
' I None
on I None
' I None
time I None
and I None
decreases I None
in I None
' I None
off I None
' I None
time I None
. I None
<eof> I None

<s> O None
Changes I None
in I None
Unified I None
Parkinson I None
' I None
s I None
Disease I None
Rating I None
Scale I None
( I None
UPDRS I None
) I None
scores I None
concurred I None
with I None
changes I None
in I None
' I None
on I None
' I None
and I None
' I None
off I None
' I None
times I None
: I None
entacapone I CHEMICAL
improved I None
total I None
, I None
activities I None
of I None
daily I None
living I None
and I None
motor I None
function I None
scores I None
, I None
but I None
it I None
had I None
no I None
effect I None
on I None
mentation I None
scores I None
. I None
<eof> I None

<s> O None
Entacapone I CHEMICAL
also I None
provided I None
benefits I None
when I None
given I None
with I None
controlled I None
release I None
levodopa I CHEMICAL
/ I None
AADC I GENE-Y
inhibitor I None
or I None
with I None
standard I None
levodopa I CHEMICAL
/ I None
AADC I GENE-Y
inhibitor I None
and I None
selegiline I CHEMICAL
in I None
small I None
trials I None
. I None
<eof> I None

<s> O None
Dopaminergic I None
events I None
, I None
including I None
dyskinesia I None
and I None
nausea I None
, I None
are I None
among I None
the I None
most I None
common I None
events I None
with I None
entacapone I CHEMICAL
, I None
and I None
are I None
related I None
to I None
the I None
drug I None
' I None
s I None
ability I None
to I None
potentiate I None
the I None
effects I None
of I None
levodopa I CHEMICAL
. I None
<eof> I None

<s> O None
Diarrhoea I None
, I None
abdominal I None
pain I None
, I None
constipation I None
and I None
urine I None
discolouration I None
are I None
the I None
most I None
common I None
nondopaminergic I None
events I None
, I None
although I None
the I None
latter I None
event I None
is I None
the I None
only I None
one I None
to I None
occur I None
consistently I None
more I None
frequently I None
with I None
entacapone I None
than I None
with I None
placebo I None
. I None
<eof> I None

<s> O None
However I None
, I None
adverse I None
events I None
of I None
any I None
type I None
infrequently I None
led I None
to I None
study I None
discontinuation I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
The I None
efficacy I None
and I None
tolerability I None
of I None
entacapone I None
administered I None
with I None
levodopa I CHEMICAL
/ I None
AADC I GENE-Y
inhibitor I None
have I None
not I None
yet I None
been I None
compared I None
with I None
those I None
of I None
other I None
strategies I None
for I None
the I None
treatment I None
of I None
Parkinson I None
' I None
s I None
disease I None
. I None
<eof> I None

<s> O None
However I None
, I None
once I None
the I None
decision I None
to I None
initiate I None
levodopa I CHEMICAL
therapy I None
has I None
been I None
made I None
, I None
studies I None
generally I None
support I None
the I None
use I None
of I None
entacapone I None
as I None
an I None
adjunct I None
to I None
levodopa I CHEMICAL
in I None
patients I None
with I None
Parkinson I None
' I None
s I None
disease I None
and I None
the I None
' I None
wearing I None
off I None
' I None
phenomenon I None
. I None
<eof> I None

<s> O None
5 I CHEMICAL
- O CHEMICAL
hydroxytryptamine O CHEMICAL
evokes I None
endothelial I GENE-Y
nitric O GENE-Y
oxide O GENE-Y
synthase O GENE-Y
activation I None
in I None
bovine I None
aortic I None
endothelial I None
cell I None
cultures I None
. I None
<eof> I None

<s> O None
Activation I None
of I None
endothelial I GENE-Y
nitric O GENE-Y
oxide O GENE-Y
synthase O GENE-Y
( I None
eNOS I GENE-Y
) I None
results I None
in I None
the I None
production I None
of I None
nitric I CHEMICAL
oxide O CHEMICAL
( I None
NO I CHEMICAL
) I None
that I None
mediates I None
the I None
vasorelaxing I None
properties I None
of I None
endothelial I None
cells I None
. I None
<eof> I None

<s> O None
The I None
goal I None
of I None
this I None
project I None
was I None
to I None
address I None
the I None
possibility I None
that I None
5 I CHEMICAL
- O CHEMICAL
hydroxytryptamine O CHEMICAL
( I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
) I None
stimulates I None
eNOS I GENE-Y
activity I None
in I None
bovine I None
aortic I None
endothelial I None
cell I None
( I None
BAEC I None
) I None
cultures I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
tested I None
the I None
hypothesis I None
that I None
5 I GENE-N
- O GENE-N
HT O GENE-N
receptors O GENE-N
mediate I None
eNOS I GENE-Y
activation I None
by I None
measuring I None
agonist I None
- I None
stimulated I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
L O CHEMICAL
- O CHEMICAL
citrulline O CHEMICAL
( I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
L O CHEMICAL
- O CHEMICAL
Cit O CHEMICAL
) I None
formation I None
in I None
BAEC I None
cultures I None
. I None
<eof> I None

<s> O None
We I None
found I None
that I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
stimulated I None
the I None
conversion I None
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
L O CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
( I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
L O CHEMICAL
- O CHEMICAL
Arg O CHEMICAL
) I None
to I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
L O CHEMICAL
- O CHEMICAL
Cit O CHEMICAL
, I None
indicating I None
eNOS I GENE-Y
activation I None
. I None
<eof> I None

<s> O None
The I None
high I None
affinity I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptor I None
agonist I None
, I None
5 I CHEMICAL
- O CHEMICAL
nonyloxytryptamine O CHEMICAL
( I None
5 I None
- I None
NOT I None
) I None
- I None
stimulated I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
L O CHEMICAL
- O CHEMICAL
Cit O CHEMICAL
turnover I None
responses I None
were I None
concentration I None
- I None
( I None
0 I None
. I None
01 I None
nM I None
to I None
100 I None
microM I None
) I None
and I None
time I None
- I None
dependent I None
. I None
<eof> I None

<s> O None
Maximal I None
responses I None
were I None
observed I None
within I None
10 I None
min I None
following I None
agonist I None
exposures I None
. I None
<eof> I None

<s> O None
These I None
responses I None
were I None
effectively I None
blocked I None
by I None
the I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptor I None
antagonist I None
, I None
isamoltane I None
, I None
the I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
/ I None
5 I GENE-N
- O GENE-N
HT2 O GENE-N
receptor O GENE-N
antagonist I None
, I None
methiothepin I CHEMICAL
, I None
and I None
the I None
eNOS I GENE-Y
selective I None
antagonists I None
( I None
0 I None
. I None
01 I None
- I None
10 I None
microM I None
) I None
: I None
L I CHEMICAL
- O CHEMICAL
Nomega O CHEMICAL
- O CHEMICAL
monomethyl O CHEMICAL
- O CHEMICAL
L O CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
( I None
L I CHEMICAL
- O CHEMICAL
NMMA O CHEMICAL
) I None
and I None
L I CHEMICAL
- O CHEMICAL
N O CHEMICAL
omega O CHEMICAL
- O CHEMICAL
iminoethyl O CHEMICAL
- O CHEMICAL
L O CHEMICAL
- O CHEMICAL
ornithine O CHEMICAL
( I None
L I CHEMICAL
- O CHEMICAL
NIO O CHEMICAL
) I None
. I None
<eof> I None

<s> O None
Pretreatment I None
of I None
BAEC I None
cultures I None
with I None
pertussis I GENE-N
toxin O GENE-N
( I None
PTX I GENE-N
; I None
1 I None
- I None
100 I None
ng I None
/ I None
ml I None
) I None
for I None
16 I None
hr I None
resulted I None
in I None
significant I None
inhibition I None
of I None
the I None
agonist I None
- I None
stimulated I None
eNOS I GENE-Y
activity I None
, I None
indicating I None
the I None
involvement I None
of I None
Gi I GENE-N
proteins O GENE-N
. I None
<eof> I None

<s> O None
These I None
findings I None
lend I None
evidence I None
of I None
a I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptor I None
/ I None
eNOS I GENE-Y
pathway I None
, I None
accounting I None
in I None
part I None
for I None
the I None
activation I None
of I None
eNOS I GENE-Y
by I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
. I None
<eof> I None

<s> O None
Further I None
investigation I None
is I None
needed I None
to I None
determine I None
the I None
role I None
of I None
other I None
vascular I None
5 I GENE-N
- O GENE-N
HT O GENE-N
receptors O GENE-N
in I None
the I None
stimulation I None
of I None
eNOS I GENE-Y
activity I None
. I None
<eof> I None

<s> O None
Caffeine I CHEMICAL
inhibits I None
the I None
checkpoint I None
kinase I GENE-N
ATM I GENE-Y
. I None
<eof> I None

<s> O None
The I None
basis I None
of I None
many I None
anti I None
- I None
cancer I None
therapies I None
is I None
the I None
use I None
of I None
genotoxic I None
agents I None
that I None
damage I None
DNA I None
and I None
thus I None
kill I None
dividing I None
cells I None
. I None
<eof> I None

<s> O None
Agents I None
that I None
cause I None
cells I None
to I None
override I None
the I None
DNA I None
- I None
damage I None
checkpoint I None
are I None
predicted I None
to I None
sensitize I None
cells I None
to I None
killing I None
by I None
genotoxic I None
agents I None
. I None
<eof> I None

<s> O None
They I None
have I None
therefore I None
been I None
sought I None
as I None
adjuncts I None
in I None
radiation I None
therapy I None
and I None
chemotherapy I None
. I None
<eof> I None

<s> O None
One I None
such I None
compound I None
, I None
caffeine I CHEMICAL
, I None
uncouples I None
cell I None
- I None
cycle I None
progression I None
from I None
the I None
replication I None
and I None
repair I None
of I None
DNA I None
[ I None
1 I None
] I None
[ I None
2 I None
] I None
. I None
<eof> I None

<s> O None
Caffeine I CHEMICAL
therefore I None
servers I None
as I None
a I None
model I None
compound I None
in I None
establishing I None
the I None
principle I None
that I None
agents I None
that I None
override I None
DNA I None
- I None
damage I None
checkpoints I None
can I None
be I None
used I None
to I None
sensitize I None
cells I None
to I None
the I None
killing I None
effects I None
of I None
genotoxic I None
drugs I None
[ I None
3 I None
] I None
. I None
<eof> I None

<s> O None
But I None
despite I None
more I None
than I None
20 I None
years I None
of I None
use I None
, I None
the I None
molecular I None
mechanisms I None
by I None
which I None
caffeine I None
affects I None
the I None
cell I None
cycle I None
and I None
checkpoint I None
responses I None
have I None
not I None
been I None
identified I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
effects I None
of I None
caffeine I None
on I None
the I None
G2 I None
/ I None
M I None
DNA I None
- I None
damage I None
checkpoint I None
in I None
human I None
cells I None
. I None
<eof> I None

<s> O None
We I None
report I None
that I None
the I None
radiation I None
- I None
induced I None
activation I None
of I None
the I None
kinase I GENE-N
Cds1 I GENE-Y
[ I None
4 I None
] I None
( I None
also I None
known I None
as I None
Chk2 I GENE-Y
[ I None
5 I None
] I None
) I None
is I None
inhibited I None
by I None
caffeine I CHEMICAL
in I None
vivo I None
and I None
that I None
ATM I GENE-Y
kinase I GENE-N
activity I None
is I None
directly I None
inhibited I None
by I None
caffeine I CHEMICAL
in I None
vitro I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
ATM I GENE-Y
provides I None
a I None
molecular I None
explanation I None
of I None
the I None
attenuation I None
of I None
DNA I None
- I None
damage I None
checkpoint I None
responses I None
and I None
for I None
the I None
increased I None
radiosensitivity I None
of I None
caffeine I CHEMICAL
- I None
treated I None
cells I None
[ I None
6 I None
] I None
[ I None
7 I None
] I None
[ I None
8 I None
] I None
. I None
<eof> I None

<s> O None
Serotonin I GENE-Y
transporter O GENE-Y
production I None
and I None
degradation I None
rates I None
: I None
studies I None
with I None
RTI I CHEMICAL
- O CHEMICAL
76 O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
objective I None
of I None
this I None
study I None
was I None
to I None
examine I None
the I None
turnover I None
of I None
the I None
serotonin I GENE-Y
transporter O GENE-Y
( I None
SERT I GENE-Y
) I None
by I None
determining I None
its I None
production I None
rate I None
( I None
r I None
) I None
, I None
degradation I None
rate I None
constant I None
( I None
k I None
) I None
and I None
half I None
- I None
life I None
of I None
recovery I None
( I None
t1 I None
/ I None
2 I None
) I None
. I None
<eof> I None

<s> O None
The I None
turnover I None
of I None
SERT I GENE-Y
was I None
determined I None
from I None
the I None
rate I None
of I None
recovery I None
of I None
binding I None
after I None
administration I None
of I None
RTI I CHEMICAL
- O CHEMICAL
76 O CHEMICAL
, I None
an I None
irreversible I None
inhibitor I None
of I None
ligand I None
binding I None
. I None
<eof> I None

<s> O None
In I None
preliminary I None
studies I None
, I None
in I None
vitro I None
incubation I None
of I None
rat I None
cerebral I None
cortex I None
with I None
RTI I CHEMICAL
- O CHEMICAL
76 O CHEMICAL
produced I None
a I None
wash I None
and I None
temperature I None
resistant I None
inhibition I None
of I None
SERT I GENE-Y
binding I None
densities I None
( I None
Bmax I None
) I None
. I None
<eof> I None

<s> O None
Citalopram I CHEMICAL
protected I None
against I None
the I None
RTI I CHEMICAL
- O CHEMICAL
76 O CHEMICAL
- I None
induced I None
inhibition I None
of I None
SERT I GENE-Y
binding I None
. I None
<eof> I None

<s> O None
Following I None
6 I None
h I None
of I None
in I None
vivo I None
intracerebroventricular I None
injections I None
of I None
100 I None
nmol I None
of I None
RTI I CHEMICAL
- O CHEMICAL
76 O CHEMICAL
, I None
there I None
was I None
a I None
dose I None
- I None
and I None
time I None
- I None
dependent I None
reduction I None
( I None
- I None
60 I None
% I None
) I None
of I None
SERT I GENE-Y
binding I None
in I None
hippocampus I None
and I None
striatum I None
, I None
without I None
a I None
change I None
in I None
the I None
Kd I None
. I None
<eof> I None

<s> O None
SERT I GENE-Y
binding I None
densities I None
recovered I None
over I None
several I None
days I None
, I None
reaching I None
control I None
levels I None
by I None
day I None
14 I None
. I None
<eof> I None

<s> O None
The I None
recovery I None
curve I None
fit I None
the I None
standard I None
model I None
of I None
protein I None
synthesis I None
and I None
degradation I None
. I None
<eof> I None

<s> O None
The I None
turnover I None
parameters I None
of I None
SERT I GENE-Y
were I None
determined I None
in I None
hippocampus I None
and I None
striatum I None
, I None
regions I None
that I None
receive I None
serotonergic I None
innervation I None
from I None
the I None
dorsal I None
and I None
median I None
midbrain I None
raphe I None
nuclei I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
In I None
the I None
hippocampus I None
, I None
the I None
production I None
rate I None
constant I None
was I None
2 I None
. I None
36 I None
fmol I None
mg I None
protein I None
( I None
- I None
1 I None
) I None
h I None
( I None
- I None
1 I None
) I None
; I None
the I None
degradation I None
rate I None
constant I None
was I None
0 I None
. I None
0077 I None
h I None
( I None
- I None
1 I None
) I None
; I None
and I None
the I None
half I None
- I None
life I None
of I None
the I None
SERT I GENE-Y
recovery I None
was I None
3 I None
. I None
4 I None
days I None
. I None
<eof> I None

<s> O None
The I None
values I None
in I None
the I None
striatum I None
were I None
similar I None
. I None
<eof> I None

<s> O None
The I None
decrease I None
and I None
recovery I None
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
HT O CHEMICAL
uptake I None
correlated I None
highly I None
( I None
r I None
= I None
0 I None
. I None
93 I None
) I None
with I None
the I None
recovery I None
of I None
SERT I GENE-Y
binding I None
. I None
<eof> I None

<s> O None
Cannabis I None
and I None
cannabinoids I None
: I None
pharmacology I None
and I None
rationale I None
for I None
clinical I None
use I None
. I None
<eof> I None

<s> O None
It I None
is I None
now I None
known I None
that I None
there I None
are I None
at I None
least I None
two I None
types I None
of I None
cannabinoid I GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
These I None
are I None
CB1 I GENE-Y
receptors I None
, I None
present I None
mainly I None
on I None
central I None
and I None
peripheral I None
neurones I None
, I None
and I None
CB2 I GENE-Y
receptors I None
, I None
present I None
mainly I None
on I None
immune I None
cells I None
. I None
<eof> I None

<s> O None
Endogenous I None
cannabinoid I GENE-N
receptor O GENE-N
agonists I None
( I None
' I None
endocannabinoids I None
' I None
) I None
have I None
also I None
been I None
identified I None
. I None
<eof> I None

<s> O None
The I None
discovery I None
of I None
this I None
' I None
endogenous I None
cannabinoid I None
system I None
' I None
has I None
led I None
to I None
the I None
development I None
of I None
selective I None
CB1 I GENE-Y
and I None
CB2 I GENE-Y
receptor I None
ligands I None
and I None
fueled I None
renewed I None
interest I None
in I None
the I None
clinical I None
potential I None
of I None
cannabinoids I None
. I None
<eof> I None

<s> O None
Two I None
cannabinoid I None
CB1 I GENE-Y
receptor I None
agonists I None
are I None
already I None
used I None
clinically I None
, I None
as I None
antiemetics I None
or I None
as I None
appetite I None
stimulants I None
. I None
<eof> I None

<s> O None
These I None
are I None
D I CHEMICAL
9 O CHEMICAL
- O CHEMICAL
tetrahydrocannabinol O CHEMICAL
( I None
THC I CHEMICAL
) I None
and I None
nabilone I CHEMICAL
. I None
<eof> I None

<s> O None
Other I None
possible I None
uses I None
for I None
CB1 I GENE-Y
receptor I None
agonists I None
include I None
the I None
suppression I None
of I None
muscle I None
spasm I None
/ I None
spasticity I None
associated I None
with I None
multiple I None
sclerosis I None
or I None
spinal I None
cord I None
injury I None
, I None
the I None
relief I None
of I None
chronic I None
pain I None
and I None
the I None
management I None
of I None
glaucoma I None
and I None
bronchial I None
asthma I None
. I None
<eof> I None

<s> O None
CB1 I GENE-Y
receptor I None
antagonists I None
may I None
also I None
have I None
clinical I None
applications I None
, I None
e I None
. I None
g I None
. I None
as I None
appetite I None
suppressants I None
and I None
in I None
the I None
management I None
of I None
schizophrenia I None
or I None
disorders I None
of I None
cognition I None
and I None
memory I None
. I None
<eof> I None

<s> O None
So I None
too I None
may I None
CB2 I GENE-Y
receptor I None
ligands I None
and I None
drugs I None
that I None
activate I None
cannabinoid I GENE-N
receptors O GENE-N
indirectly I None
by I None
augmenting I None
endocannabinoid I None
levels I None
at I None
cannabinoid I GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
When I None
taken I None
orally I None
, I None
THC I CHEMICAL
seems I None
to I None
undergo I None
variable I None
absorption I None
and I None
to I None
have I None
a I None
narrow I None
' I None
therapeutic I None
window I None
' I None
( I None
dose I None
range I None
in I None
which I None
it I None
is I None
effective I None
without I None
producing I None
significant I None
unwanted I None
effects I None
) I None
. I None
<eof> I None

<s> O None
This I None
makes I None
it I None
difficult I None
to I None
predict I None
an I None
oral I None
dose I None
that I None
will I None
be I None
both I None
effective I None
and I None
tolerable I None
to I None
a I None
patient I None
and I None
indicates I None
a I None
need I None
for I None
better I None
cannabinoid I None
formulations I None
and I None
modes I None
of I None
administration I None
. I None
<eof> I None

<s> O None
For I None
the I None
therapeutic I None
potential I None
of I None
cannabis I None
or I None
CB1 I GENE-Y
receptor I None
agonists I None
to I None
be I None
fully I None
exploited I None
, I None
it I None
will I None
be I None
important I None
to I None
establish I None
objectively I None
and I None
conclusively I None
( I None
a I None
) I None
whether I None
these I None
agents I None
have I None
efficacy I None
against I None
selected I None
symptoms I None
that I None
is I None
of I None
clinical I None
significance I None
and I None
, I None
if I None
so I None
, I None
whether I None
the I None
benefits I None
outweigh I None
the I None
risks I None
, I None
( I None
b I None
) I None
whether I None
cannabis I None
has I None
therapeutic I None
advantages I None
over I None
individual I None
cannabinoids I None
, I None
( I None
c I None
) I None
whether I None
there I None
is I None
a I None
need I None
for I None
additional I None
drug I None
treatments I None
to I None
manage I None
any I None
of I None
the I None
disorders I None
against I None
which I None
cannabinoids I None
are I None
effective I None
, I None
and I None
( I None
d I None
) I None
whether I None
it I None
will I None
be I None
possible I None
to I None
develop I None
drugs I None
that I None
have I None
reduced I None
psychotropic I None
activity I None
and I None
yet I None
retain I None
the I None
ability I None
to I None
act I None
through I None
CB1 I GENE-Y
receptors I None
to I None
produce I None
their I None
sought I None
- I None
after I None
effects I None
. I None
<eof> I None

<s> O None
Pharmacological I None
properties I None
of I None
angiotensin I GENE-N
II O GENE-N
receptor O GENE-N
antagonists I None
. I None
<eof> I None

<s> O None
The I None
availability I None
of I None
selective I None
, I None
potent I None
, I None
orally I None
active I None
and I None
long I None
acting I None
nonpeptide I None
angiotensin I GENE-Y
II O GENE-Y
type O GENE-Y
1 O GENE-Y
( O GENE-Y
AT1 O GENE-Y
) O GENE-Y
receptor O GENE-Y
antagonists I None
has I None
provided I None
the I None
opportunity I None
to I None
obtain I None
the I None
benefits I None
of I None
selectively I None
blocking I None
the I None
renin I GENE-Y
- I None
angiotensin I CHEMICAL
- I None
aldosterone I CHEMICAL
system I None
at I None
the I None
level I None
of I None
the I None
AT1 I GENE-Y
receptor I None
that I None
mediates I None
most I None
, I None
if I None
not I None
all I None
, I None
of I None
the I None
important I None
actions I None
of I None
angiotensin I CHEMICAL
II O CHEMICAL
, I None
and I None
avoid I None
the I None
nonspecificity I None
of I None
the I None
angiotensin I GENE-Y
I O GENE-Y
converting O GENE-Y
enzyme O GENE-Y
inhibitors I None
. I None
<eof> I None

<s> O None
Losartan I CHEMICAL
was I None
the I None
first I None
, I None
but I None
by I None
no I None
means I None
remained I None
the I None
only I None
, I None
AT1 I GENE-Y
receptor I None
antagonist I None
. I None
<eof> I None

<s> O None
Numerous I None
other I None
' I None
sartans I None
' I None
have I None
emerged I None
in I None
the I None
past I None
several I None
years I None
and I None
successfully I None
completed I None
clinical I None
development I None
. I None
<eof> I None

<s> O None
With I None
the I None
exception I None
of I None
eprosartan I CHEMICAL
, I None
all I None
others I None
, I None
ie I None
, I None
candesartan I CHEMICAL
, I None
irbesartan I CHEMICAL
, I None
saprisartan I CHEMICAL
, I None
tasosartan I CHEMICAL
, I None
telmisartan I CHEMICAL
, I None
valsartan I CHEMICAL
and I None
zolasartan I CHEMICAL
, I None
are I None
based I None
on I None
medications I None
of I None
losartan I None
' I None
s I None
prototypical I None
chemical I None
structure I None
. I None
<eof> I None

<s> O None
Among I None
the I None
current I None
AT1 I GENE-Y
receptor I None
antagonists I None
, I None
the I None
rank I None
order I None
of I None
the I None
relative I None
binding I None
affinities I None
( I None
highest I None
affinity I None
= I None
1 I None
) I None
is I None
: I None
candesartan I CHEMICAL
1 I None
, I None
telmisartan I CHEMICAL
10 I None
, I None
E3174 I CHEMICAL
( I None
the I None
active I None
metabolite I None
of I None
losartan I CHEMICAL
) I None
10 I None
, I None
tasosartan I CHEMICAL
20 I None
, I None
losartan I CHEMICAL
50 I None
, I None
eprosartan I CHEMICAL
100 I None
and I None
the I None
prodrug I None
candesartan I CHEMICAL
cilexetil O CHEMICAL
280 I None
. I None
<eof> I None

<s> O None
The I None
mode I None
of I None
( I None
functional I None
) I None
AT1 I GENE-Y
receptor I None
antagonism I None
has I None
been I None
characterized I None
as I None
surmountable I None
/ I None
noncompetitive I None
( I None
losartan I CHEMICAL
, I None
tasosartan I CHEMICAL
, I None
eprosartan I CHEMICAL
) I None
or I None
insurmountable I None
/ I None
noncompetitive I None
( I None
candesartan I CHEMICAL
, I None
saprisartan I CHEMICAL
, I None
zolasartan I CHEMICAL
, I None
irbesartan I CHEMICAL
, I None
valsartan I CHEMICAL
, I None
telmisartan I CHEMICAL
, I None
E3174 I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
It I None
is I None
very I None
likely I None
that I None
slow I None
dissociation I None
kinetics I None
from I None
the I None
AT1 I GENE-Y
receptor I None
underlie I None
insurmountable I None
antagonism I None
. I None
<eof> I None

<s> O None
However I None
, I None
competitive I None
or I None
noncompetitive I None
antagonism I None
does I None
not I None
determine I None
the I None
antihypertensive I None
efficacy I None
, I None
but I None
the I None
slow I None
off I None
- I None
rate I None
may I None
extend I None
the I None
occupancy I None
of I None
the I None
AT1 I GENE-Y
receptor I None
and I None
thereby I None
lengthen I None
the I None
duration I None
of I None
the I None
antihypertensive I None
effect I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
chemotherapy I None
with I None
chemohormonal I None
therapy I None
as I None
first I None
- I None
line I None
therapy I None
for I None
metastatic I None
, I None
hormone I None
- I None
sensitive I None
breast I None
cancer I None
: I None
An I None
Eastern I None
Cooperative I None
Oncology I None
Group I None
study I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
Although I None
hormonal I None
therapy I None
represents I None
standard I None
therapy I None
for I None
metastatic I None
hormone I None
- I None
sensitive I None
disease I None
, I None
many I None
patients I None
receive I None
initial I None
chemotherapy I None
because I None
of I None
the I None
location I None
, I None
bulk I None
, I None
or I None
aggressiveness I None
of I None
their I None
disease I None
. I None
<eof> I None

<s> O None
It I None
is I None
uncertain I None
whether I None
simultaneous I None
hormonal I None
therapy I None
provides I None
additional I None
benefit I None
compared I None
with I None
chemotherapy I None
alone I None
. I None
<eof> I None

<s> O None
Eastern I None
Cooperative I None
Oncology I None
Group I None
trial I None
E3186 I None
was I None
initiated I None
to I None
explore I None
this I None
question I None
. I None
<eof> I None

<s> O None
PATIENTS I None
AND I None
METHODS I None
: I None
Between I None
January I None
1988 I None
and I None
December I None
1992 I None
, I None
231 I None
patients I None
with I None
estrogen I GENE-Y
receptor O GENE-Y
( I None
ER I GENE-Y
) I None
- I None
positive I None
or I None
ER I GENE-Y
- I None
unknown I None
metastatic I None
breast I None
cancer I None
were I None
randomized I None
to I None
receive I None
either I None
chemotherapy I None
( I None
cyclophosphamide I CHEMICAL
, I None
doxorubicin I CHEMICAL
, I None
and I None
fluorouracil I CHEMICAL
inverted I None
question I None
markCAF I None
) I None
or I None
chemohormonal I None
therapy I None
( I None
CAF I None
plus I None
tamoxifen I CHEMICAL
and I None
Halotestin I CHEMICAL
inverted I None
question I None
markfluoxymesterone I CHEMICAL
; I None
Pharmacia I None
- I None
Upjohn I None
, I None
Kalamazoo I None
, I None
MI I None
inverted I None
question I None
markCAFTH I None
) I None
as I None
front I None
- I None
line I None
therapy I None
for I None
metastatic I None
breast I None
cancer I None
. I None
<eof> I None

<s> O None
Patients I None
who I None
experienced I None
a I None
complete I None
response I None
to I None
induction I None
therapy I None
either I None
received I None
or I None
did I None
not I None
receive I None
maintenance I None
cyclophosphamide I CHEMICAL
, I None
methotrexate I CHEMICAL
, I None
fluorouracil I CHEMICAL
, I None
prednisone I CHEMICAL
, I None
and I None
TH I None
as I None
a I None
secondary I None
randomization I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
The I None
response I None
rates I None
( I None
complete I None
response I None
and I None
partial I None
response I None
) I None
of I None
patients I None
who I None
received I None
CAF I None
and I None
CAFTH I None
were I None
similar I None
( I None
69 I None
. I None
2 I None
% I None
v I None
68 I None
. I None
9 I None
% I None
, I None
respectively I None
; I None
P I None
= I None
. I None
99 I None
) I None
. I None
<eof> I None

<s> O None
Time I None
to I None
treatment I None
failure I None
( I None
TTF I None
) I None
was I None
slightly I None
longer I None
for I None
patients I None
who I None
received I None
chemohormonal I None
therapy I None
compared I None
with I None
chemotherapy I None
alone I None
patients I None
( I None
13 I None
. I None
4 I None
months I None
v I None
10 I None
. I None
3 I None
months I None
, I None
respectively I None
; I None
P I None
= I None
. I None
087 I None
) I None
, I None
and I None
TTF I None
was I None
significantly I None
longer I None
in I None
ER I GENE-Y
- I None
positive I None
compared I None
with I None
ER I GENE-Y
- I None
negative I None
patients I None
( I None
17 I None
. I None
4 I None
months I None
v I None
10 I None
. I None
3 I None
months I None
, I None
respectively I None
; I None
P I None
= I None
. I None
048 I None
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
ER I GENE-Y
status I None
had I None
no I None
effect I None
on I None
overall I None
survival I None
( I None
30 I None
. I None
0 I None
months I None
for I None
CAF I None
v I None
29 I None
. I None
3 I None
months I None
for I None
CAFTH I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
In I None
patients I None
with I None
potentially I None
hormone I None
- I None
sensitive I None
metastatic I None
breast I None
cancer I None
, I None
chemohormonal I None
therapy I None
prolongs I None
TTF I None
for I None
ER I GENE-Y
- I None
positive I None
patients I None
without I None
improving I None
overall I None
survival I None
. I None
<eof> I None

<s> O None
Characterization I None
and I None
partial I None
purification I None
of I None
microsomal I None
NAD I GENE-N
( O GENE-N
P O GENE-N
) O GENE-N
H O GENE-N
: O GENE-N
quinone O GENE-N
oxidoreductases O GENE-N
. I None
<eof> I None

<s> O None
Quinone I GENE-N
oxidoreductases O GENE-N
are I None
flavoproteins I None
that I None
catalyze I None
two I None
- I None
electron I None
reduction I None
and I None
detoxification I None
of I None
quinones I CHEMICAL
. I None
<eof> I None

<s> O None
This I None
leads I None
to I None
the I None
protection I None
of I None
cells I None
against I None
toxicity I None
, I None
mutagenicity I None
, I None
and I None
cancer I None
due I None
to I None
exposure I None
to I None
environmental I None
and I None
synthetic I None
quinones I CHEMICAL
and I None
its I None
precursors I None
. I None
<eof> I None

<s> O None
Two I None
cytosolic I None
forms I None
of I None
quinone I GENE-N
oxidoreductases O GENE-N
[ I GENE-Y
NAD O GENE-Y
( O GENE-Y
P O GENE-Y
) O GENE-Y
H O GENE-Y
: O GENE-Y
quinone O GENE-Y
oxidoreductase O GENE-Y
1 O GENE-Y
( I None
NQO1 I GENE-Y
) I None
and I None
NRH I GENE-Y
: O GENE-Y
quinone O GENE-Y
oxidoreductase O GENE-Y
2 O GENE-Y
( I None
NQO2 I GENE-Y
) I None
] I None
were I None
previously I None
identified I None
, I None
purified I None
, I None
and I None
cloned I None
. I None
<eof> I None

<s> O None
A I None
role I None
of I None
cytosolic I None
NQO1 I GENE-Y
in I None
protection I None
of I None
cells I None
from I None
oxidative I None
stress I None
, I None
cytotoxicity I None
, I None
and I None
mutagenicity I None
of I None
quinones I CHEMICAL
was I None
established I None
. I None
<eof> I None

<s> O None
Currently I None
, I None
we I None
have I None
characterized I None
and I None
partially I None
purified I None
the I None
NQO I GENE-N
activity I None
from I None
rat I None
liver I None
microsomes I None
. I None
<eof> I None

<s> O None
This I None
activity I None
was I None
designated I None
as I None
microsomal I None
NQO I GENE-N
( I None
mNQO I GENE-N
) I None
. I None
<eof> I None

<s> O None
The I None
mNQO I GENE-N
activity I None
showed I None
significantly I None
higher I None
affinity I None
for I None
NADH I CHEMICAL
than I None
NADPH I CHEMICAL
as I None
electron I None
donors I None
and I None
catalyzed I None
reduction I None
of I None
2 I CHEMICAL
, O CHEMICAL
6 O CHEMICAL
- O CHEMICAL
dichlorophenolindophenol O CHEMICAL
and I None
menadione I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
mNQO I GENE-N
activity I None
was I None
insensitive I None
to I None
dicoumarol I CHEMICAL
, I None
a I None
potent I None
inhibitor I None
of I None
cytosolic I None
NQO1 I GENE-Y
. I None
<eof> I None

<s> O None
Western I None
analysis I None
of I None
microsomal I None
proteins I None
revealed I None
29 I None
- I None
and I None
18 I None
- I None
kDa I None
bands I None
that I None
cross I None
- I None
reacted I None
with I None
polyclonal I None
antibodies I None
raised I None
against I None
cytosolic I None
NQO1 I GENE-Y
. I None
<eof> I None

<s> O None
The I None
mNQO I GENE-N
activity I None
was I None
partially I None
purified I None
by I None
solubilization I None
of I None
microsomes I None
with I None
detergent I None
Chaps I None
, I None
ammonium I CHEMICAL
sulfate O CHEMICAL
fractionation I None
, I None
and I None
DEAE I CHEMICAL
- I None
Sephacel I None
column I None
chromatography I None
. I None
<eof> I None

<s> O None
The I None
microsomal I None
mNQO I GENE-N
proteins I None
are I None
expected I None
to I None
provide I None
additional I None
protection I None
after I None
cytosolic I None
NQOs I GENE-N
against I None
quinone I CHEMICAL
toxicity I None
and I None
mutagenicity I None
. I None
<eof> I None

<s> O None
Opioid I None
activity I None
profiles I None
indicate I None
similarities I None
between I None
the I None
nociceptin I GENE-Y
/ I None
orphanin I GENE-Y
FQ O GENE-Y
and I None
opioid I GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
Nociceptin I GENE-Y
( I None
orphanin I GENE-Y
FQ O GENE-Y
) I None
is I None
the I None
recently I None
discovered I None
peptide I None
agonist I None
for I None
the I None
orphan I GENE-N
receptor O GENE-N
opioid I GENE-Y
receptor O GENE-Y
- O GENE-Y
like O GENE-Y
1 O GENE-Y
( I None
ORL1 I GENE-Y
) I None
. I None
<eof> I None

<s> O None
Despite I None
the I None
high I None
sequence I None
homology I None
between I None
ORL1 I GENE-Y
and I None
the I None
opioid I GENE-N
receptors O GENE-N
, I None
most I None
opioids I None
lack I None
affinity I None
for I None
the I None
nociceptin I GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
The I None
affinity I None
and I None
functional I None
profile I None
of I None
opioids I None
possessing I None
activity I None
at I None
the I None
nociceptin I GENE-Y
receptor O GENE-Y
was I None
determined I None
using I None
[ I None
3H I None
] I None
nociceptin I None
and I None
nociceptin I None
- I None
stimulated I None
[ I CHEMICAL
35S O CHEMICAL
] O CHEMICAL
GTPgammaS O CHEMICAL
binding I None
. I None
<eof> I None

<s> O None
The I None
mu I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
- I None
selective I None
agonist I None
lofentanil I CHEMICAL
potently I None
and I None
competitively I None
displaced I None
[ I None
3H I None
] I None
nociceptin I None
at I None
rat I None
brain I None
receptors I None
( I None
IC I None
( I None
50 I None
) I None
62 I None
nM I None
) I None
. I None
<eof> I None

<s> O None
Lofentanil I CHEMICAL
exhibited I None
full I None
agonism I None
for I None
enhancement I None
of I None
[ I CHEMICAL
35S O CHEMICAL
] O CHEMICAL
GTPgammaS O CHEMICAL
binding I None
to I None
human I None
recombinant I None
ORL1 I GENE-Y
receptors I None
( I None
EC I None
( I None
50 I None
) I None
50 I None
nM I None
) I None
. I None
<eof> I None

<s> O None
The I None
related I None
piperidines I CHEMICAL
ohmefentanyl I CHEMICAL
and I None
sufentanil I CHEMICAL
and I None
the I None
nonselective I None
opioid I GENE-N
receptor O GENE-N
agonist I None
etorphine I CHEMICAL
were I None
less I None
potent I None
nociceptin I GENE-Y
receptor O GENE-Y
agonists I None
. I None
<eof> I None

<s> O None
The I None
kappa I None
( I None
1 I None
) I None
+ I None
kappa I None
( I None
3 I None
) I None
- I None
opioid I None
receptor I None
agonist I None
/ I None
mu I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
antagonist I None
naloxone I CHEMICAL
benzoylhydrazone O CHEMICAL
was I None
a I None
pure I None
antagonist I None
at I None
both I None
rat I None
brain I None
and I None
human I None
ORL1 I GENE-N
receptors I None
. I None
<eof> I None

<s> O None
The I None
nonselective I None
opioid I GENE-N
receptor O GENE-N
partial I None
agonist I None
buprenorphine I CHEMICAL
and I None
the I None
nonselective I None
opioid I GENE-N
receptor O GENE-N
antagonist I None
( I CHEMICAL
- O CHEMICAL
) O CHEMICAL
- O CHEMICAL
quadazocine O CHEMICAL
exhibited I None
pure I None
antagonism I None
at I None
rat I None
brain I None
receptors I None
, I None
but I None
displayed I None
partial I None
agonism I None
at I None
human I GENE-Y
ORL1 O GENE-Y
receptors I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
opioids I None
displaying I None
full I None
agonism I None
at I None
the I None
nociceptin I GENE-Y
receptor O GENE-Y
are I None
also I None
opioid I GENE-N
receptor O GENE-N
agonists I None
, I None
whereas I None
opioids I None
that I None
are I None
antagonists I None
or I None
partial I None
agonists I None
at I None
the I None
nociceptin I GENE-Y
receptor O GENE-Y
show I None
antagonism I None
or I None
partial I None
agonism I None
at I None
opioid I GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
the I None
stereospecificity I None
required I None
at I None
opioid I GENE-N
receptors O GENE-N
appears I None
to I None
be I None
retained I None
at I None
the I None
nociceptin I GENE-Y
receptor O GENE-Y
, I None
since I None
( I CHEMICAL
+ O CHEMICAL
) O CHEMICAL
- O CHEMICAL
quadazocine O CHEMICAL
is I None
inactive I None
at I None
both I None
receptors I None
. I None
<eof> I None

<s> O None
These I None
findings I None
illustrate I None
the I None
structural I None
and I None
functional I None
homology I None
of I None
the I None
opioid I None
recognition I None
site I None
on I None
these I None
two I None
receptor I None
classes I None
and I None
suggest I None
that I None
opioids I None
may I None
provide I None
leads I None
for I None
the I None
design I None
of I None
nonpeptide I None
nociceptin I GENE-Y
receptor O GENE-Y
agonists I None
and I None
antagonists I None
lacking I None
affinity I None
for I None
the I None
classical I None
opioid I GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
Effects I None
of I None
long I None
- I None
term I None
administration I None
of I None
UFT I None
plus I None
leucovorin I CHEMICAL
on I None
colorectal I None
tumors I None
induced I None
with I None
1 I CHEMICAL
, O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
dimethylhydrazine O CHEMICAL
in I None
rats I None
. I None
<eof> I None

<s> O None
Thymidylate I GENE-Y
synthase O GENE-Y
and I None
thymidine I GENE-Y
kinase O GENE-Y
are I None
key I None
enzymes I None
involved I None
in I None
the I None
de I None
novo I None
and I None
salvage I None
pathways I None
for I None
pyrimidine I CHEMICAL
nucleotide O CHEMICAL
synthesis I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Thymidylate I GENE-Y
synthase O GENE-Y
is I None
inhibited I None
by I None
5 I CHEMICAL
- O CHEMICAL
fluorodeoxyuridine O CHEMICAL
monophosphate O CHEMICAL
, I None
forming I None
an I None
inactive I None
ternary I None
complex I None
with I None
intracellular I None
folate I CHEMICAL
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
effects I None
of I None
1 I CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
tetrahydrofuryl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
FU O CHEMICAL
plus I None
uracil I CHEMICAL
( I None
UFT I CHEMICAL
) I None
with I None
or I None
without I None
leucovorin I CHEMICAL
on I None
1 I CHEMICAL
, O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
dimethylhydrazine O CHEMICAL
- I None
induced I None
rat I None
colorectal I None
carcinomas I None
. I None
<eof> I None

<s> O None
Thirty I None
- I None
week I None
administration I None
of I None
UFT I CHEMICAL
with I None
or I None
without I None
leucovorin I CHEMICAL
markedly I None
suppressed I None
both I None
colorectal I None
carcinogenesis I None
and I None
tumor I None
growth I None
, I None
resulted I None
in I None
the I None
increase I None
of I None
thymidylate I GENE-Y
synthase O GENE-Y
inhibition I None
and I None
the I None
decrease I None
of I None
thymidine I GENE-Y
kinase O GENE-Y
activity I None
in I None
the I None
tumor I None
cells I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
the I None
combination I None
of I None
UFT I CHEMICAL
with I None
leucovorin I CHEMICAL
could I None
be I None
useful I None
in I None
the I None
development I None
of I None
pre I None
- I None
and I None
post I None
- I None
operative I None
adjuvant I None
chemotherapy I None
programs I None
. I None
<eof> I None

<s> O None
Antizyme I GENE-N
inhibitor O GENE-N
is I None
rapidly I None
induced I None
in I None
growth I None
- I None
stimulated I None
mouse I None
fibroblasts I None
and I None
releases I None
ornithine I GENE-Y
decarboxylase O GENE-Y
from I None
antizyme I GENE-N
suppression I None
. I None
<eof> I None

<s> O None
Ornithine I GENE-Y
decarboxylase O GENE-Y
( I None
ODC I GENE-Y
) I None
catalyses I None
the I None
first I None
step I None
in I None
the I None
synthesis I None
of I None
the I None
polyamines I None
putrescine I CHEMICAL
, I None
spermidine I CHEMICAL
and I None
spermine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
polyamines I None
are I None
essential I None
for I None
cell I None
growth I None
, I None
but I None
at I None
elevated I None
levels I None
they I None
may I None
be I None
tumorigenic I None
, I None
toxic I None
, I None
or I None
may I None
induce I None
apoptosis I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
ODC I GENE-Y
activity I None
is I None
highly I None
regulated I None
. I None
<eof> I None

<s> O None
It I None
is I None
induced I None
when I None
cells I None
are I None
stimulated I None
to I None
grow I None
, I None
and I None
it I None
is I None
subjected I None
to I None
feedback I None
inhibition I None
by I None
the I None
polyamines I None
. I None
<eof> I None

<s> O None
By I None
causing I None
ribosomal I None
frameshifting I None
, I None
polyamines I None
induce I None
the I None
synthesis I None
of I None
antizyme I GENE-N
, I None
a I None
23 I None
- I None
kDa I None
protein I None
, I None
which I None
binds I None
to I None
ODC I GENE-Y
, I None
inhibits I None
its I None
activity I None
and I None
promotes I None
its I None
degradation I None
by I None
the I None
26 I GENE-N
S O GENE-N
proteasome O GENE-N
. I None
<eof> I None

<s> O None
Antizyme I GENE-N
, I None
in I None
turn I None
, I None
is I None
inhibited I None
by I None
antizyme I GENE-N
inhibitor O GENE-N
( I None
AZI I GENE-N
) I None
. I None
<eof> I None

<s> O None
We I None
describe I None
the I None
cloning I None
of I None
a I None
mouse I GENE-N
AZI O GENE-N
cDNA I None
, I None
encoding I None
a I None
protein I None
with I None
high I None
homology I None
to I None
mouse I GENE-Y
ODC O GENE-Y
. I None
<eof> I None

<s> O None
Using I None
purified I None
recombinant I None
proteins I None
, I None
we I None
show I None
that I None
AZI I GENE-N
( I None
which I None
has I None
no I None
ODC I GENE-Y
activity I None
) I None
can I None
release I None
enzymically I None
active I None
ODC I GENE-Y
from I None
antizyme I GENE-N
suppression I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
We I None
also I None
show I None
that I None
ODC I GENE-Y
reactivation I None
takes I None
place I None
in I None
mouse I None
fibroblasts I None
upon I None
transient I None
transfection I None
with I None
an I None
AZI I GENE-N
- I None
expressing I None
plasmid I None
construct I None
. I None
<eof> I None

<s> O None
Finally I None
we I None
demonstrate I None
that I None
the I None
AZI I GENE-N
mRNA I None
content I None
of I None
mouse I None
fibroblasts I None
increases I None
significantly I None
within I None
an I None
hour I None
of I None
growth I None
stimulation I None
, I None
i I None
. I None
e I None
. I None
much I None
earlier I None
than I None
ODC I GENE-Y
transcripts I None
. I None
<eof> I None

<s> O None
Our I None
results I None
indicate I None
that I None
induction I None
of I None
AZI I GENE-N
synthesis I None
may I None
represent I None
a I None
means I None
of I None
rescuing I None
ODC I GENE-Y
molecules I None
that I None
have I None
been I None
inactivated I None
and I None
tagged I None
for I None
degradation I None
by I None
antizyme I GENE-N
, I None
when I None
culture I None
conditions I None
improve I None
and I None
polyamine I None
production I None
is I None
needed I None
for I None
cell I None
growth I None
and I None
proliferation I None
. I None
<eof> I None

<s> O None
Characterization I None
of I None
human I None
recombinant I None
alpha I GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptors O GENE-Y
expressed I None
in I None
Chinese I None
hamster I None
lung I None
cells I None
using I None
extracellular I None
acidification I None
rate I None
changes I None
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
Human I GENE-Y
alpha O GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptors O GENE-Y
heterologously I None
expressed I None
in I None
Chinese I None
hamster I None
lung I None
( I None
CHL I None
) I None
fibroblasts I None
have I None
been I None
characterized I None
pharmacologically I None
using I None
a I None
cytosensor I None
microphysiometer I None
to I None
measure I None
ligand I None
- I None
induced I None
extracellular I None
acidification I None
rate I None
changes I None
. I None
<eof> I None

<s> O None
2 I None
. I None
<eof> I None

<s> O None
In I None
untransfected I None
CHL I None
cells I None
, I None
noradrenaline I CHEMICAL
had I None
no I None
effect I None
at I None
concentrations I None
up I None
to I None
100 I None
microM I None
. I None
<eof> I None

<s> O None
In I None
alpha I GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
transfected I None
cells I None
the I None
rank I None
order I None
of I None
agonist I None
potency I None
was I None
A I CHEMICAL
- O CHEMICAL
54741 O CHEMICAL
( I None
mean I None
pEC I None
( I None
50 I None
) I None
= I None
8 I None
. I None
96 I None
) I None
> I None
dexmedetomidine I CHEMICAL
( I None
8 I None
. I None
88 I None
) I None
> I None
UK I CHEMICAL
- O CHEMICAL
14304 O CHEMICAL
( I None
8 I None
. I None
42 I None
) I None
> I None
B I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
920 O CHEMICAL
( I None
7 I None
. I None
05 I None
) I None
> I None
noradrenaline I CHEMICAL
( I None
6 I None
. I None
92 I None
) I None
. I None
<eof> I None

<s> O None
A I CHEMICAL
- O CHEMICAL
54741 O CHEMICAL
, I None
UK I CHEMICAL
- O CHEMICAL
14304 O CHEMICAL
and I None
noradrenaline I CHEMICAL
had I None
the I None
same I None
maximum I None
response I None
while I None
dexmedetomidine I CHEMICAL
and I None
B I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
920 O CHEMICAL
behaved I None
as I None
partial I None
agonists I None
. I None
<eof> I None

<s> O None
3 I None
. I None
<eof> I None

<s> O None
The I None
selective I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
ligand I None
rauwolscine I CHEMICAL
antagonized I None
acidification I None
rate I None
changes I None
with I None
an I None
affinity I None
independent I None
of I None
the I None
agonist I None
used I None
; I None
the I None
affinity I None
( I None
mean I None
pK I None
( I None
B I None
) I None
) I None
against I None
noradrenaline I CHEMICAL
was I None
8 I None
. I None
43 I None
. I None
<eof> I None

<s> O None
4 I None
. I None
<eof> I None

<s> O None
The I None
selective I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
ligands I None
prazosin I CHEMICAL
and I None
doxazosin I CHEMICAL
( I None
each I None
3 I None
microM I None
) I None
had I None
no I None
effect I None
on I None
noradrenaline I CHEMICAL
responses I None
. I None
<eof> I None

<s> O None
5 I None
. I None
<eof> I None

<s> O None
Acidification I None
rate I None
changes I None
induced I None
by I None
each I None
agonist I None
were I None
abolished I None
by I None
pre I None
- I None
treatment I None
of I None
cells I None
with I None
pertussis I GENE-N
toxin O GENE-N
. I None
<eof> I None

<s> O None
6 I None
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
that I None
agonist I None
- I None
induced I None
acidification I None
rate I None
responses I None
in I None
CHL I None
cells I None
transfected I None
with I None
the I None
human I GENE-Y
alpha O GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
are I None
mediated I None
exclusively I None
by I None
the I None
recombinant I None
protein I None
, I None
via I None
pertussis I GENE-N
toxin O GENE-N
sensitive I None
G I GENE-N
( O GENE-N
i O GENE-N
/ O GENE-N
o O GENE-N
) O GENE-N
proteins O GENE-N
. I None
<eof> I None

<s> O None
Pharmacological I None
characterization I None
of I None
glucocorticoid I GENE-N
receptors O GENE-N
in I None
primary I None
human I None
bronchial I None
epithelial I None
cells I None
. I None
<eof> I None

<s> O None
Bronchial I None
epithelial I None
cells I None
play I None
an I None
important I None
role I None
in I None
amplifying I None
and I None
perpetuating I None
airway I None
inflammation I None
and I None
may I None
be I None
a I None
target I None
for I None
inhaled I None
steroids I CHEMICAL
. I None
<eof> I None

<s> O None
We I None
have I None
characterized I None
glucocorticoid I GENE-Y
receptors O GENE-Y
in I None
primary I None
human I None
bronchial I None
epithelial I None
cells I None
. I None
<eof> I None

<s> O None
Northern I None
and I None
western I None
blot I None
analyses I None
demonstrated I None
the I None
expression I None
of I None
glucocorticoid I GENE-N
receptor O GENE-N
mRNA I None
and I None
protein I None
, I None
respectively I None
, I None
in I None
primary I None
bronchial I None
epithelial I None
cells I None
. I None
<eof> I None

<s> O None
The I None
activity I None
of I None
these I None
receptors I None
was I None
shown I None
using I None
a I None
radioligand I None
binding I None
assay I None
. I None
<eof> I None

<s> O None
High I None
- I None
affinity I None
binding I None
with I None
pharmacological I None
specificity I None
was I None
demonstrated I None
for I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
dexamethasone O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
equilibrium I None
dissociation I None
constant I None
( I None
Kd I None
) I None
and I None
density I None
of I None
binding I None
sites I None
( I None
Bmax I None
) I None
for I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
dexamethasone O CHEMICAL
determined I None
from I None
saturation I None
isotherms I None
were I None
4 I None
. I None
4 I None
nM I None
x I None
/ I None
divided I None
by I None
0 I None
. I None
95 I None
( I None
SEM I None
) I None
and I None
30 I None
. I None
1 I None
fmol I None
/ I None
mg I None
protein I None
+ I None
/ I None
- I None
6 I None
. I None
4 I None
( I None
SEM I None
) I None
. I None
<eof> I None

<s> O None
Glucocorticoid I GENE-Y
receptors O GENE-Y
were I None
activated I None
by I None
dexamethasone I CHEMICAL
as I None
assessed I None
using I None
a I None
glucocorticoid I None
- I None
responsive I None
reporter I None
plasmid I None
, I None
pTAT3 I None
- I None
CAT I None
. I None
<eof> I None

<s> O None
Transfection I None
of I None
primary I None
human I None
bronchial I None
epithelial I None
cells I None
with I None
this I None
reporter I None
plasmid I None
resulted I None
in I None
35 I None
- I None
fold I None
activation I None
of I None
transcription I None
following I None
dexamethasone I CHEMICAL
stimulation I None
( I None
10 I None
( I None
- I None
6 I None
) I None
M I None
) I None
. I None
<eof> I None

<s> O None
The I None
glucocorticoid I GENE-Y
receptor O GENE-Y
antagonist I None
RU I CHEMICAL
- O CHEMICAL
486 O CHEMICAL
( I None
mifepristone I CHEMICAL
) I None
significantly I None
counteracted I None
the I None
effect I None
of I None
dexamethasone I CHEMICAL
on I None
glucocorticoid I GENE-Y
receptor O GENE-Y
activation I None
, I None
indicating I None
that I None
the I None
dexamethasone I CHEMICAL
effect I None
is I None
specific I None
and I None
is I None
mediated I None
through I None
the I None
glucocorticoid I GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
In I None
summary I None
, I None
our I None
study I None
demonstrated I None
that I None
primary I None
cultures I None
of I None
human I None
bronchial I None
epithelial I None
cells I None
possess I None
glucocorticoid I GENE-Y
receptors O GENE-Y
that I None
function I None
as I None
a I None
ligand I None
- I None
activated I None
transcriptional I None
regulator I None
. I None
<eof> I None

<s> O None
The I None
presence I None
of I None
glucocorticoid I GENE-Y
receptors O GENE-Y
confers I None
their I None
responsiveness I None
to I None
glucocorticoids I None
and I None
indicates I None
that I None
the I None
airway I None
epithelium I None
may I None
be I None
a I None
target I None
for I None
the I None
anti I None
- I None
inflammatory I None
effects I None
of I None
inhaled I None
steroids I CHEMICAL
. I None
<eof> I None

<s> O None
Molecular I None
characterization I None
of I None
the I None
surface I None
of I None
apoptotic I None
neutrophils I None
: I None
implications I None
for I None
functional I None
downregulation I None
and I None
recognition I None
by I None
phagocytes I None
. I None
<eof> I None

<s> O None
We I None
have I None
used I None
a I None
panel I None
of I None
monoclonal I None
antibodies I None
and I None
lectins I GENE-N
to I None
examine I None
the I None
profile I None
of I None
surface I None
molecule I None
expression I None
on I None
human I None
neutrophils I None
that I None
have I None
undergone I None
spontaneous I None
apoptosis I None
during I None
in I None
vitro I None
culture I None
. I None
<eof> I None

<s> O None
Neutrophil I None
apoptosis I None
was I None
found I None
to I None
be I None
accompanied I None
by I None
down I None
- I None
regulation I None
of I None
the I None
immunoglobulin I GENE-N
superfamily I None
members I None
PECAM I GENE-Y
- O GENE-Y
1 O GENE-Y
( I None
CD31 I GENE-Y
) I None
, I None
ICAM I GENE-Y
- O GENE-Y
3 O GENE-Y
( I None
CD50 I GENE-Y
) I None
, I None
CD66acde I GENE-N
, I None
and I None
CD66b I GENE-Y
and I None
the I None
integrin I GENE-N
- I None
associated I None
proteins I None
CD63 I GENE-Y
and I None
urokinase I GENE-Y
plasminogen O GENE-Y
activator O GENE-Y
receptor O GENE-Y
( I None
CD87 I GENE-Y
) I None
that I None
may I None
alter I None
the I None
potential I None
for I None
adhesive I None
interactions I None
. I None
<eof> I None

<s> O None
Cellular I None
interactions I None
may I None
be I None
further I None
influenced I None
by I None
the I None
reduction I None
of I None
the I None
expression I None
of I None
surface I None
carbohydrate I CHEMICAL
moieties I None
, I None
including I None
sialic I CHEMICAL
acid O CHEMICAL
. I None
<eof> I None

<s> O None
Reduced I None
expression I None
of I None
FcgammaRII I GENE-N
( I None
CD32 I GENE-Y
) I None
, I None
complement I GENE-Y
receptor O GENE-Y
type O GENE-Y
1 O GENE-Y
( I None
CD35 I GENE-Y
) I None
and I None
receptors I None
for I None
pro I None
- I None
inflammatory I None
mediators I None
C5a I GENE-Y
( I None
CD88 I GENE-Y
) I None
and I None
TNFalpha I GENE-Y
( I None
CD120b I GENE-Y
) I None
associated I None
with I None
apoptosis I None
might I None
limit I None
neutrophil I None
responsiveness I None
to I None
stimuli I None
that I None
trigger I None
degranulation I None
responses I None
. I None
<eof> I None

<s> O None
Although I None
many I None
of I None
the I None
receptors I None
we I None
have I None
examined I None
are I None
expressed I None
at I None
reduced I None
levels I None
on I None
apoptotic I None
neutrophils I None
, I None
we I None
found I None
that I None
there I None
was I None
differential I None
loss I None
of I None
certain I None
receptors I None
( I None
e I None
. I None
g I None
. I None
CD16 I GENE-Y
, I None
CD15 I GENE-Y
and I None
CD120b I GENE-Y
) I None
and I None
increased I None
expression I None
of I None
aminopeptidase I GENE-Y
- O GENE-Y
N O GENE-Y
( I None
CD13 I GENE-Y
) I None
. I None
<eof> I None

<s> O None
Together I None
with I None
our I None
previous I None
data I None
showing I None
that I None
expression I None
of I None
certain I None
molecules I None
e I None
. I None
g I None
. I None
LFA I GENE-Y
- O GENE-Y
3 O GENE-Y
( I None
CD58 I GENE-Y
) I None
is I None
not I None
altered I None
during I None
neutrophil I None
apoptosis I None
, I None
these I None
data I None
are I None
suggestive I None
of I None
specific I None
changes I None
in I None
receptor I None
mobilisation I None
and I None
shedding I None
associated I None
with I None
apoptosis I None
. I None
<eof> I None

<s> O None
Although I None
reduced I None
expression I None
of I None
CD63 I GENE-Y
( I None
azurophilic I None
granules I None
) I None
and I None
CR1 I GENE-Y
( I None
specific I None
granules I None
) I None
indicates I None
that I None
granule I None
mobilisation I None
does I None
not I None
accompany I None
apoptosis I None
, I None
a I None
monoclonal I None
antibody I None
( I None
BOB78 I None
) I None
, I None
that I None
recognises I None
a I None
90 I None
kDa I None
antigen I None
localised I None
in I None
intracellular I None
granules I None
, I None
defines I None
a I None
subpopulation I None
of I None
apoptotic I None
neutrophils I None
that I None
exhibit I None
nuclear I None
degradation I None
yet I None
retain I None
intact I None
plasma I None
membranes I None
. I None
<eof> I None

<s> O None
BOB78 I None
positive I None
neutrophils I None
were I None
found I None
to I None
bind I None
biotinylated I None
thrombospondin I GENE-Y
, I None
suggesting I None
that I None
this I None
mAb I None
defines I None
surface I None
molecular I None
changes I None
associated I None
with I None
exposure I None
of I None
thrombospondin I GENE-Y
binding I None
moieties I None
. I None
<eof> I None

<s> O None
A I None
positron I None
emission I None
tomography I None
study I None
of I None
quetiapine I CHEMICAL
in I None
schizophrenia I None
: I None
a I None
preliminary I None
finding I None
of I None
an I None
antipsychotic I None
effect I None
with I None
only I None
transiently I None
high I None
dopamine I GENE-Y
D2 O GENE-Y
receptor O GENE-Y
occupancy I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Quetiapine I CHEMICAL
is I None
a I None
new I None
atypical I None
antipsychotic I None
medication I None
. I None
<eof> I None

<s> O None
As I None
such I None
, I None
relatively I None
little I None
has I None
been I None
published I None
regarding I None
its I None
in I None
vivo I None
effects I None
at I None
the I None
dopamine I GENE-Y
type O GENE-Y
2 O GENE-Y
( I None
D2 I GENE-Y
) I None
and I None
serotonin I GENE-Y
type O GENE-Y
2a O GENE-Y
( O GENE-Y
5 O GENE-Y
- O GENE-Y
HT2a O GENE-Y
) O GENE-Y
receptor O GENE-Y
systems I None
. I None
<eof> I None

<s> O None
The I None
following I None
study I None
was I None
undertaken I None
to I None
explore I None
these I None
effects I None
across I None
the I None
clinical I None
dose I None
range I None
and I None
relate I None
this I None
information I None
to I None
its I None
clinical I None
profile I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Twelve I None
patients I None
with I None
schizophrenia I None
were I None
randomly I None
assigned I None
to I None
doses I None
of I None
150 I None
to I None
600 I None
mg I None
/ I None
d I None
( I None
n I None
= I None
3 I None
, I None
at I None
150 I None
, I None
300 I None
, I None
450 I None
, I None
and I None
600 I None
mg I None
/ I None
d I None
) I None
of I None
quetiapine I CHEMICAL
. I None
<eof> I None

<s> O None
After I None
3 I None
weeks I None
of I None
treatment I None
, I None
D2 I GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT2a O GENE-Y
occupancy I None
were I None
measured I None
using I None
positron I None
emission I None
tomography I None
( I None
PET I None
) I None
imaging I None
, I None
12 I None
to I None
14 I None
hours I None
after I None
the I None
last I None
dose I None
. I None
<eof> I None

<s> O None
Clinical I None
efficacy I None
and I None
adverse I None
effect I None
ratings I None
were I None
obtained I None
at I None
baseline I None
, I None
at I None
the I None
time I None
of I None
PET I None
scanning I None
, I None
and I None
at I None
12 I None
weeks I None
. I None
<eof> I None

<s> O None
Two I None
additional I None
patients I None
were I None
included I None
to I None
examine I None
the I None
effects I None
of I None
the I None
drug I None
2 I None
to I None
3 I None
hours I None
after I None
last I None
dose I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Quetiapine I CHEMICAL
was I None
an I None
effective I None
antipsychotic I None
and I None
improved I None
the I None
extrapyramidal I None
symptoms I None
and I None
prolactin I GENE-Y
level I None
elevation I None
noted I None
at I None
baseline I None
. I None
<eof> I None

<s> O None
It I None
achieved I None
these I None
results I None
with I None
minimal I None
( I None
0 I None
% I None
- I None
27 I None
% I None
) I None
D2 I GENE-Y
occupancy I None
12 I None
hours I None
after I None
the I None
last I None
dose I None
. I None
<eof> I None

<s> O None
Study I None
of I None
the I None
additional I None
subjects I None
revealed I None
that I None
quetiapine I CHEMICAL
does I None
give I None
rise I None
to I None
transiently I None
high I None
( I None
58 I None
% I None
- I None
64 I None
% I None
) I None
D2 I GENE-Y
occupancy I None
2 I None
to I None
3 I None
hours I None
after I None
a I None
single I None
dose I None
that I None
then I None
decreases I None
to I None
minimal I None
levels I None
in I None
12 I None
hours I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
Quetiapine I CHEMICAL
shows I None
a I None
transiently I None
high I None
D2 I GENE-Y
occupancy I None
, I None
which I None
decreases I None
to I None
very I None
low I None
levels I None
by I None
the I None
end I None
of I None
the I None
dosing I None
interval I None
. I None
<eof> I None

<s> O None
Quetiapine I None
' I None
s I None
low I None
D2 I GENE-Y
occupancy I None
can I None
explain I None
its I None
freedom I None
from I None
extrapyramidal I None
symptoms I None
and I None
prolactin I None
level I None
elevation I None
. I None
<eof> I None

<s> O None
The I None
data I None
suggest I None
that I None
transient I None
D2 I GENE-Y
occupancy I None
may I None
be I None
sufficient I None
for I None
its I None
antipsychotic I None
effect I None
. I None
<eof> I None

<s> O None
Future I None
studies I None
controlling I None
for I None
nonpharmacological I None
effects I None
as I None
well I None
as I None
activities I None
on I None
other I None
receptors I None
will I None
be I None
necessary I None
to I None
confirm I None
this I None
suggestion I None
. I None
<eof> I None

<s> O None
Correlations I None
of I None
receptor I None
binding I None
and I None
metabolic I None
and I None
mitogenic I None
potencies I None
of I None
insulin I GENE-Y
analogs I None
designed I None
for I None
clinical I None
use I None
. I None
<eof> I None

<s> O None
In I None
recent I None
years I None
, I None
analogs I None
of I None
human I GENE-Y
insulin O GENE-Y
have I None
been I None
engineered I None
with I None
the I None
aim I None
of I None
improving I None
therapy I None
for I None
people I None
with I None
diabetes I None
. I None
<eof> I None

<s> O None
To I None
ensure I None
that I None
the I None
safety I None
profile I None
of I None
the I None
human I None
hormone I None
is I None
not I None
compromised I None
by I None
the I None
molecular I None
modifications I None
, I None
the I None
toxico I None
- I None
pharmacological I None
properties I None
of I None
insulin I GENE-Y
analogs I None
should I None
be I None
carefully I None
monitored I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
compared I None
the I None
insulin I GENE-Y
and I None
IGF I GENE-Y
- O GENE-Y
I O GENE-Y
receptor O GENE-Y
binding I None
properties I None
and I None
metabolic I None
and I None
mitogenic I None
potencies I None
of I None
insulin I GENE-Y
aspart I None
( I None
B28Asp I None
human I GENE-Y
insulin O GENE-Y
) I None
, I None
insulin I GENE-Y
lispro I None
( I None
B28Lys I None
, I None
B29Pro I None
human I GENE-Y
insulin O GENE-Y
) I None
, I None
insulin I GENE-Y
glargine I None
( I None
A21Gly I None
, I None
B31Arg I None
, I None
B32Arg I None
human I GENE-Y
insulin O GENE-Y
) I None
, I None
insulin I GENE-Y
detemir I None
( I None
NN304 I None
) I None
[ I None
B29Lys I None
( I None
epsilon I CHEMICAL
- O CHEMICAL
tetradecanoyl O CHEMICAL
) I None
, I None
desB30 I None
human I None
insulin I GENE-Y
] I None
, I None
and I None
reference I None
insulin I GENE-Y
analogs I None
. I None
<eof> I None

<s> O None
Receptor I None
affinities I None
were I None
measured I None
using I None
purified I None
human I None
receptors I None
, I None
insulin I GENE-Y
receptor O GENE-Y
dissociation I None
rates I None
were I None
determined I None
using I None
Chinese I None
hamster I None
ovary I None
cells I None
overexpressing I None
the I None
human I GENE-Y
insulin O GENE-Y
receptor O GENE-Y
, I None
metabolic I None
potencies I None
were I None
evaluated I None
using I None
primary I None
mouse I None
adipocytes I None
, I None
and I None
mitogenic I None
potencies I None
were I None
determined I None
in I None
human I None
osteosarcoma I None
cells I None
. I None
<eof> I None

<s> O None
Metabolic I None
potencies I None
correlated I None
well I None
with I None
insulin I GENE-Y
receptor O GENE-Y
affinities I None
. I None
<eof> I None

<s> O None
Mitogenic I None
potencies I None
in I None
general I None
correlated I None
better I None
with I None
IGF I GENE-Y
- O GENE-Y
I O GENE-Y
receptor O GENE-Y
affinities I None
than I None
with I None
insulin I GENE-Y
receptor O GENE-Y
off I None
- I None
rates I None
. I None
<eof> I None

<s> O None
The I None
2 I None
rapid I None
- I None
acting I None
insulin I GENE-Y
analogs I None
aspart I None
and I None
lispro I None
resembled I None
human I GENE-Y
insulin O GENE-Y
on I None
all I None
parameters I None
, I None
except I None
for I None
a I None
slightly I None
elevated I None
IGF I GENE-Y
- O GENE-Y
I O GENE-Y
receptor O GENE-Y
affinity I None
of I None
lispro I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
2 I None
long I None
- I None
acting I None
insulin I GENE-Y
analogs I None
, I None
glargine I None
and I None
detemir I None
, I None
differed I None
significantly I None
from I None
human I GENE-Y
insulin O GENE-Y
. I None
<eof> I None

<s> O None
The I None
combination I None
of I None
the I None
B31B32diArg I None
and I None
A21Gly I None
substitutions I None
provided I None
insulin I GENE-Y
glargine I None
with I None
a I None
6 I None
- I None
to I None
8 I None
- I None
fold I None
increased I None
IGF I GENE-Y
- O GENE-Y
I O GENE-Y
receptor O GENE-Y
affinity I None
and I None
mitogenic I None
potency I None
compared I None
with I None
human I GENE-Y
insulin O GENE-Y
. I None
<eof> I None

<s> O None
The I None
attachment I None
of I None
a I None
fatty I CHEMICAL
acid O CHEMICAL
chain I None
to I None
LysB29 I None
provided I None
insulin I GENE-Y
detemir I None
with I None
reduced I None
receptor I None
affinities I None
and I None
metabolic I None
and I None
mitogenic I None
potencies I None
but I None
did I None
not I None
change I None
the I None
balance I None
between I None
mitogenic I None
and I None
metabolic I None
potencies I None
. I None
<eof> I None

<s> O None
The I None
safety I None
implications I None
of I None
the I None
increased I None
growth I None
- I None
stimulating I None
potential I None
of I None
insulin I GENE-Y
glargine I None
are I None
unclear I None
. I None
<eof> I None

<s> O None
The I None
reduced I None
in I None
vitro I None
potency I None
of I None
insulin I GENE-Y
detemir I None
might I None
explain I None
why I None
this I None
analog I None
is I None
not I None
as I None
effective I None
on I None
a I None
molar I None
basis I None
as I None
human I GENE-Y
insulin O GENE-Y
in I None
humans I None
. I None
<eof> I None

<s> O None
TWIK I GENE-Y
- O GENE-Y
2 O GENE-Y
, I None
an I None
inactivating I None
2P I GENE-Y
domain O GENE-Y
K O GENE-Y
+ O GENE-Y
channel O GENE-Y
. I None
<eof> I None

<s> O None
We I None
cloned I None
human I None
and I None
rat I None
TWIK I GENE-N
- O GENE-N
2 O GENE-N
and I None
expressed I None
this I None
novel I None
2P I GENE-N
domain O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
channel O GENE-N
in I None
transiently I None
transfected I None
COS I None
cells I None
. I None
<eof> I None

<s> O None
TWIK I GENE-Y
- O GENE-Y
2 O GENE-Y
is I None
highly I None
expressed I None
in I None
the I None
gastrointestinal I None
tract I None
, I None
the I None
vasculature I None
, I None
and I None
the I None
immune I None
system I None
. I None
<eof> I None

<s> O None
Rat I GENE-Y
TWIK O GENE-Y
- O GENE-Y
2 O GENE-Y
currents I None
are I None
about I None
15 I None
times I None
larger I None
than I None
human I GENE-Y
TWIK O GENE-Y
- O GENE-Y
2 O GENE-Y
currents I None
, I None
but I None
both I None
exhibit I None
outward I None
rectification I None
in I None
a I None
physiological I None
K I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
gradient I None
and I None
mild I None
inward I None
rectification I None
in I None
symmetrical I None
K I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
conditions I None
. I None
<eof> I None

<s> O None
TWIK I GENE-Y
- O GENE-Y
2 O GENE-Y
currents I None
are I None
inactivating I None
at I None
depolarized I None
potentials I None
, I None
and I None
the I None
kinetic I None
of I None
inactivation I None
is I None
highly I None
temperature I None
- I None
sensitive I None
. I None
<eof> I None

<s> O None
TWIK I GENE-Y
- O GENE-Y
2 O GENE-Y
shows I None
an I None
extremely I None
low I None
conductance I None
, I None
which I None
prevents I None
the I None
visualization I None
of I None
discrete I None
single I None
channel I None
events I None
. I None
<eof> I None

<s> O None
The I None
inactivation I None
and I None
rectification I None
are I None
intrinsic I None
properties I None
of I None
TWIK I GENE-Y
- O GENE-Y
2 O GENE-Y
channels I None
. I None
<eof> I None

<s> O None
In I None
a I None
physiological I None
K I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
gradient I None
, I None
TWIK I GENE-Y
- O GENE-Y
2 O GENE-Y
is I None
half I None
inhibited I None
by I None
0 I None
. I None
1 I None
mm I None
Ba I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
, I None
quinine I CHEMICAL
, I None
and I None
quinidine I CHEMICAL
. I None
<eof> I None

<s> O None
Finally I None
, I None
cysteine I CHEMICAL
53 I None
in I None
the I None
M1P1 I GENE-N
external O GENE-N
loop O GENE-N
is I None
required I None
for I None
functional I None
expression I None
of I None
TWIK I GENE-Y
- O GENE-Y
2 O GENE-Y
but I None
is I None
not I None
critical I None
for I None
subunit I None
self I None
- I None
assembly I None
. I None
<eof> I None

<s> O None
TWIK I GENE-Y
- O GENE-Y
2 O GENE-Y
is I None
the I None
first I None
reported I None
2P I GENE-Y
domain O GENE-Y
K O GENE-Y
( O GENE-Y
+ O GENE-Y
) O GENE-Y
channel O GENE-Y
that I None
inactivates I None
. I None
<eof> I None

<s> O None
The I None
base I None
- I None
line I None
, I None
transient I None
, I None
and I None
delayed I None
activities I None
of I None
TWIK I GENE-Y
- O GENE-Y
2 O GENE-Y
suggest I None
that I None
this I None
novel I None
2P I GENE-Y
domain O GENE-Y
K O GENE-Y
( O GENE-Y
+ O GENE-Y
) O GENE-Y
channel O GENE-Y
may I None
play I None
an I None
important I None
functional I None
role I None
in I None
cell I None
electrogenesis I None
. I None
<eof> I None

<s> O None
Addition I None
of I None
eicosapentaenoic I CHEMICAL
acid O CHEMICAL
to I None
gamma I CHEMICAL
- O CHEMICAL
linolenic O CHEMICAL
acid O CHEMICAL
- I None
supplemented I None
diets I None
prevents I None
serum I None
arachidonic I CHEMICAL
acid O CHEMICAL
accumulation I None
in I None
humans I None
. I None
<eof> I None

<s> O None
Previous I None
studies I None
reveal I None
that I None
supplementation I None
of I None
human I None
diets I None
with I None
gamma I CHEMICAL
- O CHEMICAL
linolenic O CHEMICAL
acid O CHEMICAL
( I None
GLA I CHEMICAL
) I None
reduces I None
the I None
generation I None
of I None
lipid I None
mediators I None
of I None
inflammation I None
and I None
attenuates I None
clinical I None
symptoms I None
of I None
chronic I None
inflammatory I None
disorders I None
such I None
as I None
rheumatoid I None
arthritis I None
. I None
<eof> I None

<s> O None
However I None
, I None
we I None
have I None
shown I None
that I None
supplementation I None
with I None
this I None
same I None
fatty I CHEMICAL
acid O CHEMICAL
also I None
causes I None
a I None
marked I None
increase I None
in I None
serum I None
arachidonate I CHEMICAL
( I None
AA I CHEMICAL
) I None
levels I None
, I None
a I None
potentially I None
harmful I None
side I None
effect I None
. I None
<eof> I None

<s> O None
The I None
objective I None
of I None
this I None
study I None
was I None
to I None
design I None
a I None
supplementation I None
strategy I None
that I None
maintained I None
the I None
capacity I None
of I None
GLA I CHEMICAL
to I None
reduce I None
lipid I None
mediators I None
without I None
causing I None
elevations I None
in I None
serum I None
AA I CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
Initial I None
in I None
vitro I None
studies I None
utilizing I None
HEP I None
- I None
G2 I None
liver I None
cells I None
revealed I None
that I None
addition I None
of I None
eicosapentaenoic I CHEMICAL
acid O CHEMICAL
( I None
EPA I CHEMICAL
) I None
blocked I None
Delta I GENE-Y
- O GENE-Y
5 O GENE-Y
- O GENE-Y
desaturase O GENE-Y
activity I None
, I None
the I None
terminal I None
enzymatic I None
step I None
in I None
AA I CHEMICAL
synthesis I None
. I None
<eof> I None

<s> O None
To I None
test I None
the I None
in I None
vivo I None
effects I None
of I None
a I None
GLA I CHEMICAL
and I None
EPA I CHEMICAL
combination I None
in I None
humans I None
, I None
adult I None
volunteers I None
consuming I None
controlled I None
diets I None
supplemented I None
these I None
diets I None
with I None
3 I None
. I None
0 I None
g I None
/ I None
d I None
of I None
GLA I CHEMICAL
and I None
EPA I CHEMICAL
. I None
<eof> I None

<s> O None
This I None
supplementation I None
strategy I None
significantly I None
increased I None
serum I None
levels I None
of I None
EPA I CHEMICAL
, I None
but I None
did I None
not I None
increase I None
AA I CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
EPA I CHEMICAL
and I None
the I None
elongation I None
product I None
of I None
GLA I CHEMICAL
, I None
dihomo I CHEMICAL
- O CHEMICAL
gamma O CHEMICAL
- O CHEMICAL
linolenic O CHEMICAL
acid O CHEMICAL
( I None
DGLA I CHEMICAL
) I None
levels I None
in I None
neutrophil I None
glycerolipids I None
increased I None
significantly I None
during I None
the I None
3 I None
- I None
wk I None
supplementation I None
period I None
. I None
<eof> I None

<s> O None
Neutrophils I None
isolated I None
from I None
volunteers I None
fed I None
diets I None
supplemented I None
with I None
GLA I CHEMICAL
and I None
EPA I CHEMICAL
released I None
similar I None
quantities I None
of I None
AA I CHEMICAL
, I None
but I None
synthesized I None
significantly I None
lower I None
quantities I None
of I None
leukotrienes I CHEMICAL
compared I None
with I None
their I None
neutrophils I None
before I None
supplementation I None
. I None
<eof> I None

<s> O None
This I None
study I None
revealed I None
that I None
a I None
GLA I CHEMICAL
and I None
EPA I CHEMICAL
supplement I None
combination I None
may I None
be I None
utilized I None
to I None
reduce I None
the I None
synthesis I None
of I None
proinflammatory I None
AA I CHEMICAL
metabolites I None
, I None
and I None
importantly I None
, I None
not I None
induce I None
potentially I None
harmful I None
increases I None
in I None
serum I None
AA I CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
a I None
K I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
channel O GENE-N
opener I None
to I None
reduce I None
transmural I None
dispersion I None
of I None
repolarization I None
and I None
prevent I None
torsade I None
de I None
pointes I None
in I None
LQT1 I None
, I None
LQT2 I None
, I None
and I None
LQT3 I None
models I None
of I None
the I None
long I None
- I None
QT I None
syndrome I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
This I None
study I None
examines I None
the I None
effects I None
of I None
nicorandil I CHEMICAL
, I None
a I None
K I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
channel O GENE-N
opener I None
, I None
on I None
transmural I None
dispersion I None
of I None
repolarization I None
( I None
TDR I None
) I None
and I None
induction I None
of I None
torsade I None
de I None
pointes I None
( I None
TdP I None
) I None
under I None
conditions I None
mimicking I None
the I None
LQT1 I None
, I None
LQT2 I None
, I None
and I None
LQT3 I None
forms I None
of I None
the I None
congenital I None
long I None
- I None
QT I None
syndrome I None
( I None
LQTS I None
) I None
. I None
<eof> I None

<s> O None
METHODS I None
AND I None
RESULTS I None
: I None
Transmembrane I None
action I None
potentials I None
of I None
epicardial I None
, I None
M I None
, I None
and I None
endocardial I None
cells I None
were I None
recorded I None
simultaneously I None
from I None
an I None
arterially I None
perfused I None
wedge I None
of I None
canine I None
left I None
ventricle I None
together I None
with I None
a I None
transmural I None
ECG I None
. I None
<eof> I None

<s> O None
Chromanol I None
293B I None
( I None
30 I None
micromol I None
/ I None
L I None
) I None
was I None
used I None
to I None
block I None
I I GENE-N
( O GENE-N
Ks O GENE-N
) O GENE-N
( I None
LQT1 I None
model I None
) I None
. I None
<eof> I None

<s> O None
Isoproterenol I CHEMICAL
( I None
50 I None
to I None
100 I None
nmol I None
/ I None
L I None
) I None
was I None
used I None
to I None
mimic I None
an I None
increase I None
in I None
beta I None
- I None
adrenergic I None
tone I None
, I None
d I CHEMICAL
- O CHEMICAL
sotalol O CHEMICAL
( I None
100 I None
micromol I None
/ I None
L I None
) I None
to I None
block I None
I I GENE-N
( O GENE-N
Kr O GENE-N
) O GENE-N
( I None
LQT2 I None
model I None
) I None
, I None
and I None
ATX I GENE-Y
- O GENE-Y
II O GENE-Y
( I None
20 I None
nmol I None
/ I None
L I None
) I None
to I None
augment I None
late I None
I I None
( I None
Na I CHEMICAL
) I None
( I None
LQT3 I None
model I None
) I None
. I None
<eof> I None

<s> O None
Isoproterenol I CHEMICAL
+ I None
chromanol I CHEMICAL
293B O CHEMICAL
, I None
d I CHEMICAL
- O CHEMICAL
sotalol O CHEMICAL
, I None
and I None
ATX I GENE-Y
- O GENE-Y
II O GENE-Y
produced I None
preferential I None
prolongation I None
of I None
the I None
action I None
potential I None
duration I None
at I None
90 I None
% I None
repolarization I None
( I None
APD I None
( I None
90 I None
) I None
) I None
of I None
the I None
M I None
cell I None
, I None
an I None
increase I None
of I None
TDR I None
, I None
and I None
spontaneous I None
as I None
well I None
as I None
stimulation I None
- I None
induced I None
TdP I None
( I None
LQT1 I None
, I None
3 I None
/ I None
6 I None
; I None
LQT2 I None
, I None
3 I None
/ I None
6 I None
; I None
LQT3 I None
, I None
5 I None
/ I None
6 I None
) I None
. I None
<eof> I None

<s> O None
Nicorandil I CHEMICAL
( I None
2 I None
to I None
20 I None
micromol I None
/ I None
L I None
) I None
abbreviated I None
the I None
QT I None
interval I None
and I None
APD I None
( I None
90 I None
) I None
of I None
the I None
3 I None
cell I None
types I None
in I None
the I None
3 I None
models I None
. I None
<eof> I None

<s> O None
High I None
concentrations I None
( I None
10 I None
to I None
20 I None
micromol I None
/ I None
L I None
) I None
completely I None
reversed I None
the I None
effects I None
of I None
293B I None
+ I None
/ I None
- I None
isoproterenol I CHEMICAL
and I None
those I None
of I None
d I CHEMICAL
- O CHEMICAL
sotalol O CHEMICAL
to I None
increase I None
APD I None
( I None
90 I None
) I None
and I None
TDR I None
and I None
to I None
induce I None
TdP I None
in I None
LQT1 I None
and I None
LQT2 I None
models I None
. I None
<eof> I None

<s> O None
Nicorandil I CHEMICAL
20 I None
micromol I None
/ I None
L I None
reversed I None
only I None
50 I None
% I None
of I None
the I None
effect I None
of I None
ATX I GENE-Y
- O GENE-Y
II O GENE-Y
and I None
failed I None
to I None
completely I None
suppress I None
TdP I None
in I None
the I None
LQT3 I None
model I None
( I None
5 I None
/ I None
6 I None
to I None
3 I None
/ I None
6 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
Our I None
data I None
suggest I None
that I None
K I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
channel O GENE-N
openers I None
may I None
be I None
capable I None
of I None
abbreviating I None
the I None
long I None
QT I None
interval I None
, I None
reducing I None
TDR I None
, I None
and I None
preventing I None
spontaneous I None
and I None
stimulation I None
- I None
induced I None
TdP I None
when I None
congenital I None
or I None
acquired I None
LQTS I None
is I None
secondary I None
to I None
reduced I None
I I GENE-N
( O GENE-N
Kr O GENE-N
) O GENE-N
or I None
I I GENE-N
( O GENE-N
Ks O GENE-N
) O GENE-N
but I None
less I None
so I None
when I None
it I None
is I None
due I None
to I None
augmented I None
late I None
I I None
( I None
Na I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
Peroxisome I GENE-Y
proliferator O GENE-Y
- O GENE-Y
activated O GENE-Y
receptor O GENE-Y
alpha O GENE-Y
( I None
PPARalpha I GENE-Y
) I None
activators I None
, I None
bezafibrate I CHEMICAL
and I None
Wy I CHEMICAL
- O CHEMICAL
14 O CHEMICAL
, O CHEMICAL
643 O CHEMICAL
, I None
increase I None
uncoupling I GENE-Y
protein O GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
levels I None
without I None
modifying I None
the I None
mitochondrial I None
membrane I None
potential I None
in I None
primary I None
culture I None
of I None
rat I None
preadipocytes I None
. I None
<eof> I None

<s> O None
Uncoupling I GENE-N
proteins O GENE-N
( I None
UCPs I GENE-N
) I None
are I None
inner I None
mitochondrial I None
membrane I None
transporters I None
which I None
act I None
as I None
pores I None
for I None
H I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
ions I None
, I None
dissipating I None
the I None
electrochemical I None
gradient I None
that I None
develops I None
during I None
mitochondrial I None
respiration I None
at I None
the I None
expense I None
of I None
ATP I None
synthesis I None
. I None
<eof> I None

<s> O None
We I None
have I None
studied I None
the I None
effects I None
of I None
two I None
fibrates I None
, I None
bezafibrate I CHEMICAL
and I None
Wy I CHEMICAL
- O CHEMICAL
14 O CHEMICAL
, O CHEMICAL
643 O CHEMICAL
, I None
on I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
and I None
UCP I GENE-Y
- O GENE-Y
2 O GENE-Y
mRNA I None
levels I None
in I None
primary I None
monolayer I None
cultures I None
of I None
rat I None
adipocytes I None
and I None
undifferentiated I None
preadipocytes I None
. I None
<eof> I None

<s> O None
Treatment I None
with I None
both I None
PPARalpha I GENE-Y
activators I None
for I None
24 I None
h I None
up I None
- I None
regulated I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
levels I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
bezafibrate I CHEMICAL
treatment I None
resulted I None
in I None
an I None
8 I None
- I None
fold I None
induction I None
in I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
levels I None
in I None
preadipocytes I None
compared I None
with I None
the I None
3 I None
. I None
5 I None
- I None
fold I None
induction I None
observed I None
in I None
adipocytes I None
. I None
<eof> I None

<s> O None
Differences I None
in I None
the I None
induction I None
of I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
between I None
these I None
cells I None
correlated I None
well I None
with I None
the I None
higher I None
expression I None
of I None
PPARalpha I GENE-Y
and I None
RXRalpha I GENE-Y
mRNA I None
values I None
in I None
preadipocytes I None
compared I None
to I None
adipocytes I None
. I None
<eof> I None

<s> O None
Wy I None
- I None
14 I None
, I None
643 I None
caused I None
similar I None
effects I None
on I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
expression I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
to I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
, I None
UCP I GENE-Y
- O GENE-Y
2 O GENE-Y
mRNA I None
levels I None
were I None
only I None
slightly I None
modified I None
by I None
bezafibrate I CHEMICAL
in I None
adipocytes I None
. I None
<eof> I None

<s> O None
The I None
induction I None
in I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
expression I None
was I None
not I None
accompanied I None
by I None
changes I None
in I None
the I None
mitochondrial I None
membrane I None
potential I None
of I None
rat I None
primary I None
preadipocytes I None
after I None
bezafibrate I CHEMICAL
or I None
Wy I CHEMICAL
- O CHEMICAL
14 O CHEMICAL
, O CHEMICAL
643 O CHEMICAL
treatment I None
. I None
<eof> I None

<s> O None
Since I None
it I None
has I None
been I None
proposed I None
that I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
could I None
be I None
involved I None
in I None
the I None
regulation I None
of I None
the I None
use I None
of I None
fatty I None
acids I None
as I None
fuel I None
substrates I None
, I None
the I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
induction I None
achieved I None
after I None
bezafibrate I CHEMICAL
and I None
Wy I CHEMICAL
- O CHEMICAL
14 O CHEMICAL
, O CHEMICAL
643 O CHEMICAL
treatment I None
may I None
indicate I None
a I None
higher I None
oxidation I None
of I None
fatty I CHEMICAL
acids O CHEMICAL
, I None
limiting I None
their I None
availability I None
to I None
be I None
stored I None
as I None
triglycerides I CHEMICAL
. I None
<eof> I None

<s> O None
This I None
change I None
may I None
result I None
in I None
a I None
reduced I None
rate I None
of I None
conversion I None
of I None
preadipocytes I None
to I None
adipocytes I None
, I None
which I None
directly I None
affects I None
fat I None
depots I None
. I None
<eof> I None

<s> O None
Schisandrin I CHEMICAL
B O CHEMICAL
protects I None
against I None
menadione I CHEMICAL
- I None
induced I None
hepatotoxicity I None
by I None
enhancing I None
DT I GENE-Y
- O GENE-Y
diaphorase O GENE-Y
activity I None
. I None
<eof> I None

<s> O None
Pretreating I None
mice I None
with I None
schisandrin I CHEMICAL
B O CHEMICAL
( I None
Sch I CHEMICAL
B O CHEMICAL
) I None
, I None
a I None
dibenzocyclooctadiene I None
derivative I None
isolated I None
from I None
the I None
fruit I None
of I None
Schisandra I None
chinensis I None
, I None
at I None
a I None
daily I None
dose I None
of I None
1 I None
mmol I None
/ I None
kg I None
for I None
3 I None
days I None
protected I None
against I None
menadione I CHEMICAL
- I None
induced I None
hepatic I None
oxidative I None
damage I None
in I None
mice I None
, I None
as I None
evidenced I None
by I None
decreases I None
in I None
plasma I None
alanine I GENE-N
aminotransferase O GENE-N
activity I None
( I None
78 I None
% I None
) I None
and I None
hepatic I None
malondialdehyde I CHEMICAL
level I None
( I None
70 I None
% I None
) I None
, I None
when I None
compared I None
with I None
the I None
menadione I CHEMICAL
intoxicated I None
control I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
define I None
the I None
biochemical I None
mechanism I None
involved I None
in I None
the I None
hepatoprotection I None
afforded I None
by I None
Sch I CHEMICAL
B O CHEMICAL
pretreatment I None
, I None
we I None
examined I None
the I None
activity I None
of I None
DT I GENE-Y
- O GENE-Y
diaphorase O GENE-Y
( I None
DTD I GENE-Y
) I None
in I None
hepatocytes I None
isolated I None
from I None
Sch I CHEMICAL
B O CHEMICAL
pretreated I None
rats I None
. I None
<eof> I None

<s> O None
Hepatocytes I None
isolated I None
from I None
Sch I CHEMICAL
B O CHEMICAL
pretreated I None
( I None
a I None
daily I None
dose I None
of I None
1 I None
mmol I None
/ I None
kg I None
for I None
3 I None
days I None
) I None
rats I None
showed I None
a I None
significant I None
increase I None
( I None
25 I None
% I None
) I None
in I None
DTD I GENE-Y
activity I None
. I None
<eof> I None

<s> O None
The I None
increase I None
in I None
DTD I GENE-Y
activity I None
was I None
associated I None
with I None
the I None
enhanced I None
rate I None
of I None
menadione I CHEMICAL
elimination I None
in I None
the I None
hepatocyte I None
culture I None
. I None
<eof> I None

<s> O None
The I None
ensemble I None
of I None
results I None
suggests I None
that I None
the I None
ability I None
of I None
Sch I CHEMICAL
B O CHEMICAL
pretreatment I None
to I None
enhance I None
hepatocellular I None
DTD I GENE-Y
activity I None
may I None
at I None
least I None
in I None
part I None
be I None
attributed I None
to I None
the I None
protection I None
against I None
menadione I CHEMICAL
hepatotoxicity I None
. I None
<eof> I None

<s> O None
Interactive I None
and I None
delayed I None
effects I None
of I None
pyridostigmine I CHEMICAL
and I None
physical I None
stress I None
on I None
biochemical I None
and I None
histological I None
changes I None
in I None
peripheral I None
tissues I None
of I None
mice I None
. I None
<eof> I None

<s> O None
Gulf I None
War I None
veterans I None
were I None
taking I None
pyridostigmine I CHEMICAL
orally I None
against I None
possible I None
exposure I None
to I None
nerve I None
agents I None
as I None
well I None
as I None
being I None
under I None
physical I None
stress I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
designed I None
to I None
investigate I None
the I None
delayed I None
effects I None
of I None
pyridostigmine I CHEMICAL
and I None
treadmill I None
exercise I None
on I None
cholinesterase I GENE-Y
activity I None
, I None
lipid I None
peroxidation I None
and I None
histology I None
of I None
peripheral I None
tissues I None
of I None
mice I None
. I None
<eof> I None

<s> O None
Male I None
NIH I None
Swiss I None
mice I None
were I None
divided I None
into I None
four I None
groups I None
of I None
15 I None
animals I None
each I None
and I None
treated I None
as I None
follows I None
: I None
sedentary I None
control I None
; I None
exercise I None
training I None
for I None
10 I None
weeks I None
; I None
pyridostigmine I CHEMICAL
( I None
1 I None
. I None
2 I None
mg I None
kg I None
( I None
- I None
1 I None
) I None
, I None
p I None
. I None
o I None
. I None
) I None
for I None
2 I None
weeks I None
during I None
weeks I None
5 I None
and I None
6 I None
; I None
and I None
pyridostigmine I CHEMICAL
plus I None
exercise I None
training I None
. I None
<eof> I None

<s> O None
The I None
mice I None
were I None
sacrificed I None
24 I None
h I None
after I None
the I None
last I None
exercise I None
, I None
and I None
blood I None
, I None
triceps I None
muscle I None
and I None
sciatic I None
nerve I None
were I None
isolated I None
and I None
analyzed I None
. I None
<eof> I None

<s> O None
The I None
group I None
treated I None
with I None
pyridostigmine I CHEMICAL
alone I None
showed I None
decreased I None
plasma I None
butyrylcholinesterase I GENE-Y
( I None
BChE I GENE-Y
) I None
activity I None
( I None
87 I None
% I None
of I None
control I None
) I None
, I None
whereas I None
pyridostigmine I CHEMICAL
plus I None
exercise I None
significantly I None
decreased I None
the I None
BChE I GENE-Y
activity I None
( I None
79 I None
% I None
of I None
control I None
) I None
, I None
indicating I None
an I None
interactive I None
effect I None
of I None
the I None
combination I None
. I None
<eof> I None

<s> O None
Acetylcholinesterase I GENE-Y
( I None
AChE I GENE-Y
) I None
activity I None
did I None
not I None
alter I None
significantly I None
in I None
red I None
blood I None
cells I None
, I None
platelets I None
or I None
sciatic I None
nerve I None
with I None
either I None
of I None
the I None
treatments I None
. I None
<eof> I None

<s> O None
However I None
, I None
AChE I GENE-Y
activity I None
in I None
triceps I None
muscle I None
decreased I None
significantly I None
( I None
78 I None
% I None
of I None
control I None
) I None
in I None
the I None
group I None
treated I None
with I None
pyridostigmine I CHEMICAL
plus I None
exercise I None
. I None
<eof> I None

<s> O None
Creatine I GENE-N
phosphokinase O GENE-N
activity I None
in I None
plasma I None
increased I None
slightly I None
( I None
compared I None
to I None
control I None
, I None
pyridostigmine I CHEMICAL
or I None
exercise I None
group I None
) I None
in I None
mice I None
treated I None
with I None
pyridostigmine I CHEMICAL
plus I None
exercise I None
, I None
which I None
may I None
be I None
indicative I None
of I None
perturbation I None
in I None
the I None
integrity I None
of I None
the I None
skeletal I None
muscle I None
due I None
to I None
combination I None
. I None
<eof> I None

<s> O None
However I None
, I None
there I None
were I None
no I None
obvious I None
histological I None
abnormalities I None
in I None
the I None
triceps I None
muscle I None
detected I None
between I None
experimental I None
and I None
control I None
groups I None
. I None
<eof> I None

<s> O None
Interaction I None
of I None
pyridostigmine I CHEMICAL
and I None
exercise I None
significantly I None
increased I None
the I None
concentration I None
of I None
the I None
end I None
product I None
of I None
lipid I None
peroxidation I None
( I None
malondialdehyde I CHEMICAL
) I None
( I None
124 I None
% I None
of I None
control I None
) I None
in I None
triceps I None
muscle I None
, I None
indicating I None
an I None
oxidative I None
stress I None
response I None
of I None
the I None
combination I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
physical I None
stress I None
enhanced I None
the I None
delayed I None
toxic I None
effects I None
of I None
a I None
subchronic I None
oral I None
dose I None
of I None
pyridostigmine I CHEMICAL
primarily I None
in I None
the I None
skeletal I None
muscle I None
of I None
mice I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
hormonal I None
agents I None
on I None
monocyte I GENE-Y
chemotactic O GENE-Y
protein O GENE-Y
- O GENE-Y
1 O GENE-Y
expression I None
by I None
endometrial I None
epithelial I None
cells I None
of I None
women I None
with I None
endometriosis I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
To I None
assess I None
whether I None
hormonal I None
agents I None
used I None
in I None
the I None
medical I None
treatment I None
of I None
endometriosis I None
, I None
such I None
as I None
danazol I CHEMICAL
and I None
GnRH I GENE-Y
agonist I None
, I None
exert I None
direct I None
regulatory I None
action I None
on I None
monocyte I GENE-Y
chemotactic O GENE-Y
protein O GENE-Y
- O GENE-Y
1 O GENE-Y
( I None
MCP I GENE-Y
- O GENE-Y
1 O GENE-Y
) I None
expression I None
by I None
endometrial I None
epithelial I None
cells I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
Primary I None
cultures I None
of I None
epithelial I None
cells I None
isolated I None
from I None
human I None
endometrium I None
were I None
exposed I None
to I None
different I None
concentrations I None
of I None
cytokines I GENE-N
and I None
steroid I CHEMICAL
hormone I None
analogs I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
MCP I GENE-Y
- O GENE-Y
1 O GENE-Y
was I None
analyzed I None
at I None
the I None
levels I None
of I None
protein I None
and I None
messenger I None
RNA I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
Gynecology I None
clinic I None
and I None
laboratory I None
of I None
endocrinology I None
of I None
reproduction I None
. I None
<eof> I None

<s> O None
PATIENT I None
( I None
S I None
) I None
: I None
Women I None
presenting I None
for I None
infertility I None
or I None
pelvic I None
pain I None
in I None
whom I None
endometriosis I None
was I None
diagnosed I None
by I None
using I None
laparoscopy I None
. I None
<eof> I None

<s> O None
INTERVENTION I None
( I None
S I None
) I None
: I None
Endometrial I None
tissue I None
biopsy I None
performed I None
at I None
laparoscopy I None
. I None
<eof> I None

<s> O None
MAIN I None
OUTCOME I None
MEASURE I None
( I None
S I None
) I None
: I None
Secretion I None
of I None
MCP I GENE-Y
- O GENE-Y
1 O GENE-Y
protein I None
was I None
measured I None
by I None
using I None
enzyme I None
- I None
linked I None
immunosorbent I None
assay I None
, I None
and I None
mRNA I None
steady I None
- I None
state I None
levels I None
were I None
measured I None
by I None
performing I None
Northern I None
blot I None
analysis I None
. I None
<eof> I None

<s> O None
RESULT I None
( I None
S I None
) I None
: I None
Buserelin I CHEMICAL
acetate O CHEMICAL
, I None
a I None
GnRH I GENE-Y
agonist I None
( I None
0 I None
. I None
1 I None
- I None
10 I None
ng I None
/ I None
mL I None
) I None
, I None
had I None
no I None
significant I None
effect I None
on I None
MCP I GENE-Y
- O GENE-Y
1 O GENE-Y
expression I None
, I None
whereas I None
danazol I CHEMICAL
( I None
10 I None
( I None
- I None
7 I None
) I None
- I None
10 I None
( I None
- I None
5 I None
) I None
M I None
) I None
, I None
a I None
testosterone I CHEMICAL
analog I None
, I None
and I None
dexamethasone I CHEMICAL
, I None
an I None
anti I None
- I None
inflammatory I None
glucocorticoid I None
hormone I None
( I None
10 I None
( I None
- I None
12 I None
) I None
- I None
10 I None
( I None
- I None
6 I None
) I None
M I None
) I None
, I None
showed I None
a I None
direct I None
and I None
a I None
dose I None
- I None
dependent I None
inhibitory I None
effect I None
on I None
MCP I GENE-Y
- O GENE-Y
1 O GENE-Y
expression I None
. I None
<eof> I None

<s> O None
This I None
effect I None
occurred I None
at I None
the I None
level I None
of I None
protein I None
and I None
mRNA I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
( I None
S I None
) I None
: I None
The I None
findings I None
of I None
the I None
study I None
may I None
affect I None
understanding I None
of I None
the I None
mechanisms I None
by I None
which I None
hormonal I None
treatments I None
act I None
on I None
endometriosis I None
and I None
influence I None
its I None
clinical I None
manifestations I None
. I None
<eof> I None

<s> O None
Pharmacological I None
modulation I None
of I None
nerve I GENE-Y
growth O GENE-Y
factor O GENE-Y
synthesis I None
: I None
a I None
mechanistic I None
comparison I None
of I None
vitamin I GENE-Y
D O GENE-Y
receptor O GENE-Y
and I None
beta I GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
agonists I None
. I None
<eof> I None

<s> O None
Increasing I None
nerve I GENE-Y
growth O GENE-Y
factor O GENE-Y
( I None
NGF I GENE-Y
) I None
in I None
the I None
PNS I None
is I None
a I None
rational I None
strategy I None
for I None
treating I None
certain I None
neurodegenerative I None
disorders I None
. I None
<eof> I None

<s> O None
The I None
present I None
studies I None
were I None
undertaken I None
to I None
compare I None
two I None
compounds I None
, I None
a I None
vitamin I CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
analogue I None
( I None
CB1093 I CHEMICAL
) I None
with I None
minimal I None
calcaemic I None
effects I None
, I None
and I None
clenbuterol I CHEMICAL
, I None
a I None
long I None
- I None
acting I None
beta I GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
agonist I None
, I None
both I None
of I None
which I None
induce I None
NGF I GENE-Y
synthesis I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Clenbuterol I CHEMICAL
caused I None
significant I None
increases I None
in I None
both I None
NGF I GENE-Y
mRNA I None
and I None
protein I None
in I None
3T3 I None
cells I None
; I None
with I None
maxima I None
at I None
10 I None
nM I None
and I None
at I None
8 I None
- I None
12 I None
h I None
exposure I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
clenbuterol I CHEMICAL
on I None
NGF I GENE-Y
mRNA I None
were I None
antagonized I None
by I None
propranolol I CHEMICAL
. I None
<eof> I None

<s> O None
Mobility I None
shift I None
assays I None
on I None
whole I None
cell I None
extracts I None
showed I None
that I None
clenbuterol I CHEMICAL
increased I None
AP1 I GENE-Y
binding I None
in I None
3T3 I None
cells I None
prior I None
to I None
increasing I None
NGF I GENE-Y
synthesis I None
. I None
<eof> I None

<s> O None
Clenbuterol I CHEMICAL
was I None
without I None
effect I None
on I None
NGF I GENE-Y
mRNA I None
levels I None
in I None
L929 I None
cells I None
, I None
whereas I None
CB1093 I CHEMICAL
caused I None
significant I None
increases I None
in I None
both I None
NGF I GENE-Y
mRNA I None
and I None
protein I None
levels I None
in I None
both I None
3T3 I None
and I None
L929 I None
cells I None
. I None
<eof> I None

<s> O None
Stimulation I None
was I None
almost I None
maximal I None
at I None
24 I None
h I None
exposure I None
and I None
was I None
sustained I None
for I None
at I None
least I None
72 I None
h I None
. I None
<eof> I None

<s> O None
The I None
magnitude I None
of I None
the I None
increase I None
was I None
much I None
greater I None
in I None
L929 I None
( I None
700 I None
% I None
increase I None
) I None
than I None
in I None
3T3 I None
cells I None
( I None
80 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Binding I None
to I None
the I None
vitamin I GENE-Y
D O GENE-Y
nuclear O GENE-Y
receptor O GENE-Y
( I None
VDR I GENE-Y
) I None
, I None
which I None
acts I None
as I None
a I None
transcription I None
factor I None
itself I None
, I None
was I None
increased I None
as I None
early I None
as I None
30 I None
min I None
after I None
exposure I None
to I None
of I None
CB1093 I CHEMICAL
and I None
maintained I None
up I None
to I None
24 I None
h I None
. I None
<eof> I None

<s> O None
Increased I None
VDR I GENE-Y
binding I None
preceded I None
increased I None
NGF I GENE-Y
mRNA I None
. I None
<eof> I None

<s> O None
A I None
150 I None
% I None
increase I None
in I None
AP I GENE-Y
- O GENE-Y
1 O GENE-Y
binding I None
was I None
also I None
evident I None
. I None
<eof> I None

<s> O None
This I None
study I None
demonstrates I None
that I None
CB1093 I CHEMICAL
and I None
clenbuterol I CHEMICAL
stimulate I None
NGF I GENE-Y
levels I None
in I None
vitro I None
and I None
that I None
AP I GENE-Y
- O GENE-Y
1 O GENE-Y
binding I None
could I None
be I None
a I None
commonality I None
between I None
the I None
mechanism I None
of I None
NGF I GENE-Y
induction I None
of I None
these I None
two I None
compounds I None
. I None
<eof> I None

<s> O None
Protective I None
effect I None
of I None
halothane I CHEMICAL
anesthesia I None
on I None
retinal I None
light I None
damage I None
: I None
inhibition I None
of I None
metabolic I None
rhodopsin I GENE-N
regeneration I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
To I None
determine I None
whether I None
the I None
volatile I None
anesthetic I None
halothane I CHEMICAL
protects I None
against I None
light I None
- I None
induced I None
photoreceptor I GENE-N
degeneration I None
in I None
the I None
rodent I None
retina I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Albino I None
mice I None
and I None
rats I None
were I None
anesthetized I None
with I None
halothane I CHEMICAL
and I None
exposed I None
to I None
high I None
levels I None
of I None
white I None
or I None
blue I None
light I None
. I None
<eof> I None

<s> O None
Nonanesthetized I None
animals I None
served I None
as I None
controls I None
. I None
<eof> I None

<s> O None
Retinal I None
morphology I None
was I None
assessed I None
by I None
light I None
microscopy I None
, I None
and I None
apoptosis I None
of I None
photoreceptor I GENE-N
cells I None
was I None
verified I None
by I None
detection I None
of I None
fragmented I None
genomic I None
DNA I None
and I None
in I None
situ I None
staining I None
of I None
apoptotic I None
nuclei I None
( I None
TUNEL I None
assay I None
) I None
. I None
<eof> I None

<s> O None
Rhodopsin I GENE-N
regeneration I None
after I None
bleaching I None
was I None
determined I None
by I None
measuring I None
rhodopsin I GENE-N
levels I None
in I None
retinas I None
of I None
mice I None
or I None
rats I None
at I None
different I None
time I None
points I None
in I None
darkness I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Halothane I CHEMICAL
anesthesia I None
reversibly I None
inhibited I None
metabolic I None
rhodopsin I GENE-N
regeneration I None
and I None
thus I None
prevented I None
rhodopsin I GENE-N
from I None
absorbing I None
high I None
numbers I None
of I None
photons I None
during I None
light I None
exposure I None
. I None
<eof> I None

<s> O None
Consequently I None
, I None
photoreceptors I GENE-N
of I None
mice I None
and I None
rats I None
anesthetized I None
with I None
halothane I CHEMICAL
were I None
completely I None
protected I None
against I None
degeneration I None
induced I None
by I None
white I None
light I None
. I None
<eof> I None

<s> O None
In I None
remarkable I None
contrast I None
, I None
however I None
, I None
halothane I CHEMICAL
anesthesia I None
did I None
not I None
protect I None
against I None
blue I None
- I None
light I None
- I None
induced I None
photoreceptor I None
cell I None
death I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
After I None
the I None
initial I None
bleach I None
, I None
halothane I CHEMICAL
impeded I None
photon I None
absorption I None
by I None
rhodopsin I GENE-N
by I None
inhibiting I None
metabolic I None
rhodopsin I GENE-N
regeneration I None
. I None
<eof> I None

<s> O None
Apparently I None
, I None
the I None
rhodopsin I GENE-N
- I None
mediated I None
uptake I None
of I None
the I None
critical I None
number I None
of I None
photons I None
to I None
initiate I None
white I None
light I None
- I None
induced I None
retinal I None
degeneration I None
was I None
prevented I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
halothane I CHEMICAL
did I None
not I None
protect I None
the I None
retina I None
against I None
blue I None
light I None
. I None
<eof> I None

<s> O None
Blue I None
light I None
can I None
efficiently I None
restore I None
functional I None
rhodopsin I GENE-N
from I None
bleaching I None
intermediates I None
through I None
a I None
process I None
termed I None
photoreversal I None
of I None
bleaching I None
. I None
<eof> I None

<s> O None
This I None
process I None
does I None
not I None
depend I None
on I None
the I None
visual I None
cycle I None
via I None
the I None
pigment I None
epithelium I None
but I None
nevertheless I None
enables I None
rhodopsin I GENE-N
molecules I None
to I None
absorb I None
the I None
critical I None
number I None
of I None
photons I None
required I None
to I None
induce I None
retinal I None
degeneration I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
antidepressant I None
activity I None
in I None
4 I None
- I None
and I None
40 I None
- I None
week I None
- I None
old I None
male I None
mice I None
in I None
the I None
forced I None
swimming I None
test I None
: I None
involvement I None
of I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptors I None
in I None
old I None
mice I None
. I None
<eof> I None

<s> O None
RATIONALE I None
: I None
A I None
recent I None
study I None
suggested I None
that I None
selective I None
serotonin I CHEMICAL
reuptake I None
inhibitors I None
were I None
inactive I None
in I None
40 I None
- I None
week I None
- I None
old I None
male I None
mice I None
in I None
the I None
mouse I None
forced I None
swimming I None
test I None
, I None
possibly I None
because I None
of I None
alteration I None
of I None
5 I GENE-N
- O GENE-N
HT1 O GENE-N
receptors I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
The I None
present I None
study I None
was I None
aimed I None
at I None
investigating I None
the I None
action I None
of I None
various I None
antidepressant I None
drugs I None
in I None
4 I None
- I None
and I None
40 I None
- I None
week I None
- I None
old I None
male I None
mice I None
using I None
the I None
mouse I None
forced I None
swimming I None
test I None
and I None
determining I None
the I None
involvement I None
of I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptors I None
mediating I None
the I None
effects I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Different I None
classes I None
of I None
antidepressants I None
[ I None
imipramine I CHEMICAL
( I None
tricyclic I CHEMICAL
) I None
, I None
maprotiline I CHEMICAL
( I None
noradrenline I CHEMICAL
reuptake I None
inhibitor I None
) I None
, I None
venlafaxine I CHEMICAL
( I None
mixed I None
serotonin I CHEMICAL
and I None
noradrenaline I CHEMICAL
reuptake I None
inhibitors I None
) I None
, I None
fluvoxamine I CHEMICAL
and I None
sertraline I CHEMICAL
( I None
selective I None
serotonin I CHEMICAL
reuptake I None
inhibitor I None
) I None
] I None
were I None
tested I None
in I None
the I None
same I None
randomised I None
experimental I None
session I None
, I None
alone I None
and I None
in I None
combination I None
with I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptor I None
agonists I None
[ I None
buspirone I CHEMICAL
( I None
partial I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
agonist I None
) I None
, I None
anpirtoline I CHEMICAL
( I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
agonist I None
) I None
] I None
in I None
the I None
mouse I None
forced I None
swimming I None
test I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
All I None
antidepressants I None
were I None
found I None
to I None
be I None
active I None
in I None
the I None
mouse I None
forced I None
swimming I None
test I None
in I None
4 I None
- I None
week I None
- I None
old I None
mice I None
and I None
40 I None
- I None
week I None
- I None
old I None
mice I None
, I None
with I None
the I None
exception I None
of I None
fluvoxamine I CHEMICAL
in I None
the I None
40 I None
- I None
week I None
- I None
old I None
mice I None
. I None
<eof> I None

<s> O None
The I None
anti I None
- I None
immobility I None
effect I None
after I None
antidepressant I None
administration I None
was I None
higher I None
in I None
4 I None
- I None
week I None
- I None
old I None
male I None
mice I None
than I None
in I None
40 I None
- I None
week I None
- I None
old I None
male I None
mice I None
. I None
<eof> I None

<s> O None
Venlafaxine I CHEMICAL
is I None
the I None
most I None
active I None
antidepressant I None
drug I None
in I None
40 I None
- I None
week I None
- I None
old I None
mice I None
. I None
<eof> I None

<s> O None
Prior I None
administration I None
of I None
buspirone I CHEMICAL
( I None
0 I None
. I None
06 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
p I None
. I None
) I None
or I None
anpirtoline I CHEMICAL
( I None
1 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
p I None
. I None
) I None
enhanced I None
the I None
antidepressant I None
- I None
like I None
effects I None
in I None
4 I None
- I None
week I None
- I None
old I None
mice I None
( I None
except I None
in I None
the I None
case I None
of I None
sertraline I CHEMICAL
, I None
8 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
In I None
elderly I None
mice I None
, I None
only I None
prior I None
administration I None
of I None
buspirone I CHEMICAL
enhanced I None
the I None
antidepressant I None
- I None
like I None
effects I None
of I None
fluvoxamine I CHEMICAL
. I None
<eof> I None

<s> O None
A I None
neurochemical I None
study I None
showed I None
that I None
significantly I None
higher I None
serotonin I CHEMICAL
and I None
dopamine I CHEMICAL
concentrations I None
were I None
found I None
in I None
40 I None
- I None
week I None
- I None
old I None
control I None
mice I None
brains I None
than I None
4 I None
- I None
week I None
- I None
old I None
control I None
mice I None
brains I None
but I None
that I None
the I None
noradrenaline I CHEMICAL
concentration I None
is I None
higher I None
in I None
4 I None
- I None
week I None
- I None
old I None
mice I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
Tricyclic I CHEMICAL
, I None
noradrenaline I CHEMICAL
reuptake I None
inhibitors I None
and I None
serotonin I CHEMICAL
reuptake I None
inhibitors I None
are I None
more I None
active I None
in I None
4 I None
- I None
week I None
- I None
old I None
mice I None
than I None
40 I None
- I None
week I None
- I None
old I None
mice I None
. I None
<eof> I None

<s> O None
Our I None
results I None
suggested I None
that I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptors I None
may I None
be I None
more I None
altered I None
than I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
receptors I None
in I None
40 I None
- I None
week I None
- I None
old I None
mice I None
. I None
<eof> I None

<s> O None
Cytochrome I GENE-N
P450 O GENE-N
4A O GENE-N
, I None
peroxisomal I None
enzymes I None
and I None
nicotinamide I CHEMICAL
cofactors I None
in I None
koala I None
liver I None
. I None
<eof> I None

<s> O None
We I None
have I None
examined I None
hepatic I None
levels I None
of I None
microsomal I None
lauric I GENE-N
acid O GENE-N
hydroxylase O GENE-N
activity I None
and I None
cyanide I None
- I None
insensitive I None
palmitoyl I None
coenzyme I None
A I None
oxidative I None
activity I None
in I None
koala I None
( I None
Phascolarctos I None
cinereus I None
) I None
and I None
tammar I None
wallaby I None
( I None
Macropus I None
eugenii I None
) I None
and I None
compared I None
our I None
results I None
to I None
those I None
determined I None
in I None
rat I None
. I None
<eof> I None

<s> O None
Microsomal I None
lauric I CHEMICAL
acid O CHEMICAL
hydroxylation I None
was I None
significantly I None
higher I None
in I None
koala I None
than I None
in I None
tammar I None
wallaby I None
or I None
rat I None
. I None
<eof> I None

<s> O None
However I None
, I None
cyanide I None
- I None
insensitive I None
palmitoyl I None
- I None
CoA I None
oxidation I None
was I None
absent I None
in I None
the I None
koala I None
. I None
<eof> I None

<s> O None
We I None
have I None
also I None
determined I None
the I None
hepatic I None
nicotinamide I CHEMICAL
cofactors I None
in I None
these I None
species I None
. I None
<eof> I None

<s> O None
Hepatic I None
nicotinamide I CHEMICAL
- O CHEMICAL
adenine O CHEMICAL
dinucleotide O CHEMICAL
( I None
NAD I CHEMICAL
) I None
and I None
the I None
ratio I None
of I None
NAD I CHEMICAL
/ I None
nicotinamide I CHEMICAL
- O CHEMICAL
adenine O CHEMICAL
dinucleotide O CHEMICAL
phosphate O CHEMICAL
( I None
NADP I CHEMICAL
) I None
were I None
higher I None
in I None
koala I None
than I None
in I None
tammar I None
wallaby I None
and I None
rat I None
liver I None
. I None
<eof> I None

<s> O None
Reverse I None
transcription I None
of I None
koala I None
liver I None
mRNA I None
, I None
followed I None
by I None
polymerase I None
chain I None
reaction I None
using I None
primers I None
based I None
on I None
highly I None
conserved I None
areas I None
in I None
the I None
CYP4A I GENE-N
family I None
led I None
to I None
the I None
cloning I None
of I None
a I None
partial I None
, I None
near I None
full I None
length I None
, I None
cDNA I None
clone I None
with I None
approximately I None
70 I None
% I None
nucleotide I CHEMICAL
and I None
deduced I None
amino I CHEMICAL
acid O CHEMICAL
sequence I None
identity I None
to I None
human I GENE-Y
CYP4A11 O GENE-Y
. I None
<eof> I None

<s> O None
The I None
CYP I GENE-N
has I None
been I None
named I None
CYP4A15 I GENE-Y
. I None
<eof> I None

<s> O None
Gemcitabine I CHEMICAL
and I None
Pemetrexed I CHEMICAL
disodium O CHEMICAL
in I None
treating I None
breast I None
cancer I None
. I None
<eof> I None

<s> O None
Pemetrexed I CHEMICAL
disodium O CHEMICAL
( I None
Alimta I CHEMICAL
, I None
LY231514 I CHEMICAL
) I None
is I None
a I None
novel I None
, I None
multitargeted I None
antifolate I None
that I None
inhibits I None
thymidylate I GENE-Y
synthase O GENE-Y
, I None
dihydrofolate I GENE-Y
reductase O GENE-Y
, I None
and I None
glycinamide I GENE-Y
ribonucleotide O GENE-Y
formyl O GENE-Y
transferase O GENE-Y
. I None
<eof> I None

<s> O None
This I None
agent I None
is I None
broadly I None
active I None
in I None
a I None
wide I None
variety I None
of I None
solid I None
tumors I None
, I None
including I None
breast I None
cancer I None
. I None
<eof> I None

<s> O None
Pemetrexed I CHEMICAL
disodium O CHEMICAL
has I None
also I None
shown I None
clinically I None
relevant I None
activity I None
in I None
combination I None
with I None
gemcitabine I CHEMICAL
( I None
Gemzar I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
This I None
combination I None
is I None
being I None
evaluated I None
for I None
the I None
treatment I None
of I None
metastatic I None
breast I None
cancer I None
. I None
<eof> I None

<s> O None
Distal I None
bowel I None
selectivity I None
in I None
the I None
chemoprevention I None
of I None
experimental I None
colon I None
carcinogenesis I None
by I None
the I None
non I None
- I None
steroidal I CHEMICAL
anti I None
- I None
inflammatory I None
drug I None
nabumetone I CHEMICAL
. I None
<eof> I None

<s> O None
Use I None
of I None
non I None
- I None
steroidal I CHEMICAL
anti I None
- I None
inflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
for I None
chemoprevention I None
of I None
colon I None
cancer I None
has I None
been I None
hindered I None
by I None
their I None
potential I None
gastro I None
- I None
intestinal I None
toxicity I None
. I None
<eof> I None

<s> O None
Nabumetone I CHEMICAL
, I None
which I None
is I None
approximately I None
10 I None
to I None
36 I None
times I None
safer I None
than I None
conventional I None
NSAIDs I None
, I None
was I None
evaluated I None
in I None
2 I None
models I None
of I None
experimental I None
colon I None
carcinogenesis I None
. I None
<eof> I None

<s> O None
In I None
azoxymethane I CHEMICAL
( I None
AOM I CHEMICAL
) I None
- I None
treated I None
Fisher I None
344 I None
rats I None
, I None
nabumetone I CHEMICAL
caused I None
dose I None
- I None
dependent I None
inhibition I None
of I None
aberrant I None
crypt I None
foci I None
( I None
ACF I None
) I None
, I None
with I None
750 I None
and I None
1 I None
, I None
500 I None
ppm I None
resulting I None
in I None
15 I None
% I None
and I None
37 I None
% I None
reductions I None
, I None
respectively I None
( I None
p I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
complex I None
ACF I None
were I None
reduced I None
by I None
48 I None
% I None
in I None
the I None
latter I None
group I None
. I None
<eof> I None

<s> O None
MIN I None
mice I None
studies I None
confirmed I None
the I None
chemopreventive I None
efficacy I None
of I None
nabumetone I CHEMICAL
, I None
with I None
900 I None
ppm I None
suppressing I None
approximately I None
half I None
of I None
the I None
intestinal I None
tumors I None
. I None
<eof> I None

<s> O None
Interestingly I None
, I None
inhibition I None
of I None
intermediate I None
biomarkers I None
in I None
both I None
models I None
was I None
markedly I None
greater I None
in I None
the I None
distal I None
than I None
the I None
proximal I None
bowel I None
. I None
<eof> I None

<s> O None
To I None
mechanistically I None
evaluate I None
this I None
regional I None
selectivity I None
, I None
we I None
assessed I None
cyclo I GENE-N
- O GENE-N
oxygenase O GENE-N
- O GENE-N
2 O GENE-N
( I None
COX I GENE-N
- O GENE-N
2 O GENE-N
) I None
expression I None
in I None
the I None
uninvolved I None
mucosa I None
and I None
demonstrated I None
a I None
3 I None
- I None
to I None
4 I None
- I None
fold I None
excess I None
in I None
the I None
distal I None
relative I None
to I None
the I None
proximal I None
bowel I None
in I None
both I None
MIN I None
mice I None
and I None
AOM I CHEMICAL
- I None
treated I None
rats I None
. I None
<eof> I None

<s> O None
We I None
then I None
investigated I None
another I None
putative I None
NSAID I None
target I None
, I None
peroxisome I GENE-N
proliferator O GENE-N
- O GENE-N
activated O GENE-N
receptor O GENE-N
- O GENE-N
delta O GENE-N
( I None
PPAR I GENE-N
- O GENE-N
delta O GENE-N
) I None
and I None
demonstrated I None
up I None
- I None
regulation I None
during I None
AOM I None
- I None
induced I None
colonic I None
tumorigenesis I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
in I None
pre I None
- I None
neoplastic I None
mucosa I None
, I None
there I None
was I None
a I None
3 I None
- I None
fold I None
excess I None
of I None
PPAR I GENE-N
- O GENE-N
delta O GENE-N
in I None
the I None
distal I None
colon I None
. I None
<eof> I None

<s> O None
We I None
demonstrate I None
that I None
nabumetone I CHEMICAL
is I None
an I None
effective I None
protective I None
agent I None
in I None
both I None
experimental I None
models I None
of I None
colon I None
carcinogenesis I None
. I None
<eof> I None

<s> O None
The I None
striking I None
distal I None
predilection I None
of I None
nabumetone I CHEMICAL
may I None
be I None
, I None
at I None
least I None
partially I None
, I None
explained I None
by I None
distal I None
bowel I None
over I None
- I None
expression I None
of I None
COX I GENE-N
- O GENE-N
2 O GENE-N
and I None
PPAR I GENE-N
- O GENE-N
delta O GENE-N
. I None
<eof> I None

<s> O None
Nuclear I None
diacylglycerol I GENE-Y
kinase O GENE-Y
- O GENE-Y
theta O GENE-Y
is I None
activated I None
in I None
response I None
to I None
alpha I GENE-Y
- O GENE-Y
thrombin O GENE-Y
. I None
<eof> I None

<s> O None
Currently I None
, I None
there I None
is I None
substantial I None
evidence I None
that I None
nuclear I None
lipid I None
metabolism I None
plays I None
a I None
critical I None
role I None
in I None
a I None
number I None
of I None
signal I None
transduction I None
cascades I None
. I None
<eof> I None

<s> O None
Previous I None
work I None
from I None
our I None
laboratory I None
showed I None
that I None
stimulation I None
of I None
quiescent I None
fibroblasts I None
with I None
alpha I GENE-Y
- O GENE-Y
thrombin O GENE-Y
leads I None
to I None
the I None
production I None
of I None
two I None
lipid I None
second I None
messengers I None
in I None
the I None
nucleus I None
: I None
an I None
increase I None
in I None
nuclear I None
diacylglycerol I CHEMICAL
mass I None
and I None
an I None
activation I None
of I None
phospholipase I None
D I None
, I None
which I None
catalyzes I None
the I None
hydrolysis I None
of I None
phosphatidylcholine I CHEMICAL
to I None
generate I None
phosphatidic I CHEMICAL
acid O CHEMICAL
. I None
<eof> I None

<s> O None
Diacylglycerol I GENE-N
kinase O GENE-N
( I None
DGK I GENE-N
) I None
catalyzes I None
the I None
conversion I None
of I None
diacylglycerol I CHEMICAL
to I None
phosphatidic I CHEMICAL
acid O CHEMICAL
, I None
making I None
it I None
an I None
attractive I None
candidate I None
for I None
a I None
signal I None
transduction I None
component I None
. I None
<eof> I None

<s> O None
There I None
is I None
substantial I None
evidence I None
that I None
this I None
activity I None
is I None
indeed I None
regulated I None
in I None
a I None
number I None
of I None
signaling I None
cascades I None
( I None
reviewed I None
by I None
van I None
Blitterswijk I None
, I None
W I None
. I None
J I None
. I None
, I None
and I None
Houssa I None
, I None
B I None
. I None
( I None
1999 I None
) I None
Chem I None
. I None
Phys I None
. I None
Lipids I None
98 I None
, I None
95 I None
- I None
108 I None
) I None
. I None
<eof> I None

<s> O None
In I None
this I None
report I None
, I None
we I None
show I None
that I None
the I None
addition I None
of I None
alpha I GENE-Y
- O GENE-Y
thrombin O GENE-Y
to I None
quiescent I None
IIC9 I None
fibroblasts I None
results I None
in I None
an I None
increase I None
in I None
nuclear I None
DGK I GENE-N
activity I None
. I None
<eof> I None

<s> O None
The I None
examination I None
of I None
nuclei I None
isolated I None
from I None
quiescent I None
IIC9 I None
cells I None
indicates I None
that I None
DGK I GENE-Y
- O GENE-Y
theta O GENE-Y
and I None
DGK I GENE-Y
- O GENE-Y
delta O GENE-Y
are I None
both I None
present I None
. I None
<eof> I None

<s> O None
We I None
took I None
advantage I None
of I None
the I None
previous I None
observations I None
that I None
phosphatidylserine I CHEMICAL
inhibits I None
DGK I GENE-Y
- O GENE-Y
delta O GENE-Y
( I None
reviewed I None
by I None
Sakane I None
, I None
F I None
. I None
, I None
Imai I None
, I None
S I None
. I None
, I None
Kai I None
, I None
M I None
. I None
, I None
Wada I None
, I None
I I None
. I None
, I None
and I None
Kanoh I None
, I None
H I None
. I None
( I None
1996 I None
) I None
J I None
. I None
Biol I None
. I None
Chem I None
. I None
271 I None
, I None
8394 I None
- I None
8401 I None
) I None
, I None
and I None
constitutively I None
active I None
RhoA I GENE-Y
inhibits I None
DGK I GENE-Y
- O GENE-Y
theta O GENE-Y
( I None
reviewed I None
by I None
Houssa I None
, I None
B I None
. I None
, I None
de I None
Widt I None
, I None
J I None
. I None
, I None
Kranenburg I None
, I None
O I None
. I None
, I None
Moolenaar I None
, I None
W I None
. I None
H I None
. I None
, I None
and I None
van I None
Blitterswijk I None
, I None
W I None
. I None
J I None
. I None
( I None
1999 I None
) I None
J I None
. I None
Biol I None
. I None
Chem I None
. I None
274 I None
, I None
6820 I None
- I None
6822 I None
) I None
to I None
identify I None
the I None
activity I None
induced I None
by I None
alpha I GENE-Y
- O GENE-Y
thrombin O GENE-Y
. I None
<eof> I None

<s> O None
Constitutively I None
active I None
RhoA I GENE-Y
inhibited I None
the I None
nuclear I None
stimulated I None
activity I None
, I None
whereas I None
phosphatidylserine I CHEMICAL
did I None
not I None
have I None
an I None
inhibitory I None
effect I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
a I None
monoclonal I None
anti I None
- I None
DGK I GENE-Y
- O GENE-Y
theta O GENE-Y
antibody I None
inhibited I None
the I None
alpha I GENE-Y
- O GENE-Y
thrombin O GENE-Y
- I None
stimulated I None
nuclear I None
activity I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
These I None
results I None
demonstrate I None
that I None
DGK I GENE-Y
- O GENE-Y
theta O GENE-Y
is I None
the I None
isoform I None
responsive I None
to I None
alpha I GENE-Y
- O GENE-Y
thrombin O GENE-Y
stimulation I None
. I None
<eof> I None

<s> O None
Western I None
blot I None
and I None
immunofluorescence I None
microscopy I None
analyses I None
showed I None
that I None
alpha I GENE-Y
- O GENE-Y
thrombin O GENE-Y
induced I None
the I None
translocation I None
of I None
DGK I GENE-Y
- O GENE-Y
theta O GENE-Y
to I None
the I None
nucleus I None
, I None
implicating I None
that I None
this I None
translocation I None
is I None
at I None
least I None
partly I None
responsible I None
for I None
the I None
increased I None
nuclear I None
activity I None
. I None
<eof> I None

<s> O None
Taken I None
together I None
, I None
these I None
data I None
are I None
the I None
first I None
to I None
demonstrate I None
an I None
agonist I None
- I None
induced I None
activity I None
of I None
nuclear I None
DGK I GENE-Y
- O GENE-Y
theta O GENE-Y
activity I None
and I None
a I None
nuclear I None
localization I None
of I None
DGK I GENE-Y
- O GENE-Y
delta O GENE-Y
. I None
<eof> I None

<s> O None
Pharmacokinetic I None
analysis I None
by I None
high I None
- I None
performance I None
liquid I None
chromatography I None
of I None
intravenous I None
nordihydroguaiaretic I CHEMICAL
acid O CHEMICAL
in I None
the I None
mouse I None
. I None
<eof> I None

<s> O None
Nordihydroguaiaretic I CHEMICAL
acid O CHEMICAL
( I None
NDGA I CHEMICAL
) I None
has I None
been I None
shown I None
to I None
inhibit I None
both I None
5 I GENE-Y
- O GENE-Y
lipoxygenase O GENE-Y
and I None
ornithine I GENE-Y
decarboxylase O GENE-Y
and I None
is I None
active I None
against I None
several I None
cancer I None
cell I None
lines I None
and I None
at I None
least I None
one I None
mouse I None
tumor I None
model I None
. I None
<eof> I None

<s> O None
Despite I None
these I None
findings I None
, I None
there I None
have I None
been I None
no I None
reports I None
on I None
the I None
pharmacokinetics I None
of I None
NDGA I CHEMICAL
. I None
<eof> I None

<s> O None
A I None
reverse I None
- I None
phase I None
high I None
- I None
performance I None
liquid I None
chromatography I None
( I None
HPLC I None
) I None
method I None
was I None
developed I None
to I None
detect I None
NDGA I CHEMICAL
in I None
mouse I None
plasma I None
. I None
<eof> I None

<s> O None
The I None
limit I None
of I None
detection I None
of I None
this I None
method I None
was I None
0 I None
. I None
5 I None
microg I None
/ I None
ml I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
NDGA I CHEMICAL
( I None
50 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
v I None
. I None
) I None
to I None
mice I None
resulted I None
in I None
a I None
peak I None
plasma I None
concentration I None
of I None
14 I None
. I None
7 I None
microg I None
/ I None
ml I None
. I None
<eof> I None

<s> O None
The I None
terminal I None
half I None
- I None
life I None
of I None
NDGA I CHEMICAL
was I None
135 I None
. I None
0 I None
min I None
with I None
a I None
clearance I None
of I None
201 I None
. I None
9 I None
ml I None
/ I None
min I None
x I None
kg I None
. I None
<eof> I None

<s> O None
Vasoconstrictive I None
drugs I None
increase I None
carbonic I GENE-Y
anhydrase O GENE-Y
I O GENE-Y
in I None
vascular I None
smooth I None
muscle I None
while I None
vasodilating I None
drugs I None
reduce I None
the I None
activity I None
of I None
this I None
isozyme I None
by I None
a I None
direct I None
mechanism I None
of I None
action I None
. I None
<eof> I None

<s> O None
Carbonic I GENE-N
anhydrase O GENE-N
( I None
CA I GENE-N
) I None
is I None
a I None
zinc I CHEMICAL
enzyme I None
that I None
catalyses I None
the I None
reversible I None
hydration I None
reaction I None
of I None
CO2 I CHEMICAL
and I None
plays I None
a I None
major I None
role I None
in I None
the I None
acid I None
- I None
base I None
balance I None
. I None
<eof> I None

<s> O None
We I None
have I None
previously I None
shown I None
that I None
certain I None
vasoconstrictive I None
therapeutic I None
agents I None
increase I None
CA I GENE-Y
I O GENE-Y
activity I None
whereas I None
vasodilating I None
drugs I None
reduce I None
the I None
activity I None
of I None
this I None
isozyme I None
by I None
a I None
direct I None
mechanism I None
of I None
action I None
. I None
<eof> I None

<s> O None
In I None
this I None
paper I None
we I None
studied I None
the I None
effect I None
of I None
other I None
vasoconstrictive I None
and I None
vasodilating I None
agents I None
on I None
CA I GENE-Y
I O GENE-Y
activity I None
in I None
order I None
to I None
elucidate I None
the I None
involvement I None
of I None
vascular I None
smooth I None
muscle I None
CA I GENE-Y
I O GENE-Y
in I None
vasoconstrictive I None
and I None
vasodilating I None
processes I None
. I None
<eof> I None

<s> O None
We I None
studied I None
the I None
in I None
vitro I None
effects I None
of I None
noradrenaline I CHEMICAL
, I None
prostaglandin I CHEMICAL
F2 O CHEMICAL
alpha O CHEMICAL
, I None
thromboxane I CHEMICAL
A2 O CHEMICAL
, I None
leukotriene I CHEMICAL
B4 O CHEMICAL
, I None
angiotensin I CHEMICAL
II O CHEMICAL
, I None
vasopressin I CHEMICAL
, I None
indomethacin I CHEMICAL
, I None
prazosin I CHEMICAL
, I None
hydralazine I CHEMICAL
, I None
clonidine I CHEMICAL
, I None
reserpine I CHEMICAL
, I None
prostaglandin I CHEMICAL
I2 O CHEMICAL
, I None
indapamide I CHEMICAL
, I None
furosemide I CHEMICAL
, I None
amlodipine I CHEMICAL
, I None
verapamil I CHEMICAL
and I None
irbesartan I CHEMICAL
on I None
purified I None
human I GENE-Y
red O GENE-Y
blood O GENE-Y
cell O GENE-Y
CA O GENE-Y
I O GENE-Y
and I None
vascular I None
smooth I None
muscle I None
CA I GENE-Y
I O GENE-Y
isolated I None
from I None
rabbits I None
. I None
<eof> I None

<s> O None
In I None
vivo I None
, I None
we I None
selected I None
six I None
groups I None
of I None
five I None
rabbits I None
each I None
, I None
which I None
were I None
administered I None
the I None
following I None
substances I None
in I None
acute I None
experiments I None
: I None
orciprenaline I CHEMICAL
( I None
group I None
1 I None
) I None
, I None
desmopressin I CHEMICAL
( I None
group I None
2 I None
) I None
, I None
verapamil I CHEMICAL
( I None
group I None
3 I None
) I None
, I None
irbesartan I CHEMICAL
( I None
group I None
4 I None
) I None
, I None
acetazolamide I CHEMICAL
( I None
group I None
5 I None
) I None
and I None
placebo I None
( I None
control I None
group I None
) I None
. I None
<eof> I None

<s> O None
Vascular I None
smooth I None
muscle I None
CA I GENE-Y
I O GENE-Y
activity I None
and I None
systolic I None
blood I None
pressure I None
were I None
determined I None
and I None
compared I None
with I None
those I None
of I None
the I None
control I None
group I None
. I None
<eof> I None

<s> O None
In I None
vitro I None
results I None
showed I None
that I None
all I None
the I None
vasoconstrictive I None
agents I None
studied I None
increased I None
purified I None
and I None
human I GENE-Y
erythrocyte O GENE-Y
CA O GENE-Y
I O GENE-Y
activity I None
as I None
well I None
as I None
vascular I None
smooth I None
muscle I None
CA I GENE-Y
I O GENE-Y
, I None
while I None
vasodilating I None
substances I None
reduced I None
the I None
activity I None
of I None
isozyme I None
by I None
a I None
direct I None
mechanism I None
of I None
action I None
. I None
<eof> I None

<s> O None
The I None
same I None
results I None
obtained I None
in I None
vivo I None
showed I None
that I None
activation I None
of I None
vascular I None
smooth I None
muscle I None
CA I GENE-Y
I O GENE-Y
increased I None
blood I None
pressure I None
while I None
its I None
inhibition I None
reduced I None
blood I None
pressure I None
. I None
<eof> I None

<s> O None
The I None
results I None
of I None
this I None
study I None
suggest I None
that I None
pHi I None
changes I None
, I None
induced I None
by I None
activating I None
or I None
inhibiting I None
CA I GENE-Y
I O GENE-Y
in I None
vascular I None
smooth I None
muscle I None
, I None
might I None
be I None
responsible I None
for I None
changes I None
in I None
vascular I None
tonus I None
. I None
<eof> I None

<s> O None
Neuroparalysis I None
and I None
oxime I CHEMICAL
efficacy I None
in I None
organophosphate I CHEMICAL
poisoning I None
: I None
a I None
study I None
of I None
butyrylcholinesterase I GENE-Y
. I None
<eof> I None

<s> O None
The I None
temporal I None
profile I None
of I None
butyrylcholinesterase I GENE-Y
( I None
BuChE I GENE-Y
) I None
and I None
in I None
vitro I None
pralidoxime I CHEMICAL
- I None
reactivated I None
BuChE I GENE-Y
was I None
studied I None
in I None
a I None
cohort I None
of I None
25 I None
organophosphate I CHEMICAL
- I None
poisoned I None
patients I None
to I None
examine I None
their I None
relationship I None
to I None
the I None
development I None
of I None
intermediate I None
syndrome I None
and I None
to I None
understand I None
reasons I None
for I None
lack I None
of I None
efficacy I None
of I None
oxime I CHEMICAL
treatment I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
severity I None
of I None
poisoning I None
( I None
assessed I None
by I None
the I None
Namba I None
Scale I None
) I None
correlated I None
significantly I None
with I None
the I None
severity I None
of I None
intermediate I None
syndrome I None
. I None
<eof> I None

<s> O None
BuChE I GENE-Y
activity I None
increased I None
significantly I None
over I None
time I None
and I None
showed I None
significant I None
relationship I None
to I None
muscle I None
power I None
. I None
<eof> I None

<s> O None
The I None
temporal I None
profile I None
of I None
the I None
enzyme I None
was I None
correlated I None
to I None
the I None
clinical I None
severity I None
of I None
poisoning I None
. I None
<eof> I None

<s> O None
Reactivation I None
potentials I None
of I None
BuChE I GENE-Y
( I None
the I None
difference I None
between I None
oxime I CHEMICAL
- I None
reactivated I None
and I None
- I None
unreactivated I None
enzyme I None
activity I None
) I None
declined I None
significantly I None
with I None
time I None
after I None
organophosphate I CHEMICAL
ingestion I None
. I None
<eof> I None

<s> O None
The I None
reactivation I None
potential I None
of I None
the I None
enzyme I None
at I None
admission I None
decreased I None
significantly I None
with I None
increasing I None
severity I None
of I None
poisoning I None
and I None
was I None
lower I None
in I None
patients I None
who I None
developed I None
intermediate I None
syndrome I None
. I None
<eof> I None

<s> O None
Patients I None
who I None
received I None
oxime I CHEMICAL
prior I None
to I None
hospitalization I None
had I None
a I None
higher I None
rate I None
of I None
intermediate I None
syndrome I None
and I None
lower I None
levels I None
of I None
BuChE I GENE-Y
at I None
admission I None
than I None
those I None
who I None
had I None
not I None
. I None
<eof> I None

<s> O None
The I None
study I None
suggests I None
that I None
( I None
i I None
) I None
BuChE I GENE-Y
reflects I None
the I None
clinical I None
course I None
of I None
poisoning I None
, I None
confirming I None
earlier I None
studies I None
; I None
( I None
ii I None
) I None
intermediate I None
syndrome I None
may I None
be I None
associated I None
with I None
a I None
persistent I None
inhibition I None
of I None
BuChE I GENE-Y
; I None
and I None
( I None
iii I None
) I None
the I None
lack I None
of I None
oxime I CHEMICAL
efficacy I None
in I None
our I None
patients I None
maybe I None
due I None
to I None
their I None
severity I None
of I None
poisoning I None
and I None
the I None
timing I None
of I None
oxime I CHEMICAL
treatment I None
. I None
<eof> I None

<s> O None
Potent I None
alpha I GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
- I None
mediated I None
vasoconstriction I None
by I None
brimonidine I CHEMICAL
in I None
porcine I None
ciliary I None
arteries I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
An I None
investigation I None
into I None
whether I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
agonists I None
induce I None
contractions I None
in I None
the I None
porcine I None
ciliary I None
arteries I None
and I None
to I None
characterize I None
the I None
functional I None
receptor I None
subtype I None
mediating I None
these I None
responses I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Isolated I None
arteries I None
from I None
the I None
intraocular I None
part I None
of I None
the I None
porcine I None
ciliary I None
artery I None
were I None
suspended I None
in I None
microvascular I None
myographs I None
for I None
isometric I None
tension I None
recording I None
. I None
<eof> I None

<s> O None
The I None
segments I None
were I None
contracted I None
with I None
the I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
agonists I None
brimonidine I CHEMICAL
, I None
apraclonidine I CHEMICAL
, I None
and I None
oxymetazoline I CHEMICAL
. I None
<eof> I None

<s> O None
To I None
determine I None
which I None
subtypes I None
of I None
the I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
mediate I None
this I None
contraction I None
, I None
antagonists I None
subselective I None
for I None
the I None
different I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptors O GENE-N
were I None
added I None
to I None
the I None
vessel I None
bath I None
before I None
concentration I None
- I None
response I None
curves I None
for I None
brimonidine I CHEMICAL
were I None
obtained I None
. I None
<eof> I None

<s> O None
The I None
following I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
antagonists I None
were I None
applied I None
: I None
BRL44408 I CHEMICAL
( I None
alpha I GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
- I None
selective I None
) I None
, I None
ARC239 I CHEMICAL
( I None
alpha I GENE-Y
( O GENE-Y
2B O GENE-Y
) O GENE-Y
- I None
and I None
alpha I GENE-Y
( O GENE-Y
2C O GENE-Y
) O GENE-Y
- I None
selective I None
) I None
, I None
and I None
prazosin I CHEMICAL
( I None
alpha I GENE-Y
( O GENE-Y
2B O GENE-Y
) O GENE-Y
- I None
and I None
alpha I GENE-Y
( O GENE-Y
2C O GENE-Y
) O GENE-Y
- I None
selective I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
The I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
agonists I None
induced I None
vasoconstriction I None
in I None
the I None
porcine I None
ciliary I None
artery I None
with I None
the I None
following I None
potency I None
order I None
( I None
EC I None
( I None
50 I None
) I None
) I None
expressed I None
in I None
nanomolar I None
: I None
brimonidine I CHEMICAL
2 I None
. I None
11 I None
, I None
oxymetazoline I CHEMICAL
5 I None
. I None
26 I None
, I None
and I None
apraclonidine I CHEMICAL
13 I None
. I None
0 I None
. I None
<eof> I None

<s> O None
As I None
a I None
reference I None
, I None
noradrenaline I CHEMICAL
was I None
tested I None
, I None
and I None
its I None
EC I None
( I None
50 I None
) I None
was I None
determined I None
to I None
be I None
247 I None
nM I None
in I None
the I None
ciliary I None
artery I None
. I None
<eof> I None

<s> O None
In I None
the I None
porcine I None
ciliary I None
arteries I None
BRL44408 I CHEMICAL
, I None
ARC239 I CHEMICAL
, I None
and I None
prazosin I CHEMICAL
caused I None
concentration I None
- I None
dependent I None
and I None
parallel I None
rightward I None
shifts I None
of I None
the I None
concentration I None
- I None
response I None
curves I None
for I None
brimonidine I CHEMICAL
. I None
<eof> I None

<s> O None
Schild I None
analyses I None
for I None
the I None
antagonists I None
against I None
brimonidine I CHEMICAL
yielded I None
regression I None
lines I None
with I None
slopes I None
of I None
unity I None
and I None
functional I None
antagonist I None
potencies I None
( I None
pK I None
( I None
B I None
) I None
) I None
for I None
BRL44408 I CHEMICAL
( I None
7 I None
. I None
8 I None
) I None
, I None
ARC I CHEMICAL
239 O CHEMICAL
( I None
5 I None
. I None
8 I None
) I None
and I None
for I None
prazosin I CHEMICAL
( I None
6 I None
. I None
0 I None
) I None
suggesting I None
the I None
presence I None
of I None
functional I None
alpha I GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptors O GENE-Y
. I None
<eof> I None

<s> O None
Moreover I None
, I None
there I None
was I None
a I None
good I None
correlation I None
of I None
pK I None
( I None
B I None
) I None
with I None
ligand I None
- I None
binding I None
affinity I None
( I None
pK I None
( I None
i I None
) I None
) I None
of I None
the I None
alpha I GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
in I None
the I None
porcine I None
eye I None
tissue I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
The I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
agonists I None
brimonidine I CHEMICAL
, I None
apraclonidine I CHEMICAL
, I None
and I None
oxymetazoline I CHEMICAL
are I None
potent I None
vasoconstrictors I None
in I None
the I None
porcine I None
ciliary I None
artery I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
work I None
, I None
it I None
was I None
shown I None
for I None
the I None
first I None
time I None
that I None
the I None
alpha I GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
subtype I None
mediates I None
this I None
contraction I None
. I None
<eof> I None

<s> O None
Gemcitabine I CHEMICAL
and I None
pemetrexed I CHEMICAL
disodium O CHEMICAL
combinations I None
in I None
vitro I None
and I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Pemetrexed I CHEMICAL
disodium O CHEMICAL
( I None
ALIMTA I CHEMICAL
) I None
is I None
a I None
novel I None
antimetabolite I None
that I None
inhibits I None
at I None
least I None
three I None
folate I CHEMICAL
- I None
dependent I None
enzymes I None
, I None
thymidylate I GENE-Y
synthase O GENE-Y
, I None
dihydrofolate I GENE-Y
reductase O GENE-Y
, I None
and I None
glycinamide I GENE-Y
ribonucleotide O GENE-Y
formyltransferase O GENE-Y
. I None
<eof> I None

<s> O None
Pemetrexed I CHEMICAL
disodium O CHEMICAL
is I None
broadly I None
active I None
in I None
a I None
wide I None
variety I None
of I None
solid I None
tumours I None
, I None
including I None
non I None
- I None
small I None
cell I None
lung I None
, I None
breast I None
, I None
bladder I None
, I None
head I None
and I None
neck I None
and I None
ovarian I None
cancers I None
. I None
<eof> I None

<s> O None
Gemcitabine I CHEMICAL
is I None
a I None
broadly I None
active I None
pyrimidine I CHEMICAL
nucleoside O CHEMICAL
antimetabolite I None
, I None
which I None
is I None
approved I None
for I None
the I None
treatment I None
of I None
pancreatic I None
and I None
non I None
- I None
small I None
cell I None
lung I None
cancers I None
. I None
<eof> I None

<s> O None
Three I None
preclinical I None
studies I None
have I None
been I None
reported I None
that I None
show I None
cytotoxic I None
synergy I None
between I None
gemcitabine I CHEMICAL
and I None
pemetrexed I CHEMICAL
. I None
<eof> I None

<s> O None
Clinical I None
activity I None
with I None
this I None
combination I None
has I None
been I None
observed I None
in I None
a I None
phase I None
I I None
study I None
, I None
with I None
partial I None
responses I None
in I None
three I None
of I None
five I None
patients I None
previously I None
treated I None
for I None
non I None
- I None
small I None
cell I None
lung I None
cancer I None
. I None
<eof> I None

<s> O None
An I None
international I None
phase I None
II I None
study I None
of I None
this I None
combination I None
in I None
non I None
- I None
small I None
cell I None
lung I None
cancer I None
is I None
ongoing I None
. I None
<eof> I None

<s> O None
Tetrahydrofolate I CHEMICAL
biosynthesis I None
in I None
plants I None
: I None
molecular I None
and I None
functional I None
characterization I None
of I None
dihydrofolate I GENE-Y
synthetase O GENE-Y
and I None
three I None
isoforms I None
of I None
folylpolyglutamate I GENE-N
synthetase O GENE-N
in I None
Arabidopsis I None
thaliana I None
. I None
<eof> I None

<s> O None
Tetrahydrofolate I CHEMICAL
coenzymes I None
involved I None
in I None
one I None
- I None
carbon I CHEMICAL
( I None
C1 I CHEMICAL
) I None
metabolism I None
are I None
polyglutamylated I None
. I None
<eof> I None

<s> O None
In I None
organisms I None
that I None
synthesize I None
tetrahydrofolate I CHEMICAL
de I None
novo I None
, I None
dihydrofolate I GENE-Y
synthetase O GENE-Y
( I None
DHFS I GENE-Y
) I None
and I None
folylpolyglutamate I GENE-N
synthetase O GENE-N
( I None
FPGS I GENE-N
) I None
catalyze I None
the I None
attachment I None
of I None
glutamate I CHEMICAL
residues I None
to I None
the I None
folate I CHEMICAL
molecule I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
we I None
isolated I None
cDNAs I None
coding I None
a I None
DHFS I GENE-Y
and I None
three I None
isoforms I None
of I None
FPGS I GENE-N
from I None
Arabidopsis I None
thaliana I None
. I None
<eof> I None

<s> O None
The I None
function I None
of I None
each I None
enzyme I None
was I None
demonstrated I None
by I None
complementation I None
of I None
yeast I None
mutants I None
deficient I None
in I None
DHFS I GENE-Y
or I None
FPGS I GENE-Y
activity I None
, I None
and I None
by I None
measuring I None
in I None
vitro I None
glutamate I CHEMICAL
incorporation I None
into I None
dihydrofolate I CHEMICAL
or I None
tetrahydrofolate I CHEMICAL
. I None
<eof> I None

<s> O None
DHFS I GENE-Y
is I None
present I None
exclusively I None
in I None
the I None
mitochondria I None
, I None
making I None
this I None
compartment I None
the I None
sole I None
site I None
of I None
synthesis I None
of I None
dihydrofolate I CHEMICAL
in I None
the I None
plant I None
cell I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
FPGS I GENE-N
is I None
present I None
as I None
distinct I None
isoforms I None
in I None
the I None
mitochondria I None
, I None
the I None
cytosol I None
, I None
and I None
the I None
chloroplast I None
. I None
<eof> I None

<s> O None
Each I None
isoform I None
is I None
encoded I None
by I None
a I None
separate I None
gene I None
, I None
a I None
situation I None
that I None
is I None
unique I None
among I None
eukaryotes I None
. I None
<eof> I None

<s> O None
The I None
compartmentation I None
of I None
FPGS I GENE-N
isoforms I None
is I None
in I None
agreement I None
with I None
the I None
predominance I None
of I None
gamma I CHEMICAL
- O CHEMICAL
glutamyl O CHEMICAL
- O CHEMICAL
conjugated O CHEMICAL
tetrahydrofolate O CHEMICAL
derivatives I None
and I None
the I None
presence I None
of I None
serine I GENE-N
hydroxymethyltransferase O GENE-N
and I None
C1 I GENE-N
- O GENE-N
tetrahydrofolate O GENE-N
interconverting O GENE-N
enzymes O GENE-N
in I None
the I None
cytosol I None
, I None
the I None
mitochondria I None
, I None
and I None
the I None
plastids I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
the I None
combination I None
of I None
FPGS I GENE-N
with I None
these I None
folate I CHEMICAL
- I None
mediated I None
reactions I None
can I None
supply I None
each I None
compartment I None
with I None
the I None
polyglutamylated I None
folate I CHEMICAL
coenzymes I None
required I None
for I None
the I None
reactions I None
of I None
C1 I CHEMICAL
metabolism I None
. I None
<eof> I None

<s> O None
Also I None
, I None
the I None
multicompartmentation I None
of I None
FPGS I GENE-N
in I None
the I None
plant I None
cell I None
suggests I None
that I None
the I None
transported I None
forms I None
of I None
folate I CHEMICAL
are I None
unconjugated I None
. I None
<eof> I None

<s> O None
Rabeprazole I CHEMICAL
: I None
an I None
update I None
of I None
its I None
use I None
in I None
acid I None
- I None
related I None
disorders I None
. I None
<eof> I None

<s> O None
UNLABELLED I None
: I None
Rabeprazole I CHEMICAL
is I None
an I None
inhibitor I None
of I None
the I None
gastric I GENE-N
proton O GENE-N
pump O GENE-N
. I None
<eof> I None

<s> O None
It I None
causes I None
dose I None
- I None
dependent I None
inhibition I None
of I None
acid I None
secretion I None
. I None
<eof> I None

<s> O None
In I None
8 I None
- I None
week I None
studies I None
, I None
among I None
patients I None
with I None
gastro I None
- I None
oesophageal I None
reflux I None
disease I None
( I None
GORD I None
) I None
, I None
rabeprazole I CHEMICAL
20 I None
mg I None
/ I None
day I None
or I None
10mg I None
twice I None
daily I None
was I None
as I None
effective I None
as I None
omeprazole I CHEMICAL
and I None
superior I None
to I None
ranitidine I CHEMICAL
in I None
the I None
healing I None
of I None
GORD I None
. I None
<eof> I None

<s> O None
Symptom I None
relief I None
with I None
rabeprazole I CHEMICAL
was I None
superior I None
to I None
that I None
provided I None
by I None
placebo I None
and I None
ranitidine I CHEMICAL
and I None
similar I None
to I None
omeprazole I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
long I None
- I None
term I None
trials I None
rabeprazole I CHEMICAL
10 I None
mg I None
/ I None
day I None
was I None
similar I None
to I None
omeprazole I CHEMICAL
20 I None
mg I None
/ I None
day I None
in I None
a I None
2 I None
- I None
year I None
study I None
and I None
superior I None
to I None
placebo I None
in I None
1 I None
- I None
year I None
studies I None
, I None
in I None
both I None
the I None
maintenance I None
of I None
healing I None
and I None
prevention I None
of I None
symptoms I None
in I None
patients I None
with I None
healed I None
GORD I None
. I None
<eof> I None

<s> O None
In I None
nonerosive I None
GORD I None
, I None
4 I None
- I None
week I None
studies I None
have I None
shown I None
rabeprazole I CHEMICAL
to I None
be I None
more I None
effective I None
than I None
placebo I None
in I None
relieving I None
heartburn I None
and I None
various I None
other I None
gastrointestinal I None
symptoms I None
. I None
<eof> I None

<s> O None
Data I None
among I None
patients I None
with I None
Barrett I None
' I None
s I None
oesophagus I None
suggest I None
rabeprazole I CHEMICAL
20 I None
mg I None
/ I None
day I None
may I None
be I None
more I None
effective I None
than I None
placebo I None
in I None
maintaining I None
healing I None
of I None
associated I None
oesophagitis I None
after I None
1 I None
year I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
One I None
- I None
week I None
triple I None
Helicobacter I None
pylori I None
eradication I None
therapy I None
with I None
rabeprazole I CHEMICAL
plus I None
clarithromycin I CHEMICAL
and I None
amoxicillin I CHEMICAL
achieved I None
eradication I None
rates I None
of I None
> I None
or I None
= I None
85 I None
% I None
. I None
<eof> I None

<s> O None
Rabeprazole I CHEMICAL
is I None
as I None
effective I None
as I None
omeprazole I CHEMICAL
and I None
lansoprazole I CHEMICAL
when I None
included I None
as I None
part I None
of I None
a I None
triple I None
- I None
therapy I None
regimen I None
for I None
the I None
eradication I None
of I None
H I None
. I None
pylori I None
. I None
<eof> I None

<s> O None
Eradication I None
rates I None
of I None
> I None
90 I None
% I None
were I None
achieved I None
when I None
rabeprazole I CHEMICAL
20 I None
to I None
40 I None
mg I None
/ I None
day I None
was I None
included I None
as I None
part I None
of I None
a I None
quadruple I None
eradication I None
regimen I None
. I None
<eof> I None

<s> O None
As I None
monotherapy I None
for I None
peptic I None
ulcer I None
healing I None
and I None
symptom I None
relief I None
, I None
4 I None
- I None
to I None
8 I None
- I None
week I None
studies I None
have I None
shown I None
rabeprazole I CHEMICAL
10 I None
to I None
40 I None
mg I None
/ I None
day I None
to I None
be I None
superior I None
to I None
placebo I None
and I None
ranitidine I CHEMICAL
and I None
have I None
similar I None
efficacy I None
to I None
omeprazole I CHEMICAL
. I None
<eof> I None

<s> O None
Preliminary I None
1 I None
- I None
year I None
data I None
among I None
16 I None
patients I None
with I None
Zollinger I None
- I None
Ellison I None
syndrome I None
suggest I None
rabeprazole I CHEMICAL
60 I None
to I None
120 I None
mg I None
/ I None
day I None
can I None
resolve I None
and I None
prevent I None
the I None
recurrence I None
of I None
symptoms I None
and I None
endoscopic I None
lesions I None
associated I None
with I None
this I None
condition I None
. I None
<eof> I None

<s> O None
In I None
clinical I None
trials I None
of I None
up I None
to I None
2 I None
years I None
' I None
duration I None
the I None
tolerability I None
of I None
rabeprazole I CHEMICAL
is I None
similar I None
to I None
that I None
of I None
placebo I None
, I None
ranitidine I CHEMICAL
and I None
omeprazole I CHEMICAL
. I None
<eof> I None

<s> O None
Common I None
adverse I None
events I None
assigned I None
to I None
rabeprazole I CHEMICAL
have I None
been I None
diarrhoea I None
, I None
headache I None
, I None
rhinitis I None
, I None
nausea I None
, I None
pharyngitis I None
and I None
abdominal I None
pain I None
. I None
<eof> I None

<s> O None
Histological I None
changes I None
and I None
increases I None
in I None
serum I None
gastrin I GENE-Y
levels I None
were I None
unremarkable I None
and I None
typical I None
of I None
proton I GENE-N
pump O GENE-N
inhibitors I None
. I None
<eof> I None

<s> O None
No I None
dosage I None
adjustment I None
is I None
necessary I None
in I None
renal I None
and I None
mild I None
to I None
moderate I None
hepatic I None
impairment I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
Rabeprazole I CHEMICAL
is I None
a I None
well I None
tolerated I None
proton I GENE-N
pump O GENE-N
inhibitor I None
. I None
<eof> I None

<s> O None
It I None
has I None
proven I None
efficacy I None
in I None
healing I None
, I None
symptom I None
relief I None
and I None
prevention I None
of I None
relapse I None
of I None
peptic I None
ulcers I None
and I None
GORD I None
and I None
can I None
form I None
part I None
of I None
effective I None
H I None
. I None
pylori I None
eradication I None
regimens I None
. I None
<eof> I None

<s> O None
It I None
is I None
an I None
important I None
alternative I None
to I None
H I None
( I None
2 I None
) I None
antagonists I None
and I None
an I None
additional I None
treatment I None
option I None
to I None
other I None
proton I GENE-N
pump O GENE-N
inhibitors I None
in I None
the I None
management I None
of I None
acid I None
- I None
related I None
disorders I None
. I None
<eof> I None

<s> O None
Angiotensin I CHEMICAL
II O CHEMICAL
suppression I None
in I None
humans I None
by I None
the I None
orally I None
active I None
renin I GENE-Y
inhibitor I None
Aliskiren I CHEMICAL
( I None
SPP100 I CHEMICAL
) I None
: I None
comparison I None
with I None
enalapril I CHEMICAL
. I None
<eof> I None

<s> O None
Renin I GENE-Y
is I None
the I None
main I None
determinant I None
of I None
angiotensin I CHEMICAL
( O CHEMICAL
Ang O CHEMICAL
) O CHEMICAL
II O CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
It I None
, I None
therefore I None
, I None
always I None
appeared I None
desirable I None
to I None
reduce I None
Ang I CHEMICAL
II O CHEMICAL
levels I None
by I None
direct I None
inhibition I None
of I None
renin I GENE-Y
. I None
<eof> I None

<s> O None
So I None
far I None
, I None
specific I None
renin I GENE-Y
inhibitors I None
lacked I None
potency I None
and I None
/ I None
or I None
oral I None
availability I None
. I None
<eof> I None

<s> O None
We I None
tested I None
the I None
new I None
orally I None
active I None
nonpeptidic I None
renin I GENE-Y
inhibitor I None
SPP100 I CHEMICAL
( I None
Aliskiren I CHEMICAL
, I None
an I None
octanamide I CHEMICAL
with I None
a I None
50 I None
% I None
inhibitory I None
concentration I None
[ I None
IC50 I None
] I None
in I None
the I None
low I None
nanomolar I None
range I None
) I None
in I None
18 I None
healthy I None
volunteers I None
on I None
a I None
constant I None
100 I None
mmol I None
/ I None
d I None
sodium I CHEMICAL
diet I None
using I None
a I None
double I None
- I None
blind I None
, I None
3 I None
- I None
way I None
crossover I None
protocol I None
. I None
<eof> I None

<s> O None
In I None
3 I None
periods I None
of I None
8 I None
days I None
, I None
separated I None
by I None
wash I None
- I None
outs I None
of I None
6 I None
days I None
, I None
each I None
volunteer I None
received I None
2 I None
dosage I None
levels I None
of I None
Aliskiren I CHEMICAL
( I None
low I None
before I None
high I None
; I None
40 I None
and I None
80 I None
or I None
160 I None
and I None
640 I None
mg I None
/ I None
d I None
) I None
and I None
randomized I None
placebo I None
or I None
20 I None
mg I None
enalapril I CHEMICAL
. I None
<eof> I None

<s> O None
Aliskiren I CHEMICAL
was I None
well I None
tolerated I None
. I None
<eof> I None

<s> O None
Not I None
surprisingly I None
, I None
blood I None
pressure I None
and I None
heart I None
rate I None
remained I None
unchanged I None
in I None
these I None
normotensive I None
subjects I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
dose I None
- I None
dependent I None
decrease I None
in I None
plasma I None
renin I GENE-Y
activity I None
, I None
Ang I CHEMICAL
I O CHEMICAL
, I None
and I None
Ang I CHEMICAL
II O CHEMICAL
following I None
single I None
doses I None
of I None
Aliskiren I CHEMICAL
starting I None
with I None
40 I None
mg I None
. I None
<eof> I None

<s> O None
Inhibition I None
was I None
still I None
marked I None
and I None
significant I None
after I None
repeated I None
dosing I None
with I None
maximal I None
decreases I None
in I None
Ang I CHEMICAL
II O CHEMICAL
levels I None
by I None
89 I None
% I None
and I None
75 I None
% I None
on I None
Days I None
1 I None
and I None
8 I None
, I None
respectively I None
, I None
when I None
the I None
highest I None
dose I None
of I None
Aliskiren I CHEMICAL
was I None
compared I None
with I None
placebo I None
. I None
<eof> I None

<s> O None
At I None
the I None
same I None
time I None
, I None
mean I None
plasma I None
active I None
renin I GENE-Y
was I None
increased I None
16 I None
- I None
and I None
34 I None
- I None
fold I None
at I None
the I None
highest I None
dose I None
of I None
Aliskiren I CHEMICAL
. I None
<eof> I None

<s> O None
Plasma I None
drug I None
levels I None
of I None
Aliskiren I CHEMICAL
were I None
dose I None
- I None
dependent I None
with I None
maximal I None
concentrations I None
reached I None
between I None
3 I None
to I None
6 I None
hours I None
after I None
administration I None
; I None
steady I None
state I None
was I None
reached I None
between I None
5 I None
and I None
8 I None
days I None
after I None
multiple I None
dosing I None
. I None
<eof> I None

<s> O None
Less I None
than I None
1 I None
% I None
of I None
dose I None
was I None
excreted I None
in I None
the I None
urine I None
. I None
<eof> I None

<s> O None
Plasma I None
and I None
urinary I None
aldosterone I CHEMICAL
levels I None
were I None
decreased I None
after I None
doses I None
of I None
Aliskiren I CHEMICAL
> I None
or I None
= I None
80 I None
mg I None
and I None
after I None
enalapril I CHEMICAL
. I None
<eof> I None

<s> O None
Aliskiren I CHEMICAL
at I None
160 I None
and I None
640 I None
mg I None
enhanced I None
natriuresis I None
on I None
Day I None
1 I None
by I None
+ I None
45 I None
% I None
and I None
+ I None
62 I None
% I None
, I None
respectively I None
, I None
compared I None
with I None
placebo I None
( I None
100 I None
% I None
, I None
ie I None
, I None
87 I None
+ I None
/ I None
- I None
11 I None
mmol I None
/ I None
24h I None
) I None
and I None
enalapril I CHEMICAL
( I None
+ I None
54 I None
% I None
) I None
; I None
kaliuresis I None
remained I None
unchanged I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
the I None
renin I GENE-Y
inhibitor I None
Aliskiren I CHEMICAL
dose I None
- I None
dependently I None
decreases I None
Ang I CHEMICAL
II O CHEMICAL
levels I None
in I None
humans I None
following I None
oral I None
administration I None
. I None
<eof> I None

<s> O None
The I None
effect I None
is I None
long I None
- I None
lasting I None
and I None
, I None
at I None
a I None
dose I None
of I None
160 I None
mg I None
, I None
is I None
equivalent I None
to I None
that I None
of I None
20 I None
mg I None
enalapril I CHEMICAL
. I None
<eof> I None

<s> O None
Aliskiren I CHEMICAL
has I None
the I None
potential I None
to I None
become I None
the I None
first I None
orally I None
active I None
renin I GENE-Y
inhibitor I None
that I None
provides I None
a I None
true I None
alternative I None
to I None
ACE I GENE-Y
- I None
inhibitors I None
and I None
Ang I GENE-N
II O GENE-N
receptor O GENE-N
antagonists I None
in I None
therapy I None
for I None
hypertension I None
and I None
other I None
cardiovascular I None
and I None
renal I None
diseases I None
. I None
<eof> I None

<s> O None
Heterogeneity I None
of I None
persistent I None
hyperinsulinaemic I None
hypoglycaemia I None
. I None
<eof> I None

<s> O None
A I None
series I None
of I None
175 I None
cases I None
. I None
<eof> I None

<s> O None
UNLABELLED I None
: I None
Hyperinsulinism I None
is I None
a I None
heterogeneous I None
disorder I None
characterised I None
by I None
severe I None
hypoglycaemia I None
due I None
to I None
an I None
inappropriate I None
oversecretion I None
of I None
insulin I GENE-Y
. I None
<eof> I None

<s> O None
In I None
a I None
personal I None
series I None
of I None
175 I None
patients I None
investigated I None
for I None
hyperinsulinaemic I None
hypoglycaemia I None
over I None
the I None
last I None
20 I None
years I None
, I None
we I None
review I None
clinical I None
presentations I None
, I None
molecular I None
studies I None
and I None
therapeutic I None
management I None
of I None
hyperinsulinism I None
. I None
<eof> I None

<s> O None
There I None
were I None
98 I None
neonatal I None
- I None
onset I None
patients I None
, I None
including I None
86 I None
permanent I None
hyperinsulinism I None
and I None
12 I None
transient I None
forms I None
, I None
68 I None
with I None
infancy I None
- I None
onset I None
and I None
nine I None
with I None
childhood I None
- I None
onset I None
. I None
<eof> I None

<s> O None
Hyperammonaemia I None
was I None
found I None
in I None
12 I None
out I None
of I None
69 I None
patients I None
tested I None
, I None
4 I None
neonates I None
and I None
8 I None
infants I None
. I None
<eof> I None

<s> O None
Neonates I None
were I None
clinically I None
more I None
severely I None
affected I None
than I None
infants I None
. I None
<eof> I None

<s> O None
Diagnosis I None
of I None
infancy I None
- I None
onset I None
hyperinsulinism I None
was I None
often I None
delayed I None
because I None
of I None
less I None
profound I None
hypoglycaemia I None
and I None
better I None
tolerance I None
to I None
hypoglycaemia I None
. I None
<eof> I None

<s> O None
Neonates I None
required I None
higher I None
rates I None
of I None
i I None
. I None
v I None
. I None
glucose I CHEMICAL
than I None
infants I None
to I None
maintain I None
normal I None
plasma I None
glucose I CHEMICAL
levels I None
( I None
16 I None
mg I None
/ I None
kg I None
per I None
min I None
versus I None
12 I None
mg I None
/ I None
kg I None
per I None
min I None
) I None
. I None
<eof> I None

<s> O None
Only I None
16 I None
% I None
of I None
neonates I None
were I None
diazoxide I CHEMICAL
- I None
sensitive I None
compared I None
to I None
66 I None
% I None
of I None
the I None
infants I None
. I None
<eof> I None

<s> O None
Neonates I None
with I None
hyperammonaemia I None
or I None
transient I None
hyperinsulinism I None
were I None
diazoxide I CHEMICAL
- I None
sensitive I None
. I None
<eof> I None

<s> O None
Most I None
neonates I None
were I None
pancreatectomised I None
whereas I None
65 I None
% I None
of I None
the I None
infants I None
were I None
treated I None
medically I None
. I None
<eof> I None

<s> O None
Among I None
surgically I None
- I None
treated I None
patients I None
, I None
47 I None
% I None
had I None
a I None
focal I None
adenomatous I None
hyperplasia I None
( I None
31 I None
neonates I None
and I None
13 I None
infants I None
) I None
and I None
53 I None
% I None
a I None
diffuse I None
form I None
of I None
hyperinsulinism I None
( I None
39 I None
neonates I None
and I None
11 I None
infants I None
) I None
. I None
<eof> I None

<s> O None
Diazoxide I CHEMICAL
- I None
responsiveness I None
in I None
the I None
focal I None
and I None
diffuse I None
forms I None
did I None
not I None
differ I None
in I None
both I None
neonates I None
and I None
infants I None
; I None
it I None
depended I None
only I None
upon I None
the I None
age I None
of I None
onset I None
of I None
hypoglycaemia I None
. I None
<eof> I None

<s> O None
One I None
or I None
two I None
mutations I None
, I None
SUR1 I GENE-Y
or I None
KIR6 I GENE-Y
. O GENE-Y
2 O GENE-Y
, I None
were I None
found I None
in I None
41 I None
of I None
73 I None
neonates I None
who I None
were I None
investigated I None
and I None
in I None
13 I None
/ I None
38 I None
infants I None
using I None
polymerase I None
chain I None
reaction I None
- I None
single I None
strand I None
conformational I None
polymorphism I None
analysis I None
of I None
both I None
genes I None
. I None
<eof> I None

<s> O None
Almost I None
all I None
patients I None
with I None
SUR1 I GENE-Y
( I None
38 I None
/ I None
41 I None
) I None
or I None
KIR6 I GENE-Y
. O GENE-Y
2 O GENE-Y
( I None
5 I None
/ I None
7 I None
) I None
mutations I None
were I None
resistant I None
to I None
diazoxide I CHEMICAL
. I None
<eof> I None

<s> O None
Ten I None
patients I None
with I None
hyperinsulinism I None
- I None
hyperammonaemia I None
syndrome I None
had I None
a I None
mutation I None
in I None
the I None
glutamate I GENE-N
dehydrogenase O GENE-N
gene I None
( I None
three I None
neonates I None
and I None
seven I None
infants I None
) I None
after I None
reverse I None
transcriptase I None
- I None
polymerase I None
chain I None
reaction I None
and I None
sequence I None
analysis I None
of I None
cDNA I None
. I None
<eof> I None

<s> O None
No I None
mutation I None
was I None
found I None
by I None
polymerase I None
chain I None
reaction I None
- I None
single I None
strand I None
conformational I None
polymorphism I None
in I None
the I None
glucokinase I GENE-Y
gene I None
. I None
<eof> I None

<s> O None
Eight I None
of I None
nine I None
patients I None
with I None
childhood I None
onset I None
hyperinsulinism I None
were I None
treated I None
surgically I None
and I None
histological I None
examination I None
confirmed I None
an I None
adenoma I None
in I None
each I None
case I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
the I None
clinical I None
severity I None
of I None
hyperinsulinism I None
varies I None
mainly I None
with I None
age I None
at I None
onset I None
of I None
hypoglycaemia I None
. I None
<eof> I None

<s> O None
The I None
heterogeneity I None
of I None
hyperinsulinism I None
has I None
major I None
consequences I None
in I None
terms I None
of I None
therapeutic I None
outcome I None
and I None
genetic I None
counselling I None
. I None
<eof> I None

<s> O None
Donepezil I CHEMICAL
hydrochloride O CHEMICAL
: I None
a I None
treatment I None
drug I None
for I None
Alzheimer I None
' I None
s I None
disease I None
. I None
<eof> I None

<s> O None
The I None
role I None
of I None
the I None
cholinergic I None
system I None
with I None
respect I None
to I None
cognitive I None
deficits I None
characteristic I None
of I None
Alzheimer I None
' I None
s I None
disease I None
( I None
AD I None
) I None
has I None
led I None
to I None
a I None
number I None
of I None
studies I None
focusing I None
on I None
the I None
development I None
of I None
acetylcholinesterase I GENE-Y
( I None
AChE I GENE-Y
) I None
inhibitors I None
as I None
a I None
drug I None
for I None
treating I None
this I None
disease I None
. I None
<eof> I None

<s> O None
The I None
earliest I None
known I None
AChE I GENE-Y
inhibitors I None
, I None
namely I None
, I None
physostigmine I CHEMICAL
and I None
tacrine I CHEMICAL
, I None
performed I None
poorly I None
in I None
clinical I None
trials I None
( I None
e I None
. I None
g I None
. I None
, I None
poor I None
oral I None
activity I None
, I None
brain I None
penetration I None
, I None
and I None
hepatotoxic I None
liability I None
) I None
. I None
<eof> I None

<s> O None
Studies I None
were I None
then I None
focused I None
on I None
finding I None
a I None
new I None
type I None
of I None
acetylcholinesterase I None
inhibitor I None
that I None
would I None
overcome I None
the I None
disadvantages I None
of I None
these I None
two I None
compounds I None
. I None
<eof> I None

<s> O None
Donepezil I CHEMICAL
hydrochloride O CHEMICAL
inaugurates I None
a I None
new I None
class I None
of I None
AChE I GENE-Y
inhibitors I None
with I None
longer I None
and I None
more I None
selective I None
action I None
and I None
with I None
manageable I None
adverse I None
effects I None
. I None
<eof> I None

<s> O None
Alefacept I GENE-Y
, I None
an I None
immunomodulatory I None
recombinant I None
LFA I GENE-Y
- O GENE-Y
3 O GENE-Y
/ I None
IgG1 I GENE-Y
fusion I None
protein I None
, I None
induces I None
CD16 I GENE-N
signaling I None
and I None
CD2 I GENE-Y
/ I None
CD16 I GENE-N
- I None
dependent I None
apoptosis I None
of I None
CD2 I None
( I None
+ I None
) I None
cells I None
. I None
<eof> I None

<s> O None
Alefacept I GENE-Y
, I None
an I None
immunomodulatory I None
recombinant I None
fusion I None
protein I None
composed I None
of I None
the I None
first I None
extracellular I None
domain I None
of I None
LFA I GENE-Y
- O GENE-Y
3 O GENE-Y
fused I None
to I None
the I None
human I GENE-N
IgG1 O GENE-N
hinge O GENE-N
, O GENE-N
C O GENE-N
( O GENE-N
H O GENE-N
) O GENE-N
2 O GENE-N
, O GENE-N
and O GENE-N
C O GENE-N
( O GENE-N
H O GENE-N
) O GENE-N
3 O GENE-N
domains O GENE-N
, I None
has I None
recently I None
been I None
shown I None
in I None
phase I None
II I None
and I None
III I None
clinical I None
trials I None
to I None
safely I None
reduce I None
disease I None
expression I None
in I None
patients I None
with I None
chronic I None
plaque I None
psoriasis I None
. I None
<eof> I None

<s> O None
Alefacept I GENE-Y
modulates I None
the I None
function I None
of I None
and I None
selectively I None
induces I None
apoptosis I None
of I None
CD2 I None
( I None
+ I None
) I None
human I None
memory I None
- I None
effector I None
T I None
cells I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
We I None
have I None
sought I None
to I None
gain I None
further I None
understanding I None
of I None
the I None
mechanisms I None
of I None
action I None
that I None
influence I None
the I None
biological I None
activity I None
of I None
alefacept I GENE-Y
and I None
may I None
contribute I None
to I None
its I None
efficacy I None
and I None
patient I None
responsiveness I None
. I None
<eof> I None

<s> O None
Specifically I None
evaluated I None
is I None
the I None
ability I None
of I None
alefacept I GENE-Y
to I None
activate I None
intracellular I None
signals I None
mediated I None
via I None
CD2 I GENE-Y
and I None
/ I None
or I None
Fc I GENE-N
gamma O GENE-N
RIII O GENE-N
( I None
CD16 I GENE-N
) I None
. I None
<eof> I None

<s> O None
Experimentation I None
using I None
isoforms I None
of I None
alefacept I GENE-Y
engineered I None
to I None
have I None
amino I CHEMICAL
acid O CHEMICAL
substitutions I None
in I None
the I None
IgG1 I GENE-N
C O GENE-N
( O GENE-N
H O GENE-N
) O GENE-N
2 O GENE-N
domain O GENE-N
that I None
impact I None
Fc I GENE-N
gamma O GENE-N
R O GENE-N
binding I None
indicate I None
that I None
alefacept I GENE-Y
mediates I None
cognate I None
interactions I None
between I None
cells I None
expressing I None
human I GENE-Y
CD2 O GENE-Y
and I None
CD16 I GENE-N
to I None
activate I None
cells I None
, I None
e I None
. I None
g I None
. I None
, I None
increase I None
extracellular I GENE-N
signal O GENE-N
- O GENE-N
regulated O GENE-N
kinase O GENE-N
phosphorylation I None
, I None
up I None
- I None
regulate I None
cell I None
surface I None
expression I None
of I None
the I None
activation I None
marker I None
CD25 I GENE-Y
, I None
and I None
induce I None
release I None
of I None
granzyme I GENE-Y
B O GENE-Y
. I None
<eof> I None

<s> O None
In I None
the I None
systems I None
used I None
, I None
this I None
signaling I None
is I None
shown I None
to I None
require I None
binding I None
to I None
CD2 I GENE-Y
and I None
CD16 I GENE-N
and I None
be I None
mediated I None
through I None
CD16 I GENE-N
, I None
but I None
not I None
CD2 I GENE-Y
. I None
<eof> I None

<s> O None
Experimentation I None
using I None
human I GENE-Y
CD2 O GENE-Y
- I None
transgenic I None
mice I None
and I None
isoforms I None
of I None
alefacept I GENE-Y
confirmed I None
the I None
requirement I None
for I None
Fc I GENE-N
gamma O GENE-N
R O GENE-N
binding I None
for I None
detection I None
of I None
the I None
pharmacological I None
effects I None
of I None
alefacept I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Thus I None
alefacept I GENE-Y
acts I None
as I None
an I None
effector I None
molecule I None
, I None
mediating I None
cognate I None
interactions I None
to I None
activate I None
Fc I None
gamma I None
R I None
( I None
+ I None
) I None
cells I None
( I None
e I None
. I None
g I None
. I None
, I None
NK I None
cells I None
) I None
to I None
induce I None
apoptosis I None
of I None
sensitive I None
CD2 I None
( I None
+ I None
) I None
target I None
cells I None
. I None
<eof> I None

<s> O None
Thalidomide I CHEMICAL
in I None
multiple I None
myeloma I None
. I None
<eof> I None

<s> O None
Thalidomide I CHEMICAL
- I None
- I None
removed I None
from I None
widespread I None
clinical I None
use I None
by I None
1962 I None
because I None
of I None
severe I None
teratogenicity I None
- I None
- I None
has I None
anti I None
- I None
angiogenic I None
and I None
immunomodulatory I None
effects I None
, I None
including I None
the I None
inhibition I None
of I None
TNF I GENE-Y
alpha O GENE-Y
. I None
<eof> I None

<s> O None
It I None
has I None
returned I None
to I None
practice I None
as I None
an I None
effective I None
oral I None
agent I None
in I None
the I None
management I None
of I None
various I None
disease I None
states I None
including I None
erythema I None
nodosum I None
leprosum I None
, I None
for I None
which I None
it I None
was I None
FDA I None
- I None
approved I None
in I None
1998 I None
, I None
and I None
more I None
recently I None
certain I None
malignancies I None
, I None
including I None
multiple I None
myeloma I None
. I None
<eof> I None

<s> O None
Whilst I None
the I None
mechanism I None
of I None
action I None
of I None
thalidomide I CHEMICAL
remains I None
incompletely I None
understood I None
, I None
considerable I None
insight I None
has I None
been I None
generated I None
by I None
extensive I None
preclinical I None
studies I None
in I None
multiple I None
myeloma I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
clinical I None
trials I None
both I None
as I None
a I None
single I None
agent I None
and I None
in I None
combination I None
have I None
confirmed I None
benefit I None
in I None
relapsed I None
and I None
refractory I None
disease I None
. I None
<eof> I None

<s> O None
Thalidomide I None
' I None
s I None
role I None
in I None
treating I None
newly I None
diagnosed I None
patients I None
is I None
currently I None
under I None
study I None
and I None
it I None
is I None
now I None
established I None
as I None
an I None
important I None
therapeutic I None
option I None
in I None
the I None
treatment I None
of I None
multiple I None
myeloma I None
. I None
<eof> I None

<s> O None
[ I None
Leflunomide I CHEMICAL
- I None
- I None
a I None
new I None
drug I None
for I None
pharmacological I None
immunomodulation I None
] I None
. I None
<eof> I None

<s> O None
The I None
novel I None
immunomodulatory I None
agent I None
leflunomide I CHEMICAL
exhibits I None
a I None
strong I None
anti I None
- I None
inflammatory I None
action I None
. I None
<eof> I None

<s> O None
This I None
isoxazole I CHEMICAL
derivative I None
is I None
chemically I None
unrelated I None
to I None
any I None
hitherto I None
applied I None
immunosuppressants I None
. I None
<eof> I None

<s> O None
As I None
a I None
prodrug I None
leflunomide I CHEMICAL
is I None
completely I None
converted I None
to I None
its I None
active I None
metabolite I None
A I CHEMICAL
77 O CHEMICAL
1726 O CHEMICAL
( I None
M1 I None
) I None
which I None
blocks I None
the I None
dihydroorotate I GENE-Y
dehydrogenase O GENE-Y
, I None
a I None
key I None
enzyme I None
of I None
the I None
pyrimidine I CHEMICAL
de I None
novo I None
synthesis I None
. I None
<eof> I None

<s> O None
Drug I None
- I None
related I None
adverse I None
effects I None
are I None
mild I None
, I None
dose I None
- I None
related I None
and I None
reversible I None
, I None
characterising I None
leflunomide I CHEMICAL
as I None
a I None
safe I None
immunosuppressant I None
. I None
<eof> I None

<s> O None
While I None
up I None
to I None
now I None
leflunomide I CHEMICAL
has I None
just I None
been I None
approved I None
for I None
therapy I None
of I None
rheumatoid I None
arthritis I None
, I None
its I None
mechanism I None
of I None
action I None
affects I None
multiple I None
inflammatory I None
pathways I None
, I None
thereby I None
suggesting I None
it I None
to I None
be I None
a I None
potent I None
therapeutic I None
agent I None
in I None
autoimmune I None
diseases I None
, I None
graft I None
rejection I None
, I None
and I None
tumour I None
therapy I None
. I None
<eof> I None

<s> O None
First I None
dermatological I None
experience I None
has I None
been I None
gained I None
in I None
psoriasis I None
and I None
bullous I None
pemphigoid I None
. I None
<eof> I None

<s> O None
The I None
role I None
of I None
leflunomide I CHEMICAL
in I None
the I None
dermatologist I None
' I None
s I None
therapeutic I None
armamentarium I None
will I None
evolve I None
during I None
the I None
next I None
years I None
. I None
<eof> I None

<s> O None
Existing I None
and I None
emerging I None
endocrine I None
therapies I None
for I None
breast I None
cancer I None
. I None
<eof> I None

<s> O None
Endocrine I None
therapy I None
is I None
first I None
- I None
line I None
therapy I None
for I None
patients I None
with I None
estrogen I GENE-Y
receptor O GENE-Y
- I None
positive I None
or I None
progesterone I GENE-Y
receptor O GENE-Y
- I None
positive I None
metastatic I None
breast I None
cancer I None
. I None
<eof> I None

<s> O None
Commonly I None
used I None
endocrine I None
therapies I None
are I None
tamoxifen I CHEMICAL
, I None
megestrol I CHEMICAL
acetate O CHEMICAL
, I None
and I None
aromatase I GENE-Y
inhibitors I None
. I None
<eof> I None

<s> O None
Although I None
tamoxifen I CHEMICAL
and I None
megestrol I CHEMICAL
acetate O CHEMICAL
have I None
a I None
favorable I None
therapeutic I None
profile I None
, I None
there I None
are I None
risks I None
associated I None
with I None
these I None
agents I None
. I None
<eof> I None

<s> O None
With I None
tamoxifen I CHEMICAL
, I None
the I None
partial I None
agonist I None
property I None
can I None
lead I None
to I None
thromboembolic I None
events I None
. I None
<eof> I None

<s> O None
An I None
important I None
adverse I None
event I None
of I None
megestrol I CHEMICAL
acetate O CHEMICAL
is I None
weight I None
gain I None
and I None
fluid I None
retention I None
in I None
some I None
patients I None
. I None
<eof> I None

<s> O None
The I None
aromatase I GENE-Y
inhibitors I None
are I None
currently I None
used I None
as I None
second I None
- I None
line I None
therapy I None
after I None
tamoxifen I CHEMICAL
failure I None
. I None
<eof> I None

<s> O None
A I None
recent I None
study I None
showed I None
that I None
anastrozole I CHEMICAL
, I None
an I None
aromatase I GENE-Y
inhibitor I None
, I None
is I None
as I None
effective I None
or I None
even I None
superior I None
to I None
tamoxifen I CHEMICAL
when I None
used I None
as I None
a I None
first I None
- I None
line I None
therapy I None
. I None
<eof> I None

<s> O None
However I None
, I None
not I None
all I None
patients I None
will I None
respond I None
to I None
currently I None
available I None
therapies I None
. I None
<eof> I None

<s> O None
A I None
new I None
class I None
of I None
drug I None
, I None
the I None
estrogen I GENE-Y
receptor O GENE-Y
downregulators I None
, I None
has I None
been I None
developed I None
. I None
<eof> I None

<s> O None
Fulvestrant I CHEMICAL
, I None
the I None
first I None
agent I None
in I None
this I None
new I None
class I None
, I None
not I None
only I None
induces I None
the I None
degradation I None
of I None
the I None
estrogen I GENE-Y
receptor O GENE-Y
but I None
also I None
is I None
an I None
estrogen I CHEMICAL
antagonist I None
; I None
further I None
, I None
its I None
lack I None
of I None
agonist I None
activity I None
provides I None
a I None
better I None
safety I None
profile I None
. I None
<eof> I None

<s> O None
Two I None
phase I None
III I None
trials I None
have I None
proven I None
that I None
fulvestrant I CHEMICAL
is I None
at I None
least I None
as I None
effective I None
as I None
anastrozole I CHEMICAL
in I None
postmenopausal I None
women I None
with I None
advanced I None
breast I None
cancer I None
. I None
<eof> I None

<s> O None
Fulvestrant I CHEMICAL
is I None
an I None
effective I None
and I None
safe I None
endocrine I None
therapy I None
for I None
postmenopausal I None
women I None
who I None
have I None
failed I None
prior I None
endocrine I None
therapy I None
. I None
<eof> I None

<s> O None
Microarray I None
and I None
biochemical I None
analysis I None
of I None
lovastatin I CHEMICAL
- I None
induced I None
apoptosis I None
of I None
squamous I None
cell I None
carcinomas I None
. I None
<eof> I None

<s> O None
We I None
recently I None
identified I None
3 I GENE-Y
- O GENE-Y
hydroxy O GENE-Y
- O GENE-Y
3 O GENE-Y
- O GENE-Y
methylglutaryl O GENE-Y
coenzyme O GENE-Y
A O GENE-Y
( O GENE-Y
HMG O GENE-Y
- O GENE-Y
CoA O GENE-Y
) O GENE-Y
reductase O GENE-Y
, I None
the I None
rate I None
- I None
limiting I None
enzyme I None
of I None
the I None
mevalonate I None
pathway I None
, I None
as I None
a I None
potential I None
therapeutic I None
target I None
of I None
the I None
head I None
and I None
neck I None
squamous I None
cell I None
carcinomas I None
( I None
HNSCC I None
) I None
and I None
cervical I None
carcinomas I None
( I None
CC I None
) I None
. I None
<eof> I None

<s> O None
The I None
products I None
of I None
this I None
complex I None
biochemical I None
pathway I None
, I None
including I None
de I None
novo I None
cholesterol I CHEMICAL
, I None
are I None
vital I None
for I None
a I None
variety I None
of I None
key I None
cellular I None
functions I None
affecting I None
membrane I None
integrity I None
, I None
cell I None
signaling I None
, I None
protein I None
synthesis I None
, I None
and I None
cell I None
cycle I None
progression I None
. I None
<eof> I None

<s> O None
Lovastatin I CHEMICAL
, I None
a I None
specific I None
inhibitor I None
of I None
HMG I GENE-Y
- O GENE-Y
CoA O GENE-Y
reductase O GENE-Y
, I None
induces I None
a I None
pronounced I None
apoptotic I None
response I None
in I None
a I None
specific I None
subset I None
of I None
tumor I None
types I None
, I None
including I None
HNSCC I None
and I None
CC I None
. I None
<eof> I None

<s> O None
The I None
mediators I None
of I None
this I None
response I None
are I None
not I None
well I None
established I None
. I None
<eof> I None

<s> O None
Identification I None
of I None
differentially I None
expressed I None
genes I None
represents I None
a I None
feasible I None
approach I None
to I None
delineate I None
these I None
mediators I None
as I None
lovastatin I CHEMICAL
has I None
the I None
potential I None
to I None
modulate I None
transcription I None
indirectly I None
by I None
perturbing I None
levels I None
of I None
sterols I None
and I None
other I None
mevalonate I CHEMICAL
metabolites I None
. I None
<eof> I None

<s> O None
Expression I None
analysis I None
following I None
treatment I None
of I None
the I None
HNSCC I None
cell I None
lines I None
SCC9 I None
or I None
SCC25 I None
with I None
10 I None
microM I None
lovastatin I CHEMICAL
for I None
1 I None
day I None
showed I None
that I None
less I None
than I None
2 I None
% I None
( I None
9 I None
cDNAs I None
) I None
of I None
the I None
588 I None
cDNAs I None
on I None
this I None
microarray I None
were I None
affected I None
in I None
both I None
cell I None
lines I None
. I None
<eof> I None

<s> O None
These I None
included I None
diazepam I GENE-Y
- O GENE-Y
binding O GENE-Y
inhibitor O GENE-Y
/ I None
acyl I GENE-Y
- O GENE-Y
CoA O GENE-Y
- O GENE-Y
binding O GENE-Y
protein O GENE-Y
, O GENE-Y
the I None
activated I GENE-Y
transcription O GENE-Y
factor O GENE-Y
4 O GENE-Y
and I None
rhoA I GENE-Y
. I None
<eof> I None

<s> O None
Because I None
the I None
biosynthesis I None
of I None
mevalonate I CHEMICAL
leads I None
to I None
its I None
incorporation I None
into I None
more I None
than I None
a I None
dozen I None
classes I None
of I None
end I None
products I None
, I None
their I None
role I None
in I None
lovastatin I CHEMICAL
- I None
induced I None
apoptosis I None
was I None
also I None
evaluated I None
. I None
<eof> I None

<s> O None
Addition I None
of I None
the I None
metabolites I None
of I None
all I None
the I None
major I None
branches I None
of I None
the I None
mevalonate I CHEMICAL
pathway I None
indicated I None
that I None
only I None
the I None
nonsterol I None
moiety I None
, I None
geranylgeranyl I CHEMICAL
pyrophosphate O CHEMICAL
( I None
GGPP I CHEMICAL
) I None
, I None
significantly I None
inhibited I None
the I None
apoptotic I None
effects I None
of I None
lovastatin I CHEMICAL
in I None
HNSCC I None
and I None
CC I None
cells I None
. I None
<eof> I None

<s> O None
Because I None
rhoA I GENE-Y
requires I None
GGPP I CHEMICAL
for I None
its I None
function I None
, I None
this I None
links I None
the I None
microarray I None
and I None
biochemical I None
data I None
and I None
identifies I None
rhoA I GENE-Y
as I None
a I None
potential I None
mediator I None
of I None
the I None
anticancer I None
properties I None
of I None
lovastatin I CHEMICAL
. I None
<eof> I None

<s> O None
Our I None
data I None
suggest I None
that I None
the I None
depletion I None
of I None
nonsterol I None
mevalonate I None
metabolites I None
, I None
particularly I None
GGPP I CHEMICAL
, I None
can I None
be I None
potential I None
mediators I None
of I None
lovastatin I CHEMICAL
- I None
induced I None
apoptosis I None
of I None
HNSCC I None
and I None
CC I None
cells I None
. I None
<eof> I None

<s> O None
Regulation I None
of I None
norepinephrine I GENE-Y
transporter O GENE-Y
abundance I None
by I None
catecholamines I CHEMICAL
and I None
desipramine I CHEMICAL
in I None
vivo I None
. I None
<eof> I None

<s> O None
The I None
norepinephrine I GENE-Y
transporter O GENE-Y
( I None
NET I GENE-Y
) I None
regulates I None
adrenoreceptor I GENE-N
signaling I None
by I None
controlling I None
the I None
availability I None
of I None
synaptic I None
norepinephrine I CHEMICAL
( I None
NE I CHEMICAL
) I None
, I None
and I None
it I None
is I None
a I None
direct I None
target I None
for I None
some I None
classes I None
of I None
antidepressant I None
drugs I None
. I None
<eof> I None

<s> O None
NET I GENE-Y
levels I None
are I None
normal I None
in I None
dopamine I GENE-Y
beta O GENE-Y
- O GENE-Y
hydroxylase O GENE-Y
knockout I None
( I None
Dbh I GENE-Y
- I None
/ I None
- I None
) I None
mice I None
that I None
lack I None
NE I CHEMICAL
, I None
demonstrating I None
that I None
the I None
NET I GENE-Y
does I None
not I None
require I None
endogenous I None
NE I CHEMICAL
for I None
appropriate I None
regulation I None
under I None
physiological I None
conditions I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
tyrosine I GENE-Y
hydroxylase O GENE-Y
knockout I None
( I None
Th I GENE-Y
- I None
/ I None
- I None
) I None
mice I None
that I None
lack I None
both I None
NE I CHEMICAL
and I None
dopamine I CHEMICAL
( I None
DA I CHEMICAL
) I None
have I None
reduced I None
levels I None
of I None
NET I GENE-Y
, I None
suggesting I None
that I None
it I None
is I None
down I None
- I None
regulated I None
by I None
a I None
complete I None
absence I None
of I None
catecholamines I CHEMICAL
and I None
not I None
NE I CHEMICAL
per I None
se I None
. I None
<eof> I None

<s> O None
Chronic I None
treatment I None
with I None
the I None
NET I GENE-Y
inhibitor I None
, I None
desipramine I CHEMICAL
( I None
DMI I None
) I None
, I None
reduced I None
NET I GENE-Y
levels I None
in I None
both I None
control I None
and I None
Dbh I GENE-Y
- I None
/ I None
- I None
mice I None
, I None
demonstrating I None
that I None
NE I CHEMICAL
is I None
not I None
required I None
for I None
the I None
regulation I None
of I None
NET I GENE-Y
by I None
antidepressant I None
drugs I None
. I None
<eof> I None

<s> O None
There I None
are I None
some I None
qualitative I None
and I None
quantitative I None
differences I None
in I None
the I None
down I None
- I None
regulation I None
of I None
the I None
NET I GENE-Y
by I None
catecholamine I None
depletion I None
and I None
DMI I None
treatment I None
, I None
suggesting I None
that I None
different I None
mechanisms I None
may I None
be I None
involved I None
. I None
<eof> I None

<s> O None
Nicotinic I GENE-N
acetylcholine O GENE-N
receptor O GENE-N
regulation I None
of I None
spinal I None
norepinephrine I CHEMICAL
release I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Neuronal I GENE-N
nicotinic O GENE-N
acetylcholine O GENE-N
receptor O GENE-N
( I None
nAChR I GENE-N
) I None
agonists I None
produce I None
antinociception I None
in I None
animals I None
. I None
<eof> I None

<s> O None
nAChRs I GENE-N
exist I None
almost I None
exclusively I None
on I None
presynaptic I None
terminals I None
in I None
the I None
central I None
nervous I None
system I None
and I None
stimulate I None
neurotransmitter I None
release I None
. I None
<eof> I None

<s> O None
This I None
study I None
tested I None
whether I None
nAChR I GENE-N
agonists I None
stimulate I None
spinal I None
release I None
of I None
the I None
neurotransmitter I None
norepinephrine I CHEMICAL
either I None
by I None
direct I None
actions I None
on I None
noradrenergic I None
terminals I None
or I None
indirectly I None
by I None
stimulating I None
release I None
of I None
other I None
neurotransmitters I None
to I None
induce I None
norepinephrine I CHEMICAL
release I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Adult I None
male I None
rats I None
were I None
anesthetized I None
and I None
microdialysis I None
probes I None
inserted I None
in I None
the I None
L2 I None
- I None
L4 I None
dermatomes I None
of I None
the I None
spinal I None
cord I None
. I None
<eof> I None

<s> O None
Probes I None
were I None
perfused I None
with I None
artificial I None
cerebrospinal I None
fluid I None
containing I None
nicotine I None
, I None
the I None
specific I None
alpha I GENE-Y
( O GENE-Y
4 O GENE-Y
) O GENE-Y
beta O GENE-Y
( O GENE-Y
2 O GENE-Y
* O GENE-Y
) O GENE-Y
nAChR O GENE-Y
agonist I None
metanicotine I CHEMICAL
, I None
or I None
nicotine I CHEMICAL
plus I None
nAChR I GENE-N
antagonists I None
and I None
norepinephrine I CHEMICAL
measured I None
in I None
the I None
microdialysates I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
specific I None
glutamate I GENE-N
receptor O GENE-N
antagonists I None
and I None
nitric I GENE-N
oxide O GENE-N
synthase O GENE-N
inhibitors I None
were I None
also I None
examined I None
. I None
<eof> I None

<s> O None
To I None
determine I None
direct I None
effects I None
on I None
noradrenergic I None
terminals I None
, I None
synaptosomes I None
were I None
prepared I None
from I None
spinal I None
cord I None
and I None
incubated I None
with I None
nAChR I GENE-N
agonists I None
and I None
antagonists I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Both I None
nicotine I CHEMICAL
and I None
metanicotine I CHEMICAL
induced I None
norepinephrine I CHEMICAL
release I None
in I None
spinal I None
microdialsyates I None
, I None
an I None
effect I None
reduced I None
by I None
nicotinic I None
antagonists I None
but I None
not I None
glutamate I CHEMICAL
antagonists I None
or I None
nitric I GENE-N
oxide O GENE-N
synthase O GENE-N
inhibitors I None
. I None
<eof> I None

<s> O None
Both I None
of I None
the I None
nicotinic I None
agonists I None
stimulated I None
norepinephrine I CHEMICAL
release I None
in I None
synaptosomes I None
, I None
and I None
the I None
effect I None
of I None
metanicotine I CHEMICAL
was I None
blocked I None
at I None
lower I None
concentrations I None
of I None
alpha I GENE-Y
( O GENE-Y
4 O GENE-Y
) O GENE-Y
beta O GENE-Y
( O GENE-Y
2 O GENE-Y
* O GENE-Y
) O GENE-Y
- I None
than I None
alpha I GENE-Y
( O GENE-Y
7 O GENE-Y
* O GENE-Y
) O GENE-Y
- I None
preferring I None
nAChR I GENE-N
antagonists I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
These I None
results I None
suggest I None
that I None
one I None
mechanism I None
by I None
which I None
nAChR I GENE-N
agonists I None
act I None
for I None
analgesia I None
is I None
to I None
stimulate I None
spinal I None
norepinephrine I CHEMICAL
release I None
. I None
<eof> I None

<s> O None
They I None
do I None
so I None
by I None
actions I None
on I None
alpha I GENE-Y
( O GENE-Y
4 O GENE-Y
) O GENE-Y
beta O GENE-Y
( O GENE-Y
2 O GENE-Y
* O GENE-Y
) O GENE-Y
nAChRs O GENE-Y
, I None
and I None
perhaps I None
other I None
subtypes I None
, I None
most I None
likely I None
located I None
on I None
noradrenergic I None
terminals I None
, I None
rather I None
than I None
by I None
indirectly I None
stimulating I None
norepinephrine I CHEMICAL
release I None
through I None
glutamate I CHEMICAL
release I None
or I None
nitric I CHEMICAL
oxide O CHEMICAL
synthesis I None
. I None
<eof> I None

<s> O None
The I None
pharmacology I None
of I None
cilostazol I CHEMICAL
. I None
<eof> I None

<s> O None
Cilostazol I CHEMICAL
( I CHEMICAL
6 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
cyclohexyl O CHEMICAL
- O CHEMICAL
1H O CHEMICAL
- O CHEMICAL
tetrazol O CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
yl O CHEMICAL
) O CHEMICAL
butoxy O CHEMICAL
] O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
dihydro O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
( O CHEMICAL
1H O CHEMICAL
) O CHEMICAL
- O CHEMICAL
quinolinone O CHEMICAL
; I None
OPC I CHEMICAL
- O CHEMICAL
13013 O CHEMICAL
) I None
is I None
a I None
2 I CHEMICAL
- O CHEMICAL
oxo O CHEMICAL
- O CHEMICAL
quinoline O CHEMICAL
derivative I None
with I None
antithrombotic I None
, I None
vasodilator I None
, I None
antimitogenic I None
and I None
cardiotonic I None
properties I None
. I None
<eof> I None

<s> O None
The I None
compound I None
is I None
a I None
potent I None
inhibitor I None
of I None
phosphodiesterase I GENE-Y
( O GENE-Y
PDE O GENE-Y
) O GENE-Y
3A O GENE-Y
, I None
the I None
isoform I None
of I None
PDE I GENE-N
3 O GENE-N
in I None
the I None
cardiovascular I None
system I None
( I None
IC50 I None
: I None
0 I None
. I None
2 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
there I None
is I None
inhibition I None
of I None
adenosine I CHEMICAL
uptake I None
, I None
eventually I None
resulting I None
in I None
changes I None
in I None
cAMP I CHEMICAL
levels I None
, I None
dependent I None
on I None
the I None
type I None
of I None
adenosine I GENE-N
receptors O GENE-N
( O GENE-N
A1 O GENE-N
or O GENE-N
A2 O GENE-N
) O GENE-N
. I None
<eof> I None

<s> O None
Cilostazol I CHEMICAL
inhibits I None
platelet I None
aggregation I None
and I None
has I None
considerable I None
antithrombotic I None
effects I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
The I None
compound I None
relaxes I None
vascular I None
smooth I None
muscle I None
and I None
inhibits I None
mitogenesis I None
and I None
migration I None
of I None
vascular I None
smooth I None
muscle I None
cells I None
. I None
<eof> I None

<s> O None
In I None
the I None
heart I None
, I None
cilostazol I CHEMICAL
causes I None
positive I None
inotropic I None
and I None
chronotropic I None
effects I None
. I None
<eof> I None

<s> O None
Most I None
, I None
if I None
not I None
all I None
, I None
of I None
these I None
actions I None
are I None
cAMP I CHEMICAL
- I None
mediated I None
, I None
including I None
the I None
modification I None
of I None
cAMP I CHEMICAL
- I None
controlled I None
gene I None
expression I None
. I None
<eof> I None

<s> O None
Cilostazol I CHEMICAL
decreases I None
levels I None
of I None
serum I None
triglycerides I None
and I None
causes I None
some I None
increase I None
in I None
HDL I GENE-N
- I None
cholesterol I CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
The I None
compound I None
has I None
a I None
number I None
of I None
additional I None
effects I None
which I None
might I None
contribute I None
to I None
its I None
overall I None
clinical I None
efficacy I None
. I None
<eof> I None

<s> O None
Cilostazol I CHEMICAL
undergoes I None
intensive I None
and I None
finally I None
complete I None
hepatic I None
metabolism I None
via I None
the I None
cytochrome I GENE-N
P450 O GENE-N
systems I None
. I None
<eof> I None

<s> O None
This I None
might I None
result I None
in I None
some I None
drug I None
interaction I None
, I None
i I None
. I None
e I None
. I None
with I None
erythromycin I CHEMICAL
and I None
omeprazole I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
half I None
- I None
life I None
is I None
approximately I None
10 I None
h I None
, I None
resulting I None
in I None
about I None
2 I None
- I None
fold I None
accumulation I None
of I None
the I None
drug I None
during I None
repeated I None
administration I None
. I None
<eof> I None

<s> O None
Identification I None
of I None
interaction I None
sites I None
of I None
cyclic I None
nucleotide I CHEMICAL
phosphodiesterase I GENE-Y
type O GENE-Y
3A O GENE-Y
with I None
milrinone I CHEMICAL
and I None
cilostazol I CHEMICAL
using I None
molecular I None
modeling I None
and I None
site I None
- I None
directed I None
mutagenesis I None
. I None
<eof> I None

<s> O None
To I None
identify I None
amino I CHEMICAL
acid O CHEMICAL
residues I None
involved I None
in I None
PDE3 I GENE-Y
- I None
selective I None
inhibitor I None
binding I None
, I None
we I None
selected I None
eight I None
presumed I None
interacting I None
residues I None
in I None
the I None
substrate I None
- I None
binding I None
pocket I None
of I None
PDE3A I GENE-Y
using I None
a I None
model I None
created I None
on I None
basis I None
of I None
homology I None
to I None
the I None
PDE4B I GENE-Y
crystal I None
structure I None
. I None
<eof> I None

<s> O None
We I None
changed I None
the I None
residues I None
to I None
alanine I CHEMICAL
using I None
site I None
- I None
directed I None
mutagenesis I None
technique I None
, I None
expressed I None
the I None
mutants I None
in I None
a I None
baculovirus I None
/ I None
Sf9 I None
cell I None
system I None
, I None
and I None
analyzed I None
the I None
kinetic I None
characteristics I None
of I None
inhibition I None
of I None
the I None
mutant I None
enzymes I None
by I None
milrinone I CHEMICAL
and I None
cilostazol I CHEMICAL
, I None
specific I None
inhibitors I None
of I None
PDE3 I GENE-Y
. I None
<eof> I None

<s> O None
The I None
mutants I None
displayed I None
differential I None
sensitivity I None
to I None
the I None
inhibitors I None
. I None
<eof> I None

<s> O None
Mutants I None
Y751A I GENE-N
, I None
D950A I GENE-N
, I None
and I None
F1004A I GENE-N
had I None
reduced I None
sensitivity I None
to I None
milrinone I CHEMICAL
( I None
K I None
( I None
i I None
) I None
changed I None
from I None
0 I None
. I None
66 I None
microM I None
for I None
the I None
recombinant I None
PDE3A I GENE-Y
to I None
7 I None
. I None
5 I None
to I None
156 I None
microM I None
for I None
the I None
mutants I None
) I None
, I None
and I None
diminished I None
sensitivity I None
to I None
cilostazol I CHEMICAL
( I None
K I None
( I None
i I None
) I None
of I None
the I None
mutants I None
were I None
18 I None
- I None
to I None
371 I None
- I None
fold I None
higher I None
than I None
that I None
of I None
the I None
recombinant I None
PDE3A I GENE-Y
) I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
mutants I None
T844A I GENE-N
, I None
F972A I GENE-N
and I None
Q975A I GENE-N
showed I None
increased I None
K I None
( I None
i I None
) I None
for I None
cilostazol I CHEMICAL
but I None
no I None
difference I None
for I None
milrinone I CHEMICAL
from I None
the I None
recombinant I None
PDE3A I GENE-Y
. I None
<eof> I None

<s> O None
Molecular I None
models I None
show I None
that I None
the I None
PDE3 I GENE-Y
inhibitors I None
cilostazol I CHEMICAL
and I None
milrinone I CHEMICAL
share I None
some I None
of I None
common I None
residues I None
but I None
interact I None
with I None
distinct I None
residues I None
at I None
the I None
active I None
site I None
, I None
suggesting I None
that I None
selective I None
inhibitors I None
can I None
be I None
designed I None
with I None
flexible I None
size I None
against I None
PDE3 I GENE-Y
active I None
site I None
. I None
<eof> I None

<s> O None
Our I None
study I None
implies I None
that I None
highly I None
conserved I None
residuals I None
Y751 I None
, I None
D950 I None
and I None
F1004 I None
in I None
the I None
PDE I GENE-Y
families I None
are I None
key I None
residues I None
for I None
binding I None
of I None
both I None
substrate I None
and I None
inhibitors I None
, I None
and I None
nonconserved I None
T844 I None
may I None
be I None
responsible I None
for I None
the I None
cilostazol I CHEMICAL
selectivity I None
of I None
PDE3A I GENE-Y
. I None
<eof> I None

<s> O None
Detailed I None
knowledge I None
of I None
the I None
structure I None
of I None
inhibitory I None
sites I None
should I None
contribute I None
to I None
development I None
of I None
more I None
potent I None
and I None
specific I None
inhibitory I None
drugs I None
. I None
<eof> I None

<s> O None
Enzymatic I None
catalysis I None
in I None
crystals I None
of I None
Escherichia I GENE-Y
coli O GENE-Y
maltodextrin O GENE-Y
phosphorylase O GENE-Y
. I None
<eof> I None

<s> O None
The I None
bacterial I None
enzyme I None
maltodextrin I GENE-N
phosphorylase O GENE-N
( I None
MalP I GENE-N
) I None
catalyses I None
the I None
phosphorolysis I None
of I None
an I None
alpha I None
- I None
1 I None
, I None
4 I None
- I None
glycosidic I None
bond I None
in I None
maltodextrins I None
, I None
removing I None
the I None
non I None
- I None
reducing I None
glucosyl I CHEMICAL
residues I None
of I None
linear I None
oligosaccharides I None
as I None
glucose I CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
phosphate O CHEMICAL
( I None
Glc1P I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
to I None
the I None
well I None
- I None
studied I None
muscle I None
glycogen I GENE-Y
phosphorylase O GENE-Y
( I None
GP I GENE-Y
) I None
, I None
MalP I GENE-Y
exhibits I None
no I None
allosteric I None
properties I None
and I None
has I None
a I None
higher I None
affinity I None
for I None
linear I None
oligosaccharides I None
than I None
GP I GENE-Y
. I None
<eof> I None

<s> O None
We I None
have I None
used I None
MalP I GENE-Y
as I None
a I None
model I None
system I None
to I None
study I None
catalysis I None
in I None
the I None
crystal I None
in I None
the I None
direction I None
of I None
maltodextrin I None
synthesis I None
. I None
<eof> I None

<s> O None
The I None
2 I None
. I None
0A I None
crystal I None
structure I None
of I None
the I None
MalP I GENE-Y
/ I None
Glc1P I CHEMICAL
binary I None
complex I None
shows I None
that I None
the I None
Glc1P I CHEMICAL
substrate I None
adopts I None
a I None
conformation I None
seen I None
previously I None
with I None
both I None
inactive I None
and I None
active I None
forms I None
of I None
mammalian I GENE-N
GP O GENE-N
, I None
with I None
the I None
phosphate I CHEMICAL
group I None
not I None
in I None
close I None
contact I None
with I None
the I None
5 I CHEMICAL
' O CHEMICAL
- O CHEMICAL
phosphate O CHEMICAL
group I None
of I None
the I None
essential I None
pyridoxal I CHEMICAL
phosphate O CHEMICAL
( I None
PLP I CHEMICAL
) I None
cofactor I None
. I None
<eof> I None

<s> O None
In I None
the I None
active I None
MalP I GENE-Y
enzyme I None
, I None
the I None
residue I None
Arg569 I None
stabilizes I None
the I None
negative I None
- I None
charged I None
Glc1P I CHEMICAL
, I None
whereas I None
in I None
the I None
inactive I None
form I None
of I None
GP I GENE-Y
this I None
key I None
residue I None
is I None
held I None
away I None
from I None
the I None
catalytic I None
site I None
by I None
loop I None
280s I None
and I None
an I None
allosteric I None
transition I None
of I None
the I None
mammalian I None
enzyme I None
is I None
required I None
for I None
activation I None
. I None
<eof> I None

<s> O None
The I None
comparison I None
between I None
MalP I GENE-Y
structures I None
shows I None
that I None
His377 I None
, I None
through I None
a I None
hydrogen I None
bond I None
with I None
the I None
6 I CHEMICAL
- O CHEMICAL
hydroxyl O CHEMICAL
group I None
of I None
Glc1P I CHEMICAL
substrate I None
, I None
triggers I None
a I None
conformational I None
change I None
of I None
the I None
380s I None
loop I None
. I None
<eof> I None

<s> O None
This I None
mobile I None
region I None
folds I None
over I None
the I None
catalytic I None
site I None
and I None
contributes I None
to I None
the I None
specific I None
recognition I None
of I None
the I None
oligosaccharide I None
and I None
to I None
the I None
synergism I None
between I None
substrates I None
in I None
promoting I None
the I None
formation I None
of I None
the I None
MalP I GENE-Y
ternary I None
complex I None
. I None
<eof> I None

<s> O None
The I None
structures I None
solved I None
after I None
the I None
diffusion I None
of I None
oligosaccharides I None
( I None
either I None
maltotetraose I CHEMICAL
, I None
G4 I None
or I None
maltopentaose I CHEMICAL
, I None
G5 I None
) I None
into I None
MalP I GENE-Y
/ I None
Glc1P I CHEMICAL
crystals I None
show I None
the I None
formation I None
of I None
phosphate I CHEMICAL
and I None
elongation I None
of I None
the I None
oligosaccharide I None
chain I None
. I None
<eof> I None

<s> O None
These I None
structures I None
, I None
refined I None
at I None
1 I None
. I None
8A I None
and I None
at I None
2 I None
. I None
2A I None
, I None
confirm I None
that I None
only I None
when I None
an I None
oligosaccharide I None
is I None
bound I None
to I None
the I None
catalytic I None
site I None
will I None
Glc1P I CHEMICAL
bend I None
its I None
phosphate I CHEMICAL
group I None
down I None
so I None
it I None
can I None
contact I None
the I None
PLP I CHEMICAL
5 I CHEMICAL
' O CHEMICAL
phosphate O CHEMICAL
group I None
and I None
promote I None
catalysis I None
. I None
<eof> I None

<s> O None
The I None
relatively I None
large I None
oligosaccharide I None
substrates I None
can I None
diffuse I None
quickly I None
into I None
the I None
MalP I GENE-Y
/ I None
Glc1P I CHEMICAL
crystals I None
and I None
the I None
enzymatic I None
reaction I None
can I None
occur I None
without I None
significant I None
crystal I None
damage I None
. I None
<eof> I None

<s> O None
These I None
structures I None
obtained I None
before I None
and I None
after I None
catalysis I None
have I None
been I None
used I None
as I None
frames I None
of I None
a I None
molecular I None
movie I None
. I None
<eof> I None

<s> O None
This I None
movie I None
reveals I None
the I None
relative I None
positions I None
of I None
substrates I None
in I None
the I None
catalytic I None
channel I None
and I None
shows I None
a I None
minimal I None
movement I None
of I None
the I None
protein I None
, I None
involving I None
mainly I None
Arg569 I None
, I None
which I None
tracks I None
the I None
substrate I None
phosphate I CHEMICAL
group I None
. I None
<eof> I None

<s> O None
The I None
pharmacokinetics I None
of I None
fondaparinux I CHEMICAL
sodium O CHEMICAL
in I None
healthy I None
volunteers I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
Fondaparinux I CHEMICAL
sodium O CHEMICAL
is I None
the I None
first I None
in I None
a I None
new I None
class I None
of I None
synthetic I None
factor I GENE-Y
Xa O GENE-Y
inhibitors I None
that I None
binds I None
reversibly I None
with I None
high I None
affinity I None
to I None
antithrombin I GENE-Y
III O GENE-Y
. I None
<eof> I None

<s> O None
It I None
has I None
been I None
investigated I None
for I None
the I None
prevention I None
and I None
treatment I None
of I None
arterial I None
and I None
venous I None
thrombotic I None
disorders I None
and I None
approved I None
for I None
use I None
at I None
a I None
dose I None
of I None
2 I None
. I None
5mg I None
once I None
daily I None
in I None
the I None
prevention I None
of I None
venous I None
thromboembolism I None
in I None
major I None
orthopaedic I None
surgery I None
. I None
<eof> I None

<s> O None
The I None
pharmacokinetics I None
of I None
fondaparinux I CHEMICAL
sodium O CHEMICAL
were I None
determined I None
in I None
eight I None
studies I None
in I None
young I None
and I None
elderly I None
healthy I None
volunteers I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
After I None
a I None
2 I None
. I None
5mg I None
subcutaneous I None
dose I None
to I None
young I None
volunteers I None
, I None
absolute I None
bioavailability I None
was I None
100 I None
% I None
and I None
absorption I None
was I None
rapid I None
and I None
complete I None
[ I None
peak I None
plasma I None
concentration I None
( I None
C I None
( I None
max I None
) I None
) I None
0 I None
. I None
34 I None
mg I None
/ I None
L I None
occurred I None
at I None
approximately I None
2 I None
hours I None
] I None
. I None
<eof> I None

<s> O None
Within I None
- I None
and I None
total I None
- I None
subject I None
variability I None
estimates I None
were I None
small I None
: I None
5 I None
. I None
5 I None
and I None
11 I None
. I None
6 I None
% I None
, I None
respectively I None
, I None
for I None
C I None
( I None
max I None
) I None
and I None
4 I None
. I None
4 I None
and I None
17 I None
. I None
5 I None
% I None
for I None
area I None
under I None
the I None
concentration I None
- I None
time I None
curve I None
( I None
AUC I None
) I None
. I None
<eof> I None

<s> O None
Steady I None
state I None
was I None
obtained I None
after I None
the I None
third I None
or I None
fourth I None
once I None
- I None
daily I None
dose I None
, I None
with I None
a I None
1 I None
. I None
3 I None
- I None
fold I None
increase I None
in I None
C I None
( I None
max I None
) I None
and I None
AUC I None
. I None
<eof> I None

<s> O None
Distribution I None
volume I None
( I None
7 I None
to I None
11L I None
) I None
was I None
limited I None
to I None
blood I None
volume I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
evidence I None
of I None
metabolism I None
. I None
<eof> I None

<s> O None
Fondaparinux I CHEMICAL
sodium O CHEMICAL
was I None
almost I None
completely I None
excreted I None
in I None
urine I None
as I None
unchanged I None
compound I None
( I None
64 I None
to I None
77 I None
% I None
of I None
the I None
dose I None
was I None
recovered I None
at I None
72 I None
hours I None
after I None
administration I None
) I None
. I None
<eof> I None

<s> O None
Plasma I None
clearance I None
was I None
5 I None
. I None
1 I None
to I None
7 I None
. I None
9 I None
ml I None
/ I None
min I None
, I None
renal I None
clearance I None
4 I None
. I None
0 I None
to I None
7 I None
. I None
9 I None
ml I None
/ I None
min I None
, I None
and I None
the I None
terminal I None
half I None
- I None
life I None
was I None
17 I None
hours I None
in I None
young I None
volunteers I None
and I None
21 I None
hours I None
in I None
elderly I None
volunteers I None
. I None
<eof> I None

<s> O None
Pharmacokinetics I None
of I None
fondaparinux I CHEMICAL
sodium O CHEMICAL
were I None
linear I None
in I None
the I None
range I None
2 I None
to I None
8mg I None
subcutaneously I None
and I None
2 I None
to I None
20mg I None
intravenously I None
. I None
<eof> I None

<s> O None
Pharmacokinetics I None
observed I None
in I None
healthy I None
elderly I None
volunteers I None
were I None
consistent I None
with I None
findings I None
in I None
young I None
male I None
volunteers I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
The I None
favourable I None
pharmacokinetic I None
profile I None
of I None
fondaparinux I CHEMICAL
sodium O CHEMICAL
is I None
likely I None
to I None
play I None
an I None
important I None
role I None
in I None
the I None
major I None
advance I None
that I None
the I None
drug I None
represents I None
in I None
the I None
prevention I None
and I None
treatment I None
of I None
thrombotic I None
disorders I None
. I None
<eof> I None

<s> O None
Molecular I None
analysis I None
of I None
PCCB I GENE-Y
gene I None
in I None
Korean I None
patients I None
with I None
propionic I CHEMICAL
acidemia I None
. I None
<eof> I None

<s> O None
Propionic I None
acidemia I None
( I None
PA I None
) I None
is I None
an I None
autosomal I None
recessive I None
inborn I None
error I None
in I None
the I None
catabolism I None
of I None
methionine I CHEMICAL
, I None
isoleucine I CHEMICAL
, I None
threonine I CHEMICAL
, I None
and I None
valine I CHEMICAL
, I None
odd I CHEMICAL
- O CHEMICAL
numbered O CHEMICAL
chain O CHEMICAL
length O CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
and I None
cholesterol I CHEMICAL
. I None
<eof> I None

<s> O None
Clinical I None
symptoms I None
are I None
very I None
heterogeneous I None
and I None
present I None
as I None
a I None
severe I None
neonatal I None
- I None
onset I None
or I None
a I None
late I None
- I None
onset I None
form I None
. I None
<eof> I None

<s> O None
It I None
is I None
caused I None
by I None
a I None
deficiency I None
of I None
propionyl I GENE-N
- O GENE-N
CoA O GENE-N
carboxylase O GENE-N
( I None
PCC I GENE-N
, I None
EC I GENE-Y
6 O GENE-Y
. O GENE-Y
4 O GENE-Y
. O GENE-Y
1 O GENE-Y
. O GENE-Y
3 O GENE-Y
) I None
, I None
a I None
biotin I CHEMICAL
- I None
dependent I None
enzyme I None
that I None
catalyzes I None
the I None
carboxylation I None
of I None
propionyl I CHEMICAL
- O CHEMICAL
CoA O CHEMICAL
to I None
D I CHEMICAL
- O CHEMICAL
methylmalonyl O CHEMICAL
- O CHEMICAL
CoA O CHEMICAL
. I None
<eof> I None

<s> O None
PCC I GENE-N
is I None
a I None
heteropolymeric I None
enzyme I None
composed I None
of I None
alpha I None
- I None
and I None
beta I None
- I None
subunits I None
. I None
<eof> I None

<s> O None
A I None
greater I None
heterogeneity I None
is I None
observed I None
in I None
the I None
PCCA I GENE-Y
gene I None
, I None
while I None
for I None
the I None
PCCB I GENE-Y
gene I None
, I None
a I None
limited I None
number I None
of I None
mutations I None
is I None
responsible I None
for I None
the I None
majority I None
of I None
the I None
alleles I None
characterized I None
in I None
both I None
Caucasian I None
and I None
Oriental I None
populations I None
. I None
<eof> I None

<s> O None
We I None
identified I None
eight I None
Korean I None
patients I None
with I None
PA I None
by I None
organic I None
acid I None
analysis I None
confirmed I None
in I None
five I None
patients I None
by I None
the I None
PCC I GENE-N
enzyme I None
assay I None
in I None
the I None
lymphoblasts I None
. I None
<eof> I None

<s> O None
Two I None
neonatal I None
- I None
onset I None
patients I None
showed I None
undetectable I None
PCC I GENE-N
activities I None
while I None
three I None
cases I None
with I None
residual I None
enzyme I None
activities I None
had I None
relatively I None
late I None
manifestations I None
. I None
<eof> I None

<s> O None
In I None
the I None
molecular I None
analysis I None
, I None
we I None
identified I None
five I None
novel I None
mutations I None
, I None
Y439C I GENE-N
, I None
1527del3 I None
, I None
1357insT I None
, I None
IVS12 I GENE-N
- O GENE-N
8T O GENE-N
- O GENE-N
- O GENE-N
> O GENE-N
A O GENE-N
, I None
and I None
31del10 I None
, I None
and I None
one I None
known I None
mutation I None
, I None
T428I I GENE-N
in I None
PCCB I GENE-Y
gene I None
. I None
<eof> I None

<s> O None
Alleleic I None
frequency I None
of I None
T428I I GENE-N
in I None
Korean I None
patients I None
with I None
PA I None
was I None
56 I None
. I None
3 I None
% I None
in I None
this I None
study I None
. I None
<eof> I None

<s> O None
Two I None
neonatal I None
- I None
onset I None
patients I None
with I None
null I None
enzyme I None
activities I None
were I None
homozygotes I None
with I None
1527del3 I None
and I None
T428I I GENE-N
, I None
respectively I None
. I None
<eof> I None

<s> O None
This I None
finding I None
implies I None
that I None
T428I I GENE-N
and I None
1527del3 I None
mutation I None
could I None
be I None
responsible I None
for I None
their I None
severe I None
clinical I None
courses I None
and I None
null I None
enzyme I None
activities I None
. I None
<eof> I None

<s> O None
The I None
mRNA I None
of I None
PCCB I GENE-Y
gene I None
in I None
T428I I GENE-N
and I None
1527del3 I None
homozygotes I None
were I None
normal I None
but I None
in I None
Western I None
blot I None
analysis I None
, I None
the I None
betaPCC I GENE-Y
- I None
subunit I None
was I None
only I None
absent I None
in I None
1527del3 I None
homozygote I None
patient I None
suggesting I None
different I None
molecular I None
pathology I None
. I None
<eof> I None

<s> O None
Atypical I None
antipsychotic I None
drugs I None
, I None
quetiapine I CHEMICAL
, I None
iloperidone I CHEMICAL
, I None
and I None
melperone I CHEMICAL
, I None
preferentially I None
increase I None
dopamine I CHEMICAL
and I None
acetylcholine I CHEMICAL
release I None
in I None
rat I None
medial I None
prefrontal I None
cortex I None
: I None
role I None
of I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
receptor I None
agonism I None
. I None
<eof> I None

<s> O None
Preferential I None
increases I None
in I None
both I None
cortical I None
dopamine I CHEMICAL
( I None
DA I CHEMICAL
) I None
and I None
acetylcholine I CHEMICAL
( I None
ACh I CHEMICAL
) I None
release I None
have I None
been I None
proposed I None
to I None
distinguish I None
the I None
atypical I None
antipsychotic I None
drugs I None
( I None
APDs I None
) I None
clozapine I CHEMICAL
, I None
olanzapine I CHEMICAL
, I None
risperidone I CHEMICAL
and I None
ziprasidone I CHEMICAL
from I None
typical I None
APDs I None
such I None
as I None
haloperidol I CHEMICAL
. I None
<eof> I None

<s> O None
Although I None
only I None
clozapine I CHEMICAL
and I None
ziprasidone I CHEMICAL
are I None
directly I None
acting I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
agonists I None
, I None
WAY100635 I CHEMICAL
, I None
a I None
selective I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
antagonist I None
, I None
partially I None
attenuates I None
these I None
atypical I None
APD I None
- I None
induced I None
increases I None
in I None
cortical I None
DA I CHEMICAL
release I None
that I None
may I None
be I None
due I None
to I None
combined I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
and I None
D I GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
blockade I None
. I None
<eof> I None

<s> O None
However I None
, I None
WAY100635 I CHEMICAL
does I None
not I None
attenuate I None
clozapine I CHEMICAL
- I None
induced I None
cortical I None
ACh I CHEMICAL
release I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
determined I None
whether I None
quetiapine I CHEMICAL
, I None
iloperidone I CHEMICAL
and I None
melperone I CHEMICAL
, I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
/ I None
D I GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
antagonist I None
atypical I None
APDs I None
, I None
also I None
increase I None
cortical I None
DA I CHEMICAL
and I None
ACh I CHEMICAL
release I None
, I None
and I None
whether I None
these I None
effects I None
are I None
related I None
to I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
agonism I None
. I None
<eof> I None

<s> O None
Quetiapine I CHEMICAL
( I None
30 I None
mg I None
/ I None
kg I None
) I None
, I None
iloperidone I CHEMICAL
( I None
1 I None
- I None
10 I None
mg I None
/ I None
kg I None
) I None
, I None
and I None
melperone I CHEMICAL
( I None
3 I None
- I None
10 I None
mg I None
/ I None
kg I None
) I None
increased I None
DA I CHEMICAL
and I None
ACh I CHEMICAL
release I None
in I None
the I None
medial I None
prefrontal I None
cortex I None
( I None
mPFC I None
) I None
. I None
<eof> I None

<s> O None
Iloperidone I CHEMICAL
( I None
10 I None
mg I None
/ I None
kg I None
) I None
and I None
melperone I CHEMICAL
( I None
10 I None
mg I None
/ I None
kg I None
) I None
, I None
but I None
not I None
quetiapine I CHEMICAL
( I None
30 I None
mg I None
/ I None
kg I None
) I None
, I None
produced I None
an I None
equivalent I None
or I None
a I None
smaller I None
increase I None
in I None
DA I CHEMICAL
release I None
in I None
the I None
nucleus I None
accumbens I None
( I None
NAC I None
) I None
, I None
respectively I None
, I None
compared I None
to I None
the I None
mPFC I None
, I None
whereas I None
none I None
of I None
them I None
increased I None
ACh I CHEMICAL
release I None
in I None
the I None
NAC I None
. I None
<eof> I None

<s> O None
WAY100635 I CHEMICAL
( I None
0 I None
. I None
2 I None
mg I None
/ I None
kg I None
) I None
, I None
which I None
alone I None
did I None
not I None
affect I None
DA I CHEMICAL
or I None
ACh I CHEMICAL
release I None
, I None
partially I None
attenuated I None
quetiapine I CHEMICAL
( I None
30 I None
mg I None
/ I None
kg I None
) I None
- I None
, I None
iloperidone I CHEMICAL
( I None
10 I None
mg I None
/ I None
kg I None
) I None
- I None
and I None
melperone I CHEMICAL
( I None
10 I None
mg I None
/ I None
kg I None
) I None
- I None
induced I None
DA I CHEMICAL
release I None
in I None
the I None
mPFC I None
. I None
<eof> I None

<s> O None
WAY100635 I CHEMICAL
also I None
partially I None
attenuated I None
quetiapine I CHEMICAL
( I None
30 I None
mg I None
/ I None
kg I None
) I None
- I None
induced I None
ACh I CHEMICAL
release I None
in I None
the I None
mPFC I None
, I None
but I None
not I None
that I None
induced I None
by I None
iloperidone I CHEMICAL
( I None
10 I None
mg I None
/ I None
kg I None
) I None
or I None
melperone I CHEMICAL
( I None
10 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
quetiapine I CHEMICAL
, I None
iloperidone I CHEMICAL
and I None
melperone I CHEMICAL
preferentially I None
increase I None
DA I CHEMICAL
release I None
in I None
the I None
mPFC I None
, I None
compared I None
to I None
the I None
NAC I None
via I None
a I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
- I None
related I None
mechanism I None
. I None
<eof> I None

<s> O None
However I None
, I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
agonism I None
may I None
be I None
important I None
only I None
for I None
quetiapine I CHEMICAL
- I None
induced I None
ACh I CHEMICAL
release I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
age I None
and I None
sex I None
on I None
the I None
disposition I None
of I None
retigabine I CHEMICAL
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
The I None
novel I None
antiepileptic I None
drug I None
retigabine I CHEMICAL
is I None
the I None
first I None
selective I None
M I GENE-N
- O GENE-N
current O GENE-N
potassium O GENE-N
channel O GENE-N
opener I None
for I None
KCNQ2 I GENE-N
/ O GENE-N
3 O GENE-N
and I None
KCNQ3 I GENE-N
/ O GENE-N
5 O GENE-N
channels I None
. I None
<eof> I None

<s> O None
Retigabine I CHEMICAL
undergoes I None
phase I None
II I None
metabolism I None
( I None
N I CHEMICAL
- I None
glucuronidation I None
, I None
acetylation I None
) I None
exclusively I None
and I None
renal I None
excretion I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
Our I None
objective I None
was I None
to I None
evaluate I None
the I None
effects I None
of I None
age I None
and I None
sex I None
on I None
the I None
pharmacokinetics I None
of I None
retigabine I CHEMICAL
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Healthy I None
young I None
( I None
age I None
range I None
, I None
18 I None
- I None
40 I None
years I None
) I None
and I None
elderly I None
( I None
age I None
range I None
, I None
66 I None
- I None
81 I None
years I None
) I None
white I None
subjects I None
( I None
12 I None
men I None
and I None
12 I None
women I None
in I None
each I None
group I None
) I None
received I None
a I None
single I None
200 I None
- I None
mg I None
oral I None
dose I None
of I None
retigabine I CHEMICAL
. I None
<eof> I None

<s> O None
After I None
dosing I None
, I None
blood I None
was I None
collected I None
over I None
a I None
72 I None
- I None
hour I None
period I None
to I None
determine I None
plasma I None
concentrations I None
of I None
retigabine I CHEMICAL
and I None
its I None
acetylated I None
metabolite I None
, I None
AWD21 I CHEMICAL
- O CHEMICAL
360 O CHEMICAL
. I None
<eof> I None

<s> O None
Pharmacokinetics I None
was I None
compared I None
for I None
age I None
group I None
and I None
sex I None
by I None
ANOVA I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
In I None
young I None
men I None
, I None
retigabine I CHEMICAL
was I None
rapidly I None
absorbed I None
, I None
with I None
the I None
maximum I None
concentration I None
occurring I None
within I None
2 I None
hours I None
, I None
and I None
was I None
eliminated I None
with I None
an I None
apparent I None
clearance I None
of I None
0 I None
. I None
67 I None
L I None
x I None
h I None
( I None
- I None
1 I None
) I None
x I None
kg I None
( I None
- I None
1 I None
) I None
and I None
a I None
mean I None
terminal I None
half I None
- I None
life I None
of I None
8 I None
. I None
5 I None
hours I None
. I None
<eof> I None

<s> O None
Subjects I None
were I None
similarly I None
exposed I None
to I None
AWD21 I CHEMICAL
- O CHEMICAL
360 O CHEMICAL
. I None
<eof> I None

<s> O None
Compared I None
with I None
young I None
men I None
, I None
young I None
women I None
had I None
higher I None
retigabine I CHEMICAL
maximum I None
concentration I None
( I None
56 I None
% I None
) I None
and I None
exposure I None
( I None
20 I None
% I None
) I None
but I None
similar I None
clearance I None
( I None
0 I None
. I None
68 I None
L I None
x I None
h I None
( I None
- I None
1 I None
) I None
x I None
kg I None
( I None
- I None
1 I None
) I None
) I None
; I None
these I None
differences I None
were I None
related I None
to I None
differences I None
in I None
body I None
weight I None
. I None
<eof> I None

<s> O None
Although I None
maximum I None
concentration I None
was I None
similar I None
in I None
elderly I None
subjects I None
, I None
retigabine I CHEMICAL
elimination I None
was I None
slower I None
( I None
30 I None
% I None
lower I None
apparent I None
clearance I None
normalized I None
for I None
weight I None
) I None
, I None
resulting I None
in I None
higher I None
exposure I None
( I None
42 I None
% I None
) I None
and I None
a I None
longer I None
half I None
- I None
life I None
( I None
30 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Because I None
phase I None
II I None
metabolism I None
is I None
scarcely I None
affected I None
by I None
age I None
, I None
these I None
differences I None
may I None
be I None
related I None
to I None
the I None
known I None
decline I None
of I None
renal I None
function I None
with I None
age I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
Although I None
there I None
are I None
no I None
substantial I None
sex I None
- I None
related I None
differences I None
in I None
the I None
disposition I None
of I None
retigabine I CHEMICAL
, I None
a I None
relevant I None
decrease I None
in I None
clearance I None
resulting I None
in I None
higher I None
exposure I None
occurs I None
in I None
elderly I None
patients I None
. I None
<eof> I None

<s> O None
The I None
results I None
suggest I None
that I None
decline I None
of I None
renal I None
function I None
with I None
age I None
may I None
account I None
for I None
some I None
of I None
the I None
observed I None
changes I None
. I None
<eof> I None

<s> O None
Selective I None
cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibition I None
does I None
not I None
affect I None
the I None
healing I None
of I None
cutaneous I None
full I None
- I None
thickness I None
incisional I None
wounds I None
in I None
SKH I None
- I None
1 I None
mice I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
The I None
inducible I None
cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
( I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
enzyme I None
is I None
upregulated I None
in I None
inflammatory I None
diseases I None
, I None
as I None
well I None
as I None
in I None
epithelial I None
cancers I None
, I None
and I None
has I None
an I None
established I None
role I None
in I None
angiogenesis I None
and I None
tissue I None
repair I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
Because I None
of I None
these I None
physiological I None
effects I None
and I None
the I None
widespread I None
use I None
of I None
the I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
, I None
celecoxib I CHEMICAL
, I None
we I None
wanted I None
to I None
determine I None
if I None
inhibition I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
would I None
affect I None
incisional I None
skin I None
wound I None
healing I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Using I None
a I None
cutaneous I None
full I None
- I None
thickness I None
, I None
sutured I None
, I None
incisional I None
wound I None
model I None
in I None
hairless I None
SKH I None
- I None
1 I None
mice I None
, I None
we I None
evaluated I None
the I None
role I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
in I None
the I None
wound I None
healing I None
process I None
by I None
comparing I None
the I None
effects I None
of I None
a I None
nonselective I None
COX I GENE-N
inhibitor I None
, I None
diclofenac I CHEMICAL
, I None
with I None
a I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
, I None
SC I None
- I None
791 I None
. I None
<eof> I None

<s> O None
Healing I None
was I None
monitored I None
for I None
up I None
to I None
28 I None
days I None
postincision I None
histologically I None
and I None
for I None
recovery I None
of I None
wound I None
strength I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
expression I None
was I None
observed I None
over I None
the I None
first I None
week I None
of I None
healing I None
, I None
peaking I None
at I None
day I None
3 I None
and I None
was I None
not I None
affected I None
by I None
treatment I None
with I None
the I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
or I None
nonselective I None
COX I GENE-N
inhibitors I None
. I None
<eof> I None

<s> O None
Infiltrating I None
macrophages I None
, I None
as I None
well I None
as I None
keratinocytes I None
and I None
dermal I None
fibroblasts I None
at I None
the I None
wound I None
site I None
, I None
expressed I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
Neither I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
, I None
nor I None
nonselective I None
COX I GENE-N
inhibition I None
had I None
a I None
significant I None
effect I None
on I None
the I None
macroscopic I None
or I None
microscopic I None
morphology I None
of I None
the I None
wounds I None
, I None
whereas I None
dexamethasone I CHEMICAL
treatment I None
resulted I None
in I None
epidermal I None
and I None
granulation I None
tissue I None
atrophy I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
neither I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
, I None
nor I None
nonselective I None
COX I GENE-N
inhibition I None
altered I None
keratinocyte I None
proliferation I None
and I None
differentiation I None
, I None
dermal I None
angiogenesis I None
or I None
the I None
recovery I None
of I None
wound I None
tensile I None
strength I None
, I None
whereas I None
dexamethasone I CHEMICAL
reduced I None
the I None
tensile I None
strength I None
of I None
the I None
wounds I None
by I None
30 I None
- I None
38 I None
% I None
throughout I None
the I None
healing I None
period I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
These I None
data I None
indicate I None
that I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibition I None
does I None
not I None
affect I None
the I None
healing I None
of I None
surgical I None
skin I None
wounds I None
. I None
<eof> I None

<s> O None
Synthesis I None
and I None
in I None
vivo I None
evaluation I None
of I None
novel I None
radiotracers I None
for I None
the I None
in I None
vivo I None
imaging I None
of I None
the I None
norepinephrine I GENE-Y
transporter O GENE-Y
. I None
<eof> I None

<s> O None
The I None
( I CHEMICAL
R O CHEMICAL
, O CHEMICAL
R O CHEMICAL
) O CHEMICAL
and O CHEMICAL
( O CHEMICAL
S O CHEMICAL
, O CHEMICAL
S O CHEMICAL
) O CHEMICAL
enantiomers O CHEMICAL
of O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
methoxyphenoxy O CHEMICAL
) O CHEMICAL
phenylmethyl O CHEMICAL
] O CHEMICAL
morpholine O CHEMICAL
( I None
MeNER I CHEMICAL
) I None
have I None
been I None
radiolabelled I None
with I None
carbon I CHEMICAL
- O CHEMICAL
11 O CHEMICAL
in I None
good I None
yield I None
and I None
at I None
high I None
specific I None
activity I None
. I None
<eof> I None

<s> O None
These I None
radiotracers I None
are I None
close I None
analogues I None
of I None
reboxetine I CHEMICAL
, I None
a I None
potent I None
and I None
selective I None
ligand I None
for I None
the I None
norepinephrine I GENE-Y
transporter O GENE-Y
( I None
NET I GENE-Y
) I None
. I None
<eof> I None

<s> O None
They I None
were I None
examined I None
as I None
potential I None
ligands I None
for I None
imaging I None
NET I GENE-Y
in I None
vivo I None
by I None
positron I None
emission I None
tomography I None
( I None
PET I None
) I None
. I None
<eof> I None

<s> O None
The I None
in I None
vivo I None
brain I None
distribution I None
of I None
both I None
[ I None
( I CHEMICAL
11 O CHEMICAL
) O CHEMICAL
C O CHEMICAL
] I None
- I None
labeled I None
enantiomers I None
were I None
evaluated I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Following I None
tail I None
- I None
vein I None
injection I None
of I None
the I None
( I None
R I None
, I None
R I None
) I None
- I None
enantiomer I None
regional I None
brain I None
uptake I None
and I None
washout I None
of I None
radioactivity I None
was I None
homogeneous I None
at I None
all I None
time I None
points I None
examined I None
( I None
5 I None
- I None
60 I None
min I None
) I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
administration I None
of I None
the I None
( I None
S I None
, I None
S I None
) I None
- I None
enantiomer I None
produced I None
a I None
heterogeneous I None
distribution I None
of I None
radioactivity I None
in I None
brain I None
with I None
highest I None
uptake I None
in I None
the I None
hypothalamus I None
, I None
a I None
NET I GENE-Y
rich I None
region I None
, I None
and I None
lowest I None
uptake I None
in I None
the I None
striatum I None
, I None
a I None
brain I None
region I None
devoid I None
of I None
NET I GENE-Y
. I None
<eof> I None

<s> O None
Hypothalamus I None
to I None
striatum I None
ratios I None
of I None
2 I None
. I None
5 I None
to I None
one I None
were I None
achieved I None
at I None
60 I None
min I None
post I None
injection I None
of I None
( I CHEMICAL
S O CHEMICAL
, O CHEMICAL
S O CHEMICAL
) O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
( O CHEMICAL
11 O CHEMICAL
) O CHEMICAL
C O CHEMICAL
] O CHEMICAL
- O CHEMICAL
MeNER O CHEMICAL
. I None
<eof> I None

<s> O None
Pre I None
- I None
injection I None
of I None
the I None
norepinephrine I CHEMICAL
reuptake I None
inhibitors I None
, I None
reboxetine I CHEMICAL
or I None
desipramine I CHEMICAL
, I None
reduced I None
hypothalamus I None
to I None
striatum I None
ratios I None
to I None
near I None
unity I None
while I None
reuptake I None
inhibitors I None
of I None
dopamine I CHEMICAL
and I None
serotonin I CHEMICAL
had I None
no I None
significant I None
effect I None
on I None
binding I None
. I None
<eof> I None

<s> O None
In I None
vitro I None
autoradiography I None
studies I None
( I None
rat I None
brain I None
slices I None
) I None
with I None
( I CHEMICAL
S O CHEMICAL
, O CHEMICAL
S O CHEMICAL
) O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
( O CHEMICAL
11 O CHEMICAL
) O CHEMICAL
C O CHEMICAL
] O CHEMICAL
- O CHEMICAL
MeNER O CHEMICAL
produced I None
a I None
regional I None
distribution I None
pattern I None
that I None
was I None
consistent I None
with I None
the I None
reported I None
distribution I None
of I None
NET I GENE-Y
. I None
<eof> I None

<s> O None
( I CHEMICAL
S O CHEMICAL
, O CHEMICAL
S O CHEMICAL
) O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
( O CHEMICAL
11 O CHEMICAL
) O CHEMICAL
C O CHEMICAL
] O CHEMICAL
- O CHEMICAL
MeNER O CHEMICAL
has I None
the I None
potential I None
to I None
be I None
the I None
first I None
successful I None
PET I None
ligand I None
to I None
image I None
NET I GENE-Y
. I None
<eof> I None

<s> O None
Histamine I GENE-Y
H1 O GENE-Y
- O GENE-Y
receptor O GENE-Y
antagonists I None
, I None
promethazine I CHEMICAL
and I None
homochlorcyclizine I CHEMICAL
, I None
increase I None
the I None
steady I None
- I None
state I None
plasma I None
concentrations I None
of I None
haloperidol I CHEMICAL
and I None
reduced I None
haloperidol I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
histamine I GENE-Y
H1 O GENE-Y
- O GENE-Y
receptor O GENE-Y
antagonists I None
, I None
promethazine I CHEMICAL
and I None
homochlorcyclizine I CHEMICAL
, I None
both I None
of I None
which I None
are I None
inhibitors I None
of I None
CYP2D6 I GENE-Y
, I None
on I None
the I None
steady I None
- I None
state I None
plasma I None
concentrations I None
( I None
Css I None
) I None
of I None
haloperidol I CHEMICAL
and I None
reduced I None
haloperidol I CHEMICAL
were I None
studied I None
in I None
23 I None
schizophrenic I None
inpatients I None
receiving I None
haloperidol I CHEMICAL
, I None
12 I None
to I None
36 I None
mg I None
/ I None
d I None
, I None
for I None
2 I None
to I None
29 I None
weeks I None
. I None
<eof> I None

<s> O None
Promethazine I CHEMICAL
, I None
150 I None
mg I None
/ I None
d I None
, I None
in I None
11 I None
patients I None
and I None
homochlorcyclizine I CHEMICAL
, I None
60 I None
mg I None
/ I None
d I None
, I None
in I None
the I None
others I None
were I None
coadministered I None
for I None
at I None
least I None
1 I None
week I None
. I None
<eof> I None

<s> O None
Blood I None
sampling I None
was I None
performed I None
before I None
and I None
during I None
coadministration I None
of I None
promethazine I CHEMICAL
or I None
homochlorcyclizine I CHEMICAL
and I None
1 I None
week I None
after I None
the I None
discontinuation I None
, I None
together I None
with I None
clinical I None
assessments I None
by I None
Brief I None
Psychiatric I None
Rating I None
Scale I None
( I None
BPRS I None
) I None
and I None
Udvalg I None
for I None
kliniske I None
undersogelser I None
( I None
UKU I None
) I None
side I None
effect I None
rating I None
scale I None
. I None
<eof> I None

<s> O None
The I None
Css I None
( I None
mean I None
+ I None
/ I None
- I None
SD I None
) I None
of I None
haloperidol I CHEMICAL
and I None
reduced I None
haloperidol I CHEMICAL
during I None
promethazine I CHEMICAL
coadministration I None
( I None
27 I None
. I None
6 I None
+ I None
/ I None
- I None
24 I None
. I None
9 I None
and I None
8 I None
. I None
6 I None
+ I None
/ I None
- I None
13 I None
. I None
2 I None
ng I None
/ I None
mL I None
) I None
were I None
significantly I None
higher I None
than I None
those I None
before I None
the I None
coadministration I None
( I None
12 I None
. I None
7 I None
+ I None
/ I None
- I None
10 I None
. I None
8 I None
and I None
5 I None
. I None
0 I None
+ I None
/ I None
- I None
6 I None
. I None
0 I None
ng I None
/ I None
mL I None
; I None
P I None
< I None
0 I None
. I None
01 I None
) I None
or I None
1 I None
week I None
after I None
the I None
discontinuation I None
( I None
15 I None
. I None
6 I None
+ I None
/ I None
- I None
14 I None
. I None
8 I None
and I None
5 I None
. I None
8 I None
+ I None
/ I None
- I None
7 I None
. I None
9 I None
ng I None
/ I None
mL I None
; I None
P I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
The I None
Css I None
of I None
haloperidol I CHEMICAL
and I None
reduced I None
haloperidol I CHEMICAL
during I None
homochlorcyclizine I CHEMICAL
coadministration I None
( I None
14 I None
. I None
9 I None
+ I None
/ I None
- I None
8 I None
. I None
1 I None
and I None
6 I None
. I None
4 I None
+ I None
/ I None
- I None
5 I None
. I None
4 I None
ng I None
/ I None
mL I None
) I None
were I None
also I None
significantly I None
higher I None
than I None
those I None
before I None
the I None
coadministration I None
( I None
10 I None
. I None
9 I None
+ I None
/ I None
- I None
7 I None
. I None
2 I None
and I None
3 I None
. I None
8 I None
+ I None
/ I None
- I None
3 I None
. I None
6 I None
ng I None
/ I None
mL I None
; I None
P I None
< I None
0 I None
. I None
01 I None
) I None
or I None
1 I None
week I None
after I None
the I None
discontinuation I None
( I None
12 I None
. I None
9 I None
+ I None
/ I None
- I None
7 I None
. I None
4 I None
and I None
4 I None
. I None
8 I None
+ I None
/ I None
- I None
4 I None
. I None
1 I None
ng I None
/ I None
mL I None
; I None
P I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
No I None
change I None
in I None
BPRS I None
or I None
UKU I None
score I None
was I None
found I None
throughout I None
the I None
study I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
the I None
current I None
study I None
suggests I None
that I None
coadministration I None
of I None
clinical I None
doses I None
of I None
promethazine I CHEMICAL
and I None
homochlorcyclizine I CHEMICAL
increases I None
the I None
Css I None
of I None
haloperidol I CHEMICAL
and I None
reduced I None
haloperidol I CHEMICAL
via I None
the I None
inhibitory I None
effects I None
on I None
the I None
CYP2D6 I GENE-Y
- I None
catalyzed I None
metabolism I None
of I None
haloperidol I CHEMICAL
and I None
reduced I None
haloperidol I CHEMICAL
. I None
<eof> I None

<s> O None
Yeast I GENE-Y
epiarginase O GENE-Y
regulation I None
, I None
an I None
enzyme I None
- I None
enzyme I None
activity I None
control I None
: I None
identification I None
of I None
residues I None
of I None
ornithine I GENE-Y
carbamoyltransferase O GENE-Y
and I None
arginase I GENE-Y
responsible I None
for I None
enzyme I None
catalytic I None
and I None
regulatory I None
activities I None
. I None
<eof> I None

<s> O None
In I None
the I None
presence I None
of I None
ornithine I CHEMICAL
and I None
arginine I CHEMICAL
, I None
ornithine I GENE-Y
carbamoyltransferase O GENE-Y
( I None
OTCase I GENE-Y
) I None
and I None
arginase I GENE-Y
form I None
a I None
one I None
- I None
to I None
- I None
one I None
enzyme I None
complex I None
in I None
which I None
the I None
activity I None
of I None
OTCase I GENE-Y
is I None
inhibited I None
whereas I None
arginase I GENE-Y
remains I None
catalytically I None
active I None
. I None
<eof> I None

<s> O None
The I None
mechanism I None
by I None
which I None
these I None
nonallosteric I None
enzymes I None
form I None
a I None
stable I None
complex I None
triggered I None
by I None
the I None
binding I None
of I None
their I None
respective I None
substrates I None
raises I None
the I None
question I None
of I None
how I None
such I None
a I None
cooperative I None
association I None
is I None
induced I None
. I None
<eof> I None

<s> O None
Analyses I None
of I None
mutations I None
in I None
both I None
enzymes I None
identify I None
residues I None
that I None
are I None
required I None
for I None
their I None
association I None
, I None
some I None
of I None
them I None
being I None
important I None
for I None
catalysis I None
. I None
<eof> I None

<s> O None
In I None
arginase I GENE-Y
, I None
two I None
cysteines I CHEMICAL
at I None
the I None
C I CHEMICAL
terminus I None
of I None
the I None
protein I None
are I None
crucial I None
for I None
its I None
epiarginase I GENE-Y
function I None
but I None
not I None
for I None
its I None
catalytic I None
activity I None
and I None
trimeric I None
structure I None
. I None
<eof> I None

<s> O None
In I None
OTCase I GENE-Y
, I None
mutations I None
of I None
putative I None
ornithine I CHEMICAL
binding I None
residues I None
, I None
Asp I CHEMICAL
- I None
182 I None
, I None
Asn I CHEMICAL
- I None
184 I None
, I None
Asn I CHEMICAL
- I None
185 I None
, I None
Cys I CHEMICAL
- I None
289 I None
, I None
and I None
Glu I CHEMICAL
- I None
256 I None
greatly I None
reduced I None
the I None
affinity I None
for I None
ornithine I CHEMICAL
and I None
impaired I None
the I None
interaction I None
with I None
arginase I GENE-Y
. I None
<eof> I None

<s> O None
The I None
four I None
lysine I CHEMICAL
residues I None
located I None
in I None
the I None
SMG I None
loop I None
, I None
Lys I CHEMICAL
- I None
260 I None
, I None
Lys I CHEMICAL
- I None
263 I None
, I None
Lys I CHEMICAL
- I None
265 I None
, I None
and I None
Lys I CHEMICAL
- I None
268 I None
, I None
also I None
play I None
an I None
important I None
role I None
in I None
mediating I None
the I None
sensitivity I None
of I None
OTCase I GENE-Y
to I None
ornithine I CHEMICAL
and I None
to I None
arginase I GENE-Y
and I None
appear I None
to I None
be I None
involved I None
in I None
transducing I None
and I None
enhancing I None
the I None
signal I None
given I None
by I None
ornithine I CHEMICAL
for I None
the I None
closure I None
of I None
the I None
catalytic I None
domain I None
. I None
<eof> I None

<s> O None
[ I None
Study I None
on I None
the I None
effect I None
of I None
cysteinyl I CHEMICAL
leukotriene O CHEMICAL
antagonist I None
, I None
pranlukast I CHEMICAL
hydrate O CHEMICAL
, I None
on I None
adhesive I None
interaction I None
between I None
eosinophils I None
and I None
pulmonary I None
endothelial I None
cells I None
] I None
. I None
<eof> I None

<s> O None
It I None
has I None
been I None
reported I None
that I None
cysteinyl I CHEMICAL
leukotriene O CHEMICAL
( I None
CysLT I CHEMICAL
) I None
antagonists I None
reduce I None
the I None
accumulation I None
of I None
eosinophils I None
in I None
the I None
asthmatic I None
airway I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
exact I None
mechanism I None
of I None
this I None
action I None
remains I None
to I None
be I None
established I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
we I None
examined I None
whether I None
a I None
CysLT I CHEMICAL
antagonist I None
modifies I None
the I None
adhesive I None
interaction I None
between I None
blood I None
eosinophils I None
and I None
endothelial I None
cells I None
. I None
<eof> I None

<s> O None
Pranlukast I CHEMICAL
hydrate O CHEMICAL
, I None
a I None
CysLT I CHEMICAL
antagonist I None
, I None
blocked I None
the I None
chemotactic I None
response I None
and I None
adhesion I None
of I None
eosinophils I None
induced I None
by I None
LTD4 I CHEMICAL
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
pranlukast I CHEMICAL
did I None
not I None
modify I None
the I None
eosinophil I None
spontaneous I None
adhesion I None
to I None
the I None
resting I None
or I None
IL I GENE-Y
- O GENE-Y
4 O GENE-Y
plus I None
TNF I GENE-Y
- O GENE-Y
alpha O GENE-Y
- I None
stimulated I None
pulmonary I None
endothelial I None
cells I None
. I None
<eof> I None

<s> O None
Similarly I None
, I None
pranlukast I CHEMICAL
did I None
not I None
modulate I None
IL I GENE-Y
- O GENE-Y
5 O GENE-Y
- I None
or I None
FMLP I None
- I None
activated I None
eosinophil I None
adhesion I None
to I None
the I None
resting I None
endothelial I None
cells I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
pranlukast I CHEMICAL
did I None
not I None
modify I None
the I None
expression I None
of I None
adhesion I None
molecules I None
on I None
endothelial I None
cells I None
stimulated I None
with I None
endothelial I None
activating I None
cytokines I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
the I None
inhibitory I None
action I None
of I None
CysLT I CHEMICAL
antagonist I None
on I None
eosinophil I None
accumulation I None
in I None
the I None
asthmatic I None
airways I None
involves I None
mechanisms I None
other I None
than I None
the I None
adhesive I None
interaction I None
between I None
eosinophils I None
and I None
endothelial I None
cells I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
in I None
vitro I None
P I GENE-N
- O GENE-N
glycoprotein O GENE-N
screening I None
assays I None
: I None
recommendations I None
for I None
their I None
use I None
in I None
drug I None
discovery I None
. I None
<eof> I None

<s> O None
The I None
ATP I GENE-N
- O GENE-N
dependent O GENE-N
drug O GENE-N
efflux O GENE-N
pump O GENE-N
P I GENE-N
- O GENE-N
glycoprotein O GENE-N
( I None
P I GENE-N
- O GENE-N
gp O GENE-N
) I None
affects I None
the I None
absorption I None
and I None
disposition I None
of I None
many I None
compounds I None
. I None
<eof> I None

<s> O None
P I GENE-N
- O GENE-N
gp O GENE-N
may I None
also I None
play I None
role I None
in I None
clinically I None
significant I None
drug I None
- I None
drug I None
interactions I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
it I None
is I None
important I None
to I None
find I None
potential I None
substrates I None
or I None
inhibitors I None
of I None
P I GENE-N
- O GENE-N
gp O GENE-N
early I None
in I None
the I None
drug I None
discovery I None
process I None
. I None
<eof> I None

<s> O None
To I None
identify I None
compounds I None
that I None
interact I None
with I None
this I None
transporter I None
, I None
several I None
P I GENE-N
- O GENE-N
gp O GENE-N
assays I None
were I None
validated I None
and I None
compared I None
by I None
testing I None
a I None
set I None
of I None
28 I None
reference I None
compounds I None
, I None
including I None
inhibitors I None
of I None
cytochrome I GENE-Y
P450 O GENE-Y
3A4 O GENE-Y
( I None
CYP3A4 I GENE-Y
) I None
. I None
<eof> I None

<s> O None
The I None
assays I None
included I None
in I None
silico I CHEMICAL
predictions I None
, I None
inhibition I None
assays I None
( I None
based I None
on I None
cellular I None
uptake I None
of I None
rhodamine I CHEMICAL
- O CHEMICAL
123 O CHEMICAL
or I None
calcein I CHEMICAL
AM O CHEMICAL
) I None
, I None
and I None
functional I None
assays I None
( I None
ATPase I GENE-N
activity I None
assay I None
and I None
transcellular I None
transport I None
assay I None
, I None
the I None
latter I None
for I None
a I None
subset I None
of I None
compounds I None
) I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
species I None
differences I None
were I None
studied I None
in I None
an I None
indirect I None
fluorescence I None
indicator I None
screening I None
assay I None
and I None
test I None
systems I None
expressing I None
porcine I None
, I None
mouse I None
, I None
or I None
human I None
P I GENE-N
- O GENE-N
gp O GENE-N
. I None
<eof> I None

<s> O None
Our I None
results I None
suggest I None
that I None
several I None
P I GENE-N
- O GENE-N
gp O GENE-N
assays I None
should I None
be I None
used I None
in I None
combination I None
to I None
classify I None
compounds I None
as I None
substrates I None
or I None
inhibitors I None
of I None
P I GENE-N
- O GENE-N
gp O GENE-N
. I None
<eof> I None

<s> O None
Recommendations I None
are I None
given I None
on I None
screening I None
strategies I None
which I None
can I None
be I None
applied I None
to I None
different I None
phases I None
of I None
the I None
drug I None
discovery I None
and I None
development I None
process I None
. I None
<eof> I None

<s> O None
Incorporation I None
of I None
trifluoroisoleucine I CHEMICAL
into I None
proteins I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Two I None
fluorinated I None
derivatives I None
of I None
isoleucine I CHEMICAL
: I None
d I CHEMICAL
, O CHEMICAL
l O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
amino O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
trifluoromethyl O CHEMICAL
pentanoic O CHEMICAL
acid O CHEMICAL
( I None
3TFI I CHEMICAL
, I None
2 I None
) I None
and I None
d I CHEMICAL
, O CHEMICAL
l O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
amino O CHEMICAL
- O CHEMICAL
5 O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
trifluoro O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
pentanoic O CHEMICAL
acid O CHEMICAL
( I None
5TFI I CHEMICAL
, I None
3 I None
) I None
were I None
prepared I None
. I None
<eof> I None

<s> O None
5TFI I CHEMICAL
was I None
incorporated I None
into I None
a I None
model I None
target I None
protein I None
, I None
murine I GENE-Y
dihydrofolate O GENE-Y
reductase O GENE-Y
( I None
mDHFR I GENE-Y
) I None
, I None
in I None
an I None
isoleucine I CHEMICAL
auxotrophic I None
Escherichia I None
coli I None
host I None
strain I None
suspended I None
in I None
5TFI I CHEMICAL
- I None
supplemented I None
minimal I None
medium I None
depleted I None
of I None
isoleucine I CHEMICAL
. I None
<eof> I None

<s> O None
Incorporation I None
of I None
5TFI I CHEMICAL
was I None
confirmed I None
by I None
tryptic I None
peptide I None
analysis I None
and I None
matrix I None
- I None
assisted I None
laser I None
desorption I None
ionization I None
mass I None
spectrometry I None
( I None
MALDI I None
- I None
MS I None
) I None
of I None
the I None
protein I None
product I None
. I None
<eof> I None

<s> O None
Amino I CHEMICAL
acid O CHEMICAL
analysis I None
showed I None
that I None
more I None
than I None
93 I None
% I None
of I None
the I None
encoded I None
isoleucine I CHEMICAL
residues I None
were I None
replaced I None
by I None
5TFI I CHEMICAL
. I None
<eof> I None

<s> O None
Measurement I None
of I None
the I None
rate I None
of I None
activation I None
of I None
5TFI I CHEMICAL
by I None
the I None
E I GENE-Y
. O GENE-Y
coli O GENE-Y
isoleucyl O GENE-Y
- O GENE-Y
tRNA O GENE-Y
synthetase O GENE-Y
( I None
IleRS I GENE-Y
) I None
yielded I None
a I None
specificity I None
constant I None
( I None
k I None
( I None
cat I None
) I None
/ I None
K I None
( I None
m I None
) I None
) I None
134 I None
- I None
fold I None
lower I None
than I None
that I None
for I None
isoleucine I CHEMICAL
. I None
<eof> I None

<s> O None
5TFI I CHEMICAL
was I None
successfully I None
introduced I None
into I None
the I None
cytokine I GENE-N
murine I GENE-Y
interleukin O GENE-Y
- O GENE-Y
2 O GENE-Y
( I None
mIL I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
at I None
the I None
encoded I None
isoleucine I CHEMICAL
positions I None
. I None
<eof> I None

<s> O None
The I None
concentration I None
of I None
fluorinated I None
protein I None
that I None
elicits I None
50 I None
% I None
of I None
the I None
maximal I None
proliferative I None
response I None
is I None
3 I None
. I None
87 I None
ng I None
/ I None
mL I None
, I None
about I None
30 I None
% I None
higher I None
than I None
that I None
of I None
wild I None
- I None
type I None
mIL I GENE-Y
- O GENE-Y
2 O GENE-Y
( I None
EC I None
( I None
50 I None
) I None
= I None
2 I None
. I None
70 I None
ng I None
/ I None
mL I None
) I None
. I None
<eof> I None

<s> O None
The I None
maximal I None
responses I None
are I None
equivalent I None
for I None
the I None
fluorinated I None
and I None
wild I None
- I None
type I None
cytokines I GENE-N
, I None
indicating I None
that I None
fluorinated I None
proteins I None
can I None
fold I None
into I None
stable I None
and I None
functional I None
structures I None
. I None
<eof> I None

<s> O None
3TFI I CHEMICAL
yielded I None
no I None
evidence I None
for I None
in I None
vivo I None
incorporation I None
into I None
recombinant I None
proteins I None
, I None
and I None
no I None
evidence I None
for I None
activation I None
by I None
IleRS I GENE-Y
in I None
vitro I None
. I None
<eof> I None

<s> O None
Analysis I None
of I None
plasmin I GENE-Y
binding I None
and I None
urokinase I GENE-Y
activation I None
of I None
plasminogen I GENE-Y
bound I None
to I None
the I None
Heymann I GENE-Y
nephritis O GENE-Y
autoantigen O GENE-Y
, I None
gp330 I GENE-Y
. I None
<eof> I None

<s> O None
Previously I None
, I None
we I None
demonstrated I None
that I None
the I None
Heymann I GENE-Y
nephritis O GENE-Y
autoantigen O GENE-Y
, I None
gp330 I GENE-Y
, I None
can I None
serve I None
as I None
a I None
receptor I None
site I None
for I None
plasminogen I GENE-Y
. I None
<eof> I None

<s> O None
This I None
binding I None
was I None
not I None
significantly I None
inhibited I None
by I None
the I None
lysine I CHEMICAL
analogue I None
epsilon I CHEMICAL
- O CHEMICAL
amino O CHEMICAL
caproic O CHEMICAL
acid O CHEMICAL
( I None
EACA I CHEMICAL
) I None
, I None
indicating I None
that I None
plasminogen I GENE-Y
binding I None
was I None
not I None
just I None
through I None
lysine I CHEMICAL
binding I None
sites I None
as I None
suggested I None
for I None
other I None
plasminogen I GENE-Y
binding I None
sites I None
. I None
<eof> I None

<s> O None
We I None
now I None
report I None
that I None
once I None
plasminogen I GENE-Y
is I None
bound I None
to I None
gp330 I GENE-Y
, I None
it I None
can I None
be I None
converted I None
to I None
its I None
active I None
form I None
of I None
plasmin I GENE-Y
by I None
urokinase I GENE-Y
. I None
<eof> I None

<s> O None
This I None
conversion I None
of I None
plasminogen I GENE-Y
to I None
plasmin I GENE-Y
proceeds I None
at I None
a I None
faster I None
rate I None
when I None
plasminogen I GENE-Y
is I None
first I None
prebound I None
to I None
gp330 I GENE-Y
. I None
<eof> I None

<s> O None
Although I None
there I None
is I None
a I None
proportional I None
increase I None
in I None
the I None
Vmax I None
of I None
the I None
urokinase I GENE-Y
- I None
catalyzed I None
reaction I None
with I None
increasing I None
gp330 I GENE-Y
concentrations I None
, I None
no I None
change I None
in I None
Km I None
was I None
observed I None
. I None
<eof> I None

<s> O None
Once I None
activated I None
, I None
plasmin I GENE-Y
remains I None
bound I None
to I None
gp330 I GENE-Y
in I None
an I None
active I None
state I None
capable I None
of I None
cleaving I None
the I None
chromogenic I None
tripeptide I None
, I None
S I None
- I None
2251 I None
. I None
<eof> I None

<s> O None
The I None
binding I None
of I None
plasmin I GENE-Y
to I None
gp330 I GENE-Y
did I None
not I None
significantly I None
change I None
its I None
enzymatic I None
activity I None
; I None
however I None
, I None
gp330 I GENE-Y
did I None
have I None
a I None
stabilizing I None
effect I None
on I None
plasmin I GENE-Y
activity I None
at I None
37 I None
degrees I None
C I None
. I None
<eof> I None

<s> O None
While I None
bound I None
to I None
gp330 I GENE-Y
, I None
plasmin I GENE-Y
is I None
protected I None
from I None
inactivation I None
by I None
its I None
natural I None
inhibitor I None
alpha I GENE-Y
2 O GENE-Y
- O GENE-Y
antiplasmin O GENE-Y
. I None
<eof> I None

<s> O None
The I None
binding I None
of I None
plasmin I GENE-Y
to I None
gp330 I GENE-Y
as I None
analyzed I None
by I None
ELISA I None
was I None
shown I None
to I None
be I None
time I None
dependent I None
, I None
reversible I None
, I None
saturable I None
, I None
and I None
specific I None
for I None
gp330 I GENE-Y
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
binding I None
of I None
both I None
plasminogen I GENE-Y
and I None
plasmin I GENE-Y
to I None
gp330 I GENE-Y
by I None
benzamidine I CHEMICAL
was I None
similar I None
, I None
although I None
EACA I CHEMICAL
inhibited I None
the I None
binding I None
of I None
plasmin I GENE-Y
to I None
gp330 I GENE-Y
slightly I None
more I None
than I None
the I None
binding I None
of I None
plasminogen I GENE-Y
to I None
gp330 I GENE-Y
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
the I None
binding I None
of I None
plasminogen I GENE-Y
to I None
gp330 I GENE-Y
serves I None
as I None
an I None
effective I None
means I None
of I None
increasing I None
the I None
rate I None
of I None
plasmin I GENE-Y
production I None
on I None
the I None
glomerular I None
and I None
tubular I None
epithelial I None
cell I None
surface I None
while I None
protecting I None
the I None
active I None
plasmin I GENE-Y
from I None
natural I None
inhibitors I None
. I None
<eof> I None

<s> O None
Functional I None
characterization I None
of I None
alpha I GENE-N
- O GENE-N
adrenoceptors O GENE-N
mediating I None
pupillary I None
dilation I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Previously I None
, I None
we I None
reported I None
that I None
the I None
alpha I GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
, I None
but I None
not I None
the I None
alpha I GENE-Y
( O GENE-Y
1D O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
, I None
mediates I None
pupillary I None
dilation I None
elicited I None
by I None
sympathetic I None
nerve I None
stimulation I None
in I None
rats I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
undertaken I None
to I None
further I None
characterize I None
the I None
alpha I GENE-N
- O GENE-N
adrenoceptor O GENE-N
subtypes I None
mediating I None
pupillary I None
dilation I None
in I None
response I None
to I None
both I None
neural I None
and I None
agonist I None
activation I None
. I None
<eof> I None

<s> O None
Pupillary I None
dilator I None
response I None
curves I None
were I None
generated I None
by I None
intravenous I None
injection I None
of I None
norepinephrine I CHEMICAL
in I None
pentobarbital I CHEMICAL
- I None
anesthetized I None
rats I None
. I None
<eof> I None

<s> O None
Involvement I None
of I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptors O GENE-N
was I None
established I None
as I None
mydriatic I None
responses I None
were I None
inhibited I None
by I None
systemic I None
administration I None
of I None
nonselective I None
alpha I GENE-N
- O GENE-N
adrenoceptor O GENE-N
antagonists I None
, I None
phentolamine I CHEMICAL
( I None
0 I None
. I None
3 I None
- I None
3 I None
mg I None
/ I None
kg I None
) I None
and I None
phenoxybenzamine I CHEMICAL
( I None
0 I None
. I None
03 I None
- I None
0 I None
. I None
3 I None
mg I None
/ I None
kg I None
) I None
, I None
as I None
well I None
as I None
by I None
the I None
selective I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
antagonist I None
, I None
prazosin I CHEMICAL
( I None
0 I None
. I None
3 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
The I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
antagonist I None
, I None
rauwolscine I CHEMICAL
( I None
0 I None
. I None
5 I None
mg I None
/ I None
kg I None
) I None
, I None
was I None
without I None
antagonistic I None
effects I None
. I None
<eof> I None

<s> O None
alpha I GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
- O GENE-Y
Adrenoceptor O GENE-Y
selective I None
antagonists I None
, I None
2 I CHEMICAL
- O CHEMICAL
( O CHEMICAL
[ O CHEMICAL
2 O CHEMICAL
, O CHEMICAL
6 O CHEMICAL
- O CHEMICAL
dimethoxyphenoxyethyl O CHEMICAL
] O CHEMICAL
aminomethyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
benzodioxane O CHEMICAL
( I None
WB I CHEMICAL
- O CHEMICAL
4101 O CHEMICAL
; I None
0 I None
. I None
1 I None
- I None
1 I None
mg I None
/ I None
kg I None
) I None
and I None
5 I CHEMICAL
- O CHEMICAL
methylurapidil O CHEMICAL
( I None
0 I None
. I None
1 I None
- I None
1 I None
mg I None
/ I None
kg I None
) I None
, I None
the I None
alpha I GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
selective I None
antagonist I None
, I None
4 I CHEMICAL
- O CHEMICAL
amino O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
benzyloxycarbonyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
( O CHEMICAL
S O CHEMICAL
) O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
[ O CHEMICAL
( O CHEMICAL
1 O CHEMICAL
, O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
dimethylethyl O CHEMICAL
) O CHEMICAL
amino O CHEMICAL
] O CHEMICAL
carbonyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
piperazinyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
6 O CHEMICAL
, O CHEMICAL
7 O CHEMICAL
- O CHEMICAL
dimethoxyquinazoline O CHEMICAL
( I None
L I CHEMICAL
- O CHEMICAL
765314 O CHEMICAL
; I None
0 I None
. I None
3 I None
- I None
1 I None
mg I None
/ I None
kg I None
) I None
, I None
as I None
well I None
as I None
the I None
alpha I GENE-Y
( O GENE-Y
1D O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
selective I None
antagonist I None
, I None
8 I CHEMICAL
- O CHEMICAL
[ O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
methoxyphenyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
piperazinyl O CHEMICAL
] O CHEMICAL
ethyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
azaspiro O CHEMICAL
[ O CHEMICAL
4 O CHEMICAL
. O CHEMICAL
5 O CHEMICAL
] O CHEMICAL
decane O CHEMICAL
- O CHEMICAL
7 O CHEMICAL
, O CHEMICAL
9 O CHEMICAL
- O CHEMICAL
dione O CHEMICAL
( I None
BMY I CHEMICAL
- O CHEMICAL
7378 O CHEMICAL
; I None
1 I None
mg I None
/ I None
kg I None
) I None
, I None
were I None
used I None
to I None
delineate I None
the I None
adrenoceptor I GENE-N
subtypes I None
involved I None
. I None
<eof> I None

<s> O None
Mydriatic I None
responses I None
to I None
norepinephrine I CHEMICAL
were I None
significantly I None
antagonized I None
by I None
intravenous I None
administration I None
of I None
both I None
WB I CHEMICAL
- O CHEMICAL
4101 O CHEMICAL
and I None
5 I CHEMICAL
- O CHEMICAL
methylurapidil O CHEMICAL
, I None
but I None
neither I None
by I None
L I CHEMICAL
- O CHEMICAL
765314 O CHEMICAL
nor I None
by I None
BMY I CHEMICAL
- O CHEMICAL
7378 O CHEMICAL
. I None
<eof> I None

<s> O None
L I CHEMICAL
- O CHEMICAL
765314 O CHEMICAL
( I None
0 I None
. I None
3 I None
- I None
3 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
v I None
. I None
) I None
was I None
also I None
ineffective I None
in I None
inhibiting I None
the I None
mydriasis I None
evoked I None
by I None
cervical I None
sympathetic I None
nerve I None
stimulation I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
alpha I GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptors O GENE-Y
do I None
not I None
mediate I None
sympathetic I None
mydriasis I None
in I None
rats I None
, I None
and I None
that I None
the I None
alpha I GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
is I None
the I None
exclusive I None
subtype I None
mediating I None
mydriatic I None
responses I None
in I None
this I None
species I None
. I None
<eof> I None

<s> O None
Colon I None
cancer I None
cells I None
with I None
high I None
invasive I None
potential I None
are I None
susceptible I None
to I None
induction I None
of I None
apoptosis I None
by I None
a I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
. I None
<eof> I None

<s> O None
Cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
( I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
expression I None
has I None
been I None
shown I None
to I None
correlate I None
with I None
the I None
invasiveness I None
of I None
colon I None
cancer I None
cells I None
. I None
<eof> I None

<s> O None
To I None
further I None
investigate I None
this I None
positive I None
correlation I None
and I None
its I None
possible I None
therapeutic I None
implications I None
, I None
a I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
, I None
etodolac I CHEMICAL
, I None
was I None
tested I None
on I None
three I None
variants I None
of I None
HT I None
- I None
29 I None
colon I None
cancer I None
cell I None
lines I None
, I None
HT I None
- I None
29 I None
/ I None
Inv1 I None
, I None
HT I None
- I None
29 I None
/ I None
Inv2 I None
and I None
HT I None
- I None
29 I None
/ I None
Inv3 I None
, I None
with I None
graded I None
increases I None
of I None
in I None
vitro I None
Matrigel I None
invasive I None
potential I None
and I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
expression I None
levels I None
. I None
<eof> I None

<s> O None
HT I None
- I None
29 I None
variants I None
with I None
higher I None
invasive I None
potential I None
were I None
found I None
to I None
be I None
more I None
sensitive I None
to I None
etodolac I CHEMICAL
by I None
in I None
vitro I None
growth I None
inhibition I None
assays I None
, I None
the I None
estimated I None
LD I None
( I None
50 I None
) I None
being I None
0 I None
. I None
5 I None
mM I None
for I None
highly I None
invasive I None
HT I None
- I None
29 I None
/ I None
Inv2 I None
and I None
HT I None
- I None
29 I None
/ I None
Inv3 I None
cells I None
, I None
0 I None
. I None
6 I None
mM I None
for I None
slightly I None
less I None
invasive I None
HT I None
- I None
29 I None
/ I None
Inv1 I None
, I None
and I None
1 I None
. I None
8 I None
mM I None
for I None
the I None
parental I None
HT I None
- I None
29 I None
. I None
<eof> I None

<s> O None
Treatment I None
of I None
the I None
highly I None
invasive I None
HT I None
- I None
29 I None
/ I None
Inv2 I None
and I None
Inv3 I None
variants I None
with I None
as I None
little I None
as I None
0 I None
. I None
1 I None
mM I None
etodolac I CHEMICAL
in I None
the I None
growth I None
medium I None
produced I None
signs I None
of I None
apoptosis I None
, I None
as I None
detected I None
by I None
DNA I None
fragmentation I None
and I None
TUNEL I None
( I None
terminal I None
deoxynucleotidyl I None
transferase I None
dUTP I CHEMICAL
- I None
biotin I CHEMICAL
nick I None
end I None
labeling I None
) I None
assay I None
. I None
<eof> I None

<s> O None
In I None
vivo I None
experiments I None
in I None
SCID I None
mice I None
showed I None
that I None
etolodac I CHEMICAL
inhibited I None
the I None
growth I None
of I None
subcutaneous I None
tumors I None
induced I None
by I None
HT I None
- I None
29 I None
/ I None
Inv3 I None
cells I None
significantly I None
more I None
than I None
those I None
by I None
the I None
parental I None
HT I None
- I None
29 I None
cells I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
have I None
a I None
potential I None
role I None
in I None
prevention I None
of I None
tumor I None
invasion I None
in I None
colon I None
cancer I None
patients I None
. I None
<eof> I None

<s> O None
Pharmacological I None
characterization I None
of I None
unique I None
prazosin I CHEMICAL
- I None
binding I None
sites I None
in I None
human I None
kidney I None
. I None
<eof> I None

<s> O None
In I None
human I None
kidney I None
, I None
we I None
found I None
unique I None
prazosin I CHEMICAL
- I None
binding I None
sites I None
that I None
were I None
insensitive I None
to I None
phentolamine I CHEMICAL
and I None
were I None
thus I None
unlikely I None
to I None
be I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptors O GENE-N
. I None
<eof> I None

<s> O None
As I None
the I None
binding I None
of I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
prazosin O CHEMICAL
to I None
phentolamine I CHEMICAL
- I None
insensitive I None
sites I None
was I None
prevented I None
by I None
100 I None
microM I None
guanabenz I CHEMICAL
, I None
the I None
insensitive I None
sites I None
were I None
evaluated I None
by I None
subtracting I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
prazosin O CHEMICAL
binding I None
in I None
the I None
presence I None
of I None
100 I None
microM I None
guanabenz I CHEMICAL
from I None
that I None
in I None
the I None
presence I None
of I None
10 I None
microM I None
phentolamine I CHEMICAL
. I None
<eof> I None

<s> O None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
Prazosin O CHEMICAL
bound I None
to I None
the I None
phentolamine I CHEMICAL
- I None
insensitive I None
sites I None
monophasically I None
with I None
a I None
high I None
affinity I None
( I None
pK I None
( I None
d I None
) I None
; I None
9 I None
. I None
1 I None
+ I None
/ I None
- I None
0 I None
. I None
08 I None
, I None
n I None
= I None
8 I None
) I None
, I None
and I None
the I None
B I None
( I None
max I None
) I None
value I None
( I None
814 I None
+ I None
/ I None
- I None
204 I None
fmol I None
mg I None
( I None
- I None
1 I None
) I None
protein I None
, I None
n I None
= I None
8 I None
) I None
was I None
more I None
than I None
ten I None
times I None
that I None
of I None
the I None
phentolamine I CHEMICAL
- I None
sensitive I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
( I None
pK I None
( I None
d I None
) I None
= I None
9 I None
. I None
9 I None
+ I None
/ I None
- I None
0 I None
. I None
13 I None
, I None
B I None
( I None
max I None
) I None
= I None
66 I None
+ I None
/ I None
- I None
23 I None
fmol I None
mg I None
( I None
- I None
1 I None
) I None
protein I None
, I None
n I None
= I None
7 I None
) I None
. I None
<eof> I None

<s> O None
The I None
phentolamine I CHEMICAL
- I None
insensitive I None
sites I None
in I None
human I None
kidney I None
were I None
highly I None
sensitive I None
to I None
other I None
quinazoline I CHEMICAL
derivatives I None
such I None
as I None
terazosin I CHEMICAL
and I None
doxazosin I CHEMICAL
. I None
<eof> I None

<s> O None
However I None
, I None
other I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
antagonists I None
( I None
tamsulosin I CHEMICAL
, I None
WB4101 I CHEMICAL
and I None
corynanthine I CHEMICAL
) I None
did I None
not I None
inhibit I None
the I None
binding I None
at I None
a I None
range I None
of I None
concentrations I None
that I None
generally I None
exhibit I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
antagonism I None
, I None
and I None
noradrenaline I CHEMICAL
, I None
rauwolscine I CHEMICAL
and I None
propranolol I CHEMICAL
were I None
without I None
effect I None
on I None
the I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
prazosin O CHEMICAL
binding I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
ligands I None
for I None
the I None
renal I None
Na I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
- O GENE-N
transporter O GENE-N
( I None
amiloride I CHEMICAL
and I None
triamterene I CHEMICAL
) I None
and I None
for I None
imidazoline I CHEMICAL
recognition I None
sites I None
( I None
guanabenz I CHEMICAL
, I None
guanfacine I CHEMICAL
and I None
agmatine I CHEMICAL
) I None
displaced I None
the I None
binding I None
of I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
prazosin O CHEMICAL
to I None
phentolamine I CHEMICAL
- I None
insensitive I None
sites I None
at I None
micromolar I None
concentrations I None
. I None
<eof> I None

<s> O None
Photoaffinity I None
labeling I None
with I None
[ I CHEMICAL
( O CHEMICAL
125 O CHEMICAL
) O CHEMICAL
I O CHEMICAL
] O CHEMICAL
iodoarylazidoprazosin O CHEMICAL
showed I None
phentolamine I CHEMICAL
- I None
insensitive I None
labeling I None
at I None
around I None
100 I None
kDa I None
, I None
a I None
molecular I None
size I None
larger I None
than I None
that I None
of I None
human I GENE-N
alpha O GENE-N
( O GENE-N
1a O GENE-N
) O GENE-N
- O GENE-N
and O GENE-N
alpha O GENE-N
( O GENE-N
1b O GENE-N
) O GENE-N
- O GENE-N
adrenoceptors O GENE-N
expressed I None
in I None
293 I None
cells I None
( I None
50 I None
- I None
60 I None
and I None
70 I None
- I None
80 I None
kDa I None
, I None
respectively I None
) I None
on I None
electrophoresis I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
there I None
was I None
no I None
detectable I None
phentolamine I CHEMICAL
- I None
insensitive I None
binding I None
site I None
but I None
were I None
phentolamine I CHEMICAL
- I None
sensitive I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptors O GENE-N
in I None
human I None
liver I None
( I None
pK I None
( I None
d I None
) I None
= I None
10 I None
. I None
0 I None
+ I None
/ I None
- I None
0 I None
. I None
06 I None
, I None
B I None
( I None
max I None
) I None
= I None
44 I None
+ I None
/ I None
- I None
6 I None
fmol I None
mg I None
( I None
- I None
1 I None
) I None
protein I None
, I None
n I None
= I None
3 I None
) I None
. I None
<eof> I None

<s> O None
Phentolamine I CHEMICAL
- I None
insensitive I None
prazosin I CHEMICAL
binding I None
sites I None
were I None
also I None
detected I None
in I None
rabbit I None
kidney I None
( I None
approximately I None
50 I None
% I None
of I None
specific I None
binding I None
sites I None
) I None
but I None
were I None
minor I None
in I None
rat I None
kidney I None
( I None
less I None
than I None
20 I None
% I None
) I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
there I None
are I None
unique I None
prazosin I CHEMICAL
- I None
binding I None
sites I None
in I None
human I None
kidney I None
, I None
the I None
pharmacological I None
profiles I None
of I None
which I None
were I None
distinct I None
from I None
those I None
of I None
known I None
adrenoceptors I None
. I None
<eof> I None

<s> O None
chi I None
- I None
Conopeptide I None
MrIA I None
partially I None
overlaps I None
desipramine I GENE-N
and O GENE-N
cocaine O GENE-N
binding O GENE-N
sites O GENE-N
on I None
the I None
human I GENE-Y
norepinephrine O GENE-Y
transporter O GENE-Y
. I None
<eof> I None

<s> O None
The I None
interactions I None
of I None
chi I None
- I None
conopeptide I None
MrIA I None
with I None
the I None
human I GENE-Y
norepinephrine O GENE-Y
transporter O GENE-Y
( I None
hNET I GENE-Y
) I None
were I None
investigated I None
by I None
determining I None
the I None
effects I None
of I None
hNET I GENE-Y
point I None
mutations I None
on I None
the I None
inhibitory I None
potency I None
of I None
MrIA I None
. I None
<eof> I None

<s> O None
The I None
mutants I None
were I None
produced I None
by I None
site I None
- I None
directed I None
mutagenesis I None
and I None
expressed I None
in I None
COS I None
- I None
7 I None
cells I None
. I None
<eof> I None

<s> O None
The I None
potency I None
of I None
MrIA I None
was I None
greater I None
for I None
inhibition I None
of I None
uptake I None
by I None
hNET I GENE-Y
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
norepinephrine O CHEMICAL
( I None
Ki I None
1 I None
. I None
89 I None
microM I None
) I None
than I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
dopamine O CHEMICAL
( I None
Ki I None
4 I None
. I None
33 I None
microM I None
) I None
, I None
and I None
the I None
human I GENE-Y
dopamine O GENE-Y
transporter O GENE-Y
and I None
serotonin I GENE-Y
transporter O GENE-Y
were I None
not I None
inhibited I None
by I None
MrIA I None
( I None
to I None
7 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
Of I None
18 I None
mutations I None
where I None
hNET I GENE-Y
amino I CHEMICAL
acid O CHEMICAL
residues I None
were I None
exchanged I None
with I None
those I None
of I None
the I None
human I GENE-Y
dopamine O GENE-Y
transporter O GENE-Y
, I None
MrIA I None
had I None
increased I None
potency I None
for I None
inhibition I None
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
norepinephrine O CHEMICAL
uptake I None
for I None
three I None
mutations I None
( I None
in I None
predicted I None
extracellular I None
loops I None
3 I None
and I None
4 I None
and I None
transmembrane I None
domain I None
( I None
TMD I None
) I None
8 I None
) I None
and I None
decreased I None
potency I None
for I None
one I None
mutation I None
( I None
in I None
TMD6 I None
and I None
intracellular I None
loop I None
( I None
IL I None
) I None
3 I None
) I None
. I None
<eof> I None

<s> O None
Of I None
the I None
12 I None
additional I None
mutations I None
in I None
TMDs I None
2 I None
, I None
4 I None
, I None
5 I None
, I None
and I None
11 I None
and I None
IL1 I None
, I None
three I None
mutations I None
( I None
in I None
TMD2 I None
and I None
IL1 I None
) I None
had I None
reduced I None
MrIA I None
inhibitory I None
potency I None
. I None
<eof> I None

<s> O None
All I None
of I None
the I None
other I None
mutations I None
tested I None
had I None
no I None
influence I None
on I None
MrIA I None
potency I None
. I None
<eof> I None

<s> O None
A I None
comparison I None
of I None
the I None
results I None
with I None
previous I None
data I None
for I None
desipramine I CHEMICAL
and I None
cocaine I None
inhibition I None
of I None
norepinephrine I CHEMICAL
uptake I None
by I None
the I None
mutant I None
hNETs I GENE-Y
reveals I None
that I None
MrIA I None
binding I None
to I None
hNET I GENE-Y
occurs I None
at I None
a I None
site I None
that I None
is I None
distinct I None
from I None
but I None
overlaps I None
with I None
the I None
binding I None
sites I None
for I None
tricyclic I CHEMICAL
antidepressants I None
and I None
cocaine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
primary I None
structure I None
of I None
porcine I GENE-Y
aminoacylase O GENE-Y
1 O GENE-Y
deduced I None
from I None
cDNA I None
sequence I None
. I None
<eof> I None

<s> O None
A I None
cDNA I None
encoding I None
the I None
complete I None
amino I CHEMICAL
acid O CHEMICAL
sequence I None
of I None
aminoacylase I GENE-Y
1 O GENE-Y
( I None
N I GENE-Y
- O GENE-Y
acylamino O GENE-Y
acid O GENE-Y
aminohydrolase O GENE-Y
, I None
ACY I GENE-Y
- O GENE-Y
1 O GENE-Y
) I None
[ I None
EC I GENE-Y
3 O GENE-Y
. O GENE-Y
5 O GENE-Y
. O GENE-Y
1 O GENE-Y
. O GENE-Y
14 O GENE-Y
] I None
, I None
a I None
dimeric I None
metalloprotein I GENE-N
having I None
two I None
Zn2 I CHEMICAL
+ O CHEMICAL
in I None
the I None
molecule I None
, I None
which I None
catalyzes I None
the I None
deacylation I None
of I None
N I CHEMICAL
- O CHEMICAL
acylated O CHEMICAL
L O CHEMICAL
- O CHEMICAL
amino O CHEMICAL
acids O CHEMICAL
except I None
L I CHEMICAL
- O CHEMICAL
aspartic O CHEMICAL
acid O CHEMICAL
, I None
has I None
been I None
isolated I None
from I None
porcine I None
kidney I None
lambda I None
gt10 I None
cDNA I None
library I None
and I None
sequenced I None
. I None
<eof> I None

<s> O None
From I None
sequence I None
analysis I None
of I None
the I None
cDNA I None
and I None
the I None
N I CHEMICAL
- I None
and I None
C I CHEMICAL
- I None
terminal I None
amino I CHEMICAL
acid O CHEMICAL
analyses I None
of I None
the I None
purified I None
protein I None
, I None
it I None
is I None
deduced I None
that I None
porcine I GENE-Y
kidney O GENE-Y
ACY O GENE-Y
- O GENE-Y
1 O GENE-Y
consists I None
of I None
two I None
identical I None
subunits I None
( I None
M I None
( I None
r I None
) I None
45 I None
, I None
260 I None
) I None
, I None
each I None
of I None
which I None
consists I None
of I None
a I None
single I None
chain I None
of I None
406 I None
amino I CHEMICAL
acids O CHEMICAL
with I None
acetylalanine I CHEMICAL
at I None
the I None
N I CHEMICAL
- I None
terminus I None
. I None
<eof> I None

<s> O None
A I None
cDNA I None
encoding I None
porcine I GENE-Y
liver O GENE-Y
ACY O GENE-Y
- O GENE-Y
1 O GENE-Y
was I None
also I None
cloned I None
. I None
<eof> I None

<s> O None
The I None
amino I CHEMICAL
acid O CHEMICAL
sequence I None
deduced I None
from I None
the I None
nucleotide I CHEMICAL
sequence I None
of I None
the I None
cDNA I None
from I None
porcine I None
liver I None
was I None
identical I None
to I None
that I None
deduced I None
for I None
porcine I GENE-Y
kidney O GENE-Y
ACY O GENE-Y
- O GENE-Y
1 O GENE-Y
. I None
<eof> I None

<s> O None
Northern I None
blot I None
analysis I None
suggested I None
that I None
ACY I GENE-Y
- O GENE-Y
1 O GENE-Y
is I None
more I None
highly I None
expressed I None
in I None
kidney I None
than I None
in I None
liver I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
the I None
amino I CHEMICAL
acid O CHEMICAL
sequence I None
of I None
porcine I GENE-Y
ACY O GENE-Y
- O GENE-Y
1 O GENE-Y
with I None
those I None
of I None
other I None
Zn2 I GENE-N
+ O GENE-N
- O GENE-N
binding O GENE-N
metalloenzymes O GENE-N
showed I None
no I None
significant I None
homologies I None
in I None
either I None
the I None
overall I None
sequence I None
or I None
the I None
consensus I None
sequences I None
for I None
the I None
metal I None
binding I None
sites I None
. I None
<eof> I None

<s> O None
This I None
indicates I None
that I None
ACY I GENE-Y
- O GENE-Y
1 O GENE-Y
is I None
a I None
new I None
type I None
of I None
metalloprotein I GENE-N
. I None
<eof> I None

<s> O None
Beta I GENE-Y
1 O GENE-Y
- O GENE-Y
adrenergic O GENE-Y
receptor O GENE-Y
polymorphisms I None
and I None
antihypertensive I None
response I None
to I None
metoprolol I CHEMICAL
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
Marked I None
interpatient I None
variability I None
exists I None
in I None
blood I None
pressure I None
response I None
to I None
beta I None
- I None
blocker I None
monotherapy I None
. I None
<eof> I None

<s> O None
We I None
tested I None
the I None
hypothesis I None
that I None
2 I None
common I None
polymorphisms I None
in I None
the I None
gene I None
for I None
beta I GENE-Y
( O GENE-Y
1 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenergic O GENE-Y
receptor O GENE-Y
are I None
associated I None
with I None
antihypertensive I None
response I None
to I None
metoprolol I CHEMICAL
in I None
patients I None
with I None
uncomplicated I None
hypertension I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Forty I None
hypertensive I None
men I None
and I None
women I None
aged I None
35 I None
to I None
65 I None
years I None
were I None
studied I None
. I None
<eof> I None

<s> O None
Baseline I None
studies I None
included I None
24 I None
- I None
hour I None
ambulatory I None
blood I None
pressure I None
monitoring I None
. I None
<eof> I None

<s> O None
Patients I None
took I None
50 I None
mg I None
metoprolol I CHEMICAL
twice I None
daily I None
with I None
weekly I None
titration I None
to I None
response I None
or I None
200 I None
mg I None
twice I None
daily I None
. I None
<eof> I None

<s> O None
After I None
a I None
minimum I None
of I None
4 I None
weeks I None
at I None
stable I None
dose I None
, I None
treatment I None
phase I None
24 I None
- I None
hour I None
ambulatory I None
blood I None
pressure I None
monitoring I None
was I None
repeated I None
. I None
<eof> I None

<s> O None
The I None
codon I None
49 I None
and I None
389 I None
genotypes I None
for I None
beta I GENE-Y
( O GENE-Y
1 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenergic O GENE-Y
receptor O GENE-Y
were I None
determined I None
by I None
polymerase I None
chain I None
reaction I None
with I None
restriction I None
fragment I None
length I None
polymorphism I None
. I None
<eof> I None

<s> O None
Multilinear I None
regression I None
was I None
performed I None
to I None
determine I None
the I None
impact I None
of I None
genotype I None
and I None
other I None
variables I None
on I None
blood I None
pressure I None
response I None
to I None
metoprolol I CHEMICAL
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Patients I None
homozygous I None
for I None
Arg I CHEMICAL
at I None
codon I None
389 I None
had I None
a I None
nearly I None
3 I None
- I None
fold I None
greater I None
reduction I None
in I None
daytime I None
diastolic I None
blood I None
pressure I None
( I None
- I None
13 I None
. I None
3 I None
% I None
+ I None
/ I None
- I None
8 I None
. I None
4 I None
% I None
versus I None
- I None
4 I None
. I None
5 I None
% I None
+ I None
/ I None
- I None
8 I None
. I None
2 I None
% I None
, I None
P I None
= I None
. I None
0018 I None
) I None
compared I None
with I None
those I None
who I None
carried I None
the I None
variant I None
allele I None
. I None
<eof> I None

<s> O None
The I None
haplotype I None
pair I None
( I None
diplotype I None
) I None
for I None
beta I GENE-Y
( O GENE-Y
1 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenergic O GENE-Y
receptor O GENE-Y
was I None
also I None
a I None
significant I None
predictor I None
of I None
response I None
, I None
with I None
patients I None
having I None
the I None
Ser49Arg389 I GENE-N
/ I None
Ser49Arg389 I GENE-N
diplotype I None
demonstrating I None
a I None
decline I None
in I None
blood I None
pressure I None
of I None
14 I None
. I None
7 I None
mm I None
Hg I None
versus I None
0 I None
. I None
5 I None
mm I None
Hg I None
in I None
patients I None
with I None
the I None
Gly49Arg389 I GENE-N
/ I None
Ser49Gly389 I GENE-N
diplotype I None
. I None
<eof> I None

<s> O None
In I None
multiregression I None
analysis I None
, I None
baseline I None
daytime I None
diastolic I None
blood I None
pressure I None
, I None
codon I None
389 I None
genotype I None
, I None
and I None
codon I None
49 I None
genotype I None
were I None
significant I None
predictors I None
of I None
blood I None
pressure I None
after I None
treatment I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
Our I None
data I None
suggest I None
that I None
beta I GENE-Y
( O GENE-Y
1 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenergic O GENE-Y
receptor O GENE-Y
polymorphisms I None
are I None
important I None
determinants I None
of I None
antihypertensive I None
response I None
to I None
metoprolol I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
the I None
future I None
, I None
codon I None
49 I None
and I None
389 I None
genotypes I None
or I None
beta I GENE-Y
( O GENE-Y
1 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenergic O GENE-Y
receptor O GENE-Y
haplotypes I None
might I None
be I None
used I None
to I None
predict I None
the I None
diastolic I None
blood I None
pressure I None
response I None
to I None
metoprolol I CHEMICAL
in I None
patients I None
with I None
hypertension I None
. I None
<eof> I None

<s> O None
Interaction I None
of I None
rofecoxib I CHEMICAL
and I None
celecoxib I CHEMICAL
with I None
warfarin I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
interaction I None
of I None
celecoxib I CHEMICAL
and I None
rofecoxib I CHEMICAL
with I None
warfarin I CHEMICAL
was I None
studied I None
. I None
<eof> I None

<s> O None
Patients I None
stable I None
on I None
warfarin I CHEMICAL
therapy I None
and I None
concurrently I None
taking I None
a I None
cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
( I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
inhibitor I None
comparator I None
( I None
traditional I None
nonsteroidal I None
antiinflammatory I None
medications I None
, I None
salsalate I CHEMICAL
, I None
or I None
acetaminophen I CHEMICAL
) I None
randomly I None
received I None
celecoxib I CHEMICAL
200 I None
mg I None
/ I None
day I None
or I None
rofecoxib I CHEMICAL
25 I None
mg I None
/ I None
day I None
for I None
three I None
weeks I None
. I None
<eof> I None

<s> O None
After I None
a I None
one I None
- I None
week I None
washout I None
period I None
, I None
the I None
patients I None
were I None
crossed I None
over I None
to I None
treatment I None
with I None
the I None
opposite I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
for I None
three I None
more I None
weeks I None
. I None
<eof> I None

<s> O None
The I None
International I None
Normalized I None
Ratio I None
( I None
INR I None
) I None
was I None
measured I None
at I None
baseline I None
and I None
at I None
weeks I None
1 I None
, I None
2 I None
, I None
and I None
3 I None
of I None
therapy I None
with I None
each I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
by I None
testing I None
blood I None
samples I None
obtained I None
by I None
finger I None
stick I None
. I None
<eof> I None

<s> O None
Data I None
for I None
16 I None
patients I None
were I None
analyzed I None
. I None
<eof> I None

<s> O None
The I None
INR I None
increased I None
by I None
13 I None
% I None
, I None
6 I None
% I None
, I None
and I None
5 I None
% I None
on I None
average I None
in I None
patients I None
taking I None
celecoxib I CHEMICAL
at I None
weeks I None
1 I None
, I None
2 I None
, I None
and I None
3 I None
, I None
respectively I None
, I None
and I None
by I None
5 I None
% I None
, I None
9 I None
% I None
, I None
and I None
5 I None
% I None
in I None
patients I None
taking I None
rofecoxib I CHEMICAL
. I None
<eof> I None

<s> O None
Changes I None
in I None
the I None
INR I None
were I None
statistically I None
significant I None
at I None
week I None
1 I None
for I None
celecoxib I CHEMICAL
and I None
at I None
week I None
2 I None
for I None
rofecoxib I CHEMICAL
. I None
<eof> I None

<s> O None
Of I None
the I None
12 I None
subjects I None
who I None
had I None
a I None
clinically I None
significant I None
> I None
or I None
= I None
15 I None
% I None
change I None
in I None
the I None
INR I None
while I None
receiving I None
either I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
, I None
4 I None
showed I None
this I None
change I None
for I None
both I None
agents I None
. I None
<eof> I None

<s> O None
Adverse I None
drug I None
reactions I None
were I None
similar I None
for I None
each I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
, I None
but I None
the I None
rate I None
of I None
edema I None
requiring I None
medical I None
intervention I None
was I None
higher I None
in I None
the I None
rofecoxib I CHEMICAL
group I None
. I None
<eof> I None

<s> O None
Significant I None
increases I None
in I None
the I None
INR I None
were I None
observed I None
in I None
patients I None
who I None
were I None
stable I None
on I None
warfarin I CHEMICAL
therapy I None
after I None
the I None
addition I None
of I None
therapy I None
with I None
rofecoxib I CHEMICAL
or I None
celecoxib I CHEMICAL
. I None
<eof> I None

<s> O None
AT1 I GENE-Y
antagonism I None
by I None
eprosartan I CHEMICAL
lowers I None
heart I None
rate I None
variability I None
and I None
baroreflex I None
gain I None
. I None
<eof> I None

<s> O None
INTRODUCTION I None
: I None
Blockade I None
of I None
the I None
renin I GENE-Y
- I None
angiotensin I CHEMICAL
system I None
( I None
RAS I None
) I None
by I None
ACE I GENE-Y
inhibitors I None
has I None
been I None
demonstrated I None
to I None
reduce I None
total I None
mortality I None
in I None
cardiovascular I None
diseases I None
. I None
<eof> I None

<s> O None
This I None
advantage I None
was I None
attributed I None
in I None
part I None
to I None
changes I None
of I None
autonomic I None
cardiovascular I None
control I None
, I None
exemplified I None
by I None
an I None
increase I None
of I None
heart I None
rate I None
variability I None
( I None
HRV I None
) I None
and I None
baroreflex I None
gain I None
( I None
BRG I None
) I None
. I None
<eof> I None

<s> O None
We I None
sought I None
to I None
assess I None
the I None
effects I None
of I None
the I None
angiotensin I GENE-Y
type O GENE-Y
1 O GENE-Y
( O GENE-Y
AT1 O GENE-Y
) O GENE-Y
receptor O GENE-Y
blocker I None
eprosartan I CHEMICAL
on I None
HRV I None
and I None
BRG I None
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
: I None
In I None
a I None
double I None
- I None
blind I None
randomized I None
cross I None
- I None
over I None
design I None
25 I None
young I None
males I None
took I None
eprosartan I CHEMICAL
( I None
600 I None
mg I None
/ I None
day I None
) I None
and I None
placebo I None
each I None
for I None
a I None
period I None
of I None
7 I None
days I None
with I None
a I None
wash I None
- I None
out I None
period I None
of I None
at I None
least I None
4 I None
weeks I None
in I None
between I None
. I None
<eof> I None

<s> O None
At I None
the I None
end I None
of I None
the I None
intake I None
phases I None
simultaneous I None
recordings I None
of I None
arterial I None
blood I None
pressure I None
( I None
AP I None
; I None
Finapres I None
) I None
and I None
electrocardiogram I None
( I None
ECG I None
) I None
were I None
taken I None
. I None
<eof> I None

<s> O None
Power I None
spectra I None
of I None
HRV I None
and I None
arterial I None
blood I None
pressure I None
variability I None
( I None
APV I None
) I None
were I None
calculated I None
by I None
fast I None
Fourier I None
transform I None
( I None
FFT I None
) I None
and I None
served I None
to I None
calculate I None
BRG I None
. I None
<eof> I None

<s> O None
Ang I GENE-Y
- O GENE-Y
II O GENE-Y
levels I None
were I None
measured I None
by I None
radioimmunoassay I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Eprosartan I CHEMICAL
tended I None
to I None
lower I None
mean I None
AP I None
, I None
it I None
slightly I None
increased I None
heart I None
rate I None
( I None
HR I None
) I None
( I None
p I None
< I None
0 I None
. I None
05 I None
) I None
, I None
and I None
markedly I None
increased I None
circulating I None
Ang I CHEMICAL
- O CHEMICAL
II O CHEMICAL
levels I None
( I None
p I None
< I None
0 I None
. I None
01 I None
) I None
. I None
<eof> I None

<s> O None
Eprosartan I CHEMICAL
diminished I None
the I None
total I None
power I None
of I None
HRV I None
( I None
p I None
< I None
0 I None
. I None
05 I None
) I None
and I None
the I None
BRG I None
( I None
p I None
< I None
0 I None
. I None
01 I None
) I None
. I None
<eof> I None

<s> O None
The I None
low I None
/ I None
high I None
frequency I None
( I None
LF I None
/ I None
HF I None
) I None
ratio I None
of I None
HRV I None
and I None
the I None
APV I None
were I None
not I None
altered I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
AT1 I GENE-Y
antagonism I None
by I None
eprosartan I CHEMICAL
lowers I None
heart I None
rate I None
variability I None
and I None
baroreflex I None
gain I None
. I None
<eof> I None

<s> O None
We I None
speculate I None
that I None
these I None
findings I None
are I None
due I None
to I None
the I None
marked I None
increase I None
in I None
circulating I None
angiotensin I CHEMICAL
II O CHEMICAL
( I None
Ang I CHEMICAL
II O CHEMICAL
) I None
. I None
<eof> I None

<s> O None
Further I None
studies I None
are I None
needed I None
to I None
clarify I None
whether I None
angiotensin I GENE-Y
type O GENE-Y
1 O GENE-Y
( I None
AT1 I GENE-Y
) I None
blockers I None
with I None
potential I None
actions I None
inside I None
the I None
blood I None
- I None
brain I None
barrier I None
( I None
BBB I None
) I None
may I None
have I None
different I None
effects I None
on I None
HRV I None
and I None
BRG I None
. I None
<eof> I None

<s> O None
Further I None
characterization I None
of I None
alpha I None
N I CHEMICAL
- O CHEMICAL
acetyl O CHEMICAL
beta I None
- I None
endorphin I None
- I None
( I None
1 I None
- I None
31 I None
) I None
regulatory I None
activity I None
, I None
I I None
: I None
Effect I None
on I None
opioid I None
- I None
and I None
alpha I None
2 I None
- I None
mediated I None
supraspinal I None
antinociception I None
in I None
mice I None
. I None
<eof> I None

<s> O None
Picomol I None
doses I None
of I None
the I None
acetylated I None
derivative I None
of I None
beta I None
- I None
endorphin I None
- I None
( I None
1 I None
- I None
31 I None
) I None
, I None
injected I None
intracerebroventricularly I None
( I None
icv I None
) I None
in I None
mice I None
, I None
reduced I None
the I None
analgesic I None
activity I None
of I None
morphine I CHEMICAL
, I None
etorphine I CHEMICAL
and I None
beta I None
- I None
endorphin I None
- I None
( I None
1 I None
- I None
31 I None
) I None
, I None
while I None
the I None
efficiency I None
of I None
DAGO I CHEMICAL
and I None
DADLE I CHEMICAL
in I None
producing I None
analgesia I None
was I None
enhanced I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
the I None
delta I None
agonists I None
DPDPE I CHEMICAL
and I None
[ I CHEMICAL
D O CHEMICAL
- O CHEMICAL
Ala2 O CHEMICAL
] O CHEMICAL
- O CHEMICAL
Deltorphin O CHEMICAL
II O CHEMICAL
were I None
not I None
altered I None
by I None
this I None
treatment I None
. I None
<eof> I None

<s> O None
After I None
alpha I None
N I CHEMICAL
- O CHEMICAL
acetyl O CHEMICAL
beta I None
- I None
endorphin I None
- I None
( I None
1 I None
- I None
31 I None
) I None
injection I None
, I None
morphine I CHEMICAL
antagonized I None
the I None
analgesia I None
of I None
DAGO I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
regulatory I None
effect I None
of I None
alpha I None
N I CHEMICAL
- O CHEMICAL
acetyl O CHEMICAL
beta I None
- I None
endorphin I None
- I None
( I None
1 I None
- I None
31 I None
) I None
was I None
exhibited I None
when I None
giving I None
the I None
peptide I None
both I None
before I None
( I None
up I None
to I None
24 I None
h I None
) I None
and I None
after I None
the I None
opioids I None
. I None
<eof> I None

<s> O None
Naloxone I CHEMICAL
did I None
not I None
prevent I None
or I None
reverse I None
that I None
modulatory I None
activity I None
; I None
moreover I None
, I None
pretreatment I None
with I None
the I None
acetylated I None
peptide I None
did I None
not I None
change I None
the I None
pA2 I None
value I None
displayed I None
by I None
the I None
antagonist I None
at I None
the I None
mu I GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
The I None
antinociceptive I None
activity I None
of I None
the I None
alpha I GENE-N
2 O GENE-N
- O GENE-N
adrenoceptor O GENE-N
agonist I None
clonidine I CHEMICAL
was I None
also I None
increased I None
in I None
mice I None
treated I None
with I None
alpha I None
N I CHEMICAL
- O CHEMICAL
acetyl O CHEMICAL
beta I None
- I None
endorphin I None
- I None
( I None
1 I None
- I None
31 I None
) I None
. I None
<eof> I None

<s> O None
The I None
reducing I None
activity I None
of I None
alpha I None
N I CHEMICAL
- O CHEMICAL
acetyl O CHEMICAL
beta I None
- I None
endorphin I None
- I None
( I None
1 I None
- I None
31 I None
) I None
upon I None
morphine I CHEMICAL
- I None
and I None
beta I None
- I None
endorphin I None
- I None
induced I None
analgesia I None
was I None
not I None
exhibited I None
in I None
mice I None
undergoing I None
treatment I None
with I None
pertussis I None
toxin I None
or I None
N I CHEMICAL
- O CHEMICAL
ethylmaleimide O CHEMICAL
, I None
agents I None
known I None
to I None
impair I None
the I None
function I None
of I None
Gi I GENE-N
/ I None
Go I GENE-N
transducer I None
proteins I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
enhancing I None
activity I None
displayed I None
by I None
this I None
peptide I None
upon I None
DAGO I CHEMICAL
- I None
DADLE I CHEMICAL
and I None
clonidine I CHEMICAL
- I None
evoked I None
antinociception I None
was I None
still I None
manifested I None
. I None
<eof> I None

<s> O None
These I None
results I None
confirm I None
and I None
strengthen I None
the I None
idea I None
of I None
alpha I None
N I CHEMICAL
- O CHEMICAL
acetyl O CHEMICAL
beta I None
- I None
endorphin I None
- I None
( I None
1 I None
- I None
31 I None
) I None
acting I None
as I None
a I None
non I None
- I None
competitive I None
regulator I None
of I None
mu I GENE-Y
opioid O GENE-Y
- I None
and I None
alpha I GENE-N
2 O GENE-N
- O GENE-N
adrenoceptor O GENE-N
- I None
mediated I None
supraspinal I None
antinociception I None
. I None
<eof> I None

<s> O None
A I None
neural I None
substrate I None
acted I None
on I None
by I None
both I None
receptors I None
( I None
likely I None
Gi I GENE-N
/ I None
Go I GENE-N
transducer I None
proteins I None
) I None
appears I None
to I None
be I None
involved I None
in I None
the I None
effects I None
of I None
that I None
neuropeptide I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
loperamide I CHEMICAL
on I None
the I None
human I None
hypothalamo I None
- I None
pituitary I None
- I None
adrenal I None
axis I None
in I None
vivo I None
and I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
Loperamide I CHEMICAL
, I None
an I None
opiate I None
agonist I None
of I None
high I None
specificity I None
for I None
mu I None
- I None
receptors I None
, I None
was I None
recently I None
reported I None
to I None
suppress I None
ACTH I GENE-Y
and I None
cortisol I CHEMICAL
levels I None
in I None
normal I None
subjects I None
, I None
but I None
not I None
in I None
patients I None
with I None
proven I None
ACTH I GENE-Y
- I None
dependent I None
Cushing I None
' I None
s I None
disease I None
. I None
<eof> I None

<s> O None
However I None
, I None
there I None
is I None
little I None
information I None
on I None
the I None
site I None
of I None
action I None
of I None
loperamide I CHEMICAL
in I None
the I None
hypothalamo I None
- I None
pituitary I None
- I None
adrenal I None
axis I None
of I None
man I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
effect I None
of I None
loperamide I CHEMICAL
on I None
pituitary I None
hormone I None
secretion I None
in I None
vivo I None
and I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
In I None
seven I None
normal I None
subjects I None
, I None
basal I None
ACTH I GENE-Y
plasma I None
levels I None
were I None
significantly I None
suppressed I None
3 I None
h I None
after I None
loperamide I CHEMICAL
administration I None
( I None
16 I None
mg I None
, I None
orally I None
) I None
from I None
5 I None
+ I None
/ I None
- I None
1 I None
to I None
2 I None
+ I None
/ I None
- I None
0 I None
pmol I None
/ I None
L I None
( I None
P I None
less I None
than I None
0 I None
. I None
0001 I None
) I None
. I None
<eof> I None

<s> O None
After I None
the I None
combined I None
pituitary I None
stimulation I None
test I None
( I None
100 I None
micrograms I None
human I GENE-Y
CRH O GENE-Y
, I None
100 I None
micrograms I None
GnRH I CHEMICAL
, I None
100 I None
micrograms I None
GH I CHEMICAL
- O CHEMICAL
releasing O CHEMICAL
hormone O CHEMICAL
, I None
and I None
200 I None
micrograms I None
TRH I CHEMICAL
) I None
, I None
the I None
ACTH I GENE-Y
peak I None
( I None
maximum I None
increase I None
at I None
30 I None
min I None
) I None
was I None
significantly I None
blunted I None
by I None
loperamide I CHEMICAL
from I None
9 I None
+ I None
/ I None
- I None
1 I None
to I None
4 I None
+ I None
/ I None
- I None
1 I None
pmol I None
/ I None
L I None
( I None
P I None
less I None
than I None
0 I None
. I None
001 I None
) I None
and I None
the I None
area I None
under I None
the I None
curve I None
of I None
ACTH I GENE-Y
from I None
0 I None
- I None
120 I None
min I None
was I None
reduced I None
from I None
35 I None
+ I None
/ I None
- I None
5 I None
to I None
23 I None
+ I None
/ I None
- I None
4 I None
pmol I None
/ I None
L I None
. I None
2 I None
h I None
( I None
P I None
less I None
than I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
insulin I GENE-Y
- I None
hypoglycemia I None
test I None
( I None
0 I None
. I None
15 I None
IU I None
/ I None
kg I None
BW I None
) I None
, I None
neither I None
the I None
ACTH I GENE-Y
peak I None
nor I None
the I None
area I None
under I None
the I None
curve I None
of I None
ACTH I GENE-Y
was I None
affected I None
by I None
loperamide I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
six I None
patients I None
with I None
Cushing I None
' I None
s I None
disease I None
and I None
one I None
patient I None
with I None
secondary I None
adrenal I None
insufficiency I None
due I None
to I None
hypothalamic I None
failure I None
, I None
neither I None
basal I None
ACTH I GENE-Y
and I None
cortisol I CHEMICAL
levels I None
nor I None
CRH I GENE-Y
- I None
stimulated I None
levels I None
were I None
influenced I None
by I None
loperamide I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
four I None
cultured I None
human I None
corticotropic I None
adenomas I None
, I None
loperamide I CHEMICAL
was I None
not I None
able I None
to I None
reduce I None
basal I None
and I None
CRH I GENE-Y
- I None
induced I None
ACTH I GENE-Y
secretion I None
. I None
<eof> I None

<s> O None
In I None
summary I None
, I None
loperamide I CHEMICAL
is I None
able I None
to I None
reduce I None
basal I None
and I None
CRH I GENE-Y
- I None
induced I None
ACTH I GENE-Y
and I None
cortisol I CHEMICAL
levels I None
in I None
normal I None
subjects I None
, I None
but I None
not I None
in I None
patients I None
with I None
Cushing I None
' I None
s I None
disease I None
or I None
secondary I None
adrenal I None
failure I None
of I None
hypothalamic I None
origin I None
. I None
<eof> I None

<s> O None
Loperamide I CHEMICAL
has I None
no I None
significant I None
effect I None
on I None
insulin I GENE-Y
- I None
hypoglycemia I None
- I None
induced I None
ACTH I GENE-Y
and I None
cortisol I CHEMICAL
levels I None
and I None
, I None
therefore I None
, I None
no I None
effect I None
on I None
stress I None
- I None
induced I None
elevation I None
of I None
cortisol I None
levels I None
. I None
<eof> I None

<s> O None
Loperamide I CHEMICAL
might I None
act I None
at I None
a I None
suprapituitary I None
site I None
in I None
man I None
in I None
vivo I None
, I None
but I None
, I None
nevertheless I None
, I None
a I None
pituitary I None
site I None
cannot I None
be I None
excluded I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
nedocromil I CHEMICAL
sodium O CHEMICAL
on I None
the I None
binding I None
of I None
N I CHEMICAL
- O CHEMICAL
formyl O CHEMICAL
- O CHEMICAL
methionyl O CHEMICAL
- O CHEMICAL
leucyl O CHEMICAL
- O CHEMICAL
phenylalanine O CHEMICAL
in I None
human I None
neutrophils I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
the I None
inhibition I None
by I None
nedocromil I CHEMICAL
sodium O CHEMICAL
of I None
the I None
specific I None
receptor I None
binding I None
of I None
FMLP I None
was I None
evaluated I None
in I None
human I None
neutrophils I None
( I None
PMNs I None
) I None
using I None
a I None
FMLP I None
- I None
( I None
3H I None
) I None
binding I None
assay I None
. I None
<eof> I None

<s> O None
The I None
time I None
course I None
of I None
the I None
binding I None
was I None
markedly I None
influenced I None
by I None
nedocromil I CHEMICAL
sodium O CHEMICAL
used I None
at I None
a I None
concentration I None
of I None
300 I None
microM I None
. I None
<eof> I None

<s> O None
No I None
significant I None
inhibition I None
was I None
obtained I None
when I None
the I None
cells I None
were I None
treated I None
with I None
nedocromil I CHEMICAL
sodium O CHEMICAL
3 I None
microM I None
or I None
with I None
sodium I CHEMICAL
cromoglycate I None
300 I None
microM I None
. I None
<eof> I None

<s> O None
FMLP I None
binding I None
is I None
essentially I None
eliminated I None
by I None
the I None
highest I None
dose I None
of I None
nedocromil I CHEMICAL
sodium O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
biologic I None
meaning I None
of I None
this I None
effect I None
in I None
asthmatic I None
patients I None
should I None
be I None
further I None
evaluated I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
nedocromil I CHEMICAL
sodium O CHEMICAL
and I None
WEB I CHEMICAL
2086 O CHEMICAL
on I None
chemoattractant I None
- I None
stimulated I None
neutrophil I None
migration I None
through I None
cellular I None
and I None
noncellular I None
barriers I None
. I None
<eof> I None

<s> O None
Nedocromil I CHEMICAL
sodium O CHEMICAL
( I None
Tilade I CHEMICAL
) I None
is I None
an I None
effective I None
therapeutic I None
agent I None
against I None
asthma I None
and I None
has I None
been I None
shown I None
to I None
exhibit I None
antiinflammatory I None
activity I None
in I None
vitro I None
; I None
however I None
, I None
its I None
mode I None
of I None
action I None
is I None
yet I None
to I None
be I None
described I None
fully I None
. I None
<eof> I None

<s> O None
Using I None
an I None
in I None
vitro I None
assay I None
designed I None
to I None
mimic I None
the I None
extravasation I None
of I None
neutrophils I None
from I None
the I None
peripheral I None
circulation I None
through I None
cellular I None
barriers I None
to I None
sites I None
of I None
inflammation I None
, I None
the I None
effect I None
of I None
nedocromil I CHEMICAL
sodium O CHEMICAL
on I None
chemoattractant I None
- I None
stimulated I None
neutrophil I None
migration I None
was I None
examined I None
. I None
<eof> I None

<s> O None
We I None
also I None
examined I None
the I None
effects I None
of I None
WEB I CHEMICAL
2086 O CHEMICAL
, I None
a I None
platelet I GENE-Y
- O GENE-Y
activating O GENE-Y
factor O GENE-Y
( O GENE-Y
PAF O GENE-Y
) O GENE-Y
receptor O GENE-Y
antagonist I None
, I None
in I None
parallel I None
. I None
<eof> I None

<s> O None
Neutrophils I None
and I None
the I None
cellular I None
barrier I None
were I None
pretreated I None
and I None
/ I None
or I None
co I None
- I None
incubated I None
with I None
nedocromil I None
or I None
WEB I CHEMICAL
2086 O CHEMICAL
and I None
the I None
effects I None
on I None
neutrophil I None
chemotaxis I None
measured I None
. I None
<eof> I None

<s> O None
In I None
all I None
treatments I None
, I None
nedocromil I CHEMICAL
did I None
not I None
significantly I None
affect I None
chemotaxis I None
through I None
cellular I None
or I None
noncellular I None
barriers I None
to I None
N I CHEMICAL
- O CHEMICAL
formyl O CHEMICAL
- O CHEMICAL
methionyl O CHEMICAL
- O CHEMICAL
leucyl O CHEMICAL
- O CHEMICAL
phenylalanine O CHEMICAL
( I None
FMLP I CHEMICAL
) I None
, I None
leukotriene I CHEMICAL
B4 O CHEMICAL
( I None
LTB4 I CHEMICAL
) I None
, I None
or I None
PAF I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
WEB I CHEMICAL
2086 O CHEMICAL
inhibited I None
PAF I CHEMICAL
- I None
induced I None
neutrophil I None
migration I None
through I None
both I None
naked I None
filters I None
and I None
endothelial I None
and I None
epithelial I None
monolayers I None
cultured I None
on I None
these I None
filters I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
while I None
nedocromil I CHEMICAL
has I None
been I None
shown I None
to I None
have I None
inhibitory I None
effects I None
on I None
neutrophils I None
and I None
is I None
an I None
effective I None
therapeutic I None
agent I None
for I None
asthma I None
and I None
inflammatory I None
conditions I None
, I None
its I None
activity I None
is I None
not I None
primarily I None
mediated I None
by I None
inhibition I None
of I None
neutrophil I None
chemotaxis I None
. I None
<eof> I None

<s> O None
Platelet I GENE-Y
- O GENE-Y
activating O GENE-Y
factor O GENE-Y
antagonists I None
may I None
partially I None
be I None
effective I None
in I None
asthma I None
through I None
inhibitory I None
effects I None
on I None
neutrophil I None
chemotaxis I None
. I None
<eof> I None

<s> O None
Ocular I None
beta I None
- I None
blockers I None
in I None
glaucoma I None
management I None
. I None
<eof> I None

<s> O None
Clinical I None
pharmacological I None
aspects I None
. I None
<eof> I None

<s> O None
Topical I None
beta I None
- I None
blockers I None
reduce I None
the I None
intraocular I None
pressure I None
( I None
IOP I None
) I None
by I None
blockade I None
of I None
sympathetic I None
nerve I None
endings I None
in I None
the I None
ciliary I None
epithelium I None
causing I None
a I None
fall I None
in I None
aqueous I None
humour I None
production I None
. I None
<eof> I None

<s> O None
Two I None
types I None
of I None
topical I None
beta I None
- I None
blockers I None
are I None
available I None
for I None
use I None
in I None
glaucoma I None
: I None
nonselective I None
, I None
which I None
block I None
both I None
beta I GENE-N
1 O GENE-N
- O GENE-N
and O GENE-N
beta O GENE-N
2 O GENE-N
- O GENE-N
adrenoceptors O GENE-N
; I None
and I None
cardioselective I None
, I None
which I None
block I None
only I None
beta I GENE-Y
1 O GENE-Y
- O GENE-Y
receptors O GENE-Y
. I None
<eof> I None

<s> O None
Of I None
the I None
beta I None
- I None
Blockers I None
commercially I None
available I None
, I None
timolol I CHEMICAL
, I None
levobunolol I CHEMICAL
, I None
metipranolol I CHEMICAL
and I None
carteolol I CHEMICAL
are I None
nonselective I None
, I None
and I None
betaxolol I CHEMICAL
is I None
cardioselective I None
. I None
<eof> I None

<s> O None
Twice I None
- I None
daily I None
timolol I CHEMICAL
is I None
probably I None
the I None
most I None
effective I None
agent I None
in I None
lowering I None
IOP I None
, I None
although I None
levobunolol I CHEMICAL
is I None
equally I None
effective I None
and I None
can I None
be I None
used I None
once I None
daily I None
with I None
little I None
difference I None
in I None
effect I None
. I None
<eof> I None

<s> O None
Carteolol I CHEMICAL
is I None
used I None
twice I None
daily I None
and I None
any I None
theoretical I None
advantage I None
in I None
diminished I None
side I None
effects I None
conferred I None
by I None
its I None
partial I None
beta I None
- I None
agonist I None
activity I None
compared I None
with I None
timolol I CHEMICAL
has I None
not I None
been I None
fully I None
substantiated I None
. I None
<eof> I None

<s> O None
Metipranolol I CHEMICAL
is I None
effective I None
twice I None
daily I None
and I None
does I None
not I None
have I None
partial I None
beta I None
- I None
agonist I None
activity I None
. I None
<eof> I None

<s> O None
Betaxolol I CHEMICAL
has I None
an I None
effect I None
comparable I None
to I None
timolol I CHEMICAL
in I None
lowering I None
IOP I None
, I None
but I None
is I None
less I None
effective I None
in I None
some I None
patients I None
. I None
<eof> I None

<s> O None
beta I None
- I None
Blockers I None
can I None
be I None
used I None
with I None
other I None
antiglaucoma I None
medications I None
, I None
but I None
their I None
combined I None
action I None
with I None
epinephrine I CHEMICAL
( I None
adrenaline I CHEMICAL
) I None
is I None
suspect I None
, I None
particularly I None
in I None
the I None
case I None
of I None
the I None
nonselective I None
beta I None
- I None
blockers I None
, I None
and I None
the I None
effect I None
should I None
be I None
assessed I None
in I None
patients I None
on I None
an I None
individual I None
basis I None
. I None
<eof> I None

<s> O None
Local I None
stinging I None
can I None
be I None
a I None
problem I None
in I None
some I None
patients I None
with I None
betaxolol I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
most I None
serious I None
side I None
effects I None
of I None
beta I None
- I None
blockers I None
are I None
the I None
exacerbation I None
of I None
chronic I None
obstructive I None
airways I None
disease I None
with I None
nonselective I None
agents I None
and I None
the I None
precipitation I None
of I None
bronchospasm I None
in I None
some I None
patients I None
. I None
<eof> I None

<s> O None
Betaxolol I CHEMICAL
seems I None
relatively I None
free I None
of I None
adverse I None
respiratory I None
effects I None
, I None
although I None
this I None
may I None
be I None
dose I None
- I None
related I None
and I None
extreme I None
caution I None
should I None
still I None
be I None
exercised I None
in I None
patients I None
with I None
any I None
history I None
of I None
respiratory I None
illness I None
. I None
<eof> I None

<s> O None
Because I None
of I None
the I None
lower I None
risk I None
of I None
precipitating I None
side I None
effects I None
, I None
betaxolol I CHEMICAL
is I None
probably I None
the I None
beta I None
- I None
blocker I None
of I None
first I None
choice I None
for I None
use I None
in I None
glaucoma I None
; I None
timolol I CHEMICAL
or I None
levobunolol I CHEMICAL
are I None
reserved I None
for I None
patients I None
who I None
do I None
not I None
respond I None
satisfactorily I None
to I None
betaxolol I CHEMICAL
and I None
are I None
quite I None
free I None
of I None
respiratory I None
disease I None
. I None
<eof> I None

<s> O None
5 I GENE-Y
- O GENE-Y
Lipoxygenase O GENE-Y
inhibitors I None
for I None
the I None
treatment I None
of I None
inflammatory I None
bowel I None
disease I None
. I None
<eof> I None

<s> O None
The I None
unique I None
role I None
of I None
the I None
enzyme I None
5 I GENE-Y
- O GENE-Y
lipoxygenase O GENE-Y
( I None
5 I GENE-Y
- O GENE-Y
LO O GENE-Y
) I None
in I None
the I None
production I None
of I None
leukotrienes I CHEMICAL
( I None
LTs I CHEMICAL
) I None
makes I None
it I None
a I None
likely I None
target I None
for I None
biochemical I None
manipulation I None
. I None
<eof> I None

<s> O None
The I None
rationale I None
for I None
using I None
5 I GENE-Y
- O GENE-Y
LO O GENE-Y
inhibitors I None
for I None
the I None
treatment I None
of I None
inflammatory I None
bowel I None
disease I None
( I None
IBD I None
) I None
is I None
based I None
on I None
the I None
increased I None
generation I None
of I None
LTs I CHEMICAL
in I None
the I None
inflamed I None
mucosa I None
, I None
LTB4 I CHEMICAL
being I None
the I None
most I None
potent I None
chemotactic I None
and I None
chemokinetic I None
metabolite I None
of I None
arachidonic I CHEMICAL
acid O CHEMICAL
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
conventional I None
drugs I None
, I None
such I None
as I None
corticosteroids I None
, I None
sulphasalazine I CHEMICAL
, I None
and I None
5 I CHEMICAL
- O CHEMICAL
aminosalicylic O CHEMICAL
acid O CHEMICAL
, I None
inhibit I None
LT I CHEMICAL
production I None
and I None
specific I None
5 I GENE-Y
- O GENE-Y
LO O GENE-Y
inhibition I None
accelerates I None
healing I None
in I None
animal I None
models I None
of I None
acute I None
colitis I None
. I None
<eof> I None

<s> O None
The I None
compounds I None
identified I None
as I None
5 I GENE-Y
- O GENE-Y
LO O GENE-Y
inhibitors I None
can I None
be I None
divided I None
into I None
antioxidants I None
, I None
substrate I None
- I None
analogous I None
, I None
and I None
a I None
large I None
miscellaneous I None
group I None
of I None
inhibitors I None
, I None
where I None
hydroxamic I CHEMICAL
acids O CHEMICAL
are I None
potent I None
and I None
more I None
selective I None
inhibitors I None
of I None
5 I GENE-Y
- O GENE-Y
LO O GENE-Y
. I None
<eof> I None

<s> O None
The I None
benzothiophene I CHEMICAL
hydroxyurea O CHEMICAL
, I None
zileuton I CHEMICAL
, I None
is I None
the I None
first I None
selective I None
5 I GENE-Y
- O GENE-Y
LO O GENE-Y
inhibitor I None
evaluated I None
for I None
the I None
treatment I None
of I None
patients I None
with I None
IBD I None
. I None
<eof> I None

<s> O None
An I None
800 I None
- I None
mg I None
oral I None
dose I None
of I None
zileuton I CHEMICAL
was I None
shown I None
to I None
reduce I None
LTB4 I CHEMICAL
, I None
but I None
not I None
prostaglandin I CHEMICAL
E2 O CHEMICAL
, I None
concentrations I None
by I None
75 I None
- I None
85 I None
% I None
in I None
rectal I None
dialysates I None
from I None
patients I None
with I None
active I None
ulcerative I None
colitis I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
efficacy I None
of I None
zileuton I CHEMICAL
800 I None
mg I None
b I None
. I None
i I None
. I None
d I None
. I None
has I None
also I None
been I None
tested I None
in I None
a I None
randomized I None
, I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
trial I None
in I None
similar I None
patients I None
. I None
<eof> I None

<s> O None
Zileuton I CHEMICAL
significantly I None
improved I None
the I None
symptom I None
scores I None
and I None
the I None
histology I None
score I None
, I None
but I None
not I None
the I None
sigmoidoscopy I None
score I None
, I None
compared I None
to I None
pretreatment I None
conditions I None
and I None
with I None
response I None
to I None
placebo I None
, I None
the I None
beneficial I None
effects I None
being I None
most I None
pronounced I None
in I None
patients I None
not I None
receiving I None
concomitant I None
sulphasalazine I CHEMICAL
treatment I None
. I None
<eof> I None

<s> O None
The I None
mean I None
inhibition I None
of I None
LTB4 I CHEMICAL
in I None
the I None
target I None
tissue I None
of I None
inflammation I None
was I None
70 I None
% I None
. I None
<eof> I None

<s> O None
The I None
proof I None
that I None
any I None
putative I None
5 I GENE-Y
- O GENE-Y
LO O GENE-Y
inhibitor I None
is I None
blocking I None
LT I CHEMICAL
production I None
is I None
an I None
important I None
stage I None
in I None
assessing I None
any I None
such I None
drug I None
. I None
<eof> I None

<s> O None
The I None
main I None
disadvantage I None
of I None
existing I None
new I None
LT I CHEMICAL
inhibitors I None
relates I None
to I None
the I None
high I None
potency I None
of I None
LTs I CHEMICAL
, I None
and I None
unless I None
a I None
higher I None
level I None
of I None
inhibition I None
can I None
be I None
achieved I None
, I None
endogenous I None
LTs I CHEMICAL
may I None
still I None
be I None
present I None
in I None
sufficient I None
amounts I None
to I None
produce I None
their I None
effects I None
. I None
<eof> I None

<s> O None
Platelet I GENE-Y
- O GENE-Y
derived O GENE-Y
growth O GENE-Y
factor O GENE-Y
( O GENE-Y
PDGF O GENE-Y
) O GENE-Y
receptor O GENE-Y
- O GENE-Y
alpha O GENE-Y
- I None
activated I None
c I GENE-Y
- O GENE-Y
Jun O GENE-Y
NH2 O GENE-Y
- O GENE-Y
terminal O GENE-Y
kinase O GENE-Y
- O GENE-Y
1 O GENE-Y
is I None
critical I None
for I None
PDGF I GENE-N
- I None
induced I None
p21WAF1 I GENE-N
/ O GENE-N
CIP1 O GENE-N
promoter O GENE-N
activity I None
independent I None
of I None
p53 I GENE-Y
. I None
<eof> I None

<s> O None
Platelet I GENE-N
- O GENE-N
derived O GENE-N
growth O GENE-N
factor O GENE-N
( I None
PDGF I GENE-N
) I None
is I None
a I None
potent I None
mitogen I None
for I None
mesenchymal I None
cells I None
. I None
<eof> I None

<s> O None
PDGF I GENE-Y
AA O GENE-Y
functions I None
as I None
a I None
" I None
competent I None
factor I None
" I None
that I None
stimulates I None
cell I None
cycle I None
entry I None
but I None
requires I None
additional I None
( I None
progression I None
) I None
factors I None
in I None
serum I None
to I None
transit I None
the I None
cell I None
cycle I None
beyond I None
the I None
G1 I None
/ I None
S I None
checkpoint I None
. I None
<eof> I None

<s> O None
Unlike I None
PDGF I GENE-Y
AA O GENE-Y
, I None
PDGF I GENE-Y
B O GENE-Y
- I None
chain I None
( I None
c I None
- I None
sis I None
) I None
homodimer I None
( I None
PDGF I GENE-Y
BB O GENE-Y
) I None
and I None
its I None
viral I None
counterpart I None
v I None
- I None
sis I None
can I None
serve I None
as I None
both I None
competent I None
and I None
progression I None
factors I None
. I None
<eof> I None

<s> O None
PDGF I GENE-Y
BB O GENE-Y
activates I None
alpha I None
- I None
and I None
beta I None
- I None
receptor I None
subunits I None
( I None
alpha I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
and I None
beta I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
) I None
and I None
induces I None
phenotypic I None
transformation I None
in I None
NIH I None
3T3 I None
cells I None
, I None
whereas I None
PDGF I GENE-Y
AA O GENE-Y
activates I None
alpha I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
only I None
and I None
fails I None
to I None
induce I None
transformation I None
. I None
<eof> I None

<s> O None
We I None
showed I None
previously I None
that I None
alpha I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
antagonizes I None
beta I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
- I None
mediated I None
transformation I None
through I None
activation I None
of I None
stress I GENE-Y
- O GENE-Y
activated O GENE-Y
protein O GENE-Y
kinase O GENE-Y
- O GENE-Y
1 O GENE-Y
/ I None
c I GENE-Y
- O GENE-Y
Jun O GENE-Y
NH2 O GENE-Y
- O GENE-Y
terminal O GENE-Y
kinase O GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
whereas I None
both I None
alpha I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
and I None
beta I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
induce I None
mitogenic I None
signals I None
. I None
<eof> I None

<s> O None
These I None
studies I None
revealed I None
a I None
striking I None
feature I None
of I None
PDGF I GENE-N
signaling I None
; I None
the I None
specificity I None
and I None
the I None
strength I None
of I None
the I None
PDGF I GENE-N
growth I None
signal I None
is I None
modulated I None
by I None
alpha I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
- I None
mediated I None
simultaneous I None
activation I None
of I None
growth I None
stimulatory I None
and I None
inhibitory I None
signals I None
, I None
whereas I None
beta I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
mainly I None
induces I None
a I None
growth I None
- I None
promoting I None
signal I None
. I None
<eof> I None

<s> O None
Here I None
we I None
demonstrate I None
that I None
PDGF I GENE-Y
BB O GENE-Y
activation I None
of I None
beta I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
alone I None
results I None
in I None
more I None
efficient I None
cell I None
cycle I None
transition I None
from I None
G1 I None
to I None
S I None
phase I None
than I None
PDGF I GENE-Y
BB O GENE-Y
activation I None
of I None
both I None
alpha I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
and I None
beta I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
. I None
<eof> I None

<s> O None
PDGF I GENE-Y
AA O GENE-Y
activation I None
of I None
alpha I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
or I None
PDGF I GENE-Y
BB O GENE-Y
activation I None
of I None
both I None
alpha I GENE-N
- O GENE-N
and O GENE-N
beta O GENE-N
- O GENE-N
PDGFRs O GENE-N
up I None
- I None
regulates I None
expression I None
of I None
p21WAF1 I GENE-Y
/ I None
CIP1 I GENE-Y
, I None
an I None
inhibitor I None
of I None
cell I None
cycle I None
- I None
dependent I None
kinases I GENE-N
and I None
a I None
downstream I None
mediator I None
of I None
the I None
tumor I None
suppressor I None
gene I None
product I None
p53 I GENE-Y
. I None
<eof> I None

<s> O None
However I None
, I None
beta I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
activation I None
alone I None
fails I None
to I None
induce I None
p21WAF1 I GENE-Y
/ I None
CIP1 I GENE-Y
expression I None
. I None
<eof> I None

<s> O None
We I None
also I None
demonstrate I None
that I None
alpha I GENE-Y
- O GENE-Y
PDGFR O GENE-Y
- I None
activated I None
JNK I GENE-Y
- O GENE-Y
1 O GENE-Y
is I None
a I None
critical I None
signaling I None
component I None
for I None
PDGF I GENE-N
induction I None
of I None
p21WAF1 I GENE-N
/ O GENE-N
CIP1 O GENE-N
promoter I None
activity I None
. I None
<eof> I None

<s> O None
The I None
ability I None
of I None
PDGF I GENE-N
/ I None
JNK I GENE-Y
- O GENE-Y
1 O GENE-Y
to I None
induce I None
p21WAF1 I GENE-N
/ O GENE-N
CIP1 O GENE-N
promoter O GENE-N
activity I None
is I None
independent I None
of I None
p53 I GENE-Y
, I None
although I None
the I None
overall I None
p21WAF1 I GENE-N
/ O GENE-N
CIP1 O GENE-N
promoter O GENE-N
activities I None
are I None
greatly I None
reduced I None
in I None
the I None
absence I None
of I None
p53 I GENE-Y
. I None
<eof> I None

<s> O None
These I None
results I None
provide I None
a I None
molecular I None
basis I None
for I None
differential I None
regulation I None
of I None
the I None
cell I None
cycle I None
and I None
transformation I None
by I None
alpha I GENE-N
- O GENE-N
and O GENE-N
beta O GENE-N
- O GENE-N
PDGFRs O GENE-N
. I None
<eof> I None

<s> O None
Searching I None
for I None
preventive I None
measures I None
of I None
cardiovascular I None
events I None
in I None
aged I None
Japanese I None
taxi I None
drivers I None
- I None
- I None
the I None
daily I None
rhythm I None
of I None
cardiovascular I None
risk I None
factors I None
during I None
a I None
night I None
duty I None
day I None
. I None
<eof> I None

<s> O None
Previous I None
studies I None
have I None
shown I None
that I None
Japanese I None
taxi I None
drivers I None
are I None
exposed I None
to I None
more I None
risk I None
factors I None
and I None
have I None
a I None
higher I None
mortality I None
rate I None
due I None
to I None
cardiovascular I None
disease I None
than I None
other I None
occupational I None
groups I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
effect I None
of I None
night I None
taxi I None
driving I None
with I None
a I None
view I None
to I None
preventing I None
acute I None
events I None
of I None
cardiovascular I None
disease I None
among I None
aged I None
taxi I None
drivers I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
nine I None
taxi I None
drivers I None
( I None
41 I None
- I None
67 I None
years I None
old I None
) I None
were I None
examined I None
for I None
urine I None
normetanephrine I CHEMICAL
/ I None
creatinine I CHEMICAL
, I None
von I GENE-Y
Willebrand O GENE-Y
factor O GENE-Y
, I None
anti I GENE-Y
- O GENE-Y
thrombin O GENE-Y
III O GENE-Y
, I None
t I GENE-Y
- O GENE-Y
plasminogen O GENE-Y
activator O GENE-Y
- I None
plasminogen I GENE-Y
activator O GENE-Y
inhibitor O GENE-Y
1 O GENE-Y
- I None
complex I None
, I None
hematocrit I None
, I None
blood I None
glucose I CHEMICAL
and I None
blood I None
pressure I None
in I None
the I None
morning I None
and I None
at I None
midnight I None
during I None
a I None
duty I None
day I None
and I None
in I None
the I None
following I None
morning I None
. I None
<eof> I None

<s> O None
At I None
the I None
same I None
time I None
, I None
the I None
blood I None
pressure I None
and I None
blood I None
glucose I CHEMICAL
of I None
46 I None
taxi I None
drivers I None
( I None
43 I None
- I None
67 I None
years I None
old I None
) I None
in I None
the I None
morning I None
after I None
a I None
night I None
duty I None
with I None
little I None
sleep I None
and I None
in I None
the I None
morning I None
after I None
daytime I None
work I None
and I None
subsequent I None
night I None
sleep I None
were I None
compared I None
. I None
<eof> I None

<s> O None
The I None
results I None
obtained I None
indicate I None
that I None
the I None
aggravation I None
of I None
sympathetic I None
nervous I None
system I None
functions I None
with I None
disturbed I None
circadian I None
rhythms I None
, I None
increased I None
blood I None
coagulation I None
and I None
blood I None
concentration I None
, I None
endothelial I None
injury I None
and I None
the I None
elevation I None
of I None
blood I None
glucose I None
at I None
midnight I None
or I None
the I None
next I None
morning I None
were I None
induced I None
by I None
their I None
night I None
work I None
. I None
<eof> I None

<s> O None
These I None
conditions I None
are I None
supposed I None
to I None
favour I None
acute I None
vascular I None
events I None
in I None
aged I None
taxi I None
drivers I None
. I None
<eof> I None

<s> O None
Preventive I None
measures I None
considered I None
include I None
social I None
support I None
for I None
anticoagulant I None
food I None
and I None
water I None
intake I None
, I None
short I None
exercise I None
and I None
walking I None
as I None
well I None
as I None
taking I None
a I None
rest I None
and I None
a I None
nap I None
during I None
night I None
work I None
. I None
<eof> I None

<s> O None
The I None
human I GENE-Y
ribonucleotide O GENE-Y
reductase O GENE-Y
subunit O GENE-Y
hRRM2 O GENE-Y
complements I None
p53R2 I GENE-Y
in I None
response I None
to I None
UV I None
- I None
induced I None
DNA I None
repair I None
in I None
cells I None
with I None
mutant I None
p53 I GENE-Y
. I None
<eof> I None

<s> O None
Ribonucleotide I GENE-N
reductase O GENE-N
( I None
RR I GENE-N
) I None
is I None
responsible I None
for I None
the I None
de I None
novo I None
conversion I None
of I None
the I None
ribonucleoside I CHEMICAL
diphosphates O CHEMICAL
to I None
deoxyribonucleoside I CHEMICAL
diphosphates O CHEMICAL
, I None
which I None
are I None
essential I None
for I None
DNA I None
synthesis I None
and I None
repair I None
. I None
<eof> I None

<s> O None
RR I GENE-N
consists I None
of I None
two I None
subunits I None
, I None
hRRM1 I GENE-Y
and I None
hRRM2 I GENE-Y
. I None
<eof> I None

<s> O None
p53R2 I GENE-Y
is I None
a I None
new I None
RR I GENE-N
family I None
member I None
. I None
<eof> I None

<s> O None
Because I None
the I None
majority I None
of I None
human I None
tumors I None
possess I None
mutant I None
p53 I GENE-Y
, I None
it I None
is I None
important I None
to I None
know I None
the I None
molecular I None
mechanism I None
by I None
which I None
mutant I None
p53 I GENE-Y
regulates I None
RR I GENE-N
and I None
to I None
what I None
extent I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
investigated I None
the I None
expression I None
and I None
function I None
of I None
p53R2 I GENE-Y
and I None
hRRM2 I GENE-Y
after I None
UV I None
treatment I None
in I None
human I None
prostate I None
cancer I None
PC3 I None
cells I None
, I None
which I None
possess I None
mutant I None
p53 I GENE-Y
with I None
a I None
truncated I None
COOH I CHEMICAL
- I None
terminal I None
, I None
and I None
in I None
human I None
oropharyngeal I None
cancer I None
KB I None
cells I None
, I None
which I None
possess I None
wild I None
- I None
type I None
p53 I GENE-Y
. I None
<eof> I None

<s> O None
p53R2 I GENE-Y
( I None
analyzed I None
by I None
Western I None
blot I None
and I None
standardized I None
relative I None
to I None
Coomassie I None
Blue I None
- I None
stained I None
band I None
) I None
was I None
down I None
- I None
regulated I None
in I None
PC3 I None
cells I None
and I None
up I None
- I None
regulated I None
in I None
KB I None
cells I None
after I None
UV I None
exposure I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
hRRM2 I GENE-Y
was I None
up I None
- I None
regulated I None
by I None
UV I None
in I None
both I None
PC3 I None
cells I None
and I None
KB I None
cells I None
. I None
<eof> I None

<s> O None
hRRM2 I GENE-Y
and I None
p53R2 I GENE-Y
mRNA I None
levels I None
were I None
assessed I None
by I None
Northern I None
blot I None
, I None
and I None
the I None
results I None
paralleled I None
that I None
of I None
the I None
Western I None
blot I None
. I None
<eof> I None

<s> O None
Coimmunoprecipitation I None
assays I None
using I None
agarose I None
- I None
conjugated I None
goat I None
antihuman I None
RRM1 I GENE-Y
antibody I None
confirmed I None
that I None
the I None
p53R2 I GENE-Y
binding I None
to I None
hRRM1 I GENE-Y
decreased I None
in I None
PC3 I None
cells I None
but I None
increased I None
in I None
KB I None
cells I None
after I None
UV I None
treatment I None
. I None
<eof> I None

<s> O None
hRRM2 I GENE-Y
binding I None
to I None
hRRM1 I GENE-N
increased I None
in I None
both I None
cell I None
lines I None
under I None
the I None
same I None
conditions I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
PC3 I None
cells I None
are I None
deficient I None
in I None
both I None
transcription I None
of I None
p53R2 I GENE-Y
and I None
binding I None
to I None
hRRM1 I GENE-Y
in I None
response I None
to I None
UV I None
irradiation I None
. I None
<eof> I None

<s> O None
Confocal I None
microscopy I None
further I None
confirmed I None
that I None
these I None
findings I None
were I None
not I None
due I None
to I None
translocation I None
of I None
hRRM2 I GENE-Y
and I None
p53R2 I GENE-Y
from I None
the I None
cytoplasm I None
to I None
the I None
nucleus I None
. I None
<eof> I None

<s> O None
RR I GENE-N
activity I None
was I None
measured I None
following I None
UV I None
treatment I None
and I None
shown I None
to I None
increase I None
in I None
PC3 I None
cells I None
. I None
<eof> I None

<s> O None
It I None
was I None
unchanged I None
in I None
proportional I None
of I None
KB I None
cells I None
. I None
<eof> I None

<s> O None
The I None
RR I GENE-N
activity I None
is I None
consistent I None
with I None
the I None
expression I None
of I None
hRRM2 I GENE-N
seen I None
in I None
the I None
Western I None
blots I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
we I None
hypothesize I None
that I None
hRRM2 I GENE-Y
complements I None
p53R2 I GENE-Y
to I None
form I None
RR I GENE-N
holoenzyme I None
and I None
maintain I None
RR I GENE-N
activity I None
in I None
PC3 I None
cells I None
after I None
UV I None
treatment I None
. I None
<eof> I None

<s> O None
To I None
further I None
confirm I None
this I None
hypothesis I None
, I None
we I None
examined I None
the I None
effect I None
of I None
RRM2 I GENE-Y
inhibitors I None
on I None
cells I None
exposed I None
to I None
UV I None
. I None
<eof> I None

<s> O None
In I None
PC3 I None
cells I None
, I None
hydroxyurea I CHEMICAL
inhibited I None
hRRM2 I GENE-Y
and I None
resulted I None
in I None
increased I None
sensitivity I None
to I None
UV I None
irradiation I None
. I None
<eof> I None

<s> O None
We I None
also I None
examined I None
the I None
effect I None
of I None
UV I None
treatment I None
on I None
the I None
colony I None
- I None
forming I None
ability I None
of I None
cells I None
transfected I None
with I None
hRRM2 I GENE-Y
as I None
well I None
as I None
p53R2 I GENE-Y
sense I None
or I None
antisense I None
expression I None
vectors I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
antisense I None
hRRM2 I GENE-Y
in I None
PC3 I None
cells I None
led I None
to I None
decreased I None
hRRM2 I GENE-Y
expression I None
and I None
resulted I None
in I None
greater I None
sensitivity I None
to I None
UV I None
than I None
observed I None
in I None
wild I None
- I None
type I None
PC3 I None
cells I None
. I None
<eof> I None

<s> O None
Taken I None
together I None
, I None
we I None
conclude I None
that I None
UV I None
- I None
induced I None
activation I None
of I None
p53R2 I GENE-Y
transcription I None
and I None
binding I None
of I None
p53R2 I GENE-N
to I None
hRRM1 I GENE-Y
to I None
form I None
RR I GENE-N
holoenzyme I None
are I None
impaired I None
in I None
the I None
p53 I GENE-Y
- I None
mutant I None
cell I None
line I None
PC3 I None
. I None
<eof> I None

<s> O None
Minocycline I CHEMICAL
reduces I None
cell I None
death I None
and I None
improves I None
functional I None
recovery I None
after I None
traumatic I None
spinal I None
cord I None
injury I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
We I None
examined I None
the I None
effects I None
of I None
minocycline I CHEMICAL
, I None
an I None
anti I None
- I None
inflammatory I None
drug I None
, I None
on I None
functional I None
recovery I None
following I None
spinal I None
cord I None
injury I None
( I None
SCI I None
) I None
. I None
<eof> I None

<s> O None
Rats I None
received I None
a I None
mild I None
, I None
weight I None
- I None
drop I None
contusion I None
injury I None
to I None
the I None
spinal I None
cord I None
and I None
were I None
treated I None
with I None
the I None
vehicle I None
or I None
minocycline I CHEMICAL
at I None
a I None
dose I None
of I None
90 I None
mg I None
/ I None
kg I None
immediately I None
after I None
SCI I None
and I None
then I None
twice I None
at I None
a I None
dose I None
of I None
45 I None
mg I None
/ I None
kg I None
every I None
12 I None
h I None
. I None
<eof> I None

<s> O None
Injecting I None
minocycline I CHEMICAL
after I None
SCI I None
improved I None
hind I None
limb I None
motor I None
function I None
as I None
determined I None
by I None
the I None
Basso I None
- I None
Beattie I None
- I None
Bresnahan I None
( I None
BBB I None
) I None
locomotor I None
open I None
field I None
behavioral I None
rating I None
test I None
. I None
<eof> I None

<s> O None
Twenty I None
four I None
to I None
38 I None
days I None
after I None
SCI I None
, I None
BBB I None
scores I None
were I None
significantly I None
higher I None
in I None
minocycline I CHEMICAL
- I None
treated I None
rats I None
as I None
compared I None
with I None
those I None
in I None
vehicle I None
- I None
treated I None
rats I None
. I None
<eof> I None

<s> O None
Morphological I None
analysis I None
showed I None
that I None
lesion I None
size I None
increased I None
progressively I None
in I None
both I None
vehicle I None
- I None
treated I None
and I None
minocycline I CHEMICAL
- I None
treated I None
spinal I None
cords I None
. I None
<eof> I None

<s> O None
However I None
, I None
in I None
response I None
to I None
treatment I None
with I None
minocycline I CHEMICAL
, I None
the I None
lesion I None
size I None
was I None
significantly I None
reduced I None
at I None
21 I None
- I None
38 I None
days I None
after I None
SCI I None
when I None
compared I None
to I None
the I None
vehicle I None
control I None
. I None
<eof> I None

<s> O None
Minocycline I CHEMICAL
treatment I None
significantly I None
reduced I None
the I None
number I None
of I None
terminal I None
deoxynucleotidyl I None
transferase I None
( I None
TdT I None
) I None
- I None
mediated I None
deoxyuridine I CHEMICAL
triphosphate O CHEMICAL
- O CHEMICAL
biotin O CHEMICAL
nick I None
end I None
labeling I None
( I None
TUNEL I None
) I None
- I None
positive I None
cells I None
24 I None
h I None
after I None
SCI I None
as I None
compared I None
to I None
that I None
of I None
the I None
vehicle I None
control I None
. I None
<eof> I None

<s> O None
DNA I None
gel I None
electrophoresis I None
also I None
revealed I None
a I None
marked I None
decrease I None
in I None
DNA I None
laddering I None
in I None
response I None
to I None
treatment I None
with I None
minocycline I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
minocycline I CHEMICAL
treatment I None
significantly I None
reduced I None
the I None
specific I None
caspase I GENE-Y
- O GENE-Y
3 O GENE-Y
activity I None
after I None
SCI I None
as I None
compared I None
to I None
that I None
of I None
vehicle I None
control I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
RT I None
- I None
PCR I None
analyses I None
revealed I None
that I None
minocycline I CHEMICAL
treatment I None
increased I None
expression I None
of I None
interleukin I GENE-Y
- O GENE-Y
10 O GENE-Y
mRNA I None
but I None
decreased I None
tumor I GENE-Y
necrosis O GENE-Y
factor O GENE-Y
- O GENE-Y
alpha O GENE-Y
expression I None
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
that I None
, I None
after I None
SCI I None
, I None
minocycline I CHEMICAL
treatment I None
modulated I None
expression I None
of I None
cytokines I GENE-N
, I None
attenuated I None
cell I None
death I None
and I None
the I None
size I None
of I None
lesions I None
, I None
and I None
improved I None
functional I None
recovery I None
in I None
the I None
injured I None
rat I None
. I None
<eof> I None

<s> O None
This I None
approach I None
may I None
provide I None
a I None
therapeutic I None
intervention I None
enabling I None
us I None
to I None
reduce I None
cell I None
death I None
and I None
improve I None
functional I None
recovery I None
after I None
SCI I None
. I None
<eof> I None

<s> O None
Innovative I None
approach I None
for I None
improvement I None
of I None
an I None
antibiotic I None
- I None
overproducing I None
industrial I None
strain I None
of I None
Streptomyces I None
albus I None
. I None
<eof> I None

<s> O None
Working I None
with I None
a I None
Streptomyces I None
albus I None
strain I None
that I None
had I None
previously I None
been I None
bred I None
to I None
produce I None
industrial I None
amounts I None
( I None
10 I None
mg I None
/ I None
ml I None
) I None
of I None
salinomycin I CHEMICAL
, I None
we I None
demonstrated I None
the I None
efficacy I None
of I None
introducing I None
drug I None
resistance I None
- I None
producing I None
mutations I None
for I None
further I None
strain I None
improvement I None
. I None
<eof> I None

<s> O None
Mutants I None
with I None
enhanced I None
salinomycin I CHEMICAL
production I None
were I None
detected I None
at I None
a I None
high I None
incidence I None
( I None
7 I None
to I None
12 I None
% I None
) I None
among I None
spontaneous I None
isolates I None
resistant I None
to I None
streptomycin I CHEMICAL
( I None
Str I None
( I None
r I None
) I None
) I None
, I None
gentamicin I CHEMICAL
, I None
or I None
rifampin I CHEMICAL
( I None
Rif I None
( I None
r I None
) I None
) I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
we I None
successfully I None
demonstrated I None
improvement I None
of I None
the I None
salinomycin I CHEMICAL
productivity I None
of I None
the I None
industrial I None
strain I None
by I None
2 I None
. I None
3 I None
- I None
fold I None
by I None
introducing I None
a I None
triple I None
mutation I None
. I None
<eof> I None

<s> O None
The I None
Str I None
( I None
r I None
) I None
mutant I None
was I None
shown I None
to I None
have I None
a I None
point I None
mutation I None
within I None
the I None
rpsL I GENE-Y
gene I None
( I None
encoding I None
ribosomal I GENE-Y
protein O GENE-Y
S12 O GENE-Y
) I None
. I None
<eof> I None

<s> O None
Likewise I None
, I None
the I None
Rif I None
( I None
r I None
) I None
mutant I None
possessed I None
a I None
mutation I None
in I None
the I None
rpoB I GENE-Y
gene I None
( I None
encoding I None
the I None
RNA I GENE-N
polymerase O GENE-N
beta O GENE-N
subunit I None
) I None
. I None
<eof> I None

<s> O None
Increased I None
productivity I None
of I None
salinomycin I CHEMICAL
in I None
the I None
Str I None
( I None
r I None
) I None
mutant I None
( I None
containing I None
the I None
K88R I GENE-N
mutation I None
in I None
the I None
S12 I GENE-Y
protein I None
) I None
may I None
be I None
a I None
result I None
of I None
an I None
aberrant I None
protein I None
synthesis I None
mechanism I None
. I None
<eof> I None

<s> O None
This I None
aberration I None
may I None
manifest I None
itself I None
as I None
enhanced I None
translation I None
activity I None
in I None
stationary I None
- I None
phase I None
cells I None
, I None
as I None
we I None
have I None
observed I None
with I None
the I None
poly I None
( I None
U I None
) I None
- I None
directed I None
cell I None
- I None
free I None
translation I None
system I None
. I None
<eof> I None

<s> O None
The I None
K88R I GENE-N
mutant I None
ribosome I None
was I None
characterized I None
by I None
increased I None
70S I GENE-N
complex O GENE-N
stability I None
in I None
low I None
Mg I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
concentrations I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
this I None
aberrant I None
protein I None
synthesis I None
ability I None
in I None
the I None
Str I None
( I None
r I None
) I None
mutant I None
, I None
which I None
is I None
a I None
result I None
of I None
increased I None
stability I None
of I None
the I None
70S I GENE-N
complex O GENE-N
, I None
is I None
responsible I None
for I None
the I None
remarkable I None
salinomycin I CHEMICAL
production I None
enhancement I None
obtained I None
. I None
<eof> I None

<s> O None
[ I None
The I None
effects I None
of I None
nandrolone I CHEMICAL
phenylpropionate O CHEMICAL
on I None
androgen I GENE-Y
receptor O GENE-Y
of I None
liver I None
and I None
sexual I None
glands I None
in I None
burned I None
rats I None
] I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
To I None
assess I None
the I None
effects I None
of I None
nandrolone I CHEMICAL
phenylpropionate O CHEMICAL
( I None
NP I CHEMICAL
) I None
on I None
androgen I GENE-Y
receptor O GENE-Y
( I None
AR I GENE-Y
) I None
of I None
liver I None
and I None
sexual I None
glands I None
in I None
burned I None
rats I None
for I None
supporting I None
the I None
clinical I None
application I None
of I None
anabolic I None
steroids I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Thirty I None
- I None
two I None
Wistar I None
rats I None
with I None
a I None
deep I None
second I None
- I None
degree I None
cutaneous I None
burn I None
of I None
20 I None
% I None
total I None
body I None
surface I None
area I None
were I None
randomly I None
divided I None
into I None
two I None
groups I None
to I None
receive I None
either I None
5 I None
mg I None
/ I None
kg I None
NP I CHEMICAL
( I None
NP I CHEMICAL
group I None
) I None
or I None
normal I None
saline I None
as I None
placebo I None
( I None
control I None
group I None
) I None
every I None
other I None
day I None
. I None
<eof> I None

<s> O None
The I None
mean I None
integrated I None
optical I None
density I None
( I None
mIOD I None
) I None
of I None
androgen I GENE-Y
receptor O GENE-Y
( I None
AR I GENE-Y
) I None
in I None
liver I None
, I None
testis I None
, I None
ovary I None
tissues I None
were I None
measured I None
by I None
immunohistochemistry I None
ENVISION I None
and I None
LSAB I None
respectively I None
on I None
the I None
4th I None
, I None
7th I None
, I None
14th I None
and I None
21st I None
days I None
after I None
scalding I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
The I None
density I None
of I None
AR I GENE-Y
in I None
liver I None
tissue I None
in I None
NP I CHEMICAL
group I None
was I None
higher I None
than I None
that I None
in I None
control I None
group I None
( I None
P I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
The I None
density I None
of I None
AR I GENE-Y
in I None
testis I None
and I None
ovary I None
tissues I None
showed I None
no I None
significant I None
difference I None
between I None
NP I CHEMICAL
group I None
and I None
control I None
group I None
at I None
every I None
time I None
- I None
point I None
( I None
P I None
> I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
The I None
side I None
- I None
effect I None
of I None
NP I CHEMICAL
at I None
this I None
dose I None
level I None
on I None
sexual I None
glands I None
seemed I None
limited I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
Nandrolone I CHEMICAL
phenylpropionate O CHEMICAL
up I None
- I None
regulated I None
the I None
density I None
of I None
AR I GENE-Y
in I None
liver I None
tissue I None
, I None
whereas I None
it I None
had I None
no I None
significant I None
effects I None
on I None
the I None
density I None
of I None
AR I GENE-Y
in I None
testis I None
and I None
ovary I None
tissues I None
. I None
<eof> I None

<s> O None
NP I CHEMICAL
was I None
used I None
with I None
safety I None
at I None
this I None
dose I None
level I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Serotonin I GENE-Y
5 O GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
2B O GENE-Y
) O GENE-Y
receptor O GENE-Y
loss I None
of I None
function I None
mutation I None
in I None
a I None
patient I None
with I None
fenfluramine I CHEMICAL
- I None
associated I None
primary I None
pulmonary I None
hypertension I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
Appetite I None
- I None
suppressant I None
drug I None
fenfluramine I None
is I None
implicated I None
in I None
primary I None
pulmonary I None
hypertension I None
( I None
PPH I None
) I None
but I None
the I None
molecular I None
pathways I None
that I None
mediate I None
this I None
effect I None
are I None
unknown I None
. I None
<eof> I None

<s> O None
A I None
mouse I None
model I None
incriminates I None
the I None
serotonin I GENE-Y
5 O GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
2B O GENE-Y
) O GENE-Y
receptor O GENE-Y
but I None
contrasts I None
with I None
other I None
models I None
where I None
this I None
receptor I None
has I None
been I None
shown I None
to I None
mediate I None
pulmonary I None
arterial I None
relaxation I None
via I None
nitric I CHEMICAL
oxide O CHEMICAL
production I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
We I None
analyzed I None
the I None
human I GENE-Y
5 O GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
2B O GENE-Y
) O GENE-Y
gene I None
in I None
10 I None
patients I None
with I None
appetite I None
- I None
suppressant I None
drug I None
- I None
associated I None
PPH I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
A I None
mutation I None
causing I None
premature I None
truncation I None
of I None
the I None
protein I None
product I None
was I None
found I None
in I None
one I None
patient I None
. I None
<eof> I None

<s> O None
The I None
mutation I None
was I None
not I None
found I None
in I None
80 I None
control I None
subjects I None
and I None
no I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
2B O GENE-Y
) O GENE-Y
mutation I None
was I None
found I None
in I None
18 I None
PPH I None
patients I None
not I None
associated I None
with I None
appetite I None
- I None
suppressants I None
. I None
<eof> I None

<s> O None
Functional I None
analysis I None
of I None
the I None
transfected I None
receptor I None
expressed I None
either I None
transiently I None
in I None
COS I None
cells I None
or I None
stably I None
in I None
CHO I CHEMICAL
cells I None
demonstrated I None
that I None
the I None
mutated I None
receptor I None
fails I None
to I None
activate I None
the I None
second I None
messenger I None
inositol I CHEMICAL
- O CHEMICAL
phosphates O CHEMICAL
cascade I None
and I None
subsequent I None
intracellular I None
calcium I CHEMICAL
release I None
, I None
in I None
spite I None
of I None
normal I None
expression I None
at I None
the I None
cell I None
membrane I None
. I None
<eof> I None

<s> O None
The I None
mutated I None
receptor I None
had I None
no I None
constitutive I None
activity I None
, I None
and I None
produced I None
no I None
dominant I None
negative I None
effect I None
on I None
the I None
wild I None
- I None
type I None
receptor I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
Loss I None
of I None
serotonin I CHEMICAL
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
2B O GENE-Y
) O GENE-Y
receptor O GENE-Y
function I None
may I None
predispose I None
to I None
fenfluramine I CHEMICAL
- I None
associated I None
PPH I None
in I None
man I None
. I None
<eof> I None

<s> O None
The I None
antileukemia I None
drug I None
2 I CHEMICAL
- O CHEMICAL
chloro O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
deoxyadenosine O CHEMICAL
: I None
an I None
intrinsic I None
transcriptional I None
antagonist I None
. I None
<eof> I None

<s> O None
The I None
nucleoside I None
analog I None
2 I CHEMICAL
- O CHEMICAL
chloro O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
deoxyadenosine O CHEMICAL
( I None
CldAdo I CHEMICAL
; I None
cladribine I CHEMICAL
) I None
is I None
effective I None
in I None
the I None
treatment I None
of I None
hairy I None
cell I None
leukemia I None
and I None
chronic I None
lymphocytic I None
leukemia I None
. I None
<eof> I None

<s> O None
CldAdo I CHEMICAL
is I None
phosphorylated I None
and I None
incorporated I None
into I None
cellular I None
DNA I None
but I None
is I None
not I None
an I None
absolute I None
chain I None
terminator I None
. I None
<eof> I None

<s> O None
We I None
demonstrated I None
by I None
in I None
vitro I None
gel I None
- I None
shift I None
assays I None
that I None
binding I None
interactions I None
of I None
the I None
human I GENE-Y
TATA O GENE-Y
box O GENE-Y
- O GENE-Y
binding O GENE-Y
protein O GENE-Y
( I None
TBP I GENE-Y
) I None
were I None
disrupted I None
on I None
2 I CHEMICAL
- O CHEMICAL
chlorodeoxyadenosine O CHEMICAL
monophosphate O CHEMICAL
( I None
CldAMP I CHEMICAL
) I None
- I None
substituted I None
TATA I GENE-N
box O GENE-N
consensus O GENE-N
sequences O GENE-N
. I None
<eof> I None

<s> O None
We I None
hypothesized I None
that I None
human I GENE-N
RNA O GENE-N
polymerase O GENE-N
II O GENE-N
( I None
pol I GENE-N
II O GENE-N
) I None
transcriptional I None
processes I None
would I None
therefore I None
be I None
affected I None
by I None
2 I CHEMICAL
- O CHEMICAL
chlorodeoxyadenosine O CHEMICAL
triphosphate O CHEMICAL
( I None
CldATP I CHEMICAL
) I None
incorporation I None
into I None
a I None
promoter I None
TATA I GENE-N
element O GENE-N
. I None
<eof> I None

<s> O None
Double I None
- I None
stranded I None
DNA I None
templates I None
containing I None
the I None
adenovirus I None
major I None
late I None
promoter I None
and I None
coding I None
sequences I None
were I None
enzymatically I None
synthesized I None
as I None
control I None
or I None
with I None
site I None
- I None
specific I None
CldAMP I CHEMICAL
residues I None
, I None
incubated I None
with I None
HeLa I None
extract I None
, I None
and I None
the I None
synthesis I None
of I None
radiolabeled I None
44 I None
- I None
base I None
transcripts I None
was I None
assessed I None
. I None
<eof> I None

<s> O None
With I None
increasing I None
amounts I None
of I None
HeLa I None
extract I None
, I None
CldAMP I CHEMICAL
substitution I None
for I None
dAMP I CHEMICAL
within I None
the I None
TATA I GENE-N
box O GENE-N
decreased I None
in I None
vitro I None
pol I GENE-N
II O GENE-N
transcription I None
by I None
approximately I None
35 I None
% I None
compared I None
with I None
control I None
substrates I None
. I None
<eof> I None

<s> O None
Time I None
- I None
course I None
studies I None
showed I None
that I None
transcript I None
production I None
increased I None
in I None
a I None
linear I None
fashion I None
on I None
control I None
substrates I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
transcription I None
on I None
CldAMP I CHEMICAL
- I None
substituted I None
TATA I GENE-N
sequences O GENE-N
reached I None
a I None
plateau I None
after I None
20 I None
min I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
CldAMP I CHEMICAL
- I None
substituted I None
promoter I None
sequences I None
trapped I None
or I None
sequestered I None
TBP I None
, I None
preventing I None
its I None
dissociation I None
from I None
DNA I None
and I None
subsequent I None
binding I None
to I None
additional I None
TATA I GENE-N
elements O GENE-N
to I None
reinitiate I None
transcription I None
. I None
<eof> I None

<s> O None
CldAdo I CHEMICAL
thus I None
represents I None
the I None
first I None
example I None
of I None
a I None
nucleoside I None
analog I None
that I None
acts I None
as I None
a I None
transcriptional I None
antagonist I None
. I None
<eof> I None

<s> O None
CldATP I CHEMICAL
incorporation I None
into I None
gene I None
regulatory I None
sequences I None
may I None
provide I None
a I None
novel I None
strategy I None
to I None
modulate I None
specific I None
protein I None
/ I None
DNA I None
interactions I None
. I None
<eof> I None

<s> O None
Blockade I None
of I None
beta I GENE-Y
1 O GENE-Y
- I None
and I None
desensitization I None
of I None
beta I GENE-Y
2 O GENE-Y
- O GENE-Y
adrenoceptors O GENE-Y
reduce I None
isoprenaline I CHEMICAL
- I None
induced I None
cardiac I None
fibrosis I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
present I None
study I None
was I None
to I None
analyse I None
the I None
role I None
of I None
beta I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
and O GENE-N
beta O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptors O GENE-N
in I None
the I None
catecholamine I CHEMICAL
- I None
induced I None
myocardial I None
remodeling I None
, I None
especially I None
the I None
interstitial I None
fibrosis I None
. I None
<eof> I None

<s> O None
Wistar I None
rats I None
were I None
subjected I None
to I None
a I None
2 I None
- I None
week I None
chronic I None
isoprenaline I CHEMICAL
administration I None
( I None
30 I None
microg I None
/ I None
kg I None
/ I None
h I None
) I None
. I None
<eof> I None

<s> O None
Rats I None
received I None
a I None
concomitant I None
treatment I None
with I None
the I None
selective I None
beta I GENE-Y
( O GENE-Y
1 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
antagonist I None
, I None
bisoprolol I CHEMICAL
( I None
50 I None
mg I None
/ I None
kg I None
/ I None
day I None
p I None
. I None
o I None
. I None
) I None
or I None
were I None
chronically I None
pretreated I None
with I None
the I None
selective I None
beta I GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
agonist I None
salbutamol I CHEMICAL
( I None
40 I None
microg I None
/ I None
kg I None
/ I None
h I None
) I None
for I None
1 I None
week I None
to I None
induce I None
beta I GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
desensitization I None
. I None
<eof> I None

<s> O None
The I None
pretreatment I None
with I None
salbutamol I CHEMICAL
induced I None
a I None
59 I None
% I None
down I None
- I None
regulation I None
of I None
left I None
ventricular I None
beta I GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptors O GENE-Y
compared I None
to I None
control I None
. I None
<eof> I None

<s> O None
The I None
extent I None
of I None
the I None
isoprenaline I CHEMICAL
- I None
induced I None
left I None
ventricular I None
fibrosis I None
was I None
significantly I None
reduced I None
in I None
both I None
the I None
bisoprolol I CHEMICAL
and I None
salbutamol I CHEMICAL
groups I None
compared I None
with I None
the I None
control I None
isoprenaline I CHEMICAL
- I None
treated I None
group I None
especially I None
in I None
the I None
apical I None
region I None
( I None
1 I None
. I None
7 I None
+ I None
/ I None
- I None
0 I None
. I None
6 I None
% I None
and I None
1 I None
. I None
4 I None
+ I None
/ I None
- I None
0 I None
. I None
3 I None
% I None
versus I None
6 I None
. I None
0 I None
+ I None
/ I None
- I None
1 I None
. I None
3 I None
% I None
, I None
respectively I None
, I None
P I None
< I None
0 I None
. I None
005 I None
) I None
. I None
<eof> I None

<s> O None
beta I GENE-Y
( O GENE-Y
1 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
blockade I None
and I None
beta I GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptors O GENE-Y
down I None
- I None
regulation I None
provided I None
similar I None
protection I None
against I None
isoprenaline I CHEMICAL
- I None
induced I None
cardiac I None
interstitial I None
fibrosis I None
suggesting I None
that I None
both I None
beta I GENE-N
- O GENE-N
adrenoceptors O GENE-N
are I None
involved I None
in I None
such I None
cardiac I None
remodeling I None
process I None
. I None
<eof> I None

<s> O None
Characterization I None
of I None
the I None
mouse I GENE-N
cold O GENE-N
- O GENE-N
menthol O GENE-N
receptor O GENE-N
TRPM8 I GENE-Y
and I None
vanilloid I GENE-Y
receptor O GENE-Y
type O GENE-Y
- O GENE-Y
1 O GENE-Y
VR1 I GENE-Y
using I None
a I None
fluorometric I None
imaging I None
plate I None
reader I None
( I None
FLIPR I None
) I None
assay I None
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
TRPM8 I GENE-Y
( I None
CMR1 I GENE-Y
) I None
is I None
a I None
Ca I GENE-N
( O GENE-N
2 O GENE-N
+ O GENE-N
) O GENE-N
- O GENE-N
permeable O GENE-N
channel O GENE-N
, I None
which I None
can I None
be I None
activated I None
by I None
low I None
temperatures I None
, I None
menthol I CHEMICAL
, I None
eucalyptol I CHEMICAL
and I None
icilin I CHEMICAL
. I None
<eof> I None

<s> O None
It I None
belongs I None
to I None
the I None
transient I GENE-N
receptor O GENE-N
potential O GENE-N
( O GENE-N
TRP O GENE-N
) O GENE-N
family O GENE-N
, I None
and I None
therefore I None
is I None
related I None
to I None
vanilloid I GENE-Y
receptor O GENE-Y
type O GENE-Y
- O GENE-Y
1 O GENE-Y
( I None
VR1 I GENE-Y
, I None
TRPV1 I GENE-Y
) I None
. I None
<eof> I None

<s> O None
We I None
tested I None
whether I None
substances I None
which I None
are I None
structurally I None
related I None
to I None
menthol I CHEMICAL
, I None
or I None
which I None
produce I None
a I None
cooling I None
sensation I None
, I None
could I None
activate I None
TRPM8 I GENE-Y
, I None
and I None
compared I None
the I None
responses I None
of I None
TRPM8 I GENE-Y
and I None
VR1 I GENE-Y
to I None
these I None
ligands I None
. I None
<eof> I None

<s> O None
2 I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
70 I None
odorants I None
and I None
menthol I CHEMICAL
- I None
related I None
substances I None
on I None
recombinant I None
mouse I GENE-Y
TRPM8 O GENE-Y
( I None
mTRPM8 I GENE-Y
) I None
, I None
expressed I None
in I None
HEK293 I None
cells I None
, I None
were I None
examined I None
using I None
a I None
FLIPR I None
assay I None
. I None
<eof> I None

<s> O None
In I None
all I None
, I None
10 I None
substances I None
( I None
linalool I CHEMICAL
, I None
geraniol I CHEMICAL
, I None
hydroxycitronellal I CHEMICAL
, I None
WS I CHEMICAL
- O CHEMICAL
3 O CHEMICAL
, I None
WS I CHEMICAL
- O CHEMICAL
23 O CHEMICAL
, I None
FrescolatMGA I CHEMICAL
, I None
FrescolatML I CHEMICAL
, I None
PMD38 I CHEMICAL
, I None
CoolactP I CHEMICAL
and I None
Cooling I CHEMICAL
Agent O CHEMICAL
10 O CHEMICAL
) I None
were I None
found I None
to I None
be I None
agonists I None
. I None
<eof> I None

<s> O None
3 I None
. I None
<eof> I None

<s> O None
The I None
EC I None
( I None
50 I None
) I None
values I None
of I None
the I None
agonists I None
defined I None
their I None
relative I None
potencies I None
: I None
icilin I CHEMICAL
( I None
0 I None
. I None
2 I None
+ I None
/ I None
- I None
0 I None
. I None
1 I None
microM I None
) I None
> I None
FrescolatML I CHEMICAL
( I None
3 I None
. I None
3 I None
+ I None
/ I None
- I None
1 I None
. I None
5 I None
microM I None
) I None
> I None
WS I CHEMICAL
- O CHEMICAL
3 O CHEMICAL
( I None
3 I None
. I None
7 I None
+ I None
/ I None
- I None
1 I None
. I None
7 I None
microM I None
) I None
> I None
( I CHEMICAL
- O CHEMICAL
) O CHEMICAL
menthol O CHEMICAL
( I None
4 I None
. I None
1 I None
+ I None
/ I None
- I None
1 I None
. I None
3 I None
microM I None
) I None
> I None
frescolatMAG I CHEMICAL
( I None
4 I None
. I None
8 I None
+ I None
/ I None
- I None
1 I None
. I None
1 I None
microM I None
) I None
> I None
cooling I CHEMICAL
agent O CHEMICAL
10 O CHEMICAL
( I None
6 I None
+ I None
/ I None
- I None
2 I None
. I None
2 I None
microM I None
) I None
> I None
( I CHEMICAL
+ O CHEMICAL
) O CHEMICAL
menthol O CHEMICAL
( I None
14 I None
. I None
4 I None
+ I None
/ I None
- I None
1 I None
. I None
3 I None
microM I None
) I None
> I None
PMD38 I CHEMICAL
( I None
31 I None
+ I None
/ I None
- I None
1 I None
. I None
1 I None
microM I None
) I None
> I None
WS I CHEMICAL
- O CHEMICAL
23 O CHEMICAL
( I None
44 I None
+ I None
/ I None
- I None
7 I None
. I None
3 I None
microM I None
) I None
> I None
Coolact I CHEMICAL
P O CHEMICAL
( I None
66 I None
+ I None
/ I None
- I None
20 I None
microM I None
) I None
> I None
geraniol I CHEMICAL
( I None
5 I None
. I None
9 I None
+ I None
/ I None
- I None
1 I None
. I None
6 I None
mM I None
) I None
> I None
linalool I CHEMICAL
( I None
6 I None
. I None
7 I None
+ I None
/ I None
- I None
2 I None
. I None
0 I None
mM I None
) I None
> I None
eucalyptol I CHEMICAL
( I None
7 I None
. I None
7 I None
+ I None
/ I None
- I None
2 I None
. I None
0 I None
mM I None
) I None
> I None
hydroxycitronellal I CHEMICAL
( I None
19 I None
. I None
6 I None
+ I None
/ I None
- I None
2 I None
. I None
2 I None
mM I None
) I None
. I None
<eof> I None

<s> O None
4 I None
. I None
<eof> I None

<s> O None
Known I None
VR1 I GENE-Y
antagonists I None
( I None
BCTC I CHEMICAL
, I None
thio I CHEMICAL
- O CHEMICAL
BCTC O CHEMICAL
and I None
capsazepine I CHEMICAL
) I None
were I None
also I None
able I None
to I None
block I None
the I None
response I None
of I None
TRPM8 I GENE-Y
to I None
menthol I CHEMICAL
( I None
IC I None
( I None
50 I None
) I None
: I None
0 I None
. I None
8 I None
+ I None
/ I None
- I None
1 I None
. I None
0 I None
, I None
3 I None
. I None
5 I None
+ I None
/ I None
- I None
1 I None
. I None
1 I None
and I None
18 I None
+ I None
/ I None
- I None
1 I None
. I None
1 I None
microM I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
5 I None
. I None
<eof> I None

<s> O None
The I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
response I None
of I None
hVR1 I GENE-Y
- I None
transfected I None
HEK293 I None
cells I None
to I None
the I None
endogenous I None
VR1 I GENE-Y
agonist I None
N I CHEMICAL
- O CHEMICAL
arachidonoyl O CHEMICAL
- O CHEMICAL
dopamine O CHEMICAL
was I None
potentiated I None
by I None
low I None
pH I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
menthol I CHEMICAL
- I None
and I None
icilin I CHEMICAL
- I None
activated I None
TRPM8 I GENE-Y
currents I None
were I None
suppressed I None
by I None
low I None
pH I None
. I None
<eof> I None

<s> O None
6 I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
in I None
the I None
present I None
study I None
, I None
we I None
identified I None
10 I None
new I None
agonists I None
and I None
three I None
antagonists I None
of I None
TRPM8 I GENE-Y
. I None
<eof> I None

<s> O None
We I None
found I None
that I None
, I None
in I None
contrast I None
to I None
VR1 I GENE-Y
, I None
TRPM8 I GENE-Y
is I None
inhibited I None
rather I None
than I None
potentiated I None
by I None
protons I None
. I None
<eof> I None

<s> O None
Inhibitory I None
effects I None
of I None
the I None
monoamine I GENE-N
oxidase O GENE-N
inhibitor I None
tranylcypromine I CHEMICAL
on I None
the I None
cytochrome I GENE-N
P450 O GENE-N
enzymes I None
CYP2C19 I GENE-Y
, I None
CYP2C9 I GENE-Y
, I None
and I None
CYP2D6 I GENE-Y
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
The I None
inhibitory I None
effects I None
of I None
tranylcypromine I CHEMICAL
, I None
a I None
nonselective I None
irreversible I None
inhibitor I None
of I None
monoamine I GENE-N
oxidase O GENE-N
( I None
MAO I GENE-N
) I None
, I None
on I None
three I None
cytochrome I GENE-N
P450 O GENE-N
( I None
CYP I GENE-N
) I None
enzymes I None
, I None
namely I None
CYP2C9 I GENE-Y
, I None
CYP2C19 I GENE-Y
, I None
and I None
CYP2D6 I GENE-Y
, I None
have I None
been I None
evaluated I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
2 I None
. I None
<eof> I None

<s> O None
The I None
studies I None
were I None
conducted I None
using I None
cDNA I None
- I None
expressed I None
human I GENE-N
CYP O GENE-N
enzymes I None
and I None
probe I None
substrates I None
. I None
<eof> I None

<s> O None
3 I None
. I None
<eof> I None

<s> O None
A I None
range I None
of I None
substrate I None
concentrations I None
was I None
coincubated I None
with I None
a I None
range I None
of I None
tranylcypromine I CHEMICAL
concentrations I None
in I None
the I None
presence I None
of I None
each I None
of I None
the I None
CYP I GENE-N
enzymes I None
at I None
37 I None
degrees I None
C I None
for I None
a I None
predetermined I None
period I None
of I None
time I None
. I None
<eof> I None

<s> O None
Product I None
concentrations I None
were I None
quantified I None
by I None
HPLC I None
with I None
UV I None
detection I None
. I None
<eof> I None

<s> O None
4 I None
. I None
<eof> I None

<s> O None
The I None
results I None
demonstrated I None
that I None
tranylcypromine I CHEMICAL
is I None
a I None
competitive I None
inhibitor I None
of I None
CYP2C19 I GENE-Y
( I None
Ki I None
= I None
32 I None
microM I None
) I None
and I None
CYP2D6 I GENE-Y
( I None
Ki I None
= I None
367 I None
microM I None
) I None
and I None
a I None
noncompetitive I None
inhibitor I None
of I None
CYP2C9 I GENE-Y
( I None
Ki I None
= I None
56 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
5 I None
. I None
<eof> I None

<s> O None
None I None
of I None
these I None
inhibitory I None
effects I None
are I None
considered I None
clinically I None
significant I None
at I None
usual I None
therapeutic I None
doses I None
. I None
<eof> I None

<s> O None
However I None
, I None
in I None
certain I None
situations I None
such I None
as I None
high I None
dose I None
tranylcypromine I CHEMICAL
therapy I None
, I None
or I None
in I None
poor I None
metabolizers I None
of I None
CYP2C19 I GENE-Y
substrates I None
, I None
clinically I None
significant I None
interactions I None
might I None
occur I None
, I None
particularly I None
when I None
tranylcypromine I CHEMICAL
is I None
coadministered I None
with I None
drugs I None
with I None
a I None
narrow I None
therapeutic I None
index I None
. I None
<eof> I None

<s> O None
Organization I None
and I None
expression I None
of I None
the I None
SLC36 I GENE-N
cluster O GENE-N
of O GENE-N
amino O GENE-N
acid O GENE-N
transporter O GENE-N
genes I None
. I None
<eof> I None

<s> O None
Three I None
closely I None
related I None
genes I None
encoding I None
amino I CHEMICAL
acid O CHEMICAL
transport I None
proteins I None
are I None
clustered I None
on I None
5q32 I None
in I None
humans I None
, I None
and I None
Chromosome I None
( I None
Chr I None
) I None
11 I None
in I None
mice I None
. I None
<eof> I None

<s> O None
The I None
human I GENE-Y
SLC36A1 O GENE-Y
gene I None
, I None
which I None
encodes I None
the I None
lysosomal I GENE-Y
amino O GENE-Y
acid O GENE-Y
transporter O GENE-Y
LYAAT1 O GENE-Y
/ I None
PAT1 I GENE-Y
, I None
generates I None
multiple I None
alternative I None
mRNAs I None
, I None
some I None
of I None
which I None
encode I None
truncated I None
proteins I None
. I None
<eof> I None

<s> O None
SLC36A1 I GENE-Y
is I None
expressed I None
in I None
numerous I None
tissues I None
, I None
whereas I None
expression I None
of I None
SLC36A2 I GENE-Y
, I None
which I None
encodes I None
the I None
glycine I GENE-N
transporter O GENE-N
tramdorinl I GENE-Y
/ I None
PAT2 I GENE-Y
, I None
is I None
most I None
abundant I None
in I None
kidney I None
and I None
muscle I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
a I None
third I None
gene I None
, I None
SLC36A3 I GENE-Y
, I None
is I None
restricted I None
to I None
testis I None
. I None
<eof> I None

<s> O None
Mouse I GENE-Y
Slc36a2 O GENE-Y
also I None
is I None
expressed I None
in I None
bone I None
and I None
fat I None
tissue I None
. I None
<eof> I None

<s> O None
Polymorphisms I None
in I None
human I GENE-Y
SLC36A2 O GENE-Y
exclude I None
it I None
as I None
a I None
candidate I None
locus I None
for I None
a I None
peripheral I None
neuropathy I None
that I None
has I None
been I None
mapped I None
to I None
5q31 I None
- I None
33 I None
. I None
<eof> I None

<s> O None
SLC36A2 I GENE-Y
is I None
a I None
candidate I None
gene I None
for I None
5q I None
- I None
myelodysplastic I None
syndrome I None
, I None
on I None
the I None
basis I None
of I None
its I None
chromosomal I None
location I None
and I None
its I None
expression I None
in I None
bone I None
. I None
<eof> I None

<s> O None
ATR I GENE-Y
regulates I None
a I None
G2 I None
- I None
phase I None
cell I None
- I None
cycle I None
checkpoint I None
in I None
Arabidopsis I None
thaliana I None
. I None
<eof> I None

<s> O None
Ataxia I GENE-Y
telangiectasia O GENE-Y
- O GENE-Y
mutated O GENE-Y
and O GENE-Y
Rad3 O GENE-Y
- O GENE-Y
related O GENE-Y
( I None
ATR I GENE-Y
) I None
plays I None
a I None
central I None
role I None
in I None
cell I None
- I None
cycle I None
regulation I None
, I None
transmitting I None
DNA I None
damage I None
signals I None
to I None
downstream I None
effectors I None
of I None
cell I None
- I None
cycle I None
progression I None
. I None
<eof> I None

<s> O None
In I None
animals I None
, I None
ATR I GENE-Y
is I None
an I None
essential I None
gene I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
find I None
that I None
Arabidopsis I None
( I None
Arabidopsis I None
thaliana I None
) I None
atr I GENE-Y
- I None
/ I None
- I None
mutants I None
were I None
viable I None
, I None
fertile I None
, I None
and I None
phenotypically I None
wild I None
- I None
type I None
in I None
the I None
absence I None
of I None
exogenous I None
DNA I None
damaging I None
agents I None
but I None
exhibit I None
altered I None
expression I None
of I None
AtRNR1 I GENE-Y
( I None
ribonucleotide I GENE-Y
reductase O GENE-Y
large O GENE-Y
subunit O GENE-Y
) I None
and I None
alteration I None
of I None
some I None
damage I None
- I None
induced I None
cell I None
- I None
cycle I None
checkpoints I None
. I None
atr I GENE-Y
mutants I None
were I None
hypersensitive I None
to I None
hydroxyurea I CHEMICAL
( I None
HU I CHEMICAL
) I None
, I None
aphidicolin I CHEMICAL
, I None
and I None
UV I None
- I None
B I None
light I None
but I None
only I None
mildly I None
sensitive I None
to I None
gamma I None
- I None
radiation I None
. I None
<eof> I None

<s> O None
G2 I None
arrest I None
was I None
observed I None
in I None
response I None
to I None
gamma I None
- I None
irradiation I None
in I None
both I None
wild I None
- I None
type I None
and I None
atr I GENE-Y
plants I None
, I None
albeit I None
with I None
slightly I None
different I None
kinetics I None
, I None
suggesting I None
that I None
ATR I GENE-Y
plays I None
a I None
secondary I None
role I None
in I None
response I None
to I None
double I None
- I None
strand I None
breaks I None
. I None
<eof> I None

<s> O None
G2 I None
arrest I None
also I None
was I None
observed I None
in I None
wild I None
- I None
type I None
plants I None
in I None
response I None
to I None
aphidicolin I CHEMICAL
but I None
was I None
defective I None
in I None
atr I GENE-Y
mutants I None
, I None
resulting I None
in I None
compaction I None
of I None
nuclei I None
and I None
subsequent I None
cell I None
death I None
. I None
<eof> I None

<s> O None
By I None
contrast I None
, I None
HU I None
- I None
treated I None
wild I None
- I None
type I None
and I None
atr I GENE-Y
plants I None
arrested I None
in I None
G1 I None
and I None
showed I None
no I None
obvious I None
signs I None
of I None
cell I None
death I None
. I None
<eof> I None

<s> O None
We I None
propose I None
that I None
, I None
in I None
plants I None
, I None
HU I None
invokes I None
a I None
novel I None
checkpoint I None
responsive I None
to I None
low I None
levels I None
of I None
deoxynucleotide I CHEMICAL
triphosphates O CHEMICAL
. I None
<eof> I None

<s> O None
These I None
results I None
demonstrate I None
the I None
important I None
role I None
of I None
cell I None
- I None
cycle I None
checkpoints I None
in I None
the I None
ability I None
of I None
plant I None
cells I None
to I None
sense I None
and I None
cope I None
with I None
problems I None
associated I None
with I None
DNA I None
replication I None
. I None
<eof> I None

<s> O None
Selective I None
activation I None
of I None
thyroid I CHEMICAL
hormone O CHEMICAL
signaling I None
pathways I None
by I None
GC I None
- I None
1 I None
: I None
a I None
new I None
approach I None
to I None
controlling I None
cholesterol I CHEMICAL
and I None
body I None
weight I None
. I None
<eof> I None

<s> O None
The I None
current I None
report I None
describes I None
progress I None
in I None
development I None
of I None
a I None
selective I None
thyroid I GENE-N
hormone O GENE-N
receptor O GENE-N
modulator I None
, I None
GC I None
- I None
1 I None
. I None
<eof> I None

<s> O None
This I None
compound I None
binds I None
selectively I None
to I None
the I None
beta I GENE-Y
- O GENE-Y
isoform O GENE-Y
of O GENE-Y
the O GENE-Y
thyroid O GENE-Y
hormone O GENE-Y
receptor O GENE-Y
, I None
and I None
its I None
uptake I None
into I None
the I None
heart I None
is I None
relatively I None
low I None
. I None
<eof> I None

<s> O None
Studies I None
in I None
rats I None
, I None
mice I None
and I None
monkeys I None
show I None
that I None
GC I None
- I None
1 I None
lowers I None
cholesterol I CHEMICAL
with I None
600 I None
- I None
to I None
1400 I None
- I None
fold I None
more I None
potency I None
and I None
approximately I None
two I None
- I None
to I None
threefold I None
more I None
efficacy I None
than I None
atorvastatin I CHEMICAL
, I None
a I None
compound I None
that I None
blocks I None
HMG I GENE-Y
- O GENE-Y
CoA O GENE-Y
reductase O GENE-Y
. I None
<eof> I None

<s> O None
GC I None
- I None
1 I None
also I None
decreases I None
plasma I None
levels I None
of I None
triglyceride I CHEMICAL
and I None
lipoprotein I GENE-N
( O GENE-N
a O GENE-N
) O GENE-N
, I None
and I None
induces I None
loss I None
of I None
fat I None
. I None
<eof> I None

<s> O None
These I None
effects I None
can I None
be I None
observed I None
under I None
conditions I None
where I None
there I None
is I None
either I None
no I None
or I None
minimal I None
effect I None
on I None
heart I None
rate I None
, I None
and I None
no I None
detectable I None
loss I None
of I None
muscle I None
. I None
<eof> I None

<s> O None
Although I None
more I None
study I None
is I None
required I None
, I None
compounds I None
of I None
this I None
class I None
deserve I None
further I None
investigation I None
for I None
treating I None
lipid I None
disorders I None
and I None
obesity I None
. I None
<eof> I None

<s> O None
Flt3 I GENE-Y
receptor O GENE-Y
tyrosine O GENE-Y
kinase O GENE-Y
as I None
a I None
drug I None
target I None
in I None
leukemia I None
. I None
<eof> I None

<s> O None
The I None
hematopoietic I GENE-N
class O GENE-N
III O GENE-N
receptor O GENE-N
tyrosine O GENE-N
kinase O GENE-N
( O GENE-N
RTK O GENE-N
) O GENE-N
Flt3 O GENE-N
( I None
Flk2 I GENE-Y
, I None
STK1 I GENE-Y
) I None
has I None
recently I None
received I None
much I None
attention I None
as I None
a I None
potential I None
drug I None
target I None
. I None
<eof> I None

<s> O None
Activation I None
of I None
Flt3 I GENE-Y
by I None
different I None
types I None
of I None
mutations I None
plays I None
an I None
important I None
role I None
for I None
proliferation I None
, I None
resistance I None
to I None
apoptosis I None
, I None
and I None
prevention I None
of I None
differentiation I None
of I None
leukemic I None
blasts I None
in I None
acute I None
myeloid I None
leukemia I None
( I None
AML I None
) I None
. I None
<eof> I None

<s> O None
At I None
least I None
one I None
type I None
of I None
such I None
mutations I None
- I None
an I None
internal I None
tandem I None
duplication I None
in I None
the I None
Flt3 I GENE-N
juxtamembrane O GENE-N
domain O GENE-N
( I None
Flt3 I GENE-N
- O GENE-N
ITD O GENE-N
) I None
- I None
has I None
been I None
associated I None
with I None
an I None
unfavorable I None
prognosis I None
. I None
<eof> I None

<s> O None
Signal I None
transduction I None
of I None
Flt3 I GENE-Y
involves I None
activation I None
of I None
several I None
conserved I None
pathways I None
, I None
including I None
the I None
RAS I GENE-N
/ I None
MAP I GENE-N
- O GENE-N
Kinase O GENE-N
and I None
the I None
phosphoinositide I GENE-N
- O GENE-N
3 O GENE-N
- O GENE-N
kinase O GENE-N
/ I None
Akt I GENE-N
signaling I None
cascades I None
. I None
<eof> I None

<s> O None
Transforming I None
versions I None
of I None
Flt3 I GENE-Y
exhibit I None
altered I None
signaling I None
, I None
for I None
example I None
a I None
very I None
pronounced I None
activation I None
of I None
STAT5 I GENE-Y
, I None
ultimately I None
resulting I None
in I None
alternate I None
profiles I None
of I None
gene I None
expression I None
and I None
cell I None
transformation I None
. I None
<eof> I None

<s> O None
Selective I None
inhibitors I None
of I None
Flt3 I GENE-Y
tyrosine I GENE-N
kinase O GENE-N
activity I None
have I None
the I None
potential I None
to I None
suppress I None
aberrant I None
Flt3 I GENE-Y
signaling I None
. I None
<eof> I None

<s> O None
Although I None
highly I None
homologous I None
to I None
other I None
class I GENE-N
III O GENE-N
RTKs O GENE-N
, I None
Flt3 I GENE-Y
is I None
resistant I None
to I None
the I None
phenylaminopyrimidine I CHEMICAL
STI571 I CHEMICAL
( I None
Gleevec I CHEMICAL
, I None
Imatinib I CHEMICAL
) I None
, I None
a I None
potent I None
inhibitor I None
of I None
other I None
RTKs I GENE-N
in I None
the I None
family I None
, I None
such I None
as I None
the I None
PDGFbeta I GENE-Y
- O GENE-Y
receptor O GENE-Y
or I None
c I GENE-Y
- O GENE-Y
Kit O GENE-Y
. I None
<eof> I None

<s> O None
STI571 I CHEMICAL
binding I None
to I None
Flt3 I GENE-Y
is I None
prevented I None
by I None
the I None
phenylalanine I CHEMICAL
691 I None
side I None
- I None
chain I None
in I None
the I None
ATP I CHEMICAL
binding I None
center I None
and I None
mutating I None
this I None
site I None
to I None
threonine I CHEMICAL
renders I None
the I None
corresponding I None
Flt3 I GENE-Y
mutant I None
sensitive I None
to I None
STI571 I CHEMICAL
. I None
<eof> I None

<s> O None
Compounds I None
of I None
several I None
other I None
structural I None
families I None
, I None
including I None
the I None
quinoxaline I CHEMICAL
AG1296 I CHEMICAL
, I None
the I None
bis I CHEMICAL
( O CHEMICAL
1H O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
indolyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
methanone O CHEMICAL
D I CHEMICAL
- O CHEMICAL
65476 O CHEMICAL
, I None
the I None
indolinones I CHEMICAL
SU5416 I CHEMICAL
and I None
SU11248 I CHEMICAL
, I None
the I None
indolocarbazoles I CHEMICAL
PKC412 I CHEMICAL
and I None
CEP I CHEMICAL
- O CHEMICAL
701 O CHEMICAL
, I None
and I None
the I None
piperazonyl I CHEMICAL
quinazoline O CHEMICAL
CT53518 I CHEMICAL
, I None
are I None
potent I None
inhibitors I None
of I None
Flt3 I GENE-Y
kinase I GENE-N
. I None
<eof> I None

<s> O None
They I None
exhibit I None
different I None
selectivity I None
profiles I None
, I None
both I None
with I None
respect I None
to I None
other I None
kinases I None
and I None
among I None
wildtype I None
Flt3 I GENE-Y
and I None
its I None
activated I None
versions I None
. I None
<eof> I None

<s> O None
These I None
compounds I None
hold I None
promise I None
as I None
novel I None
drugs I None
against I None
AML I None
and I None
as I None
probes I None
for I None
understanding I None
activation I None
mechanisms I None
and I None
signaling I None
pathways I None
in I None
the I None
class I GENE-N
III O GENE-N
RTK O GENE-N
family I None
. I None
<eof> I None

<s> O None
Novel I None
mechanism I None
of I None
action I None
for I None
hydralazine I CHEMICAL
: I None
induction I None
of I None
hypoxia I GENE-Y
- O GENE-Y
inducible O GENE-Y
factor O GENE-Y
- O GENE-Y
1alpha O GENE-Y
, I None
vascular I GENE-Y
endothelial O GENE-Y
growth O GENE-Y
factor O GENE-Y
, I None
and I None
angiogenesis I None
by I None
inhibition I None
of I None
prolyl I GENE-N
hydroxylases O GENE-N
. I None
<eof> I None

<s> O None
The I None
vasodilator I None
hydralazine I CHEMICAL
, I None
used I None
clinically I None
in I None
cardiovascular I None
therapy I None
, I None
relaxes I None
arterial I None
smooth I None
muscle I None
by I None
inhibiting I None
accumulation I None
of I None
intracellular I None
free I None
Ca2 I CHEMICAL
+ O CHEMICAL
via I None
an I None
unidentified I None
primary I None
target I None
. I None
<eof> I None

<s> O None
Collagen I GENE-N
prolyl O GENE-N
hydroxylase O GENE-N
is I None
a I None
known I None
target I None
of I None
hydralazine I CHEMICAL
. I None
<eof> I None

<s> O None
We I None
therefore I None
investigated I None
whether I None
inhibition I None
of I None
other I None
members I None
of I None
this I None
enzyme I None
family I None
, I None
namely I None
the I None
hypoxia I GENE-N
- O GENE-N
inducible O GENE-N
factor O GENE-N
( I None
HIF I GENE-N
) I None
- I None
regulating I None
O2 I CHEMICAL
- I None
dependent I None
prolyl I GENE-N
hydroxylase O GENE-N
domain O GENE-N
( I None
PHD I GENE-N
) I None
enzymes I None
, I None
could I None
represent I None
a I None
novel I None
mechanism I None
of I None
action I None
. I None
<eof> I None

<s> O None
Hydralazine I CHEMICAL
induced I None
rapid I None
and I None
transient I None
expression I None
of I None
HIF I GENE-Y
- O GENE-Y
1alpha O GENE-Y
and I None
downstream I None
targets I None
of I None
HIF I GENE-N
( I None
endothelin I GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
adrenomedullin I GENE-Y
, I None
haem I GENE-Y
oxygenase O GENE-Y
1 O GENE-Y
, I None
and I None
vascular I GENE-Y
endothelial O GENE-Y
growth O GENE-Y
factor O GENE-Y
[ I None
VEGF I GENE-Y
] I None
) I None
in I None
endothelial I None
and I None
smooth I None
muscle I None
cells I None
and I None
induced I None
endothelial I None
cell I None
- I None
specific I None
proliferation I None
. I None
<eof> I None

<s> O None
Hydralazine I CHEMICAL
dose I None
- I None
dependently I None
inhibited I None
PHD I GENE-N
activity I None
and I None
induced I None
nonhydroxylated I None
HIF I GENE-Y
- O GENE-Y
1alpha O GENE-Y
, I None
evidence I None
for I None
HIF I GENE-N
stabilization I None
specifically I None
by I None
inhibition I None
of I None
PHD I GENE-N
enzyme I None
activity I None
. I None
<eof> I None

<s> O None
In I None
vivo I None
, I None
hydralazine I CHEMICAL
induced I None
HIF I GENE-Y
- O GENE-Y
1alpha O GENE-Y
and I None
VEGF I GENE-Y
protein I None
in I None
tissue I None
extracts I None
and I None
elevated I None
plasma I None
VEGF I GENE-Y
levels I None
. I None
<eof> I None

<s> O None
In I None
sponge I None
angiogenesis I None
assays I None
, I None
hydralazine I CHEMICAL
increased I None
stromal I None
cell I None
infiltration I None
and I None
blood I None
vessel I None
density I None
versus I None
control I None
animals I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
hydralazine I CHEMICAL
activates I None
the I None
HIF I GENE-N
pathway I None
through I None
inhibition I None
of I None
PHD I GENE-N
activity I None
and I None
initiates I None
a I None
pro I None
- I None
angiogenic I None
phenotype I None
. I None
<eof> I None

<s> O None
This I None
represents I None
a I None
novel I None
mechanism I None
of I None
action I None
for I None
hydralazine I CHEMICAL
and I None
presents I None
HIF I GENE-N
as I None
a I None
potential I None
target I None
for I None
treatment I None
of I None
ischemic I None
disease I None
. I None
<eof> I None

<s> O None
Determination I None
of I None
expression I None
of I None
cyclooxygenase I GENE-N
- O GENE-N
1 O GENE-N
and O GENE-N
- O GENE-N
2 O GENE-N
isozymes I None
in I None
canine I None
tissues I None
and I None
their I None
differential I None
sensitivity I None
to I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
To I None
evaluate I None
cyclooxygenase I GENE-N
isozyme I None
distribution I None
in I None
tissues I None
from I None
dogs I None
and I None
determine I None
the I None
differential I None
sensitivity I None
of I None
canine I GENE-N
cyclooxygenase O GENE-N
( O GENE-N
COX O GENE-N
) O GENE-N
- O GENE-N
1 O GENE-N
and O GENE-N
- O GENE-N
2 O GENE-N
isozymes I None
to I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
. I None
<eof> I None

<s> O None
SAMPLE I None
POPULATION I None
: I None
Canine I None
tissue I None
samples I None
( I None
stomach I None
, I None
duodenum I None
, I None
ileum I None
, I None
jejunum I None
, I None
colon I None
, I None
spleen I None
, I None
cerebral I None
cortex I None
, I None
lung I None
, I None
ovary I None
, I None
kidney I None
, I None
and I None
liver I None
) I None
were I None
obtained I None
from I None
2 I None
dogs I None
for I None
northern I None
and I None
western I None
blot I None
analyses I None
, I None
and I None
blood I None
for I None
whole I None
blood I None
COX I GENE-N
assays I None
was I None
obtained I None
from I None
15 I None
dogs I None
. I None
<eof> I None

<s> O None
PROCEDURE I None
: I None
11 I None
NSAIDs I None
were I None
evaluated I None
to I None
determine I None
their I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
selectivity I None
in I None
whole I None
blood I None
assays I None
. I None
<eof> I None

<s> O None
The I None
concentrations I None
of I None
the I None
drug I None
needed I None
to I None
inhibit I None
50 I None
% I None
of I None
enzyme I None
activity I None
( I None
IC50 I None
) I None
were I None
then I None
calculated I None
for I None
comparison I None
. I None
<eof> I None

<s> O None
Expression I None
and I None
tissue I None
distribution I None
of I None
COX I GENE-N
isozymes I None
were I None
determined I None
by I None
northern I None
and I None
western I None
blot I None
analysis I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Aspirin I CHEMICAL
, I None
diclofenac I CHEMICAL
, I None
indomethacin I CHEMICAL
, I None
ketoprofen I CHEMICAL
, I None
meclofenamic I CHEMICAL
acid O CHEMICAL
, I None
and I None
piroxicam I CHEMICAL
had I None
little I None
selectivity I None
toward I None
COX I GENE-N
isozymes I None
, I None
whereas I None
NS398 I CHEMICAL
, I None
carprofen I CHEMICAL
, I None
tolfenamic I CHEMICAL
acid O CHEMICAL
, I None
nimesulide I CHEMICAL
, I None
and I None
etodolac I CHEMICAL
had I None
more I None
than I None
5 I None
times I None
greater I None
preference I None
for I None
inhibiting I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
than I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
. I None
<eof> I None

<s> O None
All I None
canine I None
tissues I None
examined I None
, I None
including I None
those I None
from I None
the I None
gastrointestinal I None
tract I None
, I None
coexpressed I None
COX I GENE-N
- O GENE-N
1 O GENE-N
and O GENE-N
- O GENE-N
2 O GENE-N
mRNA I None
, I None
although I None
protein I None
expression I None
was I None
observed I None
only I None
for I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
AND I None
CLINICAL I None
RELEVANCE I None
: I None
Canine I GENE-Y
COX O GENE-Y
- O GENE-Y
2 O GENE-Y
was I None
selectively I None
inhibited I None
by I None
etodolac I CHEMICAL
, I None
nimesulide I CHEMICAL
, I None
and I None
NS398 I CHEMICAL
; I None
tolfenamic I CHEMICAL
acid O CHEMICAL
and I None
carprofen I CHEMICAL
also I None
appeared I None
to I None
be I None
preferential I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
in I None
dogs I None
. I None
<eof> I None

<s> O None
The I None
roles I None
of I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
as I None
a I None
constitutive I None
housekeeping I None
enzyme I None
and I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
as I None
a I None
proinflammatory I None
inducible I None
enzyme I None
( I None
as I None
determined I None
in I None
humans I None
) I None
appear I None
to I None
apply I None
to I None
dogs I None
; I None
therefore I None
, I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
- I None
selective I None
inhibitors I None
should I None
prove I None
useful I None
in I None
reducing I None
the I None
adverse I None
effects I None
associated I None
with I None
nonselective I None
NSAIDs I None
. I None
<eof> I None

<s> O None
Ketoconazole I CHEMICAL
binds I None
to I None
the I None
human I GENE-Y
androgen O GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
Ketoconazole I CHEMICAL
, I None
an I None
imidazole I CHEMICAL
anti I None
- I None
fungal I None
agent I None
, I None
has I None
often I None
produced I None
features I None
of I None
androgen I CHEMICAL
deficiency I None
including I None
decreased I None
libido I None
, I None
gynecomastia I None
, I None
impotence I None
, I None
oligospermia I None
, I None
and I None
decreased I None
testosterone I CHEMICAL
levels I None
, I None
in I None
men I None
being I None
treated I None
for I None
chronic I None
mycotic I None
infections I None
. I None
<eof> I None

<s> O None
Based I None
on I None
these I None
potent I None
effects I None
on I None
gonadal I None
function I None
in I None
vivo I None
as I None
well I None
as I None
previous I None
work I None
in I None
vitro I None
demonstrating I None
affinity I None
of I None
ketoconazole I CHEMICAL
for I None
receptor I None
proteins I None
for I None
glucocorticoids I None
and I None
1 I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
2 O CHEMICAL
vitamin O CHEMICAL
D3 O CHEMICAL
and I None
for I None
sex I GENE-Y
steroid O GENE-Y
binding O GENE-Y
globulin O GENE-Y
( I None
SSBG I GENE-Y
) I None
, I None
the I None
binding I None
of I None
ketoconazole I CHEMICAL
to I None
human I GENE-Y
androgen O GENE-Y
receptors O GENE-Y
( I None
AR I GENE-Y
) I None
in I None
vitro I None
was I None
also I None
examined I None
. I None
<eof> I None

<s> O None
Ketoconazole I CHEMICAL
competition I None
with I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
methyltrienolone O CHEMICAL
( I None
R1881 I CHEMICAL
) I None
for I None
androgen I CHEMICAL
binding I None
sites I None
in I None
dispersed I None
, I None
intact I None
cultured I None
human I None
skin I None
fibroblasts I None
was I None
determined I None
at I None
22 I None
degrees I None
C I None
. I None
<eof> I None

<s> O None
Fifty I None
percent I None
displacement I None
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
R1881 O CHEMICAL
binding I None
to I None
AR I GENE-Y
was I None
achieved I None
by I None
6 I None
. I None
4 I None
+ I None
/ I None
- I None
1 I None
. I None
8 I None
( I None
SE I None
) I None
x I None
10 I None
( I None
- I None
5 I None
) I None
M I None
ketoconazole I CHEMICAL
. I None
<eof> I None

<s> O None
Additional I None
binding I None
studies I None
performed I None
with I None
ketoconazole I CHEMICAL
in I None
the I None
presence I None
of I None
increasing I None
amounts I None
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
R1881 O CHEMICAL
showed I None
that I None
the I None
interaction I None
of I None
ketoconazole I CHEMICAL
with I None
AR I GENE-Y
was I None
competitive I None
when I None
the I None
data I None
were I None
analyzed I None
by I None
the I None
Scatchard I None
method I None
. I None
<eof> I None

<s> O None
It I None
should I None
be I None
noted I None
, I None
however I None
, I None
that I None
the I None
dose I None
of I None
ketoconazole I CHEMICAL
required I None
for I None
50 I None
% I None
occupancy I None
of I None
the I None
androgen I GENE-Y
receptor O GENE-Y
is I None
not I None
likely I None
to I None
be I None
achieved I None
in I None
vivo I None
, I None
at I None
least I None
in I None
plasma I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
androgen I CHEMICAL
binding I None
studies I None
performed I None
with I None
other I None
imidazoles I CHEMICAL
, I None
such I None
as I None
clotrimazole I CHEMICAL
, I None
miconazole I CHEMICAL
, I None
and I None
fluconozole I CHEMICAL
, I None
revealed I None
that I None
in I None
this I None
class I None
of I None
compounds I None
only I None
ketoconazole I CHEMICAL
appears I None
to I None
interact I None
with I None
the I None
androgen I GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
Ketoconazole I CHEMICAL
appears I None
to I None
be I None
the I None
first I None
example I None
of I None
a I None
non I None
- I None
steroidal I CHEMICAL
compound I None
which I None
binds I None
competitively I None
to I None
both I None
SSBG I GENE-Y
and I None
multiple I None
steroid I GENE-N
hormone O GENE-N
receptors O GENE-N
, I None
suggesting I None
that I None
the I None
ligand I None
binding I None
sites I None
of I None
these I None
proteins I None
share I None
some I None
features I None
in I None
common I None
. I None
<eof> I None

<s> O None
P2 I GENE-N
receptor O GENE-N
mRNA I None
expression I None
profiles I None
in I None
human I None
lymphocytes I None
, I None
monocytes I None
and I None
CD34 I None
+ I None
stem I None
and I None
progenitor I None
cells I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Extracellular I None
nucleotides I CHEMICAL
( I None
ATP I CHEMICAL
, I None
ADP I CHEMICAL
, I None
UTP I CHEMICAL
and I None
UDP I CHEMICAL
) I None
exert I None
a I None
wide I None
range I None
of I None
biological I None
effects I None
in I None
blood I None
cells I None
mediated I None
by I None
multiple I None
ionotropic I None
P2X I GENE-N
receptors I None
and I None
G I GENE-N
protein O GENE-N
- O GENE-N
coupled O GENE-N
P2Y O GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
Although I None
pharmacological I None
experiments I None
have I None
suggested I None
the I None
presence I None
of I None
several I None
P2 I GENE-N
receptor O GENE-N
subtypes I None
on I None
monocytes I None
and I None
lymphocytes I None
, I None
some I None
results I None
are I None
contradictory I None
. I None
<eof> I None

<s> O None
Few I None
physiological I None
functions I None
have I None
been I None
firmly I None
established I None
to I None
a I None
specific I None
receptor I None
subtype I None
, I None
partly I None
because I None
of I None
a I None
lack I None
of I None
truly I None
selective I None
agonists I None
and I None
antagonists I None
. I None
<eof> I None

<s> O None
This I None
stimulated I None
us I None
to I None
investigate I None
the I None
expression I None
of I None
P2X I GENE-N
and I None
P2Y I GENE-N
receptors I None
in I None
human I None
lymphocytes I None
and I None
monocytes I None
with I None
a I None
newly I None
established I None
quantitative I None
mRNA I None
assay I None
for I None
P2 I GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
we I None
describe I None
for I None
the I None
first I None
time I None
the I None
expression I None
of I None
P2 I GENE-N
receptors O GENE-N
in I None
CD34 I None
+ I None
stem I None
and I None
progenitor I None
cells I None
implicating I None
a I None
potential I None
role I None
of I None
P2 I GENE-N
receptors O GENE-N
in I None
hematopoietic I None
lineage I None
and I None
progenitor I None
/ I None
stem I None
cell I None
function I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Using I None
a I None
quantitative I None
mRNA I None
assay I None
, I None
we I None
assessed I None
the I None
hypothesis I None
that I None
there I None
are I None
specific I None
P2 I GENE-N
receptor O GENE-N
profiles I None
in I None
inflammatory I None
cells I None
. I None
<eof> I None

<s> O None
The I None
P2X4 I GENE-Y
receptor I None
had I None
the I None
highest I None
expression I None
in I None
lymphocytes I None
and I None
monocytes I None
. I None
<eof> I None

<s> O None
Among I None
the I None
P2Y I GENE-N
receptors I None
, I None
P2Y12 I GENE-Y
and I None
P2Y2 I GENE-Y
had I None
highest I None
expression I None
in I None
lymphocytes I None
, I None
while I None
the I None
P2Y2 I GENE-Y
and I None
P2Y13 I GENE-Y
had I None
highest I None
expression I None
in I None
monocytes I None
. I None
<eof> I None

<s> O None
Several I None
P2 I GENE-N
receptors O GENE-N
were I None
expressed I None
( I None
P2Y2 I GENE-Y
, I None
P2Y1 I GENE-Y
, I None
P2Y12 I GENE-Y
, I None
P2Y13 I GENE-Y
, I None
P2Y11 I GENE-Y
, I None
P2X1 I GENE-Y
, I None
P2X4 I GENE-Y
) I None
in I None
CD34 I None
+ I None
stem I None
and I None
progenitor I None
cells I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
The I None
most I None
interesting I None
findings I None
were I None
the I None
high I None
mRNA I None
expression I None
of I None
P2Y12 I GENE-Y
receptors I None
in I None
lymphocytes I None
potentially I None
explaining I None
the I None
anti I None
- I None
inflammatory I None
effects I None
of I None
clopidogrel I CHEMICAL
, I None
P2Y13 I GENE-Y
receptors I None
in I None
monocytes I None
and I None
a I None
previously I None
unrecognised I None
expression I None
of I None
P2X4 I GENE-Y
in I None
lymphocytes I None
and I None
monocytes I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
for I None
the I None
first I None
time I None
P2 I GENE-N
receptor O GENE-N
mRNA I None
expression I None
patterns I None
was I None
studied I None
in I None
CD34 I None
+ I None
stem I None
and I None
progenitor I None
cells I None
. I None
<eof> I None

<s> O None
Several I None
P2 I GENE-N
receptors O GENE-N
were I None
expressed I None
( I None
P2Y2 I GENE-Y
, I None
P2Y1 I GENE-Y
, I None
P2Y12 I GENE-Y
, I None
P2Y13 I GENE-Y
, I None
P2Y11 I GENE-Y
, I None
P2X1 I GENE-Y
, I None
P2X4 I GENE-Y
) I None
, I None
indicating I None
a I None
role I None
in I None
differentiation I None
and I None
proliferation I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
it I None
is I None
possible I None
that I None
specific I None
antibodies I None
to I None
P2 I GENE-N
receptors O GENE-N
could I None
be I None
used I None
to I None
identify I None
progenitors I None
for I None
monocytes I None
, I None
lymphocytes I None
and I None
megakaryocytes I None
. I None
<eof> I None

<s> O None
Direct I None
multiplex I None
assay I None
of I None
lysosomal I None
enzymes I None
in I None
dried I None
blood I None
spots I None
for I None
newborn I None
screening I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Newborn I None
screening I None
for I None
deficiency I None
in I None
the I None
lysosomal I None
enzymes I None
that I None
cause I None
Fabry I None
, I None
Gaucher I None
, I None
Krabbe I None
, I None
Niemann I None
- I None
Pick I None
A I None
/ I None
B I None
, I None
and I None
Pompe I None
diseases I None
is I None
warranted I None
because I None
treatment I None
for I None
these I None
syndromes I None
is I None
now I None
available I None
or I None
anticipated I None
in I None
the I None
near I None
feature I None
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
multiplex I None
screening I None
method I None
for I None
all I None
five I None
lysosomal I None
enzymes I None
that I None
uses I None
newborn I None
- I None
screening I None
cards I None
containing I None
dried I None
blood I None
spots I None
as I None
the I None
enzyme I None
source I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
We I None
used I None
a I None
cassette I None
of I None
substrates I None
and I None
internal I None
standards I None
to I None
directly I None
quantify I None
the I None
enzymatic I None
activities I None
, I None
and I None
tandem I None
mass I None
spectrometry I None
for I None
enzymatic I None
product I None
detection I None
. I None
<eof> I None

<s> O None
Rehydrated I None
dried I None
blood I None
spots I None
were I None
incubated I None
with I None
the I None
enzyme I None
substrates I None
. I None
<eof> I None

<s> O None
We I None
used I None
liquid I None
- I None
liquid I None
extraction I None
followed I None
by I None
solid I None
- I None
phase I None
extraction I None
with I None
silica I None
gel I None
to I None
remove I None
buffer I None
components I None
. I None
<eof> I None

<s> O None
Acarbose I CHEMICAL
served I None
as I None
inhibitor I None
of I None
an I None
interfering I None
acid I GENE-Y
alpha O GENE-Y
- O GENE-Y
glucosidase O GENE-Y
present I None
in I None
neutrophils I None
, I None
which I None
allowed I None
the I None
lysosomal I None
enzyme I None
implicated I None
in I None
Pompe I None
disease I None
to I None
be I None
selectively I None
analyzed I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
We I None
analyzed I None
dried I None
blood I None
spots I None
from I None
5 I None
patients I None
with I None
Gaucher I None
, I None
5 I None
with I None
Niemann I None
- I None
Pick I None
A I None
/ I None
B I None
, I None
11 I None
with I None
Pompe I None
, I None
5 I None
with I None
Fabry I None
, I None
and I None
12 I None
with I None
Krabbe I None
disease I None
, I None
and I None
in I None
all I None
cases I None
the I None
enzyme I None
activities I None
were I None
below I None
the I None
minimum I None
activities I None
measured I None
in I None
a I None
collection I None
of I None
heterozygous I None
carriers I None
and I None
healthy I None
noncarrier I None
individuals I None
. I None
<eof> I None

<s> O None
The I None
enzyme I None
activities I None
measured I None
in I None
5 I None
- I None
9 I None
heterozygous I None
carriers I None
were I None
approximately I None
one I None
- I None
half I None
those I None
measured I None
with I None
15 I None
- I None
32 I None
healthy I None
individuals I None
, I None
but I None
there I None
was I None
partial I None
overlap I None
of I None
each I None
condition I None
between I None
the I None
data I None
sets I None
for I None
carriers I None
and I None
healthy I None
individuals I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
For I None
all I None
five I None
diseases I None
, I None
the I None
affected I None
individuals I None
were I None
detected I None
. I None
<eof> I None

<s> O None
The I None
assay I None
can I None
be I None
readily I None
automated I None
, I None
and I None
the I None
anticipated I None
reagent I None
and I None
supply I None
costs I None
are I None
well I None
within I None
the I None
budget I None
limits I None
of I None
newborn I None
- I None
screening I None
centers I None
. I None
<eof> I None

<s> O None
A I None
disorder I None
to I None
order I None
transition I None
accompanies I None
catalysis I None
in I None
retinaldehyde I GENE-Y
dehydrogenase O GENE-Y
type O GENE-Y
II O GENE-Y
. I None
<eof> I None

<s> O None
Retinaldehyde I GENE-Y
dehydrogenase O GENE-Y
II O GENE-Y
( I None
RalDH2 I GENE-Y
) I None
converts I None
retinal I None
to I None
the I None
transcriptional I None
regulator I None
retinoic I None
acid I None
in I None
the I None
developing I None
embryo I None
. I None
<eof> I None

<s> O None
The I None
x I None
- I None
ray I None
structure I None
of I None
the I None
enzyme I None
revealed I None
an I None
important I None
structural I None
difference I None
between I None
this I None
protein I None
and I None
other I None
aldehyde I GENE-N
dehydrogenases O GENE-N
of I None
the I None
same I None
enzyme I None
superfamily I None
; I None
a I None
20 I None
- I None
amino I CHEMICAL
acid O CHEMICAL
span I None
in I None
the I None
substrate I None
access I None
channel I None
in I None
retinaldehyde I GENE-Y
dehydrogenase O GENE-Y
II O GENE-Y
is I None
disordered I None
, I None
whereas I None
in I None
other I None
aldehyde I GENE-N
dehydrogenases O GENE-N
this I None
region I None
forms I None
a I None
well I None
defined I None
wall I None
of I None
the I None
substrate I None
access I None
channel I None
. I None
<eof> I None

<s> O None
We I None
asked I None
whether I None
this I None
disordered I None
loop I None
might I None
order I None
during I None
the I None
course I None
of I None
catalysis I None
and I None
provide I None
a I None
means I None
for I None
an I None
enzyme I None
that I None
requires I None
a I None
large I None
substrate I None
access I None
channel I None
to I None
restrict I None
access I None
to I None
the I None
catalytic I None
machinery I None
by I None
smaller I None
compounds I None
that I None
might I None
potentially I None
enter I None
the I None
active I None
site I None
and I None
be I None
metabolized I None
. I None
<eof> I None

<s> O None
Our I None
experiments I None
, I None
a I None
combination I None
of I None
kinetic I None
, I None
spectroscopic I None
, I None
and I None
crystallographic I None
techniques I None
, I None
suggest I None
that I None
a I None
disorder I None
to I None
order I None
transition I None
is I None
linked I None
to I None
catalytic I None
activity I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
carvedilol I CHEMICAL
on I None
plasma I GENE-Y
B O GENE-Y
- O GENE-Y
type O GENE-Y
natriuretic O GENE-Y
peptide O GENE-Y
concentration I None
and I None
symptoms I None
in I None
patients I None
with I None
heart I None
failure I None
and I None
preserved I None
ejection I None
fraction I None
. I None
<eof> I None

<s> O None
Although I None
the I None
benefits I None
of I None
carvedilol I CHEMICAL
in I None
patients I None
with I None
heart I None
failure I None
and I None
depressed I None
ejection I None
fraction I None
( I None
EF I None
) I None
have I None
been I None
elucidated I None
, I None
those I None
in I None
patients I None
with I None
preserved I None
EF I None
are I None
not I None
understood I None
. I None
<eof> I None

<s> O None
We I None
enrolled I None
40 I None
patients I None
with I None
mild I None
or I None
moderate I None
heart I None
failure I None
and I None
EF I None
> I None
/ I None
= I None
45 I None
% I None
. I None
<eof> I None

<s> O None
They I None
were I None
randomly I None
assigned I None
to I None
carvedilol I CHEMICAL
( I None
n I None
= I None
19 I None
) I None
or I None
conventional I None
therapy I None
( I None
n I None
= I None
21 I None
) I None
. I None
<eof> I None

<s> O None
After I None
12 I None
months I None
of I None
treatment I None
, I None
carvedilol I CHEMICAL
significantly I None
improved I None
all I None
end I None
points I None
( I None
plasma I None
concentration I None
of I None
B I GENE-Y
- O GENE-Y
type O GENE-Y
natriuretic O GENE-Y
peptide O GENE-Y
[ I None
BNP I GENE-Y
] I None
from I None
175 I None
( I None
35 I None
to I None
209 I None
) I None
to I None
106 I None
( I None
52 I None
to I None
160 I None
) I None
pg I None
/ I None
ml I None
, I None
mean I None
( I None
95 I None
% I None
confidence I None
interval I None
) I None
p I None
< I None
0 I None
. I None
01 I None
; I None
New I None
York I None
Heart I None
Association I None
functional I None
class I None
from I None
2 I None
. I None
37 I None
( I None
2 I None
. I None
13 I None
to I None
2 I None
. I None
61 I None
) I None
to I None
1 I None
. I None
56 I None
( I None
1 I None
. I None
21 I None
to I None
1 I None
. I None
91 I None
) I None
, I None
p I None
< I None
0 I None
. I None
01 I None
; I None
exercise I None
capacity I None
estimated I None
with I None
the I None
Specific I None
Activity I None
Scale I None
from I None
4 I None
. I None
75 I None
( I None
4 I None
. I None
50 I None
to I None
5 I None
. I None
00 I None
) I None
to I None
5 I None
. I None
68 I None
( I None
5 I None
. I None
22 I None
to I None
6 I None
. I None
14 I None
) I None
METs I None
, I None
p I None
< I None
0 I None
. I None
02 I None
) I None
, I None
whereas I None
conventional I None
therapy I None
did I None
not I None
( I None
plasma I GENE-Y
BNP O GENE-Y
concentration I None
from I None
150 I None
( I None
114 I None
to I None
186 I None
) I None
to I None
174 I None
( I None
100 I None
to I None
248 I None
) I None
pg I None
/ I None
ml I None
; I None
New I None
York I None
Heart I None
Association I None
functional I None
class I None
from I None
2 I None
. I None
29 I None
( I None
2 I None
. I None
08 I None
to I None
2 I None
. I None
50 I None
) I None
to I None
2 I None
. I None
11 I None
( I None
1 I None
. I None
73 I None
to I None
2 I None
. I None
49 I None
) I None
; I None
exercise I None
capacity I None
from I None
4 I None
. I None
57 I None
( I None
4 I None
. I None
34 I None
to I None
4 I None
. I None
80 I None
) I None
to I None
4 I None
. I None
72 I None
( I None
4 I None
. I None
41 I None
to I None
5 I None
. I None
03 I None
) I None
METs I None
) I None
. I None
<eof> I None

<s> O None
Univariate I None
regression I None
analyses I None
showed I None
that I None
only I None
the I None
use I None
of I None
carvedilol I CHEMICAL
was I None
correlated I None
with I None
the I None
decrease I None
in I None
plasma I GENE-Y
BNP O GENE-Y
concentration I None
( I None
p I None
< I None
0 I None
. I None
03 I None
) I None
. I None
<eof> I None

<s> O None
Multivariate I None
analyses I None
demonstrated I None
that I None
an I None
ischemic I None
cause I None
of I None
heart I None
failure I None
( I None
p I None
< I None
0 I None
. I None
02 I None
) I None
, I None
high I None
plasma I None
concentration I None
of I None
BNP I GENE-Y
( I None
p I None
< I None
0 I None
. I None
02 I None
) I None
, I None
left I None
ventricular I None
dilation I None
( I None
p I None
< I None
0 I None
. I None
03 I None
) I None
, I None
and I None
use I None
of I None
carvedilol I CHEMICAL
( I None
p I None
< I None
0 I None
. I None
04 I None
) I None
at I None
baseline I None
were I None
predictive I None
of I None
a I None
decrease I None
in I None
plasma I None
concentration I None
of I None
BNP I GENE-Y
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
carvedilol I CHEMICAL
potentially I None
decreased I None
neurohumoral I None
activation I None
, I None
decreased I None
symptoms I None
, I None
and I None
increased I None
exercise I None
capacity I None
in I None
patients I None
with I None
heart I None
failure I None
and I None
preserved I None
EF I None
. I None
<eof> I None

<s> O None
Psychopharmacology I None
of I None
anticonvulsants I None
: I None
levetiracetam I CHEMICAL
as I None
a I None
synaptic I GENE-N
vesicle O GENE-N
protein O GENE-N
modulator I None
. I None
<eof> I None

<s> O None
ISSUE I None
: I None
A I None
novel I None
mechanism I None
of I None
action I None
has I None
recently I None
been I None
described I None
for I None
levetiracetam I CHEMICAL
, I None
a I None
member I None
of I None
a I None
new I None
class I None
of I None
anticonvulsants I None
. I None
<eof> I None

<s> O None
Levetiracetam I CHEMICAL
binds I None
selectively I None
and I None
with I None
high I None
affinity I None
to I None
a I None
synaptic I GENE-N
vesicle O GENE-N
protein O GENE-N
known I None
as I None
SV2A I GENE-Y
, I None
thought I None
to I None
be I None
involved I None
with I None
synaptic I None
vesicle I None
exocytosis I None
and I None
presynaptic I None
neurotransmitter I None
release I None
. I None
<eof> I None

<s> O None
Terbinafine I CHEMICAL
: I None
mode I None
of I None
action I None
and I None
properties I None
of I None
the I None
squalene I GENE-Y
epoxidase O GENE-Y
inhibition I None
. I None
<eof> I None

<s> O None
Terbinafine I CHEMICAL
( I None
Lamisil I CHEMICAL
) I None
has I None
primarily I None
fungicidal I None
action I None
against I None
many I None
fungi I None
as I None
a I None
result I None
of I None
its I None
specific I None
mechanism I None
of I None
squalene I GENE-Y
epoxidase O GENE-Y
inhibition I None
. I None
<eof> I None

<s> O None
Treated I None
fungi I None
accumulate I None
squalene I CHEMICAL
while I None
becoming I None
deficient I None
in I None
ergosterol I CHEMICAL
, I None
an I None
essential I None
component I None
of I None
fungal I None
cell I None
membranes I None
. I None
<eof> I None

<s> O None
The I None
cidal I None
action I None
is I None
closely I None
associated I None
with I None
the I None
development I None
of I None
high I None
intracellular I None
squalene I CHEMICAL
concentrations I None
, I None
which I None
are I None
believed I None
to I None
interfere I None
with I None
fungal I None
membrane I None
function I None
and I None
cell I None
wall I None
synthesis I None
. I None
<eof> I None

<s> O None
In I None
the I None
case I None
of I None
Candida I None
albicans I None
, I None
growth I None
inhibition I None
with I None
terbinafine I CHEMICAL
appears I None
to I None
result I None
from I None
the I None
ergosterol I CHEMICAL
deficiency I None
. I None
<eof> I None

<s> O None
The I None
filamentous I None
form I None
of I None
this I None
fungus I None
is I None
more I None
susceptible I None
than I None
the I None
yeast I None
form I None
. I None
<eof> I None

<s> O None
Measurement I None
of I None
ergosterol I CHEMICAL
biosynthesis I None
by I None
incorporation I None
of I None
radiolabelled I None
precursors I None
indicates I None
a I None
correlation I None
between I None
inhibition I None
of I None
growth I None
and I None
ergosterol I CHEMICAL
biosynthesis I None
in I None
a I None
range I None
of I None
pathogenic I None
fungi I None
. I None
<eof> I None

<s> O None
Terbinafine I CHEMICAL
is I None
a I None
potent I None
non I None
- I None
competitive I None
inhibitor I None
of I None
squalene I GENE-Y
epoxidase O GENE-Y
from I None
Candida I None
( I None
Ki I None
= I None
30 I None
nM I None
) I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
inhibition I None
of I None
rat I GENE-Y
liver O GENE-Y
squalene O GENE-Y
epoxidase O GENE-Y
only I None
occurs I None
at I None
higher I None
drug I None
concentrations I None
( I None
Ki I None
= I None
77 I None
microM I None
) I None
, I None
and I None
is I None
competitive I None
with I None
squalene I CHEMICAL
. I None
<eof> I None

<s> O None
Thus I None
, I None
terbinafine I CHEMICAL
has I None
no I None
effect I None
on I None
cholesterol I CHEMICAL
biosynthesis I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Squalene I GENE-Y
epoxidase O GENE-Y
is I None
not I None
an I None
enzyme I None
of I None
the I None
cytochrome I GENE-N
P O GENE-N
- O GENE-N
450 O GENE-N
type I None
, I None
thereby I None
avoiding I None
potential I None
inhibition I None
of I None
this I None
class I None
of I None
enzymes I None
. I None
<eof> I None

<s> O None
[ I None
A I None
case I None
report I None
of I None
metastatic I None
pancreatic I None
cancer I None
that I None
responded I None
remarkably I None
to I None
the I None
combination I None
of I None
thalidomide I CHEMICAL
, I None
celecoxib I CHEMICAL
and I None
irinotecan I CHEMICAL
] I None
. I None
<eof> I None

<s> O None
The I None
prognosis I None
of I None
pancreatic I None
cancer I None
with I None
metastases I None
or I None
recurrence I None
is I None
quite I None
poor I None
. I None
<eof> I None

<s> O None
Chemotherapy I None
has I None
not I None
resulted I None
in I None
a I None
significant I None
survival I None
benefit I None
; I None
median I None
survival I None
is I None
3 I None
- I None
6 I None
months I None
. I None
<eof> I None

<s> O None
Various I None
chemotherapeutic I None
agents I None
have I None
been I None
evaluated I None
and I None
the I None
standard I None
chemotherapy I None
of I None
pancreatic I None
cancer I None
is I None
gemcitabine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
response I None
rate I None
, I None
however I None
, I None
is I None
low I None
at I None
13 I None
% I None
. I None
<eof> I None

<s> O None
Thalidomide I CHEMICAL
and I None
celecoxib I CHEMICAL
have I None
different I None
mechanisms I None
of I None
action I None
and I None
activity I None
in I None
various I None
malignant I None
tumors I None
. I None
<eof> I None

<s> O None
Both I None
have I None
been I None
evaluated I None
and I None
shown I None
to I None
demonstrate I None
activity I None
against I None
solid I None
tumors I None
. I None
<eof> I None

<s> O None
Thalidomide I CHEMICAL
decreased I None
the I None
stability I None
of I None
TNF I GENE-Y
- I None
mRNA I None
and I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
mRNA I None
. I None
<eof> I None

<s> O None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
is I None
a I None
bifunctional I None
enzyme I None
possessing I None
both I None
cyclooxygenase I GENE-N
and I None
peroxidase I GENE-N
activities I None
. I None
<eof> I None

<s> O None
Although I None
celecoxib I CHEMICAL
inhibits I None
PG I None
biosynthesis I None
, I None
most I None
do I None
not I None
affect I None
the I None
peroxidase I GENE-N
activity I None
of I None
COX I GENE-N
, I None
which I None
can I None
generate I None
proximate I None
carcinogens I None
. I None
<eof> I None

<s> O None
Because I None
thalidomide I CHEMICAL
does I None
not I None
completely I None
inhibit I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
expression I None
or I None
PG I None
biosynthesis I None
, I None
a I None
therapeutic I None
strategy I None
combining I None
celecoxib I CHEMICAL
with I None
thalidomide I CHEMICAL
might I None
be I None
more I None
effective I None
than I None
using I None
either I None
agent I None
alone I None
. I None
<eof> I None

<s> O None
Differences I None
in I None
the I None
mechanism I None
of I None
action I None
of I None
gemcitabine I CHEMICAL
and I None
irinotecan I CHEMICAL
suggest I None
that I None
a I None
change I None
of I None
gemcitabine I CHEMICAL
to I None
irinotecan I CHEMICAL
could I None
provide I None
clinically I None
efficacious I None
outcomes I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
accomplish I None
new I None
treatment I None
strategies I None
, I None
we I None
have I None
been I None
using I None
thalidomide I CHEMICAL
, I None
celecoxib I CHEMICAL
and I None
irinotecan I CHEMICAL
in I None
low I None
- I None
doses I None
. I None
<eof> I None

<s> O None
We I None
believe I None
this I None
combination I None
represents I None
a I None
viable I None
treatment I None
for I None
patients I None
of I None
pancreatic I None
cancer I None
with I None
recurrence I None
or I None
metastases I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
pitavastatin I CHEMICAL
on I None
apolipoprotein I GENE-Y
A O GENE-Y
- O GENE-Y
I O GENE-Y
production I None
in I None
HepG2 I None
cell I None
. I None
<eof> I None

<s> O None
There I None
are I None
few I None
reports I None
describing I None
the I None
mechanism I None
of I None
HDL I GENE-N
- I None
elevating I None
action I None
of I None
HMG I GENE-Y
- O GENE-Y
CoA O GENE-Y
reductase O GENE-Y
inhibitors I None
( I None
statins I None
) I None
. I None
<eof> I None

<s> O None
As I None
it I None
is I None
considered I None
that I None
the I None
key I None
step I None
of I None
HDL I GENE-N
production I None
is I None
the I None
secretion I None
of I None
apolipoprotein I GENE-Y
A O GENE-Y
- O GENE-Y
I O GENE-Y
( I None
apoA I GENE-Y
- O GENE-Y
I O GENE-Y
) I None
, I None
we I None
investigated I None
the I None
effect I None
of I None
statins I None
on I None
apoA I GENE-Y
- O GENE-Y
I O GENE-Y
synthesis I None
and I None
secretion I None
by I None
HepG2 I None
cell I None
to I None
elucidate I None
the I None
mechanism I None
of I None
the I None
action I None
. I None
<eof> I None

<s> O None
Each I None
statin I None
induced I None
apoA I GENE-Y
- O GENE-Y
I O GENE-Y
expression I None
( I None
mRNA I None
and I None
protein I None
) I None
dose I None
- I None
dependently I None
: I None
the I None
rank I None
order I None
of I None
the I None
apoA I GENE-Y
- O GENE-Y
I O GENE-Y
induction I None
pitavastatin I CHEMICAL
( I None
3 I None
microM I None
) I None
> I None
simvastatin I CHEMICAL
( I None
10 I None
microM I None
) I None
> I None
atorvastatin I CHEMICAL
( I None
30 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
The I None
induction I None
of I None
apoA I GENE-Y
- O GENE-Y
I O GENE-Y
by I None
statins I None
disappeared I None
with I None
addition I None
of I None
mevalonate I CHEMICAL
, I None
which I None
indicates I None
that I None
the I None
effect I None
is I None
HMG I GENE-Y
- O GENE-Y
CoA O GENE-Y
reductase O GENE-Y
inhibition I None
- I None
dependent I None
. I None
<eof> I None

<s> O None
Based I None
on I None
HMG I GENE-Y
- O GENE-Y
CoA O GENE-Y
reductase O GENE-Y
inhibition I None
, I None
pitavastatin I CHEMICAL
- I None
induced I None
apoA I GENE-Y
- O GENE-Y
I O GENE-Y
more I None
efficiently I None
than I None
simvastatin I CHEMICAL
and I None
atorvastatin I CHEMICAL
. I None
<eof> I None

<s> O None
Further I None
study I None
revealed I None
that I None
pitavastatin I CHEMICAL
increased I None
ABCA1 I GENE-Y
mRNA I None
in I None
HMG I GENE-Y
- O GENE-Y
CoA O GENE-Y
reductase O GENE-Y
- I None
dependent I None
manner I None
and I None
that I None
Rho I GENE-N
and I None
Rho I GENE-N
kinase O GENE-N
inhibitor I None
( I None
C3T I None
and I None
Y27632 I CHEMICAL
) I None
increased I None
apoA I GENE-Y
- O GENE-Y
I O GENE-Y
production I None
in I None
the I None
HepG2 I None
cells I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
pitavastatin I CHEMICAL
efficiently I None
increases I None
apoA I GENE-Y
- O GENE-Y
I O GENE-Y
in I None
the I None
culture I None
medium I None
of I None
HepG2 I None
cells I None
by I None
promoting I None
apoA I GENE-Y
- O GENE-Y
I O GENE-Y
production I None
through I None
inhibition I None
of I None
HMG I GENE-Y
- O GENE-Y
CoA O GENE-Y
reductase O GENE-Y
and I None
suppression I None
of I None
Rho I GENE-N
activity I None
and I None
by I None
protecting I None
apoA I GENE-Y
- O GENE-Y
I O GENE-Y
from I None
catabolism I None
through I None
ABCA1 I GENE-Y
induction I None
and I None
lipidation I None
of I None
apoA I GENE-Y
- O GENE-Y
I O GENE-Y
. I None
<eof> I None

<s> O None
A I None
multitargeted I None
, I None
metronomic I None
, I None
and I None
maximum I None
- I None
tolerated I None
dose I None
" I None
chemo I None
- I None
switch I None
" I None
regimen I None
is I None
antiangiogenic I None
, I None
producing I None
objective I None
responses I None
and I None
survival I None
benefit I None
in I None
a I None
mouse I None
model I None
of I None
cancer I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
A I None
transgenic I None
mouse I None
model I None
has I None
revealed I None
parameters I None
of I None
the I None
angiogenic I None
switch I None
during I None
multistep I None
tumorigenesis I None
of I None
pancreatic I None
islets I None
, I None
and I None
demonstrated I None
efficacy I None
of I None
antiangiogenic I None
therapies I None
. I None
<eof> I None

<s> O None
Pericytes I None
have I None
been I None
revealed I None
as I None
functionally I None
important I None
for I None
tumor I None
neovasculature I None
, I None
using I None
kinase I None
inhibitors I None
targeting I None
their I None
platelet I GENE-Y
- O GENE-Y
derived O GENE-Y
growth O GENE-Y
factor O GENE-Y
receptors O GENE-Y
( I None
PDGFRs I GENE-Y
) I None
. I None
<eof> I None

<s> O None
Additionally I None
, I None
vascular I GENE-N
endothelial O GENE-N
growth O GENE-N
factor O GENE-N
receptor O GENE-N
( I None
VEGFR I GENE-N
) I None
inhibitors I None
and I None
metronomic I None
chemotherapy I None
show I None
modest I None
benefit I None
against I None
early I None
- I None
but I None
not I None
late I None
- I None
stage I None
disease I None
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
: I None
Seeking I None
to I None
improve I None
efficacy I None
against I None
otherwise I None
intractable I None
end I None
- I None
stage I None
pancreatic I None
islet I None
tumors I None
, I None
two I None
receptor I GENE-N
tyrosine O GENE-N
kinase O GENE-N
inhibitors I None
, I None
imatinib I CHEMICAL
and I None
SU11248 I CHEMICAL
, I None
were I None
used I None
to I None
disrupt I None
PDGFR I GENE-Y
- I None
mediated I None
pericyte I None
support I None
of I None
tumor I None
endothelial I None
cells I None
in I None
concert I None
with I None
maximum I None
- I None
tolerated I None
dose I None
( I None
MTD I None
) I None
or I None
metronomic I None
chemotherapy I None
and I None
/ I None
or I None
VEGFR I GENE-N
inhibition I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Imatinib I CHEMICAL
, I None
despite I None
equivocal I None
efficacy I None
as I None
monotherapy I None
, I None
reduced I None
pericyte I None
coverage I None
of I None
tumor I None
vessels I None
and I None
enhanced I None
efficacy I None
in I None
combination I None
with I None
metronomic I None
chemotherapy I None
or I None
VEGFR I GENE-N
inhibition I None
. I None
<eof> I None

<s> O None
A I None
regimen I None
involving I None
all I None
three I None
was I None
even I None
better I None
. I None
<eof> I None

<s> O None
MTD I None
using I None
cyclophosphamide I CHEMICAL
caused I None
transitory I None
regression I None
, I None
but I None
then I None
rapid I None
regrowth I None
, I None
in I None
contrast I None
to I None
metronomic I None
cyclophosphamide I CHEMICAL
plus I None
imatinib I CHEMICAL
, I None
which I None
produced I None
stable I None
disease I None
. I None
<eof> I None

<s> O None
The I None
MTD I None
regimen I None
elicited I None
apoptosis I None
of I None
tumor I None
cells I None
but I None
not I None
endothelial I None
cells I None
, I None
whereas I None
the I None
other I None
regimens I None
increased I None
endothelial I None
cell I None
apoptosis I None
concordant I None
with I None
efficacy I None
. I None
<eof> I None

<s> O None
A I None
" I None
chemo I None
- I None
switch I None
" I None
protocol I None
, I None
involving I None
sequential I None
MTD I None
and I None
then I None
metronomic I None
chemotherapy I None
, I None
overlaid I None
with I None
multitargeted I None
inhibition I None
of I None
PDGFR I GENE-Y
and I None
VEGFR I GENE-N
, I None
gave I None
complete I None
responses I None
and I None
unprecedented I None
survival I None
advantage I None
in I None
this I None
model I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
This I None
study I None
demonstrates I None
a I None
potentially I None
tractable I None
clinical I None
strategy I None
in I None
a I None
stringent I None
preclinical I None
model I None
, I None
wherein I None
standard I None
- I None
of I None
- I None
care I None
chemotherapy I None
is I None
followed I None
by I None
a I None
novel I None
maintenance I None
regimen I None
: I None
PDFGR I GENE-Y
is I None
targeted I None
to I None
disrupt I None
pericyte I None
support I None
, I None
while I None
metronomic I None
chemotherapy I None
and I None
/ I None
or I None
VEGFR I GENE-N
inhibitors I None
target I None
consequently I None
sensitized I None
endothelial I None
cells I None
, I None
collectively I None
destabilizing I None
pre I None
- I None
existing I None
tumor I None
vasculature I None
and I None
inhibiting I None
ongoing I None
angiogenesis I None
. I None
<eof> I None

<s> O None
Preferential I None
and I None
non I None
- I None
selective I None
cyclooxygenase I GENE-N
inhibitors I None
reduce I None
inflammation I None
during I None
lipopolysaccharide I None
- I None
induced I None
synovitis I None
. I None
<eof> I None

<s> O None
Synovitis I None
in I None
horses I None
is I None
frequently I None
treated I None
by I None
administration I None
of I None
non I None
- I None
steroidal I CHEMICAL
anti I None
- I None
inflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
, I None
which I None
inhibit I None
cyclooxygenase I GENE-N
isoforms I None
( I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
and I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
. I None
<eof> I None

<s> O None
Constitutively I None
expressed I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
is I None
involved I None
in I None
physiologic I None
functions I None
such I None
as I None
maintenance I None
of I None
gastric I None
mucosal I None
integrity I None
, I None
whereas I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
is I None
up I None
- I None
regulated I None
at I None
sites I None
of I None
inflammation I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
reduce I None
inflammation I None
with I None
reduced I None
gastrointestinal I None
side I None
effects I None
as I None
compared I None
to I None
non I None
- I None
selective I None
COX I GENE-Y
inhibitors I None
. I None
<eof> I None

<s> O None
The I None
objective I None
of I None
the I None
present I None
study I None
was I None
to I None
compare I None
the I None
anti I None
- I None
inflammatory I None
effects I None
of I None
the I None
preferential I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
etodolac I None
with I None
the I None
non I None
- I None
selective I None
COX I GENE-N
inhibitor I None
phenylbutazone I CHEMICAL
in I None
horses I None
with I None
lipopolysaccharide I None
( I None
LPS I None
) I None
- I None
induced I None
synovitis I None
. I None
<eof> I None

<s> O None
Three I None
groups I None
of I None
horses I None
( I None
n I None
= I None
6 I None
) I None
received I None
no I None
treatment I None
, I None
phenylbutazone I CHEMICAL
( I None
4 I None
. I None
4 I None
mg I None
/ I None
kg I None
, I None
IV I None
, I None
q12h I None
) I None
, I None
or I None
etodolac I CHEMICAL
( I None
23 I None
mg I None
/ I None
kg I None
, I None
IV I None
, I None
q12h I None
) I None
, I None
respectively I None
, I None
2 I None
- I None
h I None
following I None
injection I None
of I None
LPS I None
into I None
one I None
middle I None
carpal I None
joint I None
. I None
<eof> I None

<s> O None
Synovial I None
fluid I None
was I None
analyzed I None
for I None
white I None
blood I None
cell I None
( I None
WBC I None
) I None
count I None
, I None
and I None
TXB2 I CHEMICAL
and I None
PGE2 I CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
Phenylbutazone I CHEMICAL
and I None
etodolac I CHEMICAL
significantly I None
reduced I None
WBC I None
count I None
6 I None
and I None
24 I None
- I None
h I None
following I None
injection I None
of I None
LPS I None
compared I None
to I None
untreated I None
horses I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
both I None
drugs I None
significantly I None
reduced I None
PGE2 I CHEMICAL
levels I None
( I None
P I None
< I None
0 I None
. I None
05 I None
) I None
6 I None
- I None
h I None
following I None
LPS I None
injection I None
, I None
whereas I None
the I None
probable I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
prostanoid I CHEMICAL
TXB2 I CHEMICAL
was I None
significantly I None
reduced I None
by I None
phenylbutazone I CHEMICAL
( I None
P I None
< I None
0 I None
. I None
05 I None
) I None
, I None
but I None
not I None
etodolac I CHEMICAL
. I None
<eof> I None

<s> O None
Etodolac I CHEMICAL
may I None
serve I None
as I None
a I None
more I None
selective I None
anti I None
- I None
inflammatory I None
agent I None
than I None
phenylbutazone I CHEMICAL
for I None
treatment I None
of I None
equine I None
synovitis I None
. I None
<eof> I None

<s> O None
Genetic I None
polymorphisms I None
predisposing I None
to I None
hyperhomocysteinemia I None
in I None
cardiac I None
transplant I None
patients I None
. I None
<eof> I None

<s> O None
Genetic I None
determinants I None
for I None
high I None
homocysteine I CHEMICAL
( I None
Hcy I CHEMICAL
) I None
levels I None
are I None
now I None
well I None
known I None
. I None
<eof> I None

<s> O None
We I None
studied I None
several I None
single I None
nucleotide I None
polymorphisms I None
( I None
SNP I None
) I None
in I None
Hcy I CHEMICAL
- I None
regulating I None
genes I None
[ I None
methylenetetrahydrofolate I GENE-Y
reductase O GENE-Y
( I None
MTHFR I GENE-Y
) I None
C677T I GENE-N
and I None
A1298C I GENE-N
; I None
methionine I GENE-Y
synthase O GENE-Y
( I None
MS I GENE-Y
) I None
A2756G I GENE-N
; I None
methionine I GENE-Y
synthase O GENE-Y
reductase O GENE-Y
( I None
MTRR I GENE-Y
) I None
A66G I GENE-N
] I None
in I None
relation I None
to I None
total I None
plasma I None
Hcy I CHEMICAL
levels I None
, I None
transplant I None
coronary I None
artery I None
disease I None
and I None
thromboembolic I None
episodes I None
in I None
84 I None
heart I None
transplant I None
patients I None
, I None
and I None
we I None
compared I None
the I None
incidence I None
of I None
these I None
polymorphisms I None
with I None
those I None
in I None
a I None
healthy I None
adult I None
controls I None
. I None
<eof> I None

<s> O None
At I None
least I None
one I None
copy I None
of I None
the I None
G I None
allele I None
of I None
the I None
MTRR I GENE-Y
A66G I GENE-N
SNP I None
was I None
found I None
in I None
a I None
significantly I None
greater I None
proportion I None
of I None
cardiac I None
transplant I None
( I None
CTX I None
) I None
recipients I None
compared I None
with I None
controls I None
( I None
94 I None
. I None
0 I None
% I None
vs I None
. I None
79 I None
. I None
9 I None
% I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
None I None
of I None
the I None
SNP I None
analyzed I None
were I None
correlated I None
with I None
total I None
Hcy I CHEMICAL
plasma I None
levels I None
or I None
the I None
presence I None
of I None
transplant I None
coronary I None
artery I None
disease I None
. I None
<eof> I None

<s> O None
However I None
, I None
MS I GENE-Y
A2756G I GENE-N
was I None
significantly I None
associated I None
with I None
cobalamin I CHEMICAL
levels I None
( I None
AA I None
genotype I None
: I None
290 I None
+ I None
/ I None
- I None
122 I None
pmol I None
/ I None
l I None
; I None
AG I None
: I None
381 I None
+ I None
/ I None
- I None
151 I None
pmol I None
/ I None
l I None
and I None
GG I None
: I None
415 I None
+ I None
/ I None
- I None
100 I None
pmol I None
/ I None
l I None
) I None
, I None
as I None
was I None
MTRR I GENE-Y
A66G I GENE-N
( I None
AA I None
: I None
478 I None
+ I None
/ I None
- I None
219 I None
pmol I None
/ I None
l I None
, I None
AG I None
: I None
306 I None
+ I None
/ I None
- I None
124 I None
pmol I None
/ I None
l I None
and I None
GG I None
: I None
306 I None
+ I None
/ I None
- I None
123 I None
pmol I None
/ I None
l I None
) I None
. I None
<eof> I None

<s> O None
MTRR I GENE-Y
A66G I GENE-N
was I None
also I None
correlated I None
with I None
serum I None
folate I None
. I None
<eof> I None

<s> O None
No I None
association I None
was I None
found I None
with I None
thromboembolic I None
events I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
there I None
was I None
a I None
significant I None
difference I None
in I None
the I None
frequency I None
of I None
the I None
G I None
allele I None
genotype I None
of I None
the I None
MTRR I GENE-Y
A66G I GENE-N
in I None
CTX I None
patients I None
versus I None
controls I None
. I None
<eof> I None

<s> O None
Differences I None
in I None
cobalamin I CHEMICAL
and I None
folate I None
levels I None
with I None
the I None
MTRR I GENE-Y
A66G I GENE-N
and I None
MS I GENE-Y
A2756G I GENE-N
polymorphisms I None
were I None
noted I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
SNP I None
in I None
Hcy I CHEMICAL
- I None
regulating I None
genes I None
may I None
be I None
important I None
determinants I None
of I None
vitamin I None
metabolism I None
in I None
CTX I None
, I None
raising I None
the I None
question I None
of I None
increased I None
vitamin I None
requirements I None
to I None
minimize I None
increased I None
plasma I None
Hcy I CHEMICAL
in I None
this I None
high I None
- I None
risk I None
group I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
bosentan I CHEMICAL
( I None
ETA I GENE-Y
/ I None
ETB I GENE-Y
receptor I None
antagonist I None
) I None
on I None
metabolic I None
changes I None
during I None
stress I None
and I None
diabetes I None
. I None
<eof> I None

<s> O None
Elevated I None
plasma I None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
levels I None
have I None
been I None
reported I None
in I None
several I None
conditions I None
such I None
as I None
stress I None
and I None
diabetes I None
. I None
<eof> I None

<s> O None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
is I None
found I None
to I None
cause I None
insulin I GENE-Y
resistance I None
and I None
to I None
stimulate I None
liver I None
glycogenolysis I None
. I None
<eof> I None

<s> O None
The I None
question I None
arises I None
whether I None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
has I None
a I None
role I None
in I None
the I None
metabolic I None
changes I None
occurring I None
in I None
such I None
conditions I None
. I None
<eof> I None

<s> O None
To I None
test I None
this I None
, I None
we I None
studied I None
the I None
possible I None
effect I None
of I None
the I None
endothelin I GENE-N
receptor O GENE-N
antagonist I None
, I None
bosentan I CHEMICAL
( I None
50 I None
and I None
100 I None
mg I None
kg I None
( I None
- I None
1 I None
) I None
) I None
on I None
serum I None
glucose I CHEMICAL
and I None
insulin I GENE-N
levels I None
as I None
well I None
as I None
on I None
liver I None
glycogen I None
contents I None
in I None
normoglycemic I None
stressed I None
animals I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
the I None
effect I None
of I None
bosentan I CHEMICAL
on I None
serum I None
glucose I CHEMICAL
and I None
insulin I GENE-N
levels I None
in I None
both I None
mild I None
and I None
severely I None
diabetic I None
rats I None
and I None
its I None
effect I None
on I None
insulin I GENE-N
- I None
induced I None
hypoglycemia I None
were I None
also I None
determined I None
. I None
<eof> I None

<s> O None
Restraining I None
water I None
immersion I None
stress I None
was I None
used I None
as I None
a I None
model I None
for I None
severe I None
stress I None
reported I None
to I None
elevate I None
plasma I None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
level I None
. I None
<eof> I None

<s> O None
Mild I None
diabetes I None
was I None
induced I None
in I None
rats I None
by I None
intraperitoneal I None
injection I None
of I None
a I None
low I None
dose I None
of I None
streptozotocin I CHEMICAL
( I None
38 I None
mg I None
kg I None
( I None
- I None
1 I None
) I None
) I None
while I None
severe I None
diabetes I None
was I None
induced I None
by I None
intraperitoneal I None
injection I None
of I None
a I None
higher I None
dose I None
of I None
streptozotocin I CHEMICAL
( I None
45 I None
mg I None
kg I None
( I None
- I None
1 I None
) I None
) I None
. I None
<eof> I None

<s> O None
Bosentan I CHEMICAL
partially I None
prevented I None
stress I None
- I None
induced I None
both I None
hyperglycemia I None
and I None
decrease I None
in I None
glycogen I None
content I None
while I None
it I None
completely I None
blocked I None
the I None
stress I None
- I None
induced I None
decrease I None
in I None
insulin I GENE-N
level I None
in I None
normoglycemic I None
stressed I None
rats I None
. I None
<eof> I None

<s> O None
Bosentan I CHEMICAL
also I None
decreased I None
serum I None
glucose I CHEMICAL
level I None
without I None
any I None
effect I None
on I None
insulin I GENE-N
secretion I None
in I None
mild I None
diabetic I None
rats I None
and I None
potentiated I None
the I None
hypoglycemic I None
action I None
of I None
insulin I GENE-N
. I None
<eof> I None

<s> O None
Modification I None
of I None
radiation I None
damage I None
to I None
mitochondrial I None
system I None
in I None
vivo I None
by I None
Podophyllum I None
hexandrum I None
: I None
mechanistic I None
aspects I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
was I None
undertaken I None
to I None
investigate I None
whether I None
RP I None
- I None
1 I None
treatment I None
protected I None
mitochondrial I None
system I None
against I None
radiation I None
damage I None
and I None
also I None
to I None
unravel I None
the I None
mechanism I None
associated I None
with I None
this I None
process I None
. I None
<eof> I None

<s> O None
Radioprotection I None
of I None
mitochondrial I None
system I None
by I None
Podophyllum I None
hexandrum I None
( I None
RP I None
- I None
1 I None
) I None
was I None
investigated I None
to I None
understand I None
its I None
mechanism I None
of I None
action I None
. I None
<eof> I None

<s> O None
Levels I None
of I None
superoxide I CHEMICAL
anion I None
( I None
O2 I CHEMICAL
- O CHEMICAL
) I None
, I None
reduced I None
or I None
oxidized I None
glutathione I CHEMICAL
( I None
GSH I CHEMICAL
or I None
GSSG I CHEMICAL
) I None
, I None
thiobarbituric I CHEMICAL
acid O CHEMICAL
reactive I None
substance I None
( I None
TBARS I None
) I None
, I None
protein I None
carbonyl I None
( I None
PC I None
) I None
, I None
ATP I CHEMICAL
, I None
NADH I GENE-N
- O GENE-N
ubiquinone O GENE-N
oxidoreductase O GENE-N
( I None
complex I GENE-N
- O GENE-N
I O GENE-N
) I None
, I None
NADH I GENE-N
- O GENE-N
cytochrome O GENE-N
c O GENE-N
oxidoreductase O GENE-N
( I None
complex I GENE-N
I O GENE-N
/ O GENE-N
II O GENE-N
) I None
, I None
succinate I GENE-N
- O GENE-N
cytochrome O GENE-N
c O GENE-N
oxidoreductase O GENE-N
( I None
complex I GENE-N
II O GENE-N
/ O GENE-N
III O GENE-N
) I None
and I None
mitochondrial I None
membrane I None
potential I None
( I None
MMP I None
) I None
were I None
studied I None
in I None
mitochondria I None
isolated I None
from I None
liver I None
of I None
mice I None
belonging I None
to I None
various I None
treatment I None
groups I None
. I None
<eof> I None

<s> O None
Whole I None
body I None
y I None
- I None
irradiation I None
( I None
10 I None
Gy I None
) I None
significantly I None
( I None
p I None
< I None
0 I None
. I None
01 I None
) I None
increased I None
the I None
formation I None
of I None
O2 I CHEMICAL
- O CHEMICAL
, I None
PC I None
, I None
and I None
TBARS I None
, I None
upto I None
24 I None
h I None
as I None
compared I None
to I None
untreated I None
control I None
. I None
<eof> I None

<s> O None
RP I None
- I None
1 I None
treatment I None
( I None
200 I None
mg I None
/ I None
kg I None
b I None
. I None
w I None
. I None
) I None
to I None
mice I None
2 I None
h I None
before I None
irradiation I None
reduced I None
the I None
radiation I None
- I None
induced I None
O2 I CHEMICAL
- O CHEMICAL
generation I None
within I None
4 I None
h I None
and I None
formation I None
of I None
TBARS I None
and I None
PC I None
upto I None
24 I None
h I None
significantly I None
( I None
p I None
< I None
0 I None
. I None
01 I None
) I None
. I None
<eof> I None

<s> O None
Singularly I None
irradiation I None
or I None
RP I None
- I None
1 I None
treatment I None
significantly I None
( I None
p I None
< I None
0 I None
. I None
01 I None
) I None
increased I None
the I None
levels I None
of I None
glutathione I CHEMICAL
within I None
an I None
hour I None
, I None
as I None
compared I None
to I None
untreated I None
control I None
. I None
<eof> I None

<s> O None
Pre I None
- I None
irradiation I None
administration I None
of I None
RP I None
- I None
1 I None
enhanced I None
levels I None
of I None
GSH I CHEMICAL
induced I None
increase I None
in I None
complex I GENE-N
I O GENE-N
( I None
upto I None
16 I None
h I None
) I None
, I None
complex I GENE-N
I O GENE-N
/ O GENE-N
III O GENE-N
( I None
4 I None
h I None
) I None
complex I GENE-N
II O GENE-N
/ O GENE-N
III O GENE-N
activity I None
( I None
upto I None
24 I None
h I None
; I None
p I None
< I None
0 I None
. I None
01 I None
) I None
and I None
inhibited I None
the I None
radiation I None
- I None
induced I None
decrease I None
in I None
MMP I None
significantly I None
( I None
24 I None
h I None
; I None
p I None
< I None
0 I None
. I None
01 I None
) I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
indicates I None
that I None
RP I None
- I None
1 I None
itself I None
modulates I None
several I None
mitichondrial I None
perameters I None
due I None
to I None
its I None
influence I None
on I None
the I None
biochemical I None
milieu I None
within I None
and I None
outside I None
the I None
cells I None
. I None
<eof> I None

<s> O None
However I None
, I None
RP I None
- I None
1 I None
treatment I None
before I None
irradiation I None
modulates I None
radiation I None
induced I None
perturbations I None
such I None
as I None
the I None
increase I None
in I None
electron I None
transport I None
chain I None
enzyme I None
activity I None
, I None
formation I None
of I None
O2 I CHEMICAL
- O CHEMICAL
, I None
TBARS I None
and I None
PC I None
to I None
offer I None
radioprotection I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
minocycline I CHEMICAL
on I None
Fas I GENE-Y
- I None
mediated I None
fulminant I None
hepatitis I None
in I None
mice I None
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
Minocycline I CHEMICAL
has I None
anti I None
- I None
inflammatory I None
and I None
antiapoptotic I None
effects I None
on I None
cartilage I None
, I None
neurons I None
and I None
periodontal I None
tissues I None
, I None
and I None
both I None
properties I None
are I None
central I None
to I None
the I None
pharmaceutical I None
treatment I None
of I None
liver I None
diseases I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
effects I None
of I None
minocycline I CHEMICAL
on I None
fulminant I None
hepatitis I None
in I None
C57BL I None
/ I None
6J I None
mice I None
induced I None
by I None
lethal I None
challenge I None
of I None
the I None
activating I None
anti I None
- I None
Fas I GENE-Y
antibody I None
, I None
Jo2 I None
. I None
<eof> I None

<s> O None
2 I None
. I None
<eof> I None

<s> O None
Intraperitoneal I None
injection I None
of I None
Jo2 I None
( I None
0 I None
. I None
6 I None
microg I None
g I None
( I None
- I None
1 I None
) I None
) I None
to I None
mice I None
resulted I None
in I None
fulminant I None
hepatitis I None
, I None
as I None
evidenced I None
by I None
increase I None
of I None
serum I GENE-N
alanine O GENE-N
/ O GENE-N
aspartate O GENE-N
transaminase O GENE-N
activities I None
and I None
histopathological I None
alterations I None
in I None
liver I None
sections I None
, I None
as I None
well I None
as I None
animal I None
death I None
. I None
<eof> I None

<s> O None
Nevertheless I None
, I None
mice I None
pretreated I None
with I None
three I None
doses I None
of I None
minocycline I CHEMICAL
( I None
5 I None
mg I None
kg I None
( I None
- I None
1 I None
) I None
) I None
resisted I None
this I None
lethal I None
effect I None
significantly I None
. I None
<eof> I None

<s> O None
Minocycline I CHEMICAL
treatment I None
improved I None
the I None
survival I None
kinetics I None
, I None
although I None
to I None
a I None
lesser I None
extent I None
, I None
when I None
mice I None
were I None
challenged I None
simultaneously I None
with I None
Jo2 I None
or I None
even I None
treated I None
30 I None
min I None
after I None
the I None
lethal I None
challenge I None
. I None
<eof> I None

<s> O None
3 I None
. I None
<eof> I None

<s> O None
Jo2 I None
- I None
induced I None
activation I None
of I None
caspase I GENE-N
- O GENE-N
3 O GENE-N
or O GENE-N
- O GENE-N
9 O GENE-N
in I None
liver I None
tissues I None
was I None
inhibited I None
by I None
minocycline I CHEMICAL
pretreatment I None
, I None
and I None
yet I None
the I None
direct I None
addition I None
of I None
minocycline I CHEMICAL
to I None
liver I None
extracts I None
from I None
Jo2 I None
- I None
challenged I None
mice I None
failed I None
to I None
block I None
caspase I GENE-N
activation I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
minocycline I CHEMICAL
efficiently I None
suppressed I None
the I None
release I None
of I None
cytochrome I GENE-Y
c O GENE-Y
from I None
mitochondria I None
of I None
the I None
liver I None
tissues I None
from I None
Jo2 I None
- I None
challenged I None
mice I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
caspase I GENE-Y
- O GENE-Y
8 O GENE-Y
activation I None
and I None
Bid I GENE-Y
truncation I None
triggered I None
by I None
Jo2 I None
were I None
not I None
diminished I None
by I None
minocycline I CHEMICAL
pretreatment I None
in I None
mouse I None
livers I None
. I None
<eof> I None

<s> O None
4 I None
. I None
<eof> I None

<s> O None
Our I None
results I None
suggest I None
that I None
easing I None
of I None
Fas I GENE-Y
- I None
triggered I None
fulminant I None
hepatitis I None
by I None
minocycline I CHEMICAL
may I None
involve I None
a I None
mitochondrial I None
apoptotic I None
pathway I None
, I None
probably I None
through I None
preventing I None
cytochrome I GENE-Y
c O GENE-Y
release I None
and I None
thereby I None
blocking I None
downstream I None
caspase I GENE-N
activation I None
. I None
<eof> I None

<s> O None
Role I None
of I None
hydrogen I CHEMICAL
sulfide O CHEMICAL
in I None
acute I None
pancreatitis I None
and I None
associated I None
lung I None
injury I None
. I None
<eof> I None

<s> O None
Hydrogen I CHEMICAL
sulfide O CHEMICAL
( I None
H2S I CHEMICAL
) I None
is I None
a I None
naturally I None
occurring I None
gas I None
with I None
potent I None
vasodilator I None
activity I None
. I None
<eof> I None

<s> O None
Cystathionine I GENE-Y
- O GENE-Y
gamma O GENE-Y
- O GENE-Y
lyase O GENE-Y
( I None
CSE I GENE-Y
) I None
and I None
cystathionine I GENE-Y
- O GENE-Y
beta O GENE-Y
- O GENE-Y
synthase O GENE-Y
( I None
CBS I GENE-Y
) I None
utilize I None
L I CHEMICAL
- O CHEMICAL
cysteine O CHEMICAL
as I None
substrate I None
to I None
form I None
H2S I CHEMICAL
. I None
<eof> I None

<s> O None
Of I None
these I None
two I None
enzymes I None
, I None
cystathionine I GENE-Y
- O GENE-Y
gamma O GENE-Y
- O GENE-Y
lyase O GENE-Y
( I None
CSE I GENE-Y
) I None
is I None
believed I None
to I None
be I None
the I None
key I None
enzyme I None
that I None
forms I None
H2S I CHEMICAL
in I None
the I None
cardiovascular I None
system I None
. I None
<eof> I None

<s> O None
Whilst I None
H2S I CHEMICAL
has I None
been I None
reported I None
to I None
relax I None
precontracted I None
rat I None
arteries I None
in I None
vitro I None
and I None
to I None
lower I None
blood I None
pressure I None
in I None
the I None
rat I None
, I None
its I None
effect I None
in I None
an I None
inflammatory I None
condition I None
such I None
as I None
acute I None
pancreatitis I None
has I None
not I None
previously I None
been I None
reported I None
. I None
<eof> I None

<s> O None
In I None
this I None
paper I None
, I None
we I None
report I None
the I None
presence I None
of I None
H2S I CHEMICAL
synthesizing I None
enzyme I None
activity I None
and I None
CSE I GENE-Y
( I None
as I None
determined I None
by I None
mRNA I None
signal I None
) I None
in I None
the I None
pancreas I None
. I None
<eof> I None

<s> O None
Also I None
, I None
prophylactic I None
, I None
as I None
well I None
as I None
therapeutic I None
, I None
treatment I None
with I None
the I None
CSE I GENE-Y
inhibitor I None
, I None
DL I CHEMICAL
- O CHEMICAL
propargylglycine O CHEMICAL
( I None
PAG I CHEMICAL
) I None
, I None
significantly I None
reduced I None
the I None
severity I None
of I None
caerulein I CHEMICAL
- I None
induced I None
pancreatitis I None
and I None
associated I None
lung I None
injury I None
, I None
as I None
determined I None
by I None
1 I None
) I None
hyperamylasemia I None
[ I None
plasma I None
amylase I GENE-N
( I None
U I None
/ I None
L I None
) I None
( I None
control I None
, I None
1204 I None
+ I None
/ I None
- I None
59 I None
) I None
; I None
prophylactic I None
treatment I None
: I None
placebo I None
, I None
10635 I None
+ I None
/ I None
- I None
305 I None
; I None
PAG I CHEMICAL
, I None
7904 I None
+ I None
/ I None
- I None
495 I None
; I None
therapeutic I None
treatment I None
: I None
placebo I None
, I None
10427 I None
+ I None
/ I None
- I None
470 I None
; I None
PAG I CHEMICAL
, I None
7811 I None
+ I None
/ I None
- I None
428 I None
; I None
P I None
< I None
0 I None
. I None
05 I None
PAG I CHEMICAL
c I None
. I None
f I None
. I None
placebo I None
; I None
n I None
= I None
24 I None
animals I None
in I None
each I None
group I None
] I None
; I None
2 I None
) I None
neutrophil I None
sequestration I None
in I None
the I None
pancreas I None
[ I None
pancreatic I None
myeloperoxidase I GENE-Y
oxidase O GENE-Y
( I None
MPO I GENE-Y
) I None
activity I None
( I None
fold I None
increase I None
over I None
control I None
) I None
( I None
prophylactic I None
treatment I None
: I None
placebo I None
, I None
5 I None
. I None
78 I None
+ I None
/ I None
- I None
0 I None
. I None
63 I None
; I None
PAG I CHEMICAL
, I None
2 I None
. I None
97 I None
+ I None
/ I None
- I None
0 I None
. I None
39 I None
; I None
therapeutic I None
treatment I None
: I None
placebo I None
, I None
5 I None
. I None
48 I None
+ I None
/ I None
- I None
0 I None
. I None
52 I None
; I None
PAG I CHEMICAL
, I None
3 I None
. I None
03 I None
+ I None
/ I None
- I None
0 I None
. I None
47 I None
; I None
P I None
< I None
0 I None
. I None
05 I None
PAG I CHEMICAL
c I None
. I None
f I None
. I None
placebo I None
; I None
n I None
= I None
24 I None
animals I None
in I None
each I None
group I None
) I None
] I None
; I None
3 I None
) I None
pancreatic I None
acinar I None
cell I None
injury I None
/ I None
necrosis I None
; I None
4 I None
) I None
lung I None
MPO I None
activity I None
( I None
fold I None
increase I None
over I None
control I None
) I None
[ I None
prophylactic I None
treatment I None
: I None
placebo I None
, I None
1 I None
. I None
99 I None
+ I None
/ I None
- I None
0 I None
. I None
16 I None
; I None
PAG I CHEMICAL
, I None
1 I None
. I None
34 I None
+ I None
/ I None
- I None
0 I None
. I None
14 I None
; I None
therapeutic I None
treatment I None
: I None
placebo I None
, I None
2 I None
. I None
03 I None
+ I None
/ I None
- I None
0 I None
. I None
12 I None
; I None
PAG I CHEMICAL
, I None
1 I None
. I None
41 I None
+ I None
/ I None
- I None
0 I None
. I None
97 I None
; I None
P I None
< I None
0 I None
. I None
05 I None
PAG I CHEMICAL
c I None
. I None
f I None
. I None
placebo I None
; I None
n I None
= I None
24 I None
animals I None
in I None
each I None
group I None
] I None
; I None
and I None
5 I None
) I None
histological I None
evidence I None
of I None
lung I None
injury I None
. I None
<eof> I None

<s> O None
These I None
effects I None
of I None
CSE I GENE-Y
blockade I None
suggest I None
an I None
important I None
proinflammatory I None
role I None
of I None
H2S I CHEMICAL
in I None
regulating I None
the I None
severity I None
of I None
pancreatitis I None
and I None
associated I None
lung I None
injury I None
and I None
raise I None
the I None
possibility I None
that I None
H2S I CHEMICAL
may I None
exert I None
similar I None
activity I None
in I None
other I None
forms I None
of I None
inflammation I None
. I None
<eof> I None

<s> O None
Atypical I None
and I None
typical I None
antipsychotic I None
drug I None
interactions I None
with I None
the I None
dopamine I GENE-Y
D2 O GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
A I None
model I None
of I None
the I None
dopamine I GENE-Y
D2 O GENE-Y
receptor O GENE-Y
was I None
used I None
to I None
study I None
the I None
receptor I None
interactions I None
of I None
dopamine I CHEMICAL
, I None
the I None
typical I None
antipsychotics I None
haloperidol I CHEMICAL
and I None
loxapine I CHEMICAL
, I None
and I None
the I None
atypical I None
antipsychotics I None
clozapine I CHEMICAL
and I None
melperone I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
atypical I None
antipsychotics I None
interacted I None
with I None
the I None
halogen I CHEMICAL
atom I None
of I None
the I None
ring I None
system I None
in I None
the I None
direction I None
of I None
the I None
transmembrane I None
helices I None
( I None
TMHs I None
) I None
2 I None
, I None
3 I None
and I None
7 I None
, I None
while I None
the I None
typical I None
had I None
the I None
corresponding I None
halogen I CHEMICAL
atom I None
in I None
the I None
direction I None
of I None
TMH5 I None
. I None
<eof> I None

<s> O None
Molecular I None
dynamics I None
simulations I None
indicated I None
that I None
the I None
average I None
helical I None
displacement I None
upon I None
binding I None
increased I None
in I None
the I None
order I None
: I None
typical I None
< I None
atypical I None
< I None
dopamine I CHEMICAL
. I None
<eof> I None

<s> O None
Upon I None
binding I None
, I None
the I None
atypical I None
induced I None
larger I None
displacements I None
into I None
TMH5 I None
than I None
did I None
the I None
typical I None
. I None
<eof> I None

<s> O None
The I None
typical I None
had I None
stronger I None
non I None
- I None
bonded I None
interactions I None
with I None
the I None
receptor I None
than I None
had I None
the I None
atypical I None
, I None
which I None
is I None
in I None
agreement I None
with I None
the I None
experimental I None
observation I None
that I None
the I None
atypical I None
antipsychotic I None
drugs I None
dissociate I None
faster I None
from I None
the I None
receptor I None
than I None
the I None
typical I None
antipsychotic I None
drugs I None
. I None
<eof> I None

<s> O None
Pharmacokinetics I None
, I None
pharmacodynamics I None
, I None
and I None
safety I None
of I None
exenatide I None
in I None
patients I None
with I None
type I None
2 I None
diabetes I None
mellitus I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
The I None
pharmacology I None
and I None
tolerability I None
of I None
exenatide I None
in I None
patients I None
with I None
type I None
2 I None
diabetes I None
mellitus I None
were I None
studied I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Two I None
randomized I None
, I None
single I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
studies I None
were I None
conducted I None
. I None
<eof> I None

<s> O None
Treatment I None
with I None
oral I None
antidiabetic I None
agents I None
was I None
stopped I None
14 I None
days I None
before I None
study I None
initiation I None
. I None
<eof> I None

<s> O None
In I None
the I None
first I None
study I None
( I None
study I None
A I None
) I None
, I None
eight I None
subjects I None
received I None
placebo I None
, I None
0 I None
. I None
1 I None
- I None
, I None
0 I None
. I None
2 I None
- I None
, I None
0 I None
. I None
3 I None
- I None
, I None
and I None
either I None
0 I None
. I None
4 I None
- I None
microg I None
/ I None
kg I None
exenatide I None
or I None
placebo I None
five I None
minutes I None
before I None
a I None
meal I None
combined I None
with I None
liquid I None
acetaminophen I CHEMICAL
( I None
to I None
assess I None
the I None
rate I None
of I None
gastric I None
emptying I None
) I None
on I None
days I None
1 I None
, I None
3 I None
, I None
5 I None
, I None
7 I None
, I None
and I None
9 I None
. I None
<eof> I None

<s> O None
In I None
the I None
second I None
study I None
( I None
study I None
B I None
) I None
, I None
subjects I None
received I None
a I None
single I None
s I None
. I None
c I None
. I None
dose I None
of I None
exenatide I None
or I None
placebo I None
on I None
consecutive I None
days I None
. I None
<eof> I None

<s> O None
Part I None
1 I None
of I None
study I None
B I None
used I None
exenatide I None
doses I None
of I None
0 I None
. I None
01 I None
and I None
0 I None
. I None
1 I None
microg I None
/ I None
kg I None
; I None
0 I None
. I None
02 I None
- I None
, I None
0 I None
. I None
05 I None
- I None
, I None
and I None
0 I None
. I None
1 I None
- I None
microg I None
/ I None
kg I None
doses I None
were I None
given I None
in I None
part I None
2 I None
. I None
<eof> I None

<s> O None
After I None
an I None
overnight I None
fast I None
, I None
the I None
study I None
drug I None
was I None
injected I None
15 I None
minutes I None
before I None
a I None
meal I None
( I None
part I None
1 I None
) I None
and I None
before I None
a I None
meal I None
and I None
acetaminophen I CHEMICAL
( I None
part I None
2 I None
) I None
. I None
<eof> I None

<s> O None
Parts I None
1 I None
and I None
2 I None
of I None
study I None
B I None
enrolled I None
six I None
and I None
eight I None
patients I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
In I None
both I None
studies I None
, I None
plasma I None
exenatide I None
pharmacokinetic I None
profiles I None
appeared I None
dose I None
proportional I None
. I None
<eof> I None

<s> O None
Exenatide I None
doses I None
of I None
0 I None
. I None
02 I None
- I None
0 I None
. I None
2 I None
microg I None
/ I None
kg I None
dose I None
- I None
dependently I None
lowered I None
postprandial I None
glucose I CHEMICAL
excursions I None
. I None
<eof> I None

<s> O None
Exenatide I None
suppressed I None
postprandial I None
plasma I None
glucagon I GENE-Y
and I None
slowed I None
gastric I None
emptying I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
serious I None
adverse I None
events I None
and I None
no I None
patient I None
withdrawals I None
related I None
to I None
treatment I None
. I None
<eof> I None

<s> O None
Nausea I None
and I None
vomiting I None
were I None
the I None
most I None
common I None
adverse I None
events I None
and I None
were I None
mild I None
to I None
moderate I None
in I None
severity I None
at I None
doses I None
ranging I None
from I None
0 I None
. I None
02 I None
to I None
0 I None
. I None
2 I None
microg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
Administration I None
of I None
preprandial I None
exenatide I None
by I None
s I None
. I None
c I None
. I None
injection I None
resulted I None
in I None
dose I None
- I None
proportional I None
exenatide I None
pharmacokinetics I None
and I None
antidiabetic I None
pharmacodynamic I None
activity I None
. I None
<eof> I None

<s> O None
At I None
doses I None
ranging I None
from I None
0 I None
. I None
02 I None
to I None
0 I None
. I None
2 I None
microg I None
/ I None
kg I None
, I None
exenatide I None
dose I None
- I None
dependently I None
reduced I None
postprandial I None
plasma I None
glucose I CHEMICAL
excursion I None
by I None
insulinotropism I None
, I None
suppression I None
of I None
plasma I None
glucagon I GENE-Y
, I None
and I None
slowing I None
of I None
gastric I None
emptying I None
. I None
<eof> I None

<s> O None
Sterol I GENE-N
transporters O GENE-N
: I None
targets I None
of I None
natural I None
sterols I CHEMICAL
and I None
new I None
lipid I None
lowering I None
drugs I None
. I None
<eof> I None

<s> O None
Recent I None
insights I None
in I None
the I None
role I None
of I None
ATP I GENE-N
- O GENE-N
binding O GENE-N
cassette O GENE-N
( O GENE-N
ABC O GENE-N
) O GENE-N
transporters O GENE-N
ABCG5 I GENE-Y
and I None
ABCG8 I GENE-Y
, I None
the I None
discovery I None
of I None
ezetimibe I CHEMICAL
, I None
the I None
first I None
approved I None
direct I None
cholesterol I CHEMICAL
absorption I None
inhibitor I None
, I None
as I None
well I None
as I None
the I None
identification I None
of I None
Niemann I GENE-Y
- O GENE-Y
Pick O GENE-Y
C1 O GENE-Y
Like O GENE-Y
1 O GENE-Y
( I None
NPC1L1 I GENE-Y
) I None
protein I None
as I None
sterol I CHEMICAL
transporter I None
in I None
the I None
gut I None
, I None
focused I None
attention I None
on I None
sterol I CHEMICAL
transport I None
processes I None
in I None
the I None
small I None
intestine I None
and I None
the I None
liver I None
. I None
<eof> I None

<s> O None
The I None
identification I None
of I None
defective I None
structures I None
in I None
the I None
ABCG5 I GENE-Y
or I None
ABCG8 I GENE-Y
transporters I None
in I None
patients I None
with I None
the I None
rare I None
disease I None
of I None
sitosterolemia I None
elucidated I None
their I None
role I None
as I None
sterol I GENE-N
efflux O GENE-N
pumps O GENE-N
regulating I None
at I None
least I None
in I None
parts I None
the I None
intestinal I None
sterol I CHEMICAL
absorption I None
and I None
the I None
hepatic I None
sterol I CHEMICAL
output I None
. I None
<eof> I None

<s> O None
ABCG5 I GENE-Y
and I None
ABCG8 I GENE-Y
themselves I None
are I None
regulated I None
by I None
cholesterol I CHEMICAL
via I None
liver I GENE-N
X O GENE-N
receptors O GENE-N
( I None
LXRs I GENE-N
) I None
, I None
which I None
are I None
also I None
activated I None
by I None
oxysterols I None
and I None
some I None
derivatives I None
of I None
plant I None
sterols I CHEMICAL
. I None
<eof> I None

<s> O None
NPC1L1 I GENE-Y
could I None
recently I None
be I None
identified I None
as I None
a I None
major I None
sterol I GENE-N
transporter O GENE-N
for I None
the I None
intestinal I None
uptake I None
of I None
cholesterol I CHEMICAL
as I None
well I None
as I None
plant I None
sterols I CHEMICAL
. I None
<eof> I None

<s> O None
Studies I None
in I None
NPC1L1 I GENE-Y
knockout I None
mice I None
indicate I None
that I None
this I None
transporter I None
is I None
essential I None
for I None
the I None
intestinal I None
uptake I None
of I None
sterols I CHEMICAL
and I None
that I None
NPC1L1 I GENE-Y
might I None
also I None
be I None
involved I None
in I None
the I None
mechanism I None
of I None
action I None
of I None
ezetimibe I CHEMICAL
. I None
<eof> I None

<s> O None
However I None
, I None
studies I None
with I None
photoreactive I None
cholesterol I CHEMICAL
as I None
well I None
as I None
with I None
photoreactive I None
ezetimibe I CHEMICAL
analogues I None
suggest I None
that I None
other I None
processes I None
might I None
also I None
be I None
involved I None
in I None
the I None
mechanism I None
of I None
action I None
of I None
ezetimibe I CHEMICAL
. I None
<eof> I None

<s> O None
[ I None
Change I None
of I None
dopamine I GENE-Y
transporter O GENE-Y
activity I None
( I None
DAT I GENE-Y
) I None
during I None
the I None
action I None
of I None
bupropion I CHEMICAL
( I None
in I None
depression I None
) I None
] I None
. I None
<eof> I None

<s> O None
Bupropion I CHEMICAL
has I None
an I None
antidepressant I None
effect I None
through I None
blocking I None
the I None
dopamine I GENE-Y
transporter O GENE-Y
. I None
<eof> I None

<s> O None
By I None
99mTc I None
- I None
TRODAT I None
- I None
SPECT I None
, I None
we I None
measured I None
the I None
baseline I None
DAT I GENE-Y
activity I None
of I None
depressed I None
patients I None
. I None
<eof> I None

<s> O None
After I None
3 I None
weeks I None
' I None
bupropion I CHEMICAL
treatment I None
we I None
studied I None
the I None
change I None
in I None
DAT I GENE-Y
activity I None
, I None
which I None
corresponds I None
to I None
the I None
occupancy I None
of I None
bupropion I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
average I None
occupancy I None
of I None
bupropion I CHEMICAL
on I None
DAT I GENE-Y
was I None
similar I None
to I None
the I None
international I None
findings I None
at I None
20 I None
. I None
84 I None
% I None
in I None
9 I None
depressed I None
patients I None
. I None
<eof> I None

<s> O None
A I None
phase I None
- I None
1 I None
trial I None
of I None
bexarotene I CHEMICAL
and I None
denileukin I None
diftitox I None
in I None
patients I None
with I None
relapsed I None
or I None
refractory I None
cutaneous I None
T I None
- I None
cell I None
lymphoma I None
. I None
<eof> I None

<s> O None
Denileukin I None
diftitox I None
, I None
a I None
genetically I None
engineered I None
fusion I None
protein I None
combining I None
the I None
enzymatically I None
active I None
domains I None
of I None
diphtheria I None
toxin I None
and I None
the I None
full I None
- I None
length I None
sequence I None
for I None
interleukin I GENE-Y
- O GENE-Y
2 O GENE-Y
( I None
IL I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
, I None
efficiently I None
targets I None
lymphoma I None
cells I None
expressing I None
the I None
high I None
- I None
affinity I None
IL I GENE-N
- O GENE-N
2 O GENE-N
receptor O GENE-N
( I None
IL I GENE-N
- O GENE-N
2R O GENE-N
) I None
consisting I None
of I None
the I None
alpha I None
/ I None
p55 I GENE-Y
/ I None
CD25 I GENE-Y
, I None
beta I None
/ I None
p75 I GENE-Y
/ I None
CD122 I GENE-Y
, I None
and I None
gamma I None
/ I None
p64 I GENE-Y
/ I None
CD132 I GENE-Y
chains I None
. I None
<eof> I None

<s> O None
In I None
vitro I None
studies I None
demonstrated I None
that I None
the I None
retinoid I GENE-N
X O GENE-N
receptor O GENE-N
( I None
RXR I GENE-N
) I None
retinoid I None
, I None
bexarotene I CHEMICAL
, I None
at I None
biologically I None
relevant I None
concentrations I None
of I None
10 I None
( I None
- I None
6 I None
) I None
M I None
to I None
10 I None
( I None
- I None
8 I None
) I None
M I None
, I None
upregulated I None
both I None
the I None
p55 I GENE-Y
and I None
p75 I GENE-Y
subunits I None
of I None
the I None
IL I GENE-N
- O GENE-N
2R O GENE-N
and I None
enhanced I None
5 I None
- I None
to I None
10 I None
- I None
fold I None
the I None
susceptibility I None
of I None
T I None
- I None
cell I None
leukemia I None
cells I None
to I None
denileukin I None
diftitox I None
. I None
<eof> I None

<s> O None
To I None
determine I None
whether I None
this I None
biomodulatory I None
effect I None
could I None
be I None
recapitulated I None
in I None
vivo I None
, I None
we I None
treated I None
14 I None
patients I None
with I None
relapsed I None
or I None
refractory I None
cutaneous I None
T I None
- I None
cell I None
lymphoma I None
with I None
escalating I None
doses I None
of I None
bexarotene I CHEMICAL
( I None
75 I None
mg I None
/ I None
day I None
- I None
300 I None
mg I None
/ I None
day I None
) I None
and I None
denileukin I None
diftitox I None
( I None
18 I None
mcg I None
/ I None
kg I None
per I None
day I None
x I None
3 I None
days I None
every I None
21 I None
days I None
) I None
in I None
a I None
phase I None
1 I None
trial I None
. I None
<eof> I None

<s> O None
Overall I None
response I None
was I None
67 I None
% I None
( I None
4 I None
complete I None
responses I None
, I None
4 I None
partial I None
responses I None
) I None
. I None
<eof> I None

<s> O None
Modulation I None
of I None
IL I GENE-N
- O GENE-N
2R O GENE-N
expression I None
was I None
observed I None
at I None
or I None
above I None
a I None
bexarotene I CHEMICAL
dose I None
of I None
150 I None
mg I None
/ I None
day I None
. I None
<eof> I None

<s> O None
Four I None
patients I None
experienced I None
grade I None
2 I None
or I None
3 I None
leukopenia I None
, I None
and I None
2 I None
had I None
grade I None
4 I None
lymphopenia I None
. I None
<eof> I None

<s> O None
Our I None
results I None
demonstrate I None
that I None
the I None
combination I None
of I None
denileukin I None
diftitox I None
and I None
bexarotene I CHEMICAL
is I None
well I None
tolerated I None
and I None
that I None
even I None
low I None
doses I None
( I None
150 I None
mg I None
/ I None
day I None
) I None
of I None
bexarotene I CHEMICAL
are I None
capable I None
of I None
in I None
vivo I None
upregulation I None
of I None
CD25 I GENE-Y
expression I None
on I None
circulating I None
leukemia I None
cells I None
. I None
<eof> I None

<s> O None
Crystal I None
structure I None
of I None
prostate I GENE-Y
- O GENE-Y
specific O GENE-Y
membrane O GENE-Y
antigen O GENE-Y
, I None
a I None
tumor I None
marker I None
and I None
peptidase I GENE-N
. I None
<eof> I None

<s> O None
Prostate I GENE-Y
- O GENE-Y
specific O GENE-Y
membrane O GENE-Y
antigen O GENE-Y
( I None
PSMA I GENE-Y
) I None
is I None
highly I None
expressed I None
in I None
prostate I None
cancer I None
cells I None
and I None
nonprostatic I None
solid I None
tumor I None
neovasculature I None
and I None
is I None
a I None
target I None
for I None
anticancer I None
imaging I None
and I None
therapeutic I None
agents I None
. I None
<eof> I None

<s> O None
PSMA I GENE-Y
acts I None
as I None
a I None
glutamate I GENE-N
carboxypeptidase O GENE-N
( I None
GCPII I GENE-Y
) I None
on I None
small I None
molecule I None
substrates I None
, I None
including I None
folate I CHEMICAL
, I None
the I None
anticancer I None
drug I None
methotrexate I CHEMICAL
, I None
and I None
the I None
neuropeptide I None
N I CHEMICAL
- O CHEMICAL
acetyl O CHEMICAL
- O CHEMICAL
l O CHEMICAL
- O CHEMICAL
aspartyl O CHEMICAL
- O CHEMICAL
l O CHEMICAL
- O CHEMICAL
glutamate O CHEMICAL
. I None
<eof> I None

<s> O None
Here I None
we I None
present I None
the I None
3 I None
. I None
5 I None
- I None
A I None
crystal I None
structure I None
of I None
the I None
PSMA I GENE-N
ectodomain O GENE-N
, I None
which I None
reveals I None
a I None
homodimer I None
with I None
structural I None
similarity I None
to I None
transferrin I GENE-N
receptor O GENE-N
, I None
a I None
receptor I None
for I None
iron I CHEMICAL
- I None
loaded I None
transferrin I GENE-Y
that I None
lacks I None
protease I GENE-N
activity I None
. I None
<eof> I None

<s> O None
Unlike I None
transferrin I GENE-N
receptor O GENE-N
, I None
the I None
protease I GENE-N
domain O GENE-N
of I None
PSMA I GENE-Y
contains I None
a I None
binuclear I None
zinc I CHEMICAL
site I None
, I None
catalytic I None
residues I None
, I None
and I None
a I None
proposed I None
substrate I None
- I None
binding I None
arginine I CHEMICAL
patch I None
. I None
<eof> I None

<s> O None
Elucidation I None
of I None
the I None
PSMA I GENE-Y
structure I None
combined I None
with I None
docking I None
studies I None
and I None
a I None
proposed I None
catalytic I None
mechanism I None
provides I None
insight I None
into I None
the I None
recognition I None
of I None
inhibitors I None
and I None
the I None
natural I None
substrate I None
N I CHEMICAL
- O CHEMICAL
acetyl O CHEMICAL
- O CHEMICAL
l O CHEMICAL
- O CHEMICAL
aspartyl O CHEMICAL
- O CHEMICAL
l O CHEMICAL
- O CHEMICAL
glutamate O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
PSMA I GENE-Y
structure I None
will I None
facilitate I None
development I None
of I None
chemotherapeutics I None
, I None
cancer I None
- I None
imaging I None
agents I None
, I None
and I None
agents I None
for I None
treatment I None
of I None
neurological I None
disorders I None
. I None
<eof> I None

<s> O None
Conversion I None
of I None
5 I GENE-N
- O GENE-N
aminolevulinate O GENE-N
synthase O GENE-N
into I None
a I None
more I None
active I None
enzyme I None
by I None
linking I None
the I None
two I None
subunits I None
: I None
spectroscopic I None
and I None
kinetic I None
properties I None
. I None
<eof> I None

<s> O None
The I None
two I None
active I None
sites I None
of I None
dimeric I None
5 I GENE-N
- O GENE-N
aminolevulinate O GENE-N
synthase O GENE-N
( I None
ALAS I GENE-N
) I None
, I None
a I None
pyridoxal I CHEMICAL
5 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
phosphate O CHEMICAL
( I None
PLP I CHEMICAL
) I None
- I None
dependent I None
enzyme I None
, I None
are I None
located I None
on I None
the I None
subunit I None
interface I None
with I None
contribution I None
of I None
essential I None
amino I CHEMICAL
acids O CHEMICAL
from I None
each I None
subunit I None
. I None
<eof> I None

<s> O None
Linking I None
the I None
two I None
subunits I None
into I None
a I None
single I None
polypeptide I None
chain I None
dimer I None
( I None
2XALAS I GENE-N
) I None
yielded I None
an I None
enzyme I None
with I None
an I None
approximate I None
sevenfold I None
greater I None
turnover I None
number I None
than I None
that I None
of I None
wild I None
- I None
type I None
ALAS I GENE-N
. I None
<eof> I None

<s> O None
Spectroscopic I None
and I None
kinetic I None
properties I None
of I None
2XALAS I GENE-N
were I None
investigated I None
to I None
explore I None
the I None
differences I None
in I None
the I None
coenzyme I None
structure I None
and I None
kinetic I None
mechanism I None
relative I None
to I None
those I None
of I None
wild I None
- I None
type I None
ALAS I GENE-N
that I None
confer I None
a I None
more I None
active I None
enzyme I None
. I None
<eof> I None

<s> O None
The I None
absorption I None
spectra I None
of I None
both I None
ALAS I GENE-N
and I None
2XALAS I GENE-N
had I None
maxima I None
at I None
410 I None
and I None
330 I None
nm I None
, I None
with I None
a I None
greater I None
A I None
( I None
410 I None
) I None
/ I None
A I None
( I None
330 I None
) I None
ratio I None
at I None
pH I None
approximately I None
7 I None
. I None
5 I None
for I None
2XALAS I GENE-N
. I None
<eof> I None

<s> O None
The I None
330 I None
nm I None
absorption I None
band I None
showed I None
an I None
intense I None
fluorescence I None
at I None
385 I None
nm I None
but I None
not I None
at I None
510 I None
nm I None
, I None
indicating I None
that I None
the I None
330 I None
nm I None
absorption I None
species I None
is I None
the I None
substituted I None
aldamine I CHEMICAL
rather I None
than I None
the I None
enolimine I CHEMICAL
form I None
of I None
the I None
Schiff I CHEMICAL
base O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
385 I None
nm I None
emission I None
intensity I None
increased I None
with I None
increasing I None
pH I None
with I None
a I None
single I None
pK I None
of I None
approximately I None
8 I None
. I None
5 I None
for I None
both I None
enzymes I None
, I None
and I None
thus I None
the I None
410 I None
and I None
330 I None
nm I None
absorption I None
species I None
were I None
attributed I None
to I None
the I None
ketoenamine I CHEMICAL
and I None
substituted I None
aldamine I CHEMICAL
, I None
respectively I None
. I None
<eof> I None

<s> O None
Transient I None
kinetic I None
analysis I None
of I None
the I None
formation I None
and I None
decay I None
of I None
the I None
quinonoid I CHEMICAL
intermediate I None
EQ I None
( I None
2 I None
) I None
indicated I None
that I None
, I None
although I None
their I None
rates I None
were I None
similar I None
in I None
ALAS I GENE-N
and I None
2XALAS I GENE-N
, I None
accumulation I None
of I None
this I None
intermediate I None
was I None
greater I None
in I None
the I None
2XALAS I GENE-N
- I None
catalyzed I None
reaction I None
. I None
<eof> I None

<s> O None
Collectively I None
, I None
these I None
results I None
suggest I None
that I None
ketoenamine I CHEMICAL
is I None
the I None
active I None
form I None
of I None
the I None
coenzyme I None
and I None
forms I None
a I None
more I None
prominent I None
coenzyme I None
structure I None
in I None
2XALAS I GENE-N
than I None
in I None
ALAS I GENE-N
at I None
pH I None
approximately I None
7 I None
. I None
5 I None
. I None
<eof> I None

<s> O None
Regulation I None
of I None
the I None
expression I None
of I None
peptidylarginine I GENE-Y
deiminase O GENE-Y
type O GENE-Y
II O GENE-Y
gene I None
( I None
PADI2 I GENE-Y
) I None
in I None
human I None
keratinocytes I None
involves I None
Sp1 I GENE-Y
and I None
Sp3 I GENE-Y
transcription I None
factors I None
. I None
<eof> I None

<s> O None
Peptidylarginine I GENE-N
deiminases O GENE-N
( I None
PAD I GENE-N
) I None
convert I None
protein I None
- I None
bound I None
arginine I CHEMICAL
residues I None
into I None
citrulline I CHEMICAL
residues I None
in I None
a I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
ion I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
Among I None
the I None
five I None
isoforms I None
( I None
PAD1 I GENE-N
, O GENE-N
2 O GENE-N
, O GENE-N
3 O GENE-N
, O GENE-N
4 O GENE-N
, O GENE-N
and O GENE-N
6 O GENE-N
) I None
existing I None
in I None
rodents I None
and I None
humans I None
, I None
PAD2 I GENE-Y
is I None
the I None
most I None
widely I None
expressed I None
in I None
both I None
species I None
, I None
tissues I None
, I None
and I None
organs I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
study I None
the I None
mechanisms I None
regulating I None
the I None
expression I None
of I None
the I None
human I GENE-Y
PAD2 O GENE-Y
gene I None
, I None
PADI2 I GENE-Y
, I None
we I None
characterized I None
its I None
promoter I None
region I None
using I None
transfected I None
human I None
keratinocytes I None
. I None
<eof> I None

<s> O None
A I None
series I None
of I None
reporter I None
gene I None
constructions I None
derived I None
from I None
the I None
2 I None
kb I None
region I None
upstream I None
of I None
the I None
transcription I GENE-N
initiation O GENE-N
site O GENE-N
defined I None
a I None
minimal I None
promoter I None
sequence I None
from I None
nucleotides I None
- I None
132 I None
to I None
- I None
41 I None
. I None
<eof> I None

<s> O None
This I None
PADI2 I GENE-Y
region I None
is I None
GC I None
- I None
rich I None
and I None
lacks I None
canonical I None
TATA I GENE-N
and I None
CAAT I GENE-N
boxes O GENE-N
. I None
<eof> I None

<s> O None
Investigation I None
of I None
cis I GENE-N
- O GENE-N
acting O GENE-N
elements O GENE-N
in I None
the I None
region I None
, I None
further I None
deletion I None
analyses I None
and I None
electrophoretic I None
mobility I None
shift I None
assays I None
using I None
specific I None
antibodies I None
revealed I None
four I None
Sp1 I GENE-N
- O GENE-N
binding O GENE-N
sites O GENE-N
and I None
identified I None
Sp1 I GENE-Y
and I None
Sp3 I GENE-Y
as I None
binding I None
factors I None
important I None
for I None
the I None
promoter I None
activity I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
Sp1 I GENE-Y
/ I None
Sp3 I GENE-Y
cooperation I None
may I None
provide I None
a I None
mechanism I None
to I None
control I None
the I None
transcription I None
of I None
PADI2 I GENE-Y
. I None
<eof> I None

<s> O None
Activator I GENE-Y
of O GENE-Y
G O GENE-Y
protein O GENE-Y
signaling O GENE-Y
3 O GENE-Y
regulates I None
opiate I None
activation I None
of I None
protein I GENE-N
kinase O GENE-N
A O GENE-N
signaling I None
and I None
relapse I None
of I None
heroin I CHEMICAL
- I None
seeking I None
behavior I None
. I None
<eof> I None

<s> O None
The I None
nucleus I None
accumbens I None
( I None
NAc I None
) I None
is I None
central I None
to I None
heroin I CHEMICAL
addiction I None
. I None
<eof> I None

<s> O None
Activation I None
of I None
opiate I GENE-N
receptors O GENE-N
in I None
the I None
NAc I None
dissociates I None
G I GENE-N
( O GENE-N
i O GENE-N
/ O GENE-N
o O GENE-N
) O GENE-N
into O GENE-N
alpha O GENE-N
and O GENE-N
betagamma O GENE-N
subunits I None
. I None
<eof> I None

<s> O None
Galpha I GENE-N
( O GENE-N
i O GENE-N
) O GENE-N
inhibits I None
cAMP I CHEMICAL
production I None
, I None
but I None
betagamma I None
regulates I None
several I None
molecular I None
pathways I None
, I None
including I None
protein I GENE-N
kinase O GENE-N
A O GENE-N
( I None
PKA I GENE-N
) I None
. I None
<eof> I None

<s> O None
We I None
show I None
in I None
NAc I None
/ I None
striatal I None
neurons I None
that I None
opiates I None
paradoxically I None
activate I None
PKA I GENE-N
signaling I None
by I None
means I None
of I None
betagamma I None
dimers I None
. I None
<eof> I None

<s> O None
Activation I None
requires I None
Galpha I GENE-Y
( O GENE-Y
i3 O GENE-Y
) O GENE-Y
and I None
an I None
activator I GENE-Y
of O GENE-Y
G O GENE-Y
protein O GENE-Y
signaling O GENE-Y
3 O GENE-Y
( I None
AGS3 I GENE-Y
) I None
. I None
<eof> I None

<s> O None
AGS3 I GENE-Y
competes I None
with I None
betagamma I None
for I None
binding I None
to I None
Galpha I GENE-Y
( O GENE-Y
i3 O GENE-Y
) O GENE-Y
- I None
GDP I None
and I None
enhances I None
the I None
action I None
of I None
unbound I None
betagamma I None
. I None
<eof> I None

<s> O None
AGS3 I GENE-Y
and I None
Galpha I GENE-Y
( O GENE-Y
i3 O GENE-Y
) O GENE-Y
knockdown I None
prevents I None
opiate I None
activation I None
of I None
PKA I GENE-N
signaling I None
. I None
<eof> I None

<s> O None
In I None
rats I None
self I None
- I None
administering I None
heroin I CHEMICAL
, I None
AGS3 I GENE-Y
antisense I None
in I None
the I None
NAc I None
core I None
, I None
but I None
not I None
shell I None
, I None
eliminates I None
reinstatement I None
of I None
heroin I CHEMICAL
- I None
seeking I None
behavior I None
, I None
a I None
model I None
of I None
human I None
relapse I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
Galpha I GENE-N
( O GENE-N
i3 O GENE-N
) O GENE-N
/ O GENE-N
betagamma O GENE-N
/ I None
AGS3 I GENE-Y
appears I None
to I None
mediate I None
mu I GENE-Y
opiate O GENE-Y
receptor O GENE-Y
activation I None
of I None
PKA I GENE-N
signaling I None
as I None
well I None
as I None
heroin I CHEMICAL
- I None
seeking I None
behavior I None
. I None
<eof> I None

<s> O None
2 I CHEMICAL
- O CHEMICAL
[ O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
Dimethylphenyl O CHEMICAL
) O CHEMICAL
piperazin O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
ylmethyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
1H O CHEMICAL
benzoimidazole O CHEMICAL
( I None
A I CHEMICAL
- O CHEMICAL
381393 O CHEMICAL
) I None
, I None
a I None
selective I None
dopamine I GENE-Y
D4 O GENE-Y
receptor O GENE-Y
antagonist I None
. I None
<eof> I None

<s> O None
2 I CHEMICAL
- O CHEMICAL
[ O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
Dimethylphenlyl O CHEMICAL
) O CHEMICAL
piperazin O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
ylmethyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
1H O CHEMICAL
benzoimidazole O CHEMICAL
( I None
A I CHEMICAL
- O CHEMICAL
381393 O CHEMICAL
) I None
was I None
identified I None
as I None
a I None
potent I None
dopamine I GENE-Y
D4 O GENE-Y
receptor O GENE-Y
antagonist I None
with I None
excellent I None
receptor I None
selectivity I None
. I None
<eof> I None

<s> O None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
- O CHEMICAL
spiperone O CHEMICAL
competition I None
binding I None
assays I None
showed I None
that I None
A I CHEMICAL
- O CHEMICAL
381393 O CHEMICAL
potently I None
bound I None
to I None
membrane I None
from I None
cells I None
expressing I None
recombinant I None
human I GENE-N
dopamine O GENE-N
D4 O GENE-N
. O GENE-N
4 O GENE-N
receptor O GENE-N
( I None
Ki I None
= I None
1 I None
. I None
5 I None
nM I None
) I None
, I None
which I None
was I None
20 I None
- I None
fold I None
higher I None
than I None
that I None
of I None
clozapine I CHEMICAL
( I None
Ki I None
= I None
30 I None
. I None
4 I None
nM I None
) I None
. I None
<eof> I None

<s> O None
A I CHEMICAL
- O CHEMICAL
381393 O CHEMICAL
exhibited I None
highly I None
selective I None
binding I None
for I None
the I None
dopamine I GENE-N
D4 O GENE-N
. O GENE-N
4 O GENE-N
receptor O GENE-N
( I None
> I None
2700 I None
- I None
fold I None
) I None
when I None
compared I None
to I None
D1 I GENE-N
, O GENE-N
D2 O GENE-N
, O GENE-N
D3 O GENE-N
and O GENE-N
D5 O GENE-N
dopamine O GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
in I None
comparison I None
to I None
clozapine I CHEMICAL
and I None
L I CHEMICAL
- O CHEMICAL
745870 O CHEMICAL
, I None
A I CHEMICAL
- O CHEMICAL
381393 O CHEMICAL
exhibits I None
better I None
receptor I None
selectivity I None
, I None
showing I None
no I None
affinity I None
up I None
to I None
10 I None
microM I None
for I None
a I None
panel I None
of I None
more I None
than I None
70 I None
receptors I None
and I None
channels I None
, I None
with I None
the I None
exception I None
of I None
moderate I None
affinity I None
for I None
5 I GENE-Y
- O GENE-Y
HT2A O GENE-Y
( I None
Ki I None
= I None
370 I None
nM I None
) I None
. I None
<eof> I None

<s> O None
A I CHEMICAL
- O CHEMICAL
381393 O CHEMICAL
potently I None
inhibited I None
the I None
functional I None
activity I None
of I None
agonist I None
- I None
induced I None
GTP I CHEMICAL
- I None
gamma I None
- I None
S I None
binding I None
assay I None
and I None
1 I None
microM I None
dopamine I CHEMICAL
induced I None
- I None
Ca2 I CHEMICAL
+ O CHEMICAL
flux I None
in I None
human I GENE-N
dopamine O GENE-N
D4 O GENE-N
. O GENE-N
4 O GENE-N
receptor O GENE-N
expressing I None
cells I None
, I None
but I None
not I None
in I None
human I GENE-N
dopamine O GENE-N
D2L O GENE-N
or O GENE-N
D3 O GENE-N
receptor O GENE-N
cells I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
to I None
L I CHEMICAL
- O CHEMICAL
745870 O CHEMICAL
, I None
A I CHEMICAL
- O CHEMICAL
381393 O CHEMICAL
did I None
not I None
exhibit I None
any I None
significant I None
intrinsic I None
activity I None
in I None
a I None
D4 I GENE-N
. O GENE-N
4 O GENE-N
receptor O GENE-N
. I None
<eof> I None

<s> O None
In I None
vivo I None
, I None
A I CHEMICAL
- O CHEMICAL
381393 O CHEMICAL
has I None
good I None
brain I None
penetration I None
after I None
subcutaneous I None
administration I None
. I None
<eof> I None

<s> O None
A I CHEMICAL
- O CHEMICAL
381393 O CHEMICAL
inhibited I None
penile I None
erection I None
induced I None
by I None
the I None
selective I None
D4 I None
agonist I None
PD168077 I CHEMICAL
in I None
conscious I None
rats I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
A I CHEMICAL
- O CHEMICAL
381393 O CHEMICAL
is I None
a I None
novel I None
selective I None
D4 I None
antagonist I None
that I None
will I None
enhance I None
the I None
ability I None
to I None
study I None
dopamine I GENE-N
D4 O GENE-N
receptors O GENE-N
both I None
in I None
vitro I None
and I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Review I None
article I None
: I None
5 I CHEMICAL
- O CHEMICAL
hydroxytryptamine O CHEMICAL
agonists I None
and I None
antagonists I None
in I None
the I None
modulation I None
of I None
gastrointestinal I None
motility I None
and I None
sensation I None
: I None
clinical I None
implications I None
. I None
<eof> I None

<s> O None
Serotonin I CHEMICAL
( I None
5 I CHEMICAL
- O CHEMICAL
hydroxytryptamine O CHEMICAL
; I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
) I None
is I None
found I None
in I None
the I None
enteric I None
nervous I None
system I None
where I None
it I None
has I None
been I None
implicated I None
in I None
controlling I None
gastrointestinal I None
motor I None
function I None
. I None
<eof> I None

<s> O None
A I None
number I None
of I None
receptor I None
or I None
recognition I None
sites I None
have I None
been I None
identified I None
in I None
the I None
gut I None
, I None
but I None
recently I None
most I None
attention I None
has I None
focused I None
on I None
the I None
5 I GENE-Y
- O GENE-Y
HT3 O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT4 O GENE-Y
receptors I None
. I None
<eof> I None

<s> O None
The I None
functional I None
role I None
of I None
the I None
5 I GENE-Y
- O GENE-Y
HT3 O GENE-Y
receptor I None
remains I None
incompletely I None
understood I None
, I None
but I None
it I None
is I None
probably I None
involved I None
in I None
the I None
modulation I None
of I None
colonic I None
motility I None
and I None
visceral I None
pain I None
in I None
the I None
gut I None
. I None
<eof> I None

<s> O None
A I None
number I None
of I None
selective I None
5 I GENE-Y
- O GENE-Y
HT3 O GENE-Y
antagonists I None
have I None
been I None
developed I None
including I None
ondansetron I CHEMICAL
, I None
granisetron I CHEMICAL
, I None
tropisetron I CHEMICAL
renzapride I CHEMICAL
and I None
zacopride I CHEMICAL
. I None
<eof> I None

<s> O None
While I None
the I None
substituted I None
benzamide I CHEMICAL
prokinetics I None
( I None
for I None
example I None
, I None
metoclopramide I CHEMICAL
, I None
cisapride I CHEMICAL
) I None
also I None
block I None
5 I GENE-Y
- O GENE-Y
HT3 O GENE-Y
receptors I None
in I None
high I None
concentrations I None
, I None
their I None
prokinetic I None
action I None
is I None
believed I None
to I None
be I None
on I None
the I None
basis I None
of I None
their I None
agonist I None
effects I None
on I None
the I None
putative I None
5 I GENE-Y
- O GENE-Y
HT4 O GENE-Y
receptor I None
. I None
<eof> I None

<s> O None
Some I None
5 I GENE-Y
- O GENE-Y
HT3 O GENE-Y
antagonists I None
have I None
5 I GENE-Y
- O GENE-Y
HT4 O GENE-Y
agonist I None
activity I None
( I None
for I None
example I None
, I None
renzapride I CHEMICAL
, I None
zacopride I CHEMICAL
) I None
and I None
others I None
do I None
not I None
( I None
for I None
example I None
, I None
ondansetron I CHEMICAL
, I None
granisetron I CHEMICAL
) I None
, I None
while I None
tropisetron I CHEMICAL
in I None
high I None
concentrations I None
is I None
a I None
5 I GENE-Y
- O GENE-Y
HT4 O GENE-Y
antagonist I None
. I None
<eof> I None

<s> O None
Based I None
on I None
the I None
pharmacological I None
data I None
, I None
it I None
has I None
been I None
suggested I None
that I None
specific I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
antagonists I None
and I None
agonists I None
may I None
prove I None
to I None
be I None
beneficial I None
in I None
a I None
number I None
of I None
gastrointestinal I None
disorders I None
including I None
the I None
irritable I None
bowel I None
syndrome I None
, I None
functional I None
dyspepsia I None
, I None
non I None
- I None
cardiac I None
chest I None
pain I None
, I None
gastrooesophageal I None
reflux I None
and I None
refractory I None
nausea I None
. I None
<eof> I None

<s> O None
In I None
this I None
review I None
, I None
the I None
rationale I None
for I None
the I None
use I None
of I None
these I None
compounds I None
is I None
discussed I None
, I None
and I None
the I None
available I None
experimental I None
evidence I None
is I None
summarized I None
. I None
<eof> I None

<s> O None
Niacin I CHEMICAL
mediates I None
lipolysis I None
in I None
adipose I None
tissue I None
through I None
its I None
G I GENE-Y
- O GENE-Y
protein O GENE-Y
coupled O GENE-Y
receptor O GENE-Y
HM74A O GENE-Y
. I None
<eof> I None

<s> O None
A I None
G I GENE-N
- O GENE-N
protein O GENE-N
coupled O GENE-N
receptor O GENE-N
to I None
niacin I CHEMICAL
( I None
nicotinic I CHEMICAL
acid O CHEMICAL
) I None
was I None
identified I None
recently I None
but I None
the I None
physiological I None
/ I None
pharmacological I None
role I None
of I None
the I None
receptor I None
remains I None
poorly I None
defined I None
. I None
<eof> I None

<s> O None
We I None
present I None
our I None
studies I None
to I None
demonstrate I None
that I None
HM74A I GENE-N
, I None
but I None
not I None
HM74 I GENE-N
, I None
binds I None
niacin I CHEMICAL
at I None
high I None
affinities I None
and I None
effectively I None
mediates I None
Gi I GENE-N
signaling I None
events I None
in I None
human I None
embryonic I None
kidney I None
HEK293 I None
cells I None
as I None
well I None
as I None
in I None
3T3L1 I None
adipocytes I None
expressing I None
HM74A I GENE-N
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
HM74A I GENE-Y
, I None
but I None
not I None
HM74 I GENE-Y
, I None
expressed I None
in I None
differentiated I None
3T3L1 I None
adipocytes I None
effectively I None
mediated I None
inhibition I None
of I None
lipolysis I None
by I None
niacin I CHEMICAL
. I None
<eof> I None

<s> O None
Our I None
results I None
provided I None
direct I None
evidence I None
indicating I None
that I None
HM74A I GENE-Y
, I None
but I None
not I None
HM74 I GENE-Y
, I None
was I None
sufficient I None
to I None
mediate I None
anti I None
- I None
lipolytic I None
effect I None
of I None
niacin I CHEMICAL
in I None
adipose I None
tissue I None
. I None
<eof> I None

<s> O None
Islet I None
cell I None
antibodies I None
in I None
normal I None
French I None
schoolchildren I None
. I None
<eof> I None

<s> O None
Islet I None
- I None
cell I None
antibodies I None
have I None
been I None
reported I None
to I None
be I None
of I None
predictive I None
value I None
for I None
the I None
future I None
development I None
of I None
Type I None
1 I None
( I None
insulin I GENE-Y
- I None
dependent I None
) I None
diabetes I None
in I None
first I None
degree I None
relatives I None
of I None
diabetic I None
patients I None
with I None
the I None
risk I None
increasing I None
in I None
these I None
subjects I None
with I None
the I None
islet I None
- I None
cell I None
antibodies I None
titre I None
. I None
<eof> I None

<s> O None
However I None
, I None
very I None
little I None
is I None
known I None
about I None
islet I None
- I None
cell I None
antibodies I None
in I None
background I None
populations I None
. I None
<eof> I None

<s> O None
Sera I None
( I None
n I None
= I None
8363 I None
) I None
from I None
schoolchildren I None
( I None
6 I None
- I None
17 I None
years I None
) I None
in I None
the I None
French I None
background I None
population I None
were I None
screened I None
for I None
the I None
presence I None
of I None
islet I None
- I None
cell I None
antibodies I None
by I None
the I None
indirect I None
immunofluorescence I None
technique I None
. I None
<eof> I None

<s> O None
Islet I None
- I None
cell I None
antibodies I None
greater I None
than I None
4 I None
. I None
5 I None
Juvenile I None
Diabetes I None
Foundation I None
units I None
were I None
found I None
in I None
150 I None
sera I None
( I None
prevalence I None
rate I None
1 I None
. I None
8 I None
% I None
; I None
95 I None
% I None
confidence I None
interval I None
1 I None
. I None
5 I None
- I None
2 I None
. I None
1 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Only I None
17 I None
sera I None
demonstrated I None
islet I None
- I None
cell I None
antibody I None
titre I None
greater I None
than I None
or I None
equal I None
to I None
24 I None
JDF I None
units I None
. I None
<eof> I None

<s> O None
No I None
particular I None
feature I None
was I None
found I None
to I None
be I None
significantly I None
different I None
between I None
islet I None
- I None
cell I None
antibody I None
- I None
positive I None
and I None
islet I None
- I None
cell I None
antibody I None
- I None
negative I None
children I None
( I None
age I None
, I None
family I None
history I None
of I None
diabetes I None
, I None
fasting I None
plasma I None
glucose I CHEMICAL
, I None
insulin I None
autoantibodies I None
) I None
. I None
<eof> I None

<s> O None
A I None
second I None
blood I None
sample I None
was I None
obtained I None
from I None
80 I None
of I None
150 I None
islet I None
- I None
cell I None
antibody I None
positive I None
children I None
after I None
a I None
mean I None
interval I None
of I None
8 I None
months I None
. I None
<eof> I None

<s> O None
Only I None
11 I None
sera I None
became I None
less I None
than I None
4 I None
. I None
5 I None
JDF I None
units I None
with I None
islet I None
- I None
cell I None
antibody I None
titres I None
being I None
stable I None
in I None
the I None
remaining I None
sera I None
, I None
including I None
the I None
high I None
- I None
titre I None
positive I None
sera I None
( I None
greater I None
than I None
or I None
equal I None
to I None
24 I None
JDF I None
units I None
) I None
. I None
<eof> I None

<s> O None
HLA I GENE-Y
- O GENE-Y
DQB O GENE-Y
typing I None
was I None
performed I None
by I None
restriction I None
mapping I None
techniques I None
in I None
80 I None
islet I None
- I None
cell I None
antibody I None
- I None
positive I None
, I None
in I None
93 I None
islet I None
- I None
cell I None
antibody I None
- I None
negative I None
and I None
in I None
213 I None
Type I None
1 I None
diabetic I None
children I None
. I None
<eof> I None

<s> O None
The I None
distribution I None
of I None
the I None
susceptibility I None
alleles I None
( I None
DQB1 I GENE-Y
- I None
Asp57 I None
- I None
negative I None
) I None
was I None
not I None
significantly I None
different I None
between I None
islet I None
- I None
cell I None
antibody I None
- I None
positive I None
and I None
islet I None
- I None
cell I None
antibody I None
- I None
negative I None
children I None
. I None
( I None
ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Effect I None
of I None
gene I None
disruptions I None
of I None
the I None
TCA I CHEMICAL
cycle I None
on I None
production I None
of I None
succinic I CHEMICAL
acid O CHEMICAL
in I None
Saccharomyces I None
cerevisiae I None
. I None
<eof> I None

<s> O None
Succinate I CHEMICAL
is I None
the I None
main I None
taste I None
component I None
produced I None
by I None
yeasts I None
during I None
sake I None
( I None
Japanese I None
rice I None
wine I None
) I None
fermentation I None
. I None
<eof> I None

<s> O None
The I None
pathway I None
leading I None
to I None
accumulation I None
of I None
succinate I CHEMICAL
was I None
examined I None
in I None
liquid I None
culture I None
in I None
the I None
presence I None
of I None
a I None
high I None
concentration I None
( I None
15 I None
% I None
) I None
of I None
glucose I CHEMICAL
under I None
aerobic I None
and I None
anaerobic I None
conditions I None
using I None
a I None
series I None
of I None
Saccharomyces I None
cerevisiae I None
strains I None
in I None
which I None
various I None
genes I None
that I None
encode I None
the I None
expression I None
of I None
enzymes I None
required I None
in I None
TCA I CHEMICAL
cycle I None
were I None
disrupted I None
. I None
<eof> I None

<s> O None
When I None
cultured I None
in I None
YPD I None
medium I None
containing I None
15 I None
% I None
glucose I CHEMICAL
under I None
aerobic I None
conditions I None
, I None
the I None
KGD1 I GENE-Y
( I None
alpha I GENE-Y
- O GENE-Y
ketoglutarate O GENE-Y
dehydrogenase O GENE-Y
) I None
gene I None
disrupted I None
mutant I None
produced I None
a I None
lower I None
level I None
of I None
succinate I CHEMICAL
than I None
the I None
wild I None
- I None
type I None
strain I None
, I None
while I None
the I None
SDH1 I GENE-Y
( I None
succinate I GENE-Y
dehydrogenase O GENE-Y
) I None
gene I None
- I None
disrupted I None
mutant I None
produced I None
an I None
increased I None
level I None
of I None
succinate I CHEMICAL
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
the I None
FUM1 I GENE-Y
( I None
fumarase I GENE-Y
) I None
gene I None
disrupted I None
mutant I None
produced I None
significantly I None
higher I None
levels I None
of I None
fumarate I CHEMICAL
but I None
did I None
not I None
form I None
malate I CHEMICAL
at I None
all I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
succinate I CHEMICAL
, I None
fumarate I CHEMICAL
and I None
malate I CHEMICAL
are I None
mainly I None
synthesized I None
through I None
the I None
TCA I CHEMICAL
cycle I None
( I None
oxidative I None
direction I None
) I None
even I None
in I None
the I None
presence I None
of I None
glucose I CHEMICAL
at I None
a I None
concentration I None
as I None
high I None
as I None
15 I None
% I None
. I None
<eof> I None

<s> O None
When I None
the I None
growth I None
condition I None
was I None
shifted I None
from I None
aerobic I None
to I None
anaerobic I None
, I None
the I None
increased I None
level I None
of I None
succinate I CHEMICAL
in I None
SDH1 I GENE-Y
disruptants I None
was I None
no I None
longer I None
observed I None
, I None
whereas I None
the I None
decreased I None
level I None
of I None
succinate I CHEMICAL
in I None
the I None
KGD1 I GENE-Y
diruptant I None
was I None
still I None
observed I None
. I None
<eof> I None

<s> O None
A I None
double I None
mutant I None
of I None
the I None
two I None
fumarate I GENE-N
reductase O GENE-N
isozyme I None
genes I None
( I None
OSM1 I GENE-Y
and I None
FRDS I GENE-Y
) I None
showed I None
a I None
succinate I CHEMICAL
productivity I None
of I None
50 I None
% I None
as I None
compared I None
to I None
the I None
parent I None
when I None
cells I None
were I None
incubated I None
in I None
glucose I CHEMICAL
- I None
buffered I None
solution I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
succinate I CHEMICAL
could I None
be I None
synthesized I None
through I None
two I None
pathways I None
, I None
namely I None
, I None
alpha I CHEMICAL
- O CHEMICAL
ketoglutarate O CHEMICAL
oxidation I None
via I None
the I None
TCA I CHEMICAL
cycle I None
and I None
fumarate I CHEMICAL
reduction I None
under I None
anaerobic I None
conditions I None
. I None
<eof> I None

<s> O None
The I None
unexpected I None
side I None
effects I None
of I None
new I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
. I None
<eof> I None

<s> O None
Conventional I None
nonselective I None
NSAIDs I None
are I None
classically I None
associated I None
with I None
a I None
risk I None
of I None
gastrointestinal I None
disorders I None
. I None
<eof> I None

<s> O None
These I None
drugs I None
have I None
a I None
broad I None
range I None
of I None
relative I None
selectivity I None
towards I None
the I None
COX I GENE-N
family I None
, I None
mainly I None
towards I None
two I None
isoforms I None
of I None
these I None
enzymes I None
: I None
COX I GENE-N
- O GENE-N
1 O GENE-N
and O GENE-N
- O GENE-N
2 O GENE-N
. I None
<eof> I None

<s> O None
As I None
examples I None
, I None
ketorolac I CHEMICAL
, I None
flurbiprofen I CHEMICAL
, I None
ketoprofen I CHEMICAL
and I None
indomethacin I CHEMICAL
have I None
increased I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
selectivity I None
when I None
compared I None
with I None
naproxen I CHEMICAL
and I None
ibuprofen I CHEMICAL
. I None
<eof> I None

<s> O None
Association I None
of I None
MTRRA66G I GENE-Y
polymorphism I None
( I None
but I None
not I None
of I None
MTHFR I GENE-Y
C677T I GENE-N
and I None
A1298C I GENE-N
, I None
MTRA2756G I GENE-Y
, I None
TCN I GENE-N
C776G I GENE-N
) I None
with I None
homocysteine I CHEMICAL
and I None
coronary I None
artery I None
disease I None
in I None
the I None
French I None
population I None
. I None
<eof> I None

<s> O None
Methylenetetrahydrofolate I GENE-Y
reductase O GENE-Y
polymorphism I None
( I None
MTHFR I GENE-Y
C677T I GENE-N
) I None
is I None
an I None
established I None
determinant I None
of I None
homocysteine I CHEMICAL
plasma I None
level I None
( I None
t I None
- I None
Hcys I CHEMICAL
) I None
while I None
its I None
association I None
with I None
coronary I None
artery I None
disease I None
( I None
CAD I None
) I None
seems I None
to I None
be I None
more I None
limited I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
association I None
of I None
the I None
substitutions I None
A2756G I GENE-N
of I None
methionine I GENE-Y
synthase O GENE-Y
( I None
MTR I GENE-Y
) I None
, I None
A66G I GENE-N
of I None
methionine I GENE-Y
synthase O GENE-Y
reductase O GENE-Y
( I None
MTRR I GENE-Y
) I None
and I None
C776G I GENE-N
of I None
transcobalamin I GENE-N
( I None
TCN I GENE-N
) I None
to I None
both I None
t I None
- I None
Hcys I CHEMICAL
and I None
CAD I None
needs I None
to I None
be I None
evaluated I None
further I None
. I None
<eof> I None

<s> O None
The I None
objective I None
was I None
to I None
evaluate I None
the I None
association I None
of I None
these I None
polymorphisms I None
with I None
t I None
- I None
Hcys I CHEMICAL
and I None
CAD I None
in I None
a I None
French I None
population I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
individual I None
and I None
combined I None
effects I None
of I None
these I None
polymorphisms I None
and I None
of I None
vitamin I CHEMICAL
B12 O CHEMICAL
and I None
folates I CHEMICAL
with I None
t I None
- I None
Hcys I None
in I None
530 I None
CAD I None
patients I None
and I None
248 I None
matched I None
healthy I None
controls I None
. I None
<eof> I None

<s> O None
t I None
- I None
Hcys I CHEMICAL
was I None
higher I None
in I None
the I None
CAD I None
group I None
than I None
in I None
controls I None
( I None
11 I None
. I None
8 I None
vs I None
10 I None
. I None
4 I None
microM I None
, I None
P I None
< I None
0 I None
. I None
0001 I None
) I None
and I None
in I None
carriers I None
of I None
MTRRAA I GENE-Y
and I None
MTHFR I GENE-Y
677TT I None
than I None
in I None
those I None
carrying I None
the I None
most I None
frequent I None
allele I None
of I None
both I None
polymorphisms I None
( I None
13 I None
. I None
8 I None
vs I None
11 I None
. I None
4 I None
microM I None
, I None
P I None
= I None
0 I None
. I None
0102 I None
and I None
12 I None
. I None
5 I None
vs I None
11 I None
. I None
0 I None
mM I None
, I None
P I None
= I None
0 I None
. I None
0065 I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
The I None
frequency I None
of I None
MTRR I GENE-Y
A I None
allele I None
was I None
higher I None
in I None
CAD I None
patients I None
than I None
in I None
controls I None
( I None
0 I None
. I None
48 I None
[ I None
95 I None
% I None
CI I None
: I None
0 I None
. I None
44 I None
- I None
0 I None
. I None
52 I None
] I None
vs I None
0 I None
. I None
38 I None
[ I None
95 I None
% I None
CI I None
: I None
0 I None
. I None
32 I None
- I None
0 I None
. I None
44 I None
] I None
, I None
P I None
= I None
0 I None
. I None
0081 I None
) I None
while I None
no I None
difference I None
was I None
observed I None
for I None
MTHFR I GENE-Y
677T I None
frequency I None
. I None
<eof> I None

<s> O None
In I None
multivariate I None
analysis I None
, I None
t I None
- I None
Hcys I CHEMICAL
> I None
median I None
and I None
MTRRAA I GENE-Y
genotype I None
were I None
two I None
significant I None
independent I None
predictors I None
of I None
CAD I None
with I None
respective I None
odds I None
ratios I None
of I None
3 I None
. I None
1 I None
( I None
95 I None
% I None
CI I None
: I None
1 I None
. I None
8 I None
- I None
5 I None
. I None
1 I None
, I None
P I None
< I None
0 I None
. I None
0001 I None
) I None
and I None
4 I None
. I None
5 I None
( I None
95 I None
% I None
CI I None
: I None
1 I None
. I None
5 I None
- I None
13 I None
. I None
1 I None
, I None
P I None
= I None
0 I None
. I None
0051 I None
) I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
in I None
contrast I None
to I None
North I None
Europe I None
studies I None
, I None
MTRRAA I GENE-Y
genotype I None
is I None
a I None
genetic I None
determinant I None
of I None
moderate I None
hyperhomocysteinemia I None
associated I None
with I None
CAD I None
in I None
a I None
French I None
population I None
without I None
vitamin I None
fortification I None
. I None
<eof> I None

<s> O None
Vitamin I CHEMICAL
E O CHEMICAL
supplementation I None
alters I None
HDL I GENE-N
- I None
cholesterol I CHEMICAL
concentration I None
and I None
paraoxonase I GENE-Y
activity I None
in I None
rabbits I None
fed I None
high I None
- I None
cholesterol I CHEMICAL
diet I None
: I None
comparison I None
with I None
probucol I CHEMICAL
. I None
<eof> I None

<s> O None
Vitamin I CHEMICAL
E O CHEMICAL
and I None
probucol I CHEMICAL
are I None
well I None
- I None
known I None
antioxidants I None
that I None
prevent I None
cells I None
from I None
the I None
oxidative I None
stress I None
, I None
which I None
is I None
a I None
risk I None
factor I None
of I None
atherosclerosis I None
. I None
<eof> I None

<s> O None
Male I None
rabbits I None
were I None
fed I None
either I None
0 I None
. I None
03 I None
% I None
vitamin I CHEMICAL
E O CHEMICAL
or I None
0 I None
. I None
05 I None
% I None
probucol I CHEMICAL
in I None
a I None
0 I None
. I None
5 I None
% I None
high I None
- I None
cholesterol I CHEMICAL
( I None
HC I None
) I None
diet I None
for I None
8 I None
weeks I None
. I None
<eof> I None

<s> O None
Vitamin I CHEMICAL
E O CHEMICAL
and I None
probucol I CHEMICAL
significantly I None
suppressed I None
an I None
increase I None
in I None
plasma I None
total I None
- I None
cholesterol I CHEMICAL
( I None
total I None
- I None
C I None
) I None
and I None
low I GENE-N
- O GENE-N
density O GENE-N
lipoprotein O GENE-N
cholesterol I CHEMICAL
compared I None
to I None
HC I None
- I None
control I None
group I None
. I None
<eof> I None

<s> O None
However I None
, I None
plasma I None
high I GENE-N
- O GENE-N
density O GENE-N
lipoprotein O GENE-N
- I None
cholesterol I CHEMICAL
( I None
HDL I GENE-N
- I None
C I None
) I None
and I None
HDL I GENE-N
- I None
C I None
/ I None
total I None
- I None
C I None
ratio I None
levels I None
and I None
plasma I None
paraoxonase I GENE-Y
activity I None
were I None
only I None
significantly I None
higher I None
in I None
vitamin I CHEMICAL
E O CHEMICAL
group I None
after I None
8 I None
weeks I None
. I None
<eof> I None

<s> O None
Hepatic I None
ACAT I GENE-Y
activity I None
was I None
significantly I None
lower I None
in I None
both I None
vitamin I CHEMICAL
E O CHEMICAL
and I None
probucol I CHEMICAL
groups I None
than I None
in I None
HC I None
- I None
control I None
group I None
, I None
while I None
HMG I GENE-Y
- O GENE-Y
CoA O GENE-Y
reductase O GENE-Y
activity I None
was I None
the I None
highest I None
only I None
in I None
the I None
probucol I CHEMICAL
group I None
. I None
<eof> I None

<s> O None
Total I None
fecal I None
sterol I CHEMICAL
content I None
was I None
significantly I None
higher I None
in I None
probucol I CHEMICAL
and I None
vitamin I CHEMICAL
E O CHEMICAL
groups I None
than I None
in I None
the I None
two I None
control I None
groups I None
. I None
<eof> I None

<s> O None
Some I None
atherogenic I None
signs I None
were I None
discovered I None
in I None
the I None
aortic I None
fatty I None
streak I None
of I None
HC I None
- I None
control I None
group I None
, I None
yet I None
not I None
in I None
other I None
groups I None
. I None
<eof> I None

<s> O None
Hepatic I None
mRNA I None
expressions I None
of I None
apo I GENE-Y
B O GENE-Y
- O GENE-Y
100 O GENE-Y
and I None
apo I GENE-Y
C O GENE-Y
- O GENE-Y
III O GENE-Y
were I None
significantly I None
lower I None
in I None
probucol I CHEMICAL
group I None
than I None
in I None
other I None
groups I None
. I None
<eof> I None

<s> O None
Vitamin I CHEMICAL
E O CHEMICAL
supplementation I None
was I None
found I None
to I None
alter I None
the I None
plasma I None
HDL I GENE-N
- I None
C I None
- I None
related I None
factors I None
; I None
meanwhile I None
, I None
probucol I CHEMICAL
supplementation I None
was I None
very I None
effective I None
in I None
enhancing I None
cholesterol I CHEMICAL
metabolism I None
, I None
except I None
for I None
a I None
negative I None
effect I None
that I None
reduced I None
plasma I None
HDL I GENE-N
- I None
C I None
concentration I None
. I None
<eof> I None

<s> O None
Molecular I None
cloning I None
and I None
radioligand I None
binding I None
characterization I None
of I None
the I None
chemokine I GENE-N
receptor O GENE-N
CCR5 O GENE-N
from I None
rhesus I None
macaque I None
and I None
human I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
determine I None
if I None
macaque I None
represents I None
a I None
suitable I None
species I None
for I None
the I None
pre I None
- I None
clinical I None
evaluation I None
of I None
novel I None
CCR5 I GENE-Y
antagonists I None
, I None
such I None
as I None
maraviroc I CHEMICAL
( I None
UK I CHEMICAL
- O CHEMICAL
427 O CHEMICAL
, O CHEMICAL
857 O CHEMICAL
) I None
. I None
<eof> I None

<s> O None
To I None
do I None
this I None
we I None
cloned I None
and I None
expressed I None
CCR5 I GENE-Y
from I None
rhesus I None
macaque I None
and I None
compared I None
the I None
binding I None
properties I None
of I None
[ I None
125I I CHEMICAL
] I None
- I None
MIP I None
- I None
1beta I None
and I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
- O CHEMICAL
maraviroc O CHEMICAL
with I None
human I GENE-Y
recombinant O GENE-Y
CCR5 O GENE-Y
. I None
<eof> I None

<s> O None
[ I None
125I I CHEMICAL
] I None
- I None
MIP I None
- I None
1beta I None
bound I None
with I None
similar I None
high I None
affinity I None
to I None
CCR5 I GENE-N
from I None
macaque I None
( I None
K I None
( I None
d I None
) I None
= I None
0 I None
. I None
24 I None
+ I None
/ I None
- I None
0 I None
. I None
05 I None
nM I None
) I None
and I None
human I None
( I None
K I None
( I None
d I None
) I None
= I None
0 I None
. I None
23 I None
+ I None
/ I None
- I None
0 I None
. I None
05 I None
nM I None
) I None
and I None
with I None
similar I None
kinetic I None
properties I None
. I None
<eof> I None

<s> O None
In I None
competition I None
binding I None
studies I None
the I None
affinity I None
of I None
a I None
range I None
of I None
human I None
chemokines I None
for I None
macaque I GENE-Y
CCR5 O GENE-Y
was I None
also I None
similar I None
to I None
human I GENE-Y
CCR5 O GENE-Y
. I None
<eof> I None

<s> O None
Maraviroc I CHEMICAL
inhibited I None
binding I None
of I None
[ I None
125I I CHEMICAL
] I None
- I None
MIP I None
- I None
1beta I None
to I None
CCR5 I GENE-N
from I None
macaque I None
and I None
human I None
with I None
similar I None
potency I None
( I None
IC50 I None
= I None
17 I None
. I None
50 I None
+ I None
/ I None
- I None
1 I None
. I None
24 I None
nM I None
and I None
7 I None
. I None
18 I None
+ I None
/ I None
- I None
0 I None
. I None
93 I None
nM I None
, I None
respectively I None
) I None
and I None
antagonised I None
MIP I None
- I None
1beta I None
induced I None
intracellular I None
calcium I CHEMICAL
release I None
mediated I None
through I None
CCR5 I GENE-N
from I None
macaque I None
and I None
human I None
with I None
similar I None
potency I None
( I None
IC50 I None
= I None
17 I None
. I None
50 I None
+ I None
/ I None
- I None
3 I None
. I None
30 I None
nM I None
and I None
12 I None
. I None
07 I None
+ I None
/ I None
- I None
1 I None
. I None
89 I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
- O CHEMICAL
maraviroc O CHEMICAL
bound I None
with I None
high I None
affinity I None
to I None
CCR5 I GENE-N
from I None
macaque I None
( I None
K I None
( I None
d I None
) I None
= I None
1 I None
. I None
36 I None
+ I None
/ I None
- I None
0 I None
. I None
07 I None
nM I None
) I None
and I None
human I None
( I None
K I None
( I None
d I None
) I None
= I None
0 I None
. I None
86 I None
+ I None
/ I None
- I None
0 I None
. I None
08 I None
nM I None
) I None
, I None
but I None
was I None
found I None
to I None
dissociate I None
approximately I None
10 I None
- I None
fold I None
more I None
quickly I None
from I None
macaque I GENE-Y
CCR5 O GENE-Y
. I None
<eof> I None

<s> O None
However I None
, I None
as I None
with I None
the I None
human I None
receptor I None
, I None
maraviroc I CHEMICAL
was I None
shown I None
to I None
be I None
a I None
high I None
affinity I None
, I None
potent I None
functional I None
antagonist I None
of I None
macaque I GENE-Y
CCR5 O GENE-Y
thereby I None
indicating I None
that I None
the I None
macaque I None
should I None
be I None
a I None
suitable I None
species I None
in I None
which I None
to I None
evaluate I None
the I None
pharmacology I None
, I None
safety I None
and I None
potential I None
mechanism I None
- I None
related I None
toxicology I None
of I None
novel I None
CCR5 I GENE-Y
antagonists I None
. I None
<eof> I None

<s> O None
A I None
novel I None
function I None
of I None
differentiation I None
revealed I None
by I None
cDNA I None
microarray I None
profiling I None
of I None
p75NTR I GENE-Y
- I None
regulated I None
gene I None
expression I None
. I None
<eof> I None

<s> O None
The I None
expression I None
of I None
the I None
p75 I GENE-Y
neurotrophin O GENE-Y
receptor O GENE-Y
( I None
p75NTR I GENE-Y
) I None
is I None
diminished I None
in I None
epithelial I None
cells I None
during I None
progression I None
of I None
prostate I None
cancer I None
in I None
vivo I None
and I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
Previous I None
studies I None
have I None
demonstrated I None
a I None
role I None
for I None
p75NTR I GENE-Y
as I None
a I None
tumor I None
suppressor I None
in I None
prostate I None
growth I None
. I None
<eof> I None

<s> O None
To I None
better I None
understand I None
the I None
molecular I None
mechanism I None
of I None
p75 I GENE-Y
( O GENE-Y
NTR O GENE-Y
) O GENE-Y
on I None
tumor I None
suppression I None
, I None
we I None
utilized I None
a I None
complementary I None
deoxyribonucleic I CHEMICAL
acid O CHEMICAL
microarray I None
composed I None
of I None
approximately I None
6 I None
, I None
000 I None
human I None
cancer I None
- I None
related I None
genes I None
to I None
determine I None
the I None
gene I None
expression I None
pattern I None
altered I None
by I None
re I None
- I None
introduction I None
of I None
p75NTR I GENE-Y
into I None
PC I None
- I None
3 I None
prostate I None
tumor I None
cells I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
the I None
transcripts I None
in I None
the I None
neo I None
and I None
p75NTR I GENE-Y
- I None
transfected I None
cells I None
revealed I None
52 I None
differentially I None
expressed I None
genes I None
, I None
of I None
which I None
21 I None
were I None
up I None
- I None
regulated I None
and I None
31 I None
were I None
down I None
- I None
regulated I None
in I None
the I None
presence I None
of I None
p75NTR I GENE-Y
. I None
<eof> I None

<s> O None
Based I None
on I None
the I None
known I None
biological I None
functions I None
of I None
the I None
p75NTR I GENE-Y
- I None
regulated I None
genes I None
, I None
we I None
observed I None
that I None
p75NTR I GENE-Y
modulated I None
the I None
expression I None
of I None
genes I None
that I None
are I None
critically I None
involved I None
in I None
the I None
regulation I None
of I None
differentiation I None
as I None
well I None
as I None
cell I None
adhesion I None
, I None
signal I None
transduction I None
, I None
apoptosis I None
, I None
tumor I None
cell I None
invasion I None
, I None
and I None
metastasis I None
. I None
<eof> I None

<s> O None
Several I None
differentially I None
expressed I None
genes I None
identified I None
by I None
microarray I None
were I None
selected I None
for I None
confirmation I None
using I None
quantitative I None
real I None
- I None
time I None
polymerase I None
chain I None
reaction I None
. I None
<eof> I None

<s> O None
Immunoblot I None
analysis I None
further I None
confirmed I None
increased I None
cellular I GENE-Y
retinoic O GENE-Y
acid O GENE-Y
- O GENE-Y
binding O GENE-Y
protein O GENE-Y
I O GENE-Y
( I None
CRABPI I GENE-Y
) I None
and I None
IGFBP5 I GENE-Y
protein I None
levels I None
and I None
decreased I None
level I None
of I None
PLAUR I GENE-Y
protein I None
with I None
increasing I None
p75NTR I GENE-Y
protein I None
expression I None
. I None
<eof> I None

<s> O None
As I None
CRABPI I GENE-Y
was I None
elevated I None
far I None
more I None
than I None
any I None
other I None
genes I None
, I None
we I None
observed I None
that I None
the I None
retinoids I CHEMICAL
, I None
all I CHEMICAL
- O CHEMICAL
trans O CHEMICAL
retinoic O CHEMICAL
acid O CHEMICAL
and I None
9 I CHEMICAL
- O CHEMICAL
cis O CHEMICAL
retinoic O CHEMICAL
acid O CHEMICAL
, I None
that I None
bind I None
CRABPI I GENE-Y
, I None
promoted I None
nitroblue I CHEMICAL
tetrazolium O CHEMICAL
- I None
associated I None
functional I None
cell I None
differentiation I None
in I None
p75NTR I GENE-Y
PC I None
- I None
3 I None
cells I None
, I None
but I None
not I None
in I None
neo I None
control I None
PC I None
- I None
3 I None
cells I None
. I None
<eof> I None

<s> O None
Subsequent I None
examination I None
of I None
the I None
retinoic I GENE-N
acid O GENE-N
receptors O GENE-N
( I GENE-N
RARs O GENE-N
) I None
expression I None
levels I None
demonstrated I None
an I None
absence I None
of I None
RAR I GENE-Y
- O GENE-Y
beta O GENE-Y
in I None
the I None
neo I None
control I None
cells I None
and I None
re I None
- I None
expression I None
in I None
the I None
p75NTR I GENE-Y
expressing I None
cells I None
, I None
consistent I None
with I None
previous I None
findings I None
where I None
RAR I GENE-Y
- O GENE-Y
beta O GENE-Y
is I None
believed I None
to I None
play I None
a I None
critical I None
role I None
as I None
a I None
tumor I None
suppressor I None
gene I None
that I None
is I None
lost I None
during I None
de I None
- I None
differentiation I None
of I None
prostate I None
epithelial I None
cells I None
. I None
<eof> I None

<s> O None
Whereas I None
the I None
RAR I GENE-N
- O GENE-N
alpha O GENE-N
and O GENE-N
- O GENE-N
gamma O GENE-N
protein I None
levels I None
remained I None
unchanged I None
, I None
retinoid I GENE-N
X O GENE-N
receptor O GENE-N
( O GENE-N
RXR O GENE-N
) O GENE-N
- O GENE-N
alpha O GENE-N
and O GENE-N
- O GENE-N
beta O GENE-N
also I None
exhibited I None
increasing I None
protein I None
levels I None
with I None
re I None
- I None
expression I None
of I None
the I None
p75NTR I GENE-Y
protein I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
the I None
ability I None
of I None
p75NTR I GENE-Y
siRNA I None
to I None
knockdown I None
levels I None
of I None
RAR I GENE-Y
- O GENE-Y
beta O GENE-Y
, I None
RXR I GENE-Y
- O GENE-Y
alpha O GENE-Y
, I None
and I None
RXR I GENE-Y
- O GENE-Y
beta O GENE-Y
supports I None
the I None
specificity I None
of I None
the I None
functional I None
involvement I None
of I None
p75NTR I GENE-Y
in I None
differentiation I None
. I None
<eof> I None

<s> O None
Hence I None
, I None
re I None
- I None
expression I None
of I None
the I None
p75NTR I GENE-Y
appears I None
to I None
partially I None
reverse I None
de I None
- I None
differentiation I None
of I None
prostate I None
cancer I None
cells I None
by I None
up I None
- I None
regulating I None
the I None
expression I None
of I None
CRABPI I GENE-Y
for I None
localized I None
sequestration I None
of I None
retinoids I CHEMICAL
that I None
are I None
available I None
to I None
newly I None
up I None
- I None
regulated I None
RAR I GENE-Y
- O GENE-Y
beta O GENE-Y
, I None
RXR I GENE-Y
- O GENE-Y
alpha O GENE-Y
, I None
and I None
RXR I GENE-Y
- O GENE-Y
beta O GENE-Y
. I None
<eof> I None

<s> O None
GPR109A I GENE-Y
( I None
PUMA I GENE-Y
- O GENE-Y
G O GENE-Y
/ I None
HM74A I GENE-Y
) I None
mediates I None
nicotinic I CHEMICAL
acid O CHEMICAL
- I None
induced I None
flushing I None
. I None
<eof> I None

<s> O None
Nicotinic I CHEMICAL
acid O CHEMICAL
( I None
niacin I CHEMICAL
) I None
has I None
long I None
been I None
used I None
as I None
an I None
antidyslipidemic I None
drug I None
. I None
<eof> I None

<s> O None
Its I None
special I None
profile I None
of I None
actions I None
, I None
especially I None
the I None
rise I None
in I None
HDL I GENE-N
- I None
cholesterol I CHEMICAL
levels I None
induced I None
by I None
nicotinic I CHEMICAL
acid O CHEMICAL
, I None
is I None
unique I None
among I None
the I None
currently I None
available I None
pharmacological I None
tools I None
to I None
treat I None
lipid I None
disorders I None
. I None
<eof> I None

<s> O None
Recently I None
, I None
a I None
G I GENE-N
- O GENE-N
protein O GENE-N
- O GENE-N
coupled O GENE-N
receptor O GENE-N
, I None
termed I None
GPR109A I GENE-Y
( I None
HM74A I GENE-Y
in I None
humans I None
, I None
PUMA I GENE-Y
- O GENE-Y
G O GENE-Y
in I None
mice I None
) I None
, I None
was I None
described I None
and I None
shown I None
to I None
mediate I None
the I None
nicotinic I CHEMICAL
acid O CHEMICAL
- I None
induced I None
antilipolytic I None
effects I None
in I None
adipocytes I None
. I None
<eof> I None

<s> O None
One I None
of I None
the I None
major I None
problems I None
of I None
the I None
pharmacotherapeutical I None
use I None
of I None
nicotinic I CHEMICAL
acid O CHEMICAL
is I None
a I None
strong I None
flushing I None
response I None
. I None
<eof> I None

<s> O None
This I None
side I None
effect I None
, I None
although I None
harmless I None
, I None
strongly I None
affects I None
patient I None
compliance I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
we I None
show I None
that I None
mice I None
lacking I None
PUMA I GENE-Y
- O GENE-Y
G O GENE-Y
did I None
not I None
show I None
nicotinic I CHEMICAL
acid O CHEMICAL
- I None
induced I None
flushing I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
flushing I None
in I None
response I None
to I None
nicotinic I CHEMICAL
acid O CHEMICAL
was I None
also I None
abrogated I None
in I None
the I None
absence I None
of I None
cyclooxygenase I GENE-Y
type O GENE-Y
1 O GENE-Y
, I None
and I None
mice I None
lacking I None
prostaglandin I GENE-N
D O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
( O GENE-N
PGD O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
) O GENE-N
and O GENE-N
prostaglandin O GENE-N
E O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
( O GENE-N
PGE O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
) O GENE-N
receptors O GENE-N
had I None
reduced I None
flushing I None
responses I None
. I None
<eof> I None

<s> O None
The I None
mouse I None
orthologue I None
of I None
GPR109A I GENE-Y
, I None
PUMA I GENE-Y
- O GENE-Y
G O GENE-Y
, I None
is I None
highly I None
expressed I None
in I None
macrophages I None
and I None
other I None
immune I None
cells I None
, I None
and I None
transplantation I None
of I None
wild I None
- I None
type I None
bone I None
marrow I None
into I None
irradiated I None
PUMA I GENE-Y
- O GENE-Y
G O GENE-Y
- I None
deficient I None
mice I None
restored I None
the I None
nicotinic I CHEMICAL
acid O CHEMICAL
- I None
induced I None
flushing I None
response I None
. I None
<eof> I None

<s> O None
Our I None
data I None
clearly I None
indicate I None
that I None
GPR109A I GENE-Y
mediates I None
nicotinic I CHEMICAL
acid O CHEMICAL
- I None
induced I None
flushing I None
and I None
that I None
this I None
effect I None
involves I None
release I None
of I None
PGE I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
and I None
PGD I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
, I None
most I None
likely I None
from I None
immune I None
cells I None
of I None
the I None
skin I None
. I None
<eof> I None

<s> O None
The I None
Arg389Gly I GENE-N
beta1 I GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
polymorphism I None
and I None
catecholamine I CHEMICAL
effects I None
on I None
plasma I None
- I None
renin I GENE-Y
activity I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
The I None
purpose I None
of I None
this I None
research I None
was I None
to I None
find I None
out I None
whether I None
, I None
in I None
humans I None
, I None
dobutamine I CHEMICAL
- I None
induced I None
hemodynamic I None
effects I None
and I None
increase I None
in I None
plasma I None
- I None
renin I GENE-Y
activity I None
( I None
PRA I None
) I None
might I None
be I None
beta1 I GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
( I None
beta1AR I GENE-Y
) I None
genotype I None
- I None
dependent I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
In I None
vitro I None
Arg389Gly I GENE-N
- I None
beta1AR I GENE-Y
polymorphism I None
exhibits I None
decreased I None
receptor I None
signaling I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
We I None
studied I None
10 I None
male I None
homozygous I None
Arg389 I None
- I None
beta1AR I GENE-Y
subjects I None
and I None
8 I None
male I None
homozygous I None
Gly389beta1AR I GENE-Y
subjects I None
; I None
to I None
avoid I None
influences I None
of I None
codon I None
49 I None
polymorphism I None
, I None
all I None
were I None
homozygous I None
Ser49 I None
- I None
beta1AR I GENE-Y
. I None
<eof> I None

<s> O None
Subjects I None
were I None
infused I None
with I None
dobutamine I CHEMICAL
( I None
1 I None
to I None
6 I None
microg I None
/ I None
kg I None
/ I None
min I None
) I None
with I None
or I None
without I None
bisoprolol I CHEMICAL
( I None
10 I None
mg I None
orally I None
) I None
pretreatment I None
, I None
and I None
PRA I None
, I None
heart I None
rate I None
, I None
contractility I None
, I None
and I None
blood I None
pressure I None
were I None
assessed I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
With I None
regard I None
to I None
PRA I None
, I None
dobutamine I CHEMICAL
increased I None
PRA I None
more I None
potently I None
in I None
Arg389 I None
- I None
beta1AR I GENE-Y
versus I None
Gly389 I None
- I None
beta1AR I GENE-Y
subjects I None
. I None
<eof> I None

<s> O None
Bisoprolol I CHEMICAL
markedly I None
suppressed I None
the I None
dobutamine I CHEMICAL
- I None
induced I None
PRA I None
increase I None
in I None
Arg389 I None
- I None
but I None
only I None
marginally I None
in I None
Gly389 I None
- I None
beta1AR I GENE-Y
subjects I None
. I None
<eof> I None

<s> O None
With I None
regard I None
to I None
hemodynamics I None
, I None
dobutamine I CHEMICAL
caused I None
larger I None
heart I None
rate I None
and I None
contractility I None
increases I None
and I None
diastolic I None
blood I None
pressure I None
decreases I None
in I None
Arg389 I None
- I None
versus I None
Gly389 I None
- I None
beta1AR I GENE-Y
subjects I None
. I None
<eof> I None

<s> O None
Bisoprolol I CHEMICAL
reduced I None
dobutamine I CHEMICAL
- I None
induced I None
heart I None
rate I None
and I None
contractility I None
increases I None
and I None
diastolic I None
blood I None
pressure I None
decreases I None
more I None
potently I None
in I None
Arg389 I None
- I None
versus I None
Gly389 I None
- I None
beta1AR I GENE-Y
subjects I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
Codon I None
389 I None
beta1AR I GENE-Y
polymorphism I None
is I None
a I None
determinant I None
not I None
only I None
of I None
hemodynamic I None
effects I None
but I None
also I None
of I None
PRA I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
beta1AR I GENE-Y
polymorphisms I None
may I None
be I None
useful I None
for I None
predicting I None
therapeutic I None
responses I None
to I None
betaAR I GENE-N
- I None
blocker I None
treatment I None
. I None
<eof> I None

<s> O None
Valproic I CHEMICAL
acid O CHEMICAL
selectively I None
inhibits I None
conversion I None
of I None
arachidonic I CHEMICAL
acid O CHEMICAL
to I None
arachidonoyl I CHEMICAL
- O CHEMICAL
CoA O CHEMICAL
by I None
brain I GENE-N
microsomal O GENE-N
long O GENE-N
- O GENE-N
chain O GENE-N
fatty O GENE-N
acyl O GENE-N
- O GENE-N
CoA O GENE-N
synthetases O GENE-N
: I None
relevance I None
to I None
bipolar I None
disorder I None
. I None
<eof> I None

<s> O None
RATIONALE I None
: I None
Several I None
drugs I None
used I None
to I None
treat I None
bipolar I None
disorder I None
( I None
lithium I CHEMICAL
and I None
carbamazepine I CHEMICAL
) I None
, I None
when I None
administered I None
chronically I None
to I None
rats I None
, I None
reduce I None
the I None
turnover I None
of I None
arachidonic I CHEMICAL
acid O CHEMICAL
, I None
but I None
not I None
docosahexaenoic I CHEMICAL
acid O CHEMICAL
, I None
in I None
brain I None
phospholipids I None
by I None
decreasing I None
the I None
activity I None
of I None
an I None
arachidonic I CHEMICAL
acid O CHEMICAL
- I None
selective I None
phospholipase I GENE-N
A O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
. I None
<eof> I None

<s> O None
Although I None
chronic I None
valproic I CHEMICAL
acid O CHEMICAL
produces I None
similar I None
effects I None
on I None
brain I None
arachidonic I CHEMICAL
acid O CHEMICAL
and I None
docosahexaenoic I CHEMICAL
acid O CHEMICAL
turnover I None
, I None
it I None
does I None
not I None
alter I None
phospholipase I GENE-N
A O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
activity I None
, I None
suggesting I None
that I None
it I None
targets I None
a I None
different I None
enzyme I None
in I None
the I None
turnover I None
pathway I None
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
/ I None
RESULTS I None
: I None
By I None
isolating I None
rat I GENE-N
brain O GENE-N
microsomal O GENE-N
long O GENE-N
- O GENE-N
chain O GENE-N
fatty O GENE-N
acyl O GENE-N
- O GENE-N
CoA O GENE-N
synthetases O GENE-N
( I None
Acsl I GENE-N
) I None
, I None
we I None
show I None
in I None
vitro I None
that I None
valproic I CHEMICAL
acid O CHEMICAL
is I None
a I None
non I None
- I None
competitive I None
inhibitor I None
of I None
Acsl I GENE-N
, I None
as I None
it I None
reduces I None
the I None
maximal I None
velocity I None
of I None
the I None
reaction I None
without I None
changing I None
the I None
affinity I None
of I None
the I None
substrate I None
for I None
the I None
enzyme I None
. I None
<eof> I None

<s> O None
While I None
valproic I CHEMICAL
acid O CHEMICAL
inhibited I None
the I None
synthesis I None
of I None
arachidonoyl I CHEMICAL
- O CHEMICAL
CoA O CHEMICAL
, I None
palmitoyl I CHEMICAL
- O CHEMICAL
CoA O CHEMICAL
, I None
and I None
docosahexaenoyl I CHEMICAL
- O CHEMICAL
CoA O CHEMICAL
, I None
the I None
K I None
( I None
i I None
) I None
for I None
inhibition I None
of I None
arachidonoyl I CHEMICAL
- O CHEMICAL
CoA O CHEMICAL
synthesis I None
( I None
14 I None
. I None
1 I None
mM I None
) I None
was I None
approximately I None
one I None
fifth I None
the I None
K I None
( I None
i I None
) I None
for I None
inhibiting I None
palmitoyl I CHEMICAL
- O CHEMICAL
CoA O CHEMICAL
( I None
85 I None
. I None
4 I None
mM I None
) I None
and I None
docosahexaenoyl I CHEMICAL
- O CHEMICAL
CoA O CHEMICAL
( I None
78 I None
. I None
2 I None
mM I None
) I None
synthesis I None
. I None
<eof> I None

<s> O None
As I None
chronic I None
administration I None
of I None
valproic I CHEMICAL
acid O CHEMICAL
in I None
bipolar I None
disorder I None
achieves I None
whole I None
- I None
brain I None
levels I None
of I None
1 I None
. I None
0 I None
to I None
1 I None
. I None
5 I None
mM I None
, I None
inhibition I None
of I None
arachidonoyl I CHEMICAL
- O CHEMICAL
CoA O CHEMICAL
formation I None
can I None
occur I None
at I None
brain I None
concentrations I None
that I None
are I None
therapeutically I None
relevant I None
to I None
this I None
disease I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
brain I GENE-N
microsomal O GENE-N
Acsl O GENE-N
did I None
not I None
produce I None
valproyl I CHEMICAL
- O CHEMICAL
CoA O CHEMICAL
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
This I None
study I None
shows I None
that I None
valproic I CHEMICAL
acid O CHEMICAL
acts I None
as I None
a I None
non I None
- I None
competitive I None
inhibitor I None
of I None
brain I GENE-N
microsomal O GENE-N
Acsl O GENE-N
, I None
and I None
that I None
inhibition I None
is I None
substrate I None
- I None
selective I None
. I None
<eof> I None

<s> O None
The I None
study I None
supports I None
the I None
hypothesis I None
that I None
valproic I CHEMICAL
acid O CHEMICAL
acts I None
in I None
bipolar I None
disorder I None
by I None
reducing I None
the I None
brain I None
arachidonic I CHEMICAL
acid O CHEMICAL
cascade I None
, I None
by I None
inhibiting I None
arachidonoyl I CHEMICAL
- O CHEMICAL
CoA O CHEMICAL
formation I None
. I None
<eof> I None

<s> O None
From I None
an I None
inborn I None
error I None
patient I None
to I None
a I None
search I None
for I None
regulatory I None
meaning I None
: I None
a I None
biotin I CHEMICAL
conducted I None
voyage I None
. I None
<eof> I None

<s> O None
This I None
article I None
summarizes I None
some I None
findings I None
of I None
a I None
research I None
that I None
I I None
have I None
pursued I None
for I None
the I None
past I None
25 I None
years I None
, I None
whose I None
roots I None
are I None
immersed I None
in I None
the I None
field I None
of I None
inherited I None
metabolic I None
disorders I None
, I None
and I None
deal I None
with I None
different I None
aspects I None
of I None
the I None
vitamin I None
biotin I CHEMICAL
, I None
starting I None
with I None
a I None
patient I None
with I None
multiple I None
carboxylase I GENE-N
deficiency I None
( I None
MCD I None
) I None
. I None
<eof> I None

<s> O None
Several I None
of I None
MCD I None
clinical I None
manifestations I None
resemble I None
those I None
of I None
infant I None
malnutrition I None
; I None
we I None
demonstrated I None
that I None
about I None
one I None
- I None
third I None
of I None
infants I None
with I None
this I None
common I None
nutritional I None
disorder I None
were I None
indeed I None
biotin I CHEMICAL
- I None
deficient I None
, I None
and I None
that I None
this I None
deficiency I None
is I None
metabolically I None
significant I None
, I None
by I None
studying I None
urine I None
instead I None
of I None
blood I None
, I None
studying I None
urinary I None
organic I None
acids I None
by I None
gas I None
chromatography I None
- I None
mass I None
spectrometry I None
. I None
<eof> I None

<s> O None
Remarkably I None
, I None
the I None
metabolic I None
abnormalities I None
became I None
apparent I None
only I None
after I None
protein I None
feeding I None
was I None
started I None
, I None
suggesting I None
that I None
this I None
phenomenon I None
may I None
contribute I None
to I None
the I None
worsening I None
of I None
malnourished I None
individuals I None
when I None
they I None
are I None
abruptly I None
fed I None
. I None
<eof> I None

<s> O None
Afterwards I None
, I None
we I None
studied I None
biotin I CHEMICAL
deficiency I None
at I None
the I None
tissue I None
level I None
. I None
<eof> I None

<s> O None
Carboxylase I GENE-N
activities I None
and I None
masses I None
were I None
significantly I None
reduced I None
in I None
liver I None
, I None
kidney I None
, I None
muscle I None
, I None
adipose I None
tissue I None
, I None
intestine I None
, I None
and I None
spleen I None
, I None
but I None
brain I None
and I None
heart I None
were I None
spared I None
; I None
their I None
mRNAs I None
remained I None
unchanged I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
holocarboxylase I GENE-Y
synthetase O GENE-Y
( I None
HCS I GENE-Y
) I None
mRNA I None
levels I None
were I None
markedly I None
low I None
in I None
the I None
deficient I None
animals I None
, I None
and I None
increased I None
upon I None
biotin I CHEMICAL
injection I None
. I None
<eof> I None

<s> O None
Over I None
2000 I None
human I None
genes I None
have I None
been I None
identified I None
that I None
depend I None
on I None
biotin I CHEMICAL
for I None
expression I None
. I None
<eof> I None

<s> O None
To I None
probe I None
into I None
the I None
" I None
logic I None
" I None
of I None
this I None
enigma I None
, I None
we I None
have I None
started I None
comparative I None
studies I None
among I None
evolutionarily I None
distant I None
organisms I None
, I None
such I None
as I None
mouse I None
and I None
Saccharomyces I None
cerevisiae I None
, I None
and I None
we I None
are I None
now I None
looking I None
for I None
biotin I CHEMICAL
effects I None
on I None
specific I None
genes I None
and I None
proteins I None
, I None
such I None
as I None
HCS I CHEMICAL
and I None
hexokinases I GENE-N
, I None
and I None
on I None
their I None
proteomes I None
. I None
<eof> I None

<s> O None
Involvement I None
of I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
and I None
up I None
- I None
regulated I None
prostaglandin I GENE-Y
E O GENE-Y
synthases O GENE-Y
in I None
phosphatidylserine I CHEMICAL
liposome I None
- I None
induced I None
prostaglandin I CHEMICAL
E2 O CHEMICAL
production I None
by I None
microglia I None
. I None
<eof> I None

<s> O None
After I None
engulfment I None
of I None
apoptotic I None
cells I None
through I None
phosphatidylserine I CHEMICAL
( I None
PS I None
) I None
- I None
mediated I None
recognition I None
, I None
microglia I None
secrete I None
prostaglandin I CHEMICAL
E2 O CHEMICAL
( I None
PGE2 I CHEMICAL
) I None
, I None
a I None
potent I None
anti I None
- I None
inflammatory I None
molecule I None
in I None
the I None
central I None
nervous I None
system I None
. I None
<eof> I None

<s> O None
Despite I None
the I None
clinical I None
significance I None
, I None
the I None
mechanism I None
underlying I None
PGE2 I CHEMICAL
production I None
by I None
phagocytosis I None
of I None
apoptotic I None
cells I None
is I None
poorly I None
understood I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
we I None
used I None
PS I None
liposomes I None
to I None
elucidate I None
the I None
phagocytic I None
pathway I None
for I None
PGE2 I CHEMICAL
production I None
in I None
microglia I None
, I None
because I None
PS I None
liposomes I None
mimic I None
the I None
effects I None
of I None
apoptotic I None
cells I None
on I None
microglia I None
/ I None
macrophages I None
. I None
<eof> I None

<s> O None
The I None
level I None
of I None
PGE2 I CHEMICAL
in I None
the I None
culture I None
medium I None
of I None
primary I None
cultured I None
rat I None
microglia I None
was I None
significantly I None
increased I None
by I None
PS I None
liposomes I None
treatment I None
but I None
not I None
by I None
phosphatidylcholine I CHEMICAL
liposomes I None
treatment I None
. I None
<eof> I None

<s> O None
The I None
specific I None
ligand I None
for I None
class I GENE-N
B O GENE-N
scavenger O GENE-N
receptor O GENE-N
( I None
SR I GENE-N
- O GENE-N
B O GENE-N
) I None
, I None
high I GENE-N
density O GENE-N
lipoprotein O GENE-N
, I None
significantly I None
suppressed I None
PS I None
liposome I None
- I None
induced I None
PGE2 I CHEMICAL
production I None
. I None
<eof> I None

<s> O None
PS I None
liposomes I None
were I None
immediately I None
phagocytosed I None
by I None
microglia I None
and I None
sorted I None
to I None
endosomes I None
/ I None
lysosomes I None
. I None
<eof> I None

<s> O None
Cyclooxygenase I GENE-N
( I GENE-Y
COX O GENE-Y
) O GENE-Y
- O GENE-Y
2 O GENE-Y
and I None
membrane I None
- I None
bound I None
prostaglandin I GENE-Y
E O GENE-Y
synthase O GENE-Y
- O GENE-Y
1 O GENE-Y
( I None
mPGES I GENE-Y
- O GENE-Y
1 O GENE-Y
) I None
were I None
induced I None
by I None
treatment I None
with I None
lipopolysaccharide I None
( I None
LPS I None
) I None
but I None
not I None
with I None
PS I None
liposomes I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
mPGES I GENE-Y
- O GENE-Y
2 O GENE-Y
and I None
cytosolic I GENE-Y
PGES O GENE-Y
( I None
cPGES I GENE-Y
) I None
that I None
are I None
functionally I None
coupled I None
with I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
were I None
upregulated I None
after I None
treatment I None
with I None
PS I None
liposomes I None
or I None
LPS I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
PS I None
liposome I None
- I None
induced I None
PGE2 I CHEMICAL
production I None
was I None
significantly I None
suppressed I None
by I None
indomethacin I CHEMICAL
, I None
a I None
preferential I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
inhibitor I None
, I None
but I None
not I None
by I None
NS I CHEMICAL
- O CHEMICAL
398 O CHEMICAL
, I None
a I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
. I None
<eof> I None

<s> O None
PS I None
liposomes I None
induced I None
activation I None
of I None
p44 I GENE-Y
/ I None
p42 I GENE-Y
extracellular I GENE-N
signal O GENE-N
- O GENE-N
regulated O GENE-N
kinase O GENE-N
( I None
ERK I GENE-N
) I None
but I None
not I None
p38 I GENE-N
mitogen I GENE-N
- O GENE-N
activated O GENE-N
protein O GENE-N
kinase O GENE-N
in I None
SR I GENE-Y
- O GENE-Y
BI O GENE-Y
independent I None
manner I None
. I None
<eof> I None

<s> O None
These I None
observations I None
strongly I None
suggest I None
that I None
the I None
up I None
- I None
regulation I None
of I None
terminal I None
PGESs I GENE-Y
that I None
are I None
preferentially I None
coupled I None
with I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
especially I None
mPGES I GENE-Y
- O GENE-Y
2 O GENE-Y
, I None
plays I None
the I None
pivotal I None
role I None
in I None
PS I None
liposome I None
- I None
induced I None
PGE2 I CHEMICAL
production I None
by I None
microglia I None
. I None
<eof> I None

<s> O None
Although I None
SR I GENE-Y
- O GENE-Y
BI O GENE-Y
plays I None
an I None
essential I None
role I None
in I None
PS I None
liposome I None
- I None
induced I None
PGE2 I CHEMICAL
production I None
, I None
other I None
PS I GENE-N
- O GENE-N
recognizing O GENE-N
receptors O GENE-N
, I None
possibly I None
PS I GENE-N
- O GENE-N
specific O GENE-N
receptor O GENE-N
, I None
could I None
also I None
promote I None
PGE2 I CHEMICAL
production I None
by I None
transducing I None
intracellular I None
signals I None
including I None
p44 I GENE-Y
/ I None
p42 I GENE-Y
ERK I GENE-N
after I None
PS I None
liposomes I None
treatment I None
. I None
<eof> I None

<s> O None
Sorafenib I CHEMICAL
: I None
scientific I None
rationales I None
for I None
single I None
- I None
agent I None
and I None
combination I None
therapy I None
in I None
clear I None
- I None
cell I None
renal I None
cell I None
carcinoma I None
. I None
<eof> I None

<s> O None
Clear I None
- I None
cell I None
renal I None
cell I None
carcinoma I None
( I None
RCC I None
) I None
is I None
characterized I None
by I None
the I None
loss I None
of I None
von I GENE-Y
Hippel O GENE-Y
- O GENE-Y
Lindau O GENE-Y
disease O GENE-Y
protein O GENE-Y
and I None
the I None
resultant I None
dysregulation I None
of I None
the I None
vascular I GENE-Y
endothelial O GENE-Y
growth O GENE-Y
factor O GENE-Y
( I None
VEGF I GENE-Y
) I None
/ I None
VEGF I GENE-N
receptor O GENE-N
( I None
VEGFR I GENE-N
) I None
, I None
platelet I GENE-Y
- O GENE-Y
derived O GENE-Y
growth O GENE-Y
factor O GENE-Y
- O GENE-Y
beta O GENE-Y
( I None
PDGF I GENE-Y
- O GENE-Y
beta O GENE-Y
) I None
/ I None
PDGF I GENE-Y
receptor O GENE-Y
- O GENE-Y
beta O GENE-Y
( I None
PDGFR I GENE-Y
- O GENE-Y
beta O GENE-Y
) I None
, I None
and I None
transforming I GENE-Y
growth O GENE-Y
factor O GENE-Y
- O GENE-Y
alpha O GENE-Y
( I None
TGF I GENE-Y
- O GENE-Y
alpha O GENE-Y
) I None
/ I None
epidermal I GENE-Y
growth O GENE-Y
factor O GENE-Y
receptor O GENE-Y
( I None
EGFR I GENE-Y
) I None
/ I None
Raf I GENE-Y
pathways I None
, I None
which I None
contribute I None
to I None
angiogenesis I None
, I None
lymphangiogenesis I None
, I None
and I None
tumor I None
cell I None
growth I None
and I None
survival I None
. I None
<eof> I None

<s> O None
Significant I None
advances I None
in I None
the I None
treatment I None
of I None
clear I None
- I None
cell I None
RCC I None
have I None
been I None
derived I None
from I None
agents I None
that I None
target I None
these I None
pathways I None
, I None
including I None
the I None
multiple I None
- I None
kinase I GENE-N
inhibitors I None
( I None
MKIs I None
) I None
sorafenib I CHEMICAL
, I None
sunitinib I CHEMICAL
, I None
and I None
AG013736 I CHEMICAL
, I None
which I None
target I None
multiple I None
VEGFRs I GENE-N
as I None
well I None
as I None
PDGFR I GENE-Y
- O GENE-Y
beta O GENE-Y
. I None
<eof> I None

<s> O None
Sorafenib I CHEMICAL
has I None
the I None
added I None
advantage I None
of I None
inhibiting I None
multiple I None
different I None
Raf I GENE-Y
isoforms I None
, I None
which I None
enables I None
it I None
to I None
target I None
TGF I GENE-Y
- O GENE-Y
alpha O GENE-Y
/ I None
EGFR I GENE-Y
signaling I None
and I None
may I None
also I None
enhance I None
its I None
inhibition I None
of I None
VEGFR I GENE-N
and I None
PDGFR I GENE-Y
- O GENE-Y
beta O GENE-Y
. I None
<eof> I None

<s> O None
This I None
review I None
will I None
examine I None
the I None
recent I None
advances I None
in I None
our I None
understanding I None
of I None
the I None
biology I None
of I None
clear I None
- I None
cell I None
RCC I None
and I None
show I None
how I None
those I None
advances I None
have I None
helped I None
delineate I None
new I None
targets I None
of I None
opportunity I None
for I None
treatment I None
. I None
<eof> I None

<s> O None
It I None
will I None
also I None
present I None
the I None
early I None
clinical I None
results I None
of I None
agents I None
that I None
target I None
the I None
pathways I None
dysregulated I None
in I None
clear I None
- I None
cell I None
RCC I None
, I None
with I None
special I None
emphasis I None
on I None
sorafenib I CHEMICAL
and I None
the I None
other I None
active I None
MKIs I None
, I None
and I None
will I None
describe I None
the I None
scientific I None
rationales I None
for I None
ongoing I None
and I None
future I None
sorafenib I CHEMICAL
- I None
based I None
combination I None
therapy I None
trials I None
in I None
RCC I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
adult I None
- I None
onset I None
type I None
II I None
citrullinemia I None
- I None
- I None
deterioration I None
of I None
clinical I None
course I None
after I None
infusion I None
of I None
hyperosmotic I None
and I None
high I None
sugar I None
solutions I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Adult I None
- I None
onset I None
type I None
II I None
citrullinemia I None
( I None
CTLN2 I None
) I None
is I None
an I None
autosomal I None
recessive I None
disorder I None
caused I None
by I None
mutations I None
of I None
SLC25A13 I GENE-Y
gene I None
encoding I None
citrin I GENE-Y
and I None
is I None
characterized I None
by I None
recurrent I None
encephalopathy I None
with I None
hyperammonemia I None
. I None
<eof> I None

<s> O None
Factors I None
affecting I None
disease I None
progression I None
remain I None
unknown I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
with I None
CTLN2 I None
, I None
whose I None
clinical I None
course I None
was I None
rapidly I None
worsened I None
by I None
the I None
administration I None
of I None
Glyceol I None
, I None
a I None
hyperosmotic I None
diuretic I None
solution I None
consisting I None
of I None
10 I None
% I None
glycerol I CHEMICAL
and I None
5 I None
% I None
fructose I CHEMICAL
in I None
saline I None
. I None
<eof> I None

<s> O None
CASE I None
REPORT I None
: I None
A I None
34 I None
- I None
year I None
- I None
old I None
man I None
was I None
admitted I None
in I None
coma I None
after I None
repeated I None
episodes I None
of I None
altered I None
consciousness I None
. I None
<eof> I None

<s> O None
His I None
plasma I None
ammonia I CHEMICAL
level I None
was I None
markedly I None
elevated I None
without I None
any I None
evidence I None
of I None
liver I None
diseases I None
. I None
<eof> I None

<s> O None
Brain I None
MRI I None
revealed I None
high I None
signal I None
intensities I None
at I None
the I None
bilateral I None
cingulate I None
gyri I None
and I None
insular I None
cortices I None
, I None
suggesting I None
hepatic I None
encephalopathy I None
. I None
<eof> I None

<s> O None
We I None
administered I None
Glyceol I None
. I None
intravenously I None
to I None
alleviate I None
brain I None
edema I None
, I None
however I None
, I None
he I None
developed I None
intractable I None
seizures I None
along I None
with I None
steep I None
increase I None
in I None
plasma I None
ammonia I CHEMICAL
levels I None
( I None
from I None
808 I None
to I None
2210 I None
microg I None
/ I None
dL I None
) I None
and I None
died I None
. I None
<eof> I None

<s> O None
The I None
diagnosis I None
of I None
CTLN2 I None
was I None
confirmed I None
by I None
elevations I None
of I None
plasma I None
citrulline I CHEMICAL
level I None
( I None
384 I None
. I None
3 I None
nmol I None
/ I None
mL I None
; I None
normal I None
17 I None
- I None
43 I None
nmol I None
/ I None
mL I None
) I None
and I None
serum I None
pancreatic I GENE-Y
secretory O GENE-Y
trypsin O GENE-Y
inhibitor O GENE-Y
( I None
PSTI I GENE-Y
) I None
( I None
110 I None
ng I None
/ I None
mL I None
; I None
normal I None
4 I None
. I None
6 I None
- I None
12 I None
. I None
2 I None
ng I None
/ I None
mL I None
) I None
, I None
decrease I None
in I None
hepatic I None
argininosuccinate I GENE-Y
synthetase O GENE-Y
activity I None
( I None
5 I None
. I None
5 I None
% I None
of I None
control I None
) I None
, I None
lack I None
of I None
hepatic I None
citrin I GENE-Y
protein I None
expression I None
and I None
mutations I None
in I None
SLC25A13 I GENE-Y
gene I None
( I None
compound I None
heterozygote I None
with I None
S225X I GENE-N
and I None
Ex1 I GENE-N
- O GENE-N
1G O GENE-N
> O GENE-N
A O GENE-N
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
Physicians I None
should I None
take I None
CTLN2 I None
into I None
consideration I None
as I None
a I None
differential I None
diagnosis I None
in I None
Asian I None
patients I None
with I None
a I None
history I None
of I None
repeated I None
unconsciousness I None
with I None
hyperammonemia I None
and I None
use I None
D I CHEMICAL
- O CHEMICAL
mannitol O CHEMICAL
but I None
not I None
glycerol I CHEMICAL
to I None
treat I None
brain I None
edema I None
in I None
patients I None
with I None
CTLN2 I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
gentamicin I CHEMICAL
binding I None
to I None
rat I None
renal I None
brush I None
- I None
border I None
membrane I None
by I None
megalin I GENE-Y
ligands I None
and I None
basic I None
peptides I None
. I None
<eof> I None

<s> O None
Our I None
previous I None
studies I None
showed I None
that I None
coadministration I None
of I None
cytochrome I GENE-Y
c O GENE-Y
and I None
a I None
20 I None
- I None
residue I None
basic I None
peptide I None
, I None
N I None
- I None
WASP181 I None
- I None
200 I None
( I None
NISHTKEKKKGKAKKKRLTK I GENE-N
, I None
pI I None
= I None
10 I None
. I None
87 I None
) I None
inhibits I None
renal I None
accumulation I None
of I None
gentamicin I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
examined I None
effects I None
of I None
ligands I None
of I None
megalin I GENE-Y
, I None
an I None
endocytic I None
receptor I None
involved I None
in I None
renal I None
uptake I None
of I None
gentamicin I CHEMICAL
, I None
and I None
basic I None
peptides I None
including I None
N I None
- I None
WASP180 I None
- I None
200 I None
and I None
its I None
mutant I None
peptides I None
on I None
gentamicin I CHEMICAL
binding I None
to I None
isolated I None
rat I None
renal I None
brush I None
- I None
border I None
membrane I None
( I None
BBM I None
) I None
. I None
<eof> I None

<s> O None
Gentamicin I CHEMICAL
binding I None
to I None
BBM I None
was I None
inhibited I None
by I None
megalin I GENE-Y
ligands I None
, I None
basic I None
peptide I None
fragments I None
of I None
cytochrome I GENE-Y
c O GENE-Y
, I None
and I None
N I None
- I None
WASP181 I None
- I None
200 I None
in I None
a I None
concentration I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
Klotz I None
plot I None
analysis I None
showed I None
that I None
N I None
- I None
WASP181 I None
- I None
200 I None
inhibited I None
the I None
binding I None
of I None
gentamicin I CHEMICAL
in I None
a I None
competitive I None
manner I None
. I None
<eof> I None

<s> O None
By I None
substituting I None
glycines I CHEMICAL
for I None
lysines I CHEMICAL
in I None
N I None
- I None
WASP181 I None
- I None
200 I None
at I None
positions I None
9 I None
and I None
15 I None
, I None
the I None
inhibitory I None
effect I None
on I None
gentamicin I CHEMICAL
binding I None
to I None
BBM I None
was I None
reduced I None
, I None
which I None
may I None
be I None
related I None
to I None
a I None
decrease I None
in I None
the I None
alpha I GENE-N
- O GENE-N
helix O GENE-N
content I None
in I None
the I None
peptide I None
. I None
<eof> I None

<s> O None
Gentamicin I CHEMICAL
binding I None
to I None
BBM I None
treated I None
with I None
trypsin I GENE-N
, I None
in I None
which I None
megalin I GENE-Y
completely I None
disappeared I None
, I None
was I None
significantly I None
but I None
not I None
completely I None
decreased I None
compared I None
with I None
the I None
native I None
BBM I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
treatment I None
of I None
BBM I None
with I None
trypsin I GENE-N
led I None
to I None
a I None
decrease I None
in I None
the I None
inhibitory I None
effect I None
of I None
N I None
- I None
WASP181 I None
- I None
200 I None
on I None
gentamicin I CHEMICAL
binding I None
. I None
<eof> I None

<s> O None
These I None
observations I None
support I None
that I None
megalin I GENE-Y
ligands I None
and I None
basic I None
peptides I None
including I None
N I None
- I None
WASP181 I None
- I None
200 I None
decrease I None
renal I None
accumulation I None
of I None
gentamicin I CHEMICAL
by I None
inhibiting I None
its I None
binding I None
to I None
BBM I None
of I None
proximal I None
tubule I None
cells I None
, I None
partly I None
interacting I None
with I None
megalin I GENE-Y
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
the I None
alpha I GENE-N
- O GENE-N
helix O GENE-N
conformation I None
may I None
play I None
an I None
important I None
role I None
in I None
the I None
inhibitory I None
effect I None
of I None
N I None
- I None
WASP181 I None
- I None
200 I None
on I None
the I None
binding I None
of I None
gentamicin I CHEMICAL
to I None
BBM I None
. I None
<eof> I None

<s> O None
Thymidylate I GENE-Y
synthase O GENE-Y
expression I None
pattern I None
, I None
expression I None
level I None
and I None
single I None
nucleotide I CHEMICAL
polymorphism I None
are I None
predictors I None
for I None
disease I None
- I None
free I None
survival I None
in I None
patients I None
of I None
colorectal I None
cancer I None
treated I None
with I None
5 I CHEMICAL
- O CHEMICAL
fluorouracil O CHEMICAL
. I None
<eof> I None

<s> O None
Several I None
variables I None
associated I None
to I None
thymidylate I GENE-Y
synthase O GENE-Y
( I None
TS I GENE-Y
) I None
, I None
the I None
biological I None
target I None
of I None
5 I CHEMICAL
- O CHEMICAL
fluorouracil O CHEMICAL
( I None
5FU I CHEMICAL
) I None
have I None
been I None
studied I None
for I None
their I None
possible I None
role I None
as I None
predictors I None
of I None
the I None
clinical I None
outcome I None
and I None
response I None
to I None
chemotherapy I None
in I None
colorectal I None
cancer I None
( I None
CRC I None
) I None
patients I None
. I None
<eof> I None

<s> O None
The I None
level I None
of I None
protein I None
expression I None
and I None
the I None
number I None
of I None
variable I None
tandem I None
- I None
repeats I None
of I None
a I None
28 I None
- I None
bp I None
sequence I None
within I None
the I None
gene I None
promoter I None
have I None
been I None
proposed I None
as I None
predictive I None
and I None
/ I None
or I None
prognostic I None
factors I None
with I None
variable I None
agreement I None
, I None
while I None
consensus I None
seems I None
to I None
be I None
achieved I None
with I None
respect I None
to I None
the I None
value I None
of I None
a I None
single I None
nucleotide I CHEMICAL
polymorphism I None
( I None
SNP I None
) I None
described I None
within I None
this I None
same I None
region I None
. I None
<eof> I None

<s> O None
More I None
recently I None
, I None
an I None
association I None
between I None
TS I None
expression I None
pattern I None
and I None
survival I None
has I None
been I None
disclosed I None
. I None
<eof> I None

<s> O None
Paraffin I None
- I None
embedded I None
sections I None
from I None
140 I None
CRC I None
patients I None
were I None
analyzed I None
by I None
immuno I None
- I None
histochemistry I None
( I None
Mab I None
TS106 I None
) I None
for I None
TS I GENE-Y
levels I None
and I None
expression I None
pattern I None
. I None
<eof> I None

<s> O None
Also I None
, I None
VNTR I None
and I None
SNP I None
were I None
determined I None
by I None
polymerase I None
- I None
chain I None
reaction I None
( I None
PCR I None
) I None
and I None
restriction I None
- I None
length I None
- I None
fragment I None
polymorphism I None
( I None
RFLP I None
) I None
in I None
123 I None
and I None
112 I None
patients I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Cytoplasmic I None
expression I None
pattern I None
tended I None
to I None
be I None
associated I None
to I None
C I None
SNP I None
( I None
p I None
= I None
0 I None
. I None
06 I None
) I None
. I None
<eof> I None

<s> O None
Low I None
TS I GENE-Y
expression I None
levels I None
, I None
cytoplasmic I None
expression I None
pattern I None
and I None
C I None
SNP I None
arose I None
as I None
variables I None
associated I None
to I None
longer I None
progression I None
- I None
free I None
survival I None
( I None
PFS I None
) I None
in I None
patients I None
treated I None
with I None
5FU I CHEMICAL
. I None
<eof> I None

<s> O None
Accordingly I None
, I None
patients I None
having I None
at I None
least I None
two I None
favourable I None
or I None
unfavourable I None
variables I None
were I None
classified I None
respectively I None
as I None
' I None
low I None
risk I None
' I None
and I None
' I None
high I None
risk I None
' I None
, I None
the I None
former I None
showing I None
significantly I None
longer I None
PFS I None
( I None
p I None
= I None
0 I None
. I None
0299 I None
) I None
. I None
<eof> I None

<s> O None
The I None
possibility I None
for I None
designing I None
a I None
selection I None
method I None
for I None
subsequent I None
therapies I None
is I None
suggested I None
on I None
the I None
basis I None
of I None
a I None
probable I None
combined I None
effect I None
of I None
the I None
above I None
mentioned I None
parameters I None
but I None
further I None
studies I None
in I None
larger I None
populations I None
are I None
needed I None
to I None
confirm I None
these I None
results I None
. I None
<eof> I None

<s> O None
Leishmania I None
donovani I None
singly I None
deficient I None
in I None
HGPRT I GENE-Y
, I None
APRT I GENE-Y
or I None
XPRT I GENE-Y
are I None
viable I None
in I None
vitro I None
and I None
within I None
mammalian I None
macrophages I None
. I None
<eof> I None

<s> O None
Leishmania I None
species I None
express I None
three I None
phosphoribosyltransferase I GENE-N
enzymes I None
, I None
hypoxanthine I GENE-Y
- O GENE-Y
guanine O GENE-Y
phosphoribosyltransferase O GENE-Y
( I None
HGPRT I GENE-Y
) I None
, I None
adenine I GENE-Y
phosphoribosyltransferase O GENE-Y
( I None
APRT I GENE-Y
) I None
, I None
and I None
xanthine I GENE-Y
phosphoribosyltransferase O GENE-Y
( I None
XPRT I GENE-Y
) I None
, I None
which I None
enable I None
this I None
genus I None
to I None
acquire I None
purine I CHEMICAL
nutrients I None
from I None
their I None
hosts I None
. I None
<eof> I None

<s> O None
To I None
test I None
whether I None
any I None
of I None
these I None
enzymes I None
is I None
essential I None
for I None
viability I None
, I None
transformation I None
into I None
amastigotes I None
, I None
and I None
infectivity I None
and I None
proliferation I None
within I None
mammalian I None
macrophages I None
, I None
Deltahgprt I None
, I None
Deltaaprt I None
, I None
and I None
Deltaxprt I None
null I None
mutants I None
were I None
created I None
by I None
targeted I None
gene I None
replacement I None
within I None
a I None
virulent I None
background I None
of I None
Leishmania I None
donovani I None
. I None
<eof> I None

<s> O None
Each I None
of I None
the I None
three I None
knockout I None
strains I None
was I None
viable I None
as I None
promastigotes I None
and I None
axenic I None
amastigotes I None
and I None
capable I None
of I None
maintaining I None
an I None
infection I None
in I None
bone I None
marrow I None
- I None
derived I None
murine I None
macrophages I None
. I None
<eof> I None

<s> O None
These I None
data I None
support I None
the I None
hypothesis I None
that I None
none I None
of I None
the I None
three I None
phosphoribosyltransferases I GENE-N
is I None
essential I None
for I None
purine I CHEMICAL
salvage I None
or I None
viability I None
by I None
itself I None
and I None
that I None
purine I CHEMICAL
salvage I None
occurs I None
through I None
multiple I None
anabolic I None
routes I None
in I None
both I None
parasite I None
life I None
cycle I None
stages I None
. I None
<eof> I None

<s> O None
In I None
addition I None
these I None
studies I None
revealed I None
the I None
presence I None
of I None
an I None
adenine I GENE-Y
aminohydrolase O GENE-Y
enzyme I None
in I None
L I None
. I None
donovani I None
axenic I None
amastigotes I None
, I None
an I None
activity I None
previously I None
thought I None
to I None
be I None
restricted I None
to I None
promastigotes I None
. I None
<eof> I None

<s> O None
Loss I None
of I None
a I None
primordial I None
identity I None
element I None
for I None
a I None
mammalian I None
mitochondrial I None
aminoacylation I None
system I None
. I None
<eof> I None

<s> O None
In I None
mammalian I None
mitochondria I None
the I None
translational I None
machinery I None
is I None
of I None
dual I None
origin I None
with I None
tRNAs I None
encoded I None
by I None
a I None
simplified I None
and I None
rapidly I None
evolving I None
mitochondrial I None
( I None
mt I None
) I None
genome I None
and I None
aminoacyl I GENE-N
- O GENE-N
tRNA O GENE-N
synthetases O GENE-N
( I None
aaRS I GENE-N
) I None
coded I None
by I None
the I None
nuclear I None
genome I None
, I None
and I None
imported I None
. I None
<eof> I None

<s> O None
Mt I None
- I None
tRNAs I None
are I None
atypical I None
with I None
biased I None
sequences I None
, I None
size I None
variations I None
in I None
loops I None
and I None
stems I None
, I None
and I None
absence I None
of I None
residues I None
forming I None
classical I None
tertiary I None
interactions I None
, I None
whereas I None
synthetases I GENE-N
appear I None
typical I None
. I None
<eof> I None

<s> O None
This I None
raises I None
questions I None
about I None
identity I None
elements I None
in I None
mt I None
- I None
tRNAs I None
and I None
adaptation I None
of I None
their I None
cognate I None
mt I GENE-N
- O GENE-N
aaRSs O GENE-N
. I None
<eof> I None

<s> O None
We I None
have I None
explored I None
here I None
the I None
human I None
mt I None
- I None
aspartate I CHEMICAL
system I None
in I None
which I None
a I None
prokaryotic I GENE-N
- O GENE-N
type O GENE-N
AspRS O GENE-N
, I None
highly I None
similar I None
to I None
the I None
Escherichia I None
coli I None
enzyme I None
, I None
recognizes I None
a I None
bizarre I None
tRNA I None
( I None
Asp I None
) I None
. I None
<eof> I None

<s> O None
Analysis I None
of I None
human I GENE-N
mt O GENE-N
- O GENE-N
tRNA O GENE-N
( O GENE-N
Asp O GENE-N
) O GENE-N
transcripts O GENE-N
confirms I None
the I None
identity I None
role I None
of I None
the I None
GUC I None
anticodon I None
as I None
in I None
other I None
aspartylation I None
systems I None
but I None
reveals I None
the I None
non I None
- I None
involvement I None
of I None
position I None
73 I None
. I None
<eof> I None

<s> O None
This I None
position I None
is I None
otherwise I None
known I None
as I None
the I None
site I None
of I None
a I None
universally I None
conserved I None
major I None
aspartate I CHEMICAL
identity I None
element I None
, I None
G73 I GENE-N
, I None
also I None
known I None
as I None
a I None
primordial I None
identity I None
signal I None
. I None
<eof> I None

<s> O None
In I None
mt I None
- I None
tRNA I None
( I None
Asp I None
) I None
, I None
position I None
73 I None
can I None
be I None
occupied I None
by I None
any I None
of I None
the I None
four I None
nucleotides I CHEMICAL
without I None
affecting I None
aspartylation I None
. I None
<eof> I None

<s> O None
Sequence I None
alignments I None
of I None
various I None
AspRSs I GENE-N
allowed I None
placing I None
Gly I CHEMICAL
- I None
269 I None
at I None
a I None
position I None
occupied I None
by I None
Asp I CHEMICAL
- I None
220 I None
, I None
the I None
residue I None
contacting I None
G73 I GENE-N
in I None
the I None
crystallographic I None
structure I None
of I None
E I GENE-Y
. O GENE-Y
coli O GENE-Y
AspRS O GENE-Y
- I None
tRNA I None
( I None
Asp I None
) I None
complex I None
. I None
<eof> I None

<s> O None
Replacing I None
this I None
glycine I CHEMICAL
by I None
an I None
aspartate I CHEMICAL
renders I None
human I GENE-Y
mt O GENE-Y
- O GENE-Y
AspRS O GENE-Y
more I None
discriminative I None
to I None
G73 I GENE-N
. I None
<eof> I None

<s> O None
Restriction I None
in I None
the I None
aspartylation I None
identity I None
set I None
, I None
driven I None
by I None
a I None
rapid I None
mutagenic I None
rate I None
of I None
the I None
mt I None
- I None
genome I None
, I None
suggests I None
a I None
reverse I None
evolution I None
of I None
the I None
mt I None
- I None
tRNA I None
( I None
Asp I None
) I None
identity I None
elements I None
in I None
regard I None
to I None
its I None
bacterial I None
ancestor I None
. I None
<eof> I None

<s> O None
Metabolic I None
syndrome I None
: I None
adenosine I GENE-N
monophosphate O GENE-N
- O GENE-N
activated O GENE-N
protein O GENE-N
kinase O GENE-N
and I None
malonyl I CHEMICAL
coenzyme O CHEMICAL
A O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
metabolic I None
syndrome I None
can I None
be I None
defined I None
as I None
a I None
state I None
of I None
metabolic I None
dysregulation I None
characterized I None
by I None
insulin I GENE-Y
resistance I None
, I None
central I None
obesity I None
, I None
and I None
a I None
predisposition I None
to I None
type I None
2 I None
diabetes I None
, I None
dyslipidemia I None
, I None
premature I None
atherosclerosis I None
, I None
and I None
other I None
diseases I None
. I None
<eof> I None

<s> O None
An I None
increasing I None
body I None
of I None
evidence I None
has I None
linked I None
the I None
metabolic I None
syndrome I None
to I None
abnormalities I None
in I None
lipid I None
metabolism I None
that I None
ultimately I None
lead I None
to I None
cellular I None
dysfunction I None
. I None
<eof> I None

<s> O None
We I None
review I None
here I None
the I None
hypothesis I None
that I None
, I None
in I None
many I None
instances I None
, I None
the I None
cause I None
of I None
these I None
lipid I None
abnormalities I None
could I None
be I None
a I None
dysregulation I None
of I None
the I None
adenosine I GENE-N
monophosphate O GENE-N
- O GENE-N
activated O GENE-N
protein O GENE-N
kinase O GENE-N
( I None
AMPK I GENE-N
) I None
/ I None
malonyl I CHEMICAL
coenzyme O CHEMICAL
A O CHEMICAL
( I None
CoA I None
) I None
fuel I None
- I None
sensing I None
and I None
signaling I None
mechanism I None
. I None
<eof> I None

<s> O None
Such I None
dysregulation I None
could I None
be I None
reflected I None
by I None
isolated I None
increases I None
in I None
malonyl I CHEMICAL
CoA O CHEMICAL
or I None
by I None
concurrent I None
changes I None
in I None
malonyl I CHEMICAL
CoA O CHEMICAL
and I None
AMPK I GENE-N
, I None
both I None
of I None
which I None
would I None
alter I None
intracellular I None
fatty I None
acid I None
partitioning I None
. I None
<eof> I None

<s> O None
The I None
possibility I None
is I None
also I None
raised I None
that I None
pharmacological I None
agents I None
and I None
other I None
factors I None
that I None
activate I None
AMPK I GENE-N
and I None
/ I None
or I None
decrease I None
malonyl I CHEMICAL
CoA O CHEMICAL
could I None
be I None
therapeutic I None
targets I None
. I None
<eof> I None

<s> O None
Chronic I None
effect I None
of I None
[ I CHEMICAL
D O CHEMICAL
- O CHEMICAL
Pen2 O CHEMICAL
, O CHEMICAL
D O CHEMICAL
- O CHEMICAL
Pen5 O CHEMICAL
] O CHEMICAL
enkephalin O CHEMICAL
on I None
rat I GENE-N
brain O GENE-N
opioid O GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
In I None
previous I None
studies I None
, I None
we I None
have I None
demonstrated I None
that I None
chronic I None
etorphine I CHEMICAL
or I None
[ I CHEMICAL
D O CHEMICAL
- O CHEMICAL
Ala2 O CHEMICAL
, O CHEMICAL
D O CHEMICAL
- O CHEMICAL
Leu5 O CHEMICAL
] O CHEMICAL
enkephalin O CHEMICAL
( I None
DADLE I CHEMICAL
) I None
treatment I None
of I None
rats I None
results I None
in I None
the I None
reduction I None
of I None
mu I GENE-N
- O GENE-N
and O GENE-N
delta O GENE-N
- O GENE-N
opioid O GENE-N
receptor O GENE-N
binding I None
activities I None
as I None
tolerance I None
develops I None
. I None
<eof> I None

<s> O None
As I None
both I None
etorphine I CHEMICAL
and I None
DADLE I CHEMICAL
are I None
relatively I None
non I None
- I None
specific I None
opioid I None
ligands I None
, I None
interacting I None
with I None
both I None
mu I GENE-N
- O GENE-N
and O GENE-N
delta O GENE-N
- O GENE-N
receptors O GENE-N
, I None
these I None
studies I None
could I None
not I None
determine I None
whether I None
down I None
- I None
regulation I None
of I None
a I None
specific I None
receptor I None
type I None
occurs I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
in I None
the I None
present I None
studies I None
, I None
animals I None
were I None
rendered I None
tolerant I None
to I None
the I None
delta I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
- I None
selective I None
agonist I None
[ I CHEMICAL
D O CHEMICAL
- O CHEMICAL
Pen2 O CHEMICAL
, O CHEMICAL
D O CHEMICAL
- O CHEMICAL
Pen5 O CHEMICAL
] O CHEMICAL
enkephalin O CHEMICAL
( I None
DPDPE I CHEMICAL
) I None
, I None
and I None
receptor I None
binding I None
activities I None
were I None
measured I None
. I None
<eof> I None

<s> O None
Treating I None
Sprague I None
- I None
Dawley I None
rats I None
with I None
increasing I None
doses I None
of I None
DPDPE I CHEMICAL
( I None
80 I None
- I None
160 I None
- I None
240 I None
- I None
320 I None
micrograms I None
/ I None
kg I None
) I None
i I None
. I None
c I None
. I None
v I None
. I None
for I None
1 I None
to I None
4 I None
days I None
resulted I None
in I None
a I None
time I None
- I None
dependent I None
increase I None
in I None
the I None
AD50 I None
of I None
DPDPE I CHEMICAL
to I None
elicit I None
an I None
antinociceptive I None
response I None
. I None
<eof> I None

<s> O None
When I None
delta I GENE-Y
- O GENE-Y
receptor O GENE-Y
binding I None
was I None
determined I None
by I None
using I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
DPDPE O CHEMICAL
, I None
a I None
40 I None
- I None
50 I None
% I None
decrease I None
in I None
binding I None
in I None
the I None
midbrain I None
and I None
cortex I None
, I None
and I None
25 I None
- I None
35 I None
% I None
decrease I None
in I None
binding I None
in I None
the I None
striatum I None
were I None
observed I None
after I None
3 I None
or I None
4 I None
days I None
of I None
DPDPE I CHEMICAL
treatment I None
. I None
<eof> I None

<s> O None
Scatchard I None
analysis I None
of I None
the I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
DPDPE O CHEMICAL
saturation I None
binding I None
data I None
revealed I None
a I None
decrease I None
in I None
Bmax I None
values I None
and I None
no I None
significant I None
change I None
in I None
Kd I None
values I None
. I None
<eof> I None

<s> O None
To I None
our I None
surprise I None
, I None
when I None
mu I GENE-Y
- O GENE-Y
receptor O GENE-Y
binding I None
was I None
determined I None
by I None
using I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
Tyr O CHEMICAL
- O CHEMICAL
D O CHEMICAL
- O CHEMICAL
Ala O CHEMICAL
- O CHEMICAL
Gly O CHEMICAL
- O CHEMICAL
MePhe O CHEMICAL
- O CHEMICAL
Gly O CHEMICAL
- O CHEMICAL
ol O CHEMICAL
( I None
DAMGO I CHEMICAL
) I None
, I None
a I None
10 I None
- I None
15 I None
% I None
decrease I None
in I None
binding I None
was I None
also I None
observed I None
in I None
the I None
midbrain I None
and I None
cortex I None
after I None
4 I None
days I None
of I None
DPDPE I CHEMICAL
treatment I None
. I None
<eof> I None

<s> O None
Our I None
conclusion I None
is I None
that I None
chronic I None
DPDPE I CHEMICAL
treatment I None
preferentially I None
reduces I None
delta I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
binding I None
activity I None
. I None
<eof> I None

<s> O None
Its I None
minor I None
effect I None
on I None
the I None
mu I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
maybe I None
due I None
to I None
an I None
interaction I None
between I None
delta I GENE-Y
cx O GENE-Y
and I None
mu I GENE-Y
cx O GENE-Y
binding I None
sites I None
. I None
<eof> I None

<s> O None
[ I None
Preclinical I None
pharmacology I None
of I None
amoxapine I CHEMICAL
and I None
amitriptyline I CHEMICAL
. I None
Implications I None
of I None
serotoninergic I None
and I None
opiodergic I None
systems I None
in I None
their I None
central I None
effect I None
in I None
rats I None
] I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
two I None
antidepressant I None
drugs I None
, I None
amoxapine I CHEMICAL
and I None
amitriptyline I CHEMICAL
, I None
that I None
belong I None
to I None
distinct I None
chemical I None
classes I None
, I None
have I None
been I None
examined I None
on I None
various I None
biochemical I None
parameters I None
related I None
to I None
serotoninergic I None
and I None
opioidergic I None
neurotransmission I None
in I None
the I None
rat I None
brain I None
and I None
spinal I None
cord I None
. I None
<eof> I None

<s> O None
In I None
vitro I None
binding I None
studies I None
showed I None
that I None
both I None
amoxapine I CHEMICAL
and I None
amitriptyline I CHEMICAL
interact I None
in I None
the I None
nanomolar I None
range I None
with I None
5 I GENE-N
- O GENE-N
HT2 O GENE-N
receptors I None
labelled I None
by I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
ketanserin O CHEMICAL
in I None
cortical I None
membranes I None
. I None
<eof> I None

<s> O None
By I None
contrast I None
, I None
neither I None
amoxapine I CHEMICAL
nor I None
amitriptyline I CHEMICAL
can I None
be I None
considered I None
as I None
possible I None
ligands I None
of I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptors I None
because I None
their I None
affinities I None
for I None
these I None
sites I None
are I None
in I None
the I None
micromolar I None
range I None
( I None
or I None
even I None
worse I None
) I None
. I None
<eof> I None

<s> O None
Interestingly I None
, I None
amoxapine I CHEMICAL
binds I None
with I None
a I None
good I None
affinity I None
( I None
IC50 I None
= I None
0 I None
. I None
30 I None
microM I None
) I None
to I None
5 I GENE-N
- O GENE-N
HT3 O GENE-N
receptors I None
labelled I None
by I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
zacopride O CHEMICAL
in I None
cortical I None
membranes I None
. I None
<eof> I None

<s> O None
Complementary I None
experiments I None
using I None
the I None
5 I GENE-N
- O GENE-N
HT3 O GENE-N
- I None
dependent I None
Bezold I None
- I None
Jarisch I None
reflex I None
confirmed I None
that I None
amoxapine I CHEMICAL
really I None
acts I None
in I None
vivo I None
as I None
a I None
5 I GENE-N
- O GENE-N
HT3 O GENE-N
antagonist I None
( I None
IC50 I None
= I None
50 I None
micrograms I None
/ I None
kg I None
i I None
. I None
v I None
. I None
) I None
, I None
whereas I None
amitriptyline I CHEMICAL
is I None
essentially I None
inactive I None
on I None
5 I GENE-N
- O GENE-N
HT3 O GENE-N
receptors I None
. I None
<eof> I None

<s> O None
The I None
second I None
part I None
of I None
this I None
study I None
consisted I None
of I None
looking I None
for I None
possible I None
changes I None
in I None
central I None
5 I GENE-N
- O GENE-N
HT O GENE-N
receptors O GENE-N
24 I None
h I None
after I None
either I None
a I None
single I None
or I None
a I None
repeated I None
( I None
for I None
14 I None
days I None
) I None
treatment I None
with I None
amoxapine I CHEMICAL
( I None
10 I None
mg I None
/ I None
kg I None
i I None
. I None
p I None
. I None
each I None
day I None
) I None
or I None
amitriptyline I CHEMICAL
( I None
10 I None
mg I None
/ I None
kg I None
i I None
. I None
p I None
. I None
) I None
. I None
<eof> I None

<s> O None
A I None
marked I None
decrease I None
in I None
the I None
density I None
of I None
5 I GENE-N
- O GENE-N
HT2 O GENE-N
receptors I None
was I None
found I None
in I None
the I None
cerebral I None
cortex I None
in I None
both I None
treatment I None
groups I None
. I None
<eof> I None

<s> O None
By I None
contrast I None
, I None
neither I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
nor I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptors I None
were I None
significantly I None
affected I None
in I None
any I None
brain I None
region I None
studied I None
. I None
<eof> I None

<s> O None
Finally I None
we I None
explored I None
whether I None
acute I None
and I None
/ I None
or I None
chronic I None
administration I None
of I None
amoxapine I CHEMICAL
or I None
amitriptyline I CHEMICAL
affected I None
the I None
levels I None
of I None
opioid I None
peptides I None
and I None
the I None
mu I GENE-N
and O GENE-N
delta O GENE-N
classes O GENE-N
of O GENE-N
opioid O GENE-N
receptors O GENE-N
in I None
various I None
regions I None
of I None
the I None
brain I None
and I None
the I None
spinal I None
cord I None
. I None
( I None
ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Desvenlafaxine I CHEMICAL
succinate O CHEMICAL
: I None
A I None
new I None
serotonin I CHEMICAL
and I None
norepinephrine I CHEMICAL
reuptake I None
inhibitor I None
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
study I None
was I None
to I None
characterize I None
a I None
new I None
chemical I None
entity I None
, I None
desvenlafaxine I CHEMICAL
succinate O CHEMICAL
( I None
DVS I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
DVS I CHEMICAL
is I None
a I None
novel I None
salt I None
form I None
of I None
the I None
isolated I None
major I None
active I None
metabolite I None
of I None
venlafaxine I CHEMICAL
. I None
<eof> I None

<s> O None
Competitive I None
radioligand I None
binding I None
assays I None
were I None
performed I None
using I None
cells I None
expressing I None
either I None
the I None
human I GENE-Y
serotonin O GENE-Y
( O GENE-Y
5 O GENE-Y
- O GENE-Y
HT O GENE-Y
) O GENE-Y
transporter O GENE-Y
( I None
hSERT I GENE-Y
) I None
or I None
norepinephrine I GENE-Y
( O GENE-Y
NE O GENE-Y
) O GENE-Y
transporter O GENE-Y
( I None
hNET I GENE-Y
) I None
with I None
K I None
( I None
i I None
) I None
values I None
for I None
DVS I CHEMICAL
of I None
40 I None
. I None
2 I None
+ I None
/ I None
- I None
1 I None
. I None
6 I None
and I None
558 I None
. I None
4 I None
+ I None
/ I None
- I None
121 I None
. I None
6 I None
nM I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
DVS I CHEMICAL
showed I None
weak I None
binding I None
affinity I None
( I None
62 I None
% I None
inhibition I None
at I None
100 I None
microM I None
) I None
at I None
the I None
human I GENE-Y
dopamine O GENE-Y
( O GENE-Y
DA O GENE-Y
) O GENE-Y
transporter O GENE-Y
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
HT O CHEMICAL
or I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
NE O CHEMICAL
uptake I None
by I None
DVS I CHEMICAL
for I None
the I None
hSERT I GENE-Y
or I None
hNET I GENE-Y
produced I None
IC50 I None
values I None
of I None
47 I None
. I None
3 I None
+ I None
/ I None
- I None
19 I None
. I None
4 I None
and I None
531 I None
. I None
3 I None
+ I None
/ I None
- I None
113 I None
. I None
0 I None
nM I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
DVS I CHEMICAL
( I None
10 I None
microM I None
) I None
, I None
examined I None
at I None
a I None
large I None
number I None
of I None
nontransporter I None
targets I None
, I None
showed I None
no I None
significant I None
activity I None
. I None
<eof> I None

<s> O None
DVS I CHEMICAL
( I None
30 I None
mg I None
/ I None
kg I None
orally I None
) I None
rapidly I None
penetrated I None
the I None
male I None
rat I None
brain I None
and I None
hypothalamus I None
. I None
<eof> I None

<s> O None
DVS I CHEMICAL
( I None
30 I None
mg I None
/ I None
kg I None
orally I None
) I None
significantly I None
increased I None
extracellular I None
NE I CHEMICAL
levels I None
compared I None
with I None
baseline I None
in I None
the I None
male I None
rat I None
hypothalamus I None
but I None
had I None
no I None
effect I None
on I None
DA I CHEMICAL
levels I None
using I None
microdialysis I None
. I None
<eof> I None

<s> O None
To I None
mimic I None
chronic I None
selective I None
serotonin I CHEMICAL
reuptake I None
inhibitor I None
treatment I None
and I None
to I None
block I None
the I None
inhibitory I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
autoreceptors I None
, I None
a I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
antagonist I None
, I None
N I CHEMICAL
- O CHEMICAL
[ O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
methoxyphenyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
piperazinyl O CHEMICAL
] O CHEMICAL
ethyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
N O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
pyridinylcyclo O CHEMICAL
hexanecarboxamide O CHEMICAL
maleate O CHEMICAL
salt O CHEMICAL
( I None
WAY I CHEMICAL
- O CHEMICAL
100635 O CHEMICAL
) I None
( I None
0 I None
. I None
3 I None
mg I None
/ I None
kg I None
s I None
. I None
c I None
. I None
) I None
, I None
was I None
administered I None
with I None
DVS I CHEMICAL
( I None
30 I None
mg I None
/ I None
kg I None
orally I None
) I None
. I None
<eof> I None

<s> O None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
increased I None
78 I None
% I None
compared I None
with I None
baseline I None
with I None
no I None
additional I None
increase I None
in I None
NE I CHEMICAL
or I None
DA I CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
DVS I CHEMICAL
is I None
a I None
new I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
and I None
NE I CHEMICAL
reuptake I None
inhibitor I None
in I None
vitro I None
and I None
in I None
vivo I None
that I None
demonstrates I None
good I None
brain I None
- I None
to I None
- I None
plasma I None
ratios I None
, I None
suggesting I None
utility I None
in I None
a I None
variety I None
of I None
central I None
nervous I None
system I None
- I None
related I None
disorders I None
. I None
<eof> I None

<s> O None
How I None
may I None
anticancer I None
chemotherapy I None
with I None
fluorouracil I CHEMICAL
be I None
individualised I None
? I None
<eof> I None

<s> O None
Fluorouracil I CHEMICAL
is I None
used I None
clinically I None
against I None
various I None
solid I None
tumours I None
. I None
<eof> I None

<s> O None
Both I None
fluorouracil I CHEMICAL
toxicity I None
and I None
pharmacokinetics I None
vary I None
highly I None
within I None
and I None
between I None
individuals I None
. I None
<eof> I None

<s> O None
The I None
reasons I None
why I None
doses I None
are I None
not I None
individualised I None
routinely I None
are I None
difficulties I None
in I None
defining I None
, I None
predicting I None
and I None
achieving I None
an I None
optimal I None
fluorouracil I CHEMICAL
exposure I None
or I None
dose I None
because I None
of I None
a I None
narrow I None
therapeutic I None
index I None
, I None
nonlinear I None
pharmacokinetics I None
, I None
variabilities I None
in I None
administration I None
rates I None
and I None
metabolism I None
, I None
and I None
in I None
targets I None
like I None
thymidylate I GENE-Y
synthase O GENE-Y
. I None
<eof> I None

<s> O None
To I None
individualise I None
fluorouracil I CHEMICAL
administration I None
before I None
the I None
first I None
dose I None
, I None
assessment I None
of I None
the I None
individual I None
dihydropyrimidine I GENE-Y
dehydrogenase O GENE-Y
( I None
DPD I GENE-Y
) I None
activity I None
may I None
be I None
useful I None
, I None
because I None
this I None
genetically I None
highly I None
polymorphic I None
enzyme I None
controls I None
approximately I None
80 I None
% I None
of I None
fluorouracil I CHEMICAL
elimination I None
. I None
<eof> I None

<s> O None
A I None
complete I None
or I None
partial I None
loss I None
of I None
DPD I GENE-Y
activity I None
in I None
0 I None
. I None
1 I None
and I None
3 I None
- I None
5 I None
% I None
of I None
Caucasians I None
, I None
respectively I None
, I None
leads I None
to I None
increased I None
fluorouracil I CHEMICAL
exposure I None
and I None
toxicity I None
. I None
<eof> I None

<s> O None
Several I None
methods I None
to I None
assess I None
DPD I GENE-Y
activity I None
in I None
patients I None
have I None
been I None
proposed I None
( I None
genotyping I None
, I None
various I None
phenotyping I None
methods I None
) I None
, I None
but I None
each I None
of I None
them I None
has I None
limitations I None
, I None
as I None
has I None
the I None
fluorouracil I CHEMICAL
test I None
dose I None
approach I None
. I None
<eof> I None

<s> O None
To I None
adapt I None
exposure I None
towards I None
fluorouracil I CHEMICAL
a I None
priori I None
, I None
a I None
combination I None
of I None
genotyping I None
and I None
phenotyping I None
may I None
yield I None
better I None
prediction I None
of I None
toxicity I None
than I None
one I None
method I None
alone I None
. I None
<eof> I None

<s> O None
A I None
prerequisite I None
for I None
dose I None
adaptation I None
is I None
the I None
definition I None
of I None
fluorouracil I CHEMICAL
exposure I None
ranges I None
with I None
sufficient I None
therapeutic I None
activity I None
, I None
but I None
without I None
serious I None
toxicity I None
. I None
<eof> I None

<s> O None
While I None
an I None
increased I None
risk I None
of I None
leukopenia I None
, I None
diarrhoea I None
, I None
stomatitis I None
, I None
and I None
hand I None
- I None
foot I None
syndrome I None
during I None
continuous I None
5 I None
- I None
day I None
infusions I None
was I None
related I None
to I None
fluorouracil I CHEMICAL
exposures I None
above I None
an I None
area I None
under I None
the I None
plasma I None
concentration I None
- I None
time I None
curve I None
( I None
AUC I None
) I None
threshold I None
of I None
25 I None
- I None
30 I None
mg I None
. I None
h I None
/ I None
L I None
, I None
tumour I None
response I None
was I None
higher I None
when I None
an I None
AUC I None
of I None
approximately I None
30 I None
mg I None
. I None
h I None
/ I None
L I None
was I None
achieved I None
, I None
illustrating I None
the I None
extremely I None
narrow I None
therapeutic I None
window I None
of I None
fluorouracil I CHEMICAL
. I None
<eof> I None

<s> O None
Pharmacokinetic I None
target I None
values I None
are I None
less I None
clear I None
for I None
other I None
regimens I None
, I None
including I None
chronomodulated I None
regimens I None
, I None
which I None
yielded I None
a I None
superior I None
clinically I None
efficacy I None
and I None
tolerability I None
in I None
several I None
trials I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
monitoring I None
of I None
fluorouracil I CHEMICAL
plasma I None
concentrations I None
seems I None
principally I None
useful I None
for I None
individual I None
a I None
posteriori I None
dose I None
adjustment I None
. I None
<eof> I None

<s> O None
Whether I None
an I None
adaptation I None
of I None
the I None
fluorouracil I CHEMICAL
starting I None
dose I None
to I None
the I None
results I None
of I None
two I None
DPD I GENE-Y
activity I None
tests I None
before I None
fluorouracil I CHEMICAL
administration I None
a I None
priori I None
, I None
and I None
the I None
adaptation I None
of I None
doses I None
to I None
fluorouracil I CHEMICAL
exposure I None
a I None
posteriori I None
is I None
a I None
reasonable I None
approach I None
to I None
better I None
prevent I None
toxicity I None
and I None
increase I None
efficacy I None
, I None
remains I None
to I None
be I None
evaluated I None
in I None
randomised I None
clinical I None
studies I None
comparing I None
these I None
strategies I None
to I None
routine I None
clinical I None
safety I None
monitoring I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
basic I GENE-Y
fibroblast O GENE-Y
growth O GENE-Y
factor O GENE-Y
correlates I None
with I None
resistance I None
to I None
paclitaxel I CHEMICAL
in I None
human I None
patient I None
tumors I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Preclinical I None
results I None
indicate I None
acidic I GENE-Y
fibroblast O GENE-Y
growth O GENE-Y
factor O GENE-Y
( I None
aFGF I GENE-Y
) I None
and I None
basic I GENE-Y
FGF O GENE-Y
( I None
bFGF I GENE-Y
) I None
present I None
in I None
solid I None
tumors I None
as I None
a I None
cause I None
of I None
broad I None
- I None
spectrum I None
chemoresistance I None
, I None
whereas I None
earlier I None
clinical I None
studies I None
suggest I None
that I None
bFGF I GENE-Y
expression I None
is I None
associated I None
with I None
opposing I None
outcomes I None
in I None
patients I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
relationship I None
between I None
FGF I GENE-N
expression I None
and I None
paclitaxel I CHEMICAL
activity I None
in I None
tumors I None
from I None
bladder I None
, I None
breast I None
, I None
head I None
and I None
neck I None
, I None
ovarian I None
, I None
and I None
prostate I None
cancer I None
patients I None
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
: I None
Tumors I None
( I None
n I None
= I None
96 I None
) I None
were I None
maintained I None
in I None
three I None
- I None
dimensional I None
histocultures I None
, I None
retaining I None
tumor I None
- I None
stromal I None
interaction I None
. I None
<eof> I None

<s> O None
Bladder I None
tumors I None
were I None
treated I None
with I None
paclitaxel I CHEMICAL
for I None
2 I None
h I None
, I None
and I None
the I None
other I None
tumors I None
for I None
24 I None
h I None
. I None
<eof> I None

<s> O None
Antiproliferative I None
and I None
proapoptotic I None
effects I None
of I None
paclitaxel I CHEMICAL
were I None
quantified I None
and I None
correlated I None
with I None
expression I None
of I None
aFGF I GENE-Y
, I None
bFGF I GENE-Y
, I None
P I GENE-N
- O GENE-N
glycoprotein O GENE-N
( I None
Pgp I GENE-N
) I None
, I None
p53 I GENE-Y
, I None
and I None
bcl I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Fifty I None
- I None
one I None
percent I None
( I None
49 I None
/ I None
96 I None
) I None
and I None
63 I None
% I None
( I None
61 I None
/ I None
96 I None
) I None
of I None
tumors I None
showed I None
aFGF I GENE-Y
and I None
bFGF I GENE-Y
staining I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
aFGF I GENE-Y
expression I None
was I None
positively I None
correlated I None
with I None
tumor I None
stage I None
( I None
p I None
< I None
0 I None
. I None
01 I None
) I None
, I None
and I None
bFGF I GENE-Y
expression I None
with I None
tumor I None
grade I None
and I None
Pgp I GENE-N
expression I None
( I None
p I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
Paclitaxel I CHEMICAL
inhibited I None
antiproliferation I None
in I None
86 I None
% I None
of I None
tumors I None
( I None
83 I None
/ I None
96 I None
) I None
, I None
with I None
an I None
average I None
inhibition I None
of I None
46 I None
+ I None
/ I None
- I None
19 I None
% I None
( I None
mean I None
+ I None
/ I None
- I None
SD I None
) I None
in I None
the I None
responding I None
tumors I None
. I None
<eof> I None

<s> O None
Paclitaxel I CHEMICAL
also I None
induced I None
apoptosis I None
in I None
96 I None
% I None
of I None
tumors I None
( I None
92 I None
/ I None
96 I None
) I None
, I None
with I None
an I None
average I None
apoptotic I None
index I None
of I None
12 I None
+ I None
/ I None
- I None
7 I None
% I None
in I None
the I None
responding I None
tumors I None
. I None
<eof> I None

<s> O None
aFGF I GENE-Y
expression I None
did I None
not I None
correlate I None
with I None
tumor I None
sensitivity I None
to I None
paclitaxel I CHEMICAL
, I None
whereas I None
bFGF I GENE-Y
expression I None
showed I None
an I None
inverse I None
correlation I None
( I None
p I None
< I None
0 I None
. I None
01 I None
) I None
. I None
<eof> I None

<s> O None
bFGF I GENE-Y
expression I None
was I None
a I None
stronger I None
predictor I None
of I None
paclitaxel I CHEMICAL
resistance I None
compared I None
to I None
Pgp I GENE-N
, I None
p53 I GENE-Y
, I None
or I None
Bcl I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
These I None
results I None
support I None
a I None
role I None
of I None
bFGF I GENE-Y
in I None
paclitaxel I CHEMICAL
resistance I None
in I None
human I None
patient I None
tumors I None
. I None
<eof> I None

<s> O None
Thyroid I GENE-N
hormone O GENE-N
receptor O GENE-N
expression I None
in I None
the I None
obligatory I None
paedomorphic I None
salamander I None
Necturus I None
maculosus I None
. I None
<eof> I None

<s> O None
Amphibian I None
metamorphosis I None
is I None
under I None
the I None
strict I None
control I None
of I None
thyroid I CHEMICAL
hormones O CHEMICAL
( I None
TH I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
These I None
hormones I None
induce I None
metamorphosis I None
by I None
controlling I None
gene I None
expression I None
through I None
binding I None
to I None
thyroid I GENE-N
hormone O GENE-N
receptors O GENE-N
( I None
TRs I GENE-N
) I None
. I None
<eof> I None

<s> O None
Necturus I None
maculosus I None
is I None
considered I None
to I None
be I None
an I None
obligatory I None
paedomorphic I None
Amphibian I None
since I None
metamorphosis I None
never I None
occurs I None
spontaneously I None
and I None
cannot I None
be I None
induced I None
by I None
pharmacological I None
means I None
. I None
<eof> I None

<s> O None
Since I None
metamorphosis I None
depends I None
on I None
the I None
acquisition I None
of I None
response I None
of I None
tadpole I None
tissues I None
to I None
thyroid I CHEMICAL
hormone O CHEMICAL
, I None
we I None
aimed I None
to I None
determine I None
TR I GENE-N
gene I None
expression I None
patterns I None
in I None
Necturus I None
maculosus I None
as I None
well I None
as I None
the I None
expression I None
of I None
two I None
TH I CHEMICAL
- I None
related I None
genes I None
: I None
Cytosolic I GENE-N
Thyroid O GENE-N
Hormone O GENE-N
- O GENE-N
Binding O GENE-N
Protein O GENE-N
( I None
CTHBP I GENE-N
) I None
- I None
M2 I GENE-N
- O GENE-N
pyruvate O GENE-N
kinase O GENE-N
, I None
a I None
gene I None
encoding I None
a I None
cytosolic I GENE-N
TH O GENE-N
binding O GENE-N
protein O GENE-N
and I None
stromelysin I GENE-Y
3 O GENE-Y
, I None
a I None
direct I None
TH I None
target I None
gene I None
in I None
Xenopus I None
laevis I None
. I None
<eof> I None

<s> O None
Tissue I None
samples I None
were I None
obtained I None
from I None
specimens I None
of I None
Necturus I None
maculosus I None
. I None
<eof> I None

<s> O None
We I None
performed I None
in I None
situ I None
hybridization I None
using I None
non I None
- I None
cross I None
- I None
hybridizing I None
RNA I None
probes I None
obtained I None
from I None
the I None
cloned I None
Necturus I GENE-Y
TRalpha O GENE-Y
and I None
TRbeta I GENE-Y
genes I None
. I None
<eof> I None

<s> O None
We I None
found I None
clear I None
expression I None
of I None
Necturus I GENE-Y
TRalpha O GENE-Y
gene I None
in I None
several I None
tissues I None
including I None
the I None
central I None
nervous I None
system I None
, I None
epithelial I None
cells I None
of I None
digestive I None
and I None
urinary I None
organs I None
, I None
as I None
well I None
as I None
myocardium I None
and I None
skeletal I None
muscle I None
. I None
<eof> I None

<s> O None
TRbeta I GENE-Y
was I None
also I None
expressed I None
in I None
the I None
brain I None
. I None
<eof> I None

<s> O None
In I None
other I None
tissues I None
, I None
hybridization I None
signals I None
were I None
too I None
low I None
to I None
draw I None
reliable I None
conclusions I None
about I None
their I None
precise I None
distribution I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
we I None
observed I None
that I None
the I None
expression I None
of I None
CTHBP I GENE-N
and I None
ST3 I GENE-Y
is I None
largely I None
distinct I None
from I None
that I None
of I None
TRs I None
. I None
<eof> I None

<s> O None
The I None
fact I None
that I None
we I None
observed I None
a I None
clear I None
expression I None
of I None
TRalpha I GENE-Y
and I None
TRbeta I GENE-Y
which I None
are I None
evolutionary I None
conserved I None
, I None
suggests I None
that I None
Necturus I None
tissues I None
express I None
TRs I GENE-N
. I None
<eof> I None

<s> O None
Our I None
results I None
thus I None
indicate I None
that I None
, I None
in I None
contrast I None
to I None
previously I None
held I None
hypotheses I None
, I None
Necturus I None
tissues I None
are I None
TH I CHEMICAL
responsive I None
. I None
<eof> I None

<s> O None
Regulation I None
of I None
retinal I None
dehydrogenases I None
and I None
retinoic I CHEMICAL
acid O CHEMICAL
synthesis I None
by I None
cholesterol I CHEMICAL
metabolites I None
. I None
<eof> I None

<s> O None
Retinoic I CHEMICAL
acid O CHEMICAL
( I None
RA I CHEMICAL
) I None
constitutes I None
the I None
major I None
active I None
ingredient I None
of I None
vitamin I CHEMICAL
A O CHEMICAL
and I None
is I None
required I None
for I None
various I None
biological I None
processes I None
. I None
<eof> I None

<s> O None
The I None
tissue I None
RA I CHEMICAL
level I None
is I None
maintained I None
through I None
a I None
cascade I None
of I None
metabolic I None
reactions I None
where I None
retinal I GENE-N
dehydrogenases O GENE-N
( I None
RALDHs I GENE-N
) I None
catalyze I None
the I None
terminal I None
reaction I None
of I None
RA I CHEMICAL
biosynthesis I None
from I None
retinal I CHEMICAL
, I None
a I None
rate I None
- I None
limiting I None
step I None
. I None
<eof> I None

<s> O None
We I None
showed I None
that I None
dietary I None
supplement I None
of I None
cholesterol I CHEMICAL
enhanced I None
the I None
expression I None
of I None
RALDH1 I GENE-N
and O GENE-N
2 O GENE-N
genes I None
and I None
the I None
cellular I None
RA I CHEMICAL
content I None
in I None
vital I None
organs I None
such I None
as I None
brain I None
, I None
kidney I None
, I None
liver I None
and I None
heart I None
. I None
<eof> I None

<s> O None
Consistently I None
, I None
the I None
cholesterol I CHEMICAL
- I None
lowering I None
agent I None
( I None
pravastatin I CHEMICAL
sodium O CHEMICAL
) I None
downregulated I None
the I None
expression I None
of I None
RALDH1 I GENE-N
and O GENE-N
2 O GENE-N
genes I None
in I None
several I None
organs I None
especially I None
the I None
liver I None
and I None
in I None
cultured I None
liver I None
cells I None
. I None
<eof> I None

<s> O None
Further I None
, I None
cholesterol I CHEMICAL
metabolites I None
, I None
predominantly I None
the I None
oxysterols I CHEMICAL
, I None
the I None
natural I None
ligands I None
for I None
liver I GENE-N
X O GENE-N
receptor O GENE-N
( I None
LXR I GENE-N
) I None
, I None
induced I None
these I None
genes I None
via I None
upregulation I None
of I None
sterol I GENE-Y
regulatory O GENE-Y
element O GENE-Y
binding O GENE-Y
protein O GENE-Y
- O GENE-Y
1c O GENE-Y
( I None
SREBP I GENE-Y
- O GENE-Y
1c O GENE-Y
) I None
that I None
bound I None
to I None
the I None
regulatory I None
regions I None
of I None
these I None
genes I None
. I None
<eof> I None

<s> O None
Knockdown I None
of I None
LXRalpha I GENE-N
/ O GENE-N
beta O GENE-N
or I None
SREBP I GENE-Y
- O GENE-Y
1c O GENE-Y
downregulated I None
the I None
expression I None
of I None
RALDH I GENE-N
genes I None
, I None
which I None
could I None
be I None
rescued I None
by I None
re I None
- I None
expressing I None
SREBP I GENE-Y
- O GENE-Y
1c O GENE-Y
, I None
suggesting I None
SREBP I GENE-Y
- O GENE-Y
1c O GENE-Y
as I None
a I None
direct I None
positive I None
regulator I None
for I None
these I None
genes I None
. I None
<eof> I None

<s> O None
This I None
study I None
uncovered I None
a I None
novel I None
crosstalk I None
between I None
cholesterol I CHEMICAL
and I None
RA I CHEMICAL
biosynthesis I None
. I None
<eof> I None

<s> O None
Reelin I GENE-Y
down I None
- I None
regulation I None
in I None
mice I None
and I None
psychosis I None
endophenotypes I None
. I None
<eof> I None

<s> O None
Reelin I GENE-Y
, I None
a I None
large I None
glycoprotein I None
secreted I None
by I None
telencephalic I None
GABAergic I None
neurons I None
, I None
plays I None
an I None
important I None
role I None
in I None
neuronal I None
guidance I None
embryonically I None
and I None
in I None
synaptic I None
plasticity I None
postnatally I None
. I None
<eof> I None

<s> O None
The I None
reeler I None
heterozygous I None
mouse I None
( I None
+ I None
/ I None
rl I None
) I None
appears I None
superficially I None
normal I None
but I None
has I None
been I None
of I None
interest I None
as I None
an I None
animal I None
model I None
for I None
psychosis I None
since I None
the I None
discovery I None
that I None
reelin I GENE-Y
is I None
50 I None
% I None
down I None
- I None
regulated I None
in I None
postmortem I None
psychotic I None
brain I None
. I None
<eof> I None

<s> O None
Brain I None
abnormalities I None
in I None
+ I None
/ I None
rl I None
are I None
similar I None
to I None
psychotic I None
brain I None
and I None
include I None
a I None
reduction I None
in I None
glutamic I GENE-Y
acid O GENE-Y
de O GENE-Y
carboxylase O GENE-Y
67 O GENE-Y
( I None
GAD67 I GENE-Y
) I None
, I None
dendritic I None
arbors I None
and I None
spine I None
density I None
in I None
cortex I None
and I None
hippocampus I None
, I None
and I None
abnormalities I None
in I None
synaptic I None
function I None
including I None
long I None
- I None
term I None
potentiation I None
( I None
LTP I None
) I None
. I None
<eof> I None

<s> O None
In I None
spite I None
of I None
these I None
abnormalities I None
, I None
behavioral I None
abnormalities I None
in I None
+ I None
/ I None
rl I None
are I None
subtle I None
and I None
controversial I None
. I None
<eof> I None

<s> O None
Recent I None
findings I None
indicate I None
that I None
the I None
reelin I GENE-N
( O GENE-N
RELN O GENE-N
) O GENE-N
and O GENE-N
GAD67 O GENE-N
promoters O GENE-N
are I None
hypermethylated I None
in I None
GABAergic I None
neurons I None
of I None
psychotic I None
postmortem I None
brain I None
and I None
that I None
DNA I GENE-Y
methyltransferase O GENE-Y
1 O GENE-Y
( I None
DNMT1 I GENE-Y
) I None
is I None
up I None
- I None
regulated I None
. I None
<eof> I None

<s> O None
Hypermethlyation I None
of I None
RELN I GENE-N
and O GENE-N
GAD67 O GENE-N
promoters O GENE-N
can I None
be I None
induced I None
by I None
treating I None
mice I None
with I None
methionine I CHEMICAL
, I None
and I None
these I None
mice I None
display I None
brain I None
and I None
behavioral I None
abnormalities I None
similar I None
to I None
+ I None
/ I None
rl I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
an I None
animal I None
model I None
that I None
combines I None
genetic I None
heterozygocity I None
with I None
epigenesis I None
holds I None
promise I None
for I None
understanding I None
the I None
role I None
of I None
Reelin I GENE-Y
down I None
- I None
regulation I None
in I None
psychosis I None
. I None
<eof> I None

<s> O None
Functional I None
and I None
bioenergetic I None
consequences I None
of I None
AT1 I GENE-Y
antagonist I None
olmesartan I CHEMICAL
medoxomil O CHEMICAL
in I None
hearts I None
with I None
postinfarction I None
LV I None
remodeling I None
. I None
<eof> I None

<s> O None
The I None
structural I None
left I None
ventricular I None
( I None
LV I None
) I None
remodeling I None
and I None
contractile I None
dysfunction I None
of I None
hearts I None
with I None
postinfarction I None
LV I None
remodeling I None
are I None
benefited I None
by I None
angiotensin I GENE-Y
II O GENE-Y
type O GENE-Y
1 O GENE-Y
receptor O GENE-Y
( I None
AT1 I GENE-Y
) I None
blocker I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
myocardial I None
bioenergetic I None
consequences I None
of I None
AT1 I GENE-Y
blocker I None
in I None
these I None
hearts I None
are I None
not I None
known I None
. I None
<eof> I None

<s> O None
To I None
investigate I None
, I None
we I None
used I None
a I None
porcine I None
model I None
of I None
postinfarction I None
LV I None
remodeling I None
produced I None
by I None
ligation I None
of I None
the I None
left I None
circumflex I None
coronary I None
artery I None
. I None
<eof> I None

<s> O None
After I None
infarction I None
, I None
7 I None
pigs I None
received I None
olmesartan I CHEMICAL
medoxomil O CHEMICAL
( I None
2 I None
mg I None
/ I None
kg I None
) I None
for I None
comparison I None
against I None
9 I None
untreated I None
and I None
10 I None
normal I None
pigs I None
. I None
<eof> I None

<s> O None
Measurements I None
of I None
hemodynamics I None
, I None
myocardial I None
perfusion I None
, I None
and I None
myocardial I None
bioenergetics I None
were I None
taken I None
7 I None
weeks I None
postinfarction I None
. I None
<eof> I None

<s> O None
The I None
treated I None
group I None
had I None
an I None
LV I None
- I None
to I None
- I None
body I None
weight I None
ratio I None
significantly I None
lower I None
than I None
the I None
untreated I None
group I None
( I None
2 I None
. I None
69 I None
+ I None
/ I None
- I None
0 I None
. I None
70 I None
, I None
2 I None
. I None
96 I None
+ I None
/ I None
- I None
0 I None
. I None
51 I None
, I None
3 I None
. I None
66 I None
+ I None
/ I None
- I None
0 I None
. I None
60 I None
g I None
/ I None
kg I None
for I None
control I None
, I None
treated I None
, I None
and I None
untreated I None
groups I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
The I None
untreated I None
group I None
had I None
a I None
mean I None
aortic I None
pressure I None
significantly I None
higher I None
than I None
the I None
control I None
( I None
73 I None
+ I None
/ I None
- I None
16 I None
, I None
86 I None
+ I None
/ I None
- I None
14 I None
, I None
and I None
94 I None
+ I None
/ I None
- I None
20 I None
mm I None
Hg I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
The I None
subendocardial I None
phosphocreatine I CHEMICAL
- I None
to I None
- I None
ATP I CHEMICAL
ratios I None
of I None
the I None
treated I None
group I None
were I None
significantly I None
higher I None
than I None
that I None
of I None
the I None
untreated I None
group I None
. I None
<eof> I None

<s> O None
The I None
untreated I None
group I None
, I None
but I None
not I None
the I None
treated I None
group I None
, I None
had I None
significant I None
reductions I None
in I None
mitochondrial I None
F0F1 I GENE-N
- O GENE-N
ATPase O GENE-N
subunits I None
compared I None
with I None
controls I None
. I None
<eof> I None

<s> O None
Congestive I None
heart I None
failure I None
as I None
evidenced I None
by I None
significant I None
ascites I None
( I None
100 I None
to I None
2000 I None
mL I None
) I None
developed I None
in I None
4 I None
of I None
the I None
9 I None
untreated I None
animals I None
, I None
but I None
was I None
absent I None
in I None
the I None
treated I None
group I None
. I None
<eof> I None

<s> O None
Animals I None
with I None
heart I None
failure I None
demonstrated I None
reductions I None
in I None
both I None
mitochondrial I None
F0F1 I GENE-N
- O GENE-N
ATPase O GENE-N
expression I None
and I None
myocardial I None
high I None
- I None
energy I None
phosphate I CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
severe I None
LV I None
dysfunction I None
and I None
accompanying I None
abnormal I None
myocardial I None
bioenergetic I None
phenotype I None
were I None
prevented I None
by I None
the I None
AT1 I GENE-Y
antagonist I None
olmesartan I CHEMICAL
medoxomil O CHEMICAL
. I None
<eof> I None

<s> O None
Regulation I None
of I None
retinoic I GENE-N
acid O GENE-N
receptors O GENE-N
alpha O GENE-N
, O GENE-N
beta O GENE-N
and I None
retinoid I GENE-Y
X O GENE-Y
receptor O GENE-Y
alpha O GENE-Y
after I None
sciatic I None
nerve I None
injury I None
. I None
<eof> I None

<s> O None
Cell I None
culture I None
experiments I None
indicated I None
that I None
activation I None
of I None
the I None
retinoic I CHEMICAL
acid O CHEMICAL
signaling I None
system I None
is I None
involved I None
in I None
axonal I None
regeneration I None
. I None
<eof> I None

<s> O None
This I None
hypothesis I None
was I None
tested I None
with I None
sciatic I None
nerve I None
injury I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Since I None
the I None
effect I None
of I None
retinoic I CHEMICAL
acid O CHEMICAL
is I None
mediated I None
via I None
retinoic I GENE-N
acid O GENE-N
receptors O GENE-N
and I None
retinoid I GENE-N
X O GENE-N
receptors O GENE-N
, I None
we I None
investigated I None
mRNA I None
and I None
protein I None
expression I None
of I None
these I None
receptors I None
during I None
injury I None
- I None
induced I None
degeneration I None
and I None
regeneration I None
. I None
<eof> I None

<s> O None
Seven I None
days I None
after I None
crush I None
injury I None
, I None
transcript I None
concentrations I None
of I None
all I None
retinoic I GENE-N
acid O GENE-N
receptors O GENE-N
and I None
of I None
retinoid I GENE-Y
X O GENE-Y
receptor O GENE-Y
alpha O GENE-Y
were I None
significantly I None
higher I None
than I None
in I None
non I None
- I None
lesioned I None
nerves I None
. I None
<eof> I None

<s> O None
Protein I None
levels I None
of I None
retinoic I GENE-Y
acid O GENE-Y
receptor O GENE-Y
alpha O GENE-Y
, I None
retinoic I GENE-Y
acid O GENE-Y
receptor O GENE-Y
beta O GENE-Y
and I None
retinoid I GENE-Y
X O GENE-Y
receptor O GENE-Y
alpha O GENE-Y
were I None
upregulated I None
4 I None
, I None
7 I None
and I None
14 I None
days I None
after I None
injury I None
. I None
<eof> I None

<s> O None
In I None
degenerating I None
nerves I None
a I None
significant I None
increase I None
of I None
retinoic I GENE-Y
acid O GENE-Y
receptor O GENE-Y
alpha O GENE-Y
was I None
detected I None
7 I None
and I None
14 I None
days I None
, I None
and I None
of I None
retinoic I GENE-Y
acid O GENE-Y
receptor O GENE-Y
beta O GENE-Y
14 I None
and I None
21 I None
days I None
after I None
complete I None
transection I None
. I None
<eof> I None

<s> O None
Immunohistochemical I None
staining I None
of I None
retinoid I GENE-N
receptors O GENE-N
revealed I None
their I None
expression I None
in I None
Schwann I None
cells I None
and I None
macrophages I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
we I None
observed I None
that I None
retinoic I GENE-Y
acid O GENE-Y
receptor O GENE-Y
alpha O GENE-Y
and I None
retinoid I GENE-Y
X O GENE-Y
receptor O GENE-Y
alpha O GENE-Y
appeared I None
in I None
the I None
cell I None
nuclei I None
of I None
macrophages I None
during I None
the I None
lesion I None
- I None
induced I None
inflammatory I None
reaction I None
, I None
and I None
that I None
retinoid I GENE-Y
X O GENE-Y
receptor O GENE-Y
alpha O GENE-Y
- I None
staining I None
co I None
- I None
localized I None
with I None
some I None
regenerating I None
axons I None
. I None
<eof> I None

<s> O None
Experiments I None
with I None
Schwann I None
cell I None
primary I None
cultures I None
revealed I None
an I None
effect I None
of I None
retinoic I CHEMICAL
acid O CHEMICAL
on I None
the I None
expression I None
of I None
the I None
neuregulin I GENE-N
receptor O GENE-N
ErbB3 I GENE-Y
, I None
suggesting I None
that I None
one I None
function I None
of I None
retinoic I CHEMICAL
acid O CHEMICAL
consists I None
in I None
the I None
regulation I None
of I None
neuroglial I None
interactions I None
after I None
peripheral I None
nerve I None
injury I None
. I None
<eof> I None

<s> O None
Cellular I None
effects I None
of I None
imatinib I CHEMICAL
on I None
medullary I None
thyroid I None
cancer I None
cells I None
harboring I None
multiple I None
endocrine I None
neoplasia I None
Type I None
2A I None
and I None
2B I None
associated I None
RET I GENE-Y
mutations I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Activating I None
mutations I None
in I None
the I None
RET I GENE-Y
gene I None
, I None
which I None
encodes I None
a I None
tyrosine I GENE-N
kinase O GENE-N
receptor O GENE-N
, I None
often I None
cause I None
medullary I None
thyroid I None
carcinoma I None
( I None
MTC I None
) I None
. I None
<eof> I None

<s> O None
Surgical I None
resection I None
is I None
the I None
only I None
curative I None
treatment I None
; I None
no I None
effective I None
systemic I None
treatment I None
is I None
available I None
. I None
<eof> I None

<s> O None
We I None
evaluated I None
imatinib I CHEMICAL
, I None
a I None
tyrosine I GENE-N
kinase O GENE-N
inhibitor I None
currently I None
used I None
to I None
treat I None
chronic I None
myelogenous I None
leukemia I None
and I None
gastrointestinal I None
stromal I None
tumors I None
, I None
as I None
a I None
potential I None
drug I None
for I None
systemic I None
treatment I None
of I None
MTC I None
, I None
in I None
2 I None
MTC I None
- I None
derived I None
cell I None
lines I None
expressing I None
multiple I None
endocrine I None
neoplasia I None
- I None
associated I None
mutant I None
RET I GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
METHODS I None
: I None
We I None
determined I None
RET I GENE-Y
expression I None
and I None
Y1062 I GENE-N
phosphorylation I None
using I None
Western I None
blot I None
analysis I None
and I None
quantitative I None
polymerase I None
chain I None
reaction I None
. I None
<eof> I None

<s> O None
We I None
determined I None
the I None
effects I None
on I None
cell I None
proliferation I None
by I None
a I None
3 I CHEMICAL
- O CHEMICAL
[ O CHEMICAL
4 O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
dimethylthiazol O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
yl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
diphenyltetrazolium O CHEMICAL
bromide O CHEMICAL
assay I None
, I None
and I None
we I None
used I None
fluorescence I None
- I None
activated I None
cell I None
sorter I None
analysis I None
with I None
annexin I None
V I None
/ I None
propidium I CHEMICAL
iodide O CHEMICAL
staining I None
to I None
study I None
imatinib I CHEMICAL
- I None
induced I None
cell I None
- I None
cycle I None
arrest I None
, I None
apoptosis I None
, I None
and I None
cell I None
death I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Imatinib I CHEMICAL
inhibited I None
RET I GENE-Y
Y1062 I GENE-N
phosphorylation I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
after I None
1 I None
. I None
5 I None
hours I None
of I None
exposure I None
. I None
<eof> I None

<s> O None
After I None
16 I None
hours I None
both I None
RET I GENE-Y
Y1062 I GENE-N
phosphorylation I None
and I None
protein I None
expression I None
levels I None
were I None
affected I None
. I None
<eof> I None

<s> O None
Dose I None
- I None
dependent I None
decreases I None
in I None
cell I None
proliferation I None
of I None
both I None
cell I None
lines I None
after I None
exposure I None
to I None
imatinib I CHEMICAL
with I None
inhibitory I None
concentration I None
of I None
50 I None
% I None
levels I None
of I None
23 I None
+ I None
/ I None
- I None
2 I None
micromol I None
/ I None
L I None
and I None
25 I None
+ I None
/ I None
- I None
4 I None
micromol I None
/ I None
L I None
were I None
seen I None
. I None
<eof> I None

<s> O None
These I None
values I None
are I None
high I None
, I None
compared I None
with I None
those I None
for I None
chronic I None
myelogenous I None
leukemia I None
and I None
gastrointestinal I None
stromal I None
tumors I None
. I None
<eof> I None

<s> O None
We I None
further I None
could I None
show I None
that I None
imatinib I CHEMICAL
induced I None
cell I None
- I None
cycle I None
arrest I None
, I None
and I None
apoptotic I None
and I None
nonapoptotic I None
cell I None
death I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
Imatinib I CHEMICAL
inhibits I None
RET I GENE-Y
- I None
mediated I None
MTC I None
cell I None
growth I None
affecting I None
RET I GENE-Y
protein I None
levels I None
in I None
vitro I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
The I None
concentration I None
of I None
imatinib I CHEMICAL
necessary I None
to I None
inhibit I None
RET I GENE-Y
in I None
vitro I None
, I None
however I None
, I None
makes I None
it I None
impossible I None
to I None
conclude I None
that I None
imatinib I CHEMICAL
monotherapy I None
will I None
be I None
a I None
good I None
option I None
for I None
systemic I None
therapy I None
of I None
MTC I None
. I None
<eof> I None

<s> O None
Cell I None
biology I None
of I None
molybdenum I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
transition I None
element I None
molybdenum I CHEMICAL
( I None
Mo I CHEMICAL
) I None
is I None
of I None
essential I None
importance I None
for I None
( I None
nearly I None
) I None
all I None
biological I None
systems I None
as I None
it I None
is I None
required I None
by I None
enzymes I None
catalyzing I None
diverse I None
key I None
reactions I None
in I None
the I None
global I None
carbon I CHEMICAL
, I None
sulfur I CHEMICAL
and I None
nitrogen I CHEMICAL
metabolism I None
. I None
<eof> I None

<s> O None
The I None
metal I None
itself I None
is I None
biologically I None
inactive I None
unless I None
it I None
is I None
complexed I None
by I None
a I None
special I None
cofactor I None
. I None
<eof> I None

<s> O None
With I None
the I None
exception I None
of I None
bacterial I GENE-N
nitrogenase O GENE-N
, I None
where I None
Mo I CHEMICAL
is I None
a I None
constituent I None
of I None
the I None
FeMo I CHEMICAL
- I None
cofactor I None
, I None
Mo I CHEMICAL
is I None
bound I None
to I None
a I None
pterin I CHEMICAL
, I None
thus I None
forming I None
the I None
molybdenum I CHEMICAL
cofactor I None
( I None
Moco I None
) I None
which I None
is I None
the I None
active I None
compound I None
at I None
the I None
catalytic I None
site I None
of I None
all I None
other I None
Mo I CHEMICAL
- I None
enzymes I None
. I None
<eof> I None

<s> O None
In I None
eukaryotes I None
, I None
the I None
most I None
prominent I None
Mo I CHEMICAL
- I None
enzymes I None
are I None
( I None
1 I None
) I None
sulfite I GENE-Y
oxidase O GENE-Y
, I None
which I None
catalyzes I None
the I None
final I None
step I None
in I None
the I None
degradation I None
of I None
sulfur I CHEMICAL
- I None
containing I None
amino I CHEMICAL
acids O CHEMICAL
and I None
is I None
involved I None
in I None
detoxifying I None
excess I None
sulfite I CHEMICAL
, I None
( I None
2 I None
) I None
xanthine I GENE-Y
dehydrogenase O GENE-Y
, I None
which I None
is I None
involved I None
in I None
purine I CHEMICAL
catabolism I None
and I None
reactive I None
oxygen I CHEMICAL
production I None
, I None
( I None
3 I None
) I None
aldehyde I GENE-Y
oxidase O GENE-Y
, I None
which I None
oxidizes I None
a I None
variety I None
of I None
aldehydes I CHEMICAL
and I None
is I None
essential I None
for I None
the I None
biosynthesis I None
of I None
the I None
phytohormone I None
abscisic I CHEMICAL
acid O CHEMICAL
, I None
and I None
in I None
autotrophic I None
organisms I None
also I None
( I None
4 I None
) I None
nitrate I GENE-N
reductase O GENE-N
, I None
which I None
catalyzes I None
the I None
key I None
step I None
in I None
inorganic I None
nitrogen I CHEMICAL
assimilation I None
. I None
<eof> I None

<s> O None
All I None
Mo I CHEMICAL
- I None
enzymes I None
, I None
except I None
plant I GENE-N
sulfite O GENE-N
oxidase O GENE-N
, I None
need I None
at I None
least I None
one I None
more I None
redox I None
active I None
center I None
, I None
many I None
of I None
them I None
involving I None
iron I CHEMICAL
in I None
electron I None
transfer I None
. I None
<eof> I None

<s> O None
The I None
biosynthesis I None
of I None
Moco I None
involves I None
the I None
complex I None
interaction I None
of I None
six I None
proteins I None
and I None
is I None
a I None
process I None
of I None
four I None
steps I None
, I None
which I None
also I None
includes I None
iron I None
as I None
well I None
as I None
copper I CHEMICAL
in I None
an I None
indispensable I None
way I None
. I None
<eof> I None

<s> O None
Moco I None
as I None
released I None
after I None
synthesis I None
is I None
likely I None
to I None
be I None
distributed I None
to I None
the I None
apoproteins I None
of I None
Mo I CHEMICAL
- I None
enzymes I None
by I None
putative I None
Moco I None
- I None
carrier I None
proteins I None
. I None
<eof> I None

<s> O None
Xanthine I GENE-Y
dehydrogenase O GENE-Y
and I None
aldehyde I GENE-Y
oxidase O GENE-Y
, I None
but I None
not I None
sulfite I GENE-Y
oxidase O GENE-Y
and I None
nitrate I GENE-N
reductase O GENE-N
, I None
require I None
the I None
post I None
- I None
translational I None
sulfuration I None
of I None
their I None
Mo I CHEMICAL
- I None
site I None
for I None
becoming I None
active I None
. I None
<eof> I None

<s> O None
This I None
final I None
maturation I None
step I None
is I None
catalyzed I None
by I None
a I None
Moco I GENE-Y
- O GENE-Y
sulfurase O GENE-Y
enzyme I None
, I None
which I None
mobilizes I None
sulfur I CHEMICAL
from I None
l I CHEMICAL
- O CHEMICAL
cysteine O CHEMICAL
in I None
a I None
pyridoxal I CHEMICAL
phosphate O CHEMICAL
- I None
dependent I None
manner I None
as I None
typical I None
for I None
cysteine I GENE-N
desulfurases O GENE-N
. I None
<eof> I None

<s> O None
[ I None
Retinoid I CHEMICAL
therapy I None
for I None
autoimmune I None
diseases I None
] I None
. I None
<eof> I None

<s> O None
Retinoid I CHEMICAL
is I None
a I None
collective I None
term I None
for I None
compounds I None
which I None
bind I None
to I None
and I None
activate I None
retinoic I GENE-N
acid O GENE-N
receptors O GENE-N
( I None
RARalpha I GENE-N
, O GENE-N
beta O GENE-N
, O GENE-N
gamma O GENE-N
and I None
RXRalpha I GENE-N
, O GENE-N
beta O GENE-N
, O GENE-N
gamma O GENE-N
) I None
, I None
members I None
of I None
nuclear I GENE-N
hormone O GENE-N
receptor O GENE-N
superfamily I None
. I None
<eof> I None

<s> O None
The I None
most I None
important I None
endogeneous I None
retinoid I CHEMICAL
is I None
all I CHEMICAL
- O CHEMICAL
trans O CHEMICAL
- O CHEMICAL
retinoic O CHEMICAL
acid O CHEMICAL
( I None
ATRA I CHEMICAL
) I None
which I None
is I None
an I None
RARalpha I GENE-N
, O GENE-N
beta O GENE-N
and O GENE-N
gamma O GENE-N
ligand I None
. I None
<eof> I None

<s> O None
ATRA I CHEMICAL
and I None
its I None
mimics I None
have I None
been I None
in I None
clinical I None
use I None
for I None
treatment I None
of I None
acute I None
promyelocytic I None
leukemia I None
( I None
APL I None
) I None
and I None
some I None
skin I None
diseases I None
. I None
<eof> I None

<s> O None
Many I None
synthetic I None
retinoids I None
have I None
been I None
developed I None
and I None
attempts I None
to I None
improve I None
their I None
medicinal I None
properties I None
have I None
been I None
made I None
. I None
<eof> I None

<s> O None
Among I None
them I None
, I None
tamibarotene I CHEMICAL
( I None
Am80 I CHEMICAL
) I None
is I None
an I None
RARalpha I GENE-Y
- I None
and I None
RARbeta I GENE-Y
- I None
specific I None
( I None
but I None
RARgamma I GENE-Y
- I None
and I None
RXRs I GENE-N
- I None
nonbinding I None
) I None
synthetic I None
retinoid I CHEMICAL
that I None
is I None
effective I None
in I None
the I None
treatment I None
of I None
psoriasis I None
patients I None
and I None
relapsed I None
APL I None
. I None
<eof> I None

<s> O None
Experimentally I None
, I None
this I None
compound I None
is I None
also I None
active I None
in I None
animal I None
models I None
of I None
rheumatoid I None
arthritis I None
and I None
experimental I None
autoimmune I None
encephalomyelitis I None
. I None
<eof> I None

<s> O None
On I None
this I None
background I None
, I None
possible I None
application I None
of I None
retinoids I CHEMICAL
for I None
the I None
treatment I None
of I None
autoimmune I None
diseases I None
was I None
discussed I None
. I None
<eof> I None

<s> O None
In I None
particular I None
, I None
Th1 I None
dominant I None
autoimmune I None
diseases I None
may I None
be I None
the I None
targets I None
of I None
the I None
retinoids I CHEMICAL
. I None
<eof> I None

<s> O None
Simvastatin I CHEMICAL
regulates I None
non I None
- I None
neuronal I None
cholinergic I None
activity I None
in I None
T I None
lymphocytes I None
via I None
CD11a I GENE-Y
- I None
mediated I None
pathways I None
. I None
<eof> I None

<s> O None
Lymphocyte I GENE-Y
function O GENE-Y
associated O GENE-Y
antigen O GENE-Y
- O GENE-Y
1 O GENE-Y
( I None
LFA I GENE-Y
- O GENE-Y
1 O GENE-Y
; I None
CD11a I GENE-Y
/ I None
CD18 I GENE-Y
) I None
is I None
an I None
important I None
mediator I None
of I None
leukocyte I None
migration I None
and I None
T I None
cell I None
activation I None
. I None
<eof> I None

<s> O None
We I None
previously I None
showed I None
that I None
antithymocyte I GENE-N
globulin O GENE-N
stimulates I None
an I None
independent I None
, I None
non I None
- I None
neuronal I None
cholinergic I None
system I None
in I None
T I None
cells I None
via I None
LFA I GENE-Y
- O GENE-Y
1 O GENE-Y
- I None
mediated I None
pathways I None
, I None
as I None
evidenced I None
by I None
increases I None
in I None
acetylcholine I CHEMICAL
( I None
ACh I CHEMICAL
) I None
synthesis I None
and I None
choline I GENE-Y
acetyltransferase O GENE-Y
( I None
ChAT I GENE-Y
) I None
mRNA I None
expression I None
. I None
<eof> I None

<s> O None
The I None
cholesterol I CHEMICAL
- I None
lowering I None
drug I None
simvastatin I CHEMICAL
inhibits I None
LFA I GENE-Y
- O GENE-Y
1 O GENE-Y
signaling I None
by I None
binding I None
to I None
an I None
allosteric I None
site I None
on I None
CD11a I GENE-Y
( I None
LFA I GENE-Y
- O GENE-Y
1 O GENE-Y
alpha O GENE-Y
chain O GENE-Y
) I None
, I None
which I None
leads I None
to I None
immunomodulation I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
we I None
investigated I None
whether I None
simvastatin I CHEMICAL
modulates I None
lymphocytic I None
cholinergic I None
activity I None
in I None
T I None
cells I None
. I None
<eof> I None

<s> O None
We I None
found I None
that I None
anti I None
- I None
CD11a I GENE-N
monoclonal I None
antibody I None
( I None
mAb I None
) I None
increased I None
ChAT I GENE-N
activity I None
, I None
ACh I CHEMICAL
synthesis I None
and I None
release I None
, I None
and I None
expression I None
of I None
ChAT I GENE-Y
and I None
M5 I GENE-Y
muscarinic O GENE-Y
ACh O GENE-Y
receptor O GENE-Y
mRNA I None
in I None
MOLT I None
- I None
3 I None
cells I None
, I None
a I None
human I None
leukemic I None
T I None
cell I None
line I None
. I None
<eof> I None

<s> O None
Simvastatin I CHEMICAL
abolished I None
these I None
anti I None
- I None
CD11a I GENE-Y
mAb I None
- I None
induced I None
increases I None
in I None
lymphocytic I None
cholinergic I None
activity I None
in I None
a I None
manner I None
independent I None
of I None
its I None
cholesterol I CHEMICAL
- I None
lowering I None
activity I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
LFA I GENE-Y
- O GENE-Y
1 O GENE-Y
contributes I None
to I None
the I None
regulation I None
of I None
lymphocytic I None
cholinergic I None
activity I None
via I None
CD11a I GENE-Y
- I None
mediated I None
pathways I None
, I None
and I None
suggest I None
that I None
simvastatin I CHEMICAL
exerts I None
its I None
immunosuppressive I None
effects I None
in I None
part I None
via I None
modification I None
of I None
lymphocytic I None
cholinergic I None
activity I None
. I None
<eof> I None

<s> O None
More I None
than I None
cool I None
: I None
promiscuous I None
relationships I None
of I None
menthol I CHEMICAL
and I None
other I None
sensory I None
compounds I None
. I None
<eof> I None

<s> O None
Several I None
temperature I GENE-N
- O GENE-N
activated O GENE-N
transient O GENE-N
receptor O GENE-N
potential O GENE-N
( O GENE-N
thermoTRP O GENE-N
) O GENE-N
ion O GENE-N
channels O GENE-N
are I None
the I None
molecular I None
receptors I None
of I None
natural I None
compounds I None
that I None
evoke I None
thermal I None
and I None
pain I None
sensations I None
. I None
<eof> I None

<s> O None
Menthol I CHEMICAL
, I None
popularly I None
known I None
for I None
its I None
cooling I None
effect I None
, I None
activates I None
TRPM8 I GENE-Y
- I None
- I None
a I None
cold I None
- I None
activated I None
thermoTRP I GENE-N
ion O GENE-N
channel O GENE-N
. I None
<eof> I None

<s> O None
However I None
, I None
human I None
physiological I None
studies I None
demonstrate I None
a I None
paradoxical I None
role I None
of I None
menthol I CHEMICAL
in I None
modulation I None
of I None
warm I None
sensation I None
, I None
and I None
here I None
, I None
we I None
show I None
that I None
menthol I CHEMICAL
also I None
activates I None
heat I None
- I None
activated I None
TRPV3 I GENE-Y
. I None
<eof> I None

<s> O None
We I None
further I None
show I None
that I None
menthol I CHEMICAL
inhibits I None
TRPA1 I GENE-Y
, I None
potentially I None
explaining I None
the I None
use I None
of I None
menthol I CHEMICAL
as I None
an I None
analgesic I None
. I None
<eof> I None

<s> O None
Similar I None
to I None
menthol I CHEMICAL
, I None
both I None
camphor I CHEMICAL
and I None
cinnamaldehyde I CHEMICAL
( I None
initially I None
reported I None
to I None
be I None
specific I None
activators I None
of I None
TRPV3 I GENE-Y
and I None
TRPA1 I GENE-Y
, I None
respectively I None
) I None
also I None
modulate I None
other I None
thermoTRPs I GENE-N
. I None
<eof> I None

<s> O None
Therefore I None
, I None
we I None
find I None
that I None
many I None
" I None
sensory I None
compounds I None
" I None
presumed I None
to I None
be I None
specific I None
have I None
a I None
promiscuous I None
relationship I None
with I None
thermoTRPs I GENE-N
. I None
<eof> I None

<s> O None
Effect I None
of I None
keratinocyte I GENE-Y
growth O GENE-Y
factor O GENE-Y
on I None
cell I None
viability I None
in I None
primary I None
cultured I None
human I None
prostate I None
cancer I None
stromal I None
cells I None
. I None
<eof> I None

<s> O None
In I None
normal I None
prostate I None
, I None
keratinocyte I GENE-Y
growth O GENE-Y
factor O GENE-Y
( I None
KGF I GENE-Y
) I None
, I None
also I None
known I None
as I None
fibroblast I GENE-Y
growth O GENE-Y
factor O GENE-Y
- O GENE-Y
7 O GENE-Y
( I None
FGF I GENE-Y
- O GENE-Y
7 O GENE-Y
) I None
serves I None
as I None
a I None
paracrine I None
growth I None
factor I None
synthesized I None
in I None
stromal I None
cells I None
that I None
acts I None
on I None
epithelial I None
cells I None
through I None
its I None
receptor I None
, I None
KGFR I GENE-Y
. I None
<eof> I None

<s> O None
KGF I GENE-Y
and I None
KGFR I GENE-Y
were I None
found I None
in I None
human I None
cancer I None
epithelial I None
cells I None
as I None
well I None
as I None
stromal I None
cells I None
. I None
<eof> I None

<s> O None
Since I None
KGF I GENE-Y
expressed I None
in I None
epithelial I None
cells I None
of I None
benign I None
prostatic I None
hyperplasia I None
( I None
BPH I None
) I None
and I None
in I None
prostate I None
cancer I None
, I None
it I None
has I None
been I None
suggested I None
that I None
KGF I GENE-Y
might I None
act I None
as I None
an I None
autocrine I None
factor I None
in I None
BPH I None
and I None
prostate I None
cancer I None
. I None
<eof> I None

<s> O None
To I None
investigate I None
the I None
roles I None
of I None
KGF I GENE-Y
in I None
cancerous I None
stroma I None
, I None
primary I None
cultured I None
human I None
prostate I None
cancer I None
stromal I None
cells I None
( I None
PCSCs I None
) I None
were I None
isolated I None
and I None
evaluated I None
. I None
<eof> I None

<s> O None
These I None
PCSCs I None
possessed I None
estrogen I GENE-Y
receptors O GENE-Y
and I None
KGFR I GENE-Y
, I None
but I None
not I None
androgen I GENE-Y
receptor O GENE-Y
as I None
determined I None
by I None
RT I None
- I None
PCR I None
and I None
Western I None
blot I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
KGF I GENE-Y
exhibited I None
mitogenic I None
and I None
anti I None
- I None
apoptotic I None
effects I None
that I None
correlated I None
with I None
induction I None
of I None
cyclin I GENE-Y
- O GENE-Y
D1 O GENE-Y
, I None
Bcl I GENE-Y
- O GENE-Y
2 O GENE-Y
, I None
Bcl I GENE-Y
- O GENE-Y
xL O GENE-Y
and I None
phospho I GENE-N
- O GENE-N
Akt O GENE-N
expression I None
in I None
PCSCs I None
, I None
where I None
treatment I None
with I None
KGF I GENE-Y
antiserum I None
abolished I None
cell I None
proliferation I None
and I None
anti I None
- I None
apoptotic I None
protein I None
expression I None
. I None
<eof> I None

<s> O None
PCSCs I None
exposed I None
to I None
KGF I GENE-Y
for I None
various I None
time I None
periods I None
resulted I None
in I None
phosphorylation I None
of I None
Akt I GENE-N
and I None
subsequent I None
up I None
- I None
regulation I None
of I None
Bcl I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
KGF I GENE-Y
modulated I None
dynamic I None
protein I None
expression I None
indicated I None
that I None
KGF I GENE-Y
triggered I None
cell I None
cycle I None
machinery I None
and I None
then I None
activated I None
anti I None
- I None
apoptotic I None
actions I None
in I None
PCSCs I None
. I None
<eof> I None

<s> O None
Cell I None
proliferation I None
analysis I None
indicated I None
that I None
tamoxifen I CHEMICAL
or I None
ICI I CHEMICAL
182 O CHEMICAL
, O CHEMICAL
780 O CHEMICAL
reduced I None
cell I None
viability I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
; I None
however I None
, I None
KGF I GENE-Y
prevented I None
this I None
inhibition I None
, I None
which I None
further I None
demonstrated I None
KGF I GENE-Y
triggered I None
anti I None
- I None
apoptotic I None
machinery I None
through I None
activating I None
Bcl I GENE-Y
- O GENE-Y
2 O GENE-Y
and I None
phospho I GENE-N
- O GENE-N
Akt O GENE-N
expression I None
. I None
<eof> I None

<s> O None
In I None
summary I None
, I None
KGF I GENE-Y
has I None
an I None
autocrine I None
effect I None
and I None
serves I None
as I None
a I None
survival I None
factor I None
in I None
primary I None
cultured I None
human I None
prostate I None
cancer I None
stromal I None
cells I None
. I None
<eof> I None

<s> O None
The I None
glutamate I GENE-N
- O GENE-N
aspartate O GENE-N
transporter O GENE-N
GLAST I GENE-N
mediates I None
glutamate I CHEMICAL
uptake I None
at I None
inner I None
hair I None
cell I None
afferent I None
synapses I None
in I None
the I None
mammalian I None
cochlea I None
. I None
<eof> I None

<s> O None
Ribbon I None
synapses I None
formed I None
between I None
inner I None
hair I None
cells I None
( I None
IHCs I None
) I None
and I None
afferent I None
dendrites I None
in I None
the I None
mammalian I None
cochlea I None
can I None
sustain I None
high I None
rates I None
of I None
release I None
, I None
placing I None
strong I None
demands I None
on I None
glutamate I CHEMICAL
clearance I None
mechanisms I None
. I None
<eof> I None

<s> O None
To I None
investigate I None
the I None
role I None
of I None
transporters I None
in I None
glutamate I CHEMICAL
removal I None
at I None
these I None
synapses I None
, I None
we I None
made I None
whole I None
- I None
cell I None
recordings I None
from I None
IHCs I None
, I None
afferent I None
dendrites I None
, I None
and I None
glial I None
cells I None
adjacent I None
to I None
IHCs I None
[ I None
inner I None
phalangeal I None
cells I None
( I None
IPCs I None
) I None
] I None
in I None
whole I None
- I None
mount I None
preparations I None
of I None
rat I None
organ I None
of I None
Corti I None
. I None
<eof> I None

<s> O None
Focal I None
application I None
of I None
the I None
transporter I None
substrate I None
D I CHEMICAL
- O CHEMICAL
aspartate O CHEMICAL
elicited I None
inward I None
currents I None
in I None
IPCs I None
, I None
which I None
were I None
larger I None
in I None
the I None
presence I None
of I None
anions I None
that I None
permeate I None
the I None
transporter I None
- I None
associated I None
anion I GENE-N
channel O GENE-N
and I None
blocked I None
by I None
the I None
transporter I None
antagonist I None
D I CHEMICAL
, O CHEMICAL
L O CHEMICAL
- O CHEMICAL
threo O CHEMICAL
- O CHEMICAL
beta O CHEMICAL
- O CHEMICAL
benzyloxyaspartate O CHEMICAL
. I None
<eof> I None

<s> O None
These I None
currents I None
were I None
produced I None
by I None
glutamate I GENE-Y
- O GENE-Y
aspartate O GENE-Y
transporters O GENE-Y
( I None
GLAST I GENE-Y
) I None
( I None
excitatory I GENE-Y
amino O GENE-Y
acid O GENE-Y
transporter O GENE-Y
1 O GENE-Y
) I None
because I None
they I None
were I None
weakly I None
inhibited I None
by I None
dihydrokainate I CHEMICAL
, I None
an I None
antagonist I None
of I None
glutamate I GENE-Y
transporter O GENE-Y
- O GENE-Y
1 O GENE-Y
( I None
excitatory I GENE-Y
amino O GENE-Y
acid O GENE-Y
transporter O GENE-Y
2 O GENE-Y
) I None
and I None
were I None
absent I None
from I None
IPCs I None
in I None
GLAST I GENE-Y
- I None
/ I None
- I None
cochleas I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
D I CHEMICAL
- O CHEMICAL
aspartate O CHEMICAL
- I None
induced I None
currents I None
in I None
outside I None
- I None
out I None
patches I None
from I None
IPCs I None
exhibited I None
larger I None
steady I None
- I None
state I None
currents I None
than I None
responses I None
elicited I None
by I None
L I CHEMICAL
- O CHEMICAL
glutamate O CHEMICAL
, I None
a I None
prominent I None
feature I None
of I None
GLAST I GENE-Y
, I None
and I None
examination I None
of I None
cochlea I None
from I None
GLAST I GENE-Y
- I None
Discosoma I None
red I None
( I None
DsRed I None
) I None
promoter I None
reporter I None
mice I None
revealed I None
that I None
DsRed I None
expression I None
was I None
restricted I None
to I None
IPCs I None
and I None
other I None
supporting I None
cells I None
surrounding I None
IHCs I None
. I None
<eof> I None

<s> O None
Saturation I None
of I None
transporters I None
by I None
photolysis I None
of I None
caged I None
D I CHEMICAL
- O CHEMICAL
aspartate O CHEMICAL
failed I None
to I None
elicit I None
transporter I None
currents I None
in I None
IHCs I None
, I None
as I None
did I None
local I None
application I None
of I None
D I CHEMICAL
- O CHEMICAL
aspartate O CHEMICAL
to I None
afferent I None
terminals I None
, I None
indicating I None
that I None
neither I None
presynaptic I None
nor I None
postsynaptic I None
membranes I None
are I None
major I None
sites I None
for I None
glutamate I CHEMICAL
removal I None
. I None
<eof> I None

<s> O None
These I None
data I None
indicate I None
that I None
GLAST I GENE-Y
in I None
supporting I None
cells I None
is I None
responsible I None
for I None
transmitter I None
uptake I None
at I None
IHC I None
afferent I None
synapses I None
. I None
<eof> I None

<s> O None
The I None
alpha I GENE-N
- O GENE-N
and O GENE-N
beta O GENE-N
- O GENE-N
adrenoceptor O GENE-N
blocking I None
activities I None
of I None
labetalol I CHEMICAL
and I None
its I None
RR I None
- I None
SR I None
( I None
50 I None
: I None
50 I None
) I None
stereoisomers I None
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
We I None
compared I None
the I None
alpha I GENE-N
1 O GENE-N
- O GENE-N
, O GENE-N
alpha O GENE-N
2 O GENE-N
- O GENE-N
and O GENE-N
beta O GENE-N
1 O GENE-N
- O GENE-N
adrenoceptor O GENE-N
blocking I None
potencies I None
of I None
labetalol I CHEMICAL
with I None
those I None
of I None
its I None
two I None
stereoisomers I None
( I None
RR I None
and I None
SR I None
) I None
in I None
pithed I None
rats I None
and I None
in I None
homogenized I None
rat I None
cerebral I None
cortex I None
and I None
heart I None
. I None
<eof> I None

<s> O None
2 I None
. I None
<eof> I None

<s> O None
In I None
pithed I None
rats I None
, I None
labetalol I CHEMICAL
and I None
the I None
RR I None
- I None
SR I None
combination I None
were I None
given I None
orally I None
either I None
at I None
doses I None
of I None
25 I None
and I None
50 I None
mg I None
kg I None
- I None
1 I None
body I None
wt I None
. I None
or I None
intravenously I None
at I None
doses I None
of I None
1 I None
and I None
5 I None
mg I None
kg I None
- I None
1 I None
body I None
wt I None
. I None
<eof> I None

<s> O None
Prazosin I CHEMICAL
4 I None
and I None
20 I None
micrograms I None
kg I None
- I None
1 I None
body I None
wt I None
. I None
and I None
propranolol I CHEMICAL
1 I None
and I None
5 I None
mg I None
kg I None
- I None
1 I None
body I None
wt I None
. I None
, I None
were I None
given I None
intravenously I None
for I None
comparison I None
studies I None
of I None
potency I None
at I None
alpha I GENE-N
1 O GENE-N
- O GENE-N
and O GENE-N
beta O GENE-N
1 O GENE-N
- O GENE-N
adrenoceptors O GENE-N
, I None
respectively I None
. I None
<eof> I None

<s> O None
Effects I None
were I None
studied I None
before I None
and I None
after I None
i I None
. I None
v I None
. I None
administration I None
of I None
either I None
phenylephrine I CHEMICAL
( I None
at I None
doses I None
which I None
increased I None
the I None
mean I None
arterial I None
pressure I None
by I None
approximately I None
80 I None
mmHg I None
) I None
or I None
isoprenaline I CHEMICAL
( I None
at I None
doses I None
that I None
increased I None
heart I None
rate I None
by I None
approximately I None
100 I None
beats I None
min I None
- I None
1 I None
) I None
. I None
<eof> I None

<s> O None
3 I None
. I None
<eof> I None

<s> O None
In I None
pithed I None
rats I None
, I None
labetalol I CHEMICAL
and I None
the I None
RR I None
- I None
SR I None
combination I None
antagonized I None
, I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
, I None
the I None
pressor I None
effect I None
of I None
phenylephrine I CHEMICAL
( I None
P I None
less I None
than I None
0 I None
. I None
05 I None
) I None
and I None
the I None
chronotropic I None
effect I None
of I None
isoprenaline I CHEMICAL
( I None
P I None
less I None
than I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
Following I None
both I None
oral I None
and I None
intravenous I None
dosing I None
, I None
the I None
RR I None
- I None
SR I None
combination I None
was I None
twice I None
potent I None
as I None
labetalol I CHEMICAL
in I None
terms I None
of I None
alpha I GENE-N
1 O GENE-N
- O GENE-N
and O GENE-N
beta O GENE-N
1 O GENE-N
- O GENE-N
adrenoceptor O GENE-N
antagonism I None
at I None
equivalent I None
doses I None
. I None
<eof> I None

<s> O None
4 I None
. I None
<eof> I None

<s> O None
Labetalol I CHEMICAL
and I None
the I None
enantiomers I None
lacked I None
affinity I None
at I None
alpha I GENE-N
2 O GENE-N
- O GENE-N
adrenoceptors O GENE-N
while I None
at I None
alpha I GENE-N
1 O GENE-N
- O GENE-N
adrenoceptors O GENE-N
the I None
order I None
of I None
potency I None
was I None
prazosin I CHEMICAL
much I None
greater I None
than I None
RR I None
- I None
SR I None
greater I None
than I None
labetalol I CHEMICAL
. I None
<eof> I None

<s> O None
At I None
beta I GENE-Y
1 O GENE-Y
- O GENE-Y
adrenoceptors O GENE-Y
, I None
the I None
affinity I None
of I None
the I None
compound I None
RR I None
- I None
SR I None
was I None
about I None
3 I None
times I None
that I None
of I None
labetalol I CHEMICAL
. I None
5 I None
. I None
<eof> I None

<s> O None
As I None
labetalol I CHEMICAL
is I None
a I None
mixture I None
of I None
active I None
( I None
RR I None
and I None
SR I None
) I None
and I None
inactive I None
( I None
SS I None
and I None
SR I None
) I None
enantiomers I None
( I None
in I None
terms I None
of I None
alpha I GENE-N
and O GENE-N
beta O GENE-N
receptor O GENE-N
actions I None
) I None
, I None
the I None
combination I None
of I None
RR I None
and I None
SR I None
may I None
be I None
a I None
valuable I None
substitute I None
for I None
labetalol I CHEMICAL
in I None
the I None
treatment I None
of I None
systemic I None
hypertension I None
. I None
<eof> I None

<s> O None
Although I None
the I None
potential I None
for I None
non I None
- I None
specific I None
side I None
effects I None
( I None
common I None
to I None
all I None
four I None
enantiomers I None
) I None
could I None
be I None
expected I None
to I None
be I None
diminished I None
, I None
recent I None
reports I None
by I None
postmarketing I None
surveillance I None
indicate I None
that I None
the I None
RR I None
isomer I None
( I None
dilevalol I CHEMICAL
) I None
can I None
induce I None
liver I None
toxicity I None
. I None
<eof> I None

<s> O None
Interestingly I None
, I None
labetalol I CHEMICAL
is I None
devoid I None
of I None
this I None
effect I None
; I None
whether I None
the I None
combination I None
of I None
RR I None
and I None
SR I None
enantiomers I None
could I None
be I None
of I None
clinical I None
importance I None
warrants I None
further I None
investigation I None
. I None
<eof> I None

<s> O None
Overexpression I None
of I None
proline I GENE-Y
oxidase O GENE-Y
induces I None
proline I CHEMICAL
- I None
dependent I None
and I None
mitochondria I None
- I None
mediated I None
apoptosis I None
. I None
<eof> I None

<s> O None
Proline I GENE-Y
oxidase O GENE-Y
( I None
POX I GENE-Y
) I None
, I None
a I None
mitochondrial I None
inner I None
- I None
membrane I None
protein I None
, I None
catalyzes I None
the I None
rate I None
- I None
limiting I None
oxidation I None
of I None
proline I CHEMICAL
to I None
pyrroline I CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
carboxylate O CHEMICAL
( I None
P5C I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
Previously I None
we I None
showed I None
that I None
overexpression I None
of I None
POX I GENE-Y
is I None
associated I None
with I None
generation I None
of I None
reactive I None
oxygen I CHEMICAL
species I None
( I None
ROS I None
) I None
and I None
apoptosis I None
in I None
POX I GENE-Y
- I None
inducible I None
colorectal I None
cancer I None
cells I None
, I None
DLD I None
- I None
1 I None
. I None
POX I GENE-Y
. I None
<eof> I None

<s> O None
We I None
also I None
showed I None
expression I None
of I None
mitochondrial I None
MnSOD I GENE-Y
partially I None
blunts I None
POX I GENE-Y
- I None
induced I None
ROS I None
generation I None
and I None
apoptosis I None
. I None
<eof> I None

<s> O None
To I None
further I None
investigate I None
the I None
molecular I None
basis I None
of I None
POX I GENE-Y
- I None
induced I None
apoptosis I None
, I None
we I None
utilized I None
the I None
DLD I None
- I None
1 I None
. I None
POX I GENE-Y
cells I None
to I None
show I None
that I None
cells I None
overproducing I None
POX I GENE-Y
exhibit I None
an I None
L I CHEMICAL
- O CHEMICAL
proline O CHEMICAL
- I None
dependent I None
apoptotic I None
response I None
. I None
<eof> I None

<s> O None
The I None
apoptotic I None
effect I None
is I None
specific I None
for I None
L I CHEMICAL
- O CHEMICAL
proline O CHEMICAL
, I None
detectable I None
at I None
0 I None
. I None
2 I None
mM I None
, I None
maximal I None
at I None
1 I None
mM I None
, I None
and I None
occurs I None
during I None
48 I None
- I None
72 I None
h I None
following I None
the I None
addition I None
of I None
L I CHEMICAL
- O CHEMICAL
proline O CHEMICAL
to I None
cells I None
with I None
maximally I None
induced I None
POX I GENE-Y
. I None
<eof> I None

<s> O None
The I None
apoptotic I None
response I None
is I None
mitochondria I None
- I None
mediated I None
with I None
release I None
of I None
cytochrome I GENE-Y
c O GENE-Y
, I None
activation I None
of I None
caspase I GENE-Y
- O GENE-Y
9 O GENE-Y
, I None
chromatin I None
condensation I None
/ I None
DNA I None
fragmentation I None
, I None
and I None
cell I None
shrinkage I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
in I None
the I None
presence I None
of I None
proline I CHEMICAL
, I None
high I None
POX I GENE-Y
activity I None
is I None
sufficient I None
to I None
induce I None
mitochondria I None
- I None
mediated I None
apoptosis I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
norepinephrine I GENE-Y
transporter O GENE-Y
inactivation I None
on I None
locomotor I None
activity I None
in I None
mice I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Acute I None
administration I None
of I None
different I None
classes I None
of I None
antidepressants I None
can I None
enhance I None
or I None
reduce I None
spontaneous I None
locomotor I None
activity I None
in I None
a I None
novel I None
environment I None
, I None
but I None
the I None
effects I None
of I None
chronic I None
antidepressant I None
treatment I None
on I None
spontaneous I None
locomotor I None
activity I None
in I None
novel I None
and I None
familiar I None
environments I None
are I None
less I None
well I None
characterized I None
. I None
<eof> I None

<s> O None
Because I None
norepinephrine I CHEMICAL
is I None
an I None
important I None
regulator I None
of I None
spontaneous I None
locomotor I None
activity I None
, I None
we I None
speculated I None
that I None
norepinephrine I GENE-Y
transporter O GENE-Y
blockade I None
contributes I None
to I None
the I None
effects I None
of I None
some I None
antidepressants I None
on I None
spontaneous I None
locomotor I None
activity I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Antidepressant I None
drugs I None
( I None
reboxetine I CHEMICAL
, I None
desipramine I CHEMICAL
, I None
imipramine I CHEMICAL
, I None
venlafaxine I CHEMICAL
, I None
bupropion I CHEMICAL
) I None
were I None
administered I None
acutely I None
( I None
intraperitoneal I None
) I None
or I None
chronically I None
( I None
via I None
osmotic I None
minipump I None
) I None
to I None
control I None
and I None
norepinephrine I GENE-Y
transporter O GENE-Y
knockout I None
mice I None
, I None
and I None
spontaneous I None
locomotor I None
activity I None
in I None
novel I None
or I None
familiar I None
environments I None
was I None
recorded I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Acute I None
treatment I None
with I None
most I None
norepinephrine I GENE-Y
transporter O GENE-Y
- I None
blocking I None
antidepressants I None
decreased I None
spontaneous I None
locomotor I None
activity I None
in I None
a I None
novel I None
environment I None
, I None
whereas I None
chronic I None
treatment I None
decreased I None
spontaneous I None
locomotor I None
activity I None
in I None
both I None
novel I None
and I None
familiar I None
environments I None
. I None
<eof> I None

<s> O None
The I None
exception I None
was I None
bupropion I CHEMICAL
, I None
a I None
dual I None
norepinephrine I GENE-Y
transporter O GENE-Y
/ I None
dopamine I GENE-Y
transporter O GENE-Y
blocker I None
, I None
which I None
tended I None
to I None
increase I None
spontaneous I None
locomotor I None
activity I None
. I None
<eof> I None

<s> O None
Coadministration I None
of I None
reboxetine I CHEMICAL
and I None
the I None
dopamine I GENE-Y
transporter O GENE-Y
blocker I None
GBR I CHEMICAL
12909 O CHEMICAL
also I None
increased I None
spontaneous I None
locomotor I None
activity I None
. I None
<eof> I None

<s> O None
Norepinephrine I GENE-Y
transporter O GENE-Y
knockout I None
mice I None
had I None
low I None
basal I None
spontaneous I None
locomotor I None
activity I None
, I None
which I None
was I None
increased I None
by I None
bupropion I CHEMICAL
, I None
whereas I None
reboxetine I CHEMICAL
had I None
no I None
effect I None
in I None
norepinephrine I GENE-Y
transporter O GENE-Y
knockout I None
mice I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
Acute I None
or I None
chronic I None
inactivation I None
of I None
the I None
norepinephrine I GENE-Y
transporter O GENE-Y
decreases I None
spontaneous I None
locomotor I None
activity I None
in I None
novel I None
and I None
familiar I None
environments I None
unless I None
coupled I None
with I None
dopamine I GENE-Y
transporter O GENE-Y
blockade I None
. I None
<eof> I None

<s> O None
Treatment I None
of I None
Postmenopausal I None
Breast I None
Cancer I None
with I None
Selective I None
Estrogen I GENE-Y
Receptor O GENE-Y
Modulators I None
( I None
SERMs I None
) I None
. I None
<eof> I None

<s> O None
Endocrine I None
therapy I None
that I None
targets I None
the I None
estrogen I GENE-Y
receptor O GENE-Y
( I None
ER I GENE-Y
) I None
is I None
a I None
standard I None
of I None
care I None
for I None
the I None
treatment I None
of I None
postmenopausal I None
women I None
with I None
ER I GENE-Y
- I None
positive I None
breast I None
cancer I None
. I None
<eof> I None

<s> O None
The I None
selective I None
ER I GENE-Y
modulator I None
( I None
SERM I None
) I None
tamoxifen I CHEMICAL
has I None
been I None
in I None
use I None
for I None
the I None
treatment I None
of I None
advanced I None
breast I None
cancer I None
for I None
more I None
than I None
30 I None
years I None
and I None
is I None
currently I None
a I None
treatment I None
option I None
for I None
all I None
stages I None
of I None
ER I GENE-Y
- I None
positive I None
disease I None
. I None
<eof> I None

<s> O None
Tamoxifen I CHEMICAL
blocks I None
the I None
action I None
of I None
estrogen I CHEMICAL
by I None
binding I None
to I None
the I None
ER I GENE-Y
, I None
and I None
possesses I None
both I None
ER I GENE-Y
- I None
agonist I None
and I None
antagonist I None
properties I None
. I None
<eof> I None

<s> O None
Unfortunately I None
, I None
long I None
- I None
term I None
use I None
of I None
tamoxifen I CHEMICAL
is I None
associated I None
with I None
several I None
important I None
concerns I None
including I None
an I None
increased I None
risk I None
of I None
endometrial I None
cancer I None
and I None
thromboembolic I None
complications I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
many I None
patients I None
who I None
initially I None
respond I None
to I None
tamoxifen I CHEMICAL
eventually I None
relapse I None
with I None
resistant I None
disease I None
. I None
<eof> I None

<s> O None
New I None
treatment I None
approaches I None
are I None
therefore I None
required I None
. I None
<eof> I None

<s> O None
A I None
number I None
of I None
alternative I None
SERMs I None
have I None
been I None
tested I None
as I None
substitutes I None
for I None
tamoxifen I CHEMICAL
. I None
<eof> I None

<s> O None
These I None
include I None
; I None
toremifene I CHEMICAL
, I None
droloxifene I CHEMICAL
, I None
idoxifene I CHEMICAL
, I None
and I None
keoxifene I CHEMICAL
. I None
<eof> I None

<s> O None
Unfortunately I None
, I None
the I None
SERMs I None
have I None
not I None
proved I None
to I None
be I None
more I None
effective I None
than I None
tamoxifen I CHEMICAL
for I None
the I None
treatment I None
of I None
advanced I None
breast I None
cancer I None
and I None
have I None
shown I None
a I None
high I None
level I None
of I None
cross I None
- I None
resistance I None
with I None
tamoxifen I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
subsequent I None
development I None
of I None
the I None
aromatase I GENE-Y
inhibitors I None
( I None
AIs I None
) I None
is I None
an I None
important I None
therapeutic I None
advance I None
by I None
creating I None
a I None
" I None
no I None
estrogen I CHEMICAL
" I None
environment I None
. I None
<eof> I None

<s> O None
Another I None
approach I None
is I None
the I None
development I None
of I None
pure I None
antiestrogens I None
. I None
<eof> I None

<s> O None
Fulvestrant I CHEMICAL
is I None
a I None
novel I None
ER I GENE-Y
antagonist I None
that I None
destroys I None
the I None
ER I GENE-Y
and I None
its I None
signaling I None
pathway I None
and I None
is I None
not I None
associated I None
with I None
tamoxifen I CHEMICAL
- I None
like I None
agonist I None
effects I None
. I None
<eof> I None

<s> O None
It I None
produces I None
high I None
response I None
rates I None
compared I None
with I None
other I None
SERMs I None
and I None
is I None
not I None
cross I None
- I None
resistant I None
to I None
tamoxifen I CHEMICAL
or I None
aromatase I GENE-Y
inhibitors I None
and I None
is I None
equally I None
as I None
effective I None
as I None
the I None
AI I None
anastrozole I CHEMICAL
in I None
the I None
treatment I None
of I None
postmenopausal I None
women I None
with I None
advanced I None
breast I None
cancer I None
who I None
have I None
progressed I None
on I None
prior I None
adjuvant I None
tamoxifen I CHEMICAL
therapy I None
. I None
<eof> I None

<s> O None
This I None
review I None
article I None
discusses I None
the I None
significant I None
and I None
continuing I None
value I None
of I None
SERMs I None
for I None
the I None
treatment I None
of I None
postmenopausal I None
ER I GENE-Y
- I None
positive I None
breast I None
cancer I None
. I None
<eof> I None

<s> O None
A I None
46 I None
- I None
amino I CHEMICAL
acid O CHEMICAL
segment I None
in I None
phosphodiesterase I GENE-Y
- O GENE-Y
5 O GENE-Y
GAF I GENE-N
- O GENE-N
B O GENE-N
domain O GENE-N
provides I None
for I None
high I None
vardenafil I CHEMICAL
potency I None
over I None
sildenafil I CHEMICAL
and I None
tadalafil I CHEMICAL
and I None
is I None
involved I None
in I None
phosphodiesterase I GENE-Y
- O GENE-Y
5 O GENE-Y
dimerization I None
. I None
<eof> I None

<s> O None
Phosphodiesterase I GENE-Y
- O GENE-Y
5 O GENE-Y
( I None
PDE5 I GENE-Y
) I None
contains I None
a I None
catalytic I None
domain I None
( I None
C I None
domain I None
) I None
that I None
hydrolyzes I None
cGMP I CHEMICAL
and I None
a I None
regulatory I None
domain I None
( I None
R I None
domain I None
) I None
that I None
contains I None
two I None
mammalian I GENE-N
cGMP O GENE-N
- O GENE-N
binding O GENE-N
phosphodiesterase O GENE-N
, I None
Anabaena I GENE-Y
adenylyl O GENE-Y
cyclases O GENE-Y
, I None
Escherichia I GENE-Y
coli O GENE-Y
FhlAs O GENE-Y
( I GENE-N
GAFs O GENE-N
) O GENE-N
( O GENE-N
A O GENE-N
and O GENE-N
B O GENE-N
) O GENE-N
and I None
a I None
phosphorylation I None
site I None
for I None
cyclic I GENE-N
nucleotide O GENE-N
- O GENE-N
dependent O GENE-N
protein O GENE-N
kinases O GENE-N
( I None
cNPKs I GENE-N
) I None
. I None
<eof> I None

<s> O None
Binding I None
of I None
cGMP I CHEMICAL
to I None
GAF I GENE-N
- O GENE-N
A O GENE-N
increases I None
cNPK I GENE-N
phosphorylation I None
of I None
PDE5 I GENE-Y
and I None
improves I None
catalytic I None
site I None
affinity I None
for I None
cGMP I CHEMICAL
or I None
inhibitors I None
. I None
<eof> I None

<s> O None
GAF I GENE-N
- O GENE-N
B O GENE-N
contributes I None
to I None
dimerization I None
of I None
PDE5 I GENE-Y
, I None
inhibition I None
of I None
cGMP I CHEMICAL
binding I None
to I None
GAF I GENE-N
- O GENE-N
A O GENE-N
, I None
and I None
sequestration I None
of I None
the I None
phosphorylation I None
site I None
. I None
<eof> I None

<s> O None
To I None
probe I None
potential I None
PDE5 I GENE-N
R O GENE-N
domain O GENE-N
effects I None
on I None
catalytic I None
site I None
affinity I None
for I None
certain I None
inhibitors I None
, I None
four I None
N I CHEMICAL
- I None
terminal I None
truncation I None
mutants I None
were I None
generated I None
: I None
PDE5Delta1 I GENE-Y
- O GENE-Y
321 O GENE-Y
contained I None
GAF I GENE-N
- O GENE-N
B O GENE-N
domain O GENE-N
, I None
C I None
domain I None
, I None
and I None
the I None
sequence I None
between I None
GAF I GENE-N
- O GENE-N
A O GENE-N
and O GENE-N
- O GENE-N
B O GENE-N
; I None
PDE5Delta1 I GENE-Y
- O GENE-Y
419 O GENE-Y
contained I None
GAF I GENE-N
- O GENE-N
B O GENE-N
and O GENE-N
C O GENE-N
domain O GENE-N
; I None
PDE5Delta1 I GENE-Y
- O GENE-Y
465 O GENE-Y
contained I None
the I None
C I None
domain I None
and I None
the I None
C I CHEMICAL
- I None
terminal I None
portion I None
of I None
GAF I GENE-N
- O GENE-N
B O GENE-N
; I None
and I None
PDE5Delta1 I GENE-Y
- O GENE-Y
534 O GENE-Y
contained I None
only I None
C I None
domain I None
. I None
<eof> I None

<s> O None
Truncated I None
proteins I None
with I None
a I None
complete I None
GAF I GENE-N
- O GENE-N
B O GENE-N
were I None
dimers I None
, I None
but I None
those I None
lacking I None
the I None
N I CHEMICAL
- I None
terminal I None
46 I None
amino I CHEMICAL
acids O CHEMICAL
of I None
GAF I GENE-N
- O GENE-N
B O GENE-N
were I None
monomers I None
, I None
indicating I None
that I None
these I None
residues I None
are I None
vital I None
for I None
GAF I GENE-N
- O GENE-N
B O GENE-N
- I None
mediated I None
PDE5 I GENE-Y
dimerization I None
. I None
<eof> I None

<s> O None
K I None
( I None
m I None
) I None
values I None
of I None
the I None
mutants I None
for I None
cGMP I CHEMICAL
were I None
similar I None
to I None
that I None
of I None
full I None
- I None
length I None
PDE5 I GENE-Y
. I None
<eof> I None

<s> O None
All I None
PDE5 I GENE-Y
constructs I None
had I None
similar I None
affinities I None
for I None
3 I CHEMICAL
- O CHEMICAL
isobutyl O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
methylxanthine O CHEMICAL
, I None
sildenafil I CHEMICAL
, I None
tadalafil I CHEMICAL
, I None
and I None
UK I CHEMICAL
- O CHEMICAL
122764 O CHEMICAL
, I None
but I None
mutants I None
containing I None
a I None
complete I None
GAF I GENE-N
- O GENE-N
B O GENE-N
had I None
7 I None
- I None
to I None
18 I None
- I None
fold I None
higher I None
affinity I None
for I None
vardenafil I CHEMICAL
- I None
based I None
compounds I None
compared I None
with I None
those I None
lacking I None
a I None
complete I None
GAF I GENE-N
- O GENE-N
B O GENE-N
. I None
<eof> I None

<s> O None
This I None
indicated I None
that I None
the I None
N I CHEMICAL
- I None
terminal I None
46 I None
amino I CHEMICAL
acids O CHEMICAL
in I None
GAF I GENE-N
- O GENE-N
B O GENE-N
are I None
required I None
for I None
high I None
vardenafil I CHEMICAL
potency I None
. I None
<eof> I None

<s> O None
This I None
is I None
the I None
first I None
evidence I None
that I None
PDE5 I GENE-N
R O GENE-N
domain O GENE-N
, I None
and I None
GAF I GENE-N
- O GENE-N
B O GENE-N
in I None
particular I None
, I None
influences I None
affinity I None
and I None
selectivity I None
of I None
the I None
catalytic I None
site I None
for I None
certain I None
classes I None
of I None
inhibitors I None
. I None
<eof> I None

<s> O None
Telmisartan I CHEMICAL
downregulates I None
angiotensin I GENE-Y
II O GENE-Y
type O GENE-Y
1 O GENE-Y
receptor O GENE-Y
through I None
activation I None
of I None
peroxisome I GENE-Y
proliferator O GENE-Y
- O GENE-Y
activated O GENE-Y
receptor O GENE-Y
gamma O GENE-Y
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
Telmisartan I CHEMICAL
, I None
an I None
angiotensin I GENE-Y
II O GENE-Y
type O GENE-Y
1 O GENE-Y
receptor O GENE-Y
( I None
AT1R I GENE-Y
) I None
antagonist I None
, I None
was I None
found I None
to I None
have I None
a I None
unique I None
property I None
: I None
it I None
is I None
a I None
partial I None
agonist I None
of I None
peroxisome I GENE-Y
proliferator O GENE-Y
- O GENE-Y
activated O GENE-Y
receptor O GENE-Y
gamma O GENE-Y
( I None
PPARgamma I GENE-Y
) I None
. I None
<eof> I None

<s> O None
Since I None
previous I None
studies I None
have I None
demonstrated I None
that I None
PPARgamma I GENE-Y
activators I None
suppressed I None
AT1R I GENE-Y
expression I None
, I None
we I None
examined I None
whether I None
telmisartan I CHEMICAL
affects I None
AT1R I GENE-Y
expression I None
in I None
vascular I None
smooth I None
muscle I None
cells I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Vascular I None
smooth I None
muscle I None
cells I None
were I None
derived I None
from I None
the I None
thoracic I None
aorta I None
of I None
Wistar I None
- I None
Kyoto I None
rat I None
. I None
<eof> I None

<s> O None
Northern I None
and I None
Western I None
blotting I None
analysis I None
were I None
used I None
to I None
examine I None
AT1R I GENE-Y
mRNA I None
and I None
protein I None
expression I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
DEAE I None
- I None
dextran I None
method I None
was I None
used I None
for I None
transfection I None
, I None
and I None
the I None
promoter I None
activity I None
of I None
AT1R I GENE-Y
was I None
examined I None
by I None
luciferase I None
assay I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Telmisartan I CHEMICAL
decreased I None
the I None
expression I None
of I None
AT1R I GENE-Y
at I None
the I None
mRNA I None
and I None
protein I None
levels I None
in I None
a I None
dose I None
- I None
and I None
time I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
Decreased I None
AT1R I GENE-N
promoter O GENE-N
activity I None
with I None
unchanged I None
mRNA I None
stability I None
suggested I None
that I None
telmisartan I CHEMICAL
suppressed I None
AT1R I GENE-Y
gene I None
expression I None
at I None
the I None
transcriptional I None
level I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
expression I None
of I None
AT1R I GENE-Y
was I None
not I None
suppressed I None
by I None
other I None
AT1R I GENE-Y
antagonists I None
such I None
as I None
candesartan I CHEMICAL
or I None
olmesartan I CHEMICAL
. I None
<eof> I None

<s> O None
Since I None
the I None
suppression I None
of I None
AT1R I GENE-Y
expression I None
was I None
prevented I None
by I None
pretreatment I None
with I None
GW9662 I CHEMICAL
, I None
a I None
PPARgamma I GENE-Y
antagonist I None
, I None
PPARgamma I GENE-Y
should I None
have I None
participated I None
in I None
the I None
process I None
. I None
<eof> I None

<s> O None
The I None
deletion I None
and I None
mutation I None
analysis I None
of I None
the I None
AT1R I GENE-Y
gene I None
promoter I None
indicated I None
that I None
a I None
GC I GENE-N
box O GENE-N
located I None
in I None
the I None
proximal I None
promoter I None
region I None
is I None
responsible I None
for I None
the I None
telmisartan I CHEMICAL
- I None
induced I None
downregulation I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
Our I None
data I None
provides I None
a I None
novel I None
insight I None
into I None
an I None
effect I None
of I None
telmisartan I CHEMICAL
: I None
telmisartan I CHEMICAL
inhibits I None
AT1R I GENE-Y
gene I None
expression I None
through I None
PPARgamma I GENE-Y
activation I None
. I None
<eof> I None

<s> O None
The I None
dual I None
inhibition I None
of I None
angiotensin I GENE-Y
II O GENE-Y
function I None
by I None
telmisartan I None
- I None
AT1R I GENE-Y
blockade I None
and I None
downregulation I None
- I None
would I None
contribute I None
to I None
more I None
complete I None
inhibition I None
of I None
the I None
renin I GENE-Y
- I None
angiotensin I GENE-Y
system I None
. I None
<eof> I None

<s> O None
Secretion I None
of I None
L I CHEMICAL
- O CHEMICAL
glutamate O CHEMICAL
from I None
osteoclasts I None
through I None
transcytosis I None
. I None
<eof> I None

<s> O None
Osteoclasts I None
are I None
involved I None
in I None
the I None
catabolism I None
of I None
the I None
bone I None
matrix I None
and I None
eliminate I None
the I None
resulting I None
degradation I None
products I None
through I None
transcytosis I None
, I None
but I None
the I None
molecular I None
mechanism I None
and I None
regulation I None
of I None
transcytosis I None
remain I None
poorly I None
understood I None
. I None
<eof> I None

<s> O None
Upon I None
differentiation I None
, I None
osteoclasts I None
express I None
vesicular I GENE-Y
glutamate O GENE-Y
transporter O GENE-Y
1 O GENE-Y
( I None
VGLUT1 I GENE-Y
) I None
, I None
which I None
is I None
essential I None
for I None
vesicular I None
storage I None
and I None
subsequent I None
exocytosis I None
of I None
glutamate I CHEMICAL
in I None
neurons I None
. I None
<eof> I None

<s> O None
VGLUT1 I GENE-Y
is I None
localized I None
in I None
transcytotic I None
vesicles I None
and I None
accumulates I None
L I CHEMICAL
- O CHEMICAL
glutamate O CHEMICAL
. I None
<eof> I None

<s> O None
Osteoclasts I None
secrete I None
L I CHEMICAL
- O CHEMICAL
glutamate O CHEMICAL
and I None
the I None
bone I None
degradation I None
products I None
upon I None
stimulation I None
with I None
KCl I CHEMICAL
or I None
ATP I CHEMICAL
in I None
a I None
Ca2 I CHEMICAL
+ O CHEMICAL
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
KCl I CHEMICAL
- I None
and I None
ATP I CHEMICAL
- I None
dependent I None
secretion I None
of I None
L I CHEMICAL
- O CHEMICAL
glutamate O CHEMICAL
was I None
absent I None
in I None
osteoclasts I None
prepared I None
from I None
VGLUT1 I GENE-Y
- I None
/ I None
- I None
knockout I None
mice I None
. I None
<eof> I None

<s> O None
Osteoclasts I None
express I None
mGluR8 I GENE-Y
, I None
a I None
class I GENE-N
III O GENE-N
metabotropic O GENE-N
glutamate O GENE-N
receptor O GENE-N
. I None
<eof> I None

<s> O None
Its I None
stimulation I None
by I None
a I None
specific I None
agonist I None
inhibits I None
secretion I None
of I None
L I CHEMICAL
- O CHEMICAL
glutamate O CHEMICAL
and I None
bone I None
degradation I None
products I None
, I None
whereas I None
its I None
suppression I None
by I None
a I None
specific I None
antagonist I None
stimulates I None
bone I None
resorption I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
it I None
was I None
found I None
that I None
VGLUT1 I GENE-Y
- I None
/ I None
- I None
mice I None
develop I None
osteoporosis I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
in I None
bone I None
- I None
resorbing I None
osteoclasts I None
, I None
L I CHEMICAL
- O CHEMICAL
glutamate O CHEMICAL
and I None
bone I None
degradation I None
products I None
are I None
secreted I None
through I None
transcytosis I None
and I None
the I None
released I None
L I CHEMICAL
- O CHEMICAL
glutamate O CHEMICAL
is I None
involved I None
in I None
autoregulation I None
of I None
transcytosis I None
. I None
<eof> I None

<s> O None
Glutamate I CHEMICAL
signaling I None
may I None
play I None
an I None
important I None
role I None
in I None
the I None
bone I None
homeostasis I None
. I None
<eof> I None

<s> O None
Synthesis I None
, I None
dihydrofolate I GENE-Y
reductase O GENE-Y
inhibition I None
, I None
antitumor I None
testing I None
, I None
and I None
molecular I None
modeling I None
study I None
of I None
some I None
new I None
4 I CHEMICAL
( O CHEMICAL
3H O CHEMICAL
) O CHEMICAL
- O CHEMICAL
quinazolinone O CHEMICAL
analogs I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
produce I None
potent I None
new I None
leads I None
for I None
anticancer I None
drugs I None
, I None
a I None
new I None
series I None
of I None
quinazoline I CHEMICAL
analogs I None
was I None
designed I None
to I None
resemble I None
methotrexate I CHEMICAL
( I None
MTX I CHEMICAL
, I None
1 I None
) I None
structure I None
features I None
and I None
fitted I None
with I None
functional I None
groups I None
believed I None
to I None
enhance I None
inhibition I None
of I None
mammalian I GENE-N
DHFR O GENE-N
activity I None
. I None
<eof> I None

<s> O None
Molecular I None
modeling I None
studies I None
were I None
used I None
to I None
assess I None
the I None
fit I None
of I None
these I None
compounds I None
within I None
the I None
active I None
site I None
of I None
human I GENE-Y
DHFR O GENE-Y
. I None
<eof> I None

<s> O None
The I None
synthesized I None
compounds I None
were I None
evaluated I None
for I None
their I None
ability I None
to I None
inhibit I None
mammalian I GENE-N
DHFR O GENE-N
in I None
vitro I None
and I None
for I None
their I None
antitumor I None
activity I None
in I None
a I None
standard I None
in I None
vitro I None
tissue I None
culture I None
assay I None
panel I None
. I None
<eof> I None

<s> O None
Compounds I None
28 I None
, I None
30 I None
, I None
and I None
31 I None
were I None
the I None
most I None
active I None
DHFR I GENE-Y
inhibitors I None
with I None
IC I None
( I None
50 I None
) I None
values I None
of I None
0 I None
. I None
5 I None
, I None
0 I None
. I None
4 I None
, I None
and I None
0 I None
. I None
4microM I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
most I None
active I None
antitumor I None
agents I None
in I None
this I None
study I None
were I None
compounds I None
19 I None
, I None
31 I None
, I None
41 I None
, I None
and I None
47 I None
with I None
median I None
growth I None
inhibitory I None
concentrations I None
( I None
GI I None
( I None
50 I None
) I None
) I None
of I None
20 I None
. I None
1 I None
, I None
23 I None
. I None
5 I None
, I None
26 I None
. I None
7 I None
, I None
and I None
9 I None
. I None
1microM I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Of I None
this I None
series I None
of I None
compounds I None
, I None
only I None
compound I None
31 I None
combined I None
antitumor I None
potency I None
with I None
potent I None
DHFR I GENE-Y
inhibition I None
; I None
the I None
other I None
active I None
antitumor I None
compounds I None
( I None
19 I None
, I None
41 I None
, I None
and I None
47 I None
) I None
all I None
had I None
DHFR I GENE-Y
IC I None
( I None
50 I None
) I None
values I None
above I None
15microM I None
, I None
suggesting I None
that I None
they I None
might I None
exert I None
their I None
antitumor I None
potency I None
through I None
some I None
other I None
mode I None
of I None
action I None
. I None
<eof> I None

<s> O None
Alternatively I None
, I None
the I None
compounds I None
could I None
differ I None
significantly I None
in I None
uptake I None
or I None
concentration I None
within I None
mammalian I None
cells I None
. I None
<eof> I None

<s> O None
Hyperphagia I None
alters I None
expression I None
of I None
hypothalamic I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptor I None
genes I None
and I None
plasma I None
des I GENE-Y
- O GENE-Y
acyl O GENE-Y
ghrelin O GENE-Y
levels I None
in I None
Ay I None
mice I None
. I None
<eof> I None

<s> O None
The I None
central I None
melanocortin I GENE-Y
( I None
MC I GENE-Y
) I None
pathway I None
is I None
suggested I None
to I None
mediate I None
satiety I None
signaling I None
downstream I None
of I None
serotonin I GENE-Y
( O GENE-Y
5 O GENE-Y
- O GENE-Y
HT O GENE-Y
) O GENE-Y
2C O GENE-Y
receptors O GENE-Y
. I None
<eof> I None

<s> O None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
receptor I None
mutant I None
mice I None
consume I None
more I None
food I None
, I None
which I None
leads I None
to I None
late I None
- I None
onset I None
obesity I None
and I None
impaired I None
glucose I CHEMICAL
tolerance I None
. I None
<eof> I None

<s> O None
Ay I None
mice I None
with I None
ectopic I None
expression I None
of I None
the I None
agouti I GENE-Y
peptide O GENE-Y
, I None
which I None
leads I None
to I None
a I None
perturbation I None
of I None
the I None
central I None
MC I GENE-Y
pathway I None
, I None
develop I None
obesity I None
and I None
diabetes I None
, I None
associated I None
with I None
low I None
levels I None
of I None
plasma I None
total I None
ghrelin I GENE-Y
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
report I None
that I None
5 I None
- I None
wk I None
- I None
old I None
Ay I None
mice I None
consumed I None
more I None
food I None
in I None
association I None
with I None
decreases I None
in I None
levels I None
of I None
plasma I None
des I GENE-Y
- O GENE-Y
acyl O GENE-Y
ghrelin O GENE-Y
, I None
but I None
not I None
active I None
ghrelin I GENE-Y
, I None
and I None
increases I None
in I None
hypothalamic I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptor I None
gene I None
expression I None
compared I None
with I None
wild I None
- I None
type I None
mice I None
matched I None
for I None
age I None
and I None
body I None
weight I None
. I None
<eof> I None

<s> O None
These I None
alterations I None
were I None
also I None
observed I None
in I None
8 I None
- I None
wk I None
- I None
old I None
obese I None
Ay I None
mice I None
. I None
<eof> I None

<s> O None
Restricted I None
feeding I None
significantly I None
decreased I None
hypothalamic I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptor I None
gene I None
expression I None
in I None
association I None
with I None
a I None
reversal I None
of I None
the I None
decreases I None
in I None
plasma I None
des I GENE-Y
- O GENE-Y
acyl O GENE-Y
ghrelin O GENE-Y
levels I None
in I None
5 I None
- I None
wk I None
- I None
old I None
Ay I None
mice I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
restricted I None
feeding I None
reduced I None
body I None
weight I None
, I None
hyperinsulinemia I None
, I None
and I None
hyperglycemia I None
in I None
association I None
with I None
increases I None
in I None
plasma I None
des I GENE-Y
- O GENE-Y
acyl O GENE-Y
ghrelin O GENE-Y
levels I None
in I None
8 I None
- I None
wk I None
- I None
old I None
obese I None
Ay I None
mice I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
m I CHEMICAL
- O CHEMICAL
chlorophenylpiperazine O CHEMICAL
and I None
fenfluramine I CHEMICAL
, I None
both I None
of I None
which I None
induce I None
anorexic I None
effects I None
via I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
receptors I None
and I None
/ I None
or I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptors I None
, I None
suppressed I None
food I None
intake I None
in I None
5 I None
- I None
and I None
8 I None
- I None
wk I None
- I None
old I None
Ay I None
mice I None
, I None
whereas I None
the I None
anorexic I None
effects I None
were I None
attenuated I None
in I None
food I None
- I None
restricted I None
Ay I None
mice I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
the I None
agouti I GENE-Y
peptide O GENE-Y
down I None
- I None
regulates I None
hypothalamic I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT1B O GENE-Y
receptor I None
gene I None
expression I None
under I None
restricted I None
feeding I None
conditions I None
, I None
whereas I None
chronic I None
hyperphagia I None
increases I None
the I None
expression I None
of I None
these I None
genes I None
and I None
decreases I None
plasma I None
des I GENE-Y
- O GENE-Y
acyl O GENE-Y
ghrelin O GENE-Y
levels I None
in I None
Ay I None
mice I None
. I None
<eof> I None

<s> O None
Gonadotropin I GENE-Y
- O GENE-Y
releasing O GENE-Y
hormone O GENE-Y
antagonist I None
in I None
the I None
management I None
of I None
prostate I None
cancer I None
. I None
<eof> I None

<s> O None
Luteinizing I GENE-Y
hormone O GENE-Y
- O GENE-Y
releasing O GENE-Y
hormone O GENE-Y
( I None
LHRH I GENE-Y
) I None
agonist I None
therapy I None
to I None
induce I None
medical I None
castration I None
has I None
become I None
the I None
most I None
common I None
form I None
of I None
hormonal I None
therapy I None
for I None
advanced I None
and I None
metastatic I None
prostate I None
cancer I None
. I None
<eof> I None

<s> O None
When I None
treatment I None
is I None
started I None
, I None
LHRH I GENE-Y
agonists I None
initially I None
stimulate I None
the I None
release I None
of I None
LH I GENE-N
, I None
causing I None
a I None
surge I None
in I None
serum I None
testosterone I CHEMICAL
that I None
can I None
precipitate I None
a I None
" I None
flare I None
" I None
phenomenon I None
or I None
worsening I None
of I None
disease I None
, I None
particularly I None
in I None
patients I None
with I None
bone I None
metastatic I None
disease I None
. I None
<eof> I None

<s> O None
Gonadotropin I GENE-Y
- O GENE-Y
releasing O GENE-Y
hormone O GENE-Y
( O GENE-Y
GnRH O GENE-Y
) O GENE-Y
receptor O GENE-Y
antagonism I None
represents I None
a I None
newer I None
approach I None
to I None
medical I None
castration I None
. I None
<eof> I None

<s> O None
Abarelix I None
is I None
a I None
pure I None
GnRH I GENE-Y
receptor O GENE-Y
antagonist I None
that I None
is I None
devoid I None
of I None
any I None
LHRH I GENE-Y
agonist I None
activity I None
. I None
<eof> I None

<s> O None
Results I None
from I None
1 I None
phase I None
II I None
and I None
3 I None
phase I None
III I None
clinical I None
trials I None
demonstrate I None
that I None
abarelix I None
produces I None
medical I None
castration I None
more I None
quickly I None
and I None
without I None
causing I None
testosterone I CHEMICAL
surge I None
, I None
as I None
compared I None
with I None
LHRH I GENE-Y
agonists I None
with I None
or I None
without I None
a I None
nonsteroidal I None
antagonist I None
. I None
<eof> I None

<s> O None
The I None
safety I None
profile I None
in I None
terms I None
of I None
adverse I None
events I None
is I None
comparable I None
between I None
the I None
2 I None
types I None
of I None
treatment I None
, I None
but I None
the I None
lack I None
of I None
testosterone I CHEMICAL
surge I None
with I None
abarelix I None
might I None
confer I None
a I None
safety I None
advantage I None
by I None
abolishing I None
the I None
risk I None
of I None
a I None
disease I None
flare I None
. I None
<eof> I None

<s> O None
Diet I None
and I None
gene I None
expression I None
: I None
delta I GENE-N
- O GENE-N
5 O GENE-N
and O GENE-N
delta O GENE-N
- O GENE-N
6 O GENE-N
desaturases O GENE-N
in I None
healthy I None
Chinese I None
and I None
European I None
subjects I None
. I None
<eof> I None

<s> O None
AIM I None
: I None
To I None
compare I None
the I None
composition I None
of I None
fatty I CHEMICAL
acids O CHEMICAL
( I None
FAs I CHEMICAL
) I None
in I None
diet I None
, I None
and I None
the I None
expression I None
of I None
delta I GENE-Y
- O GENE-Y
6 O GENE-Y
desaturase O GENE-Y
( I None
D6D I GENE-Y
) I None
and I None
delta I GENE-Y
- O GENE-Y
5 O GENE-Y
desaturase O GENE-Y
( I None
D5D I GENE-Y
) I None
genes I None
in I None
peripheral I None
blood I None
mononuclear I None
cells I None
( I None
PBMCs I None
) I None
between I None
Chinese I None
and I None
Europeans I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Three I None
- I None
day I None
dietary I None
records I None
from I None
20 I None
subjects I None
from I None
Beijing I None
, I None
China I None
( I None
n I None
= I None
10 I None
) I None
and I None
Kent I None
, I None
UK I None
( I None
n I None
= I None
10 I None
) I None
were I None
analysed I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
PBMC I None
D6D I GENE-Y
and I None
D5D I GENE-Y
genes I None
of I None
the I None
subjects I None
was I None
determined I None
using I None
RT I None
- I None
PCR I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
The I None
dietary I None
intake I None
of I None
Chinese I None
subjects I None
contained I None
less I None
saturated I CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
( I None
SFAs I CHEMICAL
) I None
and I None
monounsaturated I CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
( I None
MUFAs I CHEMICAL
) I None
, I None
but I None
more I None
essential I CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
( I None
EFAs I CHEMICAL
) I None
than I None
that I None
of I None
Europeans I None
. I None
<eof> I None

<s> O None
Levels I None
of I None
expression I None
of I None
PBMC I None
D6D I GENE-Y
and I None
D5D I GENE-Y
genes I None
of I None
Chinese I None
subjects I None
were I None
significantly I None
lower I None
than I None
those I None
of I None
Europeans I None
. I None
<eof> I None

<s> O None
A I None
significant I None
positive I None
correlation I None
was I None
found I None
between I None
dietary I None
intake I None
of I None
total I None
SFAs I None
and I None
total I None
MUFAs I None
and I None
expression I None
of I None
PBMC I None
D6D I GENE-Y
and I None
D5D I GENE-Y
genes I None
, I None
but I None
a I None
significant I None
negative I None
correlation I None
between I None
dietary I None
intake I None
of I None
linoleic I CHEMICAL
acid O CHEMICAL
( I None
LA I CHEMICAL
) I None
and I None
alpha I CHEMICAL
- O CHEMICAL
linolenic O CHEMICAL
acid O CHEMICAL
( I None
LNA I CHEMICAL
) I None
and I None
the I None
expression I None
of I None
PBMC I None
D6D I GENE-Y
and I None
D5D I GENE-Y
genes I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
Intake I None
of I None
high I None
SFAs I CHEMICAL
and I None
MUFAs I CHEMICAL
appears I None
to I None
increase I None
expression I None
of I None
PBMC I None
D6D I GENE-Y
and I None
D5D I GENE-Y
genes I None
, I None
whilst I None
high I None
EFAs I CHEMICAL
intake I None
appears I None
to I None
decrease I None
expression I None
of I None
PBMC I None
D6D I GENE-Y
and I None
D5D I GENE-Y
genes I None
. I None
<eof> I None

<s> O None
A I None
follow I None
- I None
up I None
study I None
of I None
the I None
expression I None
of I None
D6D I GENE-Y
and I None
D5D I GENE-Y
genes I None
in I None
Chinese I None
who I None
live I None
in I None
European I None
countries I None
with I None
high I None
SFA I CHEMICAL
and I None
MUFA I CHEMICAL
diets I None
would I None
be I None
of I None
interest I None
. I None
<eof> I None

<s> O None
The I None
evolution I None
of I None
progesterone I GENE-Y
receptor O GENE-Y
ligands I None
. I None
<eof> I None

<s> O None
Progesterone I CHEMICAL
is I None
one I None
of I None
the I None
first I None
nuclear I GENE-N
receptor O GENE-N
hormones I None
to I None
be I None
described I None
functionally I None
and I None
subsequently I None
approached I None
as I None
a I None
drug I None
target I None
. I None
<eof> I None

<s> O None
Because I None
progesterone I CHEMICAL
( I None
1 I None
) I None
affects I None
both I None
menstruation I None
and I None
gestation I None
via I None
the I None
progesterone I GENE-Y
receptor O GENE-Y
( I None
PR I GENE-Y
) I None
, I None
research I None
aimed I None
at I None
modulating I None
its I None
activity I None
is I None
usually I None
surrounded I None
by I None
controversy I None
. I None
<eof> I None

<s> O None
However I None
, I None
ligands I None
for I None
PR I GENE-Y
were I None
developed I None
into I None
drugs I None
, I None
and I None
their I None
evolution I None
can I None
be I None
crudely I None
divided I None
into I None
three I None
periods I None
: I None
( I None
1 I None
) I None
drug I None
- I None
like I None
steroids I CHEMICAL
that I None
mimic I None
the I None
gestational I None
properties I None
of I None
progesterone I CHEMICAL
; I None
( I None
2 I None
) I None
drug I None
- I None
like I None
steroids I CHEMICAL
with I None
different I None
properties I None
from I None
progesterone I CHEMICAL
and I None
expanded I None
therapeutic I None
applications I None
; I None
and I None
( I None
3 I None
) I None
non I None
- I None
steroidal I CHEMICAL
PR I GENE-Y
ligands I None
with I None
improved I None
selectivity I None
and I None
modulator I None
properties I None
and I None
further I None
expanded I None
therapeutic I None
applications I None
. I None
<eof> I None

<s> O None
Although I None
the I None
latter I None
have I None
yet I None
to I None
see I None
widespread I None
clinical I None
applications I None
, I None
their I None
development I None
is I None
founded I None
on I None
a I None
half I None
century I None
of I None
research I None
, I None
and I None
they I None
represent I None
the I None
future I None
for I None
this I None
drug I None
target I None
. I None
<eof> I None

<s> O None
Decitabine I CHEMICAL
- I None
- I None
bedside I None
to I None
bench I None
. I None
<eof> I None

<s> O None
PURPOSE I None
OF I None
THE I None
REVIEW I None
: I None
Epigenetic I None
changes I None
marked I None
by I None
DNA I None
methylation I None
are I None
known I None
to I None
contribute I None
to I None
the I None
malignant I None
transformation I None
of I None
cells I None
by I None
silencing I None
critical I None
genes I None
. I None
<eof> I None

<s> O None
Decitabine I CHEMICAL
inhibits I None
DNA I GENE-N
methyltransferase O GENE-N
and I None
has I None
shown I None
therapeutic I None
effects I None
in I None
patients I None
with I None
hematologic I None
malignancies I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
connection I None
between I None
the I None
clinical I None
activity I None
of I None
decitabine I CHEMICAL
and I None
its I None
demethylating I None
activity I None
is I None
not I None
clear I None
. I None
<eof> I None

<s> O None
Herein I None
, I None
we I None
summarize I None
the I None
results I None
of I None
recent I None
clinical I None
trials I None
of I None
decitabine I CHEMICAL
in I None
hematologic I None
malignancies I None
, I None
and I None
review I None
the I None
translational I None
research I None
into I None
decitabine I None
' I None
s I None
mechanism I None
of I None
clinical I None
activity I None
. I None
<eof> I None

<s> O None
RECENT I None
FINDINGS I None
: I None
Low I None
- I None
dose I None
decitabine I CHEMICAL
has I None
been I None
studied I None
recently I None
in I None
multiple I None
clinical I None
trials I None
and I None
has I None
been I None
shown I None
to I None
be I None
effective I None
for I None
treatment I None
of I None
myelodysplastic I None
syndromes I None
. I None
<eof> I None

<s> O None
Correlative I None
laboratory I None
studies I None
of I None
clinical I None
trials I None
have I None
shown I None
that I None
decitabine I CHEMICAL
induces I None
global I None
hypomethylation I None
as I None
well I None
as I None
hypomethylation I None
of I None
gene I None
- I None
specific I None
promoters I None
and I None
activation I None
of I None
gene I None
expression I None
. I None
<eof> I None

<s> O None
Past I None
a I None
given I None
threshold I None
, I None
induction I None
of I None
higher I None
degrees I None
of I None
hypomethylation I None
is I None
not I None
directly I None
associated I None
with I None
a I None
better I None
clinical I None
outcome I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
studies I None
have I None
suggested I None
that I None
patients I None
with I None
promoter I None
hypermethylation I None
of I None
p15 I GENE-Y
( O GENE-Y
INK4B O GENE-Y
) O GENE-Y
at I None
baseline I None
have I None
paradoxically I None
a I None
lower I None
chance I None
of I None
achieving I None
response I None
than I None
those I None
without I None
hypermethylation I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
several I None
other I None
genes I None
activated I None
by I None
decitabine I CHEMICAL
were I None
independent I None
of I None
hypomethylation I None
in I None
the I None
promoter I None
regions I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
While I None
at I None
least I None
part I None
of I None
decitabine I None
' I None
s I None
activity I None
is I None
through I None
induction I None
of I None
hypomethylation I None
and I None
reactivation I None
of I None
critical I None
genes I None
, I None
mechanisms I None
independent I None
from I None
hypomethylation I None
are I None
also I None
important I None
for I None
decitabine I None
' I None
s I None
antitumor I None
activity I None
. I None
<eof> I None

<s> O None
[ I None
Efalizumab I None
] I None
. I None
<eof> I None

<s> O None
Efalizumab I None
( I None
Raptiva I None
, I None
Serono I None
) I None
is I None
a I None
humanised I None
monoclonal I None
antibody I None
( I None
IgG1 I GENE-Y
) I None
produced I None
by I None
biotechnology I None
. I None
<eof> I None

<s> O None
This I None
antibody I None
has I None
a I None
novel I None
place I None
among I None
biotherapies I None
for I None
psoriasis I None
. I None
<eof> I None

<s> O None
It I None
is I None
bound I None
to I None
the I None
CD11a I GENE-Y
subunit I None
of I None
a I None
surface I None
molecule I None
of I None
the I None
T I None
lymphocyte I None
LFA I GENE-N
- O GENE-N
1 O GENE-N
( I None
Leucocyte I GENE-N
Function O GENE-N
- O GENE-N
associated O GENE-N
Antigen O GENE-N
- O GENE-N
1 O GENE-N
) I None
. I None
<eof> I None

<s> O None
This I None
molecule I None
is I None
essential I None
for I None
binding I None
of I None
T I None
lymphocytes I None
to I None
the I None
ICAM I GENE-Y
- O GENE-Y
1 O GENE-Y
molecule I None
( I None
Intercellular I GENE-Y
Adhesion O GENE-Y
Molecule O GENE-Y
- O GENE-Y
1 O GENE-Y
) I None
found I None
on I None
antigen I None
- I None
presenting I None
cells I None
, I None
endothelial I None
cells I None
and I None
keratinocytes I None
. I None
<eof> I None

<s> O None
Binding I None
of I None
efalizumab I None
to I None
CD11a I GENE-Y
prevents I None
binding I None
of I None
LFA I GENE-N
- O GENE-N
1 O GENE-N
to I None
ICAM I GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
thus I None
inhibiting I None
several I None
steps I None
in I None
the I None
immunological I None
process I None
responsible I None
for I None
formation I None
of I None
psoriatic I None
plaque I None
( I None
activation I None
of I None
naive I None
T I None
lymphocytes I None
to I None
memory I None
T I None
lymphocytes I None
, I None
lymphocyte I None
migration I None
and I None
reactivation I None
of I None
T I None
lymphocytes I None
in I None
skin I None
) I None
. I None
<eof> I None

<s> O None
Efalizumab I None
was I None
approved I None
in I None
the I None
United I None
States I None
by I None
the I None
FDA I None
( I None
Food I None
and I None
Drug I None
Administration I None
) I None
in I None
2003 I None
for I None
the I None
treatment I None
of I None
moderate I None
- I None
to I None
- I None
severe I None
psoriasis I None
requiring I None
systemic I None
therapy I None
. I None
<eof> I None

<s> O None
It I None
may I None
be I None
used I None
as I None
first I None
- I None
line I None
therapy I None
in I None
the I None
United I None
States I None
in I None
this I None
indication I None
. I None
<eof> I None

<s> O None
In I None
France I None
, I None
marketing I None
authorisation I None
( I None
MA I None
) I None
was I None
granted I None
more I None
recently I None
in I None
September I None
2005 I None
. I None
<eof> I None

<s> O None
The I None
indications I None
are I None
moderate I None
- I None
to I None
- I None
severe I None
cutaneous I None
plaque I None
psoriasis I None
in I None
adults I None
in I None
cases I None
of I None
failure I None
, I None
intolerance I None
or I None
contraindication I None
of I None
at I None
least I None
two I None
systemic I None
treatments I None
including I None
phototherapy I None
, I None
methotrexate I CHEMICAL
and I None
cyclosporine I CHEMICAL
. I None
<eof> I None

<s> O None
Current I None
clinical I None
trial I None
data I None
is I None
available I None
for I None
3500 I None
patients I None
with I None
plaque I None
psoriasis I None
. I None
<eof> I None

<s> O None
A I None
75 I None
% I None
improvement I None
in I None
PASI I None
score I None
was I None
seen I None
in I None
between I None
22 I None
and I None
39 I None
% I None
of I None
patients I None
treated I None
with I None
efalizumab I None
( I None
vs I None
. I None
2 I None
to I None
5 I None
% I None
for I None
patients I None
on I None
placebo I None
) I None
in I None
a I None
single I None
weekly I None
subcutaneous I None
injection I None
( I None
1 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
A I None
study I None
in I None
good I None
responders I None
confirms I None
the I None
continuing I None
long I None
- I None
term I None
efficacy I None
of I None
prescription I None
of I None
the I None
drug I None
up I None
to I None
36 I None
months I None
( I None
with I None
at I None
least I None
a I None
75 I None
% I None
improvement I None
in I None
PASI I None
score I None
in I None
53 I None
% I None
of I None
patients I None
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
it I None
is I None
not I None
effective I None
against I None
joint I None
involvement I None
in I None
psoriasis I None
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
side I None
- I None
effects I None
( I None
incidence I None
> I None
1 I None
/ I None
100 I None
) I None
are I None
influenza I None
- I None
like I None
syndrome I None
, I None
risk I None
of I None
outbreak I None
of I None
cutaneous I None
psoriasis I None
during I None
or I None
after I None
discontinuation I None
of I None
treatment I None
, I None
worsening I None
of I None
arthralgia I None
, I None
minor I None
hypersensitivity I None
reactions I None
, I None
reversible I None
changes I None
in I None
laboratory I None
values I None
( I None
hyperlymphocytosis I None
, I None
elevated I None
alkaline I GENE-N
phosphatases O GENE-N
and I None
transaminases I GENE-N
) I None
. I None
<eof> I None

<s> O None
Because I None
of I None
rare I None
cases I None
of I None
thrombocytopenia I None
( I None
incidence I None
< I None
1 I None
/ I None
100 I None
) I None
, I None
reversible I None
on I None
discontinuation I None
of I None
treatment I None
, I None
monthly I None
monitoring I None
of I None
platelet I None
counts I None
is I None
required I None
over I None
the I None
first I None
3 I None
months I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
There I None
are I None
currently I None
no I None
randomised I None
studies I None
comparing I None
the I None
various I None
systemic I None
treatments I None
( I None
standard I None
therapy I None
and I None
biotherapy I None
) I None
for I None
psoriasis I None
. I None
<eof> I None

<s> O None
However I None
, I None
on I None
extrapolation I None
of I None
the I None
available I None
results I None
concerning I None
efficacy I None
( I None
PASI I None
- I None
75 I None
after I None
12 I None
weeks I None
of I None
treatment I None
) I None
, I None
efalizumab I None
appears I None
to I None
be I None
less I None
efficacious I None
than I None
anti I None
- I None
TNF I GENE-Y
alpha O GENE-Y
agents I None
. I None
<eof> I None

<s> O None
This I None
drug I None
constitutes I None
an I None
additional I None
treatment I None
option I None
and I None
its I None
position I None
in I None
the I None
therapeutic I None
arsenal I CHEMICAL
will I None
depend I None
upon I None
its I None
long I None
- I None
term I None
benefit I None
/ I None
risk I None
ratio I None
in I None
relation I None
to I None
other I None
biotherapies I None
. I None
<eof> I None

<s> O None
Multiple I None
pathways I None
for I None
cationic I None
amino I CHEMICAL
acid O CHEMICAL
transport I None
in I None
rat I None
seminiferous I None
tubule I None
cells I None
. I None
<eof> I None

<s> O None
Arginine I CHEMICAL
and I None
ornithine I CHEMICAL
are I None
known I None
to I None
be I None
important I None
for I None
various I None
biological I None
processes I None
in I None
the I None
testis I None
, I None
but I None
the I None
delivery I None
of I None
extracellular I None
cationic I None
amino I CHEMICAL
acids O CHEMICAL
to I None
the I None
seminiferous I None
tubule I None
cells I None
remains I None
poorly I None
understood I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
activity I None
and I None
expression I None
of I None
cationic I GENE-N
amino O GENE-N
acid O GENE-N
transporters O GENE-N
in I None
isolated I None
rat I None
Sertoli I None
cells I None
, I None
peritubular I None
cells I None
, I None
pachytene I None
spermatocytes I None
, I None
and I None
early I None
spermatids I None
. I None
<eof> I None

<s> O None
We I None
assessed I None
the I None
l I CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
uptake I None
kinetics I None
, I None
Na I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
dependence I None
of I None
transport I None
, I None
profiles I None
of I None
cis I None
inhibition I None
of I None
uptake I None
by I None
cationic I None
and I None
neutral I None
amino I CHEMICAL
acids O CHEMICAL
, I None
and I None
sensitivity I None
to I None
trans I None
stimulation I None
of I None
cationic I GENE-N
amino O GENE-N
acid O GENE-N
transporters O GENE-N
, I None
and I None
studied I None
the I None
expression I None
of I None
the I None
genes I None
encoding I None
them I None
by I None
RT I None
- I None
PCR I None
. I None
<eof> I None

<s> O None
Our I None
data I None
suggest I None
that I None
l I CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
is I None
taken I None
up I None
by I None
Sertoli I None
cells I None
and I None
peritubular I None
cells I None
, I None
principally I None
via I None
system I None
y I None
( I None
+ I None
) I None
L I None
( I None
SLC3A2 I GENE-Y
/ I None
SLC7A6 I GENE-Y
) I None
and I None
system I None
y I None
( I None
+ I None
) I None
( I None
SLC7A1 I GENE-Y
and I None
SLC7A2 I GENE-Y
) I None
, I None
with I None
system I None
B I None
( I None
0 I None
+ I None
) I None
making I None
a I None
minor I None
contribution I None
. I None
<eof> I None

<s> O None
By I None
contrast I None
, I None
system I None
B I None
( I None
0 I None
+ I None
) I None
, I None
associated I None
with I None
system I None
y I None
( I None
+ I None
) I None
L I None
( I None
SLC3A2 I GENE-Y
/ I None
SLC7A7 I GENE-Y
and I None
SLC7A6 I GENE-Y
) I None
, I None
made I None
a I None
major I None
contribution I None
to I None
the I None
transport I None
of I None
cationic I None
amino I CHEMICAL
acids O CHEMICAL
in I None
pachytene I None
spermatocytes I None
and I None
early I None
spermatids I None
. I None
<eof> I None

<s> O None
Sertoli I None
cells I None
had I None
higher I None
rates I None
of I None
l I CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
transport I None
than I None
the I None
other I None
seminiferous I None
tubule I None
cells I None
. I None
<eof> I None

<s> O None
This I None
high I None
efficiency I None
of I None
arginine I CHEMICAL
transport I None
in I None
Sertoli I None
cells I None
and I None
the I None
properties I None
of I None
the I None
y I None
( I None
+ I None
) I None
L I None
system I None
predominating I None
in I None
these I None
cells I None
strongly I None
suggest I None
that I None
Sertoli I None
cells I None
play I None
a I None
key I None
role I None
in I None
supplying I None
germ I None
cells I None
with I None
l I CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
and I None
other I None
cationic I None
amino I CHEMICAL
acids O CHEMICAL
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
whereas I None
cytokines I GENE-N
induce I None
nitric I CHEMICAL
oxide O CHEMICAL
( I None
NO I CHEMICAL
) I None
production I None
in I None
peritubular I None
and I None
Sertoli I None
cells I None
, I None
little I None
or I None
no I None
upregulation I None
of I None
arginine I CHEMICAL
transport I None
by I None
cytokines I GENE-N
was I None
observed I None
in I None
these I None
cells I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
NO I CHEMICAL
synthesis I None
does I None
not I None
depend I None
on I None
the I None
stimulation I None
of I None
arginine I CHEMICAL
transport I None
in I None
these I None
somatic I None
tubular I None
cells I None
. I None
<eof> I None

<s> O None
Transition I None
- I None
state I None
structure I None
of I None
human I GENE-Y
5 O GENE-Y
' O GENE-Y
- O GENE-Y
methylthioadenosine O GENE-Y
phosphorylase O GENE-Y
. I None
<eof> I None

<s> O None
Kinetic I None
isotope I None
effects I None
( I None
KIEs I None
) I None
and I None
computer I None
modeling I None
using I None
density I None
functional I None
theory I None
were I None
used I None
to I None
approximate I None
the I None
transition I None
state I None
of I None
human I GENE-Y
5 O GENE-Y
' O GENE-Y
- O GENE-Y
methylthioadenosine O GENE-Y
phosphorylase O GENE-Y
( I None
MTAP I GENE-Y
) I None
. I None
<eof> I None

<s> O None
KIEs I None
were I None
measured I None
on I None
the I None
arsenolysis I None
of I None
5 I CHEMICAL
' O CHEMICAL
- O CHEMICAL
methylthioadenosine O CHEMICAL
( I None
MTA I CHEMICAL
) I None
catalyzed I None
by I None
MTAP I GENE-Y
and I None
were I None
corrected I None
for I None
the I None
forward I None
commitment I None
to I None
catalysis I None
. I None
<eof> I None

<s> O None
Intrinsic I None
KIEs I None
were I None
obtained I None
for I None
[ I CHEMICAL
1 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
, O CHEMICAL
[ O CHEMICAL
1 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
( O CHEMICAL
14 O CHEMICAL
) O CHEMICAL
C O CHEMICAL
] O CHEMICAL
, O CHEMICAL
[ O CHEMICAL
2 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
, O CHEMICAL
[ O CHEMICAL
4 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
, O CHEMICAL
[ O CHEMICAL
5 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
] O CHEMICAL
, O CHEMICAL
[ O CHEMICAL
9 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
15 O CHEMICAL
) O CHEMICAL
N O CHEMICAL
] O CHEMICAL
, O CHEMICAL
and O CHEMICAL
[ O CHEMICAL
Me O CHEMICAL
- O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
] O CHEMICAL
MTAs O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
primary I None
intrinsic I None
KIEs I None
( I None
1 I CHEMICAL
' O CHEMICAL
- O CHEMICAL
( O CHEMICAL
14 O CHEMICAL
) O CHEMICAL
C O CHEMICAL
and I None
9 I CHEMICAL
- O CHEMICAL
( O CHEMICAL
15 O CHEMICAL
) O CHEMICAL
N O CHEMICAL
) I None
suggest I None
that I None
MTAP I GENE-Y
has I None
a I None
dissociative I None
S I None
( I None
N I None
) I None
1 I None
transition I None
state I None
with I None
its I None
cationic I None
center I None
at I None
the I None
anomeric I None
carbon I CHEMICAL
and I None
insignificant I None
bond I None
order I None
to I None
the I None
leaving I None
group I None
. I None
<eof> I None

<s> O None
The I None
9 I CHEMICAL
- O CHEMICAL
( O CHEMICAL
15 O CHEMICAL
) O CHEMICAL
N O CHEMICAL
intrinsic I None
KIE I None
of I None
1 I None
. I None
039 I None
also I None
establishes I None
an I None
anionic I None
character I None
for I None
the I None
adenine I CHEMICAL
leaving I None
group I None
, I None
whereas I None
the I None
alpha I None
- I None
primary I None
1 I CHEMICAL
' O CHEMICAL
- O CHEMICAL
( O CHEMICAL
14 O CHEMICAL
) O CHEMICAL
C O CHEMICAL
KIE I None
of I None
1 I None
. I None
031 I None
indicates I None
significant I None
nucleophilic I None
participation I None
at I None
the I None
transition I None
state I None
. I None
<eof> I None

<s> O None
Computational I None
matching I None
of I None
the I None
calculated I None
EIEs I None
to I None
the I None
intrinsic I None
isotope I None
effects I None
places I None
the I None
oxygen I CHEMICAL
nucleophile I None
2 I None
. I None
0 I None
Angstrom I None
from I None
the I None
anomeric I None
carbon I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
4 I CHEMICAL
' O CHEMICAL
- O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
KIE I None
is I None
sensitive I None
to I None
the I None
polarization I None
of I None
the I None
3 I CHEMICAL
' O CHEMICAL
- O CHEMICAL
OH O CHEMICAL
group I None
. I None
<eof> I None

<s> O None
Calculations I None
suggest I None
that I None
a I None
4 I CHEMICAL
' O CHEMICAL
- O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
KIE I None
of I None
1 I None
. I None
047 I None
is I None
consistent I None
with I None
ionization I None
of I None
the I None
3 I CHEMICAL
' O CHEMICAL
- O CHEMICAL
OH O CHEMICAL
group I None
, I None
indicating I None
formation I None
of I None
a I None
zwitterion I None
at I None
the I None
transition I None
state I None
. I None
<eof> I None

<s> O None
The I None
transition I None
state I None
has I None
cationic I None
character I None
at I None
the I None
anomeric I None
carbon I CHEMICAL
and I None
is I None
anionic I None
at I None
the I None
3 I CHEMICAL
' O CHEMICAL
- O CHEMICAL
OH O CHEMICAL
oxygen I CHEMICAL
, I None
with I None
an I None
anionic I None
leaving I None
group I None
. I None
<eof> I None

<s> O None
The I None
isotope I None
effects I None
predicted I None
a I None
3 I None
' I None
- I None
endo I None
conformation I None
for I None
the I None
ribosyl I CHEMICAL
zwitterion O CHEMICAL
, I None
corresponding I None
to I None
a I None
H1 I CHEMICAL
' O CHEMICAL
- O CHEMICAL
C1 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
C2 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
H2 O CHEMICAL
' O CHEMICAL
torsional I None
angle I None
of I None
33 I None
degrees I None
. I None
<eof> I None

<s> O None
The I None
[ I None
Me I CHEMICAL
- O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
] I None
and I None
[ I None
5 I CHEMICAL
' O CHEMICAL
- O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
] I None
KIEs I None
arise I None
predominantly I None
from I None
the I None
negative I None
hyperconjugation I None
of I None
the I None
lone I None
pairs I None
of I None
sulfur I CHEMICAL
with I None
the I None
sigma I None
( I None
C I CHEMICAL
- O CHEMICAL
H O CHEMICAL
) I None
antibonding I None
orbitals I None
. I None
<eof> I None

<s> O None
Human I GENE-Y
MTAP O GENE-Y
is I None
characterized I None
by I None
a I None
late I None
S I None
( I None
N I None
) I None
1 I None
transition I None
state I None
with I None
significant I None
participation I None
of I None
the I None
phosphate I CHEMICAL
nucleophile I None
. I None
<eof> I None

<s> O None
Sequestration I None
of I None
retinyl I CHEMICAL
esters O CHEMICAL
is I None
essential I None
for I None
retinoid I None
signaling I None
in I None
the I None
zebrafish I None
embryo I None
. I None
<eof> I None

<s> O None
For I None
vertebrate I None
development I None
, I None
vitamin I CHEMICAL
A O CHEMICAL
( I None
all I CHEMICAL
- O CHEMICAL
trans O CHEMICAL
retinol O CHEMICAL
) I None
is I None
required I None
in I None
quantitative I None
different I None
amounts I None
and I None
spatiotemporal I None
distribution I None
for I None
the I None
production I None
of I None
retinoic I CHEMICAL
acid O CHEMICAL
, I None
a I None
nuclear I None
hormone I None
receptor I None
ligand I None
, I None
and I None
11 I CHEMICAL
- O CHEMICAL
cis O CHEMICAL
retinal O CHEMICAL
, I None
the I None
chromophore I None
of I None
visual I None
pigments I None
. I None
<eof> I None

<s> O None
We I None
show I None
here I None
for I None
zebrafish I None
that I None
embryonic I None
retinoid I None
homeostasis I None
essentially I None
depends I None
on I None
the I None
activity I None
of I None
a I None
leci I GENE-Y
- O GENE-Y
thin O GENE-Y
: O GENE-Y
retinol O GENE-Y
acyltransferase O GENE-Y
( I None
Lratb I GENE-Y
) I None
. I None
<eof> I None

<s> O None
During I None
embryogenesis I None
, I None
lratb I GENE-Y
is I None
expressed I None
in I None
mostly I None
non I None
- I None
overlapping I None
domains I None
opposite I None
to I None
retinal I GENE-Y
dehydrogenase O GENE-Y
2 O GENE-Y
( I None
raldh2 I GENE-Y
) I None
, I None
the I None
key I None
enzyme I None
for I None
retinoic I CHEMICAL
acid O CHEMICAL
synthesis I None
. I None
<eof> I None

<s> O None
Blocking I None
retinyl I CHEMICAL
ester O CHEMICAL
formation I None
by I None
a I None
targeted I None
knock I None
down I None
of I None
Lratb I GENE-Y
results I None
in I None
significantly I None
increased I None
retinoic I CHEMICAL
acid O CHEMICAL
levels I None
, I None
which I None
lead I None
to I None
severe I None
embryonic I None
patterning I None
defects I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
we I None
provide I None
evidence I None
that I None
a I None
balanced I None
competition I None
between I None
Lratb I GENE-Y
and I None
Raldh2 I GENE-Y
for I None
yolk I None
vitamin I CHEMICAL
A O CHEMICAL
defines I None
embryonic I None
compartments I None
either I None
for I None
retinyl I CHEMICAL
ester O CHEMICAL
or I None
retinoic I CHEMICAL
acid O CHEMICAL
synthesis I None
. I None
<eof> I None

<s> O None
This I None
homeostatic I None
mechanism I None
dynamically I None
adjusts I None
embryonic I None
retinoic I CHEMICAL
acid O CHEMICAL
levels I None
for I None
gene I None
regulation I None
, I None
concomitantly I None
sequestering I None
excess I None
yolk I None
vitamin I CHEMICAL
A O CHEMICAL
in I None
the I None
form I None
of I None
retinyl I None
esters I None
for I None
the I None
establishment I None
of I None
larval I None
vision I None
later I None
during I None
development I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
Ehlers I None
Danlos I None
syndrome I None
type I None
VI I None
. I None
<eof> I None

<s> O None
Ehlers I None
Danlos I None
type I None
VI I None
is I None
a I None
rare I None
autosomal I None
recessive I None
connective I None
tissue I None
disease I None
involving I None
primarily I None
the I None
skin I None
and I None
joints I None
. I None
<eof> I None

<s> O None
The I None
main I None
feature I None
of I None
the I None
condition I None
is I None
neonatal I None
hypotonia I None
and I None
rare I None
complications I None
are I None
ruptures I None
of I None
arteries I None
and I None
the I None
eye I None
globe I None
. I None
<eof> I None

<s> O None
A I None
4 I None
year I None
old I None
girl I None
with I None
a I None
typical I None
clinical I None
presentation I None
and I None
molecular I None
diagnosis I None
of I None
EDS I None
VI I None
is I None
presented I None
. I None
<eof> I None

<s> O None
Sequencing I None
of I None
PLOD1 I GENE-Y
gene I None
revealed I None
a I None
homozygous I None
deletion I None
in I None
exon I None
13 I None
( I None
c I None
. I None
1362delC I None
) I None
, I None
leading I None
to I None
a I None
frameshift I None
and I None
truncation I None
of I None
the I None
lysyl I GENE-N
hydroxylase O GENE-N
, I None
an I None
enzyme I None
necessary I None
for I None
collagen I GENE-N
biosynthesis I None
. I None
<eof> I None

<s> O None
Early I None
diagnosis I None
allowed I None
treatment I None
with I None
high I None
doses I None
of I None
ascorbic I CHEMICAL
acid O CHEMICAL
in I None
order I None
to I None
prevent I None
complications I None
, I None
genetic I None
counseling I None
of I None
the I None
family I None
and I None
prenatal I None
diagnosis I None
of I None
an I None
unaffected I None
embryo I None
. I None
<eof> I None

<s> O None
Molecular I None
modeling I None
of I None
purinergic I GENE-N
receptor O GENE-N
P2Y12 I GENE-Y
and I None
interaction I None
with I None
its I None
antagonists I None
. I None
<eof> I None

<s> O None
Purinergic I GENE-N
receptors O GENE-N
are I None
a I None
class I None
of I None
cell I None
surface I None
receptors I None
for I None
purines I CHEMICAL
that I None
prefer I None
ATP I CHEMICAL
or I None
ADP I CHEMICAL
over I None
adenosine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
surface I None
receptors I None
for I None
extracellular I None
nucleotides I CHEMICAL
are I None
called I None
P2 I GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
They I None
are I None
activated I None
by I None
both I None
pyrimidine I CHEMICAL
and O CHEMICAL
purine O CHEMICAL
nucleotides O CHEMICAL
. I None
<eof> I None

<s> O None
ADP I CHEMICAL
initiates I None
platelet I None
aggregation I None
by I None
' I None
simultaneous I None
activation I None
of I None
two I None
G I GENE-N
protein O GENE-N
- O GENE-N
coupled O GENE-N
receptors O GENE-N
, I None
P2Y1 I GENE-Y
and I None
P2Y12 I GENE-Y
. I None
<eof> I None

<s> O None
P2Y12 I GENE-Y
has I None
been I None
shown I None
to I None
be I None
the I None
target I None
of I None
the I None
thienopyridine I CHEMICAL
drugs I None
, I None
ticlopidine I CHEMICAL
and I None
clopidogrel I CHEMICAL
. I None
<eof> I None

<s> O None
Here I None
, I None
the I None
active I None
sites I None
of I None
P2Y12 I GENE-Y
for I None
ATP I CHEMICAL
as I None
well I None
as I None
ADP I CHEMICAL
are I None
predicted I None
by I None
bioinformatics I None
and I None
molecular I None
modeling I None
. I None
<eof> I None

<s> O None
First I None
, I None
the I None
three I None
- I None
dimensional I None
( I None
3D I None
) I None
structure I None
of I None
P2Y12 I GENE-Y
was I None
constructed I None
by I None
InsightII I None
/ I None
Homology I None
module I None
using I None
the I None
corresponding I None
bovine I GENE-Y
rhodopsin O GENE-Y
( I None
PDB I GENE-Y
code O GENE-Y
: O GENE-Y
1HZX O GENE-Y
) I None
as I None
the I None
template I None
. I None
<eof> I None

<s> O None
Then I None
the I None
primary I None
structures I None
were I None
optimized I None
by I None
energy I None
minimization I None
that I None
has I None
been I None
successfully I None
accepted I None
by I None
the I None
Protein I None
Data I None
Bank I None
( I None
PDB I GENE-Y
code O GENE-Y
: O GENE-Y
1VZ1 O GENE-Y
) I None
. I None
<eof> I None

<s> O None
Second I None
, I None
a I None
simple I None
scoring I None
matrix I None
was I None
built I None
up I None
based I None
on I None
the I None
analysis I None
of I None
13 I None
known I None
ATP I CHEMICAL
- I None
binding I None
proteins I None
. I None
<eof> I None

<s> O None
And I None
the I None
most I None
probable I None
active I None
sites I None
of I None
P2Y12 I GENE-Y
were I None
predicted I None
using I None
the I None
scoring I None
matrix I None
, I None
which I None
include I None
three I None
distant I None
areas I None
: I None
" I None
head I None
area I None
" I None
( I None
LGTGPLRTFV I CHEMICAL
, I None
87 I None
- I None
96 I None
) I None
, I None
" I None
middle I None
area I None
" I None
( I None
VGLITNGLAM I CHEMICAL
, I None
38 I None
- I None
47 I None
, I None
and I None
LGAKILSVVI I CHEMICAL
, I None
139 I None
- I None
148 I None
) I None
, I None
and I None
" I None
bottom I None
area I None
" I None
( I None
RTRGVGKVPR I CHEMICAL
, I None
222 I None
- I None
231 I None
) I None
. I None
<eof> I None

<s> O None
Subsequently I None
the I None
structural I None
model I None
of I None
P2Y12 I GENE-Y
was I None
docked I None
with I None
ATP I CHEMICAL
/ I None
ADP I CHEMICAL
in I None
comparison I None
with I None
P2Y1 I GENE-Y
( I None
PDB I GENE-Y
code O GENE-Y
1ddd O GENE-Y
) I None
. I None
<eof> I None

<s> O None
As I None
a I None
comparison I None
, I None
we I None
docked I None
its I None
antagonists I None
, I None
such I None
as I None
ticlopidine I CHEMICAL
and I None
clopidogrel I CHEMICAL
, I None
to I None
the I None
most I None
probable I None
sites I None
and I None
calculated I None
their I None
intermolecular I None
energy I None
. I None
<eof> I None

<s> O None
Our I None
results I None
imply I None
that I None
P2Y12 I GENE-Y
has I None
the I None
potential I None
to I None
be I None
inhibited I None
by I None
ADP I CHEMICAL
/ I None
ATP I CHEMICAL
analogs I None
, I None
and I None
it I None
suggests I None
that I None
P2Y12 I GENE-Y
acts I None
as I None
a I None
target I None
of I None
new I None
drugs I None
that I None
inhibit I None
platelet I None
aggregation I None
. I None
<eof> I None

<s> O None
Cadmium I CHEMICAL
induces I None
mitogenic I None
signaling I None
in I None
breast I None
cancer I None
cell I None
by I None
an I None
ERalpha I GENE-Y
- I None
dependent I None
mechanism I None
. I None
<eof> I None

<s> O None
Breast I None
cancer I None
( I None
BC I None
) I None
is I None
linked I None
to I None
estrogen I None
exposure I None
. I None
<eof> I None

<s> O None
Estradiol I CHEMICAL
( I None
E2 I CHEMICAL
) I None
stimulates I None
BC I None
cells I None
proliferation I None
by I None
binding I None
the I None
estrogen I GENE-Y
receptor O GENE-Y
( I None
ER I GENE-Y
) I None
. I None
<eof> I None

<s> O None
Hormone I None
- I None
related I None
cancers I None
have I None
been I None
linked I None
to I None
estrogenic I None
environmental I None
contaminants I None
. I None
<eof> I None

<s> O None
Cadmium I CHEMICAL
( I None
Cd I CHEMICAL
) I None
a I None
toxic I None
pollutant I None
, I None
acts I None
as I None
estrogens I None
in I None
BC I None
cells I None
. I None
<eof> I None

<s> O None
Purpose I None
of I None
our I None
study I None
was I None
to I None
evaluate I None
whether I None
Cd I CHEMICAL
regulates I None
MCF I None
- I None
7 I None
cell I None
proliferation I None
by I None
activating I None
ERK1 I GENE-N
/ O GENE-N
2 O GENE-N
, I None
Akt I GENE-N
and I None
PDGFRalpha I GENE-Y
kinases I GENE-N
. I None
<eof> I None

<s> O None
Cd I CHEMICAL
increased I None
cell I None
proliferation I None
and I None
the I None
ER I GENE-Y
- I None
antagonist I None
ICI I None
182 I None
, I None
780 I None
blunted I None
it I None
. I None
<eof> I None

<s> O None
To I None
characterize I None
an I None
ER I GENE-Y
- I None
dependent I None
mechanism I None
, I None
ERalpha I GENE-N
/ O GENE-N
beta O GENE-N
expression I None
was I None
evaluated I None
. I None
<eof> I None

<s> O None
Cd I CHEMICAL
decreased I None
ERalpha I GENE-Y
expression I None
, I None
but I None
not I None
ERbeta I GENE-Y
. I None
<eof> I None

<s> O None
Cd I CHEMICAL
also I None
increased I None
ERK1 I GENE-N
/ O GENE-N
2 O GENE-N
, I None
Akt I GENE-N
and I None
PDGFRalpha I GENE-Y
phosphorylation I None
while I None
ICI I None
blocked I None
it I None
. I None
<eof> I None

<s> O None
Since I None
stimulation I None
of I None
phosphorylation I None
was I None
slower I None
than I None
expected I None
, I None
c I GENE-Y
- O GENE-Y
fos O GENE-Y
and I None
c I GENE-Y
- O GENE-Y
jun O GENE-Y
proto I None
- I None
oncogenes I None
, I None
and I None
PDGFA I GENE-Y
were I None
analyzed I None
. I None
<eof> I None

<s> O None
Cd I CHEMICAL
rapidly I None
increased I None
c I GENE-N
- O GENE-N
jun O GENE-N
, I None
c I GENE-N
- O GENE-N
fos O GENE-N
and I None
PDGFA I GENE-Y
expression I None
. I None
<eof> I None

<s> O None
Cells I None
were I None
also I None
co I None
- I None
incubated I None
with I None
the I None
Cd I CHEMICAL
and I None
specific I None
kinases I GENE-N
inhibitors I None
, I None
which I None
blocked I None
the I None
Cd I CHEMICAL
- I None
stimulated I None
proliferation I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
our I None
results I None
indicate I None
that I None
Cd I CHEMICAL
increases I None
BC I None
cell I None
proliferation I None
in I None
vitro I None
by I None
stimulating I None
Akt I GENE-N
, I None
ERK1 I GENE-N
/ O GENE-N
2 O GENE-N
and I None
PDGFRalpha I GENE-Y
kinases I GENE-N
activity I None
likely I None
by I None
activating I None
c I GENE-Y
- O GENE-Y
fos O GENE-Y
, I None
c I GENE-Y
- O GENE-Y
jun O GENE-Y
and I None
PDGFA I GENE-Y
by I None
an I None
ERalpha I GENE-Y
- I None
dependent I None
mechanism I None
. I None
<eof> I None

<s> O None
Gonadotropin I CHEMICAL
- O CHEMICAL
releasing O CHEMICAL
hormone O CHEMICAL
functionally I None
antagonizes I None
testosterone I CHEMICAL
activation I None
of I None
the I None
human I GENE-Y
androgen O GENE-Y
receptor O GENE-Y
in I None
prostate I None
cells I None
through I None
focal I None
adhesion I None
complexes I None
involving I None
Hic I GENE-Y
- O GENE-Y
5 O GENE-Y
. I None
<eof> I None

<s> O None
Gonadotropin I CHEMICAL
- O CHEMICAL
releasing O CHEMICAL
hormone O CHEMICAL
( I None
GnRH I CHEMICAL
) I None
analogs I None
constitute I None
the I None
most I None
widely I None
employed I None
medical I None
treatment I None
for I None
prostatic I None
cancer I None
. I None
<eof> I None

<s> O None
The I None
predominant I None
mechanism I None
of I None
action I None
is I None
presumed I None
to I None
be I None
via I None
the I None
inhibition I None
of I None
gonadotropins I None
and I None
resultant I None
decrease I None
in I None
androgen I None
. I None
<eof> I None

<s> O None
However I None
, I None
GnRH I CHEMICAL
analogs I None
have I None
also I None
been I None
shown I None
to I None
directly I None
inhibit I None
prostate I None
cancer I None
cells I None
both I None
in I None
vitro I None
and I None
in I None
vivo I None
through I None
antiproliferative I None
cell I None
cycle I None
arrest I None
and I None
stimulation I None
of I None
apoptosis I None
. I None
<eof> I None

<s> O None
Since I None
the I None
GnRH I GENE-Y
receptor O GENE-Y
has I None
been I None
shown I None
to I None
affect I None
sex I GENE-N
steroid O GENE-N
hormone O GENE-N
receptor O GENE-N
function I None
, I None
we I None
considered I None
that I None
part I None
of I None
GnRH I CHEMICAL
analog I None
actions I None
on I None
prostate I None
cells I None
may I None
be I None
mediated I None
through I None
modulation I None
of I None
the I None
human I GENE-Y
androgen O GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
Using I None
a I None
model I None
HEK293 I None
cell I None
line I None
expressing I None
the I None
GnRH I GENE-Y
receptor O GENE-Y
, I None
we I None
demonstrated I None
a I None
novel I None
signalling I None
pathway I None
of I None
the I None
GnRH I GENE-Y
receptor O GENE-Y
that I None
induces I None
nuclear I None
translocation I None
of I None
the I None
androgen I GENE-Y
receptor O GENE-Y
that I None
renders I None
it I None
transcriptionally I None
inactive I None
. I None
<eof> I None

<s> O None
This I None
mechanism I None
involves I None
the I None
calcium I CHEMICAL
- I None
dependent I None
tyrosine I GENE-N
kinase O GENE-N
Pyk2 I GENE-Y
, I None
the I None
non I GENE-N
- O GENE-N
receptor O GENE-N
tyrosine O GENE-N
kinase O GENE-N
c I GENE-Y
- O GENE-Y
Src O GENE-Y
and I None
the I None
focal I GENE-N
adhesion O GENE-N
protein O GENE-N
/ I None
steroid I GENE-N
receptor O GENE-N
co O GENE-N
- O GENE-N
factor O GENE-N
, I None
Hic I GENE-Y
- O GENE-Y
5 O GENE-Y
. I None
<eof> I None

<s> O None
In I None
this I None
setting I None
there I None
is I None
a I None
GnRH I CHEMICAL
- I None
induced I None
association I None
and I None
nuclear I None
translocation I None
of I None
the I None
androgen I GENE-Y
receptor O GENE-Y
with I None
Hic I GENE-Y
- O GENE-Y
5 O GENE-Y
. I None
<eof> I None

<s> O None
GnRH I CHEMICAL
- I None
induced I None
Pyk2 I GENE-Y
activation I None
opposed I None
the I None
association I None
of I None
Hic I GENE-Y
- O GENE-Y
5 O GENE-Y
with I None
androgen I GENE-Y
receptor O GENE-Y
as I None
overexpression I None
of I None
a I None
dominant I None
negative I None
Pyk2 I GENE-Y
enhanced I None
the I None
GnRH I CHEMICAL
- I None
induced I None
nuclear I None
translocation I None
of I None
a I None
green I None
fluorescent I None
protein I None
- I None
tagged I None
human I GENE-Y
androgen O GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
GnRH I CHEMICAL
- I None
induced I None
c I GENE-Y
- O GENE-Y
Src O GENE-Y
activation I None
resulted I None
in I None
the I None
phosphorylation I None
of I None
expressed I None
Hic I GENE-Y
- O GENE-Y
5 O GENE-Y
and I None
promoted I None
its I None
association I None
with I None
the I None
human I GENE-Y
androgen O GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
In I None
contrast I None
to I None
testosterone I CHEMICAL
, I None
GnRH I CHEMICAL
- I None
induced I None
nuclear I None
translocation I None
did I None
not I None
transcriptionally I None
activate I None
the I None
androgen I GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
We I None
then I None
demonstrated I None
that I None
GnRH I CHEMICAL
can I None
also I None
stimulate I None
androgen I GENE-Y
receptor O GENE-Y
mobilization I None
in I None
human I None
prostate I None
PC3 I None
, I None
BPH I None
- I None
1 I None
and I None
LNCaP I None
cells I None
, I None
and I None
in I None
cultured I None
rat I None
ventral I None
prostate I None
cells I None
through I None
the I None
same I None
mechanism I None
. I None
<eof> I None

<s> O None
To I None
determine I None
if I None
GnRH I CHEMICAL
could I None
antagonize I None
androgen I None
effects I None
in I None
normal I None
tissue I None
, I None
we I None
examined I None
the I None
effect I None
of I None
GnRH I CHEMICAL
on I None
rat I None
ventral I None
prostate I None
organ I None
cultures I None
and I None
demonstrated I None
that I None
GnRH I CHEMICAL
can I None
functionally I None
antagonize I None
the I None
actions I None
of I None
testosterone I CHEMICAL
on I None
prostate I None
cell I None
proliferation I None
and I None
tissue I None
growth I None
. I None
<eof> I None

<s> O None
This I None
antagonism I None
of I None
testosterone I CHEMICAL
action I None
by I None
GnRH I CHEMICAL
may I None
underlie I None
in I None
part I None
the I None
capacity I None
of I None
GnRH I GENE-Y
receptor O GENE-Y
activation I None
to I None
inhibit I None
prostate I None
tumor I None
growth I None
. I None
<eof> I None

<s> O None
Trace I GENE-Y
amine O GENE-Y
- O GENE-Y
associated O GENE-Y
receptor O GENE-Y
1 O GENE-Y
displays I None
species I None
- I None
dependent I None
stereoselectivity I None
for I None
isomers I None
of I None
methamphetamine I CHEMICAL
, I None
amphetamine I CHEMICAL
, I None
and I None
para I CHEMICAL
- O CHEMICAL
hydroxyamphetamine O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
synthetic I None
amines I CHEMICAL
methamphetamine I CHEMICAL
( I None
METH I CHEMICAL
) I None
, I None
amphetamine I CHEMICAL
( I None
AMPH I CHEMICAL
) I None
, I None
and I None
their I None
metabolite I None
para I CHEMICAL
- O CHEMICAL
hydroxyamphetamine O CHEMICAL
( I None
POHA I CHEMICAL
) I None
are I None
chemically I None
and I None
structurally I None
related I None
to I None
the I None
catecholamine I CHEMICAL
neurotransmitters I None
and I None
a I None
small I None
group I None
of I None
endogenous I None
biogenic I None
amines I CHEMICAL
collectively I None
referred I None
to I None
as I None
the I None
trace I None
amines I CHEMICAL
( I None
TAs I None
) I None
. I None
<eof> I None

<s> O None
Recently I None
, I None
it I None
was I None
reported I None
that I None
METH I CHEMICAL
, I None
AMPH I CHEMICAL
, I None
POHA I CHEMICAL
, I None
and I None
the I None
TAs I None
para I CHEMICAL
- O CHEMICAL
tyramine O CHEMICAL
( I None
TYR I CHEMICAL
) I None
and I None
beta I CHEMICAL
- O CHEMICAL
phenylethylamine O CHEMICAL
( I None
PEA I CHEMICAL
) I None
stimulate I None
cAMP I CHEMICAL
production I None
in I None
human I None
embryonic I None
kidney I None
( I None
HEK I None
) I None
- I None
293 I None
cells I None
expressing I None
rat I GENE-Y
trace O GENE-Y
amine O GENE-Y
- O GENE-Y
associated O GENE-Y
receptor O GENE-Y
1 O GENE-Y
( I None
rTAAR1 I GENE-Y
) I None
. I None
<eof> I None

<s> O None
The I None
discovery I None
that I None
METH I CHEMICAL
and I None
AMPH I CHEMICAL
activate I None
the I None
rTAAR1 I GENE-Y
motivated I None
us I None
to I None
study I None
the I None
effect I None
of I None
these I None
drugs I None
on I None
the I None
mouse I GENE-Y
TAAR1 O GENE-Y
( I None
mTAAR1 I GENE-Y
) I None
and I None
a I None
human I None
- I None
rat I None
chimera I None
( I None
hrChTAAR1 I GENE-Y
) I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
because I None
S I None
- I None
( I None
+ I None
) I None
- I None
isomers I None
of I None
METH I CHEMICAL
and I None
AMPH I CHEMICAL
are I None
reported I None
to I None
be I None
more I None
potent I None
and I None
efficacious I None
in I None
vivo I None
than I None
R I None
- I None
( I None
- I None
) I None
, I None
we I None
determined I None
the I None
enantiomeric I None
selectivity I None
of I None
all I None
three I None
species I None
of I None
TAAR1 I GENE-Y
. I None
<eof> I None

<s> O None
In I None
response I None
to I None
METH I CHEMICAL
, I None
AMPH I CHEMICAL
, I None
or I None
POHA I CHEMICAL
exposure I None
, I None
the I None
accumulation I None
of I None
cAMP I CHEMICAL
by I None
HEK I None
- I None
293 I None
cells I None
stably I None
expressing I None
different I None
species I None
of I None
TAAR1 I GENE-Y
was I None
concentration I None
- I None
and I None
isomer I None
- I None
dependent I None
. I None
<eof> I None

<s> O None
EC50 I None
values I None
for I None
S I CHEMICAL
- O CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
- O CHEMICAL
METH O CHEMICAL
were I None
0 I None
. I None
89 I None
, I None
0 I None
. I None
92 I None
, I None
and I None
4 I None
. I None
44 I None
microM I None
for I None
rTAAR1 I GENE-Y
, I None
mTAAR1 I GENE-Y
, I None
and I None
h I GENE-Y
- O GENE-Y
rChTAAR1 O GENE-Y
, I None
respectively I None
. I None
<eof> I None

<s> O None
PEA I CHEMICAL
was I None
a I None
potent I None
and I None
full I None
agonist I None
at I None
each I None
species I None
of I None
TAAR1 I GENE-Y
, I None
whereas I None
TYR I CHEMICAL
was I None
a I None
full I None
agonist I None
for I None
the I None
rodent I GENE-Y
TAAR1s O GENE-Y
but I None
was I None
a I None
partial I None
agonist I None
at I None
h I GENE-Y
- O GENE-Y
rChTAAR1 O GENE-Y
. I None
<eof> I None

<s> O None
Interestingly I None
, I None
both I None
isomers I None
of I None
METH I CHEMICAL
were I None
full I None
agonists I None
at I None
mTAAR1 I GENE-Y
and I None
h I GENE-Y
- O GENE-Y
rChTAAR1 O GENE-Y
, I None
whereas I None
both I None
were I None
partial I None
agonists I None
at I None
rTAAR1 I GENE-Y
. I None
<eof> I None

<s> O None
Taken I None
together I None
, I None
these I None
in I None
vitro I None
results I None
suggest I None
that I None
, I None
in I None
vivo I None
, I None
TAAR1 I GENE-Y
could I None
be I None
a I None
novel I None
mediator I None
of I None
the I None
effects I None
of I None
these I None
drugs I None
. I None
<eof> I None

<s> O None
Regulation I None
of I None
pancreatic I None
endocrine I None
cell I None
differentiation I None
by I None
sulphated I None
proteoglycans I None
. I None
<eof> I None

<s> O None
AIMS I None
/ I None
HYPOTHESIS I None
: I None
Epithelium I None
- I None
mesenchyme I None
interactions I None
play I None
a I None
major I None
role I None
in I None
pancreas I None
development I None
. I None
<eof> I None

<s> O None
Recently I None
, I None
we I None
demonstrated I None
that I None
embryonic I None
pancreatic I None
mesenchyme I None
enhanced I None
progenitor I None
cell I None
proliferation I None
but I None
inhibited I None
endocrine I None
cell I None
differentiation I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
investigated I None
the I None
role I None
played I None
by I None
sulphated I None
proteoglycans I None
, I None
which I None
are I None
known I None
to I None
be I None
essential I None
to I None
embryonic I None
development I None
, I None
in I None
this I None
inhibitory I None
effect I None
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
: I None
We I None
first I None
determined I None
the I None
expression I None
of I None
the I None
genes I None
encoding I None
glypicans I GENE-N
, I None
syndecans I GENE-N
and I None
the I None
main I None
glycosaminoglycan I None
chain I None
- I None
modifying I None
enzymes I None
in I None
immature I None
embryonic I None
day I None
( I None
E I None
) I None
13 I None
. I None
5 I None
and I None
more I None
differentiated I None
E17 I None
. I None
5 I None
rat I None
pancreases I None
. I None
<eof> I None

<s> O None
Next I None
, I None
using I None
an I None
in I None
vitro I None
model I None
of I None
pancreas I None
development I None
, I None
we I None
blocked I None
the I None
action I None
of I None
endogenous I None
sulphated I None
proteoglycans I None
by I None
treating I None
embryonic I None
pancreases I None
in I None
culture I None
with I None
chlorate I CHEMICAL
, I None
an I None
inhibitor I None
of I None
proteoglycan I None
sulphation I None
, I None
and I None
examined I None
the I None
effects I None
on I None
pancreatic I None
endocrine I None
cell I None
differentiation I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
We I None
first I None
showed I None
that I None
expression I None
of I None
the I None
genes I None
encoding I None
glypicans I GENE-N
1 O GENE-N
, O GENE-N
2 O GENE-N
, O GENE-N
3 O GENE-N
and O GENE-N
5 O GENE-N
and I None
heparan I GENE-Y
sulphate O GENE-Y
2 O GENE-Y
- O GENE-Y
sulfotransferase O GENE-Y
decreased I None
between I None
E13 I None
. I None
5 I None
and I None
E17 I None
. I None
5 I None
. I None
<eof> I None

<s> O None
We I None
next I None
found I None
that I None
alteration I None
of I None
proteoglycan I None
action I None
by I None
chlorate I CHEMICAL
blocked I None
the I None
inhibitory I None
effect I None
of I None
the I None
mesenchyme I None
on I None
endocrine I None
differentiation I None
. I None
<eof> I None

<s> O None
Chlorate I CHEMICAL
- I None
treated I None
pancreases I None
exhibited I None
a I None
dramatic I None
increase I None
in I None
beta I None
cell I None
number I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
( I None
169 I None
- I None
and I None
375 I None
- I None
fold I None
increase I None
with I None
30 I None
mmol I None
/ I None
l I None
and I None
40 I None
mmol I None
/ I None
l I None
chlorate I CHEMICAL
, I None
respectively I None
) I None
and I None
in I None
alpha I None
cell I None
development I None
. I None
<eof> I None

<s> O None
Insulin I GENE-N
- I None
positive I None
cells I None
that I None
developed I None
in I None
the I None
presence I None
of I None
chlorate I CHEMICAL
exhibited I None
a I None
phenotype I None
of I None
mature I None
cells I None
with I None
regard I None
to I None
the I None
expression I None
of I None
the I None
following I None
genes I None
: I None
pancreatic I GENE-Y
and O GENE-Y
duodenal O GENE-Y
homeobox O GENE-Y
gene O GENE-Y
1 O GENE-Y
( I None
Pdx1 I GENE-Y
) I None
, I None
proprotein I GENE-Y
convertase O GENE-Y
subtilisin O GENE-Y
/ O GENE-Y
kexin O GENE-Y
type O GENE-Y
1 O GENE-Y
( I None
Pcsk1 I GENE-Y
; I None
previously I None
known I None
as I None
pro I GENE-Y
- O GENE-Y
hormone O GENE-Y
convertase O GENE-Y
1 O GENE-Y
/ O GENE-Y
3 O GENE-Y
) I None
, I None
proprotein I GENE-Y
convertase O GENE-Y
subtilisin O GENE-Y
/ O GENE-Y
kexin O GENE-Y
type O GENE-Y
2 O GENE-Y
( I None
Pcsk2 I GENE-Y
; I None
previously I None
known I None
as I None
pro I GENE-Y
- O GENE-Y
hormone O GENE-Y
convertase O GENE-Y
2 O GENE-Y
) I None
and I None
solute I GENE-Y
carrier O GENE-Y
family O GENE-Y
2 O GENE-Y
( O GENE-Y
facilitated O GENE-Y
glucose O GENE-Y
transporter O GENE-Y
) O GENE-Y
, O GENE-Y
member O GENE-Y
2 O GENE-Y
( I None
Slc2a1 I GENE-Y
; I None
previously I None
known I None
as I None
glucose I GENE-Y
transporter O GENE-Y
2 O GENE-Y
) I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
we I None
showed I None
that I None
chlorate I CHEMICAL
activated I None
endocrine I None
cell I None
development I None
by I None
inducing I None
neurogenin I GENE-Y
3 O GENE-Y
( I None
Neurog3 I GENE-Y
) I None
expression I None
in I None
early I None
endocrine I None
progenitor I None
cells I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
/ I None
INTERPRETATION I None
: I None
We I None
demonstrated I None
that I None
sulphated I None
proteoglycans I None
control I None
pancreatic I None
endocrine I None
cell I None
differentiation I None
. I None
<eof> I None

<s> O None
Understanding I None
the I None
mechanism I None
by I None
which I None
sulphated I None
proteoglycans I None
affect I None
beta I None
cell I None
development I None
could I None
be I None
useful I None
in I None
the I None
generation I None
of I None
beta I None
cells I None
from I None
embryonic I None
stem I None
cells I None
. I None
<eof> I None

<s> O None
Carbonic I GENE-N
anhydrase O GENE-N
inhibitors I None
. I None
<eof> I None

<s> O None
DNA I None
cloning I None
, I None
characterization I None
, I None
and I None
inhibition I None
studies I None
of I None
the I None
human I GENE-Y
secretory O GENE-Y
isoform O GENE-Y
VI O GENE-Y
, I None
a I None
new I None
target I None
for I None
sulfonamide I CHEMICAL
and I None
sulfamate I CHEMICAL
inhibitors I None
. I None
<eof> I None

<s> O None
The I None
secretory I None
isozyme I None
of I None
human I GENE-N
carbonic O GENE-N
anhydrase O GENE-N
( I None
hCA I GENE-N
, I None
EC I GENE-N
4 O GENE-N
. O GENE-N
2 O GENE-N
. O GENE-N
1 O GENE-N
. O GENE-N
1 O GENE-N
) I None
, I None
hCA I GENE-Y
VI O GENE-Y
, I None
has I None
been I None
cloned I None
, I None
expressed I None
, I None
and I None
purified I None
in I None
a I None
bacterial I None
expression I None
system I None
. I None
<eof> I None

<s> O None
The I None
kinetic I None
parameters I None
for I None
the I None
CO2 I CHEMICAL
hydration I None
reaction I None
proved I None
hCA I GENE-Y
VI O GENE-Y
to I None
possess I None
a I None
kcat I None
of I None
3 I None
. I None
4 I None
x I None
10 I None
( I None
5 I None
) I None
s I None
- I None
1 I None
and I None
kcat I None
/ I None
KM I None
of I None
4 I None
. I None
9 I None
x I None
10 I None
( I None
7 I None
) I None
M I None
- I None
1 I None
s I None
- I None
1 I None
( I None
at I None
pH I None
7 I None
. I None
5 I None
and I None
20 I None
degrees I None
C I None
) I None
. I None
<eof> I None

<s> O None
hCA I GENE-Y
VI O GENE-Y
has I None
a I None
significant I None
catalytic I None
activity I None
for I None
the I None
physiological I None
reaction I None
on I None
the I None
same I None
order I None
of I None
magnitude I None
as I None
the I None
ubiquitous I None
isoform I None
CA I GENE-N
I O GENE-N
or I None
the I None
transmembrane I None
, I None
tumor I None
- I None
associated I None
isozyme I None
CA I GENE-N
IX O GENE-N
. I None
<eof> I None

<s> O None
A I None
series I None
of I None
sulfonamides I CHEMICAL
and I None
one I None
sulfamate I CHEMICAL
have I None
been I None
tested I None
for I None
their I None
interaction I None
with I None
this I None
isozyme I None
. I None
<eof> I None

<s> O None
Simple I None
benzenesulfonamides I CHEMICAL
were I None
rather I None
ineffective I None
hCA I GENE-Y
VI O GENE-Y
inhibitors I None
, I None
with I None
inhibition I None
constants I None
in I None
the I None
range I None
of I None
1090 I None
- I None
6680 I None
nM I None
. I None
<eof> I None

<s> O None
Better I None
inhibitors I None
were I None
detected I None
among I None
such I None
derivatives I None
bearing I None
2 I CHEMICAL
- O CHEMICAL
or O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
amino O CHEMICAL
- I None
, I None
4 I CHEMICAL
- O CHEMICAL
aminomethyl O CHEMICAL
- I None
, I None
or I None
4 I CHEMICAL
- O CHEMICAL
hydroxymethyl O CHEMICAL
moieties I None
or I None
among I None
halogenated I None
sulfanilamides I CHEMICAL
( I None
KI I None
values I None
of I None
608 I None
- I None
955 I None
nM I None
) I None
. I None
<eof> I None

<s> O None
Some I None
clinically I None
used I None
compounds I None
, I None
such I None
as I None
acetazolamide I CHEMICAL
, I None
methazolamide I CHEMICAL
, I None
ethoxzolamide I CHEMICAL
, I None
dichlorophenamide I CHEMICAL
, I None
dorzolamide I CHEMICAL
, I None
brinzolamide I CHEMICAL
, I None
topiramate I CHEMICAL
, I None
sulpiride I CHEMICAL
, I None
and I None
indisulam I CHEMICAL
, I None
or I None
the I None
orphan I None
drug I None
benzolamide I CHEMICAL
, I None
showed I None
effective I None
hCA I GENE-Y
VI O GENE-Y
inhibitory I None
activity I None
, I None
with I None
inhibition I None
constants I None
of I None
0 I None
. I None
8 I None
- I None
79 I None
nM I None
. I None
<eof> I None

<s> O None
The I None
best I None
inhibitors I None
were I None
brinzolamide I CHEMICAL
and I None
sulpiride I CHEMICAL
( I None
KI I None
values I None
of I None
0 I None
. I None
8 I None
- I None
0 I None
. I None
9 I None
nM I None
) I None
, I None
the I None
latter I None
compound I None
being I None
also I None
a I None
CA I GENE-Y
VI O GENE-Y
- I None
selective I None
inhibitor I None
. I None
<eof> I None

<s> O None
The I None
metallic I None
taste I None
reported I None
as I None
a I None
side I None
effect I None
after I None
the I None
treatment I None
with I None
systemic I None
sulfonamides I CHEMICAL
may I None
be I None
due I None
to I None
the I None
inhibition I None
of I None
the I None
salivary I GENE-Y
CA O GENE-Y
VI O GENE-Y
. I None
<eof> I None

<s> O None
Some I None
of I None
the I None
compounds I None
investigated I None
in I None
this I None
study I None
might I None
be I None
used I None
as I None
additives I None
in I None
toothpastes I None
for I None
reducing I None
the I None
acidification I None
produced I None
by I None
the I None
relevant I None
CO2 I CHEMICAL
hydrase I None
activity I None
of I None
enamel I None
CA I GENE-Y
VI O GENE-Y
, I None
which I None
leads I None
to I None
the I None
formation I None
of I None
protons I None
and I None
bicarbonate I CHEMICAL
and I None
may I None
have I None
a I None
role I None
in I None
cariogenesis I None
. I None
<eof> I None

<s> O None
Role I None
of I None
the I None
calcium I GENE-N
modulated O GENE-N
cyclases O GENE-N
in I None
the I None
development I None
of I None
the I None
retinal I CHEMICAL
projections I None
. I None
<eof> I None

<s> O None
Transmembrane I None
isoforms I None
of I None
adenylate I GENE-N
cyclases O GENE-N
( I None
AC I GENE-N
) I None
integrate I None
a I None
wide I None
variety I None
of I None
extracellular I None
signals I None
from I None
neurotransmitters I None
to I None
morphogens I None
and I None
can I None
also I None
regulate I None
cAMP I CHEMICAL
production I None
in I None
response I None
to I None
calcium I CHEMICAL
entry I None
. I None
<eof> I None

<s> O None
Based I None
on I None
observations I None
in I None
the I None
barrelless I None
mouse I None
strain I None
, I None
the I None
Adcy1 I GENE-Y
gene I None
( I None
AC1 I GENE-Y
) I None
was I None
involved I None
in I None
the I None
segregation I None
of I None
binocular I None
retinal I CHEMICAL
inputs I None
. I None
<eof> I None

<s> O None
To I None
determine I None
the I None
potential I None
role I None
of I None
other I None
AC I GENE-N
isoforms I None
we I None
localized I None
the I None
Adcy I GENE-N
genes I None
in I None
the I None
visual I None
centres I None
during I None
development I None
, I None
using I None
in I None
situ I None
hybridization I None
. I None
<eof> I None

<s> O None
Six I None
different I None
AC I GENE-N
subtypes I None
were I None
found I None
in I None
the I None
developing I None
retinal I None
ganglion I None
cell I None
layer I None
( I None
RGC I None
; I None
AC1 I GENE-Y
, I None
AC2 I GENE-Y
, I None
AC3 I GENE-Y
, I None
AC5 I GENE-Y
, I None
AC8 I GENE-Y
, I None
and I None
AC9 I GENE-Y
) I None
, I None
and I None
three I None
AC I GENE-N
subtypes I None
were I None
expressed I None
in I None
the I None
central I None
brain I None
targets I None
, I None
the I None
dorsal I None
lateral I None
geniculate I None
nucleus I None
( I None
AC1 I GENE-Y
and I None
AC8 I GENE-Y
) I None
, I None
the I None
ventral I None
lateral I None
geniculate I None
nucleus I None
( I None
AC2 I GENE-Y
and I None
AC8 I GENE-Y
) I None
and I None
the I None
superior I None
colliculus I None
( I None
AC1 I GENE-Y
, I None
AC2 I GENE-Y
, I None
AC8 I GENE-Y
) I None
. I None
<eof> I None

<s> O None
Using I None
a I None
genetic I None
approach I None
we I None
tested I None
the I None
role I None
of I None
the I None
calcium I GENE-N
modulated O GENE-N
cyclases O GENE-N
AC1 I GENE-Y
, I None
AC5 I GENE-Y
and I None
AC8 I GENE-Y
for I None
the I None
segregation I None
retinal I CHEMICAL
fibres I None
. I None
<eof> I None

<s> O None
Ipsilateral I None
retinal I CHEMICAL
axons I None
remained I None
exuberant I None
in I None
the I None
AC1 I GENE-Y
( I None
- I None
/ I None
- I None
) I None
mice I None
, I None
with I None
overlapping I None
retinal I CHEMICAL
projections I None
from I None
both I None
eyes I None
in I None
the I None
superior I None
colliculus I None
and I None
the I None
visual I None
thalamus I None
. I None
<eof> I None

<s> O None
These I None
abnormalities I None
were I None
similar I None
to I None
those I None
of I None
barrelless I None
mouse I None
mutants I None
. I None
<eof> I None

<s> O None
No I None
abnormalities I None
were I None
detectable I None
in I None
the I None
AC5 I GENE-Y
( I None
- I None
/ I None
- I None
) I None
or I None
the I None
AC8 I GENE-Y
( I None
- I None
/ I None
- I None
) I None
mice I None
. I None
<eof> I None

<s> O None
Similar I None
abnormalities I None
were I None
noted I None
in I None
the I None
single I None
AC1 I GENE-Y
( I None
- I None
/ I None
- I None
) I None
and I None
the I None
AC1 I GENE-Y
/ I None
AC8 I GENE-Y
double I None
- I None
knockout I None
mice I None
( I None
DKO I None
) I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
only I None
AC1 I GENE-Y
is I None
required I None
for I None
the I None
maturation I None
of I None
the I None
retinal I CHEMICAL
axon I None
terminals I None
whereas I None
AC5 I GENE-Y
and I None
AC8 I GENE-Y
are I None
not I None
needed I None
. I None
<eof> I None

<s> O None
The I None
specificity I None
of I None
AC1 I GENE-Y
' O GENE-Y
s O GENE-Y
action I None
is I None
linked I None
to I None
its I None
cellular I None
localization I None
in I None
the I None
RGCs I None
and I None
to I None
its I None
distinctive I None
functional I None
profile I None
, I None
compared I None
with I None
the I None
other I None
cyclases I GENE-N
expressed I None
in I None
the I None
same I None
cells I None
. I None
<eof> I None

<s> O None
Pirfenidone I CHEMICAL
inhibits I None
TGF I GENE-Y
- O GENE-Y
beta O GENE-Y
expression I None
in I None
malignant I None
glioma I None
cells I None
. I None
<eof> I None

<s> O None
Due I None
to I None
its I None
immunosuppressive I None
properties I None
, I None
the I None
cytokine I GENE-N
transforming I GENE-Y
growth O GENE-Y
factor O GENE-Y
( O GENE-Y
TGF O GENE-Y
) O GENE-Y
- O GENE-Y
beta O GENE-Y
has I None
become I None
a I None
promising I None
target I None
in I None
the I None
experimental I None
treatment I None
of I None
human I None
malignant I None
gliomas I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
report I None
that I None
the I None
antifibrotic I None
drug I None
5 I CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
phenyl O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
1H O CHEMICAL
) O CHEMICAL
- O CHEMICAL
pyridone O CHEMICAL
( I None
pirfenidone I CHEMICAL
, I None
PFD I CHEMICAL
) I None
elicits I None
growth I None
- I None
inhibitory I None
effects I None
and I None
reduces I None
TGF I GENE-Y
- O GENE-Y
beta2 O GENE-Y
protein I None
levels I None
in I None
human I None
glioma I None
cell I None
lines I None
. I None
<eof> I None

<s> O None
This I None
reduction I None
in I None
TGF I GENE-Y
- O GENE-Y
beta2 O GENE-Y
is I None
biologically I None
relevant I None
since I None
PFD I CHEMICAL
treatment I None
reduces I None
the I None
growth I None
inhibition I None
of I None
TGF I GENE-Y
- O GENE-Y
beta O GENE-Y
- I None
sensitive I None
CCL I None
- I None
64 I None
cells I None
mediated I None
by I None
conditioned I None
media I None
of I None
glioma I None
cells I None
. I None
<eof> I None

